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The	  brain	  is	  the	  most	  complex	  organ	  in	  our	  body.	  Indeed,	  it	  is	  perhaps	  the	  most	  complex	  structure	  we	  have	  
ever	   encountered	   in	   nature.	   Both	   structurally	   and	   functionally,	   there	   are	   many	   peculiarities	   that	  
differentiate	   the	  brain	   from	  all	  other	  organs.	  The	  brain	   is	  our	   connection	   to	   the	  world	  around	  us	  and	  by	  
governing	  nervous	  system	  and	  higher	  function,	  any	  disturbance	  induces	  severe	  neurological	  and	  psychiatric	  
disorders	  that	  can	  have	  a	  devastating	  effect	  on	  quality	  of	  life.	  
Our	  understanding	  of	   the	  physiology	  and	  biochemistry	  of	   the	  brain	  has	   improved	  dramatically	   in	   the	   last	  
two	  decades.	   In	  particular,	   the	  critical	   role	  of	  cations,	   including	  magnesium,	  has	  become	  evident,	  even	   if	  
incompletely	  understood	  at	  a	  mechanistic	  level.	  The	  exact	  role	  and	  regulation	  of	  magnesium,	  in	  particular,	  
remains	  elusive,	   largely	  because	   intracellular	   levels	  are	  so	  difficult	  to	  quantify	  routinely.	  Nonetheless,	  the	  
importance	  of	  magnesium	  to	  normal	  central	  nervous	  system	  activity	   is	  self-­‐evident	  given	  the	  complicated	  
homeostatic	  mechanisms	   that	  maintain	   the	   concentration	   of	   this	   cation	  within	   strict	   limits	   essential	   for	  
normal	   physiology	   and	   metabolism.	   There	   is	   also	   considerable	   accumulating	   evidence	   to	   suggest	   that	  
alterations	  to	  some	  brain	  functions	  in	  both	  normal	  and	  pathological	  conditions	  may	  be	  linked	  to	  alterations	  
in	  local	  magnesium	  concentration.	  	  
This	  book,	  containing	  chapters	  written	  by	  some	  of	  the	  foremost	  experts	  in	  the	  field	  of	  magnesium	  research,	  
brings	   together	   the	   latest	   in	   experimental	   and	   clinical	   magnesium	   research	   as	   it	   relates	   to	   the	   central	  
nervous	   system.	   It	   offers	   a	   complete	   and	   updated	   view	   of	  magnesium’s	   involvement	   in	   central	   nervous	  
system	  function	  and	  in	  so	  doing,	  brings	  together	  two	  main	  pillars	  of	  contemporary	  neuroscience	  research,	  
namely	  providing	  an	  explanation	  for	  the	  molecular	  mechanisms	  involved	  in	  brain	  function,	  and	  emphasizing	  
the	  connections	  between	  the	  molecular	  changes	  and	  behaviour.	  
It	  is	  the	  untiring	  efforts	  of	  those	  magnesium	  researchers	  who	  have	  dedicated	  their	  lives	  to	  unravelling	  the	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The	  cytosolic	  free	  magnesium	  concentration	  can	  be	  assessed	   in	  vivo	   in	  the	  human	  brain	  by	  phosphorus	  
magnetic	  resonance	  spectroscopy.	  This	  technique	  has	  been	  employed	  in	  the	  human	  brain,	  providing	  new	  
hints	  on	   the	  Mg2+	  homeostasis	  and	  on	   its	   involvement	  on	   the	  cellular	  bioenergetics.	  The	   free	   cytosolic	  
[Mg2+]	  measured	   in	   the	  human	  brain	   is	  about	  half	  of	   that	  assessed	   in	   the	  human	  skeletal	  muscle.	  This	  
result	   is	   likely	   related	   to	   the	   lower	   ATP	   concentration	   of	   brain	   tissue.	   The	   possibility	   to	   assess	   the	  
cytosolic	   [Mg2+]	   in	   the	   human	   brain	   opened	   the	   chance	   to	   study	   the	   involvement	   of	  Mg2+	   in	   different	  
neurological	  pathologies,	  and	  particularly	  in	  those	  where	  the	  defective	  mitochondrial	  energy	  production	  
represents	  the	  primary	  causative	  factor	  in	  pathogenesis.	  The	  results	  obtained,	  studying	  patients	  affected	  
by	  different	  types	  of	  mitochondrial	  cytopathies,	  helped	  to	  clarify	  the	  functional	  relationship	  between	  the	  
energy	   metabolism	   and	   free	   [Mg2+],	   providing	   evidence	   that	   the	   cytosolic	   [Mg2+]	   is	   a	   function	   of	   the	  
energy	  charge	  of	  brain	  cells	  and	  a	  defective	  mitochondrial	  respiration	  causes	  a	  derangement	  of	  cytosolic	  
[Mg2+]	  homeostasis.	  A	  reduced	  cytosolic	  [Mg2+]	  has	  been	  also	  found	  in	  the	  occipital	  lobes	  of	  patients	  with	  
different	  types	  of	  migraine	  and	  cluster	  headache,	  showing	  among	  migraine	  patients	  a	   trend	   in	  keeping	  
with	  the	  severity	  of	  clinical	  phenotype.	   In	  addition,	  the	  assessment	  by	  phosphorus	  magnetic	  resonance	  
spectroscopy	   of	   brain	   [Mg2+]	   can	   help	   in	   the	   differential	   diagnosis	   of	   Multiple	   System	   Atrophy	   and	  
Parkinson's	   disease,	   offering	   a	   new	   diagnostic	   tool	   that	   may	   help	   to	   differentiate	   neurodegenerative	  




Inorganic	   phosphate	   (Pi),	   phosphocreatine	   (PCr),	  
and	  ATP	  are	  the	  principal	  Mg+2	  ligands	  among	  the	  
phosphorylated	   molecules	   present	   in	   the	   cell	  
cytosol	   detectable	   by	   phosphorus	   magnetic	  
resonance	   spectroscopy	   (31P-­‐MRS)	   (Figure	   1).	  
Nevertheless,	  in	  the	  cytosol	  matrix,	  magnesium	  is	  
primarily	  bound	  to	  ATP.	  As	  a	  consequence,	  in	  the	  
living	  organism,	  ATP	  is	  present	  mainly	  in	  the	  form	  
MgATP2-­‐	   (Iotti	  et	   al.,	   1996)	   (Figure	   2)	   that	   is	   the	  
active	   species	   in	   enzyme	   binding	   (Kuby	   and	  
Noltman,	  1959),	  as	  well	  as	   the	  energy	  producing	  
form	   in	   active	   transport	   (Skou,	   1982;	   Repke,	  
1982)	   and	   muscular	   contraction	   (Ramirez	   and	  
Marecek	  1980;	  Wells	  et	  al.,	  1980).	  	  
	  
The	   amount	   of	   magnesium	   bound	   to	   ATP	   shifts	  
the	  resonance	  frequencies	  measured	  by	  31P-­‐MRS	  
of	   signals	   coming	   from	   the	   three	   phosphoric	  
groups	  α,	   β,	   γ	   of	   the	   molecule	   (chemical	   shift).	  
Due	  to	  the	  chemical	  equilibrium	  between	  the	  Mg	  
bound	  to	  ATP	  and	  free	  Mg2+,	  the	  chemical	  shift	  of	  
ATP	  signals	  is	  function	  of	  free	  Mg2+	  concentration	  
(Figure	   3).	   The	   in	   vivo	   assessment	   of	   cytosolic	  
Mg2+	   concentration	   ([Mg2+])	   in	   the	   human	   brain	  
needs	   a	   specific	   calibration	   curve	   that	   should	  
satisfy	  precise	  criteria.	  In	  particular,	  the	  calibration	  
curve	   should	   take	   into	   account:	   i)	   other	   ions	  
present	  in	  the	  cell	  cytosol	  competing	  with	  Mg2+	  in	  
binding	   ATP	   such	   as	   H+,	   Na+,	   K+,	   and	   ii)	   other	  
ligands	   such	   as	   ADP,	   PCr	   and	   Pi	   competing	  with	  
ATP	  in	  binding	  Mg2+	  (Iotti	  et	  al.,	  1996).	  
	  
Operatively,	   [Mg2+]	   is	   assessed	   by	   31P-­‐MRS	   from	  
the	  chemical	  shift	  of	  β-­‐ATP	  being	  measured	  from	  
the	   signal	   of	   either	   α-­‐ATP	   (Gupta	   et	   al.,	   1984;	  
Williams	   and	   Smith,	   1995)	   or	   PCr	   (Taylor	   et	   al.,	  
1991;	   Halvorson	   et	   al.,	   1992).	   The	   reliability	   of	  
the	   in	   vivo	   measurements	   depends	   on	   the	  
availability	   of	   an	   appropriate	   in	   vitro	   calibration	  
method	  to	  determine	  the	  limits	  of	  chemical	  shifts	  
of	   unbound	   ATP	   and	   Mg-­‐ATP	   complexes.	   As	   a	  
result,	   the	   calibration	   method	   has	   to	   take	   into	  
account	   the	   two	   issues	   mentioned	   above	  
together	   with	   other	   variables	   such	   as	   the	   ionic	  
strength,	   temperature	   and	   pH	   of	   the	   medium.	  
Besides,	  to	  have	  a	  precise	  measurement	  of	  β-­‐ATP





Figure	   1.	   Scheme	   of	   the	  main	   phosphorylated	  molecules	   present	   in	   the	   brain	   cell	   cytosol	   detectable	   by	  
phosphorus	  magnetic	   resonance	   spectroscopy.	   Inorganic	  phosphate	   (Pi),	   phosphocreatine	   (PCr),	   and	  ATP	  
are	  the	  principal	  magnesium	  ligands.	  
	  
	  
chemical	  shift	  it	  must	  be	  taken	  into	  account	  that	  
the	   shifts	   of	   both	   α-­‐ATP	   and	   PCr	   change	   as	   a	  
function	  of	   [Mg2+]	   (Iotti	  et	  al.,	   1996).	   The	  earlier	  
works	  of	  Gupta	  (Gupta	  et	  al.,	  1978;	  Gupta	  et	  al.,	  
1983;	   Gupta	   et	   al.,	   1984)	   were	   based	   on	   the	  
assumption	  of	   the	  presence	  of	  only	  one	  ATP-­‐Mg	  
complex.	   In	   the	   1990s	   several	   studies	   were	  
published	   proposing	   more	   accurate	   calibration	  
methods	   taking	   into	   account	   equilibria	   involving	  
few	   different	   chemical	   species	   (Mosher	   et	   al.,	  
1992;	   Halvorson	   et	   al.,	   1992;	   Golding	   and	  
Golding,	  1995).	  Nevertheless,	  the	  influence	  of	  the	  
ionic	   strength	   (I)	   of	   the	   medium	   on	   the	  
equilibrium	   constants	   of	   the	   species	   present	   in	  
the	   calibration	   solutions	   must	   be	   taken	   into	  
account	   as	   discussed	   in	   one	   report	   published	   in	  
those	  years	  (Mottet	  et	  al.,	  1994).	  
	  
In	   the	  next	  section	  the	  methodological	  approach	  
used	  to	  build	  the	  calibration	  curve	  for	  the	  	  [Mg2+]	  
determination	   in	   human	   brain	   by	   31P-­‐MRS	   is	  
analytically	  presented.	  	  
	  
Building	  a	  calibration	  curve	  for	  the	  [Mg2+]	  
determination	  in	  human	  brain	  by	  31P	  MRS	  
	  
The	  accuracy	  and	  reliability	  of	  in	  vivo	  assessment	  
of	   [Mg2+]	   mainly	   depend	   on	   the	   availability	   of	  
calibration	  curves	  based	  on	  precise	   in	  vitro	  NMR	  
measurements	   performed	   on	   appropriate	  
solutions	  that	  mimic,	  as	  far	  as	  possible,	  the	  in	  vivo	  
conditions	   of	   the	   tissue	   to	   be	   studied.	   As	   a	  
consequence,	   these	   solutions	   will	   contain	  
molecules	  involved	  in	  multiple	  equilibria	  in	  which	  
several	   ligands	   (Lewis	   base)	   interact	   with	   metal	  
ions	   (Lewis	  acid),	   and	  among	   them	  Mg2+	  and	  H+.	  
Typically,	   to	   build	   a	   calibration	   curve,	   a	   titration	  
of	   the	   species	   of	   interest	   must	   be	   performed,	  
linking	   its	   concentration	   to	   the	   experimental	  
NMR	   measurement.	   [Mg2+]	   can	   be	   assessed	   by	  
31P	  MRS	   from	   the	   chemical	   shift	  of	  β-­‐ATP	   signal,	  
which	   in	   turn	   depends	   on	   the	   fraction	   of	   total	  
ATP	  bound	  to	  Mg2+.	  Quite	  problematic	   is	  the	  use	  
of	  a	  Mg	  electrode	  to	  measure	  [Mg2+]	  in	  a	  complex	  	  




Figure	   2.	   Concentration	   of	   the	   major	   ATP-­‐
containing	  species	  present	  in	  solutions	  mimicking	  
the	   cell	   brain	   cytosol	   plotted	   versus	   pMg.	  
Solutions	   composition	  were:	  ATP	  =	   3	  mM,	  phos-­‐
phocreatine	   =	   4.5	   mM,	   K2HPO4	   =	   1.0	   mM,	   and	  
variable	  amounts	  of	  MgCl2	  at	  pH	  =	  7.00,	  37	  °C	  and	  
ionic	   strength	   0.25	  M.	   Adapted	   from	   Iotti	  et	   al.,	  
1996.	  
	  
mixture,	   having	   to	   deal	   with	   interferences	   and	  
lack	  of	  accuracy.	  
	  
A	  convenient	  approach	  to	  measure	   the	   [Mg2+]	   in	  
a	   multi-­‐equilibrium	   system	   is	   using	   appropriate	  
algorithms	   and	   software,	   which	   are	   currently	  
available,	   allowing	   a	   quantitative	   chemical	  
speciation	  of	  any	  component	  present	  in	  solution,	  
given	   a	   set	   of	   stability	   and	   acidic	   dissociation	  
constants.	   In	   this	   approach,	   a	   pivotal	   step	   is	   the	  
definition	   of	   the	   chemical	   model	   better	  
describing	   the	   multi-­‐equilibrium	   system	   present	  
in	   solution.	   After	   the	   characterization	   of	   ligands	  
and	  Lewis	  acids	  as	  the	  basic	  species,	  the	  next	  step	  
is	   the	   delineation	   of	   all	   the	   possible	   equilibria	  
between	  them.	  
	  
In	  the	  calibration	  curve	  specifically	  developed	  for	  
the	   in	   vivo	   assessment	  of	   [Mg2+]	   in	  human	  brain	  
(Iotti	   et	   al.,	   1996)	   the	   chemical	   model	   was	  
defined	  by	  choosing	  four	  ligands—ATP4-­‐,	  PO4
3-­‐,	  Cl-­‐	  
and	  PCr2-­‐	  and	  four	  Lewis	  acids—Na+,	  K+,	  Mg2+	  and	  
H+	   as	   basic	   species,	   giving	   raise	   to	   the	   multi-­‐
equilibrium	  system	  shown	  in	  Figure	  4.	  
	  
An	   obligatory	   prerequisite	   for	   the	   analysis	   of	  
spectra	   recorded	   in	   vitro	   is	   a	   reliable	   and	  
homogeneous	  set	  of	  equilibrium	  constants	   to	  be	  
used	  in	  the	  quantitative	  speciation	  of	  the	  experi-­‐
mental	  solutions.	  Therefore,	  if	  the	  equilibrium	  
	  
Figure	  3.	  Top:	  Sagittal	  slice	  image	  of	  human	  brain	  
acquired	   by	   magnetic	   resonance	   imaging.	   The	  
brain	   volume	   within	   vertical	   axes	   defines	   the	  
region	  of	  occipital	  lobes.	  Bottom:	  31P-­‐MRS	  spectra	  
acquired	   from	  occipital	   lobes	  placing	   the	  surface	  
coil	   directly	   on	   the	   skull.	   Abbreviations:	   Pi,	  
inorganic	   phosphate;	   PCr,	   phosphocreatine;	  
α, β, γ, ATP	   phosphoric	   groups;	   PME,	   phospho-­‐
monoesters;	   PDE,	   phosphodiesters.	   Brain	   cytosolic	  




constants	   reported	   in	   the	   literature	   do	   not	  
conform	   to	   the	   conditions	   of	   temperature	   and	  
ionic	   strength	   used	   in	   the	   experiments,	   suitable	  
corrections,	   using	   Van't	   Hoff	   and/or	   Davies	  
equations,	  have	  to	  be	  applied	  to	  account	   for	  the	  
different	  conditions	  of	  NMR	  experiments	  (Iotti	  et	  
al.,	  1996).	  
	  
Furthermore,	   the	   literature	   is	   rich	   with	   data	  
pertaining	   to	   interactions	   between	   metal	   ions	  
and	   ligands	   in	   solution,	   but	   the	   reported	   values	  
are	   often	   characterized	   by	   extremely	   variable	  
levels	   of	   precision	   and	   accuracy.	   Williams	   and	  
colleagues	   (Duffield	   et	   al.,	   1991)	   discussed	   the	  
problems	   related	   to	   the	   determination	   of	   the	  
magnitude	  of	  quantities	  of	  biological/environ-­‐	  	  





Figure	  4.	  Scheme	  of	   the	  chemical	  model	  used	  to	  
build	   the	  calibration	  curve	   for	   the	  assessment	  of	  
brain	   cytosolic	   [Mg2+]	   by	   31P-­‐MRS.	   Four	   ligands	  
(ATP4-­‐,	   PO4
3-­‐,	   Cl-­‐,	   and	   PCr2-­‐)	   and	   four	   Lewis	   acids	  




mental	  interest	  and	  to	  its	  associated	  error.	  When	  
these	   quantities	   are	   used	   for	   the	   chemical	  
speciation	  of	  natural	  systems,	  the	  results	  bear	  an	  
uncertainty	   directly	   related	   to	   the	   errors	   which	  
affect	   the	   original	   quantities.	   Hence,	   a	   careful	  
examination	  of	  the	  published	  values	  of	  equilibrium	  
constants	   for	   the	   reactions	   involved	   in	   the	  
chemical	  model	  chosen,	  must	  be	  performed.	  
	  
Another	   consideration	   to	   bear	   in	   mind	   is	   when	  
using	   protonation	   constants	   that	   have	   been	  
determined	   with	   the	   so-­‐called	   "incomplete	  
convention"	   (Halvorson	   et	   al.,	   1992),	   in	   which	  
hydrogen	  ion	  activity	  is	  used	  instead	  of	  hydrogen	  
ion	   concentration	   in	   the	   expression	   used	   to	  
define	   the	   equilibrium	   constants.	   This	   can	  
generate	   confusion	   when	   such	   constants	   are	  
used	   together	   with	   others	   that	   are	   expressed	  
solely	   in	   terms	   of	   concentration.	   Therefore,	   a	  
coherent	   and	   internally	   consistent	   set	   of	  
equilibrium	  constants	  has	   to	  be	   collected,	  which	  
are	  valid	  at	  37	  °C	  and	  at	  I	  =	  0.25	  M,	  the	  conditions	  
of	  solutions	  that	  mimic	  the	  in	  vivo	  environment.	  
	  
To	   handle	   the	   relevant	   number	   of	   different	  
equilibria	   taken	   into	   consideration,	   an	   algorithm	  
was	   developed	   that	   allowed	   a	   quantitative	  
chemical	   speciation	   of	   the	   Mg2+-­‐binding	  
molecules	   with	   the	   goal	   of	   building	   a	   semi-­‐
empirical	   equation	   that	   correlates	   the	   chemical	  
shift	   of	   the	   β-­‐ATP	   signal	   measured	   by	   in	   vitro	  
NMR	   measurements	   in	   the	   calibration	   solutions	  
to	   [Mg2+]	   calculated,	   taking	   into	   account	   the	  
amount	   of	   Mg2+	   bound	   to	   all	   constituents	   in	  
solution.	   As	   a	   result,	   the	   concentrations	   of	   all	  
species	   present	   under	   a	   given	   set	   of	   conditions	  
(i.e.	   total	   concentrations	   of	   all	   reagents)	   were	  
determined	  by	  the	  program	  HYSS	  (Alderighi	  et	  al.,	  
1999),	   a	   specific	   software	   program,	   utilized	   for	  
chemical	   speciation.	   Using	   this	   software	   it	   was	  
possible	   to	   derive	   the	   concentration	   of	   free	  
magnesium	   in	   any	   condition.	   HYSS	   requires	   two	  
sets	   of	   data:	   a	   chemical	   model	   and	   the	  
experimental	  conditions.	  The	  model	  was	  the	  one	  
reported	   in	  Figure	  4,	  by	  specifying	  values	  for	  the	  
equilibrium	   constants	   βabc....	   and	   the	   corresp-­‐
onding	   stoichiometric	   coefficients	   a,	   b,	   c,	   ....,	  
considering	   that	   the	   general	   reaction	   between	  
reagents	  A,	   B,	   C	   ...	   to	   give	   a	   chemical	   species	  of	  
formula	  AaBbCc…:	  	  
	  
aA+bB+cC+…	  ⇆ AaBbCc	  
	  






A[ ]a B[ ]b C[ ]c
	  
	  
Electric	   charges	   have	   been	   omitted	   for	   the	   sake	  
of	  simplicity.	  By	  using	  this	  approach	  and	  different	  
calibration	   solutions	   prepared	   to	   mimic	   the	   in	  
vivo	   metabolic	   conditions	   of	   brain,	   it	   has	   been	  
possible	   to	   obtain,	   following	   an	   heuristic	  
procedure,	  the	  following	  equation:	  





where	   x1,	   x2,	   x3,	   x4,	   x5	   are	   the	   calculated	  
parameters,	  δ	  is	  the	  measured	  chemical	  shift,	  and	  
pMg	  =	  -­‐log10	  [Mg
2+].	  This	  equation	  can	  be	  seen	  as	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a	  more	  general	  expression	  of	  the	  typical	  titration	  
curve	   in	   which	   x1	   is	   the	   pK	   of	   the	   equilibrium	  
involved	  and	  with	  x3,	  x5	  =	  1.	  More	  precisely,	  two	  
different	  equations	  were	  obtained,	  where	  pMg	  is	  
expressed	  as	  a	   function	  of	   the	  chemical	   shifts	  of	  
β-­‐ATP	  from	  PCr	   (δβ)	  or	   from	  α-­‐ATP	  (δαβ)	   (Iotti	  et	  
al.,	  1996).	  However,	  the	  calibration	  curve	  obtained	  
using	   δβ	   as	   experimental	   variable	   showed	   to	   be	  
more	  accurate	  than	  that	  obtained	  using	  δαβ	  (Iotti	  	  
et	   al.,	   1996).	   This	   is	   because	   the	  measurements	  
of	  δαβ	   in	  spectra	  obtained	   in	  vivo	  are	  usually	  less	  
accurate	  than	  those	  of	  δβ,	  due	  to	  the	  unresolved	  
resonances	  of	  α-­‐ADP,	  NAD,	  NADH	  underlying	  up-­‐
field	  the	  α-­‐ATP	  peak.	  Furthermore,	  PCr	  resonates	  
alone	  and	  is	  symmetric,	  allowing	  a	  more	  accurate	  
identification	   of	   the	   centroid	   of	   the	   peak.	  
Therefore,	   δβ	   should	   be	   preferable	   to	   δαβ	   as	  
experimental	   variable	   for	   the	   in	   vivo	   measure-­‐
ments	  of	  brain	  cytosolic	  free	  [Mg2+].	  According	  to	  
this,	  the	  equation	  to	  be	  used	  is:	  
	  
pMg	  =	  4.24	  –	  log10[(δβ	  -­‐	  18.58)
0.42
	  /(15.74	  -­‐	  δβ)
0.84]	  
	  
The	   specific	   software	   package	   MAGIC-­‐BC	   based	  
on	   the	  equation	   reported	   above	  has	  been	  made	  
available	   at	   http://www.cermiv.unibo.it.	   It	   is	  
worth	   underlying	   that,	   in	   principle,	   by	   this	  
approach	   it	   is	   possible	   to	   assess	   the	   concen-­‐
tration	   of	   any	   species	   independently	   of	   the	  
degree	   of	   complexity	   of	   the	   system	   under	  
investigation,	   with	   the	   restriction	   of	   only	   two	  
requisites:	   i)	   a	   precise	  definition	  of	   the	   chemical	  
model	   and	   ii)	   the	   knowledge	   of	   the	   equilibrium	  
constants	  of	  the	  chemical	  reactions	  involved.	  
	  
Cytosolic	  [Mg2+]	  in	  human	  brain	  
	  
The	   cytosolic	   [Mg2+]	   assessed	   by	   31P-­‐MRS	   in	   the	  
occipital	   lobes	   of	   human	   brain	   of	   36	   control	  
subjects	   (22	   men	   and	   14	   women)	   of	   mean	   age	  
36.4	   ±	   17.1	   (SD)	   (16	   -­‐	   67	   years)	   was	   0.182	   mM	  
(Iotti	  et	  al.,	  1996).	  Brain	  studies	  were	  performed	  
on	   occipital	   lobes	   by	   placing	   the	   surface	   coil	  
directly	   on	   the	   skull	   in	   the	   occipital	   region	   and	  
precisely	   positioned	   by	   imaging	   the	   brain	   as	  
shown	   in	   Figure	   3.	   The	   free	   cytosolic	   [Mg2+]	  
measured	  in	  the	  human	  brain	  is	  about	  half	  of	  that	  
assessed	   in	   the	   human	   calf	   muscle	   (Iotti	   et	   al.,	  
2000;	   Iotti	   and	   Malucelli,	   2008).	   This	   result	   is	  
likely	   related	   to	   the	   lower	   ATP	   concentration	   of	  
brain	  tissue	  (3	  mM)	  compared	  to	  that	  of	  skeletal	  
muscle	  (8	  mM),	  ATP	  being	  the	  major	  binding	  site	  
present	   in	   the	   cellular	   milieu.	   Nevertheless,	   the	  
value	   found	   of	   0.182	   mM	   is	   lower	   than	   that	  
obtained	  by	  others	  (Taylor	  et	  al.,	  1991;	  Halvorson	  
et	  al.,	  1992).	  This	   is	  not	  a	  surprising	  result	  as	  the	  
model	   considered	   in	   building	   this	   calibration	  
curve	  contains	  more	  species	  that	  bind	  Mg2+	  than	  
in	   all	   other	   approaches	   published.	   As	   a	   conseq-­‐
uence,	  a	   lower	  value	  of	  cytosolic	   free	   [Mg2+]	  has	  
to	  be	  expected.	   If	   the	  model	  described	  previously,	  
upon	   which	   the	   cytosolic	   [Mg2+]	   assessment	   is	  
based,	   had	   taken	   into	   account	   more	   species	  
binding	  Mg2+,	   the	   resulting	   value	  of	   brain	   [Mg2+]	  
would	  be	  even	  lower.	  Therefore,	  we	  believe	  that	  
the	  present	  brain	  [Mg2+]	  value	  is	  a	  good	  estimate	  
of	   the	   cytosolic	   free	   ion	   concentration,	   which	  
however	  could	  still	  be	  slightly	  overestimated.	  
	  	  
In	   the	   cohort	   of	   subjects	   studied,	   there	   was	   no	  
significant	   difference	   in	   cytosolic	   [Mg2+]	   as	   a	  
function	  of	  age	  and	  sex.	  This	  shows	  that	  the	  sum	  
of	  anions	  binding	  Mg2+in	  vivo	  does	  not	  change	  in	  
the	   brain	   cortex	   during	   the	   life	   span	   studied	  
and/or	   that	   regulatory	   mechanisms	   exist	   to	  
maintain	   the	   cytosolic	   free	   [Mg2+]	   constant.	   The	  
possibility	   to	   assess	   the	   free	   cytosolic	   [Mg2+]	   in	  
the	  human	  brain	  opened	  the	  chance	  to	  study	  the	  
involvement	   of	   Mg	   in	   different	   neurological	  
pathologies.	   Particularly	   interesting	   are	   mito-­‐
chondrial	  cytopathies	  and	  migraines	  in	  which	  the	  
defective	   mitochondrial	   energy	   production	   is	  
respectively	   the	   primary	   causative	   or	   putative	  
pathogenetic	  factor.	  
	  
Brain	  [Mg2+]	  in	  mitochondrial	  cytopathies	  
	  
31P-­‐MRS	  was	  used	  to	  assess	  the	  free	  [Mg2+]	  in	  the	  
occipital	   lobes	   of	   patients	   affected	   by	   different	  
types	  of	  mitochondrial	  cytopathies	  due	  to	  known	  
enzyme	   and/or	   mitochondrial	   DNA	   defects	   to	  
clarify	   the	   functional	   relationship	   between	   the	  
energy	   metabolism	   and	   the	   concentration	   of	  
cytosolic	  free	  magnesium	  (Barbiroli	  et	  al.,	  1999a).	  
In	  particular,	  19	  subjects	  (9	  women	  and	  10	  men)	  
of	   mean	   age	   43	   ±	   19	   (SD)	   (13-­‐75	   years)	   with	  
mitochondrial	   cytopathies	   were	   studied	   (see	  
Table	   1).	   Treatment	   with	   oral	   CoQ10	   (150	  
mg/day)	  was	   given	   for	   six	  months	   to	   9	   patients.	  
All	  patients	  displayed	   significantly	   low	  cytosolic	  
[Mg2+],	  well	  below	  the	  95%	  confidence	  interval	  of	  
control	   values	   (Figure	   5).	   Since	   the	   mtDNA	  
mutations	   and	   enzyme	   defects	   found	   in	   these	  
patients	   (Table	   1)	   are	   known	   to	   be	   primarily	  
responsible	   for	   brain	   defective	   mitochondrial	  
respiration,	   this	   outcome	   strongly	   suggests	   that	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Table	  1.	   Patients	  with	  mitochondrial	   cytopathies	  due	   to	   known	  enzyme/mtDNA	  defect/s.	   COX	  =	   cytochrome	  
oxidase.	   Patients	   1-­‐4,	   10,	   12-­‐14	   and	  16	  were	   treated	  with	  CoQ10	   (150	  mg/day	   for	   six	  months).	  Adapted	  




Sex/age	  (years)	   Diagnosis	   Enzyme	  defect	  or	  mtDNA	  bp	  
mutation/deletion	  
1*	   F/61	   CPEO	   COX	  
2*	   M/75	   CPEO	   COX	  
3*	   F/69	   CPEO	   mtDNA	  deletion	  
4*	   M/66	   CPEO	   COX	  
5	   F/21	   LHON	   3460	  
6	   M/26	   LHON	   11778	  
7	   M/33	   LHON	   11778	  
8	   F/61	   LHON	   11778	  
9	   F/54	   LHON	   11778	  
10*	   M/33	   LHON	   3460	  
11	   M/51	   LHON	   11778	  +	  4216	  +	  13708	  
12*	   M/56	   LHON	   11778	  
13*	   M/36	   LHON	   11778	  
14*	   M/25	   LHON	   11778	  
15	   F/41	   NARP	   8993	  
16*	   F/13	   NARP	   8993	  
17	   F/16	   MERFF	   8344	  
18	   M/49	   MELAS	   3243	  
19	   F/38	   MEM	   mtDNA	  deletion	  
Abbreviations:	  *	  treated	  with	  CoQ10;	  CPEO,	  chronic	  progressive	  external	  ophthalmoplegia;	  LHON,	  Leber's	  
hereditary	   optic	   neuropathy;	   NARP,	   neuropathy	   ataxia	   and	   retinitis	   pigmentosa;	   MEM,	   mitochondrial	  
encephalomyopathy;	  MERF,	  myoclonic	   epilepsy	  with	   ragged	   red	   fibres;	  MELAS,	  mitochondrial	  myopathy	  
encephalopathy,	  lactic	  acidosis,	  and	  stroke.	  
	  
	  
the	   low	   cytosolic	   [Mg2+]	   found	   in	   these	   patients	  
was	  secondary	  to	  failure	  of	  the	  respiratory	  chain.	  	  
	  
Nine	  of	  the	  19	  patients	  investigated	  were	  treated	  
with	   CoQ,	   which	   improved	   the	   efficiency	   of	   the	  
respiratory	  chain	  (Barbiroli	  et	  al.,	  1999a).	  Admin-­‐
istration	  of	  CoQ	  also	  increased	  cytosolic	  [Mg2+]	  in	  
all	   treated	   patients	   (Figure	   5).	   The	   increased	  
efficiency	   of	   oxidative	   phosphorylation	   following	  
treatment	   with	   CoQ	   accompanied	   by	   an	  
increased	   cytosolic	   free	   [Mg2+]	   gives	   further	  
support	   to	   the	   hypothesis	   that	   changes	   in	   brain	  
cytosolic	  [Mg2+]	  were	  secondary	  to	  the	  improved	  
efficiency	  of	  mitochondrial	  energy	  production.	  	  
	  
According	   to	   this	   view,	   the	   cytosolic	   [Mg2+]	   is	   a	  
function	  of	  the	  energy	  charge	  of	  brain	  cells	  and	  a	  
defective	   mitochondrial	   respiration	   causes	   a	  
derangement	   of	   cytosolic	   [Mg2+]	   homeostasis.	  
This	   interpretation	   is	   consistent	   with	   the	  
observations	   of	   several	   reports	   that	   indicate	  
mitochondria	  as	  the	  primary	  pool	  for	  the	  increase	  
and	   decrease	   in	   cellular	   magnesium	   content,	  
suggesting	   that	   mitochondria	   might	   act	   as	  
magnesium	  stores	  (Kubota	  et	  al.,	  2005;	  Farruggia	  
et	   al.,	   2006)	   and	   play	   a	   key	   role	   in	   regulating	  








Figure	   5.	   Brain	   cytosolic	   [Mg2+]	   assessed	   in	   the	  
occipital	   lobes	   of	   patients	   with	   mitochondrial	  
cytopathies	  (open	  symbols).	  The	  values	  from	  nine	  
of	   these	   patients	   after	   treatment	   with	   CoQ	   are	  
shown	   by	   closed	   symbols.	   Dashed	   areas	  
represent	   the	   95%	   confidence	   intervals	   of	   36	  
healthy	   control	   subjects.	   Adapted	   from	   Barbiroli	  
et	  al.,	  1999a.	  
	  
	  
Brain	   [Mg2+]	   in	   different	   types	   of	  migraine	   and	  
cluster	  headache	  
	  
Low	  cytosolic	  free	  magnesium	  has	  been	  found	  in	  
the	   brains	   of	   patients	   with	   migraine	   with	   and	  
without	   aura	   during	   attacks	   (Ramadan	   et	   al.,	  
1989)	   and	   interictally	   in	   young	   patients	   with	  
migraine	  with	  aura	  (Lodi	  et	  al.,	  1997).	  It	  has	  been	  
suggested	   that	   low	   free	   magnesium	   may	  
contribute	  to	  the	  bioenergetic	  deficit	  in	  headache	  
patients	   as	   magnesium	   is	   essential	   for	   mito-­‐
chondrial	   membrane	   stability	   and	   coupling	   of	  
oxidative	   phosphorylation	   (Welch	   and	   Ramadan,	  
1995).	  Migraine	  headache	  is	  a	  common	  feature	  in	  
patients	   with	   mitochondrial	   encephalomyopathies	  
where	   deficient	   brain	  mitochondrial	   oxidation	   is	  
due	   to	  mutations	   of	  mitochondrial	   DNA.	   In	   fact,	  
several	  studies	  contributed	  to	  disclose	  an	  altered	  
energy	  metabolism	   in	   the	   brain	   of	   patients	  with	  
different	  types	  of	  migraine	  and	  cluster	  headache	  
(Barbiroli	   et	   al.,	   1992;	   Montagna	   et	   al.,	   1994;	  
Montagna	   et	   al.,	   1997),	   although	   the	   molecular	  
mechanisms	   leading	   to	   oxidative	   deficit	   in	  
migraine	  and	  cluster	  headache	  are	  unknown.	  On	  
the	  other	  hand,	  as	  shown	  in	  the	  previous	  section,	  
the	   reduction	   in	   cytosolic	   [Mg2+]	   seems	   to	   be	  
secondary	   to	   the	   bioenergetics	   deficit	   in	   the	  
brains	   of	   patients	   with	   different	   mitochondrial	  
encephalomyopathies.	  These	  outcomes	  provided	  
the	  rationale	  to	  perform	  an	  extensive	  study	  to	  	  
assess	   the	   brain	   Mg2+	   by	   31P-­‐MRS	   in	   different	  
form	   of	  migraines	   and	   in	   cluster	   headache	   (Lodi	  
et	   al.,	   2001).	   The	   study	   was	   performed	   in	   78	  
patients	   with	   different	   forms	   of	   migraine	   in	  
attack-­‐free	   periods	   (7	   with	   migraine	   stroke,	   13	  
with	   migraine	   with	   prolonged	   aura,	   37	   with	  
migraine	  with	  typical	  aura	  or	  basilar	  migraine,	  21	  
with	  migraine	  without	  aura),	  and	  13	  patients	  with	  
cluster	   headache.	   In	   the	   occipital	   lobes	   of	   all	  
subgroups	   of	   migraine	   and	   in	   cluster	   headache	  
patients	   cytosolic	   [Mg2+]	  was	   significantly	   reduced.	  
Among	   migraine	   patients	   the	   level	   of	   cytosolic	  
free	  [Mg2+]	  correlated	  with	  the	  severity	  of	  clinical	  
phenotype,	  showing	  the	  lowest	  values	  in	  patients	  
with	  migraine	   stroke	   and	   the	  highest	   in	   patients	  
with	  migraine	  without	  aura,	  as	  shown	  in	  Figure	  6	  
(Lodi	  et	  al.,	  2001).	  Again,	  the	  results	  of	  this	  study	  
sustain	   the	   hypothesis	   that	   the	   reduction	   of	  
cytosolic	   [Mg2+]	   in	   tissues	   with	   defective	  
mitochondrial	   functionality	   is	   secondary	   to	   the	  
bioenergetics	   deficit,	   hence	   the	   reduction	   of	  
brain	   cytosolic	   free	   [Mg2+]	   is	   unlikely	   to	   be	   a	  







Figure	  6.	  Concentration	  of	  cytosolic	  [Mg2+]	  in	  the	  
occipital	   lobes	   of	   patients	   with	   migraine	   and	  
cluster	  headache	   compared	  with	  healthy	   control	  
subjects.	   Abbreviations:	   MS,	   migraine	   stroke;	  
MwPA,	   migraine	   with	   prolonged	   aura;	   MwA,	  
migraine	   with	   typical	   aura	   or	   basilar	   migraine;	  
MwoA,	   migraine	   without	   aura;	   CH,	   cluster	  
headache.	  All	   values	  are	   reported	  as	  mean	  ±	  SE.	  
Adapted	  from	  Lodi	  et	  al.,	  2001.	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Brain	  [Mg2+]	  in	  the	  differential	  diagnosis	  of	  
multiple	  system	  atrophy	  and	  idiopathic	  
Parkinson’s	  disease	  
	  
An	   in	   vivo	   study	   by	   31P-­‐MRS	   showed	   that	   the	  
combined	  measurement	  of	   [PCr]	  and	   free	   [Mg2+]	  
could	  help	  to	  differentiate	  patients	  with	  Multiple	  
System	   Atrophy	   (MSA)	   from	   those	   with	  
Parkinson's	  disease	   (PD)	   (Barbiroli	  et	  al.,	   1999b).	  
MSA	   is	   a	   group	   of	   multisystem	   degenerative	  
diseases	  that	  have	  several	  clinical	  features	  of	  PD.	  
Furthermore,	   not	   all	   the	   signs	   in	   MSA	   become	  
evident	  at	   the	   same	   time,	   rendering	  difficult	   the	  
differentiation	  from	  PD.	  Therefore,	  differentiating	  
MSA	   from	   PD	   can	   be	   complicated	   and	   the	  
diagnosis	   of	  MSA	   represents	   a	   clinical	   challenge.	  
The	   study	  was	   carried	  out	  on	   the	  occipital	   lobes	  
of	   15	   patients	   with	   MSA	   and	   13	   patients	   with	  
idiopathic	  PD.	  
	  
In	  the	  occipital	  lobes	  of	  MSA	  patients	  we	  found	  a	  
31P-­‐MRS	   spectroscopy	   pattern	   suggestive	   of	  
defective	   brain	   mitochondrial	   respiration	   with	  
low	   [PCr]	   and	   high	   [Pi].	   However,	   the	   brain	  
cytosolic	   [Mg2+]	   of	   MSA	   patients	   did	   not	   differ	  
significantly	   from	   control	   values,	   displaying	   a	  
peculiar	   pattern	   compared	   to	   mitochondrial	  
cytopathies.	  On	   the	   other	   hand,	   PD	   patients	   did	  
not	   exhibit	   in	   their	   occipital	   lobes	   the	  metabolic	  
pattern	   typical	   of	   mitochondrial	   malfunction,	  
showing	   an	   increased	   [Pi],	   decreased	   cytosolic	  
[Mg2+]	   and	   unchanged	   [PCr]	   and	   pH.	   Although	  
there	   is	   a	   highly	   significant	   difference	   in	   both	  
[PCr]	   and	   [Mg2+]	   between	  MSA	   and	   PD	   patients	  
when	   compared	   as	   groups,	   there	   is	   a	   small	  
overlap	   of	   [PCr]	   and	   [Mg2+]	   values	   between	   the	  
two	   groups	   when	   considering	   single	   individuals	  
(Barbiroli	   et	   al.,	   1999b).	   However,	   taking	   into	  
consideration	   both	   variables	   at	   the	   same	   time,	  
the	   individual	   patients	   with	   MSA	   can	   be	  





Figure	   7.	   Plot	   of	   the	   distribution	   patterns	   of	   13	  
patients	   with	   Idiopathic	   Parkinson’s	   Disease	  
(closed	   symbols)	   and	   15	   patients	   with	   Multiple	  
System	  Atrophy	   (open	   symbols)	   as	   a	   function	   of	  
brain	   [PCr]	  and	   free	   [Mg2+]	  assessed	  by	   31P-­‐MRS.	  
[PCr]	   and	   [Mg2+]	   alone	   were	   able	   to	   classify	  
respectively	   75%	   and	   85%	   of	   the	   patients.	  
Discriminant	  analysis	  using	   contemporarily	   these	  
two	   independent	   parameters	   correctly	   classified	  
93%	  of	  cases.	  Adapted	  from	  Barbiroli	  et	  al.,	  1999b.	  
	  
	  
with	  a	  probability	  of	  93%,	  the	  degree	  of	   	  uncert-­‐
ainty	   being	   due	   to	   two	   cases	   (one	   case	   in	   each	  
group,	  Figure	  7).	  The	  results	  of	  the	  study	  revealed	  
an	   abnormal	   bioenergetics	   in	   MSA	   and	   a	  
decreased	  cytosolic	  [Mg2+]	  content	  in	  PD,	  offering	  
a	   new	   diagnostic	   tool	   that	   may	   help	   to	   differ-­‐
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Magnesium	  (Mg2+)	  is	  the	  fourth	  most	  abundant	  cation	  in	  the	  whole	  body	  and	  the	  second	  most	  abundant	  
cation	   within	   the	   cell.	   Numerous	   cellular	   functions	   and	   enzymes,	   including	   ion	   channels,	   metabolic	  
cycles,	   and	   signalling	   pathways	   are	   regulated	   by	  Mg2+.	   Our	   understanding	   of	   how	   cells	   regulate	  Mg2+	  
homeostasis	  and	  transport	  has	  registered	  significant	  progress	  in	  recent	  time.	  Yet,	  several	  aspects	  of	  Mg2+	  
homeostasis	   within	   cellular	   organelles,	   and	   the	   nature	   of	   the	   Mg2+	   extrusion	   mechanisms	   at	   the	   cell	  
membrane,	   are	   still	   undefined.	   The	   present	   work	   attempts	   to	   provide	   a	   comprehensive	   and	   updated	  
review	  of	   the	  mechanisms	   regulating	   cellular	  Mg2+	   homeostasis	   in	   eukaryotic	   cells	   under	   physiological	  





Mammalian	   cells	   contain	   high	   concentrations	   of	  
total	   and	   free	   magnesium	   ion	   (Mg2+).	   These	  
concentrations	   are	   essential	   to	   regulate	  
numerous	   cellular	   functions	   and	   enzymes,	  
including	   ion	   channels,	   metabolic	   cycles,	   and	  
signalling	  pathways.	  While	  the	  increasing	  number	  
of	  observations	  supports	  a	  key	  regulatory	  role	  for	  
Mg2+	   within	   the	   cell,	   our	   understanding	   of	   how	  
Mg2+	  homeostasis	  is	  regulated	  at	  the	  cellular	  and	  
subcellular	  level	  remains	  sketchy	  and	  incomplete.	  
There	   are	   both	   conceptual	   and	   methodological	  
reasons	  for	  this	  limitation.	  The	  relative	  slow	  turn-­‐
over	   of	   Mg2+	   across	   the	   plasma	   membrane	   or	  
other	   biological	   membranes	   in	   the	   absence	   of	  
metabolic	   and	   hormonal	   stimuli,	   the	   absolute	  
abundance	  of	  total	  and	  free	  Mg2+	  within	  the	  cell,	  
and	  the	  limited	  occurrence	  of	  significant	  changes	  
in	  free	  [Mg2+]	  have	  all	  contributed	  for	  a	  long	  time	  
to	  the	  assumption	  that	  cellular	  Mg2+	  concentration	  
does	  not	  change	  significantly,	  and	   is	   consistently	  
at	  a	   level	  adequate	   for	   its	   role	  as	  a	  co-­‐factor	   for	  
various	   cellular	   enzymes	   and	   proteins.	  
Consequently,	   this	   conceptual	   assumption	   has	  
limited	   the	   interest	   to	   develop	   techniques	   and	  
methodologies	   able	   to	   rapidly	   and	   accurately	  
quantify	   changes	   in	   cellular	  Mg2+	   content.	   In	   the	  
last	  two	  decades,	  however,	  an	  increasing	  number	  
of	   experimental	   and	   clinical	   observations	   have	  
challenged	   this	   assumption.	   More	   than	   1000	  
entries	   in	   the	   literature	   highlight	   the	   regulatory	  
role	   of	   Mg2+	   on	   various	   cellular	   functions	   and	  
cycles,	   and	   indicate	   the	   occurrence	   of	   major	  
fluxes	   of	   Mg2+	   across	   the	   plasma	   membrane	   of	  
various	   mammalian	   cells	   under	   a	   variety	   of	  
metabolic	   or	   hormonal	   stimuli.	   In	   turn,	   these	  
fluxes	   have	   resulted	   in	   appreciable	   changes	   in	  
cytosolic	   free	   [Mg2+]	   and	   total	   Mg2+	   content	  
within	   the	   cell	   and	   cellular	   organelles.	  
Furthermore,	   genetic	   and	   electrophysiological	  
approaches	   in	   bacteria,	   yeast	   and	   mammalian	  
cells	   have	   identified	   several	   Mg2+	   entry	  
mechanisms	   that	   operate	   either	   at	   the	   cell	  
membrane	   level	   or	   in	   the	  membrane	   of	   cellular	  
organelles	  such	  as	  mitochondria	  and	  Golgi.	  At	  the	  
same	   time,	   the	   increased	   interest	   in	   biological	  
functions	   regulated	   by	   Mg2+	   has	   stimulated	   the	  
development	   of	   methodological	   approaches	  
aimed	   at	   better	   detecting	   and	   quantifying	  
variations	   in	   cellular	   Mg2+	   level,	   and	   renewed	  
interest	   in	   relating	   alterations	   in	   Mg2+	   homeo-­‐
stasis	  with	   the	   onset	   of	   specific	   pathologies	   and	  
complications	   in	   human	   patients.	   All	   these	  
different	  aspects	  will	  be	  elucidated	  in	  the	  present	  
review	  to	  provide	  a	  framework	  as	  comprehensive	  
as	   possible	   to	   correlate	   changes	   in	   cellular	  Mg2+	  
homeostasis	   and	   content	   with	   variations	   in	   the	  
function	   of	   specific	   enzymes,	   which	   ultimately	  
affect	   the	   modus	   operandi	   of	   different	   cellular	  
organelles	  and	  cell	  types.	  
	  
Cellular	  Mg2+	  distribution	  
	  
Direct	  and	  indirect	  measurement	  of	  total	  cellular	  
Mg2+
	  
content	   by	   various	   techniques	   consistently	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indicates	   that	   total	   Mg2+	   concentration	   ranges	  
between	   17	   to	   20mM	   in	   the	   majority	   of	  
mammalian	   cell	   types	   examined	   (Romani	   and	  
Scarpa,	   1992;	  Wolf	  et	   al.,	   2003).	  Determinations	  
of	  total	  and	  free	  Mg2+	  concentrations	  by	  electron	  
probe	   X-­‐rays	   microanalysis	   (EPXMA),	   31P-­‐NMR,	  
selective	   Mg2+-­‐electrode,	   13C-­‐NMR	   citrate/iso-­‐
citrate	   ratio	   or	   fluorescent	   indicators	   (Table	   I	   in	  
Romani	   and	   Scarpa,	   1992,	   and	   in	   Wolf	   and	  
Cittadini,	   2003)	   localize	   major	   amounts	   of	   Mg2+	  
within	   mitochondria,	   nucleus,	   and	   endo-­‐(sarco)-­‐
plasmic	   reticulum,	   with	   total	   concentrations	  
ranging	   between	   15	   to	   18	  mM	   in	   each	   of	   these	  
organelles.	   Binding	   of	   Mg2+	   by	   phospholipids,	  
proteins,	   nucleic	   acids,	   chromatin	   and	  
nucleotides	   has	   been	   invoked	   to	   explain	   the	  
persistence	   of	   such	   a	   high	   Mg2+	   concentration	  
within	   these	   organelles.	   Although	   the	   specific	  
modality	   and	   nature	   of	   these	   bindings	   have	   not	  
been	   fully	   investigated,	   experimental	   evidence	  
indicates	  that	  only	  a	  small	  fraction	  of	  such	  a	  large	  
Mg2+	   content	   is	   actually	   free	   in	   the	   lumen	   of	  
these	   structures.	   Concentrations	   of	   0.8	   and	   1.2	  
mM	   free	   [Mg2+]	   have	   been	   measured	   in	   the	  
matrix	  of	  cardiac	  and	   liver	  mitochondria	   (Jung	  et	  
al.,	  1990;	  Rutter	  et	  al.,	  1990).	  No	  determinations	  
of	   free	   [Mg2+]	   are	   available	   for	   the	   nucleus	   and	  
the	   endo-­‐(sarco)-­‐plasmic	   reticulum.	   The	   porous	  
structure	   of	   the	   nuclear	   envelope	   makes	   it	  
reasonable	   to	  envision	  that	   the	   intranuclear	   free	  
[Mg2+]	  is	  similar	  to	  the	  concentration	  measured	  in	  
the	   cytoplasm.	   The	   free	   [Mg2+]	  within	   the	   endo-­‐
(sarco)-­‐plasmic	   reticulum	   lumen	   cannot	   be	  
reliably	   determined	   due	   to	   the	   elevated	   milli-­‐
molar	   concentration	   of	   Ca2+	   inside	   the	   organelle	  
(Somlyo	  et	  al.,	  1985),	  and	  the	  high	  affinity	  of	  the	  
fluorescent	   dyes	  Mag-­‐Fura	   or	  Mag-­‐Indo	   for	   Ca2+	  
(50mM)	   as	   compared	   to	   Mg2+	   (1.5	   mM)	   (Hofer	  
and	  Machen,	  1993).	  A	   third	  considerable	  pool	  of	  
Mg2+	  (~4-­‐5mM)	  is	  present	  in	  the	  cytoplasm	  in	  the	  
form	  of	  a	  complex	  with	  ATP,	  and	  other	  phospho-­‐
nucleotides	  and	  phosphometabolites	  (Scarpa	  and	  
Brinley,	  1981).	  Because	  of	  its	  abundance	  (~	  5mM)	  
and	   Mg2+	   binding	   affinity	   (Kd	   ~78µM),	   ATP	  
constitutes	   the	   largest	   metabolic	   pool	   able	   to	  
bind	   Mg2+	   within	   the	   cytoplasm	   and	   the	   mito-­‐
chondria	  matrix	   as	   well	   (Luthi	   et	   al.,	   1999).	   The	  
binding/buffering	   capacity	   of	   ATP,	   phospho-­‐
nucleotides	   and	   phosphometabolites,	   and	  
possibly	  proteins,	  maintains	   cytosolic	   free	   [Mg2+]	  
between	   0.5-­‐1mM,	   or	   less	   than	   5%	   of	   total	  
cellular	  Mg2+	  content	  in	  almost	  all	  the	  cells	  and	  
tissues	   examined	   (Table	   I	   in	  Romani	   and	   Scarpa,	  
1992).	   Similar	   values	   have	   been	   obtained	   using	  
fluorescent	   dyes,	   31P-­‐NMR	   and	   citrate/isocitrate	  
ratio	   (Romani	   and	   Scarpa,	   1992).	   Overall,	   these	  
results	   support	   the	   presence	   of	   a	   very	   limited	  
chemical	  Mg2+
	  
gradient	  across	  the	  cell	  membrane,	  
and	   across	   the	  membrane	   of	   cellular	   organelles.	  
In	  erythrocytes,	  which	  lack	  cellular	  Mg2+	  compart-­‐
mentation,	   Flatman	   and	   Lew	   (1981)	   have	  
observed	   three	   kinetically	   distinct	   binding	   pools	  
for	   Mg2+:	   a	   low	   capacity,	   high	   affinity	   pool	  
represented	  by	   cell	  proteins,	   and	   two	  pools	   that	  
correspond	   reasonably	   well	   to	   ATP	   and	   2,3-­‐
diphosphoglycerate	   (2,3-­‐DPG)	   respectively	  
(Gunther	   et	   al.,	   1995).	   This	   model	   has	   been	  
further	   refined	   by	   Raftos	   et	   al.,	   (1999)	   to	   take	  
into	   account	  Mg2+	   binding	   by	   hemoglobin	   under	  
oxygenated	  and	  not	  oxygenated	  conditions.	  
	  
Limited	   information	   is	  available	  about	   the	  ability	  
of	   proteins	   to	   bind	   Mg2+	   within	   the	   cell	   and	  
cellular	  organelles.	  Aside	  from	  calmodulin	  (Oki	  et	  
al.,	   1997),	   troponin	   C	   (Wang	   et	   al.,	   1998),	  
parvalbumin	   (Allouche	   et	   al.,	   1999),	   and	   S100	  
protein	   (Ogoma	   et	   al.,	   1992),	   there	   is	   no	  
indication	  as	  to	  whether	  other	  cytosolic	  or	   intra-­‐
organelle	   proteins	   can	   bind	   substantial	   amounts	  
of	  Mg2+	   and	   contribute	   to	   the	   elevated	   concen-­‐
trations	   of	   total	   Mg2+	   measured	   within	   the	  
mitochondria	   or	   discrete	   regions	   of	   the	   endo-­‐
(sarco)-­‐plasmic	   reticulum.	   An	   early	   report	   by	  
Bogucka	  and	  Wojitczak	  (1971)	  has	  suggested	  the	  
presence	  of	   two	  proteins	  able	   to	  bind	  Mg2+	  with	  
high	   affinity/low	   capacity	   and	   high	   capacity/low	  
affinity,	   respectively,	   in	   the	   intermembraneous	  
space	   of	   the	   mitochondrion.	   However,	   no	  
subsequent	   study	   has	   confirmed	   their	   presence	  
or	   identified	   the	   proteins.	   The	   presence	   of	  Mg2+	  
binding	  sites	  has	  been	  indicated	  for	  several	  other	  
cellular	   proteins,	   but	   no	   clear	   information	   is	  
available	   as	   to	   whether	   these	   proteins	   do	   bind	  
Mg2+	  under	  basal	  conditions	  and	  whether	  binding	  
changes	   to	   a	   significant	   extent	   following	  
hormonal	   or	  metabolic	   stimuli,	   or	   under	   pathol-­‐
ogical	   conditions.	   Moreover,	   the	   potential	  
physiological	  relevance	  of	  Mg2+	  binding	  by	  any	  of	  
the	   mentioned	   proteins	   has	   been	   called	   into	  
question	   by	   the	   observation	   that	   parvalbumin	  
null	   mice	   do	   not	   exhibit	   hypomagnesaemia	   or	  
significant	   changes	   in	   tissue	   Mg2+	   handling	   and	  
homeostasis	  (Belge	  et	  al.,	  2007).	  
	  
Taking	   into	   account	   the	   cellular	   distribution	   and	  
assuming	   a	   Mg2+	   concentration	   in	   plasma	   and	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extracellular	   fluid	   of	   1.2-­‐1.4	   mM,	   one-­‐third	   of	  
which	   is	   binding	   extracellular	   proteins	   (e.g.	  
albumin)	   or	   other	   biochemical	   moieties	   (Geigy,	  
1984),	   it	  appears	   that	  most	  mammalian	  cells	  are	  
at	  or	  near	  zero	  trans	  condition	  as	   far	   it	  concerns	  
the	  chemical	  free	  [Mg2+]	  concentration	  across	  the	  
cell	   membrane	   or	   the	   biomembrane	   of	   cellular	  
organelles	   (e.g.	   mitochondria).	   Because	   the	  
electrochemical	  equilibrium	  potential	   for	   cellular	  
free	   [Mg2+]	   is	   approximately	   50mM	   in	   most	  
mammalian	   cells	   under	   resting	   conditions	  
(Flatman,	   1984),	   it	   is	   evident	   that	   mechanisms	  
must	   operate	   in	   the	   cell	  membrane	   to	  maintain	  
cytosolic	  free	  Mg2+
	  
and	  total	  cellular	  Mg2+	  content	  
within	  the	  measured	  levels.	  	  
	  
Mg2+	  transport	  mechanisms	  
	  
Eukaryotes	   retain	   their	   cellular	   Mg2+	   content	  
virtually	  unaltered	  under	   resting	  conditions	  even	  
when	  exposed	  to	  a	  significant	  gradient	  across	  the	  
cell	   membrane	   (e.g.	   culturing	   in	   virtually	   zero	  
extracellular	   Mg2+	   content)	   (Wolf	   et	   al.,	   2003;	  
Romani,	   2007).	   Atomic	   absorbance	   spectro-­‐
photometry	   determinations	   and	   radioisotopic	  
equilibrium	   indicate	  Mg2+	   turnover	   rates	   ranging	  
from	  1	  hour	  (adipocytes)	  to	  several	  days	  (lymph-­‐
ocytes)	   as	   a	   result	   of	   structural	   and	   functional	  
specificity	   of	   different	   tissues	   and	   cells	   (Romani,	  
2007).	   Within	   the	   same	   cell	   types	   discrepancies	  
can	   be	   observed	   based	   upon	   the	   experimental	  
conditions	   or	   the	  modality	   of	   isolation,	   e.g.	   cells	  
in	   situ	   versus	   freshly	   isolated	  cells	  versus	  cells	   in	  
culture.	   For	   example,	   cardiac	   ventricular	   myo-­‐
cytes	   attain	   28Mg	   equilibrium	   within	   3	   hours	   in	  
the	   whole	   animal	   but	   require	   72-­‐80	   hours,	   as	  
dispersed	   cells	   incubated	   at	   37oC,	   or	   even	   a	  
longer	   period	   of	   times	   when	   exposed	   to	   20oC	  
(Polimeni	   and	   Page,	   1974;	   Rogers	   et	   al.,	   1960;	  
Rogers,	   1961).	   Lymphocytes	   also	   present	  
differences	   in	   amplitude	   (or	   operation)	   of	   Mg2+	  
transport	  depending	  on	  whether	  they	  are	  freshly	  
isolated	   (Wolf	  et	   al.,	   1997)	   or	   cultured	   (Maguire	  
and	  Erdos,	  1978)	  cells.	  	  
	  
For	  a	  long	  time,	  the	  slow	  Mg2+	  turnover	  observed	  
in	   various	   tissues	  or	   cells	   has	   contributed	   to	   the	  
erroneous	   idea	   that	  Mg2+	   content	   in	  mammalian	  
cells	  does	  not	  change,	  or	  changes	  at	  such	  a	  slow	  
pace	  that	  it	  lacks	  physiological	  significance.	  In	  the	  
last	   twenty	   years,	   this	   notion	   has	   been	  
completely	   reverted	   by	   a	   large	   body	   of	  
experimental	  evidence,	  which	  indicates	  that	  large	  
fluxes	  of	  Mg2+	  can	  cross	  the	  plasma	  membrane	  of	  
eukaryotic	   cells	   within	   minutes	   from	   the	  
application	   of	   metabolic	   or	   hormonal	   stimuli,	  
with	   relatively	   small	   changes	   in	   free	   Mg2+	   level	  
(Romani,	   2007;	   Grubbs	   and	   Maguire,	   1987;	  
Romani	   and	   Scarpa,	   2000;	   Romani	   and	  Maguire,	  
2002).	   Lymphocytes	   (Gunther	   and	   Vormann,	  
1990;	  Wolf	  et	  al.,	  1997),	  erythrocytes	  (Matsuura,	  
1993),	   cardiac	  myocytes	   (Vormann	  and	  Gunther,	  
1987;	   Romani	   and	   Scarpa,	   1990a)	   and	   liver	   cells	  
(Jakob	   et	   al.,	   1989;	   Romani	   and	   Scarpa,	   1990b;	  
Gunther	  et	  al.,	   1991)	  are	   just	  a	   few	  examples	  of	  
the	  mammalian	  cells	   that	  have	  been	  reported	  to	  
extrude	   10%	   to	   20%	   of	   their	   total	   cellular	   Mg2+	  
content	   in	   less	   than	   10min	   from	   the	   application	  
of	  adrenergic	  or	  metabolic	  stimuli.	  The	  amplitude	  
and	   rapidity	   of	   these	   fluxes	   presuppose	   the	  
presence	   and	   operation	   of	   powerful	   transport	  
mechanisms	  able	  to	  move	  large	  amounts	  of	  Mg2+	  
in	   and	   out	   of	  mammalian	   cells	   following	   various	  
stimuli	   (for	   a	   list	   of	   experimental	   models	   and	  
conditions	   see	   Romani	   and	   Scarpa,	   2000).	   In	  
addition,	   the	  operation	  of	  Mg2+	   entry	  mechanisms	  
appears	   to	   be	   tightly	   coupled	  with	   the	   ability	   of	  
the	   cell	   to	   rapidly	   and	   efficiently	   buffering	   the	  
magnesium	   ions	   accumulated,	   as	   suggested	   by	  
the	  limited	  changes	  in	  cytosolic	  free	  [Mg2+]i	  in	  the	  
large	  majority	   of	   conditions	   tested	   (Fatholahi	   et	  
al.,	  2000;	  Kubota	  et	  al.,	  2005).	  	  
	  
The	  Mg2+	  transport	  mechanisms	  operating	  at	  the	  
level	  of	  the	  cell	  membrane	  or	  in	  the	  membrane	  of	  
cellular	   organelles	   are	   represented	   by	   channels	  
and	   exchangers.	   While	   channels	   are	  
predominantly	   involved	   in	   Mg2+	   accumulation,	  
exchangers	   mediate	   essentially	   Mg2+	   extrusion.	  
The	   majority	   of	   recently	   identified	   Mg2+	   entry	  
mechanisms	   operate	   in	   the	   cell	   membrane	   but	  
two	   of	   them	   have	   been	   located	   in	   the	  
mitochondrial	   membrane	   and	   the	   Golgi	   system,	  
respectively.	   For	   the	   most	   part,	   these	   entry	  
mechanisms	   present	   a	   modest	   selectivity	   for	  
Mg2+,	   and	   do	   not	   appear	   to	   be	   involved	   in	  Mg2+	  
extrusion.	   No	   information	   is	   currently	   available	  
about	   the	   mechanisms	   that	   contribute	   to	  
maintain	   an	   elevated	  Mg2+	   concentration	   within	  
the	   lumen	   of	   the	   endoplasmic	   (sarcoplasmic)	  
reticulum.	  	  
	  
What	   it	   follows	   is	   a	   general	   description	   of	   our	  
current	   knowledge	   about	   the	   channels	   and	  
exchangers	   involved	   in	   Mg2+	   transport	   across	  
biological	  membranes	  (summarized	  in	  Table	  1).	  	  




Magnesium	   ions	   enter	   the	   cell	   via	   channels	   or	  
channel-­‐like	   mechanisms.	   Channels	   able	   to	  
transport	  Mg2+	   into	   the	   cell	   have	  been	  originally	  
described	   in	   prokaryotes	   (Kehres	   et	   al.,	   1998;	  
Moncrief	   and	   Maguire,	   1999),	   including	   proto-­‐
zoans	   (Preston,	   1990),	   but	   recently	   several	  Mg2+	  
entry	  mechanisms	  with	  channels	  or	  channels-­‐like	  
features	  have	  been	   identified	   in	  eukaryotic	  cells.	  
Some	   of	   these	   mechanisms	   exhibit	   a	   relatively	  
high	   specificity	   for	   Mg2+	   but	   they	   can	   permeate	  
other	   divalent	   cations	   as	   well.	   Whereas	   the	  
majority	  of	  these	  channels	  are	  located	  in	  the	  cell	  
membrane	  or	  perhaps	  translocate	  between	  early	  
endosomal	  vesicles	  and	  the	  cell	  membrane,	  other	  
are	   specifically	   located	   in	   the	   mitochondrial	  
membrane	  or	  in	  the	  Golgi	  cysternae.	  Because	  the	  
identification	   and	   characterization	   of	   these	  
eukaryotic	  Mg2+	  transporting	  channels	  is	  far	  from	  
being	   complete,	   information	   relative	   to	   their	  
regulation	   is	   still	   largely	   fragmentary.	   The	  
abundance	   of	  mechanisms	   favouring	  Mg2+	   entry	  
into	   the	   cell	   also	   raises	   the	   question	   as	   to	  what	  
extent	   the	   different	   mechanisms	   cooperate	   to	  
modulate	   Mg2+	   entry	   or	   exert	   an	   absolute	   (or	  
relative	  predominance)	  in	  specific	  cells	  under	  well	  
defined	  conditions.	  	  
	  
TRPM	  Channels	  
TRPM7	   (Nadler	   et	   al.,	   2001)	   and	   TRPM6	  
(Schlingmann	  et	  al.,	  2002)	  were	  the	  first	  channels	  
identified	   as	   being	   able	   to	   transport	   Mg2+	   into	  
mammalian	   cells.	   While	   Fleig	   and	   her	   group	  
(Nadler	  et	  al.,	  2001)	  reported	  a	  preferential	  Mg2+	  
permeation	   through	   the	   LTRPC7	   channel	   (i.e.	  
TRPM7	   based	   on	   the	   current	   nomenclature),	  
genetic	   analysis	   (Schlingmann	   et	   al.,	   2002)	  
indicated,	   more	   or	   less	   at	   the	   same	   time,	   that	  
TRPM6,	   another	   member	   of	   the	   melastatin	  
subfamily	   of	   TRP	   channels,	   exhibits	   a	   selective	  
Mg2+	   permeation.	   At	   variance	   of	   the	   ubiquitous	  
nature	   of	   TRPM7,	   TRMP6	   is	   specifically	   localized	  
in	   the	   colon	   and	   the	   distal	   convolute	   tubule	   of	  
the	   nephron,	   a	   distribution	   that	   strongly	  
emphases	  the	  role	  of	  TRPM6	  in	  controlling	  whole	  
body	  Mg2+	   homeostasis	   via	   intestinal	   absorption	  
and	  renal	  resorption.	  In	  contrast,	  it	  would	  appear	  
that	   TRPM7	   is	   more	   in	   control	   of	   Mg2+	  
homeostasis	  in	  individual	  cells.	  
	  
The	   original	   observations	   have	   led	   to	   a	   flurry	   of	  
studies	   aimed	   at	   better	   understanding	   the	   role,	  
regulation	  and	  interaction	  of	  these	  channels	  with	  
other	   cellular	   components	   involved	   to	   a	   varying	  
degree	   in	  Mg2+	  homeostasis,	  and	  presently	  more	  
than	  190	  publications	  relative	  to	  TRPM7	  and	  110	  
publications	   relative	   to	   TRPM6	   can	   be	   found	   in	  
the	   literature.	   Although	   sharing	   several	   similarities	  
in	   terms	   of	   structure	   and	   operation,	   these	   two	  
channels	   differ	   in	   various	   aspects	   ranging	   from	  
location	  to	  hormonal	  modulation.	  
	  
•	  TRPM7	   	  
The	  key	   role	  of	  TRPM7	   in	   transporting	  Mg2+	   into	  
cells	   and	   modulating	   cell	   growth	   was	   first	  
evidenced	   by	   Nadler	   et	   al.,	   (2001).	   At	   the	   time,	  
the	  channel	  was	  identified	  as	  LTRPC7	  or	  long	  TRP	  
channel	  7	  owing	  to	  the	  presence	  of	  a	  particularly	  
long	   extension	   outside	   the	   channel	   segment	  
(Yamaguchi	  et	  al.,	  2001).	  Due	  to	  the	  presence	  of	  
an	   alpha-­‐kinase	   domain	   at	   the	   C-­‐terminus	  
(Ryazanova	   et	   al.,	   2001)	   and	   its	   functional	  
homology	   to	   eEF2-­‐kinase	   (Ryazanov,	   2002),	   this	  
protein	   was	   already	   known	   as	   CHAK1	   (channel	  
kinase	   1)	   (Ryazanova	   et	   al.,	   2001).	   Shortly	   after	  
the	  observation	  of	  Nadler	  et	  al.,	  (2001),	  Runnels	  et	  
al.,	   (2001)	   evidenced	   the	   peculiar	   structure	   of	  
TRPM7,	   combining	   a	   channel	   structure	   with	   an	  
alpha-­‐kinase	  domain	  at	  the	  C-­‐terminus.	  Although	  
originally	   investigated	   for	   a	   possible	   role	   in	   Ca2+	  
signalling	   in	   lymphocyte,	   it	   became	   rapidly	  
apparent	   that	   the	   channel	   would	   preferentially	  
carry	  Mg2+	  and	  Ca2+	  (Nadler	  et	  al.,	  2001)	  but	  also	  
trace	  amounts	  of	  divalent	  cations	  such	  as	  Ni2+	  and	  
Zn2+	   (Bessac	   and	   Fleig,	   2007;	   Monteilh-­‐Zoller	   et	  
al.,	  2003).	  	  	  
	  
Located	   on	   the	   human	   chromosome	   15	   at	   the	  
locus	  15q21,	  the	  protein	  is	  formed	  by	  1865	  amino	  
acids	   arranged	   to	   possibly	   form	   10	   trans-­‐
membrane	   domains,	   with	   both	   the	   C-­‐	   and	   N-­‐	  
termini	   internalized.	   The	   protein	   is	   ubiquitously	  
expressed	   albeit	   to	   a	   varying	   extent	   in	   all	  
mammalian	   cells	   tested	   so	   far.	   The	   functional	  
structure	   is	   supposed	   to	   be	   a	   tetramer	   but	  
disagreement	  exists	  as	  to	  whether	  it	  is	  formed	  by	  
4	   identical	   monomers	   or	   by	   a	   combination	   of	  
TRPM7	   and	   TRPM6	   (see	   following	   section)	  
arranged	  with	  a	  varying	  stoichiometry	  in	  different	  
portion	  of	   the	  cell	  membrane	  or	   in	  different	   cell	  
types.	   Voets	   and	   colleagues	   reported	   the	  
functional	  expression	  of	  TRPM6	  channels	  in	  HEK-­‐
293	   cells	   with	   electrophysiological	   properties	  
similar	  to	  those	  of	  TRPM7	  (Voets	  et	  al.,	  2004).	  In	  
contrast,	   Chubanov	   et	   al.,	   (2004)	   reported	   the	  




Table	  1.	  Mg2+	  transporters	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Schlingmann	  et	  al.,	  2002	  
Nadler	  et	  al.,	  2001	  
	  







Simon	  et	  al.,	  1999	  
Hou	  et	  al.,	  2009	  
	   MagT1	   MagT1	   0.2	  mM	   Channel	   Goytain	  and	  Quamme,	  2005a	  
Zou	  and	  Clapham,	  2009	  
	  
	   SLC41	   SLC41A1	  
SLC41A2	  
0.7	  -­‐	  3	  mM	  
0.7	  -­‐	  3	  mM	  
Carrier	  
Carrier	  
Goytain	  and	  Quamme,	  2005b	  
Goytain	  and	  Quamme,	  2005c	  
Sahni	  et	  al.,	  2007	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  et	  al.,	  2008a	  
 









Goytain	  et	  al.,	  2008b 
Goytain	  et	  al.,	  2008b 
Mitochondria	   	   Mrs2	   Mrs2/AtMrs2,	  Lpe10	   ~1.5	  mM	   Channel	   Koliske	  et	  al.,	  2003	  
	  






Goytain	  and	  Quamme,	  2008 










	   	   	   	   	  
	  	  	  Cell	  Membrane	   Na+/Mg2+	  exchanger	   ND	   15-­‐20	  mM	   Antiport	   Gunther	  and	  Vormann,	  1984	  
Tashiro	  and	  Konishi,	  1997	  
Cefaratti	  et	  al.,	  1998	  
	  
	   Na+-­‐	  independent	   ND	  (choline?)	   ~20mM	   Exchanger	  (?)	   Ebel	  et	  al.,	  2002	  
	  
	   SLC41	   SLC41A1	   ~0.7	  mM	   Carrier	   Kolisek	  et	  al.,	  2008	  
	  
	   H+/Mg2+	  exchanger	   AtMHX#	   ~15mM	   Exchanger	   Shaul	  et	  al.,	  1999	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when	   the	  channel	   is	  expressed	  by	   itself	   in	  either	  
HEK-­‐293	  cells	  or	  X.	  Laevis	  oocytes,	  and	  suggested	  
that	   TRPM7	   co-­‐expression	   was	   required	   for	  
TRPM6	  to	   incorporate	   into	  channel	  complexes	  at	  
the	   plasma	   membrane	   level.	   Schmitz	   et	   al.,	  
(2005)	  subsequently	  confirmed	  the	  association	  of	  
TRPM6	  and	  TRPM7	  channel	   proteins	   to	  obtain	   a	  
functional	   structure.	   Yet,	   a	   detailed	   functional	  
characterization	   of	   the	   TRPM6/7	   chimeric	  
channel	   remained	   undefined	   (Chubanov	   et	   al.,	  
2005)	   until	   Yue	   and	   collaborators	   addressed	   the	  
issue	  in	  two	  elegant	  electro-­‐physiology	  studies	  (Li	  
et	  al.,	  2006;	  Li	  et	  al.,	  2007).	   In	  these	  studies,	   the	  
authors	  demonstrate	  that	  TRPM6	  and	  TRPM7	  can	  
indeed	  form	  a	  chimeric	  heterotetramer,	  and	  that	  
TRPM6,	   TRPM7,	   and	   TRPM6/7	   constitute	   three	  
distinct	   ion	   channels	   with	   different	   divalent	  
cation	   permeability,	   pH	   sensitivity,	   and	   unique	  
single	   channel	   conductance.	   In	   addition,	   these	  
authors	   reported	   that	   2-­‐APB	   can	   differentially	  
regulate	  the	  channel	  activities	  of	  TRPM6,	  TRPM7,	  
and	  TRPM6/7,	  markedly	  increasing	  Mg2+	  and	  Ca2+	  
entry	   through	   TRPM6	   (Li	   et	   al.,	   2006).	   Based	   on	  
these	   results,	   it	   would	   then	   appear	   that	   TRPM6	  
can	   form	   either	   functional	   homotetrameric	  
channels	  or	  hetero-­‐tetrameric	  TRPM6/7	  channels	  
(Gwanyanya	   et	   al.,	   2004).	   A	   corollary	   of	   this	  
observation	   would	   be	   that	   TRPM6,	   TRPM7,	   and	  
TRPM6/7	  channels	  may	  play	  different	  roles	  under	  
various	  physiological	  or	  pathological	  conditions	  in	  
different	   tissues.	   A	   detailed	   mapping	   of	   the	  
distribution	   of	   homomeric	   TRPM7	   versus	  
heteromeric	  TRPM6/7	  channels	  in	  various	  tissues,	  
however,	   is	  still	   lacking,	   leaving	  their	  relative	  role	  
largely	  undefined.	  
	  
More	   recently,	   some	   light	  has	  been	   shed	  on	   the	  
modality	   of	   TRPM7	   regulation.	   At	   the	   direct	  
channel	  level,	  TRPM7	  inward	  current	  is	  markedly	  
enhanced	   by	   protons,	   which	   compete	   with	   Ca2+	  
and	  Mg2+	  for	  binding	  sites,	  most	  likely	  at	  the	  level	  
of	   the	   channel	   pore,	   thereby	   releasing	   the	  
blockade	   of	   divalent	   cations	   on	   inward	   mono-­‐
valent	  currents	  (Bessac	  and	  Fleig,	  2007;	  Monteilh-­‐
Zoller	  et	  al.,	  2003).	  Not	  only	  extracellular	  protons	  
significantly	   increased	   monovalent	   cation	  
permeability,	   but	   higher	   proton	   concentrations	  
are	   required	   to	   induce	   50%	  of	  maximal	   increase	  
in	   TRPM7	   currents	   under	   conditions	   in	   which	  
extracellular	   Ca2+	   and	   Mg2+	   concentrations	   are	  
increased.	  Following	   the	   increase	   in	  extracellular	  
H+	  concentration,	  in	  fact,	  the	  apparent	  affinity	  for	  
Ca2+	  and	  Mg2+	   is	  significantly	  diminished.	  This	  set	  
of	  observation	   suggests	   that	  at	  physiological	  pH,	  
Ca2+	   and	   Mg2+	   bind	   to	   TRPM7	   and	   inhibit	   the	  
monovalent	   cation	   currents.	   At	   higher	   H+	  
concentrations,	  instead,	  the	  affinity	  of	  TRPM7	  for	  
Ca2+	   and	   Mg2+	   is	   decreased,	   thus	   allowing	  
monovalent	   cations	   to	   permeate	   the	   channel	  
(Jiang	   et	   al.,	   2005).	   Another	   level	   of	   regulation	  
appears	   to	   be	   provided	   by	   PIP2,	   as	   initially	  
reported	   by	   Clapham	   and	   his	   collaborators	  
(Runnels	   et	   al.,	   2002).	   This	   observation	   was	   not	  
confirmed	   by	   Fleig’s	   group,	   which	   instead	  
reported	  a	  regulatory	  role	  by	  cAMP	  (Takezawa	  et	  
al.,	   2004).	  More	   recently,	   however,	   Langeslag	  et	  
al.,	   (2007)	   have	   observed	   that	   the	   depletion	   in	  
PIP2	   level	   resulting	   from	   PLC-­‐activation	  
counteracts	  TRPM7	  activation.	  It	  would	  therefore	  
appear	   that	   either	   PLC-­‐activation	   accelerates	  
TRPM7	   ‘rundown’	   via	   PIP2	   depletion	   or	   PIP2	  
depletion	  plays	  a	  feedback	  regulatory	  role	  on	  the	  
channel	  activation	  by	  PLC	  (Langeslag	  et	  al.,	  2007).	  
Additional	  evidence	  for	  a	  regulatory	  role	  by	  PIP2	  
on	   TRPM7	   has	   been	   provided	   by	   Mubagwa’s	  
group	   (Gwanyanya	  et	   al.,	   2006;	  Macianskiene	  et	  
al.,	   2008).	   This	   group,	   in	   fact,	   has	   reported	   that	  
inhibition	   of	   phospholipase	   C	   or	   addition	   of	  
exogenous	   PIP2	   decreases	   the	   run-­‐down	   of	   the	  
channel	   whereas	   the	   extracellular	   addition	   of	  
phenylephrine	  accelerates	  it	  (Macianskiene	  et	  al.,	  
2008).	   In	   addition,	   this	   group	   has	   observed	   that	  
both	   ATP	   (Gwanyanya	   et	   al.,	   2006)	   and	   non-­‐
hydrolysable	   GTP	   analogs	  modulate	   the	   channel	  
activity,	   most	   likely	   by	   forming	   MgATP	   and	   by	  
accelerating	   the	   channel	   run-­‐down	   via	  
phospholipase-­‐C	   activation,	   respectively	  
(Macianskiene	  et	   al.,	   2008).	   	   The	   regulatory	   role	  
of	   PIP2	   on	   TRPM7	   is	   further	   emphasized	   by	   the	  
experimental	   evidence	   that	   agonists	   like	  
bradykinin	   or	   angiotensin-­‐II,	   which	   activate	  
phospholipase-­‐C	   coupled	   receptors	   via	   Gq	  
signalling	   (Touyz	   et	   al.,	   2006;	   Langeslag	   et	   al.,	  
2007)	  can	  modulate	  the	  channel	  activity	  via	  PIP2	  
metabolism.	   Interestingly,	  TRPM7	  activation	  only	  
takes	   place	   in	   the	   presence	   of	   a	   physiological	  
cellular	   [Mg2+]i,	   whereas	   reducing	   this	   concen-­‐
tration	   below	   its	   physiological	   level	   with	   EDTA-­‐
AM	   results	   in	   a	   PLC-­‐mediated	   inactivation	   of	  
TRPM7	   activity,	   most	   likely	   via	   PIP2	   depletion	  
(Langeslag	  et	  al.,	  2007).	  	  
	  
The	   interaction	   between	   TRPM7	   and	  
phosphatidyl-­‐inositol	   metabolites	   is	   further	  
supported	   by	   the	   observation	   that	   TRPM7	   is	  
required	   for	   a	   sustained	   phosphoinositide-­‐3-­‐
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kinase	   signalling	   in	   lymphocytes	   (Sahni	   and	  
Scharenberg,	   2008).	   In	   the	   presence	   of	   a	  
physiological	  concentration	  of	  extracellular	  Mg2+,	  
TRPM7-­‐deficient	  cells	  rapidly	  down-­‐regulate	  their	  
rate	   of	   growth	   as	   a	   result	   of	   a	   signalling	  
deactivation	   downstream	   PI3-­‐Kinase	   (Sahni	   and	  
Scharenberg,	  2008),	  the	  phenotype	  being	  rescued	  
by	  supplementing	  the	  culture	  medium	  with	  Mg2+	  
(Sahni	  and	  Scharenberg,	  2008).	  	  
	  
A	  structural	  peculiarity	  of	  TRPM7	  is	  the	  presence	  
of	   an	   alpha-­‐kinase	   at	   the	   C-­‐terminus,	   which	  
specifically	  phosphorylates	  serine	  and	  threonines	  
located	   in	   an	   alpha-­‐helix	   (Middelbeek	   et	   al.,	  
2010).	   Initial	   experimental	   evidence	   (Runnels	   et	  
al.,	  2002)	   invoked	  an	  essential	  role	  of	  this	  kinase	  
domain	   in	   modulating	   channel	   activation	   and	  
gating.	   Subsequent	   studies,	   however,	   failed	   to	  
fully	   support	   this	   initial	   claim,	   as	   they	   indicated	  
that	   TRPM7	   channels	   lacking	   the	   kinase	   domain	  
could	  still	  be	  activated	  by	  internal	  Mg2+	  depletion	  
(Schmitz	   et	   al.,	   2003).	   One	   consequence	   of	  
lacking	   the	   kinase	   domain,	   however,	   is	   the	  
inability	   of	   properly	   phosphorylating	   and	  
consequently	   activating	   downstream	   cellular	  
components.	   Yet,	   little	   is	   know	   about	   the	  
molecular	   mechanisms	   activating	   the	   kinase	  
domain.	   A	   recent	   study	   by	   Clark	   et	   al.,	   (2006)	  
strongly	  suggests	  that	  autophosphorylation	  plays	  
a	   significant	   role	   in	   target	   recognition	   by	   the	  
TRMP7	  kinase	  domain.	  Phosphomapping	  by	  mass	  
spectrometry	   has	   confirmed	   the	   massing	  
autophosphorylation	   of	   TRPM7	   kinase	   domain,	  
which	  –	   in	   turn	  –	   increases	   the	   rate	  of	   substrate	  
phosphorylation.	   The	   phosphomapping	   has	   also	  
identified	   the	   majority	   (37	   out	   of	   46)	   of	   the	  
autophosphor-­‐ylation	   sites	   in	   a	   Ser/Thr	   rich	  
region	  immediately	  preceding	  the	  kinase	  catalytic	  
domain	  (Clark	  et	  al.,	  2008).	  Deletion	  of	  this	  region	  
does	   not	   affect	   the	   intrinsic	   catalytic	   activity	   of	  
the	   kinase	   but	   prevents	   substrate	  
phosphorylation,	   confirming	   the	   role	   of	   this	  
region	   in	   substrate	   recognition	   (Clark	   et	   al.,	  
2008).	   Although	   this	   Ser/Thr	   region	   is	   poorly	  
conserved	  at	  the	  amino	  acid	  sequence	  in	  TRPM6,	  
the	   kinase	   domain	   of	   this	   channel	   appears	   to	  
require	  a	  similar	  massive	  autophos-­‐phorylation	  of	  
its	   Sr/Thr	   residues	   for	   proper	   substrate	  
recognition	   and	   efficient	   target	   phosphorylation	  
(Clark	  et	  al.,	  2008).	  
	  
So	   far,	   only	   annexin	   I	   (Dorovkov	   and	   Ryazanov,	  
2004),	  myosin	  IIA	  heavy	  chain	  (Clark	  et	  al.,	  2008a;	  
Clark	  et	  al.,	   2008b),	  and	  calpain	   (Su	  et	  al.,	   2006)	  
have	   been	   clearly	   identified	   as	   substrates	  
phosphorylated	   by	   TRPM7	   kinase	   domain.	  
Although	   the	   number	   of	   targets	   is	   rather	  
restricted,	   it	   appears	   that	   TRPM7	   is	   playing	   a	  
double	   role	   within	   cells	   by	   regulating	   Mg2+	  
homeostasis	   on	   the	   one	   hand,	   and	   cellular	  
functions	  centered	  on	  cell	  adhesion,	  contractility	  
and	   (anti)-­‐inflammatory	   processes	   on	   the	   other	  
hand.	   This	   double	   role	   of	   TRPM7	  within	   cells,	   in	  
particular	  smooth	  muscle	  cells,	   is	  emphasized	  by	  
a	   recent	   observation	   by	   Touyz	   and	   colleagues	  
(Paravicini	  et	  al.,	  2009).	  In	  this	  study,	  the	  authors	  
report	   that	   aortic	   segments	   of	   mice	   exhibiting	  
low	   intracellular	   Mg2+	   levels	   present	   increased	  
medial	   cross-­‐section	   and	   increased	   TRPM7	  
expression	   but	   decreased	   levels	   of	   annexin-­‐I	  
expression.	   As	   annexin-­‐I	   has	   a	   major	   anti-­‐
inflammatory	  role	  (Parente	  and	  Solito,	  2004),	  the	  
results	   of	   this	   study	   suggest	   a	   potential	  
regulatory	   role	   of	   TRPM7	   in	   regulating	   vascular	  
structure	  and	  integrity,	  as	  well	  as	  inflammation.	  
	  
As	   our	   understanding	   of	   TRPM7	   expression	   and	  
regulation	   has	   improved,	   evidence	   of	   a	   major	  
functional	   role	   of	   the	   channel	   in	   neuronal	  
function	  and	  survival	  under	  hypoxia	  or	   ischemic-­‐
reperfusion	   conditions	   has	   increased.	   Owing	   to	  
its	  ability	  to	  transport	  either	  Ca2+	  or	  Mg2+,	  TRPM7	  
exhibits	   an	   ambivalent	   role	   based	   upon	   the	  
permeating	   cation.	   Following	   activation	   by	  
reactive	   oxygen/nitrogen	   species	   and	   prolonged	  
oxygen	   and	   glucose	   deprivation,	   TRPM7	   favours	  
Ca2+	  fluxes	  that	  result	  in	  a	  toxic	  event	  for	  neurons	  
(Aarts	  et	  al.,	  2003).	  In	  contrast,	  Mg2+	  permeation	  
of	   the	   channel	   enhances	  anti-­‐apoptotic	   and	   cell-­‐
survival	  mechanisms,	  preventing	  the	  anoxic	  death	  
of	  neurons	  (Clark	  et	  al.,	  2006).	  The	  essential	  role	  
of	   TRPM7	   in	   detecting	   extracellular	   divalent	  
cations	   is	  supported	  by	  a	  recent	  study	  by	  Wei	  et	  
al.,	   (2007),	  which	   indicates	   that	  activation	  of	   the	  
channel	   by	   low	   extracellular	   divalent	   cations	   is	  
lethal	   to	   the	   cell.	   At	   the	   same	   time,	   Jiang	  et	   al.,	  
(2008)	  have	  reported	  that	  occlusion	  of	  the	  middle	  
cerebral	   artery	   for	   1	   hour	   enhances	   TRPM7	  
expression	   in	   ipsilateral	   hippocampus,	   with	  
deleterious	   consequences	   for	   the	   neurons.	   The	  
increased	   expression	   of	   TRPM7	   and	   its	  
consequences	   are	   largely	   counteracted	   by	   pre-­‐
treatment	  with	  nerve	  growth	  factor	  via	  activation	  
of	   TrkA	   pathway	   (Jiang	   et	   al.,	   2008).	   More	  
recently,	   application	   of	   5-­‐lipoxygenase	   inhibitors	  
can	   block	   TRPM7	   current	   without	   affecting	  
Magnesium	  in	  the	  Central	  Nervous	  System	   	   Chapter	  2	  
	  
 21	  
protein	   expression	   and	   cell	   membrane	  
concentration,	   de	   facto	   preventing	   cell	   death	  
(Chen	  et	  al.,	  2010).	  	  	  
	  
The	  involvement	  of	  TRPM7	  is	  not	  restricted	  to	  the	  
sympathetic	   nervous	   system	   but	   extends	   to	   the	  
parasympathetic	   system	   as	   well,	   in	   which	   the	  
channel	   facilitates	   the	   fusion	   of	   cholinergic	  
vesicles	   with	   the	   plasma	   membrane	   without	  
affecting	   large	   dense	   core	   vesicle	   secretion	  
(Brauchi	  et	  al.,	  2008).	  	  
	  
Despite	   the	   data	   accumulated	   since	   its	  
identification	   as	   a	   preferential	   Mg2+	   channel,	   a	  
recent	   report	  by	  Clapham’s	  group	  has	  cast	  some	  
concern	   about	   the	   effective	   role	   of	   TRPM7	   in	  
regulating	  Mg2+	  homeostasis	   (Jin	  et	  al.,	   2008).	   In	  
their	  report,	  the	  authors	  indicate	  that	  TRPM7	  null	  
mouse	   present	   an	   altered	   embryonic	   develop-­‐
ment,	   and	   that	   tissue	   specific	   deletion	   of	   the	  
channel	   in	   T	   cell	   lineage	   disrupts	   thymopoiesis,	  
leading	   to	   the	   progressive	   depletion	   of	   thymic	  
medullary	  cells.	  Deletion	  of	  TRPM7,	  however,	  did	  
not	   affect	   acute	   accumulation	   of	   Mg2+	   nor	  
impacted	   total	   cellular	   Mg2+	   content	   in	   T	   cells.	  
The	  synthesis	  of	  several	  growth	  factors,	  however,	  
was	   significantly	   dysregulated,	   resulting	   in	   an	  
altered	   differentiation	   of	   thymic	   epithelial	   cells	  
(Jin	  et	  al.,	  2008).	  TRPM7,	  therefore,	  appears	  to	  be	  
the	   first	   TRP	   channel	  with	   a	   non-­‐redundant	   and	  
actually	   essential	   role	   in	   embryogenesis	   and	  
thymopoiesis.	   Whether	   these	   defects	   are	   the	  
result	   of	   an	   altered	   Ca2+	   rather	   than	   Mg2+	  
homeostasis	   is	   presently	   undefined.	   It	   is	   also	  
unclear	  how	  the	  removal	  of	  this	  protein	  results	  in	  
an	  altered	  cellular	  differentiation	  process.	  	  
	  
•	  	  TRPM6	  
The	  unique	  localization	  of	  TRPM6	  channels	  in	  the	  
colon	  and	   the	   renal	   distal	   convolute	   tubule,	   two	  
epithelia	  otherwise	  highly	  impermeable	  to	  salt	  re-­‐
absorption,	   highlights	   the	   specific	   role	   of	   this	  
channel	   in	   controlling	   intestinal	  Mg2+	   absorption	  
and	   renal	   Mg2+	   resorption,	   and	   consequently	  
contributing	  to	  whole-­‐body	  Mg2+	  homeostasis.	  
	  
The	  TRPM6	   gene	  was	   originally	   identified	   as	   the	  
site	   of	   various	   mutations	   responsible	   for	  
Hypomagnesaemia	   with	   Secondary	   Hypocal-­‐
caemia	  (HSH),	  a	  rare	  autosomal	  recessive	  disease	  
characterized	   by	   Mg2+	   and	   Ca2+	   wasting,	   whose	  
symptoms	  could	  be	  ameliorated	  by	  massive	  intra-­‐	  
venous	  Mg2+	  administration	  followed	  by	  oral	  Mg2+	  
supplementation	   (Schlingmann	   et	   al.,	   2002).	  
Surprisingly,	   while	   hypocalcaemia	   is	   completely	  
alleviated	   by	   this	   treatment,	   the	   patients	  
continue	  to	  present	  serum	  Mg2+	  level	  around	  0.5-­‐
0.6	  mmol/L,	  i.e.	  about	  half	  the	  physiological	  level	  
(Schlingmann	   et	   al.,	   2002).	   Because	   the	   primary	  
defect	   in	   these	   patients	   is	   at	   the	   level	   of	   the	  
TRPM6	   expressed	   in	   the	   intestine	   (Schlingmann	  
et	  al.,	  2002),	  the	  excess	  Mg2+	  supplementation	  is	  
rapidly	   filtered	   at	   the	   glomerular	   level	   and	  
increases	  passive	   renal	  absorption	  via	  paracellin-­‐
1	  (see	  next	  section).	  Trans-­‐cellular	  absorption	  via	  
renal	   TRPM6,	   however,	   remains	   depressed	   and	  
unable	   to	   restore	  physiological	   serum	  Mg2+	   level	  
(Schlingmann	  et	  al.,	  2002).	  	  
	  
At	   the	   functional	   level,	   experimental	   evidence	  
suggests	   that	   the	   channel	   forms	   a	   tetramer	  
within	  the	  plasma	  membrane.	  As	  indicated	  in	  the	  
previous	  section,	  questions	  remain	  as	  to	  whether	  
the	  channel	  forms	  a	  homo-­‐tetramer,	  or	  a	  hetero-­‐
tetramer	   with	   TRPM7,	   with	   a	   varying	   stoich-­‐
iometry.	   Irrespective	   of	   the	   possibilities,	   several	  
TRPM6	   mutations	   have	   been	   identified	   (Walder	  
et	   al.,	   2002).	   The	   majority	   of	   these	   mutations	  
result	   in	   the	   expression	  of	   a	   truncated	   and	  non-­‐
functional	   channel	   (Walder	   et	   al.,	   2002).	   The	  
missense	   mutation	   S141L,	   on	   the	   other	   hand,	  
occurs	   at	   the	   N-­‐terminus	   of	   the	   channel	   and	  
prevents	   its	   proper	   assembly	   as	   a	   homo-­‐
tetramer,	   or	   a	   hetero-­‐tetramer	   with	   TRPM7	  
(Walder	  et	  al.,	  2002).	  Another	  missense	  identified	  
in	   humans	   is	   the	   P1017R	  mutation	   (Walder	  et	   al.,	  
2002),	   which	   appears	   to	   occur	   in	   a	   region	  
putatively	   identified	   as	   the	   pore	   region	   of	   the	  
channel.	  Yet,	  this	  mutation	  affects	  negatively	  and	  
more	   significantly	   TRPM7	   function	   when	   this	  
protein	   is	   co-­‐expressed	   with	   TRPM6	   (Walder	   et	  
al.,	   2002).	  More	   recently,	   TRPM6	  null	  mice	  have	  
been	  developed	  by	  Sheffield	  and	  his	  collaborators	  
(Walder	  et	  al.,	  2009).	  The	  heterozygous	  Trpm6+/-­‐	  
have	   for	   the	  most	   part	   normal	   electrolyte	   levels	  
aside	   for	  a	  modest	   low	  plasma	  Mg2+	   level	   (~0.67	  
vs.	  0.75,	  (Walder	  et	  al.,	  2009).	  The	  majority	  of	  the	  
homozygous	   Trpm6-­‐/-­‐	   animals	   die	   by	   embryonic	  
day	  12.5.	  Most	  of	  the	  few	  animals	  that	  survive	  to	  
term	   present	   significant	   neural	   tube	   defects,	  
consisting	   primarily	   of	   both	   exencephaly	   and	  
spina	   bifida	   occulta.	   Administration	   of	   high	   Mg	  
diet	   to	   dams	   improves	   offspring	   survival	   to	  
weaning	  (Walder	  et	  al.,	  2009).	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A	   peculiarity	   TRPM6	   shares	   with	   TRPM7	   is	   the	  
presence	   of	   an	   alpha-­‐kinase	   domain	   at	   the	   C-­‐
terminus.	  Originally,	  TRPM6	  was	  known	  as	  CHAK2	  
(channel	   kinase	   2)	   (Ryazanov,	   2002)	   due	   to	   the	  
presence	  of	  this	  kinase	  domain,	  which	  presents	  a	  
functional	   homology	   to	   eEF2-­‐kinase	   (Ryazanov,	  
2002).	   At	   variance	   of	   other	   kinases,	   this	   domain	  
phosphorylates	   serine	   and	   threonine	   residues	  
located	   within	   an	   alpha-­‐helix	   instead	   of	   a	   beta-­‐
sheet	   (Ryazanova	   et	   al.,	   2001;	   Ryazanov,	   2002;	  
Middelbeek	   et	   al.,	   2010).	   Owing	   to	   their	   dual	  
function	   as	   a	   channel	   and	   a	   kinase,	   TRPM6	   and	  
TRPM7	  are	  currently	  referred	  to	  as	  chanzymes.	  As	  
in	   the	   case	   of	   TRPM7,	   removal	   of	   the	   kinase	  
domain	   does	   not	   abolish	   entirely	   the	   channel	  
activity	   but	   modulates	   the	   extent	   to	   which	   the	  
channel	  is	  regulated	  by	  intra-­‐cellular	  free	  Mg2+	  or	  
MgATP	   complex	   (Chubanov	  et	  al.,	   2004;	   Schmitz	  
et	  al.,	  2005;	  Chubanov	  et	  al.,	  2005;	  Li	  et	  al.,	  2005;	  
Thebault	   et	   al.,	   2008).	   Hence,	   the	   targets	  
phosphorylated	   by	   the	   kinase	   must	   be	   located	  
downstream	   from	   the	   protein.	   At	   variance	   of	  
what	   reported	   for	   the	   kinase	   domain	   of	   TRPM7	  
(see	   previous	   section)	   no	   phosphorylation	  
substrate	   for	   the	  TRPM6	  kinase	  has	  been	  clearly	  
identified	   up-­‐to-­‐date,	   with	   the	   exception	   of	  
TRPM7	   itself.	   Data	   from	   the	   Ryazanov’s	   group	  
clearly	   indicate	   that	   the	   TRPM6	   kinase	   domain	  
can	   phosphorylate	   TRPM7	   channel	   within	   a	  
heterotetramer	  structure	  while	  the	  opposite	  does	  
not	   occur	   (Schmitz	   et	   al.,	   2005).	   Due	   to	   the	  
limited	   information	   available,	   it	   is	   largely	  
undefined	   as	   to	   whether	   the	   kinase	   domain	   of	  
TRPM7	   and	   TRMP6	   phosphorylate	   similar	   or	  
different	  substrates	   in	  the	  tissues	   in	  which	  these	  
chanzymes	  are	  specifically	  expressed.	  	  
	  
How	   exactly	   the	   expression	   and/or	   activity	   of	  
TRPM6	   channel	   are	   modulated	   in	   vivo	   is	   slowly	  
being	   elucidated.	   Estrogens	   (17ß-­‐estradiol)	  
markedly	  upregulate	  TRPM6	  mRNA	  in	  both	  colon	  
and	   kidney	   while	   having	   no	   effect	   on	   TRPM7	  
mRNA	   (Groenestege	   et	   al.,	   2006;	   Cao	   et	   al.,	  
2009).	   In	   the	  absence	  of	  estrogen,	   the	   repressor	  
of	   estrogen	   receptor	   activity	   (REA)	   binds	   to	   the	  
6th,	   7th	   and	   8th	   beta-­‐sheets	   of	   TRPM6	   kinase	  
domain	   in	   a	  phosphorylation-­‐dependent	  manner	  
and	   inhibits	   TRPM6	   activity	   (Cao	   et	   al.,	   2009).	  
Short-­‐term	   estrogen	   administration	   dissociates	  
the	  binding	  between	  REA	  and	  TRPM6,	  resulting	  in	  
an	   increased	   channel	   activity	   (Cao	   et	   al.,	   2009).	  
Dietary	  Mg2+	   restriction	   also	   upregulates	   TRPM6	  
mRNA	   in	   both	   colon	   and	   kidney	   but	   does	   not	  
affect	   TRPM7	   mRNA	   (Groenestege	   et	   al.,	   2006;	  
Rondon	   et	   al.,	   2008).	   	   In	   contrast,	   an	   Mg2+	  
enriched	   diet	   upregulates	   TRPM6	  mRNA	   only	   in	  
the	  colon,	  in	  keeping	  with	  an	  increased	  intestinal	  
absorption	   (Groenestege	   et	   al.,	   2006).	   Mice	  
selected	  for	  the	  their	  low	  erythrocyte	  and	  plasma	  
Mg2+	   status	   exhibit	   hypomagnesaemia	   and	  
hypomagnesuria,	   and	   increased	   TRPM6	  
expression	   in	   kidney	   and	   intestine	   when	   fed	   a	  
severely	  Mg2+-­‐deficient	  diet	  (Rondon	  et	  al.,	  2008).	  
Feeding	  the	  mice	  an	  Mg2+	  adequate	  diet	  resulted,	  
instead,	   in	   hypomagnesaemia	   and	   hypermag-­‐
nesuria,	   and	   lower	   intestinal	   and	   renal	   TRPM6	  
expression	   (Rondon	  et	   al.,	   2008).	   These	   changes	  
in	  TRPM6	  expression	  and	  Mg2+	  level	  in	  blood	  and	  
urine	   were	   not	   observed	   in	   mice	   exhibiting	  
normal	  or	  high	  erythrocyte	  and	  plasma	  Mg2+	  level	  
(Rondon	  et	  al.,	  2008).	  It	  is	  becoming	  progressively	  
apparent,	   therefore,	   that	   genetic	   factors	   control	  
TRPM6	   expression	   and	   activity,	   and	   that	   dietary	  
Mg2+	   restriction	   increases	   Mg2+	   resorption,	   the	  
process	  correlating	  well	  with	  an	  increased	  TRPM6	  
expression	   in	   both	   intestine	   and	   kidney	  
(Groenestege	  et	  al.,	  2006;	  Rondon	  et	  al.,	  2008).	  
	  
As	  already	  observed	  for	  TRPM7,	  intracellular	  ATP	  
specifically	   decreased	   TRPM6	   current	   (Chubanov	  
et	  al.,	  2004;	  Schmitz	  et	  al.,	  2005;	  Chubanov	  et	  al.,	  
2005;	   Li	  et	   al.,	   2005;	   Thebault	  et	   al.,	   2008).	   The	  
inhibitory	   site	   resides	   in	   the	   conserved	   ATP-­‐
binding	  motif	  GXG(A)XXG	  within	  the	  alpha-­‐kinase	  
domain	   (Thebault	   et	   al.,	   2008).	   Either	   the	   full	  
deletion	  of	  the	  kinase	  domain	  or	  point	  mutations	  
within	   the	  ATP-­‐binding	  motif	   (G1955D)	  completely	  
prevents	  the	  inhibitory	  effect	  of	  intracellular	  ATP.	  
The	   effect	   of	   ATP,	   however,	   is	   independent	   of	  
alpha-­‐kinase	   autophosphorylation	   activity	  
(Thebault	  et	  al.,	  2008).	  
	  
The	   activity	   of	   TRPM6	   channels	   can	   also	   be	  
modulated	   by	   cellular	   signalling	   molecules.	  
Bindels	  and	  collaborators	   (Cao	  et	  al.,	  2008)	  have	  
reported	  that	  over-­‐expression	  of	  RACK1	  (receptor	  
for	  activated	  protein	  kinase	  C)	   results	   in	  a	  direct	  
binding	   of	   this	   protein	   to	   the	   alpha-­‐kinase	  
domain	   of	   TRPM6,	   and	   possibly	   TRPM7	   due	   to	  
the	   high	   homology	   (>84%)	   between	   the	   two	  
kinase	  domains.	  The	  TRPM6	  site	  binding	  RACK1	  is	  
restricted	   to	   the	   region	   between	   amino	   acids	  
1857	   and	   1885	   (6th,	   7th	   and	   8th	   b	   sheets).	  
Interestingly,	  these	  are	  the	  same	  sheets	  involved	  
in	  REA	  regulation	  (Cao	  et	  al.,	  2009).	  The	  interplay	  
between	   REA	   and	   RACK1	   in	   modulating	   the	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channel	   activity,	   however,	   still	   remains	  
undefined.	   Accessibility	   analysis	   of	   the	   RACK1	  
binding	   site	   suggests	   that	   18	   of	   the	   28	   amino	  
acids	  of	  this	  site	  are	  localized	  at	  the	  surface	  of	  the	  
TRPM6	  alpha-­‐kinase	  domain	  (Cao	  et	  al.,	  2008).	  As	  
a	  result	  of	  this	  interaction,	  the	  channel	  activity	  of	  
TRPM6	   and	   TRPM7	   are	   inhibited.	   As	   it	   could	   be	  
anticipated,	  co-­‐expression	  of	  RACK1with	  a	  alpha-­‐
kinase	   deleted	   TRPM6	   mutant	   fails	   to	   suppress	  
channel	   activity.	   The	   inhibitory	   effect	   of	   RACK1	  
fully	   depends	   on	   the	   autophosphorylation	   of	  
threonine	  1851	   (T1851)	  within	   the	   kinase	  domain.	  
This	   residue	   is	   localized	   at	   the	   end	   of	   the	   4th	  
alpha-­‐helix	   adjacent	   to	   the	   RACK1	   binding	   site.	  
Mutation	   of	   T1851	   to	   alanine	   (T1851A)	   or	   to	  
aspartate	   (T1851D)	   significantly	   decreases	   TRPM6	  
autophosphorylation	   while	   leaving	   unaltered	  
RACK1	  binding.	  The	  inhibitory	  effect	  of	  RACK1	  on	  
the	   channel	   activity,	   however,	   is	   completely	  
abolished	   only	   in	   the	   case	   of	   T1851A	   mutation	  
while	   it	   persists	   in	   the	   case	   of	   T1851D	   mutation	  
(Cao	   et	   al.,	   2008).	   Interestingly,	   T1851D	  
autophosphorylation	   strongly	   depends	   on	   Mg2+	  
concentration,	   steadily	   increasing	   for	  
concentrations	  between	  0.1	  to	  1mM.	  In	  contrast,	  
T1851A	   mutant	   is	   less	   sensitive	   to	   intracellular	  
Mg2+	   concentrations	   as	   compared	   to	   the	   wild	  
type	   (IC50	   ~0.7	   vs.	   0.5mM,	   respectively).	   Under	  
conditions	   in	  which	  protein	   kinase	  C	   is	   activated	  
(e.g.	   pre-­‐incubation	   with	   PMA),	   the	   inhibitory	  
effect	   of	   RACK1	   on	   TRPM6	   channel	   activity	   is	  
completely	   prevented	   (Cao	   et	   al.,	   2008).	   The	  
inhibition,	   however,	   can	   be	   restored	   by	   pre-­‐
treatment	   with	   the	   PKC	   inhibitor	   chelerythrine	  
(Cao	  et	  al.,	   2008),	   suggesting	  a	   competing	  effect	  
of	  PKC	  for	  RACK1.	  
	  
A	   recent	   study	  of	  Groenestege	  et	  al.,	   (2007)	  has	  
evidenced	   the	   role	   of	   EGF	   as	   an	   autocrine/	  
paracrine	  magnesiotropic	   hormone.	   By	   engaging	  
its	   receptor	   in	   the	   basolateral	   domain	   of	   the	  
distal	   convolute	   tubule,	   EGF	   is	   able	   to	   activate	  
TRPM6	   at	   the	   apical	   domain	   of	   the	   cell	   and	  
induce	   cellular	   Mg2+	   accumulation.	   Point	  
mutation	   in	   the	   pro-­‐EGF	   (P1070L)	   retains	   EGF	  
secretion	   to	   the	   apical	   membrane	   and	   disrupts	  
this	  cascade	  of	  events,	  ultimately	  resulting	  in	  the	  
Mg2+	   wasting	   typical	   of	   isolated	   recessive	   renal	  
hypo-­‐magnesemia	  (IRH).	  An	  alteration	  of	  the	  axis	  
EGF/TRPM6/Mg2+	   reabsorption/renal	  Mg2+	  wasting	  
is	   also	   observed	   in	   cancer	   patients	   undergoing	  
treatment	   with	   antibodies	   anti-­‐EGFR	  
(Cunningham	  et	  al.,	  2004;	  Dimke	  et	  al.,	  2010),	  as	  
the	   antibody	   antagonizes	   the	   stimulation	   of	  
TRPM6	   activity	   via	   EGF.	   The	   modality	   by	   which	  
EGF	  modulates	  TRPM6	  activity	  and/or	  expression	  
appears	  to	   involve	  ERK1/2	  signalling.	  A	  report	  by	  
Ikari	   et	   al.,	   (2008)	   indicates	   that	   the	   stimulation	  
of	   NRK-­‐52E	   cells	   by	   EGF	   results	   in	   an	   increased	  
phosphorylation	   of	   ERK1/2	   and	   an	   increased	  
expression	   of	   TRPM6	   in	   a	   time-­‐dependent	  
manner	   (Ikari	   et	   al.,	   2008)	   via	   modulation	   by	  
adaptin	   protein-­‐1	   (AP-­‐1)	   (Ikari	   et	   al.,	   2010).	   The	  
process	  is	  prevented	  by	  the	  use	  of	  antagonists	  for	  
integrin	   avb3	   or	   for	   MEK1/MEK2	   activity,	   or	   by	  
the	   use	   of	   siRNA	   for	   TRPM6	   (Ikari	   et	   al.,	   2008).	  
How	  exactly	  EGF,	  integrin,	  and	  ERK1/2	  interact	  to	  
enhance	   TRPM6	   expression	   needs	   further	  
elucidation.	   It	   is	   in	   fact	   unclear	   whether	   the	  
activation	   of	   this	   signalling	   axis	   is	   connected	   to	  
the	   release	   of	   RACK1-­‐mediated	   inhibition	   of	  
TRPM6	  activity	  mentioned	  previously	   (Cao	  et	  al.,	  
2008).	   The	   modality	   by	   which	   apically	  
accumulated	  Mg2+	   is	   transported	   across	   the	   cell	  
to	  be	  delivered	  to	  basolateral	  domain	  of	   the	  cell	  
to	  be	  extruded	   into	  the	  blood	  stream	  also	  needs	  
further	   elucidation.	   One	   hypothesis	   is	   that	  
parvalbumin	   and	   calbindin-­‐D28k,	   two	   proteins	  
abundantly	   present	   within	   cells	   of	   the	   distal	  
convolute	  tubule	  of	  the	  nephron,	  can	  operate	  the	  
transcellular	   transport	   of	   Mg2+	   accumulated	   at	  
the	  apical	  domain,	  or	  at	  least	  accelerate	  the	  rate	  
of	   delivery	   at	   the	   basolateral	   domain.	   However,	  
as	   mentioned	   previously,	   parvalbumin	   null	   mice	  
do	  not	  show	  detectable	  defects	  in	  Mg2+	  excretion	  
or	   homeostasis	   (Belge	   et	   al.,	   2007),	   de	   facto	  
questioning	   whether	   parvalbumin	   does	   play	   a	  
role	   in	   the	   process	   or	   other	   proteins	   can	  
compensate	  for	  its	  absence	  in	  the	  null	  model.	  	  	  	  	  	  	  	  	  	  
	  	  
Claudins	  
Paracellin	   1	   (claudin	   16)	   was	   the	   first	   Mg2+	  
transporting	  protein	  to	  be	  identified	  in	  mammals	  
(Simon	   et	   al.,	   1999).	   The	   identification	   was	  
rendered	   possible	   by	   the	   genetic	   analysis	   of	  
patients	   affected	   by	   Familial	   Hypomagnesaemia	  
with	   Hypercalciuria	   and	   Nephrocalcinosis	  
(FHHNC),	   a	   disease	   characterized	   by	   massive	  
renal	   Mg2+	   and	   Ca2+	   wasting	   that	   leads	   rapidly	  
and	   irreversibly	   to	   renal	   failure	   (Simon	   et	   al.,	  
1999).	   At	   variance	   of	   what	   is	   described	   for	  
patients	   with	   TRPM6	   mutations,	   the	   symptoms	  
and	  the	  progressive	  renal	  deterioration	  in	  FHHNC	  
patients	   are	   not	   ameliorated	   by	   Mg2+	  
supplementation	   (Simon	   et	   al.,	   1999).	   The	   gene	  
responsible	   for	   this	   disease	   was	   identified	   by	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Lifton	   and	   collaborators	   in	   1999	   and	   named	  
Paracellin-­‐1	   (PCLN-­‐1)	   (Simon	   et	   al.,	   1999).	  More	  
than	   20	   mutations	   affecting	   paracellin-­‐1	  
trafficking	   or	   permeability	   have	   been	   identified	  
up-­‐to-­‐date	   (Kausalya	   et	   al.,	   2006).	   PCLN-­‐1	  
encodes	   for	   paracellin-­‐1	   (PCLN-­‐1),	   also	   termed	  
claudin-­‐16.	   This	   protein	   is	   a	   member	   of	   the	  
claudin	   family	   ((Lal-­‐Nag	  and	  Morin,	  2009),	  which	  
comprehends	   a	   group	   of	   tight	   junction	   proteins	  
that	  present	  4	  transmembrane	  spans	  coordinated	  
by	   2	   extracellular	   loops,	   and	   both	   C-­‐	   and	   N-­‐
termini	  on	  the	  cytoplasm	  side.	  	  
	  
Claudin-­‐16	   mediates	   paracellular	   Ca2+	   and	   Mg2+	  
fluxes	   throughout	   the	   nephron.	   Yet,	   discrepancy	  
exists	   about	   the	  modality	   by	   which	   these	   fluxes	  
are	   generated.	   Data	   obtained	   in	   LLC-­‐PK1	   (a	  
porcine	   renal	   cell	   line)	   suggest	   that	   claudin-­‐16	  
mediates	   paracellular	   Na+-­‐permeation	   which,	   in	  
turn,	   generates	   a	   positive	   potential	   within	   the	  
lumen	  that	  acts	  as	  the	  driving	  force	  for	  Mg2+	  and	  
Ca2+	   resorption	   (Hou	   et	   al.,	   2005).	   In	   contrast,	  
data	   in	   MDCK	   cells	   indicate	   a	   decrease	   in	   Na+-­‐
permeability	   and	   an	   increase	   in	   Mg2+	  
permeability	   (Ikari	   et	   al.,	   2006).	   It	   is	   unclear	  
whether	   these	   discrepancies	   reflect	   a	   different	  
modus	  operandi	  in	  cell	  lines	  of	  differing	  origin,	  or	  
depend	  on	  the	  experimental	  conditions	  utilized	  in	  
the	   two	   studies.	   It	   is	   evident,	   however,	   that	  
PCLN-­‐1	   expression	   is	  modulated	  based	  upon	   the	  
magnesium	   concentration	   present	   in	   the	  
extracellular	  medium	  (Efrati	  et	  al.,	  2005).	  	  
	  
At	   the	   functional	   level,	   claudin-­‐16	   has	   to	   be	  
delivered	  correctly	   to	   the	   tight	   junction	  where	   it	  
interacts	   with	   the	   scaffolding	   protein	   ZO-­‐1	  
(Muller	   et	   al.,	   2003).	   The	   association	   and	  
dissociation	  of	  claudin-­‐16	  and	  ZO-­‐1	  appear	  to	  be	  
regulated	   via	   PKA-­‐mediated	   phosphorylation	   of	  
Ser217	   in	   claudin-­‐16	   (Muller	   et	   al.,	   2003).	   The	  
dephosphorylation	   of	   this	   residue,	   as	   it	   occurs	  
upon	  activation	  of	   the	  Calcium	  Sensing	  Receptor	  
(CaSR)	   (Khan	  and	  Conigrave,	  2010)	   results	   in	   the	  
dissociation	   of	   claudin-­‐16	   from	   ZO-­‐1	   and	   its	  
accumulation	   in	   the	   lysosomal	   compartment	  
(Ikari	   et	   al.,	   2006).	   Mutations	   of	   Ser	   217	   can	  
therefore	   accelerate	   claudin-­‐16	   turnover	   and	  
modulate	   its	   function.	   Mutation	   of	   Threo233	  
(T233R)	   also	   impairs	   the	   interaction	   between	  
claudin-­‐16	   and	   ZO-­‐1,	   and	   favours	   the	  
accumulation	   of	   claudin-­‐166	   into	   lysosomes	  
(Muller	   et	   al.,	   2003;	   Ikari	   et	   al.,	   2006).	   More	  
recently,	   evidence	   has	   emerged	   indicating	   the	  
involvement	  of	  another	  claudin	   isoform,	  claudin-­‐
19,	  in	  mediating	  Mg2+	  and	  Ca2+	  resorption	  (Hou	  et	  
al.,	   2009)	   by	   forming	   a	   head-­‐to-­‐head	   cation-­‐
selective	   complex	  with	   claudin-­‐16	  at	   the	   level	  of	  
the	   tight	   junction.	  While	   the	  channel	   function	  of	  
claudin-­‐16	   may	   not	   depend	   on	   its	   association	  
with	   claudin-­‐19,	   claudin-­‐19	   plays	   an	  
indispensable	   role	   in	   recruiting	   claudin-­‐16	   to	  
form	   a	   co-­‐polymer	   at	   the	   level	   of	   the	   tight	  
junction	  and	  in	  switching	  the	  channel	  from	  anion	  
to	   cation	   selective	   (Hou	   et	   al.,	   2009).	   The	  
heteromeric	   association	  between	  claudin-­‐16	  and	  
claudin-­‐19	   is	   dramatically	   affected	   by	   point	  
mutations	   in	  claudin-­‐16	   (L145P,	  L151F,	  G191R,	  A209T,	  
and	  F232C)	  and	  claudin-­‐19	  (L90P	  and	  G123R),	  which	  
abolish	   the	  physiological	   synergism	  between	   the	  
two	   proteins	   and	   result	   in	   the	   development	   of	  
FHHNC.	  	  	  
	  
MagT1	  
This	   protein	   was	   identified	   by	   Goytain	   and	  
Quamme	   (2005a)	   in	   human	   epithelial	   cells	   that	  
upregulate	  the	  encoding	  gene	  following	  exposure	  
to	   low-­‐Mg2+	   concentrations	   in	   the	   culture	  
medium.	   The	   protein	   encoded	   by	   this	   gene	   has	  
an	   estimated	  molecular	  weight	   of	   38	   KDa	   and	   5	  
transmembrane	   domains.	   The	   mature	   MagT1	  
protein,	   however,	   would	   contain	   4	  
transmembrane	   spans	   owing	   to	   the	   cleavage	   of	  
the	   first	   transmembrane	   segment	   located	   near	  
the	   C-­‐terminus.	   At	   variance	   of	   SLC41	   (Section	  
3.3.1)	   and	  Mrs2	   (discussed	   in	   the	   next	   Section),	  
MagT1	  does	  not	  exhibit	  any	  significant	  degree	  of	  
homology	   to	   prokaryotic	   Mg2+	   transporters,	   but	  
has	   some	   similarities	   with	   the	   oligosaccharide	  
transferase	   complex	   OST3/OST6	   that	   regulates	  
protein	   glycosylation	   in	   the	   endoplasmic	  
reticulum	   in	   yeast	   (Shibatani	   et	   al.,	   2005).	   The	  
murine	  orthologue	  of	  MagT1	   is	   highly	   expressed	  
in	   liver,	  heart,	  kidney	  and	  colon,	  with	  detectable	  
levels	   in	   lung,	   brain	   and	   spleen	   (Goytain	   and	  
Quamme,	   2005a).	   For	   the	   most	   part,	   MagT1	  
levels	   in	   these	   tissues	   are	   consistent	   with	   the	  
mRNA	  levels,	  the	  only	  exception	  being	  the	  liver	  in	  
which	   a	   low	   protein	   level	   is	   detected	   (Goytain	  
and	   Quamme,	   2005a).	   At	   variance	   of	   the	   other	  
transporters	   described	   in	   this	   section,	   MagT1	  
appears	  to	  possess	  high	  specificity	  for	  Mg2+	  (Km	  =	  
0.23mM).	   The	   Mg2+-­‐elicited	   currents	   are	   not	  
inhibited	  by	  Ca2+	  but	  can	  be	  inhibited	  by	  Ni2+,	  Zn2+	  
and	  Mn2+,	   although	   the	   required	   concentrations	  
(>0.2mM)	   far	   exceed	   the	   physiological	  
concentrations	   of	   these	   cations	   in	   extracellular	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fluids.	   Interestingly,	   nitrendipine	   at	   ~10mM	   can	  
inhibit	   the	   Mg2+	   current	   whereas	   the	   more	  
common	   nifedipine	   does	   not,	   even	   at	   much	  
higher	   concentrations	   (Goytain	   and	   Quamme,	  
2005a).	   Virtually	   no	   information	   is	   available	  
about	  N33,	  a	  second	  member	  of	  the	  MagT	  family.	  
Although	   able	   to	   transport	   Mg2+,	   this	   protein	  
does	   not	   show	   the	   same	   high	   specificity	  
presented	  by	  MagT1	  for	  the	  cation,	  and	  can	  also	  
mediate	   the	   transport	   of	   Fe2+,	   Mn2+	   and	   Cu2+	  
(Goytain	  and	  Quamme,	  2005a).	  
	  
Based	   upon	   these	   observations,	   MagT1	   appears	  
to	  possess	  channel-­‐like	  characteristics	  and	  a	  high	  
selectivity	   for	  Mg2+.	   The	   latter	   evidence	   strongly	  
suggests	   that	   this	   transporter	   can	   play	   an	  
essential	   role	   in	   regulating	   Mg2+	   homeostasis	   in	  
mammalian	   cells.	   Support	   to	   this	   hypothesis	   is	  
provided	   by	   the	   report	   of	   Zhou	   and	   Clapham	  
(2009)	   that	   knock-­‐out	   of	  MagT1,	   and	   its	   human	  
homolog	   TUSC3,	   in	   HEK-­‐293	   cells	   results	   in	   a	  
major	   reduction	   of	   cellular	   Mg2+	   content.	   These	  
authors	  also	  provide	  evidence	  that	  either	  protein	  
can	  complement	  the	  yeast	  Mg2+	  transporter	  ALR1	  
(Zhou	   and	   Clapham,	   2009).	   Interestingly,	   the	  
mRNA	   levels	   of	   MagT1	   but	   not	   those	   of	   TUSC3	  
increase	   markedly	   following	   exposure	   of	  
expressing	   cells	   to	   low	   extracellular	   Mg2+	  
concentrations	   for	  1	  day	  and	  2	  days.	   	   Incubation	  
of	   the	   cells	   in	   high	   extracellular	   Mg2+	  
concentration	  has	  no	  effect	  on	  the	  expression	  of	  
either	  protein	  (Zhou	  and	  Clapham,	  2009).	  	  	  
	  
Mrs2	  
This	   protein	   was	   identified	   during	   a	   screening	  
aimed	  at	  isolating	  nuclear	  genes	  suppressing	  RNA	  
splicing	   defects	   in	   yeast	   mitochondrial	   introns	  
(Wiesenberger	   et	   al.,	   1992).	   The	   three	   main	  
characteristics	   observed	   in	   yeasts	   deficient	   in	  
Mrs2	  are:	  1)	  a	  splicing	  phenotype,	  2)	  a	  significant	  
reduction	   in	   cytochromes,	   and	   3)	   a	   deficit	   in	  
mitochondria	   respiration	   to	   the	   point	   that	   the	  
yeasts	   become	   unable	   to	   grow	   on	   non-­‐
fermentable	  substrates.	  	  
	  
Structurally,	   Mrs2	   shows	   short	   regions	   of	  
homology	   to	   the	   bacterial	   transporter	   CorA	   (Bui	  
et	   al.,	   1999),	   and	   shares	   a	   similar	   membrane	  
topology	   with	   2	   transmembrane	   domains.	  
Mutants	   lacking	   Mrs2	   can	   be	   rescued	   by	   CorA	  
fused	   to	   the	   mitochondrial	   N-­‐terminus	   leader	  
sequence	   of	   Mrs2,	   which	   guarantees	   proper	  
insertion	   in	   the	  mitochondrial	  membrane.	   These	  
mutants	  also	  present	  a	  decrease	  in	  mitochondrial	  
Mg2+	  content,	  which	  strongly	  supports	  a	  key	  role	  
of	   Mrs2	   in	   regulating	   mitochondrial	   Mg2+	  
homeostasis.	   Studies	   carried	   out	   with	   the	  
fluorescent	  indicator	  Mag-­‐Fura	  indicate	  a	  marked	  
decrease	   in	   mitochondrial	   matrix	   Mg2+	   level	   in	  
yeast	   lacking	   Mrs2	   protein	   whereas	   the	   over-­‐
expression	   of	   the	   protein	   results	   in	   a	   rapid	   and	  
marked	   increase	   in	   matrix	   free	   Mg2+	   (Kolisek	   et	  
al.,	   2003).	   Mrs2	   apparently	   functions	   as	   a	  
channel,	   and	   its	   function	   is	   modulated	   by	  
mitochondrial	  Dy	  as	  well	  as	  by	  inhibitors	  of	  F0-­‐F1-­‐
ATPase	   or	   ANT,	   which	   substantially	   decrease	  
Mg2+	  influx.	  Highly	  conserved	  motifs	  in	  the	  middle	  
region	   of	   the	   protein,	   corresponding	   to	   the	  
coiled-­‐coil	   portion	   of	   the	   channel,	   appear	   to	   be	  
essential	   to	   form	   functional	   channels,	   or	   to	   gate	  
the	   channel.	   More	   recently,	   Schweyen	   and	   his	  
collaborators	   (Piskacek	   et	   al.,	   2009)	   have	  
confirmed	   in	   HEK293	   cells	   some	   of	   the	  
mitochondrial	   modifications	   observed	   in	   yeasts.	  
These	   authors,	   in	   fact,	   have	   reported	   that	   HEK	  
293	  cells	  deprived	  of	  Mrs2	  (Piskacek	  et	  al.,	  2009)	  
lack	   complex	   I	   expression	   in	   mitochondria	   and	  
present	   reduced	   level	   of	   mitochondrial	   Mg2+.	  
Furthermore,	   the	   cells	   show	   a	   change	   in	  
configuration	  as	  well	  as	  an	  increased	  incidence	  in	  
apoptosis,	   which	   within	   2	   weeks	   results	   in	   a	  
complete	   loss	   of	   cell	   viability	   (Piskacek	   et	   al.,	  
2009).	   It	   still	   remains	   to	   be	   elucidated	   whether	  
the	   decrease	   in	   mitochondrial	   Mg2+	   simply	  
depends	  on	  the	  absence	  of	  Mrs2,	  or	  is	  related	  to	  
some	  extent	   to	   the	  absence	  of	   complex	   I,	  which	  
affects	  mitochondrial	   Dy	   and	   consequently	  Mg2+	  
retention	  within	  the	  organelle	  (Akerman,	  1981).	  
	  
Mammalian	   cells	   express	   a	   single	   orthologue	   of	  
Mrs2,	   which	   can	   rescue	   Mg2+	   deficient	   yeast	  
strain	  (Zsurka	  et	  al.,	  2001).	  Hence,	  it	  appears	  that	  
the	   mammalian/human	   Mrs2	   homologue	  
functions	   in	   a	   manner	   similar	   to	   the	   yeast	  
homologue	   in	   mediating	   Mg2+	   entry	   in	  
mitochondria.	  Under	  conditions	  in	  which	  Mrs2p	  is	  
absent,	  the	  operation	  of	  an	  alternative	  but	  much	  
slower	   mitochondrial	   Mg2+	   entry	   mechanism	   is	  
observed.	   Although	   this	   pathway	   restores	   Mg2+	  
homeostasis	   only	   partially,	   it	   does	   rescue	   the	  
phenotype	  of	  Mrs2	  deficient	  yeast,	  ensuring	  their	  
survival.	   No	   information	   is	   presently	   available	  
about	  the	   identity,	  abundance,	  and	  regulation	  of	  
this	   alternative	   transporter	   in	   mitochondria.	  
Taken	   together,	   the	   data	   on	   Mrs2	   suggest	   that	  
Mg2+	   is	   dynamically	   regulated	   within	   the	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mitochondrion,	  in	  which	  it	  plays	  a	  significant	  role	  
in	  modulating	  mitochondrial	  dehydrogenases	  and	  
oxygen	   consumption	   (Panov	   and	   Scarpa,	   1996a;	  
Panov	  and	  Scarpa,	  1996b).	  	  
	  	  
MMgTs	  
This	   gene	   family	   comprehends	   two	   proteins	  
termed	  MMgT1	  and	  MMgT2	  (for	  membrane	  Mg2+	  
transporter	   1	   and	   2)	   by	   Goytain	   and	   Quamme,	  
who	   identified	   them	   by	   microarray	   analysis	  
screening	   (Goytain	   and	   Quamme,	   2008).	   The	  
chromosomal	   location	   of	   these	   proteins	   in	   the	  
mouse	   is	   XA5	   for	  MMgT1	  and	  11B2	   for	  MMgT2.	  
In	   the	   rat,	   the	   respective	   locations	   are	   Xq36	   for	  
MMgT1	  and	  10q23	  for	  MMgT2.	  Human	  MMgT1	  is	  
instead	  located	  on	  Xq26.3	  (Goytain	  and	  Quamme,	  
2008).	   Immunohistochemistry	   assessment	  
indicates	  that	  MMgT1	  and	  MMgT2	  are	  essentially	  
located	   in	   the	   Golgi	   complex	   and	   post-­‐Golgi	  
vesicles,	   where	   they	   may	   contribute	   to	   the	  
regulation	   of	  Mg2+	   dependent	   enzymes	   involved	  
in	   protein	   assembly	   and	   glycosylation	   (Goytain	  
and	  Quamme,	   2008).	   This	   localization,	   however,	  
does	  not	  exclude	   that	   these	  proteins	  may	  play	  a	  
role	   in	   modulating	   Mg2+	   homeostasis	   at	   sites	  
downstream	   the	   Golgi	   network.	   Widely	  
distributed	   in	   tissues,	   these	   proteins	   are	   formed	  
by	   131	   (MMgT1)	   and	   123	   (MMgT2)	   amino	   acids	  
assembled	   into	   two	   predicted	   transmembrane	  
domains.	   This	   suggests	   that	   these	   proteins	   can	  
form	   homo-­‐oligomeric	   and	   possibly	   hetero-­‐
oligomeric	   channels	   to	   favour	  Mg2+	   permeation.	  
MMgT-­‐mediated	  Mg2+	  uptake	   is	   saturable	  with	  a	  
Km	  ~1.5mM	  for	  MMgT1	  and	  ~0.6mM	  for	  MMgT2,	  
and	   these	   values	   do	   not	   vary	   significantly	   with	  
voltage.	   However,	   MMgT1	   and	   MMgT2	   are	   not	  
specific	   for	   Mg2+	   but	   they	   can	   transport	   other	  
cations	  as	  well.	   Some	  slight	  differences	   in	  cation	  
permeation	   exist	   between	   the	   two	   isoforms.	  
Whereas	   MMgT1	   mediates	   Sr2+,	   Fe2+,	   Co2+	   and	  
Cu2+	   transport	   in	   addition	   to	   Mg2+,	   MMgT2	  
favours	   Sr2+,	   Co2+,	   Cu2+,	   Ba2+	   and	  Mn2+	   transport	  
(Goytain	   and	   Quamme,	   2008).	  
Electrophysiological	   experiments	   indicate	   that	  
Mg2+-­‐generated	   current	   in	  MMgT1	   are	   inhibited	  
by	   0.2mM	   Mn2+	   but	   not	   by	   Gd3+	   or	   Ni2+.	  
Consistent	   with	   what	   reported	   for	   other	   Mg2+	  
transport	   mechanisms,	   MMgT1	   mRNA	   increases	  
~2.5	   fold	   in	   the	   kidney	   cortex	   of	   mice	   on	   low-­‐
Mg2+	   diet	   and	   ~3.5	   fold	   in	  MDCT	   epithelial	   cells	  
culture	   in	   low	   Mg2+	   medium.	   Under	   similar	  
experimental	  conditions	  MMgT2	  mRNA	  increases	  
~1.5	   fold	   in	   kidney	   cortex	   and	   ~3	   fold	   in	   MDCT	  
cells	   (Goytain	  and	  Quamme,	  2008).	  We	  refer	  the	  
interested	  audience	  to	  reviews	  by	  Schmitz	  et	  al.,	  
(2007),	   Bindels’	   group	   (Alexander	   et	   al.,	   2008),	  
and	   Quamme	   (2010)	   for	   a	   more	   in-­‐depth	  
elucidation	  of	   the	  specifics	  of	  TRPM6/7	  channels	  
and	   other	   Mg2+	   entry	   mechanisms	   summarily	  
described	  in	  this	  section.	  
	  
Exchangers	  
While	   Mg2+	   entry	   appears	   to	   be	   mediated	   by	  
channels	   or	   channels-­‐like	   mechanisms,	   Mg2+	  
extrusion	   is	   mediated	   by	   two	   mechanisms	  
operating	   as	   exchangers.	   Based	   upon	   the	  
electrochemical	   requirements	   favouring	   Mg2+	  
extrusion,	   these	   mechanisms	   are	   referred	   to	   as	  
Na+-­‐dependent	   and	   Na+-­‐independent	   Mg2+	  
exchanger,	   respectively	   (Table	   1).	   Because	  
neither	   of	   these	   two	   mechanisms	   has	   been	  
cloned,	   information	   about	   their	   operation,	  
abundance	   and	   tissue	   specificity	   remains	  mostly	  
circumstantial	   or	   indirect	   based	   upon	   experi-­‐
mental	  conditions	  or	  pharmacological	  inhibition.	  	  
	  
Na-­‐dependent	  (Na+/Mg2+	  Exchanger)	  
The	   first	   evidence	   of	   the	   operation	   of	   a	   Mg2+	  
transport	   mechanism	   in	   mammalian	   cells	   was	  
provided	  by	  Gunther	  et	  al.,	   (1984).	   In	   this	   and	  a	  
subsequent	   publication	   (Gunther	   and	   Vormann,	  
1985),	   these	   authors	   detailed	   the	   presence	   and	  
operation	   of	   an	   amiloride-­‐inhibited,	   Na+-­‐
dependent,	  Mg2+	  extrusion	  mechanism	  in	  chicken	  
red	  blood	   cells.	   This	   initial	   observation	  has	  been	  
subsequently	   confirmed	   by	   other	   groups	   in	  
mammalian	   red	   blood	   cells	   (Feray	   and	   Garay,	  
1986;	   Flatman	   and	   Smith,	   1990;	   Xu	   and	   Willis,	  
1994)	   including	   human	   erythrocytes	   (Ludi	   and	  
Schatzmannm	  1987;	  Vormann	  et	  al.,	  1984;	  Raftos	  
et	  al.,	   1999),	   and	   in	   a	   variety	  of	  mammalian	   cell	  
types	  (see	  Romani	  and	  Scarpa,	  2000	  for	  a	  list).	  In	  
addition,	  observation	  from	  Vormann	  and	  Gunther	  
(Vormann	   and	   Gunther,	   1987;	   Gunther	   and	  
Vormann,	   1992a),	   Wolf	   and	   collaborators	   (Wolf	  
et	  al.,	  1996;	  Wolf	  et	  al.,	  1997),	  and	  our	  laboratory	  
(Romani	   and	   Scarpa,	   1990a;	   Romani	   and	   Scarpa	  
1990b;	   Romani	   et	   al.,	   1993a;	   Romani	   et	   al.,	  
1993b;	   Fagan	   and	   Romani,	   2000;	   Fagan	   and	  
Romani,	  2001;	  Cefaratti	  and	  Ruse,	  2007;	  Cefaratti	  
and	   Romani,	   2007)	   has	   provided	   compelling	  
evidence	   that	   this	   Na+-­‐dependent,	   amiloride-­‐
inhibited	   Mg2+	   extrusion	   mechanisms	   is	  
specifically	   coupled	   to	   cAMP-­‐production	   within	  
the	  cells.	  From	  the	  experimental	  stand-­‐point	   it	   is	  
irrelevant	   whether	   cellular	   cAMP	   increases	   via	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stimulation	   of	   β-­‐adrenergic,	   glucagon,	   or	   PGE2	  
receptors,	   or	   via	   administration	   of	   forskolin	   or	  
cell-­‐permeant	   cyclic-­‐AMP	   analogs.	   All	   these	  
conditions,	   in	   fact,	   result	   in	   the	  activation	  of	   the	  
Na+-­‐dependent	   Mg2+	   extrusion	   mechanism	   via	  
phosphorylation.	   Conversely,	   pre-­‐treatment	   of	  
cells	   with	   inhibitors	   of	   adenylyl	   cyclase	   (e.g.	   Rp-­‐
cAMP)	   completely	   blocks	   Mg2+	   mobilization	  
irrespective	   of	   the	   modality	   utilized	   to	   enhance	  
cAMP	  level	  (Wolf	  et	  al.,	  1997).	  
	  
Because	   the	   Mg2+	   extrusion	   mediated	   by	   this	  
exchanger	   strictly	   depends	  on	   the	  presence	  of	   a	  
physiological	   concentration	   of	   Na+	   in	   the	  
extracellular	  milieu	   (Romani	  et	   al.,	   1993a;	   Fagan	  
and	   Romani,	   2000),	   it	   is	   generally	   accepted	   that	  
the	  Na+-­‐dependent	  Mg2+	  extrusion	  mechanisms	  is	  
a	   Na+/Mg2+	   exchanger.	   As	   this	   Mg2+	   extrusion	  
mechanism	  has	  not	  been	  functionally	  cloned,	  we	  
lack	   detailed	   information	   about	   its	   membrane	  
abundance,	   structure,	  proximity	   to	  other	  cellular	  
transporters	  with	  whom	  it	  may	  possibly	   interact,	  
and	   stoichiometry.	   Early	   reports	  by	  Gunther	  and	  
Vormann	   (1985)	   suggest	   the	   operation	   of	  
electroneutral	   bases	   (2Na+in:1	  Mg
2+
out)	   at	   least	   in	  
chicken	   or	   turkey	   erythrocytes.	   This	   notion	   has	  
not	   been	   confirmed	   in	   mammalian	   erythrocytes	  
including	   human	   red	   blood	   cells,	   in	   which	   the	  
exchanger	  appears	  to	  operate	  electrogenically	  on	  
a	   1Na+in:1	   Mg
2+
out	   ratio	   (Ludi	   and	   Schatzmann,	  
1987;	   Flatman,	   1990;	   Xu	   and	   Willis,	   1994).	   The	  
discrepancy	   between	   these	   reports	   is	   not	  
apparent	   although	   it	   may	   depend	   on	   the	  
experimental	  model	  (i.e.	  cell	  isolation	  vs	  cultured	  
cells),	   composition	   of	   incubation	   medium,	   or	  
modality	   of	   cellular	  Mg2+	   loading.	   Irrespective	  of	  
the	   stoichiometry	   of	   exchange	   and	   the	   exper-­‐
imental	  model,	  however,	  all	   the	  obtained	  results	  
consistently	   indicate	  a	  Km	   for	  Na
+	  between	  15	   to	  
20	   mM	   (Gunther,	   1996;	   Tashiro	   and	   Konishi,	  
1997;	   Cefaratti	   et	   al.,	   1998).	   Pharmacological	  
inhibition	   has	   done	   little	   to	   enhance	   our	  
understanding	  of	  the	  modality	  of	  operation	  of	  the	  
putative	   Na+/Mg2+	   exchanger.	   Amiloride,	  
imipramine	   and	   quinidine	   represent	   the	   three	  
most	  widely	  utilized	   inhibitors	   of	  Na+-­‐dependent	  
Mg2+	   extrusion	   (Gunther	   and	   Vormann,	   1984;	  
Feray	   and	   Garay,	   1988;	   Gunther	   and	   Vormann,	  
1992a).	   However,	   because	   of	   their	   limited	  
specificity,	  it	  is	  unclear	  as	  to	  whether	  they	  inhibit	  
the	  Na+/Mg2+-­‐exchanger	  directly,	   or	   indirectly	  by	  
operating	   on	   other	   transport	   mechanisms	  
including	  Na+	   and	   K+	   channel,	   ultimately	   altering	  
the	  cell	  membrane	  potential	  and	  the	  driving	  force	  
for	  Mg2+	  transport	  across	  the	  plasma	  membrane.	  	  
	  
Despite	   intense	   research,	   the	   Na+/Mg2+	  
exchanger	   is	   not	   cloned	   as	   yet.	   Work	   by	  
Schweigel,	  Martens	  and	  colleagues	   (Schweigel	  et	  
al.,	   2000)	   in	   mammalian	   rumen	   support	   the	  
operation	   of	   a	   Na+/Mg2+	   exchanger	   with	   kinetic	  
parameters	   and	   characteristics	   similar	   to	   those	  
described	   by	   other	   groups	   in	   a	   various	  
mammalian	   cell	   types.	   Furthermore,	   by	   using	   a	  
hybridoma	   screening	   procedure,	   this	   group	   has	  
generated	   monoclonal	   antibodies	   against	   the	  
Na+/Mg2+	  exchanger	  present	  in	  porcine	  red	  blood	  
cells.	  Incubation	  of	  sheep	  rumen	  epithelial	  cells	  in	  
the	  presence	  of	  these	  antibodies	  has	  resulted	  in	  a	  
significant	   inhibition	   of	   Mg2+	   extrusion	   via	   this	  
exchanger	   (Schweigel	  et	  al.,	   2000).	  Western	  blot	  
analysis	  utilizing	  these	  antibodies	  has	  evidenced	  a	  
protein	   band	   of	   ~70	   KDa	   mr,	   which	   could	  
tentatively	   correspond	   to	   the	   Na+/Mg2+	  
exchanger	  (Schweigel	  et	  al.,	  2000).	  This	  is	  the	  first	  
time	  that	  information	  about	  the	  molecular	  size	  of	  
the	   elusive	  Na+/Mg2+	   exchanger	   is	   obtained,	   and	  
the	   utilization	   of	   these	   antibodies	   could	  
represent	  an	   ideal	   tool	   to	   identify	  and	   recognize	  
this	  transporter	  in	  mammalian	  tissue.	  	  
	  	  
Na+-­‐independent	  
Under	  conditions	   in	  which	  no	  extracellular	  Na+	   is	  
available	   to	   exchange	   for	   intracellular	   Mg2+,	   an	  
alternative	   Na+-­‐independent	   Mg2+	   extrusion	  
mechanism	   becomes	   evident.	   The	   specificity	   of	  
this	   transporter,	   however,	   is	   far	   from	   being	  
characterized.	  Different	  cations,	   including	  Ca2+	  or	  
Mn2+,	  as	  well	  as	  anions	  (e.g.	  HCO3
-­‐,	  Cl-­‐,	  or	  choline)	  
(Gunther,	   1993;	   Ebel	   et	   al.,	   2002)	   have	   been	  
reported	   to	   be	   utilized	   by	   this	   mechanism	   to	  
extrude	   Mg2+	   from	   the	   cell.	   Hence,	   it	   remains	  
unclear	   whether	   we	   are	   in	   the	   presence	   of	  
distinct	  transport	  mechanisms,	  or	  in	  the	  presence	  
of	  a	  transporter	  that	  can	  operate	  as	  an	  antiporter	  
for	  cations	  or	  a	  synporter	   for	  cations	  and	  anions	  
based	  upon	   the	  experimental	   conditions.	  Also,	   it	  
is	  unclear	  whether	  the	  Na+-­‐independent	  pathway	  
is	   activated	   by	   hormonal	   stimulation.	   Results	  
obtained	  in	  liver	  cells	  (Keenan	  et	  al.,	  1996;	  Fagan	  
and	   Romani,	   2000;	   Fagan	   and	   Romani,	   2001)	  
indicate	   that	   the	   stimulation	   by	   mix	   adrenergic	  
agonists	  (e.g.	  epinephrine)	  elicit	  a	  Mg2+	  extrusion	  
that	   is	   equivalent	   to	   the	   sum	  of	   the	   amounts	   of	  
Mg2+	  mobilized	  by	  the	  separate	  stimulation	  of	  a1-­‐	  
and	  b-­‐adrenergic	  receptors.	  More	  specifically,	  the	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selective	   stimulation	   of	   a1-­‐adrenergic	   receptors	  
by	   phenylephrine	   requires	   the	   presence	   of	  
physiological	  concentrations	  of	  both	  Na+	  and	  Ca2+	  
in	   the	   extracellular	   medium	   to	   elicit	   Mg2+	  
extrusion	   from	   liver	   cells	   (Fagan	   and	   Romani,	  
2000;	   Fagan	   and	   Romani,	   2001).	   As	  
phenylephrine	  stimulation	  appears	  to	  operate	  via	  
Ca2+-­‐CaM	   to	   induce	   Mg2+	   extrusion,	   it	   is	  
undefined	   whether	   this	   signalling	   pathway	  
represents	   an	   alternative	   modality	   of	   activation	  
of	  the	  Na+/Mg2+	  exchanger,	  or	  it	  activates	  instead	  
a	  different	  Mg2+	  extrusion	  mechanism	  that	  can	  be	  
reconciled	   at	   least	   in	   part	   with	   the	  
aforementioned	   Na+-­‐independent	   mechanism.	  
Adding	  to	  the	  uncertainty,	  Ebel	  and	  collaborators	  
(Ebel	   et	   al.,	   2002)	   have	   suggested	   that	   in	   red	  
blood	  cells	  and	  hepatocytes	  the	  Na+-­‐independent	  
Mg2+	  extrusion	  occurs	  via	  the	  choline	  transporter,	  
which	   can	   be	   inhibited	   rather	   specifically	   by	  
cinchona	  alkaloids.	  
	  
One	   controversial	   issue	   is	   whether	   the	   Na+-­‐
dependent	   and	   Na+-­‐independent	   mechanisms	  
operate	   as	   ATPases	   or	   require	   ATP	   for	   their	  
operation.	  Reports	  by	  Gunther	  and	  collaborators	  
(Gunther	  et	  al.,	  1990;	  Ebel	  et	  al.,	  2004)	  indicate	  a	  
certain	   dependence	   of	   Na+-­‐dependent	   Mg2+	  
extrusion	   on	   the	   presence	   of	   a	   physiological	  
concentration	   of	   cellular	   ATP,	   the	   absence	   or	  
decrease	   in	   cellular	   ATP	   content	   resulting	   in	   a	  
reduced	  Mg2+	  efflux	  from	  the	  cell	  (Gunther	  et	  al.,	  
1990;	  Ebel	  et	  al.,	  2004).	   In	   the	  particular	  case	  of	  
red	  blood	  cells,	  ATP	  and	  2,3	  bisphosphoglycerate	  
both	   contribute	   to	   Mg2+	   homeostasis	   and	  
transport	   (Gunther	   et	   al.,	   1995).	   A	   regulatory	  
effect	  of	  ATP	  on	  Mg2+	  extrusion	  is	  not	  observed	  in	  
purified	   liver	   plasma	   membrane	   vesicles	  
(Cefaratti	   et	   al.,	   1998).	   It	   is	   true	   that	   no	   Mg2+	  
extrusion	   is	   observed	   in	   alkaline	   phosphatase-­‐
treated	   basolateral	   liver	   plasma	   membrane	  
vesicles	   in	   the	   absence	   of	   ATP	   (Cefaratti	   and	  
Romani,	   2007),	   but	   this	   observation	   can	  
reasonably	   be	   explained	   by	   the	   requirement	   of	  
ATP	   to	  phosphorylate	   and	  activate	   the	  Na+/Mg2+	  
exchanger	   in	   the	   presence	   of	   PKA	   catalytic	  
subunit	  (Cefaratti	  and	  Romani,	  2007).	  	  
	  
Mg2+/H+	  	  
This	  exchange	  mechanism,	  originally	   identified	  in	  
A.	   thaliana	   and	   termed	   AtMHX,	   appears	   to	   be	  
present	   in	   all	   plants	   (Shaul	   et	   al.,	   1999).	   This	  
transporter	  presents	  11	  putative	  transmembrane	  
domains,	   is	   exclusively	   localized	   in	   the	   vacuolar	  
membrane	   of	   the	   plant,	   and	   electrogenically	  
exchanges	   protons	   with	   Mg2+	   or	   Zn2+.	  
Interestingly,	   the	   ectopic	   overexpression	   of	   the	  
transporter	   in	  tobacco	  plants	  sensitizes	  the	  plant	  
to	   grow	   in	   the	   presence	   of	   elevated	  
concentrations	   of	   Mg2+	   (or	   Zn2+)	   (Shaul	   et	   al.,	  
1999).	   Presently,	   no	   corresponding	   gene	   and	  
transporter	   have	   been	   identified	   in	   mammalian	  
cells,	   although	   evidence	   for	   a	   direct	   or	   indirect	  
exchange	  of	  Mg2+	  for	  H+	  under	  certain	  conditions	  
has	   been	   provided	   by	   Gunther	   (Gunther	   and	  
Vormann,	   1990a).	   An	   enhanced	   extrusion	   of	  
cellular	   Mg2+	   has	   been	   observed	   in	   cells	  
incubated	   in	  an	  acidic	  extracellular	  environment,	  
in	   which	   an	   inwardly	   oriented	   H+	   gradient	   is	  
imposed,	   provided	   that	   extracellular	   Na+	   is	  
present	  (Gunther	  and	  Vormann,	  1990a;	  Dalal	  and	  
Romani,	   2010).	   Amiloride	   derivates	   that	   inhibit	  
with	   high	   affinity	   the	   Na+/H+	   exchanger	   are	  
ineffective	   at	   blocking	   Mg2+	   extrusion	   under	  
these	   experimental	   conditions	   (Gunzel	   and	  
Schlue,	  1996),	  thus	  excluding	  that	  Mg2+	  extrusion	  
depends	   on	   the	   operation	   in	   reverse	   of	   the	  
Na+/H+	   exchanger	   in	   parallel	   with	   the	   forward	  
operation	  of	  the	  Na+/Mg2+	  exchanger.	  	  	  	  	  
	  
Carriers	  
This	   section	  groups	   several	  novel	  Mg2+	   transport	  
mechanisms	  of	  murine	  or	  human	  origin	  identified	  
as	   a	   result	   of	   diet	   restriction	   (i.e.	  Mg2+-­‐deficient	  
diet)	  or	  medium	  restriction	  (i.e.	   low	  extracellular	  
Mg2+	   content).	   Due	   to	   the	   limited	   information	  
available	   and	   controversies	   in	   their	   modus	  
operandi,	   these	   transport	   mechanisms	   are	   non-­‐
descriptively	  classified	  as	  carriers.	  	  	  
	  
SLC41	  
This	   family	   of	   Mg2+	   transport	   mechanisms	  
includes	  three	  members	  (A1,	  A2,	  and	  A3)	  that	  are	  
distantly	  related	  to	  the	  prokaryotic	  MgtE	  channel	  
identified	   by	   Maguire	   (Smith	   et	   al.,	   1995).	   	   We	  
will	   discuss	   predominantly	   SLC41A1	   and	   A2	  
isoforms	   since	   no	   study	   has	   addressed	   function	  
and	  structure	  of	  the	  SLC41A3	  isoform.	  	  	  
	  
SLC41A1	  was	  the	  first	  member	  of	  this	  family	  to	  be	  
identified	   (Wabakken	  et	  al.,	  2003).	  Based	  on	   the	  
hydrophobic	   profile,	   this	   protein	   of	   ~56	   kDa	  Mr	  
was	   predicted	   to	   possess	   10	   transmembrane	  
domains,	  two	  of	  which	  presented	  a	  discrete	  level	  
of	  homology	  with	  MgtE	  (Wabakken	  et	  al.,	  2003).	  
Northern	   blot	   analysis	   indicates	   a	   wide	  
distribution	   of	   the	   SLC41A1	   gene,	   but	   its	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abundance	   varies	   markedly	   among	   tissues,	   the	  
highest	   expression	   being	   in	   heart	   and	   testis	   and	  
the	   lowest	   being	   in	   hematopoietic	   tissues	   and	  
cells	   (Wabakken	   et	   al.,	   2003).	   While	   modest	  
under	   basal	   conditions,	   the	   expression	   of	   this	  
gene	  is	  markedly	  up-­‐regulated	  in	  the	  renal	  cortex	  
of	   mice	   fed	   low	   Mg2+	   diet	   for	   several	   days	  
(Goytain	   and	   Quamme,	   2005b).	   Functional	  
expression	   of	   mouse	   SLC41A1	   in	   X.	   oocyte	  
indicates	  that	  this	  protein	  can	  transport	  Mg2+	  but	  
also	   Fe2+,	   Cu2+,	   Zn2+	   and	   Cd2+	   while	   Ca2+	   is	   not	  
transported	   nor	   inhibits	  Mg2+	   transport	   (Goytain	  
and	   Qaumme,	   2005b).	   The	   original	  
characterization	   of	   Mg2+	   generated	   current,	  
which	   would	   be	   tentatively	   consistent	   with	  
SLC41A1	   operating	   as	   a	   channel	   (Goytain	   and	  
Qaumme,	   2005b)	   or	   an	   electrogenic	   exchanger	  
similar	   to	   the	  Na/Ca	   exchanger	   (Quednau	   et	   al.,	  
2004),	  contrasts	  with	  a	  recent	  report	  by	  Kolisek	  et	  
al.,	   (2008).	   In	   this	   study	   the	   authors	   strongly	  
advocate	   for	   SLC41A1	  operating	  as	   a	   carrier	   and	  
predominantly	   favouring	  Mg2+	   efflux	   rather	   than	  
influx.	   Following	   overexpression	   of	   SLC41A1	   in	  
HEK293	   cells	   1)	   no	   detectable	   Mg2+	   currents	   is	  
observed;	   2)	   incubation	   of	   cells	   in	   Mg2+-­‐free	  
media	   results	   in	   a	   significant	   reduction	   of	   total	  
Mg2+	   content	   and	   [Mg2+]i;	   3)	   the	   amplitude	   of	  
Mg2+	   loss	   depends	   on	   the	   number	   of	   SLC41A1	  
molecules	   expressed	   in	   the	   membrane	   and	   the	  
induction	  time,	  and	  4)	  the	  changes	   in	  [Mg2+]i	  are	  
temperature	  sensitive	  but	  insensitive	  to	  the	  Mg2+	  
channel	   blocker	   CoHexamine	   (Kolisek	   et	   al.,	  
2008).	   Furthermore,	   Kolisek	   and	   collaborators	  
suggest	   that	   SLC41A1	   forms	   high	   molecular	  
weight	  complexes	  within	  the	  cell	  membrane	  with	  
masses	   ranging	   from	   1236	   KDa	   to	   ~360	   kDa,	   in	  
stark	  contrast	  to	  the	  56	  KDa	  Mr	  of	  the	  monomer	  
(Kolisek	   et	   al.,	   2008).	   Whether	   this	   observation	  
indicates	  that	  the	  SLC41A1	  monomer	  forms	  large	  
multimeric	   complexes	   and/or	   interacts	   with	  
auxiliary	   proteins	   is	   presently	   undefined.	   The	  
reason	   for	   the	   absence	   of	   Mg2+-­‐generated	  
currents	  in	  this	  study	  as	  compared	  to	  the	  original	  
observation	   by	   Goytain	   and	  Quamme	   (2005b)	   is	  
not	   apparent.	   One	   possibility	   is	   that	   the	  murine	  
(Goytain	   and	   Qaumme,	   2005b)	   and	   human	  
orthologs	   (Kolisek	   et	   al.,	   2008)	   operate	  
differently.	  Based	  upon	  their	  high	  degree	  (>90%)	  
of	  homology,	  the	  mouse	  and	  human	  SLC41A1	  are	  
expected	  to	  operate	  in	  a	  similar	  manner.	  Yet,	  the	  
possibility	   that	   point	  mutations	   can	   dramatically	  
alter	   SLC41A1	   ion	   specificity	   and	   modality	   of	  
function	   cannot	  be	   completely	  dismissed.	   In	   this	  
respect,	   it	   has	   to	   be	   noted	   that	   Goytain	   and	  
Quamme	  (2005b)	  did	  not	  report	  a	  dependency	  of	  
SLC41A1	   operation	   on	   Na+	   or	   other	   cations	   or	  
anions	   following	   expression	   in	   X.	   oocytes,	  
whereas	  Kolisek	  and	  collaborators	   (Kolisek	  et	  al.,	  
2008)	   observed	   a	   marked	   Cl-­‐	   conductance	  
following	   expression	   in	   HEK293	   cells,	   which	  was	  
abolished	   by	   DIDS.	   Whether	   this	   reflects	   the	  
operation	  of	  additional	   transport	  mechanisms	  or	  
the	  presence	  of	   structural	   differences	   in	   the	   cell	  
membrane	   of	   HEK293	   cells	   as	   compared	   to	   X.	  
oocyte	   are	   possibilities	   that	   need	   further	  
investigation.	  
	  
Two	  additional	  SLC41	  isoforms	  were	  identified	  in	  
both	   humans	   and	   mice.	   SLC41A2	   also	   transport	  
Mg2+	  as	  well	  as	  other	  divalent	  cations	  albeit	  with	  
a	   different	   selectivity	   and	   inhibition	   profile	   than	  
SLC41A1	   (Goytain	   and	   Qaumme,	   2005c).	   Aside	  
from	  Mg2+,	  SLC41A2	  can	  carry	  Ba2+,	  Ni2+,	  Co2+,	  Fe2+	  
and	  Mn2+	  but	  not	  Ca2+,	  Cu2+	  or	  Zn2+.	  At	  variance	  of	  
SLC41A1,	  Mg2+	  transport	  via	  SLC41A2	  is	   inhibited	  
by	   Ca2+	   (Goytain	   and	   Qaumme,	   2005c).	   Both	  
SLC41A1	   and	   A2	   generate	   Mg2+	   currents	   in	   X.	  
oocyte,	  and	  the	  ionic	  uptake	  is	  voltage	  dependent	  
with	   an	   apparent	   affinity	   of	   0.75	   mM	   and	   0.31	  
mM,	   respectively	   (Goytain	  and	  Qaumme,	  2005b;	  
Goytain	   and	   Qaumme,	   2005c).	   Also	   SLC41A2	   is	  
widely	   expressed	   in	  mammalian	   tissues,	   but	   the	  
expression	   is	   not	   affected	   by	   low	   Mg2+	   diet	  
(Goytain	   and	  Qaumme,	  2005c).	  At	   the	   structural	  
level,	   SLC41A2	   shares	   >70%	   homology	   with	  
SLC41A1,	   and	   is	   also	   thought	   to	   have	   10	   trans-­‐
membrane	   domains,	   although	   this	   hypothesis	   is	  
not	   supported	   by	   a	   recent	   study	   (Sahni	   et	   al.,	  
2007)	   that	   instead	   suggests	   a	   structural	  
arrangement	   of	   2	   x	   five	   trans-­‐membrane	   spans	  
linked	   together	   by	   a	   supplementary	   span	  motif.	  
Hydrophobicity	  analysis	   indicates	  that	  the	  C-­‐	  and	  
N-­‐	   termini	   are	   located	   on	   different	   sites	   of	   the	  
cell	   membrane	   (Sahni	   et	   al.,	   2007),	   a	  
configuration	   that	  will	   be	   consistent	  with	  a	   total	  
of	  11	  trans-­‐membrane	  segments.	  	  
	  
ACDP2	  
The	   human	   ACDP	   gene	   family	   was	   identified	   by	  
Wang	  and	  collaborators	  (Wang	  et	  al.,	  2003a)	  as	  a	  
possible	   candidate	   of	   the	   urofacial	   syndrome.	  
Mapped	  to	  10q23-­‐10q24	  chromosome,	  this	  gene	  
family	  comprises	  4	  isoforms	  differentially	  located	  
in	   human	   tissues.	   ACDP1	   is	   essentially	   restricted	  
to	   brain.	   ACDP2	   is	   more	   widely	   expressed,	   but	  
still	   retains	   the	  highest	  expression	   in	  brain	  while	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being	  absent	  in	  skeletal	  muscle.	  Both	  ACDP3	  and	  
ACDP4	   are	   ubiquitous,	   but	   have	   the	   highest	  
expression	  in	  the	  heart	  (Wang	  et	  al.,	  2003b).	  The	  
murine	   distribution	   of	   ACDP	   isoforms	   is	   very	  
similar	   to	   that	  observed	   in	  humans	   (Wang	  et	  al.,	  
2004).	  Termed	  ancient	  conserved	  domain	  protein	  
because	   all	   isoforms	   have	   one	   domain	   in	  
common	   that	   appears	   to	   be	   phylogenetically	  
conserved	   from	   bacteria	   to	   man	   (Wang	   et	   al.,	  
2003a),	   these	   proteins	   share	   >50%	   homology	   to	  
the	   CorC	   transporter,	   which	   together	   with	   CorB	  
and	   CorD	   plays	   a	   role	   in	   Mg2+	   efflux	   in	   pro-­‐
karyotes.	  Over-­‐expression	  of	  ACDP2	  in	  X.	  oocytes	  
indicates	   that	   this	  protein	   can	   transport	   a	  broad	  
range	   of	   divalent	   cations	   including	   Mg2+,	   Co2+,	  
Mn2+,	  Sr2+,	  Ba2+,	  Cu2+,	  and	  Fe2+	  while	  Zn2+	  can	  inhibit	  
its	   activity	   (Goytain	   and	   Quamme,	   2005d).	  Mg2+	  
transport	   via	   ACDP2	   is	   voltage	   dependent	   and	  
occurs	   with	   a	   Km	   of	   ~0.5mM.	   The	   transport,	  
however,	   operates	   independently	   of	   Na+	   or	   Cl-­‐	  
ions	   (Goytain	   and	   Quamme,	   2005d).	   As	   in	   the	  
case	  of	  SLC41A1,	  the	  ACDP2	  gene	  becomes	  over-­‐
expressed	   following	   a	  Mg2+	   deficient	   diet	   (Goytain	  
and	  Qaumme,	  2005).	  	  	  
	  
NIPA	  
Located	  in	  the	  SPG6	  locus	  of	  chromosome	  15q11-­‐
q13,	   the	   NIPA1	   gene	   is	   so	   called	   for	   ‘non-­‐
imprinted	   in	   Prader-­‐Willi/Angelman	   syndrome,	   a	  
disease	   characterized	   by	   a	   complex	   develop-­‐
mental	   and	  multisystem	   disorder	   (Butler,	   1990).	  
Located	   among	   about	   30	   genes	   linked	   to	   this	  
disease	   (Butler,	   1990),	   NIPA1	   has	   also	   been	  
implicated	   in	   autosomal	   dominant	   hereditary	  
spastic	   paraplegia	   (HSP).	   The	   human	   and	  mouse	  
genome	   contain	   four	   members	   of	   the	   NIPA	  
family,	   termed	   NIPA1	   trough	   NIPA4,	   with	   an	  
overall	   similarity	   of	   ~40%.	   Homology	   between	  
human	  and	  mice	  proteins	   is	  high	  at	  around	  98%.	  
Studies	   conducted	   by	   Goytain	   and	   Quamme	  
indicate	   that	   both	   NIPA1	   and	   NIPA2	   (Goytain	   et	  
al.,	   2007;	   Goytain	   et	   al.,	   2008a)	   can	   operate	   as	  
Mg2+	  transporter.	  Characterized	  by	  a	  sequence	  of	  
323	   (NIPA1)	   and	   359	   amino	   acids	   (NIPA2)	  
arranged	  to	  form	  9	  and	  8	  transmembrane	  spans,	  
respectively,	   these	   two	   proteins	   can	   be	  
distinguished	  based	  on	  their	  Km	  and	  specificity	  for	  
Mg2+.	   While	   both	   proteins	   transport	   Mg2+	   in	   a	  
saturable	   fashion,	   NIPA1	   has	   a	   Km	   for	   Mg
2+	   of	  
~0.66mM	   (Goytain	   et	   al.,	   2007)	   as	   compared	   to	  
0.31mM	   for	   NIPA2	   (Goytain	   et	   al.,	   2008a).	   In	  
addition,	   NIPA2	   is	   highly	   specific	   for	   Mg2+	   while	  
NIPA1	  can	  also	  transport	  Sr2+,	  Fe2+	  or	  Co2+,	  albeit	  
to	   a	   lesser	   extent	   (Goytain	   et	   al.,	   2007).	   NIPA3,	  
instead,	   transports	   Sr2+,	   Ba2+,	   Fe2+	   and	   Cu2+	  
whereas	  NIPA4	   transport	   Sr2+	   and	   Ba2+.	   Interest-­‐
ingly,	  point	  mutations	  in	  NIPA1	  (i.e.	  G100R	  or	  T45R)	  
represent	   the	   basis	   for	   the	   insurgence	   of	  
autosomal	   dominant	   HSP	   (Rainier	   et	   al.,	   2003).	  
Both	   the	   glycine	   and	   threonine	   residues	   are	  
conserved	   among	   ortholog	   NIPA1	   channels	   in	  
different	  species.	  There	  are	  no	  similar	  consensus	  
sites	   in	   the	   paralogs	   NIPA2,	   NIPA3	   and	   NIPA4,	  
implying	  that	  the	  folding	  of	  these	  proteins	  might	  
be	   different.	   Although	   NIPA2	   appears	   to	   be	  
normal	   in	   HSP	   patients,	   it	   cannot	   functionally	  
replace	  NIPA1	   to	  ameliorate	  HSP	   symptoms,	  nor	  
can	   NIPA3	   or	   NIPA4	   substitute	   for	   the	   defective	  
NIPA1.	   This	   is	   somewhat	   surprising	   for	  NIPA2	   as	  
the	  gene	  encoding	   for	   this	  protein	   is	   part	  of	   the	  
30	   gene	   clusters	   associated	  with	   the	   Prade-­‐Willi	  
syndrome	   together	   with	  NIPA1.	   Presently,	   there	  
is	   no	   information	   available	   as	   to	   whether	   the	  
Prade-­‐Willi	  syndrome	  presents	  alterations	  in	  Mg2+	  
homeostasis.	  	  	  	  	  	  
	  
Huntingtin	  
The	  use	  of	  oligonucleotide	  microarray	  analysis	  to	  
screen	  for	  Mg2+-­‐regulated	  transcripts	  in	  epithelial	  
cells	   indicates	   Huntingtin-­‐interacting	   protein	   14	  
(HIP14)	   and	   its	   related	   protein	   HIP14-­‐like	  
(HIP14L)	   as	   significantly	   (~	  3fold)	  upregulated	  by	  
low-­‐extracellular	   Mg2+	   (Goytain	   et	   al.,	   2008b).	  
Formed	   by	   approximately	   532	   amino	   acids	  
organized	   in	   6	   transmembrane	   spans,	   HIP14	  
presents	   a	   strong	   sequence	   similarity	   to	   the	  
ankyrin	   repeat	   protein	   Akr1p	   (Li	   and	   Li,	   2004),	  
and	   a	   69%	   homology	   to	   HIP14L.	   In	   addition,	  
HIP14	   possesses	   a	   cytoplasmic	   DHHC	   cysteine-­‐
rich	   domain.	   Defined	   by	   the	   Asp-­‐His-­‐His-­‐Cys	  
sequence	   motif,	   this	   domain	   confers	   palmitoyl-­‐
acyltransferase	  activity	  to	  the	  protein	  and	  gives	  it	  
the	  ability	   to	  palmitoylate	  membrane	   components	  
and	  modulate	  their	  structure.	  Mg2+	  accumulation	  
via	  HIP14	  and	  HIP14L	  appears	  to	  be	  electrogenic,	  
voltage-­‐dependent,	   and	   saturable	   with	   Km	   of	  
~0.87	  and	  ~0.74mM,	  respectively	   (Goytain	  et	  al.,	  
2008b).	   Inhibition	  of	  palmitoylation	  activity	  by	  2-­‐
Br-­‐palmitate	   or	   deletion	   of	   the	   DHHC	   domain	  
decreases	  HIP14	  mediated	  Mg2+	  accumulation	  by	  
~50%,	   suggesting	   that	   palmitoylation	   is	   not	  
required	   for	   basal	   Mg2+	   transport.	   The	  
widespread	   tissue	   distribution	   and	   intracellular	  
localization	   of	   HIP14	   (nuclear	   and	   perinuclear	  
regions,	   Golgi	   complex,	   mitochondria,	   micro-­‐
tubules,	   endosomes,	   clathrin-­‐coated	   and	   non-­‐
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coated	  vesicles,	  and	  plasma	  membrane)(Yanai	  et	  
al.,	  2006)	  has	  implicated	  this	  protein	  in	  numerous	  
cellular	   processes	   including	   transcriptional	  
regulation,	  mitochondrial	  bioenergetics,	  structural	  
scaffolding,	   vesicle	   trafficking,	   endocytosis,	   and	  
dendrite	   formation	   (Yanai	   et	   al.,	   2006).	   Its	  
primary	   location,	   however,	   appears	   to	   be	   in	   the	  
Golgi	   and	   post-­‐Golgi	   vesicles	   (Yanai	   et	   al.,	   2006;	  
Goytain	   et	   al.,	   2008b).	   Hence,	   it	   can	   be	  
hypothesized	   that	   the	   ability	   of	   this	   protein	   to	  
favour	   Mg2+	   accumulation	   is	   linked	   to	   some	  
extent	  to	  the	  role	  HIP14	  plays	  in	  the	  physiological	  
functioning	   of	   the	   compart-­‐ments	   in	   which	   the	  
protein	   is	   located.	   At	   the	   pathological	   level,	   the	  
neuropathology	   of	   Huntington	   disease	   and	   the	  
occurrence	   of	   progressive	   neurodegenerative	  
disorders,	   cognitive	   deficits	   and	   choreic	  
movements	   typical	   of	   this	   disease	   are	   linked	   to	  
the	   abnormal	   expansion	   of	   glutamine	   residues	  
from	  <34	   to	   >37	   at	   the	   18th	   amino	   acid	   position	  
(Li	   and	   Li,	   2004).	   Presently,	   the	   mechanism	  
responsible	  for	  the	  insurgence	  of	  these	  defects	  is	  
unknown	   (Li	   and	   Li,	   2004).	   Similarly	   unknown	   is	  
whether	   the	   poly-­‐glutamine	   expansion	   alters	  
Mg2+	   transport,	   and	   whether	   perturbation	   of	  
Mg2+	  homeostasis	  plays	  any	  role	  in	  the	  uprising	  of	  
the	   neuronal	   defects	   typical	   of	   Huntington	  
disease.	  	  
	  
Mg2+	  transport	  in	  purified	  plasma	  membrane	  
vesicles	  	  
Because	  of	  the	   lack	  of	  functional	  cloning,	  several	  
laboratories	   including	   ours	   have	   resorted	   to	   the	  
use	   of	   plasma	   membrane	   vesicles	   to	   better	  
characterize	   how	   different	   Mg2+	   extrusion	  
mechanisms	  operate	   in	  particular	   cell	   types.	  The	  
plasma	   membrane	   model	   presents	   several	  
advantages	  including:	  1)	  the	  possibility	  to	  provide	  
a	   well	   defined	   ionic	   extra-­‐	   and	   intra-­‐vesicular	  
milieu	  composition	  to	  determine	  the	  modality	  of	  
operation	   of	   the	   various	  Mg2+	   transporters;	   and	  
2)	   the	   ability	   to	   investigate	   the	  operation	  of	   the	  
different	   Mg2+	   extrusion	   mechanisms	   in	   the	  
absence	   of	   Mg2+	   buffering	   by	   ATP,	   proteins	   or	  
other	   cytosolic	   components,	   and	   partitioning	  
within	   intracellular	   organelles.	   By	   purifying	   total	  
liver	   plasma	   membrane	   or	   cardiac	   sarcolemmal	  
vesicles	  as	  well	  as	  specific	  hepatic	  subpopulations	  
enriched	   in	   basolateral	   or	   apical	   domains,	   our	  
laboratory	   has	   been	   able	   to	   provide	   a	   better	  
understanding	   of	   the	   selective	   location	   and	  
specificity	   of	   the	   Na+-­‐	   dependent	   and	   Na+-­‐
independent	  Mg2+	   extrusion	  mechanisms	   in	   liver	  
cells	  and	  cardiac	  myocytes.	  	  
	  
The	  Na+-­‐dependent	  extrusion	  mechanism	  located	  
in	   the	   basolateral	   domain	   of	   the	   hepatocyte	   is	  
selectively	  activated	  by	  Na+	  (Cefaratti	  et	  al.,	  1998;	  
Cefaratti	   et	   al.,	   2000),	   and	   specifically	   inhibited	  
by	   imipramine	   (Cefaratti	   et	   al.,	   2000),	   but	   not	  
amiloride	  and	  amiloride	  derivates	  (Cefaratti	  et	  al.,	  
2000).	   Furthermore,	   the	   operation	   of	   the	  
exchanger	   is	   completely	   inhibited	   by	   pre-­‐
treatment	   of	   basolateral	   vesicles	   with	   alkaline	  
phosphatase,	  and	  restored	  by	  loading	  the	  vesicles	  
with	  ATP	  and	  PKA	  catalytic	  subunit	  (Cefaratti	  and	  
Ruse,	  2007;	  Cefaratti	  and	  Romani,	  2007),	   leaning	  
further	   support	   to	   the	  notion	   that	   this	  exchange	  
mechanism	  becomes	  operative	  upon	  phosphoryl-­‐
ation	   by	   cAMP.	   The	   Na+/Mg2+	   exchanger	  
continues	   to	   operate	   in	   the	   presence	   of	   zero	  
trans	  Mg2+	  across	  the	  plasma	  membrane	  (i.e.,	  20	  
mM	   Mg2+	   inside	   and	   outside	   the	   vesicles),	   an	  
indication	   that	   Mg2+	   extrusion	   does	   not	   depend	  
on	   the	   trans-­‐membrane	   gradient	   for	   Mg2+	   but	  
rather	  on	  that	  of	  Na+,	  with	  a	  Km	  lower	  than	  20mM	  
(Cefaratti	   et	   al.,	   1998),	   in	   good	   agreement	   with	  
kinetic	   data	   obtained	   in	   isolated	   hepatocytes	  
(Romani	   et	   al.,	   1993b)	   and	   other	   cell	   types	  
(Tashiro	   and	   Konishi,	   1997).	   Experiments	   based	  
on	  TPP+	  distribution	  have	   confirmed	   the	  electro-­‐
genicity	   of	   this	   exchange	   mechanism	   in	   plasma	  
membrane	   vesicles,	   and	   suggested	   a	   1Na+in	   for	  
1Mg2+out	   exchange	   ratio	   under	   the	   majority	   of	  
experimental	   conditions	   tested	   (Cefaratti	   et	   al.,	  
1998;	   Cefaratti	   et	   al.,	   2000;	   Cefaratti	   and	   Ruse,	  
2007).	   Interestingly,	   removal	  of	   intravesicular	  Cl-­‐	  
switches	   the	   stoichiometric	   ratio	   of	   the	  
exchanger	   from	   electrogenic	   to	   electroneutral	  
(i.e.	   2Na+in	   for	   1Mg
2+
out)	   (Cefaratti	   and	   Romani,	  
2011).	   Moreover,	   in	   the	   presence	   of	   intra-­‐
vesicular	   Cl-­‐	   an	   extrusion	   of	   ~35nmol	   Cl-­‐/mg	  
protein	  is	  observed	  within	  1min	  from	  the	  addition	  
of	   external	   Na+,	   in	   concomitance	   with	   the	  
extrusion	   of	   Mg2+	   and	   the	   accumulation	   of	  
external	   Na+	   into	   the	   vesicles	   (Cefaratti	   and	  
Romani,	   2011).	   Chloride	   ion	   extrusion	   is	   not	  
inhibited	  by	  anion	  transport	  inhibitors	  like	  DNDS,	  
DIDS,	  or	  niflumic	  acid,	  nor	  is	  it	  blocked	  by	  NKCC1	  
inhibitors	   like	   bumetanide	   or	   furosemide	  
(Cefaratti	  and	  Romani,	  2011),	  thus	  excluding	  that	  
it	   occurs	   via	  one	  of	   these	  mechanisms.	   The	  only	  
agent	  able	  to	  block	  the	  Cl-­‐	  extrusion	  is	  imipramine	  
(Cefaratti	  and	  Romani,	  2011),	  which	  specifically	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blocks	   the	   Na+/Mg2+	   exchanger	   operating	   in	   the	  
basolateral	   domain	   of	   the	   hepatocyte	   (Cefaratti	  
et	  al.,	  2000).	  Hence,	   it	  would	  appear	  that	  Cl-­‐	  can	  
be	  extruded	  either	  via	  the	  Na+/Mg2+	  exchanger	  or	  
via	   Cl-­‐	   channels	   for	   partial	   charge	   compensation	  
(Cefaratti	  and	  Romani,	  2011).	  The	  possibility	  of	  a	  
Cl-­‐	   extrusion	   via	   the	   Na+/Mg2+	   exchanger	   has	  
been	   suggested	   by	   (Rasgado-­‐Flores	   et	   al.,	   1994)	  
in	   dialyzed	   squid	   axons,	   and	   it	   would	   also	   be	   in	  
good	  agreement	  with	  the	  observation	  by	  Gunther	  
and	   collab-­‐orators	   that	   intracellular	   Cl-­‐	   has	   a	  
stimulatory	   role	   on	   the	   activity	   of	   the	   Na+/Mg2+	  
antiport	   in	   red	   blood	   cells	   (Ebel	   and	   Gunther,	  
2003).	  
	  
The	  basolateral	  domain	  of	   the	  hepatocyte	   is	   not	  
the	   only	   site	   in	   which	   the	   operation	   of	   a	   Mg2+	  
extrusion	   mechanism	   has	   been	   observed.	  
Experiments	   carried	   out	   in	   liver	   plasma	  
membrane	   vesicles	   enriched	   in	   apical	   domain	  
indicate	   the	  presence	  of	   two	  apparently	  distinct,	  
unidirectional	  Mg2+	  transport	  mechanisms,	  which	  
extrude	  intravesicular	  Mg2+	  for	  extravesicular	  Na+	  
and	  Ca2+,	  respectively	  (Cefaratti	  et	  al.,	  2000).	  	  
	  
This	   apical	   Na+-­‐dependent	   Mg2+	   transporter	  
presents	   a	   Km	   for	   Na
+
	  
comparable	   to	   the	   baso-­‐
lateral	   transporter,	  and	  selectively	  uses	  Na+	  over	  
other	  monovalent	  cations	   in	  a	  manner	  similar	   to	  
the	   basolateral	   exchanger.	   Like	   the	   basolateral	  
antiport,	   this	   exchanger	   transports	   electro-­‐
genically	   1Na+in:1Mg
2+
out	   (Cefaratti	   et	   al.,	   2000).	  
From	   the	   pharmacological	   standpoint	   the	   apical	  
and	   basolateral	   exchanger	   can	   be	   distinguished	  
based	   on	   the	   specific	   inhibition	   of	   the	   apical	  
exchanger	   by	   amiloride	   (Cefaratti	   et	   al.,	   2000),	  
although	  it	  retains	  a	  significant	  level	  of	  sensitivity	  
to	   imipramine	   inhibition,	  whereas	  only	   imipramine	  
can	  block	  the	  basolateral	  antiport	  (Cefaratti	  et	  al.,	  
2000).	   The	   apical	   exchanger	   can	   also	   be	  
distinguished	  from	  the	  basolateral	  antiport	  based	  
on	   its	   inability	   to	   operate	   in	   reverse	   mode	  
(Cefaratti	  et	  al.,	  2000).	  	  	  	  
	  
The	  Ca2+-­‐dependent	  Mg2+	  extrusion	  mechanism	  is	  
specifically	   located	   in	   the	   apical	   domain	   of	   the	  
hepatocytes,	   is	   activated	   by	   micromolar	   Ca2+	  
concentration	   (Km<50µM),	   and	   is	   insensitive	   to	  
alkaline	   phosphatase	   pre-­‐treatment	   (Cefaratti	  
and	  Ruse,	  2007;	  Cefaratti	  and	  Romani,	  2007).	  The	  
Mg2+	  extrusion	  elicited	  by	  this	  antiport	  occurs	  on	  
electro-­‐neutral	   basis	   (i.e.	   1Ca2+in:1Mg
2+
out)	  
(Cefaratti	   and	   Ruse,	   2007).	   The	   exchanger,	  
however,	  is	  not	  Ca2+	  specific,	  as	  Mg2+	  extrusion	  is	  
observed	  following	  the	  extravesicular	  addition	  of	  
micromolar	   concentrations	   of	   other	   divalent	  
cations	   (Ca2+>>Co2+=Mn2+>Sr2+>>Ba2+>Cu2+>>Cd2+)	  
(Cefaratti	   et	   al.,	   2000).	   Similarly	   to	   the	   apical	  
Na+/Mg2+	   antiport,	   the	   Ca2+-­‐dependent	  
mechanism	   is	   inhibited	   by	   amiloride	   or	  
imipramine	   (Cefaratti	   et	   al.,	   2000).	   This	  
observation	  raises	  the	  question	  as	  to	  whether	  we	  
are	   in	   the	   presence	   of	   two	   distinct	   apical	  
mechanisms,	   modulated	   by	   Na+	   and	   cations,	  
respectively.	   Several	   lines	   of	   evidence,	   however,	  
do	  not	  fully	  support	  this	  possibility.	  First,	   the	  co-­‐
addition	  of	  Na+	  and	  Ca2+	  in	  purified	  apical	  plasma	  
membrane	   vesicles	   subpopulations	   does	   not	  
appear	   to	   significantly	   enlarge	   Mg2+	   extrusion	  
(Romani,	   personal	   observation).	   Second,	  
amiloride	   inhibits	   both	   exchangers	   to	   a	  
comparable	   extent	   at	   a	   similar	   concentration	  
(Cefaratti	   et	   al.,	   2000).	   Third,	   alkaline	  
phosphatase	   treatment	  does	  not	  affect	   the	  Mg2+	  
extrusion	   elicited	   by	   either	   exchanger	   in	   apical	  
liver	   plasma	   membrane	   vesicles	   (Cefaratti	   and	  
Ruse,	  2007;	  Cefaratti	  and	  Romani,	  2007).	  Fourth,	  
neither	   of	   these	   exchangers	   can	   operate	   in	  
reverse	   at	   variance	   of	   the	   basolateral	   Na+/Mg2+	  
antiport.	   Taken	   together,	   these	   observations	  
suggest	   the	  operation	  of	  a	  non-­‐selective	  exchange	  
mechanism	  able	  to	  utilize	  monovalent	  or	  divalent	  
cations	   to	   promote	   Mg2+	   extrusion.	   At	   the	  
present	  time,	  the	  physiological	  implication	  for	  the	  
operation	   of	   such	   an	   exchanger	   in	   the	   apical	  
domain	   of	   the	   hepatocyte	   is	   not	   fully	   clear.	  
Circumstantial	  evidence,	  however,	  might	  support	  
a	   possible	   role	   of	   Mg2+	   in	   limiting	   Ca2+	  
sedimentation	   in	   the	   bile	   with	   consequent	  
formation	  of	  bile	  stones	  (Moore,	  1990).	  	  
	  
The	   operation	   of	   functionally	   similar	   Na+-­‐	   and	  
Ca2+-­‐dependent	   Mg2+	   extrusion	   mechanisms	   has	  
also	   been	   observed	   in	   cardiac	   sarcolemma	  
vesicles	   (Cefaratti	   and	   Romani,	   2007).	   As	   in	   the	  
case	   of	   liver	   plasma	  membrane	   vesicles,	   cardiac	  
sarcolemma	  vesicles	  do	  not	  require	  intravesicular	  
ATP	   for	   the	   operation	   of	   Mg2+	   transporters	  
(Cefaratti	   and	   Romani,	   2007),	   and	   pretreatment	  
of	   the	   vesicles	   with	   alkaline	   phosphatase	  
specifically	   inhibits	   the	   Na+-­‐dependent	   Mg2+	  
extrusion	   mechanism	   (Cefaratti	   and	   Romani,	  
2007).	   For	   technical	   reasons,	   it	   is	   presently	  
unknown	   whether	   the	   Ca2+/Mg2+	   exchanger	   in	  
sarcolemmal	   vesicles	   can	   also	   utilize	   Na+	   to	  
promote	  Mg2+	  extrusion.	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The	   operation	   of	   specific	   Mg2+	   accumulation	  
mechanisms	   has	   also	   been	   observed	   in	   plasma	  
membrane	   vesicles	   from	   brush	   border	   cells	   of	  
rabbit	   ileum	   (Juttner	   and	   Ebel,	   1998)	   and	   from	  
the	   duodenum	   and	   jejunum	   of	   rat	   (Baillien	   and	  
Cogneau,	   1995).	   By	   using	   membrane	   vesicles	  
from	   rabbit	   ileum	   and	   cell	   permeant	   and	   non-­‐
permeant	   Mag-­‐Fura,	   Juttner	   and	   Ebel	   have	  
observed	   the	   operation	   of	   a	   saturable	   Mg2+	  
uptake	   mechanism	   when	   the	   intracellular	   Na+	  
concentration	  is	  higher	  than	  the	  extracellular	  one	  
(Baillien	   and	   Cogneau,	   1995).	   This	   process	  
becomes	   inoperative	   when	   the	   Na+	   gradient	   is	  
reversed	   (i.e.,	   [Na+]i<[Na
+]o),	   the	   vesicles	   are	   in	  
zero	   trans	   condition	   for	   Na+,	   or	   external	   Na+	   is	  
removed.	   At	   variance	   with	   the	   transporter	  
observed	  in	  liver	  plasma	  membrane,	  the	  pathway	  
in	   ileum	  vesicles	   is	  not	  reversible	  and	  appears	  to	  
be	  electroneutral.	  Yet,	  it	  possesses	  a	  Km	  for	  Na
+	  of	  
16mM,	  a	  value	  similar	  to	  the	  Km	  calculated	  in	  liver	  
plasma	   membranes	   (Cefaratti	   et	   al.,	   1998),	   in	  
smooth	   muscle	   cells	   from	   guinea	   pig	   tenia	  
caecum	   (Tashiro	   and	   Konishi,	   1997),	   and	   in	  
chicken	   erythrocytes	   (Schatzmann,	   1993).	  
Another	  similarity	  with	  the	  transporter	  operating	  
in	  basolateral	  liver	  plasma	  membranes	  is	  the	  lack	  
of	   inhibition	   by	   amiloride	   analogs.	   In	   good	  
agreement	   with	   reports	   from	   Gunther	   and	  
collaborators	   (Ebel	   and	   Gunther,	   2003),	   this	  
transporter	  is	  modulated	  by	  intravesicular	  anions,	  
especially	   Cl-­‐	   and	   SCN-­‐,	   and	  markedly	   stimulated	  
by	   antagonists	   of	   anion	   transport	   (e.g.,	   H2-­‐DIDS)	  
(Juttner	  and	  Ebel,	  1998).	  	  
	  
The	  main	  difference	  between	  plasma	  membrane	  
vesicles	   from	   duodenum	   and	   jejunum	   (Baillien	  
and	  Cogneau,	  1995)	   is	   that	   a	   single	  Mg2+	  uptake	  
mechanism	  operates	   in	  the	  duodenum	  with	  a	  Km	  
of	   0.8mM,	  whereas	   two	   transporters	   operate	   in	  
the	   jejunum	  with	   Km	   values	   of	   0.15	   and	   2.4mM,	  
respectively.	   In	  both	   these	  experimental	  models,	  
Mg2+	  but	  not	  Ca2+	  accumulation	  is	  reduced	  in	  the	  
presence	   of	   alkaline	   phosphatase	   inhibitors	  
(Baillien	   et	   al.,	   2005),	   suggesting	   that	   Ca2+	   and	  
Mg2+
	  
are	   transported	   via	   distinct	   pathways.	   This	  
hypothesis	   is	   further	   supported	   by	   the	  
observation	   that	   Mg2+	   accumulation	   is	   inhibited	  
by	  amiloride	  but	  not	  by	  Ca2+	  channel	  antagonists.	  
Consistent	   with	   the	   report	   by	   Juttner	   and	   Ebel	  
(Juttner	   and	   Ebel,	   1998),	   Mg2+	   accumulation	   is	  
stimulated	   by	   an	   intravesicular	   electronegative	  
potential	   or	   an	   alkaline	   pHo	   (Baillien	   and	  
Cogneau,	   1995).	   The	   effect	   of	   external	   pH,	  
however,	  is	  lost	  when	  [Mg2+]o>1mM	  (Baillien	  and	  
Cogneau,	  1995).	  Under	  the	  latter	  condition,	  Mg2+	  
accumulation	  is	  enhanced	  by	  the	  presence	  of	  Na+	  
or	   K+	   in	   the	   extravesicular	   space	   but	   is	   inhibited	  
by	   the	   presence	   of	   divalent	   cations	  
(Co2+>Mn2+>Ca2+>Ni2+>Ba2+>Sr2+)	   (Baillien	   and	  
Cogneau,	  1995).	  	  
	  
Regulation	  of	  Mg2+	  transport	  and	  homeostasis	  
	  
While	   mammalian	   cells	   retains	   their	   basal	   Mg2+	  
content	   virtually	   unchanged	   under	   resting	  
conditions,	   compelling	   evidence	   supports	   the	  
ability	   of	   different	   hormones	   to	   induce	   the	  
movement	   of	   large	   amount	   of	   Mg2+	   in	   either	  
direction	   across	   the	   eukaryotes	   cell	   membrane.	  
As	   a	   result	   of	   these	   movements,	   changes	   in	  
serum,	   total	   and	   to	   a	   lesser	   extent	   free	   Mg2+	  
content	   have	   been	   observed.	   Further,	   these	  
changes	  have	  resulted	  in	  detectable	  variations	   in	  
Mg2+	   level	   within	   organelles,	   especially	   mito-­‐
chondria,	   with	   major	   repercussions	   on	   cellular	  
bioenergetics.	   A	   full	   understanding	   of	   the	  
physiological	   relevance	   of	   these	   changes	   in	  
cellular	  Mg2+	  content	  is	  far	  from	  complete.	  Yet,	  a	  
picture	  is	  slowly	  emerging,	  which	  relates	  changes	  
in	   total	   Mg2+	   content	   to	   the	   utilization	   of	  
metabolites	   (e.g.	   glucose)	   or	   to	   meaningful	  
changes	   in	  Mg2+	  content	  within	  discrete	  portions	  
of	   the	   cell	   or	   cellular	   organelles,	   whereby	  
variations	   in	   total	   Mg2+	   content	   translate	   into	  
changes	   in	   concentrations	   able	   to	  modulate	   the	  




Several	   classes	   of	   hormones	   induce	   Mg2+	  
extrusion	   from	   various	   cell	   types	   or	   perfused	  
tissues.	   For	   the	   most	   part,	   these	   hormones	   are	  
catecholamine	  or	  hormones	  that	  increase	  cellular	  
cAMP	  level	  by	  activating	  different	  GPCR	  receptors	  
at	  the	  cell	  membrane	  level.	  The	  extrusion	  elicited	  
by	   these	   agents	   affects	   to	   a	   varying	   extent	   the	  
Mg2+	   pools	   present	   within	   cytoplasm	   as	   well	   as	  
within	   cellular	   compartments.	   The	   extrusion	  
across	  the	  cell	  membrane	  primarily	  occurs	  via	  the	  
Na+/Mg2+	   exchanger	   previously	   described	  
although	   a	   (partial)	   contribution	   of	   the	   Na+-­‐
independent	   pathway	   cannot	   be	   excluded.	  
Magnesium	   extrusion	   can	   also	   be	   observed	  
following	   metabolic	   treatments	   that	   decrease	  
cellular	   ATP	   content,	   the	   main	   Mg2+	   buffering	  
component.	   Interestingly,	   several	   of	   the	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hormones	  that	  induce	  Mg2+	  extrusion	  also	  elicit	  a	  
glucose	   output	   from	   hepatocytes.	   Hence,	   it	  
would	   appear	   that	   at	   least	   in	   this	   organ	   Mg2+	  
extrusion	   is	   functionally	   associated	   with	   glucose	  
transport	  and	  utilization.	  	  	  	  
	  
Cyclic-­‐AMP	  Dependent	  Extrusion	  
Elliot	   and	   Rizack	   were	   the	   first	   to	   report	   an	  
accumulation	  of	  Mg2+	  in	  adipocytes	  stimulated	  by	  
adreno-­‐corticotrophic	  hormone	  in	  1974,	  although	  
they	   did	   not	   elucidate	   the	  modality	   of	   transport	  
(Elliot	   and	   Rizack,	   1974).	   The	   first	   extensive	  
characterization	   of	   an	   hormonal	   effect	   on	   Mg2+	  
transport	  was	  provided	  by	  Maguire	  and	  colleagues	  
in	   S49	   lymphoma	   cells	   and	  primary	   lymphocytes	  
stimulated	   by	   beta-­‐adrenergic	   agonist	   or	   PGE1	  
(Bird	   and	   Maguire,	   1978;	   Erdos	   and	   Maguire,	  
1980;	   Erdos	   and	   Maguire,	   1983;	   Grubbs	   et	   al.,	  
1984).	   Maguire	   and	   Erdos	   (1978)	   also	   provided	  
the	   first	   observation	   that	   stimulation	   of	   protein	  
kinase	   C	   enhanced	   Mg2+	   influx	   in	   S49	   cells	  
whereas	   beta-­‐adrenergic	   stimulation	   inhibited	  
the	  process.	  Observation	   carried	  out	   in	   S49	   cells	  
lacking	   protein	   kinase	   A	   or	   adenylyl	   cyclase,	  
however,	  indicated	  that	  cAMP	  was	  not	  mediating	  
the	   inhibitory	   effect	   of	   beta-­‐adrenergic	   agonists	  
(Maguire	   and	   Erdos,	   1978;	   Maguire	   and	   Erdos,	  
1980).	   At	   variance	   of	   what	   observed	   in	   primary	  
lymphocytes	  (Wolf	  et	  al.,	  1997),	  Mg2+	  transport	  in	  
S49	   cells	   appears	   to	   be	   independent	   of	   extra-­‐	  
cellular	  Na+	  concentration	  or	  membrane	  potential	  
(Grubbs	   and	  Maguire,	   unpublished	   observation).	  
Further,	  Mg2+	  turnover	  in	  S49	  required	  more	  than	  
40	   hours	   as	   compared	   to	   the	   much	   faster	   Ca2+	  
turn-­‐over,	  which	  was	  accomplished	  in	  less	  than	  3	  
hours	  (Grubbs	  et	  al.,	  1985).	  	  
	  
These	  initial	  observations	  were	  followed	  by	  a	  long	  
series	   of	   report	   supporting	   the	   notion	   that	   b-­‐
adrenergic	   agonists	   and	   other	   hormones	   control	  
Mg2+	   homeostasis	   in	   mammalian	   cells.	   In	   the	  
majority	  of	   eukaryotic	   cells,	   hormones	  or	   agents	  
that	   increase	   cellular	   cAMP	   level	   elicit	   a	  
significant	  extrusion	  of	  Mg2+	  into	  the	  extracellular	  
space	   or	   the	   circulation	   (Vormann	   and	   Gunther,	  
1987;	   Romani	   and	   Scarpa,	   1990a;	   Romani	   and	  
Scarpa,	  1990b).	  This	  effect	  has	  been	  observed	   in	  
cardiac	   ventricular	   myocytes	   (Vormann	   and	  
Gunther,	   1987;	   Romani	   and	   Scarpa,	   1990a;	  
Romani	  et	  al.,	  1993a;	  Howarth	  et	  al.,	  1994),	   liver	  
cells	   (Romani	   and	  Scarpa,	  1990b;	  Gunther	  et	  al.,	  
1991;	   Romani	   et	   al.,	   1993b;	   Fagan	   and	   Romani,	  
2000;	   Fagan	   and	   Romani,	   2001),	   red	   blood	   cells	  
(Matsuura	  et	  al.,	  1993),	  thymocytes	  (Gunther	  and	  
Vormann,	   1990b),	   and	   Erhlich	   ascites	   cells	   (Wolf	  
et	   al.,	   1994)	   among	  other	   cells	   (see	  Romani	   and	  
Scarpa,	   2000	   for	   a	  more	   comprehensive	   list),	   as	  
well	   as	   in	   whole	   anesthetized	   animals	   (Gunther	  
and	   Vormann,	   1992;	   Keenan	   et	   al.,	   1995).	   In	   all	  
cellular	  models,	  Mg2+	   extrusion	   is	   a	   fast	   process	  
that	  reaches	  the	  maximum	  within	  8min	  from	  the	  
application	   of	   the	   stimulus	   irrespective	   of	   the	  
hormone	   (catecholamine,	   isoproterenol,	   glucagon,	  
PGE1,	   or	   arachidonic	   acid)	   (Vormann	   and	  
Gunther,	   1987;	   Gunther	   and	   Vormann,	   1990a;	  
Romani	   and	   Scarpa,	   1990a;	   Romani	   and	   Scarpa	  
1990b;	   Matsuura	   et	   al.,	   1993;	   Howarth	   et	   al.,	  
1994;	  Wolf	  et	  al.,	  1994)	  or	  agent	  (i.e.	  forskolin	  or	  
cell	  permeant	  cyclic	  AMP	  analogs)	  (Vormann	  and	  
Gunther,	   1987;	   Gunther	   and	   Vormann,	   1990a;	  
Romani	   and	   Scarpa,	   1990a;	   Romani	   and	   Scarpa,	  
1990b;	   Matsuura	   et	   al.,	   1993;	   Romani	   et	   al.,	  
1993b;	   Fagan	   and	   Romani	   2000;	   Fagan	   and	  
Romani,	   2001)	  utilized	   to	   increase	   cellular	   cAMP	  
level.	   The	   key	   role	   of	   cAMP	   in	  modulating	  Mg2+	  
extrusion	  is	  further	  emphasized	  by	  the	  observation	  
that	  pretreatment	  with	  hormones	  or	  agents	  that	  
either	   decrease	   cAMP	   production,	   such	   as	  
carbachol	   (Romani	   and	   Scarpa,	   1990a;	   Romani	  
and	   Scarpa,	   1990b;	   Romani	   et	   al.,	   1993b)	   and	  
insulin	   (Romani	   et	   al.,	   2000),	   or	   prevent	   PKA	  
activation	   (e.g.	   Rp-­‐cAMP	   (Wolf	   et	   al.,	   1997))	  
inhibits	   cellular	   Mg2+	   mobilization.	   In	   an	   open	  
perfusion	   system,	   the	   amount	   of	  Mg2+	   extruded	  
from	   the	   organ	   returns	   towards	   baseline	   level	  
within	   8min	   from	   the	   application	   of	   the	   agonist	  
irrespective	   of	   its	   dose	   or	   persistence	   in	   the	  
perfusate	   (Romani	   and	   Scarpa,	   1990a;	   Romani	  
and	   Scarpa,	   1990b),	   suggesting	   a	   rapid	  
mobilization	  of	  Mg2+	   from	  a	  well	  defined	  cellular	  
pool	   that	   is	   rapidly	   depleted	   of	   its	   content.	   This	  
notion	   is	   further	  supported	  by	   the	  evidence	   that	  
submaximal	  doses	  of	  agonist	  sequentially	  infused	  
within	  a	  few	  minutes	  from	  each	  other	  elicit	  Mg2+	  
extrusions	  of	  progressively	  decreasing	  amplitudes	  
(Gunther	   and	   Vormann,	   1990a).	   Under	   all	   these	  
conditions,	   limited	   changes	   in	   cytosolic	   free	  
[Mg2+]i	   are	   observed	   (Fatholahi	   et	   al.,	   2000;	  
Amano	   et	   al.,	   2000),	   suggesting	   that	   Mg2+	   is	  
rapidly	   released	   from	   its	   binding	   and	   buffering	  
sites,	   or	   form	   cellular	   organelle(s)	   and	   extruded	  
across	   the	   cell	   membrane.	   Independent	   of	   the	  
hormone	   utilized	   the	   cAMP-­‐mediated	   Mg2+	  
extrusion	   occurs	   via	   the	   putative	   Na+/Mg2+	  
exchanger	  described	  previously.	   In	   fact,	  either	  the	  
removal	   of	   extracellular	   Na+	   (Gunther,	   1996)	   or	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the	   presence	   of	   agents	   like	   amiloride	   (Vormann	  
and	   Gunther,	   1987;	   Gunther,	   1996),	   which	  
inhibits	   Na+	   transport	   albeit	   in	   a	   non-­‐specific	  
manner,	   abolishes	   to	   a	   large	   extent	   the	   Mg2+	  
extrusion.	   Under	   either	   of	   these	   conditions,	   the	  
amplitude	   of	   Mg2+	   extrusion	   across	   the	   cell	  
membrane	   is	   hampered	   and	   a	   more	   sustained	  
rise	  in	  cytosolic	  free	  [Mg2+]i	  is	  observed	  (Fatholahi	  
et	  al.,	  2000;	  Amano	  et	  al.,	  2000),	   supporting	   the	  
notion	  that	  blocking	  Na+	  transport	  prevents	  Mg2+	  
from	   being	   extruded	   across	   the	   cell	   membrane	  
but	   not	   its	   released	   from	  binding/buffering	   sites	  
and/or	  cellular	  pool(s)	  into	  the	  cytoplasm.	  	  
	  
Cyclic-­‐AMP	  Independent	  Extrusion	  
In	   1989,	   Jakob	   and	   collaborators	   reported	   the	  
first	   observation	   that	   phenylephrine	   can	   also	  
elicit	   Mg2+	   extrusion	   from	   liver	   cells	   via	   alpha1-­‐
adrenergic	   stimulation	   (Jakob	   et	   al.,	   1989).	  
Subsequently,	   our	   laboratory	   (Keenan	   et	   al.,	  
1996;	   Fagan	   and	   Romani,	   2000)	   confirmed	   this	  
observation	  and	  provided	   the	   first	  evidence	   that	  
the	   stimulation	  of	  α1-­‐	   and	  β-­‐adrenergic	   receptor	  
are	   not	   alternative	   but	   rather	   additive	   and	  
complementary	   processes	   in	   eliciting	   Mg2+	  
extrusion	   from	   liver	   cells,	   especially	   when	   the	  
two	   classes	   of	   receptors	   are	   stimulated	   by	   mix	  
adrenergic	   agonists	   such	   as	   epinephrine	   or	  
norepinephrine	   (Keenan	   et	   al.,	   1996;	   Fagan	   and	  
Romani,	   2000).	   Pre-­‐treatment	   with	   insulin	   only	  
abolishes	   β-­‐adrenergic	   receptor	   mediated	   Mg2+	  
extrusion	   but	   leaves	   unaffected	   the	   Mg2+	  
mobilization	  mediated	   via	  α1-­‐adrenergic	   receptors	  
(Keenan	   et	   al.,	   1996).	   The	   inhibitory	   effect	   of	  
insulin	   persists	   even	   in	   cells	   treated	   with	   cell-­‐	  
permeant	  cAMP	  analogs	   (Keenan	  et	  al.,	  1996).	  A	  
similar	  inhibitory	  effect	  of	  insulin	  on	  b-­‐adrenergic	  
receptor	   mediated,	   cAMP-­‐modulated	   Mg2+	  
extrusion	  has	  been	  observed	  in	  cardiac	  myocytes	  
(Romani	   et	   al.,	   2000).	   This	   inhibition	   has	   been	  
largely	   interpreted	   as	   the	   consequence	   of	   an	  
inhibitory	   effect	   of	   insulin	   on	   the	   b-­‐adrenergic	  
receptor	  (Karoor	  et	  al.,	  1995)	  or	  a	  positive	  effect	  
of	   the	   hormone	   on	   the	   cytosolic	   phospho-­‐
diesterase	  degrading	  cAMP	  (Smoake	  et	  al.,	  1995).	  
A	   more	   recent	   report	   by	   Romero	   and	  
collaborators	   (Ferreira	   et	   al.,	   2004),	   however,	  
suggests	   that	   insulin	   can	   also	   modulate	   directly	  
the	   Na+/Mg2+	   exchanger,	   at	   least	   in	   red	   blood	  
cells.	  	  
	  
Fagan	   and	   Romani	   (2000;	   2001)	   further	  
investigated	   the	   modality	   of	   Mg2+	   extrusion	  
following	   α1-­‐adrenergic	   receptor	   stimulation	   in	  
liver	   cells.	   Their	   observation	   indicates	   that	  
phenylephrine-­‐induced	   Mg2+	   extrusion	   strictly	  
depends	   on	   the	   activation	   of	   capacitative	   Ca2+	  
entry	  (Fagan	  and	  Romani,	  2001).	  Inhibition	  of	  IP3-­‐
induced	   Ca2+	   release	   from	   the	   endoplasmic	  
reticulum,	   chelation	   of	   cytosolic	   Ca2+,	   or	  
inhibition	  of	  Ca2+	  entry	  at	   the	  plasma	  membrane	  
level	  all	   result	   in	  the	  complete	   inhibition	  of	  Mg2+	  
extrusion	   from	   the	   hepatocyte	   (Fagan	   and	  
Romani,	   2001).	   The	   scant	   information	   available	  
about	   possible	   binding	   of	   Mg2+	   by	   cellular	  
proteins	  prevented	  the	  authors	  from	  ascertaining	  
whether	   the	   extruded	  Mg2+	   was	  mobilized	   from	  
the	   ER	   or	   displaced	   from	   cytosolic	   binding	   sites	  
following	   the	   massive	   entry	   of	   Ca2+	   across	   the	  
hepatocyte	   cell	   membrane	   (Fagan	   and	   Romani,	  
2001,	  and	  refs	  therein).	  Extracellular	  Na+	  and	  Ca2+	  
are	  both	  required	  for	  the	  phenylephrine-­‐induced	  
Mg2+	   extrusion	   to	   occur	   (Fagan	   and	   Romani,	  
2001).	   The	   absence	   of	   extracellular	   Ca2+,	   in	   fact,	  
decreases	   the	   amplitude	   of	   Mg2+	   extrusion	   by	  
~15%	   to	   20%	   whereas	   extracellular	   Na+	   is	  
responsible	  for	  the	  remaining	  80%	  to	  85%	  of	  the	  
extrusion.	   It	   is	   presently	   unclear	   whether	   Mg2+	  
extrusion	   occurs	   via	   the	   Ca2+-­‐activated	   Na+-­‐
dependent	   mechanism	   observed	   in	   the	   apical	  
domain	   of	   the	   hepatocyte,	   or	   whether	   Na+	   is	  
required	   to	   maintain	   membrane	   potential	   and	  
facilitate	   Ca2+	   entry	   across	   the	   hepatocyte	   cell	  
membrane.	   It	   has	   to	   be	   noted,	   however,	   that	   in	  
the	   absence	   of	   receptor	   activation,	   thapsigargin	  
administration	   can	   mimic	   phenylephrine	  
stimulation	   and	   elicit	   Mg2+	   extrusion	   from	   the	  
hepatocyte,	   even	   in	   the	   absence	   of	   extracellular	  
Ca2+	   (Fagan	   and	   Romani,	   2001),	   although	   to	   a	  
lesser	   extent.	   Hence,	   it	   would	   appear	   that	   an	  
optimal	   level	  of	  cytosolic	  Ca2+	  has	   to	  be	  attained	  
in	   order	   for	   Mg2+	   extrusion	   to	   occur	   via	  
displacement	   from	   cellular	   binding	   sites	   or	   via	   a	  
Ca2+-­‐calmodulin-­‐activated	  mechanism	  (Fagan	  and	  
Romani,	  2001).	  	  	  	  	  	  	  	  
	  
Mg2+	  homeostasis	  and	  glucose	  
The	   presence	   of	   redundant	   Mg2+	   extrusion	  
mechanisms	   or	   modalities	   of	   activation	   of	   a	  
common	   Mg2+	   extrusion	   pathway	   raises	   the	  
question	  of	  the	  physiological	  significance	  of	  Mg2+	  
mobilization	   in	   mammalian	   cells.	   In	   the	   case	   of	  
cardiac	   myocytes,	   an	   increase	   in	   extracellular	  
Mg2+	  level	  has	  been	  associated	  with	  a	  modulatory	  
effect	  on	  the	  open	  probability	  of	  the	  L-­‐type	  Ca2+-­‐
channels	   (Wang	   and	   Berlin,	   2006)	   and	   a	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temporary	   decrease	   in	   SA	   node	   action	   potential	  
(Howarth	   et	   al.,	   1994).	   In	   the	   case	   of	   liver	   cells,	  
instead,	  Mg2+	  transport	  has	  been	  associated	  with	  
a	   regulatory	   role	   on	   glucose	   transport	   and	  
utilization.	   Under	   conditions	   in	   which	   hormones	  
like	   catecholamine	   (Keenan	   et	   al.,	   1996;	   Fagan	  
and	  Romani,	  2000),	  glucagon	  (Fagan	  and	  Romani,	  
2000),	   or	   phenylephrine	   (Keenan	   et	   al.,	   1996;	  
Fagan	   and	   Romani,	   2000)	   elicit	   Mg2+	   extrusion	  
from	  liver	  cells,	  a	  concomitant	  release	  of	  hepatic	  
glucose,	   mostly	   via	   glycogenolysis,	   has	   been	  
observed	   (Fagan	   and	   Romani,	   2000).	  
Interestingly,	   inhibition	   of	   Mg2+	   extrusion	   by	  
amiloride	  or	   imipramine	  also	  results	   in	  a	  marked	  
inhibition	   of	   hepatic	   glucose	   output	   (Fagan	   and	  
Romani,	   2000).	   The	   converse	   is	   also	   true.	  
Inhibition	   of	   glucose	   transport	   activity	   by	  
phlorethin	   results	   in	   a	   qualitatively	   similar	  
inhibition	   of	   Mg2+	   extrusion	   from	   liver	   cells	  
(Fagan	   and	   Romani,	   2000).	   The	   presence	   of	   a	  
close	   functional	   ‘link’	  between	  glucose	  and	  Mg2+	  
homeostasis	   is	   further	   emphasized	   by	   the	  
observation	   that	   overnight	   starvation	   results	   in	  
the	   complete	   depletion	   of	   hepatic	   glycogen	   and	  
glucose	   as	   well	   as	   in	   a	  marked	   decrease	   (minus	  
15%)	   of	   total	  Mg2+	   content	   as	   a	   consequence	   of	  
the	   activation	   of	   the	   pro-­‐glycemic	   hormones	  
catecholamine	  and	  glucagon	  (Torres	  et	  al.,	  2005).	  
Noteworthy,	   this	   decrease	   in	   hepatic	   Mg2+	  
content	   is	   equivalent	   to	   that	   elicited	   via	   in	   vitro	  
stimulation	   of	   perfused	   livers	   by	   the	   same	  
hormones	   (Torres	  et	  al.,	  2005),	  or	   that	  observed	  
in	  the	  liver	  of	  type-­‐I	  diabetic	  animals	  (Fagan	  et	  al.,	  
2004),	   which	   are	  markedly	   decreased	   in	   cellular	  
glycogen.	   The	   functional	   link	   between	   glucose	  
and	   Mg2+	   homeostasis	   is	   also	   observed	   under	  
conditions	   in	   which	   glucose	   accumulation	   is	  
stimulated	   by	   insulin	   or	   similar	   hormones	   in	  
cardiac	   ventricular	   myocytes	   (Romani	   et	   al.,	  
2000)	   or	   pancreatic	   beta	   cells	   (Henquin	   et	   al.,	  
1983).	   In	  both	  experimental	  models,	  the	  amount	  
of	   Mg2+	   accumulated	   within	   the	   cells	   is	   directly	  
proportional	   to	   the	  amplitude	  of	  glucose	  accum-­‐
ulation.	  Conversely,	  decreasing	  extracellular	  Mg2+	  
concentration	   directly	   reduces	   the	   amount	   of	  
glucose	  accumulated	  within	   the	   cells	   (Fagan	  and	  
Romani,	  2000;	  Romani	  et	  al.,	  2000).	  
	  
Although	   indirect,	   a	   clear	   proof	   of	   the	  
glucose/Mg2+	  relationship	   is	  provided	  by	  diabetic	  
conditions.	  Work	  by	  Altura’s	  group	  (Resnick	  et	  al.,	  
1993)	   and	   more	   recently	   by	   Resnick	   (Resnick,	  
1993)	  and	  Barbagallo	  (Barbagallo	  and	  Dominguez,	  
2007)	   indicate	   that	   cellular	   Mg2+	   content	   is	  
markedly	   decreased	   under	   type-­‐I	   and	   type-­‐II	  
diabetes.	   Originally	   observed	   in	   red	   blood	   cells	  
(Resnick	   et	   al.,	   1993;	   Resnick,	   1993;	   Barbagallo	  
and	   Dominguez,	   2007),	   the	   decrease	   has	   also	  
been	   reported	   in	   various	   other	   tissues	   including	  
muscles,	   liver	   (Fagan	   et	   al.,	   2004),	   and	   cardiac	  
myocytes	   (Reed	  et	   al.,	   2008).	   Interestingly,	  Mg2+	  
extrusion	   via	   β-­‐adrenergic	   signalling	   remains	  
operative	   and	   is	   actually	   up-­‐regulated	   in	   liver	  
cells	   from	   diabetic	   animals	   (Fagan	   et	   al.,	   2004)	  
while	  it	  is	  markedly	  inhibited	  in	  cardiac	  myocytes	  
from	   the	   same	   animals	   (Reed	   et	   al.,	   2008).	  
Whether	  this	  reflects	  a	  differential	  operation	  and	  
modulation	   of	   β2-­‐adrenergic	   receptors	   in	   liver	  
cells	  vs	  β1-­‐adrenergic	  receptors	   in	  cardiac	  cells	   is	  
not	   completely	   clear.	   Both	   cell	   models	   show	   a	  
marked	   inhibition	   of	   the	   Mg2+	   entry	  
mechanism(s),	  which	  persists	  also	  in	   liver	  plasma	  
membrane	   vesicles	   (Fagan	  et	   al.,	   2004;	   Cefaratti	  
et	   al.,	   2004).	   Addition	   of	   glucose	   or	   glycogen	   to	  
plasma	  membrane	  vesicles	  from	  diabetic	  animals	  
renormalizes	   the	   amplitude	   of	   Mg2+	   extrusion,	  
but	   is	   ineffective	  at	   restoring	  Mg2+	   accumulation	  
in	   vesicles	   (Cefaratti	   et	   al.,	   2004).	   The	   defect	   in	  
total	  cellular	  Mg2+	  content	  appears	  to	  be	  strongly	  
associated	  with	  the	  decrease	  in	  protein	  synthesis	  
and	  ATP	  production	  detected	  in	  the	  cells	  (Reed	  et	  
al.,	  2008).	  Supplementation	  of	  exogenous	   insulin	  
restores	   both	   these	   parameters	   as	   well	   as	  Mg2+	  
homeostasis	   and	   extrusion	   provided	   that	   insulin	  
is	   administered	   for	   at	   least	   two	   weeks	   (reed	   et	  
al.,	  2008).	  As	  indicated	  previously,	  it	  appears	  that	  
the	   role	   of	   insulin	   in	   modulating	   Mg2+	  
homeostasis	   is	   not	   restricted	   to	   controlling	  
glucose	   homeostasis	   and	   accumulation	   or	   the	  
release	   of	   pro-­‐glycemic	   hormones	   like	   glucagon,	  
but	   extends	   to	   a	   direct	   modulation	   of	   the	  
Na+/Mg2+	   exchanger	   (Ferreira	   et	   al.,	   2004).	   The	  
latter	   effect	   would	   not	   only	   directly	   increase	  
cellular	   Mg2+	   content	   but	   it	   could	   also	  
reverberate	   on	   the	   insulin	   receptor	   itself.	   Data	  
obtained	  in	  animals	  maintained	  on	  low	  Mg2+	  diet	  
indicate	   that	   a	  decrease	   in	   cellular	  Mg2+	   content	  
affects	   the	   ability	   of	   the	   insulin	   receptor	   to	  
properly	   phosphorylate	   the	   downstream	   insulin	  
receptor	   substrate	   (IRS)	   and	   propagate	   the	  
signalling	  within	  muscle	  cells	  (Suarez	  et	  al.,	  1995).	  
This	  result	  might	  be	  of	  relevance	  in	  explaining	  the	  
decrease	   in	   glucose	   accumulation	   observed	   in	  
skeletal	   muscles	   under	   diabetic	   conditions	  
(Suarez	  et	  al.,	  1995).	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Mg2+	  homeostasis	  and	  ATP	  
Hormonal	   stimuli	   represent	   the	   most	   dynamic	  
modality	  by	  which	  a	  cell	  can	  rapidly	  extrude	  10%	  
to	  15%	  of	   its	   total	  cellular	  Mg2+	  content	  within	  a	  
few	  minutes	   from	  the	  application	  of	   the	  agonist.	  
Mg2+,	   however,	   can	   also	   be	   extruded	   following	  
the	   treatment	   with	   various	   agents	   that	   impact	  
cellular	   ATP	   content	   and	   production.	   Cyanide	  
(Harman	   et	   al.,	   1990;	   Dalal	   and	   Romani,	   2010),	  
mitochondrial	   uncouplers	   (Akerman,	   1981;	  
Kubota	   et	   al.,	   2005),	   fructose	   (Gaussin	   et	   al.,	  
1997),	   ethanol	   (Tessman	   and	   Romani,	   1998),	   or	  
hypoxia	  (Gasbarrini	  et	  al.,	  1992)	  are	  just	  some	  of	  
the	   agents	   whose	   addition	   impact	   cellular	   Mg2+	  
homeostasis.	   All	   these	   agents,	   in	   fact,	   have	   in	  
common	  that	  they	  decrease	  cellular	  ATP	  content	  
by	   either	   preventing	   the	   mitochondrial	   electron	  
chain	   from	   generating	   ATP	   at	   various	   levels	  
(cyanide	   or	   uncouplers),	   or	   by	   acting	   as	   an	   ATP	  
trap	   (fructose),	   or	   by	   altering	   the	   redox	   state	   of	  
pyridine	   nucleotide	  within	   the	  mitochondrion	   or	  
the	   cell	   (ethanol).	   As	   ATP	   represents	   the	   major	  
buffering	   component	   for	   Mg2+	   within	   the	   cell	  
(Scarpa	   and	   Brinley,	   1981;	   Luthi	   et	   al.,	   1999),	   a	  
decrease	   in	   this	   phosphonucleotide	   moiety	  
results	  in	  an	  increase	  in	  cytosolic	  free	  [Mg2+]i,	  and	  
ultimately	  in	  a	  detectable	  extrusion	  from	  the	  cell	  
(Harman	   et	   al.,	   1990;	   Gasbarrini	   et	   al.,	   1992;	  
Gaussin	  et	  al.,	  1997;	  Tessman	  and	  Romani,	  1998;	  
Dalal	  and	  Romani,	  2010).	  The	  Mg2+	  extrusion	  can	  
be	   observed	   to	   a	   larger	   extent	   in	   erythrocytes,	  
which	   possess	   limited	   cellular	   buffering	   capacity	  
and	  no	  compartmentation	  (Hwa	  et	  al.,	  1993),	  but	  
it	   can	   also	   be	   observed	   in	   cells	   that	   present	  
additional	   buffering	   by	   proteins	   or	   cellular	  
organelles	   in	   addition	   to	   phosphonucleotides	  
(Harman	   et	   al.,	   1990;	   Gasbarrini	   et	   al.,	   1992;	  
Gaussin	  et	  al.,	  1997;	  Tessman	  and	  Romani,	  1998;	  
Dalal	  and	  Romani,	  2010).	   In	  the	  case	  of	  fructose,	  
the	   changes	   in	   cytosolic	   Mg2+	   have	   been	  
associated	   with	   an	   activation	   of	   the	   glycogen	  
phosphorylase,	   which	   ultimately	   results	   in	  
glycogenolysis	   activation	   and	   glucose	   utilization	  
to	  restore	  ATP	  levels	  (Gaussin	  et	  al.,	  1997).	  In	  the	  
majority	   of	   these	   experimental	   conditions,	   the	  
increase	   in	   cytosolic	   free	   [Mg2+]i	   is	   usually	  
modest,	   and	   considerably	   lower	   than	   the	  
increase	   expected	   to	   occur	   based	   upon	   the	  
corresponding	   decrease	   in	   ATP	   level,	   which	  
strongly	   supports	   the	  notion	   that	  Mg2+	   is	   for	   the	  
most	   part	   extruded	   from	   the	   cell.	   Furthermore,	  
as	  ATP	  level	  decreases	  as	  a	  result	  of	  mitochondria	  
poisoning	  or	  changes	  in	  pyridine	  nucleotide	  ratio,	  
it	  would	  appear	  that	  not	  phosphorylation	  but	  the	  
rise	  in	  cytosolic	  Mg2+	  albeit	  modest	  is	  sufficient	  to	  
activate	  the	  Mg2+	  extrusion	  mechanism	  and	   limit	  
the	   rise	   in	   cytosolic	   free	   Mg2+	   concentration	   to	  
approximately	  100-­‐200	  mM	  at	  the	  most	  (Harman	  
et	  al.,	  1999).	  
	  
Cellular	   ATP	   plays	   a	   key	   role	   in	   regulating	   Mg2+	  
extrusion.	   Evidence	   for	   this	   role	   has	   been	  
provided	   in	   the	   giant	   squid	   axon	   (Di	   Polo	   and	  
Beauge’,	   1988)	   as	   well	   as	   in	   mammalian	  
hepatocytes	   (Gunther	   and	   Hollriegl,	   1993)	   or	  
erythrocytes	  (Gunther	  et	  al.,	  1995).	  In	  squid	  axon,	  
the	   Na+-­‐dependent	   Mg2+	   extrusion	   requires	   a	  
physiological	   level	   of	   ATP.	   As	   the	   phospho-­‐
nucleotide	  level	  decreases,	  so	  does	  the	  amplitude	  
of	   extrusion	   (Gunther	   and	   Hollriegl,	   1993).	   In	  
erythrocytes	   and	   hepatocytes,	   instead,	   ATP	  
appears	   to	   regulate	   the	   Na+-­‐independent	   Mg2+	  
extrusion	   process	   (Gunther	   and	   Hollriegl,	   1993;	  
Gunther	   et	   al.,	   1995).	   The	   exact	   role	   of	   ATP	   in	  
regulating	   the	   process,	   however,	   is	   unclear	   as	   it	  
does	   not	   appear	   that	   the	   extrusion	   process	   is	  
mediated	  by	  an	  ATPase	  mechanism.	  This	  notion	  is	  
supported	  by	   the	  observation	   that	  a	  decrease	   in	  
cellular	  ATP	  level	  (as	   it	  occurs	  for	  example	  under	  
diabetic	   or	   alcoholic	   conditions)	   paradoxically	  
results	   in	   an	   increased	  extrusion	  of	  Mg2+	   via	   the	  
Na+-­‐dependent	   mechanism	   in	   a	   manner	   directly	  
proportional	   to	   the	   decrease	   in	   ATP	   level	  
(Tessman	  and	  Romani,	  1998;	  Fagan	  et	  al.,	  2004).	  
Hence,	   it	   appears	   that	   the	   role	   of	   ATP	   is	  
predominantly	   that	   of	   a	   ligand	   for	  Mg2+	   both	   in	  
the	   cytoplasm	   and	   the	   mitochondrial	   matrix	  
(Scarpa	  and	  Brinley,	  1981;	  Luthi	  et	  al.,	  1999),	  and	  
that	   a	   decrease	   in	   ATP	   results	   in	   an	   increase	   in	  
free	  Mg2+	  and	   its	  consequent	  extrusion	   from	  the	  
cell.	  	  
	  
Mg2+	  accumulation	  	  
The	   identification	   of	   several	   Mg2+	   entry	  
mechanisms	  strongly	  support	  the	  hypothesis	  that	  
cellular	   Mg2+	   is	   dynamically	   maintained	   through	  
the	  operation	  of	  entry	  and	  exit	  mechanisms	  that	  
are	   differentially	   regulated	   by	   hormones	   and	  
metabolic	   conditions.	   A	   striking	   difference	   is	  
there,	   however,	   between	   the	  Mg2+	   exit	   and	   the	  
Mg2+	   entry	   mechanisms.	   In	   the	   case	   of	   Mg2+	  
extrusion	   mechanisms	   we	   have	   a	   good	  
understanding	   of	   the	   signalling	   activating	   these	  
mechanisms	   but	   we	   lack	   any	   structural	  
information	   about	   the	   mechanisms	   themselves.	  
In	   the	   case	   of	   Mg2+	   entry	   mechanisms,	   instead,	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we	  do	  have	   structural	   information	  about	   several	  
of	   these	   mechanisms	   but	   for	   the	   most	   part	   we	  
lack	   detailed	   information	   about	   their	   individual	  
activation	   by	   hormones	   or	   second	   messengers,	  
and	   their	   possible	   cooperation	   under	   specific	  
conditions.	  	  
	  
Role	  of	  Protein	  Kinase	  C	  
Experimental	  evidence	  indicates	  that	  mammalian	  
cells	   can	  accumulate	   large	  amounts	  of	  Mg2+	  as	  a	  
result	   of	   hormonal	   stimulation.	   Hormones	   like	  
carbachol,	   vasopressin,	   angiotensin-­‐II,	   or	   insulin	  
have	   been	   indicated	   as	   able	   to	   either	   inhibit	  
cAMP-­‐mediated	   Mg2+	   extrusion	   or	   reverse	   the	  
extrusion	   into	  Mg2+	   accumulation	   in	   various	   cell	  
types	   (Romani	  and	  Scarpa,	  1990a;	  Romani	  et	  al.,	  
2000).	  The	   list	  of	  cells	   that	   respond	  to	  hormonal	  
stimulation	   by	   accumulating	   Mg2+	   is	   rather	   long	  
[see	   Romani	   and	   Scarpa,	   2000	   for	   a	   list],	   and	  
involve	  all	  kind	  of	  cells:	  cardiac	  myocytes	  (Romani	  
and	  Scarpa,	  1990a;	  Romani	  et	  al.,	  2000),	  smooth	  
muscle	   cells	   (Touyz	   and	   Schiffrin,	   1996),	  
hepatocytes	  (Romani	  and	  Scarpa,	  1990b;	  Romani	  
et	   al.,	   1992),	   platelets	   (Hwang	   et	   al.,	   1993),	  
lymphocytes	   (Grubbs	   and	   Maguire,	   1986),	  
fibroblasts	   (Ishijima	   and	   Tatibana,	   1994),	   and	  
pancreatic	   beta	   cells	   (Henquin	  et	   al.,	   1983),	   just	  
to	   name	   a	   few.	   In	   addition	   to	   inhibiting	   cAMP	  
production,	   several	   of	   the	   hormones	   indicated	  
above	  can	  activate	  protein	  kinase	  C	  (PKC)	  as	  part	  
of	   their	   cellular	   signalling.	  Evidence	   supporting	  a	  
role	   of	   PKC	   in	  mediating	  Mg2+	   accumulation	   has	  
been	   provided	   by	   several	   laboratories.	   Maguire	  
and	   collaborators	   have	   indicated	   that	   adminis-­‐
tration	   of	   phorbol-­‐myristate	   acetate	   (PMA),	  
which	   directly	   activates	   PKC,	   elicits	   a	   marked	  
accumulation	   of	   Mg2+	   in	   S49	   lymphoma	   cells	  
(Erdos	   and	   Maguire,	   1983).	   A	   similar	   effect	   of	  
PMA	   has	   been	   reported	   by	   Somogyi’s	   group	   in	  
thymocytes	   (Csermely	   et	   al.,	   1987),	   and	   by	   our	  
laboratory	   in	   cardiac	   myocytes	   (Romani	   et	   al.,	  
1992)	   and	   hepatocytes	   (Romani	   et	   al.,	   1992).	  
Furthermore,	  our	  group	  has	  reported	  that	  down-­‐
regulation	  of	  PKC	  by	  exposure	  to	  a	   large	  dose	  of	  
PMA	  for	  3	  hours	  completely	  abolishes	  the	  ability	  
of	   cardiac	   and	   liver	   cells	   to	   accumulate	   Mg2+	  
while	   leaving	   unaffected	   the	   responsiveness	   of	  
these	  cells	   to	  adrenergic	  agonists	   (Romani	  et	  al.,	  
1992).	   An	   inhibitory	   effect	   has	   also	   been	  
observed	   following	   administration	   of	   the	   PKC	  
inhibitors	   calphostin	   (Touyz	   and	   Schiffrin,	   1996)	  
or	   staurosporine	   (Gunther	   and	   Vormann,	   1995).	  
Alteration	   in	   PKC	   distribution	   and	   activity	   and	  
defective	   accumulation	   of	   Mg2+	   has	   been	  
observed	  in	  arterial	  smooth	  muscle	  cells	  (Yang	  et	  
al.,	   2001),	   hepatocytes	   of	   animals	   exposed	   to	  
alcohol	   (Torres	  et	   al.,	   2010),	   and	   in	   liver	   cells	   of	  
diabetic	  animals	  (Tang	  et	  al.,	  1993).	  	  
	  
Protein	   kinase	   C	   activation	   is	   only	   part	   of	   the	  
integral	  response	  of	  hormones	   like	  angiotensin-­‐II	  
or	   vasopressin.	   The	   interaction	   of	   these	  
hormones	   with	   their	   receptor,	   in	   fact,	   activates	  
phospholipase	  C	  which,	  in	  turn	  hydrolyses	  PIP2	  to	  
generate	   diacylglycerol	   (DAG)	   and	   IP3.	   In	   turn,	  
these	   two	   molecules	   activate	   protein	   kinase	   C	  
and	   IP3	   receptor	   in	   the	   ER,	   respectively.	  
Activation	   of	   the	   latter	   receptor	   results	   in	   a	  
marked	   but	   transient	   increase	   in	   cytosolic	   Ca2+,	  
and	  in	  a	  more	  sustained	  entry	  of	  Ca2+	  through	  the	  
capacitative	   Ca2+	   entry	   mechanism.	   Hence,	   Ca2+	  
signalling	  is	  an	  integral	  component	  of	  the	  cellular	  
response	   elicited	   by	   these	   hormones.	   Yet,	   the	  
contribution	   of	   this	   second	   messenger	   in	  
mediating	   Mg2+	   accumulation	   is	   poorly	   defined.	  
Liver	   cells	   loaded	   with	   Bapta-­‐AM,	   which	  
effectively	   chelates	   cytosolic	   Ca2+,	   are	   unable	   to	  
extrude	   and	   accumulate	   Mg2+	   following	  
stimulation	   by	   phenylephrine	   and	   PMA,	  
respectively	   (Romani	  et	  al.,	   1993b).	   The	  artificial	  
increase	   in	   cytosolic	  Ca2+	  elicited	  by	   thapsigargin	  
administration	   also	   prevents	   Mg2+	   accumulation	  
(Romani	   et	   al.,	   1993b)	   and	   actually	   induces	   a	  
Mg2+	   extrusion	   from	   the	   liver	   cell	   if	   applied	   for	  
more	   than	  3-­‐5	  min	   (Romani	  et	  al.,	   1993b;	   Fagan	  
and	   Romani,	   2001).	   Because	   of	   the	   different	  
time-­‐scale	   and	   amplitude	   of	   the	   changes	   in	  
cellular	   Ca2+	   and	   Mg2+	   content	   (Romani	   et	   al.,	  
1993b),	   it	   is	   difficult	   to	   properly	   correlate	   these	  
experimental	   variations.	   Cytosolic	   free	   Ca2+	  
transiently	  increases	  several	  orders	  of	  magnitude	  
while	  cytosolic	   free	  Mg2+,	  which	   is	  already	   in	  the	  
millimolar	   or	   submillimolar	   range,	   increases	   by	  
~10-­‐15%	   (Fatholahi	   et	   al.,	   2000)	   at	   the	   most,	  
although	   in	   absolute	   terms	   this	   amount	   is	   far	  
larger	   than	   the	   overall	   change	   in	   cytosolic	   Ca2+	  
mass.	  	  
	  
An	   unresolved	   point	   of	   inconsistency	   in	   the	   role	  
of	   Ca2+	   and	   PKC	   signalling	   in	   regulating	   Mg2+	  
accumulation	   is	  provided	  by	  the	  reports	  that	  the	  
administration	  of	  phenylephrine,	  which	  activates	  
PKC	   signalling	   in	   addition	   to	   the	   inositol	   1,4,5	  
trisphosphate/Ca2+	  pathway,	  does	  not	  elicit	  Mg2+	  
accumulation	  but	   induces	   a	  Mg2+	   extrusion	   from	  
liver	   cells	   (Fagan	   and	   Romani,	   2001).	   This	   point	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raises	   the	   question	   as	   to	   what	   modulates	   the	  
differential	   response	   of	   the	   cell	   to	   the	  
administration	   of	   phenylephrine	   or	   vasopressin.	  
One	   possibility	   could	   be	   that	   different	   PKC	  
isoforms	   are	   activated	   under	   one	   condition	   and	  
not	   the	  other.	  For	  example,	  hepatocytes	  possess	  
3	  classical	  and	  at	  least	  2	  novel	  PKC	  isoforms	  (Tang	  
et	   al.,	   1993).	   Thus,	   it	   is	   reasonable	   to	   envisage	  
that	  one	  isoform	  (or	  class	  of	  isoforms)	  is	  involved	  
in	  mediating	  Mg2+	  accumulation	  whereas	  another	  
isoform	   (or	   class	   of	   isoforms)	   is	   involved	   in	  
modulating	   Mg2+	   extrusion.	   Consistent	   with	   this	  
hypothesis,	   recent	   data	   from	   our	   laboratory	  
suggests	   that	   PKCe	   is	   essential	   for	   Mg2+	  
accumulation	  to	  occur	  (Torres	  et	  al.,	  2010).	  Under	  
conditions	  in	  which	  the	  expression	  of	  this	  isoform	  
is	   inhibited	   by	   antisense	   or	   its	   translocation	   to	  
the	  cell	  membrane	  is	  prevented	  —	  for	  example	  —
by	  ethanol	  administration,	  no	  Mg2+	  accumulation	  
can	  be	  detected	  in	  liver	  cells	  (Torres	  et	  al.,	  2010).	  
Interestingly,	   this	   PKC	   isoform	   has	   the	   highest	  
affinity	   for	  Mg2+	  among	  all	  PKC	   isoenzymes,	  with	  
a	  Km	  of	   ~1mM	   (Konno	  et	  al.,	   1989),	   close	   to	   the	  
physiological	   free	   [Mg2+]i	   measured	   in	   the	  
cytoplasm	  of	  the	  hepatocyte	  (Corkey	  et	  al.,	  1986;	  
Fatholahi	  et	  al.,	  2000)	  and	  other	  mammalian	  cells	  
as	  well	   (Touyz	  and	  Schiffrin,	  1996).	  Although	   the	  
mechanism	   ultimately	   responsible	   for	   Mg2+	  
accumulation	   into	   the	   hepatocyte	   has	   not	   been	  
identified,	   it	   is	   worth	   considering	   the	   recent	  
observation	   by	   Bindels	   and	   collaborators	   that	   in	  
the	  absence	  of	  PKC	  activation	  or	  following	  RACK1	  
over-­‐expression,	   RACK1	   can	  bind	   to	   TRPM6,	   and	  
possibly	  TRPM7,	  at	  the	  level	  of	  the	  kinase	  domain	  
and	  inhibit	  the	  channel	  activity	  (Cao	  et	  al.,	  2008).	  	  
	  
Role	  of	  MAPKs	  
These	  results	  mentioned	  above,	  however,	  do	  not	  
exclude	   the	   possibility	   that	   additional	   signalling	  
pathways	   (e.g.	   MAPKS)	   are	   involved	   in	  
determining	   the	   differing	   response	   of	   the	  
hepatocyte	   under	   apparently	   similar	   stimulatory	  
conditions.	   In	   agreement	   with	   previous	   reports	  
from	   Altura’s	   group	   (Yang	   et	   al.,	   2000)	   and	  
Touyz’s	   laboratory	   (Touyz	   and	   Yao,	   2003),	   our	  
laboratory	   has	   evidenced	   that	   pharmacological	  
inhibition	  of	  ERK1/2	  and	  p38	  MAPKs	  in	   liver	  cells	  
abolishes	   PKC	   mediated	   Mg2+	   accumulation	  
(Torres	  et	  al.,	   2006).	   In	   this	   respect,	   it	   has	   to	  be	  
noted	  that	  the	  inhibition	  of	  MAPKs	  hampers	  Mg2+	  
accumulation	   in	   vascular	   smooth	   muscle	   cells,	  
and	   significantly	   affect	   cyclin	   activity	   (Touyz	   and	  
Yao,	   2003)	   and	   consequently	   the	   ability	   of	   the	  
cells	  to	  progress	  in	  the	  cell	  cycle	  (Touyz	  and	  Yao,	  
2003).	   This	   effect	   may	   occur	   via	   changes	   in	  
nuclear	   functions	   directly	   regulated	   by	   Mg2+,	   as	  
proposed	  by	  Rubin	   (2005)	   and/or	   via	   changes	   in	  
nuclear	   functions	   of	   ERK2,	   which	   depends	   on	  
Mg2+	   level	   to	   properly	   dimerize,	   translocate	   and	  
activate	  specific	  nuclear	  targets	  (Waas	  and	  Dalby,	  
2003).	   The	   role	   of	   ERK1/2	   in	   Mg2+	   regulation	   is	  
further	   emphasized	   by	   the	   recent	   report	   that	  
increased	   phosphorylation	   of	   ERK1/2	   and	  
increased	   expression	   of	   TRPM6	   has	   been	  
observed	   upon	   EGF	   administration	   to	   renal	  
epithelial	   cells	   (Ikari	   et	   al.,	   2008;	   Ikari	   et	   al.,	  
2010).	   The	   role	   of	   these	  MAPKs,	   however,	   is	   far	  
from	   being	   elucidated	   as	   this	   kinase	   appears	   to	  
be	   involved	   to	   some	   extent	   in	   also	   mediating	  
Mg2+	   extrusion	   (Kim	   et	   al.,	   2005;	   Torres	   et	   al.,	  
2006).	  	  
	  
Role	  of	  EGF	  
As	   mentioned,	   direct	   and	   indirect	   evidence	  
suggests	   a	   key	   role	   of	   EGF	   in	   modulating	   Mg2+	  
accumulation,	   at	   least	   in	   kidney	   cells.	   The	  
administration	   of	   EGF	   controls	   proper	   operation	  
of	  TRPM6	  in	  the	  apical	  domain	  of	  renal	  epithelial	  
cells	   to	   promote	  Mg2+	   accumulation	   (Ikari	  et	   al.,	  
2008;	   Thebault	   et	   al.,	   2009;	   Ikari	   et	   al.,	   2010).	  
Point	  mutations	  in	  EGF	  sequence	  result	  in	  limited	  
function	   of	   TRPM6,	   and	   limited	   or	   no	   Mg2+	  
accumulation	  within	  the	  cells	  (van	  der	  Wjist	  et	  al.,	  
2009).	   The	   modulation	   of	   TRPM6	   appears	   to	  
occur	   via	   MAPKs	   signalling,	   most	   likely	   ERK1/2	  
coupled	  to	  activator	  protein-­‐1	  (AP-­‐1)	  (Ikari	  et	  al.,	  
2010).	   Indirect	   evidence	   of	   EGF	   regulation	   is	  
provided	  by	  the	  evidence	  that	  antibodies	  against	  
EGF	   used	   in	   several	   forms	   of	   colon	   cancer	  
(Cunningham	   et	   al.,	   2004;	   Dimke	   et	   al.,	   2010)	  
induce	  Mg2+	  wasting	  and	  hypomagnesaemia.	  
	  	  	  
Serum	  Mg2+	  level	  and	  Mg2+	  sensing	  mechanism	  	  
	  
The	  experimental	  evidence	  that	  mammalian	  cells	  
accumulate	   or	   extrude	   Mg2+	   under	   a	   variety	   of	  
experimental	  conditions	  suggests	  the	  presence	  of	  
a	   sensor	   for	   the	   cytosolic	   Mg2+	   concentration,	  
whereby	   the	   cell	   would	   operate	   accordingly	  
either	   extruding	   the	   excess	   cation	   or	  
accumulating	   it	   to	   restore	   the	   ‘set-­‐point’.	  
Compelling	   evidence	   for	   the	   presence	   of	   such	   a	  
sensor	  mechanism	  is	  provided	  by	  the	  observation	  
that	   prolonged	   exposure	   to	   0mM	   [Mg2+]o	  
decreases	   cytosolic	   free	   Mg2+	   concentration	   by	  
approximately	   50%	   in	   cardiac	   ventricular	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myocytes	   (Quamme	   and	   Rabkin,	   1990),	   MDKC	  
(Quamme	   and	   Dai,	   1990),	   or	  MDCT	   cells	   (Dai	   et	  
al.,	   1997).	   The	   new	   cytosolic	   Mg2+	   level	   is	  
maintained	   as	   long	   as	   the	   cells	   are	   incubated	   in	  
the	  presence	  of	  0	  mM	  [Mg2+]o,	  but	  returns	  to	  the	  
normal	   level	   as	   soon	   as	   [Mg2+]o	   is	   increased	  
(Quamme	   and	   Rabkin,	   1990;	   Quamme	   and	   Dai,	  
1990;	  Dai	  et	  al.,	  1997),	   in	  a	  frame	  of	  time	  that	   is	  
directly	   proportional	   to	   the	   extracellular	   Mg2+	  
concentration	   utilized	   (Quamme	   and	   Rabkin,	  
1990;	  Quamme	   and	  Dai,	   1990;	   Dai	  et	   al.,	   1997).	  
The	  process	   is	  prevented	  by	   the	  presence	  of	   the	  
L-­‐type	   Ca2+-­‐channel	   inhibitors	   verapamil	   or	  
nifedipine,	   or	   La3+	   in	   the	   extracellular	   milieu	  
(Quamme	   and	   Rabkin,	   1990).	   The	   absence	   of	  
significant	   changes	   in	   cytosolic	   free	   Ca2+	  
concentration	   under	   these	   experimental	  
conditions	   suggests	   a	   direct	   effect	   of	   these	  
inhibitory	   agents	   on	   the	   Mg2+	   entry	   mechanism	  
(Quamme	  and	  Rabkin,	  1990).	  This	  observation	  led	  
the	  authors	  to	  propose	  the	  operation	  of	  a	  specific	  
Mg2+	   channel	   in	   these	   cells,	   anticipating	   the	  
identification	   of	   TRPM6	   (Schlingmann	   et	   al.,	  
2002)	  and	  TRPM7	  (Nadler	  et	  al.,	  2001)	  as	  specific	  
Mg2+	  channels.	  	  	  
	  
Mg2+	   accumulation	   is	   favoured	   by	   ion	   re-­‐
distribution.	   In	   fact,	   renal	   epithelial	   cells	  
accumulate	  Mg2+	  as	  a	  result	  of	  phosphate	  (Dai	  et	  
al.,	   1997)	   or	   potassium	   (Dai	   et	   al.,	   1991)	  
redistribution	   across	   the	   cell	   membrane.	   The	  
dependence	   of	   Mg2+	   accumulation	   on	   K+	  
redistribution	   across	   the	   plasma	   membrane	  
suggests	   that	   Mg2+	   transport	   is	   the	   result	   of	  
changes	   in	   membrane	   potential,	   possibly	   for	  
charge	   compensation	   (Schweigel	   et	   al.,	   1999;	  
Tashiro	   et	   al.,	   2002;	   Schweigel	   and	   Martens,	  
2003).	  In	  this	  respect,	  it	  is	  interesting	  to	  note	  that	  
pathological	   conditions	   characterized	   by	   a	  marked	  
decrease	   in	   tissue	   Mg2+	   content	   (e.g.,	   diabetes)	  
(Fagan	  et	  al.,	   2004)	   are	   also	   characterized	  by	   an	  
inability	   to	   properly	   transport	   potassium	  
(Mondon	   et	   al.,	   1974;	   Taylor	   and	   Agius,	   1988).	  
Whether	  the	  effect	  on	  K+	  occurs	  through	  changes	  
in	   membrane	   potential,	   or	   indirectly	   via	   a	  
reduced	  operation	  of	   the	  Na+/K+-­‐ATPase	  coupled	  
to	   the	   operation	   in	   reverse	   of	   the	   Na+/Mg2+	  
exchanger	   (Gunther	   and	   Vormann,	   1995),	   is	   a	  
matter	  for	  future	  investigation.	  	  	  
	  	  
Humans	  and	  many	  mammals	  present	  a	  circulating	  
Mg2+	   level	   of	   ~1.2-­‐1.4	   mEq/L	   (Geigy,	   1984;	  
Mudge,	  1989).	  Clinical	  and	  experimental	  evidence	  
indicates	   that	   serum	   Mg2+	   level	   decreases	   in	  
humans	   and	   animals	   in	   several	   chronic	   diseases	  
(Fagan	   et	   al.,	   2004).	   Yet,	   there	   is	   a	   remarkable	  
lack	   of	   information	   as	   to	   whether	   serum	   Mg2+	  
undergoes	   circadian	   fluctuations	   following	  
hormonal	   or	   non-­‐hormonal	   stimuli	   (e.g.,	   fasting	  
or	   exercise).	   The	   infusion	   of	   catecholamine	   in	  
conscious	   humans	   (Joborn	   et	   al.,	   1985;	   Bailly	   et	  
al.,	   1990)	   or	   ovine	   (Rayssiguier,	   1977),	   or	   the	  
administration	  of	  isoproterenol	  (Guideri,	  1992)	  or	  
epinephrine	   in	   the	   presence	   of	  α1-­‐adrenoceptor	  
blockade	   (Rayssiguier,	   1977)	   have	   provided	  
contrasting	   results.	   More	   recent	   results,	  
however,	   would	   indicate	   that	   isoproterenol	  
infusion	   elicits	   in	   a	   marked	   dose-­‐	   and	   time-­‐
dependent	   increase	   in	   circulating	   Mg2+	   content	  
(Gunther	   and	   Vormann,	   1992;	   Keenan	   et	   al.,	  
1995).	   The	   increase	   is	   serum	   Mg2+
	  
is	   maximal	  
within	   20min	   from	   the	   agent	   administration	  
(Keenan	  et	  al.,	  1995),	  and	  remains	  unchanged	  up	  
to	   2	   hours	   even	   following	   the	   removal	   of	   the	  
agonist	   (Keenan	   et	   al.,	   1995).	   This	   time	   frame	  
indicates	   that	   the	   increase	   in	   serum	  Mg2+	   is	   not	  
dependent	  on	  the	   increase	   in	  heart	   rate	  and	  the	  
decrease	  in	  mean	  arterial	  pressure	  elicited	  by	  the	  
β-­‐adrenergic	   agonist	   (Keenan	   et	   al.,	   1995).	   In	  
fact,	   the	   infusion	  of	   sodium	  nitroprusside,	  which	  
mimics	   the	   decrease	   in	   mean	   arterial	   pressure	  
induced	  by	  isoproterenol,	  has	  no	  effect	  on	  serum	  
Mg2+
	  
levels	  (Keenan	  et	  al.,	  1995).	  The	  persistence	  
of	  an	  elevated	  serum	  Mg2+	  level	  for	  up	  to	  2	  hours	  
also	   implies	  that	  operation	  of	  secondary	  and	  not	  
fully	   elucidated	   mechanisms	   activated	   by	   the	  
stimulation	   of	   β-­‐adrenergic	   receptor.	   Consistent	  
with	   the	   larger	   distribution	   of	   β2	   versus	   β1	  
adrenergic	  receptors	  in	  the	  body	  (Molinoff,	  1984;	  
Barnes,	  1995),	  the	  increase	  in	  serum	  Mg2+	  occurs	  
via	   the	   specific	   activation	   of	   β2-­‐adrenergic	  
receptor,	  as	   it	   is	  mimicked	  by	  the	  administration	  
of	  the	  selective	  β2-­‐adrenergic	  agonist	  salbutamol,	  
and	   it	   is	   inhibited	   by	   the	   specific	   β2-­‐blocker	   ICI-­‐
118551	   (Keenan	   et	   al.,	   1995).	   Due	   to	   the	  
amplitude	   of	   the	   increase	   in	  Mg2+	   level	   into	   the	  
bloodstream,	  it	  is	  reasonable	  to	  envisage	  that	  the	  
adrenergic	   agonists	   are	   mobilizing	   Mg2+	   from	  
more	   than	   one	   tissue	   (Keenan	  et	   al.,	   1995).	   The	  
involvement	   of	   bone	   has	   been	   proposed	   by	  
Gunther	  and	  co-­‐workers	   (Gunther	  and	  Vormann,	  
1992)	  based	  on	  the	  observation	  that	  the	  infusion	  
of	   carbonic	   anhydrase	   inhibitor	   prevents	  
isoproterenol-­‐mediated	   Mg2+	   mobilization	   into	  
the	   blood	   of	   anesthetized	   rats.	   Based	   upon	   the	  
pre-­‐infusion	   level	  of	   serum	  Mg2+,	   the	  glomerular	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filtration	   rate	   (1.62	   mL/min),	   and	   the	   fractional	  
excretion	   (17%)	   (Shafik	   and	   Quamme,	   1989),	  
changes	   in	   renal	   excretion	   do	   not	   appear	   to	  
contribute	   significantly	   to	   the	   increase	   in	   serum	  
Mg2+	   level,	   at	   least	   during	   the	   first	   two	   hours	  
following	   adrenergic	   agonist	   infusion.	   It	   is	  
interesting	  to	  note,	  however,	  that	  hormones	  that	  
increase	   plasma	   Mg2+	   by	   mobilizing	   the	   cation	  
from	  different	   organs	   or	   tissues	   usually	   increase	  
Mg2+	   resorption	   in	   the	   Henle’s	   loop,	   de	   facto	  
preventing	  any	  net	  loss	  of	  Mg2+.	  	  
	  
The	  inconsistency	  of	  changes	  in	  serum	  Mg2+	  level	  
observed	   in	   the	   literature,	   however,	   does	   not	  
have	   a	   clear	   explanation.	   Several	   factors	   may	  
contribute	   to	   this	   incongruity,	   including	   the	  
proportion	   of	   b-­‐adrenergic	   receptor	   subtypes	   in	  
different	   experimental	   models,	   the	   ability	   of	  
adrenergic	   agonists	   to	   stimulate	   with	   various	  
potency	  different	  adrenergic	   receptors	   subtypes,	  
and	   the	   modality,	   rate	   and	   duration	   of	   drug	  
infusion.	   This	   inconsistency	   has	   also	   hampered	  
our	  ability	  to	  assign	  a	  physiological	  significance	  to	  
the	   eventual	   increase	   in	   serum	   Mg2+	   level	  
following	  catecholamine	  infusion.	  The	  observation	  
that	   serum	   Mg2+	   level	   increases	   under	   certain	  
conditions	   may	   imply	   that	   specific	   organs	   or	  
tissues	   have	   the	   ability	   to	   sense	   these	   changes	  
and	   act	   accordingly.	   Presently,	   no	   specific	   Mg2+	  
sensing	  mechanism	  has	  been	  identified.	  However,	  
the	  Ca2+	  sensing	  receptor	  (Brown	  et	  al.,	  1993)	  can	  
senses	  changes	  in	  circulating	  Mg2+	  level	  in	  a	  range	  
of	   concentrations	   far	   higher	   than	   those	   of	   Ca2+	  
(Nemeth	   and	   Scarpa,	   1987)	   but	   consistent	   with	  
the	   increase	   in	   serum	  Mg2+	   level	   reported	   in	   the	  
literature	   (Gunther	   and	   Vormann,	   1992;	   Keenan	  
et	   al.,	   1995).	   The	   observation	   that	   in	   distal	  
convoluted	  tubule	  cells	  (MDCT)	  of	  the	  mouse	  the	  
Ca2+-­‐sensing	   receptor	   can	   be	   activated	   with	  
comparable	   sensitivity	   by	   both	   extracellular	   Ca2+	  
and	   Mg2+	   (Bapty	   et	   al.,	   1998a)	   suggests	  
interesting	   hypotheses	   in	   terms	   of	   whole	   body	  
physiology.	   The	   activation	   of	   this	   sensor	  
mechanism	   would	   inhibit	   glucagon-­‐	   or	  
vasopressin-­‐mediated	  entry	  of	  Mg2+	   into	   the	   cell	  
(Bapty	   et	   al.,	   1998b)	   and	   favour	   the	   elimination	  
of	   the	   cation	   with	   the	   urine.	   This	   would	   then	  
explain	   the	   clinical	   and	   experimental	   evidence	  
that	  hypermagnesemia	  and	  hypercalcemia	  inhibit	  
hormone-­‐stimulated	   cAMP-­‐mediated	   resorption	  
of	  Mg2+	  and	  Ca2+	  along	  the	  different	  segments	  of	  
the	   nephron	   (Quamme	  and	  Dirks,	   1980).	   Also,	   it	  
would	  represent	  a	  distal	  regulatory	  mechanism	  to	  
restore	   magnesemia	   to	   a	   physiological	   level	  
following	   the	   increase	   observed	   in	   anesthetized	  
animals	   infused	   with	   adrenergic	   agonists	  
(Gunther	   and	   Vormann,	   1992;	   Keenan	   et	   al.,	  
1995).	   Whether	   this	   sensing	   mechanism	   and/or	  
its	   associated	   modulatory	   components	   are	  
altered	   under	   diabetic	   conditions	   in	   which	   an	  
increased	   magnesuria	   is	   observed	   it	   remains	   to	  
be	  elucidated.	  	  
	  
At	   variance	   of	   an	   increase	   in	   calcemia,	   which	   is	  
associated	   with	   muscle	   weakness	   and	  
arrhythmia,	   an	   increase	   in	   serum	   Mg2+	   level	  
appears	  to	  be	  well	  tolerated	   in	  vivo.	  Rats	  infused	  
with	   boluses	   of	   Mg2+	   that	   increase	   serum	   Mg2+	  
level	   by	   50%	   do	   not	   exhibit	   significant	   systemic	  
hemodynamic	   changes	   but	   show	   a	   marked	  
increase	   in	   coronary	   artery	   flow	   (Dipette	   et	   al.,	  
1987).	   Baboons	   infused	   with	   pharmacological	  
doses	   of	  Mg2+	   sufficient	   to	   prevent	   epinephrine-­‐
induced	   cardiac	   arrhythmias	   show	   a	   significant	  
attenuation	   of	   the	   epinephrine-­‐induced	   increase	  
in	   mean	   arterial	   pressure	   and	   systemic	   vascular	  
resistance	   (Stanbury,	   1948).	   It	   would	   appear,	  
therefore,	   that	   an	   elevated	   level	   of	   [Mg2+]o	   can	  
regulate	   catecholamine	   release	   from	   peripheral	  
and	   adrenal	   sources	   (James	   et	   al.,	   1988)	   and	  
modulate	   cardiac	   contractility	   (Howarth	   et	   al.,	  
1994).	   Taken	   together,	   these	   observations	  
suggest	   that	   an	   increase	   in	   serum	   Mg2+	   level	  
following	   adrenergic	   stimulation	   can:	   1)	   act	   as	   a	  
feed-­‐back	   mechanism	   to	   modulate	   catechol-­‐
amine	   release	   and	   activity;	   and	   2)	   contribute	   to	  
improved	  blood	  flow	  and	  O2	  delivery	  to	  the	  heart	  
and	   possibly	   other	   tissues	   at	   a	   time	   when	   an	  
increase	  in	  energy	  production	  is	  expected.	  	  
	  	  
Physiological	  role	  of	  intracellular	  Mg2+	  
	  
The	   conclusions	   presented	   in	   the	   previous	  
sections	  strongly	  suggest	  a	  key	  role	  for	  Mg2+	  as	  an	  
indispensable	  component	  for	  enzymes,	  phospho-­‐
metabolites,	   and	   channel	   activity	   (Grubbs	   and	  
Maguire,	   1987;	   Romani	   and	   Scarpa,	   1992).	  
Several	  glycolytic	  enzymes,	   including	  hexokinase,	  
phosphofructokinase,	   phosphoglycerate	   mutase,	  
phosphoglycerate	   kinase,	   enolase	   and	   pyruvate	  
kinase,	   show	   activation	   at	   low	   and	   inhibition	   at	  
high	   Mg2+	   concentrations	   (Otto	   et	   al.,	   1974;	  
Garfinkel	   and	   Garfinkel,	   1988).	   The	   adenylate	  
cyclase	  is	  another	  example	  of	  an	  enzyme	  directly	  
regulated	   by	   Mg2+	   (reviewed	   in	   Maguire,	   1984).	  
All	   these	  processes	  occur	  at	  Mg2+	  concentrations	  
Intracellular	  Mg	  homeostasis	   	   Chapter	  2	  
 
 42	  
between	   0.5	   to	   1mM,	  which	   are	  well	  within	   the	  
fluctuations	   in	   free	   [Mg2+]i	   measured	   in	   the	  
cytoplasm	   of	   various	   cells	   including	   hepatocyte	  
(Corkey	   et	   al.,	   1986).	  With	   the	   exception	   of	   the	  
glycolytic	   enzymes,	   studies	   attempting	   to	  
evidence	   a	   regulatory	   role	   of	   Mg2+	   for	   cytosolic	  
enzymes	   have	   been	   disappointing,	   mostly	  
because	  of	   the	  underlying	   assumption	   that	  Mg2+	  
would	   operate	   as	   Ca2+	   in	   modulating	   enzyme	  
activity.	   At	   variance	   from	   Ca2+,	   Mg2+	   concen-­‐
tration	  in	  the	  cytoplasm	  and	  extracellular	  fluids	  is	  
in	   the	   millimolar	   or	   submillimolar	   range.	  
Consequently,	   an	   increase	   or	   decrease	   in	  
cytosolic	   Mg2+	   level	   equivalent	   to	   the	   changes	  
observed	   for	   Ca2+	   will	   go	   largely	   undetected	   by	  
the	  common	  fluorescent	  or	   31P-­‐NMR	  techniques.	  
Heretofore,	   a	   role	  of	  Mg2+	   as	   transient	   regulator	  
of	  cytosolic	  enzymes	  appears	  to	  be	  unlikely.	  It	  has	  
to	  be	  noted	  that	  even	  under	  conditions	   in	  which	  
hormonal	   and	   non-­‐hormonal	   stimuli	   elicit	  major	  
fluxes	   of	  Mg2+	   across	   the	   cell	   plasma	  membrane	  
in	  either	  direction,	  massive	  translocations	  of	  Mg2+	  
that	   increase	   or	   decrease	   the	   total	   cellular	  Mg2+	  
content	   by	   1	   to	   2mM	   (or	   5-­‐10%	   of	   total	   cell	  
content)	   result	   in	   minor	   or	   no	   changes	   in	  
cytosolic	   free	   [Mg2+]i	   (Harman	   et	   al.,	   1990;	  
Romani	   et	   al.,	   2000).	   This	   disconnect	   can	   be	  
explained	   by	   assuming	   that	   the	   source	   or	  
destination	   of	   transported	   Mg2+	   is	   a	   cellular	  
compartment	   or	   organelle,	   or	   a	   major	   binding	  
site,	   or	   that	   Mg2+	   is	   highly	   buffered.	   Hence,	  
regulation	   of	   cellular	   functions	   by	   Mg2+	   should	  
not	   be	   necessarily	   expected	   to	   occur	   in	   the	  
cytosol	  but	  within	  organelles,	  and	   in	  the	  plasma,	  
where	  Mg2+	  concentration	  can	  rapidly	  increase	  or	  
decrease	  more	  than	  20%	  (Gunther	  and	  Vormann,	  
1992;	  Keenan	  et	  al.,	  1995).	  	  
	  	  
In	   the	   following	   pages	   we	   will	   highlight	   what	   is	  
known	  about	  regulatory	  effects	  of	  extracellular	  or	  
intracellular	   Mg2+	   on	   the	   operation	   of	   cation	  
channels	   in	  the	  plasma	  membrane,	  as	  well	  as	  on	  
mitochondria	   respiration	   and	   volume	   following	  
changes	  in	  Mg2+	  concentration	  within	  the	  organelle.	  	  
	  	  
Ca2+-­‐	  and	  K+-­‐channels	  	  
The	   first	   report	   of	   a	   regulatory	   effect	   of	  
intracellular	   free	   Mg2+	   on	   calcium	   channels	   was	  
by	   White	   and	   Hartzell	   (1988).	   These	   authors	  
reported	   that	   increasing	   intracellular	   free	   [Mg2+]i	  
from	   0.3	   to	   3.0mM	   by	   internal	   perfusion	   had	   a	  
dual	  effect	  in	  cardiac	  ventricular	  myocytes.	  It	  had	  	  
a	   small	   effect	   on	   basal	   L-­‐type	   Ca2+-­‐channels	  
current	  (ICa)	  but	  decreased	  by	  more	  than	  50%	  the	  
amplitude	   of	   ICa	   elevated	   by	   cAMP-­‐dependent	  
phosphorylation.	  The	  effect	  of	  Mg2+	  was	  not	  due	  
to	   changes	   in	   cAMP	   concentration	   or	   in	   the	  
velocity	  of	  phosphorylation	  but	  appeared	  to	  be	  a	  
direct	  effect	  on	  the	  phosphorylated	  channel	  or	  on	  
the	   channel	   dephosphorylation	   rate	   (White	   and	  
Hartzell,	  1988).	  Similar	  results	  were	  also	  reported	  
by	  Agus	   and	  Morad	   (1991)	   in	   guinea	   pig	   cardiac	  
myocytes.	  The	  block	   induced	  by	  Mg2+on	  the	  Ca2+	  
current	   depended	   on	   a	   direct	   effect	   on	   the	  
inactivation	   state	   of	   the	   channel	   as	   the	   block	  
persisted	   in	   the	   presence	   and	   in	   the	   absence	   of	  
cAMP	   and	   was	   not	   reversed	   by	   elevation	   of	  
extracellular	   Ca2+	   concentration	   or	   addition	   of	  
catecholamine	   (Agus	   and	   Morad,	   1991).	   The	  
effect	   of	  Mg2+	   on	   Ca2+-­‐channels	   is	   not	   restricted	  
to	   cardiac	   cells	   or	   to	   an	   intra-­‐cellular	   site	   of	  
action.	   Bara	   and	   Guiet-­‐Bara	   (2001)	   have	   shown	  
that	   in	   vascular	   smooth	   muscle	   cells	   and	  
endothelial	   cells	   in	   human	   placenta,	  MgCl2	   (and	  
to	  a	   lesser	  extent	  MgSO4)	   regulates	   the	   influx	  of	  
Ca2+	   through	   voltage-­‐gated	   Ca2+	   channels	   by	  
acting	  at	  an	  extracellular	  site	  on	  the	  channel,	  thus	  
modulating	  the	  tonus	  of	  the	  vessels.	  Evidence	  for	  
a	   similar	   block	   by	   extracellular	   Mg2+	   on	   T-­‐type	  
Ca2+-­‐channels	   has	   been	   provided	   by	   Serrano	   et	  
al.,	   (2000).	   The	   modulatory	   effect	   of	   Mg2+	  
appears	  to	  take	  place	  at	  the	  EF-­‐hand	  motif	  of	  the	  
COOH-­‐terminus	   of	   Cav1.2	   channels	   as	   recently	  
evidence	  by	  Catterall	  and	  his	  group	  (Brunet	  et	  al.,	  
2006).	  
	  
Extracellular	  Mg2+	   also	  modulates	   the	   activity	   of	  
store-­‐operated	   Ca2+	   channels.	   Studies	   in	   intact,	  
pressurized	   rat	  mesenteric	   arteries	  with	  myogenic	  
tone	   indicate	   that	  10	  mM	  extracellular	  Mg2+	   can	  
mimic	   nifedipine	   in	   preventing	   or	   reversing	   the	  
vasoconstriction	   elicited	   by	   phenylephrine	  
administration,	   but	   not	   that	   induced	   by	   K+	  
depolarization	   (Zhang	   et	   al.,	   2002).	   Therefore,	  
Mg2+	  abolishes	  the	  vasoconstriction	  attributed	  to	  
Ca2+	   entry	   through	   store-­‐operated	   channels,	  
which	   are	   activated	   following	   phenylephrine	  
administration,	   contributing	   to	   maintain	   both	  
myogenic	   tone	   and	   α1-­‐adrenoceptor-­‐induced	  
tonic	   vasoconstriction.	   These	   data	   may	   have	  
direct	   implication	   to	   explain	   some	   of	   the	  
modifications	   that	   occur	   under	   hypertensive	  
conditions,	   in	   which	   a	   decrease	   in	   plasma	   Mg2+	  
has	  often	  been	  reported.	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Intracellular	   Mg2+	   also	   affects	   he	   operation	   of	  
store-­‐operated	   calcium	   release-­‐activated	   Ca2+	  
(CRAC)	  channels	  (Prakriya	  and	  Lewis,	  2002).	  CRAC	  
channels	   are	   highly	   Ca2+-­‐selective	   under	  
physiological	  ionic	  conditions	  whereas	  removal	  of	  
extracellular	   divalent	   cations	   makes	   them	   freely	  
permeable	   to	   monovalent	   cations,	   in	   particular	  
Na+.	   Experimental	   evidence	   indicates	   that	   intra-­‐
cellular	   Mg2+	   can	   modulate	   the	   activity	   and	  
selectivity	   of	   these	   channels	   therefore	   affecting	  
monovalent	   cation	  permeability.	  While	   an	   effect	  
of	  intracellular	  Mg2+	  on	  CRAC	  channels	  cannot	  be	  
completely	   excluded,	   a	   report	   by	   Prakriya	   and	  
Lewis	   (2002)	   suggests	   that	   the	   channels	  
modulated	   by	   intracellular	   Mg2+	   are	   not	   CRAC	  
channels,	   but	   a	   different	   class	   of	   channels	   that	  
open	   when	   Mg2+	   is	   washed	   out	   of	   the	   cytosol.	  
These	   channels	   have	   therefore	   been	   termed	  
Mg2+-­‐inhibited	   cation	   (MIC)	   channels,	   as	   they	  
present	   distinctive	   functional	   parameters	   in	  
terms	   of	   inhibition,	   regulation,	   ion	   permeation	  
and	  selectivity	  (Prakriya	  and	  Lewis,	  2002).	  	  
	  
Potassium	   channels	   are	   also	   targets	   for	   Mg2+.	  
Matsuda	   (1991)	   has	   reported	   that	   the	   presence	  
of	  Mg2+	   on	   the	   cytoplasmic	   side	   of	   the	   inwardly	  
rectifying	  K+	  channel	  blocks	  the	  outward	  currents	  
without	   affecting	   the	   inward	   currents.	   The	  Mg2+	  
block	   is	   achieved	   at	   a	   half-­‐saturation	  
concentration	   of	   1.7µM.	   When	   the	   Mg2+	  
concentration	   is	   elevated	   to	   2-­‐10µM,	   the	  
outward	   current	   fluctuated	   between	   two	  
intermediate	   sublevels	   in	   addition	   to	   the	   fully	  
open	   and	   closed	   configuration.	   However,	   these	  
concentrations	   of	   Mg2+	   are	   far	   from	   being	  
physiological	   and	   it	   is	   difficult	   to	   envision	   the	  
occurrence	   of	   a	   similar	   regulatory	   effect	   under	  
normal	   conditions	   without	   invoking	   Mg2+	  
microcompartmentation.	   A	   regulatory	   role	   of	  
intracellular	   Mg2+	   on	   Kv	   channels	   in	   vascular	  
smooth	   muscle	   cells	   has	   been	   observed	   by	  
Tammaro	   et	   al.,	   (2005).	   These	   authors	   have	  
observed	  that	  an	  increase	  in	  intracellular	  Mg2+	   in	  
a	   range	   of	   concentrations	   consistent	   with	   its	  
physiological	  variations	  can	  slow	  down	  the	  kinetic	  
of	   activation	   of	   the	   Kv	   channel,	   cause	   inward	  
rectification	   at	   positive	   membrane	   potentials,	  
and	   shift	   the	   voltage-­‐dependent	   inactivation	  
(Tammaro	  et	  al.,	  2005).	  Overall,	  this	  represents	  a	  
novel	   mechanism	   for	   the	   regulation	   of	   this	  
channel	  in	  the	  vasculature.	  Intracellular	  Mg2+	  also	  
modulates	   large-­‐conductance	   (BK	   type)	   Ca2+-­‐
dependent	   K+	   channels	   by	   either	   blocking	   the	  
pore	   of	   BK	   channels	   in	   a	   voltage-­‐dependent	  
manner,	  or	  by	  activating	   the	  channels	   independ-­‐
ently	   of	   changes	   in	   Ca2+	   and	   voltage	   by	  
preferentially	   binding	   to	   the	   channel	   open	  
conformation	   at	   a	   site	   different	   from	   Ca2+	   sites.	  
Interestingly,	  Mg2+	  may	  also	  bind	  to	  Ca2+	  sites	  and	  
competitively	   inhibit	   Ca2+-­‐dependent	   activation	  
(Shi	  et	  al.,	  2002).	  
	  
The	   inhibitory	   effect	   of	  Mg2+	   is	   not	   restricted	   to	  
cell	   membrane	   channels.	   Experimental	   evidence	  
by	  Bednarczyk	  et	  al.,	  (2005)	  indicates	  that	  Mg2+	  in	  
the	   mitochondrial	   matrix	   can	   modulate	   gating	  
and	  conductance	  of	  mitochondrial	  KATP	   channels,	  
which	  play	  a	  key	  role	  under	  ischemia/reperfusion	  
conditions.	  	  
	  
Mitochondrial	  dehydrogenases	  	  
Mitochondria	  represent	  one	  of	  the	  major	  cellular	  
pools	   for	  Mg2+,	   its	   concentration	   being	   14	   to	   16	  
mM	  (Gunther,	  1986).	  Evidence	  from	  this	  (Romani	  
et	   al.,	   1991)	   and	   other	   laboratories	   (Zhang	   and	  
Melvin,	  1992;	  Zhang	  and	  Melvin,	  1996;	  Kubota	  et	  
al.,	   2005)	   suggests	   that	   Mg2+	   can	   be	   mobilized	  
from	   mitochondria	   under	   various	   conditions	  
including	  hormone-­‐mediated	  increase	  in	  cytosolic	  
cAMP	  level	  through	  a	  mechanism(s)	  that	  has	  not	  
been	  fully	  elucidated	  but	  it	  appears	  to	  involve	  the	  
adenine	   nucleotide	   translocase	   (Romani	   et	   al.,	  
1991).	   Several	   reviews	   have	   analyzed	   in	   detail	  
how	   Mg2+	   homeostasis	   is	   regulated	   in	   the	  
organelle	  (Flatman,	  1984;	  Gunther,	  1986;	  Ogoma	  
et	   al.,	   1992),	   and	   we	   refer	   to	   those	   reviews	   for	  
further	   information.	   This	   section	   will	   focus	   on	  
some	   recent	   evidence	  about	   a	   role	  of	   intra-­‐	   and	  
extra-­‐mitochondrial	   Mg2+	   on	   the	   activity	   of	  
specific	  mitochondrial	  proteins.	  	  
	  
It	   is	   commonly	   accepted	   that	   changes	   in	   matrix	  
Ca2+	   can	   affect	   the	   rate	   of	   mitochondrial	   de-­‐
hydrogenases	   and	   therefore	   the	   rate	   of	  
respiration	   (McCormack	   et	   al.,	   1990;	   Hansford,	  
1994).	   Yet,	   limited	   evidence	   supports	   a	   similar	  
role	   for	   Mg2+	   although	   the	   activity	   of	   several	  
mitochondrial	   dehydrogenases	   has	   been	   observed	  
to	   increase	   within	   minutes	   from	   the	   application	  
of	   hormonal	   or	   metabolic	   stimuli	   despite	   the	  
absence	  of	  a	  detectable	  increase	  in	  mitochondrial	  
Ca2+	   (Moravec	   and	   Bond,	   1991;	   Moravec	   and	  
Bond,	  1992).	  The	  role	  of	  matrix	  Mg2+	  as	  regulator	  
of	  dehydrogenases	  and	  consequently	  mitochondrial	  
respiration	   has	   been	   investigated	   by	   measuring	  
the	   activity	   of	   several	   dehydrogenases	   in	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mitochondria	   under	   conditions	   in	   which	   matrix	  
Ca2+	   and/or	   Mg2+	   concentration	   were	   varied.	  
From	  those	  data,	   it	  appears	  that	  α-­‐ketoglutarate	  
dehydrogenase	  and	  pyruvate	  dehydrogenase	  are	  
not	   regulated	  by	   changes	   in	  mitochondrial	  Mg2+,	  
whereas	  Mg2+	   removal	   increases	  several	   fold	   the	  
activity	   of	   succinate	   and	   glutamate	   dehydro-­‐
genases	   (Panov	   and	   Scarpa,	   1996a;	   Panov	   and	  
Scarpa,	   1996b).	   This	   evidence	   would	   therefore	  
indicate	   that	   changes	   in	  matrix	  Mg2+	   content	   (in	  
combination	  with	  or	   in	   alternative	   to	   changes	   in	  
mitochondrial	   Ca2+)	   can	   control	   mitochondria	  
respiration,	   at	   least	   under	   well	   defined	  
conditions.	   In	   this	   respect,	   mitochondrial	   Mg2+	  
content	   appears	   to	   change	   quite	   significantly	  
during	  transition	  from	  state	  3	  to	  state	  4	  (Brierley	  
et	   al.,	   1987),	   affecting	   at	   the	   same	   time	   the	  
amplitude	   of	   mitochondria	   respiration.	   In	  
addition,	  data	  from	  our	  laboratory	  (Romani	  et	  al.,	  
1991),	  Zhang	  and	  Melvin	  (1996),	  and	  Kubota	  et	  al	  
(2005)	   would	   suggest	   that	   mitochondrial	   Mg2+	  
can	   be	   mobilized	   by	   catecholamine	   stimulation	  
via	   cAMP.	   Hence,	   the	   enhanced	   mitochondrial	  
respiration	   elicited	   by	   catecholamine	   could	  
depend,	   at	   least	   in	   part,	   on	   cAMP-­‐mediated	  
modulation	  of	  mitochondrial	  Mg2+,	  which,	  in	  turn,	  
will	   stimulate	   directly	   some	   dehydrogenases	  
while	   rendering	   others	   more	   susceptible	   to	   the	  
Ca2+	  concentrations	  present	   in	   the	  mitochondrial	  
matrix.	  	  
	  
The	   regulatory	   effect	   of	   Mg2+	   on	   mitochondrial	  
function	   is	   not	   restricted	   to	   the	  dehydrogenases	  
activity	  but	  affects	  also	  the	  anion	  channel	  present	  
in	   the	   mitochondrial	   membrane	   (Beavis	   and	  
Powers,	   2004)	   as	   well	   as	   the	   opening	   of	   the	  
permeability	  transition	  pore	  (Dolder	  et	  al.,	  2003).	  
The	   mitochondrial	   inner	   membrane	   anion	  
channel	   (IMAC)	   transports	   various	  anions,	   and	   is	  
involved	   in	   regulating	   the	   organelle	   volume	   in	  
conjunction	   with	   the	   K+/H+	   antiporter.	   Although	  
its	  fine	  regulation	  is	  not	  completely	  elucidated	  as	  
yet,	   experimental	   evidence	   suggests	   that	   matrix	  
Mg2+	   and	   protons	   inhibit	   IMAC,	   maintaining	   the	  
channel	   in	   its	   closed	   state	   (Beavis	   and	   Powers,	  
2004).	  Kinetic	  studies	  by	  Beavis	  and	  collaborators	  
further	   support	   a	   main	   role	   of	   Mg2+	   in	  
maintaining	  the	  channel	  in	  a	  condition	  that	  would	  
allow	  fine	  modulation	  by	  small	  changes	  in	  pH	  and	  
proton	   distribution	   under	   physiological	   conditions	  
(Beavis	  and	  Powers,	  2004).	  	  
	  	  
The	   permeability	   transition	   pore	   (PTP)	   is	   a	  
proteinaceous	   pore	   that	   opens	   in	   the	   inner	  
mitochondrial	   membrane	   following	   a	   marked	  
decrease	   in	   membrane	   potential	   and	   results	   in	  
the	   rapid	   equilibration	   and	   redistribution	   of	  
matrix	  and	  extramitochondrial	  solutes	  down	  their	  
concentrations	   gradient.	  While	   it	   is	   still	   debated	  
exactly	   which	   proteins	   participate	   in	   the	   pore	  
formation	   and	   how	   the	   pore	   opens,	   it	   is	   well	  
established	  that	  an	  increase	  in	  mitochondrial	  Ca2+	  
content	   facilitates	   the	   opening	   whereas	   an	  
increase	   in	   mitochondrial	   Mg2+	   antagonizes	   it.	  
This	   effect	   can	   be	   appreciated	   well	   in	   yeasts,	  
which	  do	  not	  possess	  a	  canonical	  PTP	  (Bradshaw	  
and	   Pfeiffer,	   2006).	   According	   to	   one	   model	   of	  
regulation,	   creatine	   kinase	   can	   regulate	   the	  
opening	   of	   the	   permeability	   transition	   pore	   by	  
tightly	   associating	   to	   the	   mitochondrial	  
membrane	   and	   remaining	   in	   an	   active	   state	  
(Dolder	   et	   al.,	   2003).	   Both	   these	   processes	   are	  
Mg2+-­‐dependent,	   and	   Mg2+	   removal	   from	   the	  
extramitochondrial	   environment	   results	   in	   a	  
decline	   in	   creatine	   kinas	   activity	   and	   in	   the	  
opening	   of	   the	   permeability	   transition	   pore	  
Dolder	  et	  al.,	  2003).	  	  	  	  
	  
Considering	   the	   effect	   of	  Mg2+	   on	  mitochondrial	  
function	   and	   channels	   (see	   previous	   section),	   it	  
appears	   that	   Mg2+	   plays	   more	   than	   one	   role	  
within	  this	  organelle	  regulating:	  1)	  mitochondrial	  
volume;	   2)	   ion	   composition;	   3)	   ATP	   production;	  
and	  4)	  metabolic	  interaction	  with	  the	  hosting	  cell.	  	  
	  
Reticular	  G6Pase	  
The	   Endoplasmic	   Reticulum	   (ER)	   represents	   one	  
of	   the	   major	   cellular	   Mg2+	   pools,	   with	   a	   total	  
concentration	  of	  14	  to	  18mM	  (Romani	  and	  Scarpa,	  
1992).	  Yet,	   limited	   information	   is	  available	  about	  
any	   major	   role	   of	   luminal	   Mg2+	   on	   reticular	  
functions	   other	   than	   protein	   synthesis	   (Rubin,	  
2005).	   It	   is	   also	   unknown	   whether	   Mg2+	   is	  
buffered	   or	   chelated	   by	   endoluminal	   proteins	   in	  
the	   same	   way	   that	   Ca2+	   is	   complexed.	  
Furthermore,	   we	   do	   not	   have	   any	   information	  
about	   the	   transport	   mechanism(s)	   that	   allow(s)	  
ER	   (and	   SR)	   to	   attain	   and	  maintain	   such	   a	   large	  
luminal	  Mg2+	  concentration.	  
	  
Work	   by	   Volpe	   and	   collaborators	   (Volpe	   et	   al.,	  
1990;	   Volpe	   and	   Vezu’,	   1993),	   Gusev	   and	   Niggli	  
(2008),	  and	  Laver	  and	  Honen	  (2008)	  suggests	  that	  
cytosolic	  and	  perhaps	  luminal	  Mg2+	  concentration	  
can	   have	   a	   major	   effect	   in	   limiting	   Ca2+	   uptake	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into	  the	  ER/SR	  and	  its	  release	  from	  the	  organelle	  
via	  IP3	  (Volpe	  et	  al.,	  1990)	  and	  ryanodine	  receptor	  
(Laver	   and	   Honen,	   2008).	   In	   the	   latter	   case,	   a	  
direct	   effect	   of	   Mg2+	   on	   the	   receptor	   has	   been	  
observed	   (Gusev	   and	   Niggli,	   2008;	   Laver	   and	  
Honen,	   2008).	   Less	   clear	   is	   whether	   a	   similar	  
effect	   takes	   also	   place	   at	   the	   level	   of	   the	   IP3	  
receptor.	   More	   recently,	   our	   laboratory	   has	  
reported	   that	   cytosolic	   Mg2+	   can	   have	   a	  
regulatory	  role	  on	  the	  activity	  of	  reticular	  glucose	  
6-­‐phosphatase	   (G6Pase)	   in	   liver	   cells	   (Doleh	   and	  
Romani,	   2007).	   This	   effect	   is	   biphasic,	   with	   an	  
optimal	  stimulatory	  effect	  at	  ~0.5mM	  [Mg2+]i	  and	  
an	   inhibitory	   effect	   at	   higher	   concentrations	  
(Doleh	   and	   Romani,	   2007).	   The	   effect	   of	   Mg2+	  
appears	   to	   take	   place	   at	   the	   level	   of	   the	   G6Pi	  
transport	   component	   of	   the	   G6Pase	   enzymatic	  
complex	   in	   that	   it	   can	   be	   inhibited	   by	   EDTA	   (as	  
Mg2+	   chelating	   agent)	   or	   taurocholic	   acid,	   which	  
permeabilizes	  the	  ER	  membrane	  and	  allows	  G6Pi	  
to	   bypass	   the	   transport	   mechanism	   and	   be	  
delivered	   directly	   to	   the	   catalytic	   site	   of	   the	  
G6Pase	  within	  the	  ER	   lumen	  (Doleh	  and	  Romani,	  
2007).	   Investigation	   is	   in	   progress	   to	   determine	  
whether	  Mg2+	   exerts	   a	   similar	  modulatory	   effect	  
on	  other	  ER	  enzymes.	  
	  
Cell	  pH	  and	  volume	  	  
As	   mentioned	   earlier,	   exposure	   of	   the	   cell	   to	  
cyanide	   (Dalal	   and	   Romani,	   2010),	   fructose	  
(Gaussin	   et	   al.,	   1997),	   hypoxia	   (Harman	   et	   al.,	  
1990;	   Gasbarrini	   et	   al.,	   1992),	   ethanol	   (Tessman	  
and	   Romani,	   1998),	   or	   choline	   chloride	   (Romani	  
et	   al.,	   1993b)	   results	   in	   a	   marked	   cellular	  
acidification	  associated	  with	  a	  decrease	  in	  cellular	  
ATP	   content	   and	   a	   major	   Mg2+	   extrusion.	   This	  
extrusion	   is	   the	   consequence	   of	   a	   decrease	   in	  
buffering	   capacity	   (ATP	   loss)	   as	   well	   as	   binding	  
affinity.	   Now,	   a	   report	   by	   Yamaguchi	   and	  
Ishikawa	   (2008)	   highlights	   a	   new	   and	   important	  
regulatory	   role	   of	   intracellular	   Mg2+	   on	   the	  
operation	   of	   the	   electrogenic	   Na+-­‐HCO3
-­‐	   co-­‐
transporter	  NBCe1-­‐B	  in	  a	  range	  of	  concentrations	  
that	   are	   consistent	   with	   the	   variations	   in	   Mg2+	  
content	   measured	   within	   the	   cytoplasm	   of	  
various	   cell	   types	   (Grubbs	   and	   Maguire,	   1987).	  
This	  regulatory	  effect	   is	  exerted	  by	  Mg2+	  and	  not	  
by	  MgATP,	   and	   requires	   a	   functional	  N-­‐terminus	  
on	   the	   NBCe1-­‐B	   transporter	   (Yamaguchi	   and	  
Ishikawa,	   2008).	   It	   is	   still	   unclear	   whether	   Mg2+	  
binds	   the	   N-­‐terminus	   of	   the	   transporter	   directly	  
or	   exerts	   its	   effects	   via	   an	   intermediate,	   Mg2+-­‐
modulated	   regulatory	   protein	   (Yamaguchi	   and	  
Ishikawa,	  2008).	  At	  a	  cytosolic	  [Mg2+]	  of	  ~1mM	  (a	  
physiological	  Mg2+	  concentration	  measured	  in	  the	  
cytosol	   of	   various	   cells	   (Corkey	   et	   al.,	   1986;	  
Grubbs	  and	  Maguire,	  1987),	  the	  NBCe1-­‐B	  current	  
is	   inhibited	   by	   ~50%,	   and	   no	   detectable	   current	  
can	  be	  measured	  for	  free	  Mg2+	  concentrations	  of	  
3-­‐5mM.	  
	  
More	   or	   less	   at	   the	   same	   time,	   the	   group	   of	  
Hirano	  and	  collaborators	  reported	  that	  increasing	  
cellular	   Mg2+	   content	   has	   a	   stimulatory	   role	   on	  
the	   expression	   of	   aquaporin	   3	   in	   CaCo-­‐3	   cells	  
(Okahira	  et	   al.,	   2008).	   This	   isoform	  of	   aquaporin	  
is	   highly	   expressed	   in	   the	   gastro-­‐intestinal	   tract,	  
in	  which	  it	  absorbs	  water,	  glycerol	  and	  urea.	  The	  
effect	   of	   Mg2+	   on	   aquaporin	   mRNA	   expression	  
appears	  to	  involve	  cAMP/PKA/CREB	  signalling,	  as	  
well	   as	   we	   MEK1/2	   and	   MSK1	   (Okahira	   et	   al.,	  
2008),	  suggesting	  short-­‐	  and	  long-­‐term	  regulation	  
on	  the	  activity	  and	  expression	  of	  this	  protein.	  It	  is	  
presently	  undefined	  whether	  Mg2+	  exerts	  a	   similar	  
regulatory	   role	   on	   other	   aquaporin	   isoforms.	  
Moreover,	   as	   aquaporin	   3	   is	   also	   expressed	   in	  
brain,	   erythrocytes,	   kidney,	   and	   skin,	   a	  
modulatory	   role	   of	   Mg2+	   on	   the	   protein	  
expression	   in	   these	   tissues	   may	   have	   major	  
relevance	   for	   various	   physiological	   and/or	  
pathological	  conditions.	  
	  
Taken	   together,	   these	   two	   sets	   of	   information	  
suggest	   that	   Mg2+	   can	   have	   a	   major	   regulatory	  
role	   on	   cellular	   pH,	   cellular	   volume,	   and	   cellular	  
cation	   concentration,	   especially	   Na+.	   Also,	   as	  
aquaporin	   3	   mediates	   glycerol	   and	   urea	  
accumulation,	   possible	   repercussions	   on	   fatty	  
acid	   metabolism	   and	   urea	   cycle	   must	   be	   taken	  
into	  proper	  consideration.	  	  	  	  	  	  	  	  	  
	  
Cell	  cycle	  
Cell	  cycle	  (Maguire,	  1988;	  Sgambato	  et	  al.,	  1999;	  
Touyz	  et	  Yao,	  2003),	  cell	  proliferation	  (Wolf	  et	  al.,	  
2009b)	   and	   cell	   differentiation	   (Covacci	   et	   al.,	  
1998;	  Wolf	  et	  al.,	  1998;	  Di	  Francesco	  et	  al.,	  1998)	  
have	  all	  been	  associated	  with	  the	  maintenance	  of	  
an	   optimal	   cellular	  Mg2+	   level.	   Under	   conditions	  
in	  which	  cellular	  Mg2+	  accessibility	  is	  restricted	  or	  
reduced,	   cell	   proliferation	   and	   cell	   cycle	  
progression	  are	  markedly	  impaired.	  A	  decrease	  in	  
extracellular	   Mg2+	   content	   also	   affects	   cell	  
differentiation	   (Covacci	   et	   al.,	   1998;	  Wolf	   et	   al.,	  
1998;	  Di	  Francesco	  et	  al.,	  1998).	  The	  mechanisms	  
by	   which	   a	   decrease	   in	   cellular	   Mg2+	   content	  
affects	   these	   cellular	   processes	   have	   been	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attributed	   to	   defective	   MAPKs	   (Touyz	   and	   Yao,	  
2003)	  and	  p27	  (Sgambato	  et	  al.,	  1999)	  signalling,	  
increased	   oxidative	   stress	   level	   (Wolf	   et	   al.,	  
2009b),	   and	   decreased	   MgATP	   levels	   (Di	  
Francesco	   et	   al.,	   1998;	   Rubin,	   2005).	   Because	  
cellular	   MgATP	   level	   is	   at	   a	   level	   optimal	   for	  
protein	  synthesis	   (Rubin,	  2005),	  any	  alteration	   in	  
this	   metabolic	   parameter	   will	   have	   major	  
repercussion	   on	   the	   proper	   functioning	   of	   the	  
cell.	  In	  addition,	  extracellular	  Mg2+	  levels	  regulate	  
integrins	   signalling,	   de	   facto	   modulating	   the	  
interaction	   among	   cells	   and	   between	   cells	   and	  
extracellular	  matrix	   (Trache	  et	   al.,	   2010).	  Hence,	  
consistent	  with	  the	  long-­‐term	  regulatory	  function	  
of	  Mg2+	  proposed	  by	  Grubbs	  and	  Maguire	  (1987)	  
several	  years	  ago,	  all	  these	  observations	  underlie	  
the	  important	  role	  of	  Mg2+	  to	  guarantee	  cell	  cycle	  
progression	   and	   retention	   of	   proper	   cell	  
morphology	  and	  function,	  avoiding	  undesired	  	  
	  
progression	   towards	   cell	   death	   or	   neoplastic	  
destiny	  (Wolf	  et	  al.,	  2009a).	  	  	  
	  
Conclusions	  	  
	  	   	  
In	   the	   last	   few	   years,	   our	   understanding	   of	  
cellular	   and	   whole	   body	   Mg2+	   homeostasis	   has	  
significantly	  advanced.	  While	  it	  still	  lags	  behind	  as	  
compared	   to	   the	   knowledge	   available	   for	   other	  
ions	  such	  as	  Ca2+,	  H+,	  K+	  or	  Na+,	  the	  identification	  
of	   putative	   Mg2+	   channels	   and	   transport	  
mechanisms	   in	   the	   membrane	   of	   the	   cell	   or	  
mitochondria,	   as	   well	   as	   an	   improved	  
understanding	   of	   the	   signalling	   pathways	   and	  
conditions	   regulating	   Mg2+	   transport	   are	  
providing	   new	   tools	   to	   address	   essential	  
questions	  about	  the	  physiological	  role	  Mg2+	  plays	  
inside	  the	  cell	  and	  in	  the	  whole	  body.	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The	   finding	   that	  magnesium	   levels	  are	   reduced	   in	  acute	  and	  chronic	  brain	  diseases	  has	   led	   to	  a	   recent	  
surge	   in	   interest	   in	   the	   role	   of	   magnesium	   in	   the	   normal	   and	   injured	   nervous	   system,	   although	   the	  
mechanisms	  of	  magnesium	  decline	  in	  pathological	  conditions	  and	  its	  availability	  in	  the	  neural	  tissue	  after	  
administration	   are	   not	   fully	   understood.	   The	   brain	   has	   two	  main	   barrier	   systems:	   (1)	   the	   blood-­‐brain	  
barrier	  (BBB)	  formed	  by	  brain	  capillary	  endothelial	  cells	  which	  separate	  the	  blood	  from	  the	  extracellular	  
fluid	   in	   the	   neuropil;	   and	   (2)	   the	   blood-­‐CSF	   barrier	   (BCSFB)	   formed	   by	   choroidal	   epithelial	   cells	  which	  
separate	   the	   blood	   from	   the	   CSF.	   Genetic	   studies	   in	   families	   with	   hereditary	   hypomagnesemia	   have	  
identified	  mutations	   in	   two	   genes	   encoding	   claudin-­‐16	   (paracellin-­‐1)	   and	   claudin-­‐19,	   both	   localized	   at	  
tight	   junctions	   between	   nephron	   epithelial	   cells	   and	   providing	   passive	   paracellular	   conductance	   for	  
magnesium	  in	  the	  kidney.	  Endothelial	  cells	  of	  the	  BBB	  also	  express	  claudins,	  although	  whether	  members	  
of	  the	  claudin	  family	  expressed	  at	  the	  BBB	  and	  BCSFB	  have	  similar	  conductance	  for	  magnesium	  akin	  to	  
the	  role	  of	  claudin-­‐16	  and	  -­‐19	  in	  the	  nephron	  remains	  to	  be	  confirmed.	  Recently,	  the	  transient	  receptor	  
potential	  melastatin	   (TRPM)	  members	   TRPM6	  and	   TRPM7	  have	   been	   identified	   as	   cation	   channels	   for	  
magnesium	  transport.	  Although	   it	   is	  not	  known	  if	  choroidal	  epithelial	  cells	  express	  TRPM6	  and	  TRPM7,	  
these	  molecules	  are	  expressed	  by	  brain	  endothelial	   cells	  and	  may	  play	  a	   role	   in	  magnesium	   transport.	  
While	   it	   is	   evident	   that	   magnesium	   enters	   the	   CNS	   through	   the	   BBB	   and	   is	   actively	   transported	   by	  






Magnesium	   is	   a	   critical	   cation	   and	   an	   essential	  
nutrient	   for	   normal	   body	   functions;	   hence	  
mechanisms	  exist	  in	  the	  body	  for	  its	  homeostasis	  
through	   a	   highly	   integrated	   feedback	   system	  
involving	   intestinal	   absorption,	   renal	   excretion,	  
bone	  metabolism	  and	  the	  parathyroid	  gland	  (Dai	  
et	   al.,	   2001).	  Magnesium	   is	   involved	   in	   a	  myriad	  
of	   biochemical	   processes	   including	   acting	   as	   a	  
cofactor	   in	   the	   activation	   of	   many	   intracellular	  
enzymes	  (Aikawa,	  1976;	  Ebel	  and	  Gunther,	  1980;	  
Gunther,	   2008)	   and	   is	   important	   for	   protein	  
synthesis	   (Terasaki	   and	   Rubin	   1985)	   and	   cell	  
membrane	   stabilization	   (Bara	   and	   Guiet-­‐Bara	  
1984).	   Magnesium	   deficiency	   reduces	   protein	  
synthesis,	   serum	   antibody	   activity	   and	   the	  
immune	   response	   (McCoy	   and	   Kenney,	   1975),	  
and	   induces	   CNS	   epileptiform	   activity	   (Morris,	  
1992)	   and	   hypomagnesemic	   tetany	   (Fontenot	   et	  
al.,	   1989).	   There	   is	   an	   inverse	   correlation	  
between	   dietary	  magnesium	   and	   the	   level	   of	   C-­‐
reactive	   protein	   (a	  marker	   of	   inflammation)	   and	  
the	   level	   of	   E-­‐selectin	   (a	   marker	   of	   endothelial	  
cell	   dysfunction)	   (Song	   et	   al.,	   2007).	   Recent	  
technical	   developments	   have	   allowed	   better	  
assessment	   of	   the	   levels	   of	   magnesium	   in	   the	  
body,	   although	   the	   blood,	   which	   is	   used	   in	  
routine	   testing,	   contains	   only	   0.3%	   of	   the	   total	  
body	  magnesium	  (Elin,	  1987).	  Approximately	  one	  
half	   of	   the	  magnesium	   contained	   in	   the	   body	   is	  
stored	   in	   the	   bone,	   while	   the	   rest	   exists	   in	   the	  
soft	   tissues,	   mainly	   in	   the	   intracellular	  
compartment,	  with	  less	  that	  1%	  being	  present	  in	  
the	   extracellular	   compartment	   (Elin,	   1988).	  
Indeed,	  magnesium	   is	   the	   second	  most	   common	  
cation	   in	   the	   intracellular	   compartment	   after	  
potassium.	   More	   than	   one	   half	   of	   the	   plasma	  
content	   of	   magnesium	   is	   bound	   to	   plasma	  
proteins,	   and	   the	   remaining	   free	   ionized	  
magnesium	   (Mg2+),	   the	   metabolically	   active	  
fraction,	   is	   held	   within	   a	   narrow	   range	   (0.53-­‐
0.67mM)	   in	   normal	   healthy	   controls	   (Altura	   and	  
Altura,	  1991).	  The	  recom-­‐mended	  daily	  allowance	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ranges	   from	   320	   to	   420mg/day	   for	   women	   and	  
men,	  respectively	  (Bergman	  et	  al.,	  2009).	  	  
	  
There	  has	   been	   a	   recent	   surge	   in	   interest	   in	   the	  
dynamics	   and	   role	   of	   magnesium	   in	   the	   normal	  
and	   injured	   brain	   due	   to	   accumulating	   evidence	  
of	  a	  reduction	   in	  the	   level	  of	   total	  and	  free	  Mg2+	  
in	   the	   brain	   in	   acute	   and	   chronic	   neurological	  
diseases	   (Vink	   et	   al.,	   1987;	   2009).	   In	   intensive	  
care	   patients	   with	   traumatic	   brain	   injury	   (TBI)	  
reduction	   of	   serum	   ionized	  Mg2+	   correlates	  with	  
the	  severity	  of	  TBI	  as	  determined	  by	  the	  Glasgow	  
Coma	   Scale	   Score	   (Kahraman	   et	   al.,	   2003).	   In	  
experimental	   TBI	   in	   the	   rat	   there	   is	   a	   sustained	  
decline	   in	   intracellular	   Mg2+,	   detected	   by	  
phosphorus	   magnetic	   resonance	   spectroscopy,	  
that	   correlates	  with	  motor	   deficit	   (Cernak	   et	   al.,	  
2004;	   Heath	   and	   Vink,	   1996),	   while	   magnesium	  
administration	   significantly	   improves	   motor	  
outcome	   (Heath	   and	   Vink	   1999;	   Turner	   et	   al.,	  
2004).	   Magnesium	   administration	   reduces	   TBI-­‐
induced	  brain	  edema	   (Feldman	   et	   al.,	   1996)	   and	  
restores	   blood-­‐brain	   barrier	   (BBB)	   effectiveness	  
to	   Evans	   blue	   tracer	   when	   compared	   to	   injured	  
non-­‐treated	   rats	   (Esen	   et	   al.,	   2003;	   Imer	   et	   al.,	  
2009).	   Magnesium	   also	   reduces	   brain	   edema	  
after	   cold-­‐induced	   brain	   injury	   (Turkoglu	   et	   al.,	  
2008).	   However,	   the	  mechanisms	   of	  magnesium	  
decline	   in	   pathological	   conditions	   and	   its	  
availability	  in	  the	  neural	  tissue	  after	  administration	  
are	  still	  unclear	  (Vink	  et	  al.,	  2009).	  	  
	  
Therapeutically,	  magnesium	  can	  be	  administered	  
orally,	   intravenously	   or	   intramuscularly	   (Elin,	  
1988).	   It	   is	   most	   commonly	   used	   used	   as	  
magnesium	  chloride,	  sulphate,	  gluconate,	  acetate	  
(Fine	   et	   al.,	   1991)	   or	   lactate	   (Fine	   et	   al.,	   1991;	  
Simoes	   Fernandes	   et	   al.,	   1985).	   Magnesium	  
therapy	   has	   been	   utilized	   in	   numerous	  
experimental	   and	   clinical	   settings	   including	  
migraine	   (Peikert	  et	  al.,	  1996),	  asthma	  (Cheuk	  et	  
al.,	   2005),	   depression	   (Eby	   and	   Eby,	   2006),	  
anxiety	   (Kara	   et	   al.,	   2002),	   diabetes	   (Resnick	   et	  
al.,	   1993;	   Wester	   and	   Dyckner,	   1987),	  
hypertension	   (Wester	   and	   Dyckner,	   1987),	   atrial	  
fibrillation	  (Fanning	  et	  al.,	  1991),	  sleep	  disorders,	  
insomnia	   and	   chronic	   fatigue	   (Takahashi	   et	   al.,	  
1992),	   dementia	   (Glick,	   1990),	   osteoporosis	  
(Sojka	  and	  Weaver,	  1995),	  fibromyalgia	  (Porter	  et	  
al.,	   2010),	   pain	   (Soave	   et	   al.,	   2009),	   eclampsia	  
(Euser	  and	  Cipolla,	  2009),	  constipation	   (Guerrera	  
et	  al.,	  2009),	  cerebral	  palsy	  (Rouse,	  2009),	  lacunar	  
stroke	   (Muir	   et	   al.,	   2004),	   TBI	   (McIntosh	   et	   al.,	  
1988)	  and	  aneurysmal	  subarachnoid	  hemorrhage	  
(van	  den	  Bergh,	  2009;	  Yahia	  et	  al.,	  2005).	  
	  
The	   current	   review	  will	   briefly	  outline	   the	   status	  
of	  magnesium	   in	   the	   body,	   then	  will	   summarize	  
current	   knowledge	   of	   its	   distribution	   in	   the	   CNS	  
and	  discuss	  its	  transport	  across	  barrier	  membranes	  
in	   the	   brain	   compared	   to	   its	   transport	   in	   other	  
organs	  such	  as	  the	  kidney.	  
	  
Magnesium	  absorption	  and	  excretion	  
	  
Much	   of	   our	   knowledge	   about	   magnesium	  
absorption	  and	  excretion	  was	  gained	  in	  the	  latter	  
part	   of	   the	   twentieth	   century	   and	  particularly	   in	  
the	   nineties.	   Studies	   of	   normal	   subjects	   showed	  
that	   magnesium	   bioavailability	   from	   high	  
magnesium	   containing	   food	   sources	   such	   as	  
almonds	   is	   equal	   to	   that	   obtained	   from	   soluble	  
magnesium	   acetate,	   but	   enteric	   coating	   of	  
magnesium	   chloride	   impairs	   magnesium	  
bioavailability	   (Fine	   et	   al.,	   1991).	   Magnesium	  
absorption	   occurs	   mainly	   in	   the	   small	   intestine	  
(Brannan	   et	   al.,	   1976;	   Graham	   et	   al.,	   1960;	  
Schroeder	   et	   al.,	   1969).	   The	   kinetics	   and	   rate	   of	  
magnesium	   absorption	   are	   not	   dependant	   on	  
calcium	  intake	  (Brannan	  et	  al.,	  1976).	  Under	  basal	  
conditions	  the	  small	  intestine	  absorbs	  30–50%	  of	  
the	  magnesium	   intake,	   although	   this	   percentage	  
diminishes	  with	  senescence,	  chronic	  renal	  disease	  
and	   increasing	   intake	   (Musso	   2009).	   The	  
fractional	   magnesium	   absorption	   appears	   to	   fall	  
progressively	   so	   that	  absorption	  as	  a	   function	  of	  
intake	   is	   curvilinear	   (Fine	   et	   al.,	   1991).	   The	   fecal	  
magnesium	  appears	  to	  be	  primarily	  derived	  from	  
material	   that	   is	  not	  absorbed	  by	  the	  body	  rather	  
than	   magnesium	   secreted	   by	   the	   intestine	  
(Aikawa,	   1976).	   Approximately	   80%	   of	   the	  
absorbed	   magnesium	   passes	   in	   the	   glomerular	  
filtrate	   (Dai	   et	   al.,	   2001;	   Quamme	   and	   de	  
Rouffignac,	  2000).	  
	  
More	  that	  95%	  of	  the	  magnesium	  filtered	  by	  the	  
glomerulus	   is	   reclaimed	   mainly	   in	   the	   thick	  
ascending	  loop	  of	  Henle	  (60-­‐70%)	  and	  to	  a	  lesser	  
extent	   (10-­‐15%)	   in	   the	   proximal	   convoluted	  
tubules	   (Brunette	   et	   al.,	   1974;	   Dai	   et	   al.,	   2001;	  
Quamme	   1997;	   Quamme	   and	   de	   Rouffignac,	  
2000).	  A	  further	  10%	  of	  magnesium	  in	  the	  filtrate	  
is	   claimed	   in	   the	   distal	   convoluted	   tubule	   (de	  
Rouffignac	  and	  Quamme,	  1994)	  and	  this	  segment	  
contributes	  to	  magnesium	  conservation	  (Quamme	  




via	 the	 paracellular	 route	 (de	 Rouffignac	 and	
Quamme,	 1994),	 being	 driven	 by	 the	 trans-
epithelial	voltage	 (Quamme,	1997;	Quamme	and	
de	 Rouffignac,	 2000),	 where	 positive	 luminal	
charge	favors	movement	of	magnesium	from	the	
luminal	 to	 the	 abluminal	 side	 of	 nephron	
epithelium	 (Quamme,	 1997).	On	 the	 other	 hand	
magnesium	 transport	 in	 the	 distal	 convoluted	
tubule	 is	 active	 and	 transcellular	 (Quamme,	 1	
997).	 While	 the	 mechanisms	 of	 magnesium	
transport	were	unclear	and	speculative	(Dai	et	al,	
2001;	 Quamme	 and	 Dirks,	 1980)	 more	 recent	
reports	point	to	specific	paracellular	 (Efrati	et	al,	
2005;	 Simon	 et	 al,	 1999)	 and	 transcellular	





Two	 main	 fluid	 compartments	 are	 associated	
with	 the	 brain,	 the	 extracellular	 fluid	 (ECF)	 that	
bathes	 neurons	 and	 glial	 cells,	 and	 the	
cerebrospinal	 fluid	 (CSF)	 located	 in	 the	








arachnoid	mater	 is	 impermeable	 to	CSF	contained	 in	 the	subarachnoid	space	 (SAS).	The	arachnoid	mater	
forms	the	arachnoid	granulations	(AG)	that	pierce	the	dural	wall	of	the	superior	sagittal	sinus	and	drain	the	
CSF	 into	 the	venous	blood.	Brain	 capillaries	 (BC)	are	 lined	with	endothelial	 cells	 joined	by	 tight	 junctions	
and	form	the	BBB,	thus	they	control	 the	composition	of	the	extracellular	 fluid	 (ECF).	Ventricles	 (V)	of	 the	
brain	contain	CSF	produced	mainly	by	the	choroidal	epithelium,	which	covers	the	choroid	plexuses	(CP)	and	
form	the	BCSFB.	The	ventricles	are	lined	with	ependymal	cells	(E),	which	are	continuous	with	the	choroidal	
epithelium	at	 the	neck	of	 the	choroid	plexus.	The	core	of	 the	choroid	plexus	 is	 formed	of	pia	mater	and	
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Exchange	   between	   the	   blood	   and	   these	   fluid	  
compartments	  can	  potentially	  occur	  at	  four	  sites,	  
which	   have	   barrier	   mechanisms:	   (1)	   brain	  
capillary	  endothelial	  cells,	  which	  separate	  the	  ECF	  
from	   the	   blood	   and	   form	   the	   BBB;	   (2)	   the	  
choroidal	  epithelial	  cells	  at	  the	  ventricular	  surface	  
of	  the	  choroid	  plexuses,	  which	  interface	  between	  
the	   blood	   and	   the	   CSF	   and	   form	   the	   blood-­‐CSF	  
barrier	   (BCSFB);	   (3)	   the	   arachnoid	   mater,	   which	  
surrounds	   the	   CSF	   contained	   within	   the	  
subarachnoid	   space;	   (4)	   the	   circumventricular	  
organs	   of	   the	   brain,	   which	   have	   fenestrated	  
capillaries.	   The	   four	   sites	   form	   potential	   entry	  
routes	   for	  water,	  molecules,	   electrolytes,	   toxins,	  
pathogens	  and	  drugs	  (Segal,	  2000).	  
	  
The	  arachnoid	  mater	  and	  circumventricular	  
organs	  
The	   arachnoid	   mater	   forms	   an	   external	   barrier,	  
the	  morphological	  substrates	  of	  which	  are	  the	  flat	  
tightly	   packed	   mesothelial	   cells	   (the	   arachnoid	  
barrier	   cell	   layer)	   with	   their	   numerous	   tight	  
junctions.	   They	   separate	   the	   CSF	   from	   the	  
subdural	   space	   and	   the	   dura	   (Fig.1),	   which	   has	  
fenestrated	   capillaries	   (Nabeshima	   et	   al.,	   1975;	  
Vandenabeele	   et	   al.,	   1996).	   The	   arachnoid	   is	  
avascular	   (Alcolado	   et	   al.,	   1988)	   and,	   relative	   to	  
brain	   capillaries,	   has	   a	   much	   less	   surface	   area,	  
thus	   its	   contribution	   to	   transport	   from	   the	  
subdural	  space	  to	  the	  CSF	  and	  brain	  is	  negligible.	  
Also	   the	   circumventricular	   organs	   of	   the	   brain,	  
although	   they	   have	   fenestrated	   capillaries	  
(McKinley	  et	  al.,	  2003;	  Sunn	  et	  al.,	  2003),	  they	  are	  
provided	   with	   an	   internal	   mechanism	   that	  
contributes	   to	  a	  barrier	  between	   these	  sites	  and	  
the	   surrounding	   brain.	   They	   have	   rapid	   venous	  
return	  systems,	  which	  compensates	  for	  the	  leaky	  
capillaries,	   effectively	   preventing	   the	   spread	   of	  
marker	  molecules	  to	  the	  surrounding	  brain	  tissue	  
(Hashimoto,	   1988;	   Segal,	   2000).	   Therefore,	   the	  
two	   main	   routes	   that	   are	   likely	   to	   have	   greater	  
involvement	  in	  the	  regulation	  of	  the	  ECF	  and	  CSF	  
environments	  are	   the	  BBB	  and	  BCSFB	   (Abbott	   et	  
al.,	  2010).	  	  
	  
The	  blood-­‐brain	  barrier	  (BBB)	  
The	  concept	  of	  a	  BBB	  has	  been	  proposed	  over	  a	  
century	   ago	   (Bradbury	   1979)	   and	   is	   still	   being	  
developed	   (Wolburg	   et	   al.,	   2009).	   The	   BBB	   is	  
formed	   by	   endothelial	   cells	   of	   brain	   capillaries,	  
the	  characteristics	  of	  which	  are	  influenced	  by	  the	  
surrounding	   microenvironment,	   including	   astro-­‐
cytes	  and	  pericytes	   (Wolburg	  et	  al.,	  2009).	  Apart	  
from	   capillaries	   in	   the	   circumventricular	   organs	  
which	  have	  fenestrated	  endothelial	  cells,	  those	  in	  
the	   rest	   of	   the	   brain	   are	   lined	   with	   specialized	  
endothelial	   cells	   which	   show	   few	   endocytotic	  
vesicles,	   have	   no	   fenestrations	   and	   are	   rich	   in	  
mitochondria	   (Brightman	   and	   Reese,	   1969;	  
Fenstermacher	  et	  al.,	  1988;	  Reese	  and	  Karnovsky,	  
1967;	  Rubin	  and	  Staddon,	  1999;	  Sedlakova	  et	  al.,	  
1999).	  Brain	  endothelial	  cells	  have	  high	  electrical	  
resistance	   (Butt	   et	   al.,	   1990)	   and	   are	   joined	   by	  
tight	  junctions	  (TJs)	  (Begley	  and	  Brightman,	  2003;	  
Rubin	   and	   Staddon,	   1999).	   These	   TJs	   have	   long	  
been	   recognized	   as	   the	   sites	   of	   exclusion	   of	  
protein	   tracers	   as	   detected	   by	   electron	  
microscopy	   (Brightman	   and	   Reese	   1969;	   Reese	  
and	   Karnovsky	   1967;	   Sedlakova	   et	   al.,	   1999).	  
Freeze-­‐fracture	   electron	   microscopy	   revealed	  
that	   these	   tight	   junctions	  have	  an	  elaborate	  and	  
complex	   arrangement	   of	   network	   of	   inter-­‐
connecting	  strands	  of	  intramembranous	  particles,	  
that	   particularly	   cleave	   with	   the	   P-­‐face	   leaving	  
corresponding	   grooves	   on	   the	   E-­‐face	   of	   replicas	  
of	  the	  split	  membrane	  (Sedlakova	  et	  al.,	  1999).	  
	  
The	  BBB	  therefore	  plays	  a	  pivotal	  role	  in	  the	  tight	  
regulation	   and	   rigorous	   stabilization	   of	   the	  
chemical	   composition	   of	   brain	   ECF	   against	  
fluctuations	   in	   the	   plasma	   chemistry,	   thus	  
promoting	   normal	   neuronal	   signaling.	   The	  
privileged	  status	  of	   the	  brain	  being	  protected	  by	  
the	  BBB	  has	   a	   downside,	   in	   restricting	   access	   by	  
drugs	  and	  therapeutic	  agents	  into	  the	  brain	  when	  
needed	  (Abbott	  and	  Romero,	  1996).	  Although	  the	  
barrier	  nature	  of	  the	  BBB	  has	  been	  emphasized,	  it	  
is	  obviously	  a	  selective	  barrier,	  as	   it	  should	  allow	  
passage	   of	   nutrients	   and	   electrolytes.	   Thus	  
endothelial	   cells	   of	   brain	   vessels	   are	   endowed	  
with	  a	  host	  of	  receptors,	  enzymes	  and	  carriers	  in	  
a	   polarized	   distribution	   to	   promote	   selective	  
transport	   (Abbott	   et	   al.,	   2010;	   Betz	   et	   al.,	   1980;	  
Ohtsuki	  and	  Terasaki,	  2007;	  Roberts	  et	  al.,	  2008).	  
Brain	   endothelial	   cells	   express	   the	   glucose	  
transporter	  Glut-­‐1	  protein	  (Dick	  et	  al.,	  1984;	  Harik	  
et	   al.,	   1994;	   Ohtsuki	   and	   Terasaki,	   2007;	  
Pardridge	  et	  al.,	  1990;	  Pardridge,	  1991),	  which	   is	  
coupled	   to	   neuronal	   demand	   (Leybaert,	   2005)	  
and	   its	   expression	   increases	   in	   hypoxia	   (Harik	   et	  
al.,	   1994).	   Rat	   brain	   endothelial	   cells	   express	   a	  
barrier	   antigen	   (Sternberger	   and	   Sternberger,	  
1987),	  neutralization	  of	  which	  leads	  to	  reversible	  
opening	   of	   the	   BBB	   to	   exogenous	   and	  
endogenous	   proteins	   (Ghabriel	   et	   al.,	   2000;	  
2004).	   Lipophilic	   molecules	   can	   penetrate	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endothelial	   cell	   membranes	   by	   diffusion,	  
although	  some	  of	  these	  may	  be	  effluxed	  via	  ABC	  
transporters,	   such	   as	   P-­‐glyco-­‐protein	   (Begley	  
2004;	   Miller,	   2010;	   Shen	   and	   Zhang,	   2010).	  
Macromolecules	  may	  cross	  the	  BBB	  via	  receptor-­‐
mediated	  transcytosis	  (Descamps	  et	  al.,	  1996),	  or	  
adsorptive-­‐mediated	   transcytosis	   (Villegas	   and	  
Broadwell,	   1993;	   Zlokovic	   et	   al.,	   1990).	   Water-­‐
soluble	  nutrients	  and	  metabolites	  can	  to	  a	  limited	  
degree	  pass	  passively	  across	  the	  BBB,	  but	  greater	  
bulks	   of	   water,	   hydrophilic	   molecules	   and	  
electrolytes	   have	   to	   be	   transported	   via	   carrier	  
systems	  and	  channels	  (Zhang	  et	  al.,	  2002).	  Amino	  
acids,	  nucleosides,	  small	  peptides,	  organic	  anions	  
and	   organic	   cations	   are	   transported	   via	   solute	  
carriers	  (Abbott	  et	  al.,	  2010;	  Koepsell	  et	  al.,	  2003;	  
Ohtsuki	  and	  Terasaki,	  2007).	  	  
	  
Unlike	  in	  other	  organs,	  such	  as	  the	  intestinal	  wall	  
where	   the	   extracellular	   space	   is	   large	   and	   is	  
occupied	   by	   loose	   connective	   tissue,	   that	   of	   the	  
brain	   is	   very	   narrow	   as	   neuronal	   and	   glial	  
membranes	  are	  closely	  apposed	   leaving	  a	  gap	  of	  
20-­‐50	  nm	  (Vanharreveld	  et	  al.,	  1965)	  with	  a	  small	  
volume	  of	  ECF.	  A	  small	  change	  in	  the	  ECF	  volume	  
may	   lead	   to	   large	   alterations	   in	   electrolyte	  
concentrations,	   deleteriously	   affecting	   neuronal	  
excitability	   (Amiry-­‐Moghaddam	   and	   Ottersen,	  
2003).	   Hence	   water	   transport	   across	   the	   BBB	   is	  
intricately	   linked	   to	   ions	   transport.	   Brain	  
perivascular	   astrocytic	   foot	   processes,	   sub-­‐pial	  
astrocytes	   and	   the	   ependyma,	   which	   lines	   the	  
ventricles,	   express	   the	   water	   channels	   AQP-­‐4	  
(Amiry-­‐Moghaddam	  and	  Ottersen,	  2003;	  Li	  et	  al.,	  
2009;	   Nielsen	   et	   al.,	   1997).	  More	   recent	   studies	  
demonstrated	   that	   brain	   endothelial	   cells	   also	  
express	   AQP-­‐4	   at	   their	   luminal	   and	   abluminal	  
membranes,	  albeit	  at	  a	  much	   lower	  density	  than	  
in	   astrocytic	   foot	   processes	   (Amiry-­‐Moghaddam	  
and	  Ottersen,	  2003;	  Kobayashi	   et	  al.,	   2001).	   The	  
link	   between	   water	   movements	   and	   electrolyte	  
concentrations	  is	  further	  strengthened	  by	  the	  co-­‐
expression	   of	   AQP4	   and	   Kir-­‐4.1	   potassium	  
channels,	   and	   the	   discovery	   that	   water	   move-­‐
ment	   is	   associated	   with	   potassium	   fluxes	   in	   the	  
same	  direction	  (Amiry-­‐Moghaddam	  and	  Ottersen,	  
2003;	   Niermann	   et	   al.,	   2001).	   The	   BBB	   is	  
relatively	   permeable	   to	   water,	   allowing	   a	   slow	  
bulk	   flow	   (Abbott,	  2004)	  but	   less	   so	   to	   ions	   (Go,	  
1997).	   Electrolytes	   homeostasis	   in	   the	   ECF	   is	  
actively	  maintained	  by	  the	  BBB,	  as	  evidenced	  by	  a	  
high	   Na+,	   K+-­‐ATPase	   activity	   in	   brain	   endothelial	  
cells	   (Bauer	   et	   al.,	   1990;	   Go,	   1997;	   Seda	   et	   al.,	  
1984).	  Potassium	  concentration	  in	  the	  ECF	  is	  kept	  
at	   a	   lower	   level	   than	   that	   of	   plasma	   (Hansen,	  
1985).	  
	  
The	  blood-­‐CSF	  barrier	  (BCSFB)	  
The	  brain	  has	   four	   choroid	  plexuses	   that	  project	  
into	   the	   two	   lateral	   ventricles	   and	   the	   third	   and	  
fourth	  ventricles.	   Each	  choroid	  plexus	   contains	  a	  
core	  of	  loosely	  arranged	  stroma	  derived	  from	  the	  
leptomeninges.	   Their	   ventricular	   surface	   is	  
extremely	   fringed	   (Fig.1).	   The	   core	  of	   the	  plexus	  
is	   richly	  supplied	  with	  capillaries,	   the	  endothelial	  
cells	   of	  which	  have	   fenestrations	   and	   leaky	   tight	  
junctions	   (Wolburg	   and	   Paulus,	   2010).	   Large	  
molecules	   such	   as	   peroxidase	   penetrate	   the	  
choroid	   plexus	   capillaries	   and	   enter	   the	  
interstitial	   space	   in	   the	   core	   of	   the	   plexus	  
(Brightman,	  1968).	  As	   the	  plexus	   invaginates	   the	  
ventricle	  it	  acquires	  a	  covering	  of	  ependyma,	  the	  
cell	   layer	   that	   forms	   the	   lining	   of	   the	   ventricle	  
(Fig.1).	  This	  ependymal	  covering	   is	  known	  as	   the	  
choroidal	  epithelium,	  which,	  although	  continuous	  
with	  the	  rest	  of	  the	  ependyma	  at	  the	  neck	  of	  the	  
choroid	   plexus,	   is	   structurally	   and	   functionally	  
different,	  as	  it	  becomes	  modified	  and	  specialized	  
to	   form	   the	   BCSFB	   (Brightman	   1968;	   Redzic	   and	  
Segal	   2004;	   Tripathi	   1973).	   The	   choroidal	  
epithelium	  therefore	  separates	   the	  CSF	   from	  the	  
milieu	  of	  the	  plexus	  core	  with	  its	  leaky	  capillaries.	  
Choroidal	   epithelial	   cells	   are	   joined	   by	   tight	  
junctions,	   which	   occlude	   the	   paracellular	   route	  
(Wolburg	   and	   Lippoldt,	   2002;	   Wolburg	   and	  
Paulus,	   2010).	   Choroidal	   epithelial	   cells	   actively	  
produce	   the	   CSF	   and	   regulate	   its	   electrolyte,	  
protein	   and	   water	   content	   (Bradbury	   et	   al.,	  
1963).	  Choroidal	  epithelial	  cells	  express	  the	  water	  
channels	  AQP-­‐1	  (Agre	  et	  al.,	  1993;	  Nielsen	  et	  al.,	  
1993).	   In	   addition	   to	   their	  main	   function	   of	   CSF	  
secretion	   choroidal	   epithelial	   cells	   transport	  
some	   substances	   from	   the	   blood	   to	   the	   CSF,	   for	  
example,	   nucleotides	   and	   ascorbic	   acid,	   and	  
actively	   removes	   other	   substances	   from	   the	   CSF	  
(Go,	  1997).	  	  
	  
There	   is	   no	   barrier	   between	   the	   brain	   and	   CSF	  
located	  in	  the	  subarachnoid	  space,	  as	  the	  cells	  of	  
the	   pia	   mater	   on	   the	   brain	   surface	   have	   gap	  
junctions	   and	   no	   tight	   junctions	   (Alcolado	   et	   al.,	  
1988).	  Peroxidase	  perfused	  into	  the	  subarachnoid	  
space	   penetrates	   between	   pia	   mater	   cells,	  
through	   the	   basement	   membrane	   of	   astrocytes	  
at	   the	   brain	   surface	   and	   between	   astrocytes	  
(outer	   glia	   limitans)	   to	   enter	   the	   neuropil	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(Brightman	  and	  Reese,	  1969).	  Also	  free	  exchange	  
occurs	  between	  the	  CSF	   located	   in	  the	  ventricles	  
and	  the	  brain	  ECF	  across	  the	  ependymal	  lining	  of	  
the	   ventricles,	   as	   peroxidase	   injected	   into	   the	  
ventricles	   enter	   the	   neuropil	   (Brightman	   and	  
Reese,	   1969),	   thus	   the	   CSF	   and	   the	   ECF	   of	   the	  
brain	  equilibrate.	  	  
	  
Magnesium	  transport	  across	  barrier	  membranes	  
including	  the	  BBB	  and	  BCSFB	  
	  
Magnesium	  transport	  in	  the	  kidney	  
The	  kidney	  is	  the	  main	  contributor	  to	  magnesium	  
homeostasis,	   thus	   it	   is	   not	   surprising	   that	  
research	   efforts	   to	   understand	   magnesium	  
transport	  were	   focused	  on	   epithelial	   cells	   of	   the	  
nephron.	   During	   the	   last	   decade	   greater	  
understanding	   of	   the	   transport	   of	   magnesium	  
across	   cell	   membranes	   was	   gained	   through	  
genetic	   studies	   in	   families	   with	   hereditary	  
abnormal	  magnesium	  balance,	  positional	   cloning	  
and	   knockout	   mice	   investigations	   (Hoenderop	  
and	   Bindels,	   2005).	   Such	   studies	   led	   to	   the	  
identification	  of	  genes	  encoding	  proteins	  involved	  
in	  the	  transport	  of	  magnesium.	  One	  human	  gene,	  
the	   paracellin-­‐1	   (PCLN-­‐1),	   encodes	   the	   protein	  
paracellin-­‐1.	   PCLN-­‐1	   mRNA	   was	   detected	   using	  
RT-­‐PCR	   in	   the	   thick	   ascending	   limb	   of	   Henle’s	  
loop	   and	   the	   distal	   convoluted	   tubule	   of	   the	  
kidney	   in	   the	   rabbit	   (Simon	   et	   al.,	   1999)	   and	  
rodents	  (Weber	  et	  al.,	  2001).	  The	  PCLN-­‐1	  protein	  
was	  also	  detected	  using	  immunocytochemistry	  in	  
the	   same	   segments	   in	   rabbit	   kidney	   using	   an	  
antibody	   to	   PCLN-­‐1	   (Simon	   et	   al.,	   1999).	   Using	  
confocal	   microscopy	   and	   double	   immuno-­‐
fluorescence	   for	   PCLN-­‐1	   and	   occuldin,	   a	   tight	  
junction	  ubiquitous	  protein	   (Furuse	  et	  al.,	  1993),	  
demonstrated	   colocalisation	   of	   the	   two	   proteins	  
to	  intercellular	  tight	  junction	  at	  both	  segments	  of	  
rabbit	   nephrons	   (Simon	   et	   al.,	   1999).	   The	  
paracellin-­‐1	   protein	   is	   a	   member	   of	   the	   claudin	  
family	   (claudin	   16)	   (Simon	   et	   al.,	   1999).	   Families	  
with	   mutation	   in	   PCLN-­‐1	   gene	   show	   hypo-­‐
magnesemia	   and	   renal	   magnesium	   wasting	  
(Simon	   et	   al.,	   1999).	   The	   paracellin-­‐1	   located	   in	  
the	   tight	   junction	   between	   epithelial	   cells	   in	   the	  
nephron	  acts	  as	  a	  passive	  channel	  for	  reabsorbing	  
magnesium	   along	   the	   paracellular	   route	   being	  
favored	   by	   the	   positive	   luminal	   charge.	   Because	  
these	  families	  also	  show	  hypercalciurea	  and	  	  
urinary	   calculi,	   it	   was	   suggested	   that	   PCLN-­‐1	   is	  
also	   a	   conductance	   for	   calcium	   (Simon	   et	   al.,	  
1999).	   Such	   discovery	   modified	   the	   previously	  
prevalent	   view	   that	   tight	   junctions	   exist	   to	  
prevent	   passage	   of	   molecules	   and	   are	   static;	  
rather,	  they	  do	  provide	  selective	  barriers.	  Further	  
studies	  on	  human	  recessive	  renal	  magnesium	  loss	  
mapped	   a	   second	   locus	   on	   chromosome	   1p34.2	  
and	   have	   identified	  mutations	   in	  CLDN19,	  which	  
encodes	   the	   TJ	   protein	   claudin-­‐19	   expressed	   in	  
the	  nephron	  tubules	  (Konrad	  et	  al.,	  2006).	  
	  
Recently	  plasma	  membrane	  cation	  channels	   that	  
belong	   to	   the	   transient	   receptor	   potential	   (TRP)	  
superfamily	   have	   been	   described	   and	   were	  
classified	   into	   7	   subfamilies.	   The	   closely	   related	  
subfamilies	   TRPC,	   TRPV,	   TRPM,	   TRPN	   and	   TRPA	  
are	   classified	   as	   group	  1,	  while	   group	  2	   includes	  
TRPML	   and	   TRPP	   (Montell	   2005).	   The	   TRPM	  
subfamily	   includes	   8	  members,	   of	   which	   TRPM6	  
and	   TRMP7	   have	   been	   recognized	   as	   highly	  
permeable	  Mg2+	  transporters	  into	  cells,	  and	  have	  
been	  particularly	  studied	  in	  epithelial	  cells	  of	  the	  
nephron	   (Aikawa	   1976;	   Dai	   et	   al.,	   2001).	   In	  
familial	   autosomal-­‐recessive	   hypomagnesemia	  
with	   sec-­‐ondary	   hypocalcemia,	   affected	   infants	  
suffer	   from	  seizures	  and	  tetany	  due	  to	  abnormal	  
handling	   of	   Mg2+	   in	   intestinal	   absorption	   and	  
renal	  reabsorption.	  Genetic	  analysis	  pointed	  to	  a	  
gene,	   TRPM6,	   which	   was	   mutated	   in	   these	  
patients	  (Schlingmann	  et	  al.,	  2002;	  Walder	  et	  al.,	  
2002).	  Using	  immunocytochemistry,	  it	  was	  shown	  
that	   TRPM6	   protein	   is	   localized	   to	   the	   apical	  
membrane	   of	   renal	   distal	   convoluted	   tubules	  
epithelium,	   the	   site	   of	   active	   reclaiming	   of	  
magnesium,	   and	   also	   at	   the	   brush	   border	   of	  
apical	   membranes	   of	   intestinal	   epithelium,	   the	  
main	  site	  of	  magnesium	  absorption	  (Voets	  et	  al.,	  
2004).	  Patch-­‐clamp	  analysis	  and	  measurement	  of	  
intracellular	   magnesium	   indicated	   that	   TRPM6	  
forms	   all	   or	   at	   least	   part	   of	   the	   magnesium	  
channel	   in	   absorbing	   epithelia	   (Voets	   et	   al.,	  
2004).	   It	   has	   been	   suggested	   that	   mammary	  
epithelial	   cells	   in	   culture,	   with	   high	   and	   low	  
magnesium	   content,	   adapt	   to	   low	   magnesium	  
availability	  by	  upregulating	  magnesium	   influx	   via	  
TRPM6,	   and	   to	   high	   magnesium	   availability	   by	  
increasing	   magnesium	   efflux	   primarily	   via	  
Na+/Mg2+	   exchange	   (Wolf	   et	   al.,	   2010).	   The	  
TRPM7	   also	   has	   a	   central	   role	   in	   Mg2+	  
homeostasis,	   because	   TRPM7-­‐deficient	   cells	  
become	   Mg2+	   deficient,	   and	   cannot	   survive	  
(Schmitz	  et	  al.,	  2003).	  
	  
Magnesium	  transport	  across	  the	  BBB	  
Magnesium	   entry	   into	   the	   brain	   correlates	   with	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maturation	   of	   the	   BBB.	   In	   fetal	   sheep	   and	   the	  
guinea	  pig,	  there	  is	  a	  drop	  in	  the	  concentration	  of	  
Mg2+	   in	   the	   cerebral	   hemispheres,	   which	  
corresponds	   approximately	   to	   the	   minimum	   in	  
potassium	  content	  and	  the	  maximum	  in	  chloride	  
and	   sodium	   contents	   (Bradbury	   et	   al.,	   1972).	  
During	   rat	  postnatal	  development,	  brain	  content	  
of	  magnesium	   shows	   regional	   variations.	   At	   day	  
5,	   magnesium	   is	   most	   marked	   in	   the	   pons	   and	  
medulla	  and	   least	  marked	   in	  the	  cerebral	  cortex.	  
Magnesium	  levels	   in	  all	   regions	  decline	  after	  day	  
5,	   in	  parallel	  with	   the	  decrease	   in	  water	   content	  
and	  the	  increase	  in	  tissue	  weight,	  suggesting	  that	  
the	   maturation	   of	   the	   BBB	   plays	   an	   important	  
role	  in	  brain	  magnesium	  homeostasis	  (Chan	  et	  al.,	  
1992).	  	  
	  
Magnesium	  is	  able	  to	  cross	  the	  BBB	  (Sacco	  et	  al.,	  
2007),	  and	  it	  is	  transported	  via	  the	  barrier	  with	  a	  
net	   flux	   from	   the	   blood	   into	   the	   parenchyma.	  
Active	   magnesium	   transport	   from	   blood	   to	   the	  
extracellular	  fluid	  of	  the	  brain	  is	  evidenced	  by	  its	  
higher	   concentration	   in	   the	   cortical	   extracellular	  
fluid	   than	   its	   concentration	   in	   the	   plasma-­‐
dialysate	  or	  cisternal	  CSF	  (Bito,	  1969).	  Magnesium	  
administration	   attenuates	   cell	   death	   due	   to	  
cytoskeletal	  alteration	  (Saatman	  et	  al.,	  2001)	  and	  
reduces	   apoptosis	   and	   the	   expression	   of	   p53	  
following	   TBI	   (Lee	   et	   al.,	   2004).	   Thus	   its	  
administration	  rectifies	  the	  decline	  in	  intracellular	  
Mg2+	  levels	  and	  cellular	  functions	  (Saatman	  et	  al.,	  
2001).	   In	   experimental	   closed	   head	   trauma,	  
treatment	  with	  magnesium	   restores	   the	   polarity	  
of	  astrocytes,	  in	  terms	  of	  aquaporin-­‐4	  distribution,	  
to	   a	   preinjury	   state	   (Ghabriel	   et	   al.,	   2006).	   A	  
similar	   protective	   effect	   for	   magnesium	   was	  
demonstrated	   in	   induced	   hypoglycemia	   (Kaya	   et	  
al.,	   2001).	   This	   indicates	   replenishing	   of	  
magnesium	   in	   the	   extracellular	   space	   of	   the	  
brain.	  However,	   the	  question	  remains,	  how	  does	  
magnesium	  cross	  endothelial	  cells	  of	  the	  BBB?	   Is	  
magnesium	  transport	  across	  the	  BBB	  similar	  to	  its	  
transport	   across	   nephron	   epithelial	   cells?	   If	   so,	  
does	  Mg2+	   cross	   the	  BBB	  via	  a	  paracellular	   route	  
or	  a	  transcellular	  route	  or	  both?	  
	  
Concerning	   the	   paracellular	   route,	   the	   proposed	  
role	   for	   PCLN-­‐1	   (claudin-­‐16)	   in	   the	   nephron	  
(Simon	   et	  al.,	  1999),	  acting	  as	  a	  conductance	   for	  
Mg2+,	   and	   its	   exclusive	   location	   in	   the	   kidney	  
(Efrati	  et	  al.,	  2005;	  Weber	  et	  al.,	  2001),	  raise	  the	  
possibility	   that	   other	   members	   of	   the	   claudin	  
family	   may	   play	   a	   similar	   role	   for	   paracellular	  
conductance	   across	   other	   barrier	   membranes.	  
Members	  of	  the	  claudin	  family	  are	  involved	  in	  the	  
formation	  of	  TJ	  strands	  in	  various	  tissues	  (Morita	  
et	  al.,	  1999).	  There	  is	  tissue-­‐specific	  expression	  of	  
claudin	   members	   in	   tight	   junctions,	   with	   a	  
specific	   colocalisation	  of	   occludin	  with	   some	  but	  
not	   all	   claudins	   (Peppi	   and	   Ghabriel,	   2004).	  
Magnesium	   is	   important	   for	   cell	   membrane	  
stabilization.	   In	   the	  CNS,	   the	  myelin	   sheath	   is	  an	  
elaboration	   of	   the	   cell	   membrane	   of	  
oligodendrocytes,	   which	   express	   claudin-­‐11.	   In	  
claudin-­‐11-­‐deficient	   mice,	   the	   TJs	   are	   absent	   in	  
the	  myelin	   sheath	   of	   oligodendrocytes	   and	  mice	  
show	   demyelination	   (Gow	   et	   al.,	   1999).	   This	  
indicates	   that	   claudin-­‐11	   is	   an	   important	  
component	   in	   the	   stability	   and	   formation	   of	   the	  
myelin	   tight	   junctions.	   Also	   endothelial	   cells	   of	  
brain	   microvessels	   express	   several	   claudins,	  
including	   claudin-­‐1,	   -­‐3,	   -­‐5	   and	   -­‐12	   (Coisne	   et	   al.,	  
2005;	   Liebner	   et	   al.,	   2000;	   Matter	   and	   Balda,	  
2003;	   Morita	   et	   al.,	   1999;	   Tsukita	   and	   Furuse,	  
1999;	   Wolburg	   et	   al.,	   2003).	   Breakdown	   of	   the	  
BBB	   in	   experimental	   autoimmune	   encephalo-­‐
myelitis	   in	   the	   mouse	   and	   the	   leaky	   vessels	   in	  
human	   glioblastoma	   multiforme	   are	   accom-­‐
panied	   by	   selective	   loss	   of	   claudin-­‐3	   in	   BBB	   TJs	  
(Wolburg	   et	   al.,	   2003).	   Although	   direct	   link	  
between	  Mg2+	  permeability	  and	  claudins	  has	  not	  
been	   established	   in	   the	   CNS	   similar	   to	   the	   link	  
between	   claudin-­‐16	   and	   epithelial	   cells	   of	   the	  
nephron,	   it	   is	   tempting	   to	   speculate	   that,	   in	  
addition	   to	   their	   supporting	   role	   in	   the	  
morphology	   the	  BBB	  TJs,	   claudins	   in	  TJs	  of	  brain	  
endothelial	   cells	   may	   contribute	   to	   Mg2+	  
conductance	  at	  the	  BBB.	  It	  is	  also	  speculated	  here	  
that	   claudin-­‐11	   in	   the	  CNS	  myelin,	   in	  addition	   to	  
its	   morphological	   supporting	   role,	   may	   act	   as	   a	  
conductance	   for	   Mg2+	   across	   the	   consecutive	  
myelin	   lamellae,	   providing	   a	   faster	   access	   route	  
from	  the	  ECF	  to	  the	  periaxonal	  space.	  
	  
Concerning	  the	  transport	  of	  Mg2+	  across	  the	  BBB	  
via	  a	  transcellular	  route,	  it	  may	  also	  be	  prudent	  to	  
compare	  the	  BBB	  to	  other	  barrier	  membranes.	  As	  
stated	   above,	   TRPM6	   transporter	   protein	   has	  
been	   localized	   to	   the	   apical	   membrane	   of	   renal	  
distal	   convoluted	   tubules	   epithelium,	   the	   site	   of	  
active	   reclaiming	   of	   magnesium	   (Voets	   et	   al.,	  
2004),	  and	  TRPM7	  in	  the	  kidney	  also	  has	  a	  central	  
role	  in	  Mg2+	  homeostasis	  (Schmitz	  et	  al.,	  2003).	  In	  
mouse	   brain,	   using	   quantitative	   RT-­‐PCR,	   TRPM3	  
and	   TRPM7	  mRNA	  were	   detected	   at	   high	   levels,	  
and	  19	  other	   isoforms	  were	  also	  present	   (Brown	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et	   al.,	   2008;	   Kunert-­‐Keil	   et	   al.,	   2006).	   Also	   in	  
human	   brain	   TRPM1,	   2,	   3,	   6	   and	   7	   have	   been	  
detected	   using	   RT-­‐PCR	   (Fonfria	   et	   al.,	   2006).	  
Evidence	   of	   TRPM	   presence	   in	   brain	   endothelial	  
cells	  was	  obtained	  from	  endothelial	  cell	  cultures.	  
Immortalized	   mouse	   brain	   microvessel	   endo-­‐
thelial	  cells,	  freshly	  isolated	  cerebral	  microvessels	  
and	   primary	   cultured	   rat	   brain	   endothelial	   cells	  
express	   multiple	   TRPC	   and	   TRPV	   isoforms,	   and	  
also	   TRPM2,	  M3,	  M4,	   and	  M7	  mRNA	   (Brown	   et	  
al.,	   2008).	   We	   would	   like	   to	   suggest	   therefore	  
that	   the	   TRPM6	   and	   TRPM7,	   the	   gatekeepers	   of	  
magnesium	   (Schlingmann	   et	  al.,	   2007),	   are	   likely	  
to	   play	   a	   main	   role	   in	   brain	   endothelial	   cell	  
transport	   of	   magnesium	   via	   the	   transcellular	  
route.	  Western	  blotting	  and	  immunofluorescence	  
assays	   for	   TRPM6	   and	   TRPM7	   similar	   to	   those	  
performed	   for	   TRPV4	   in	   mouse	   cerebral	  
microvascular	   endothelial	   cells	   (Ma	   et	   al.,	   2008)	  
would	   support	   this	   suggestion.	   Also	   direct	  
evidence	   may	   be	   obtained	   from	   measuring	  
intracellular	   magnesium	   in	   endothelial	   cell	  
culture	   similar	   to	   previous	   reports	   on	  mammary	  
epithelial	  cells	  in	  culture	  (Voets	  et	  al.,	  2004)	  
	  
Magnesium	  transport	  across	  the	  blood-­‐CSF	  
barrier	  
What	   has	   become	   apparent	   from	   experimental	  
research	   and	   human	   studies	   is	   that	   magnesium	  
concentration	   in	   the	   CSF	   is	   actively	   maintained	  
above	   that	   of	   the	   plasma,	   and	   changes	   in	   CSF	  
magnesium	   lag	   behind	   changes	   in	   its	  
concentration	   in	   the	   plasma	   and	   are	   less	  
pronounced	   (Bradbury	   and	   Sarna,	   1977;	   Morris,	  
1992).	  Thus	  electrolyte	  composition	  in	  the	  CSF	  of	  
adult	  mammals	   is	   different	   from	   that	   of	   plasma	  
and	   is	   more	   stable,	   suggesting	   the	   existence	   of	  
mechanisms	   for	   electrolyte	   homeostasis	   in	   the	  
CSF,	   necessary	   for	   normal	   brain	   function	  
(Bradbury	   et	   al.,	   1972;	   Somjen,	   2002).	   The	  
mechanisms	   determining	   the	   concentrations	   of	  
ions	   in	   CSF	   appear	   to	   develop	   at	   different	   and	  
largely	  independent	  rates	  (Bradbury	  et	  al.,	  1972).	  
In	   the	   dog	   (Oppelt	   et	   al.,	   1963)	   and	   human	  
(Nischwitz	   et	   al.,	   2008)	   the	   concentration	   of	  
magnesium	   is	   higher	   in	   the	   CSF	   compared	   to	  
plasma.	   Also	   in	   fetal	   sheep	   and	   guinea	   pigs	  
magnesium	   concentration	   in	   the	   CSF	   is	   slightly	  
higher	  than	  that	  of	  plasma	  (Amtorp	  and	  Sorensen,	  
1974;	   Bradbury	   et	   al.,	   1972).	   An	   investigation	   of	  
the	   permeability	   of	   the	   human	   BCSFB	   to	  
magnesium	   carried	   out	   in	   29	   individuals,	   using	  
paired	   serum	   and	   CSF	   samples,	   showed	   a	  mean	  
CSF/serum	   ratio	   of	   1.3	   (Nischwitz	   et	   al.,	   2008).	  
This	   study	   also	   compared	   magnesium	   to	   other	  
metals,	  and	  suggested	  that	  low	  molecular	  weight	  
species	  such	  as	  magnesium	  and	  calcium	  cross	  the	  
BCSFB	   through	   less	   specific	   ion	   channels	  
compared	   to	   high	  molecular	  weight	  metals	   such	  
as	   iron,	   copper	   and	   zinc,	   which	   can	   pass	   the	  
barrier	  only	  via	  well	  controlled	  receptor	  mediated	  
pathways	  (Nischwitz	  et	  al.,	  2008)	  
	  
The	   choroidal	   epithelium	   plays	   an	   active	   role	   in	  
maintaining	  the	  level	  of	  magnesium	  in	  the	  CSF	  by	  
sensing	   changes	   in	   the	  CSF	  and	  altering	   the	   rate	  
of	   active	   magnesium	   secretion	   (Oppelt	   et	   al.,	  
1963;	   Reed	   and	   Yen	   1978).	   Physiological	   studies	  
of	   isolated	  choroid	  plexus	  of	  sheep	  (Allsop	  1986)	  
and	   cat	   (Reed	   and	   Yen	   1978)	   showed	   that	   the	  
choroid	   plexus	   is	   able	   to	   transfer	   magnesium	  
against	  a	  concentration	  gradient.	  An	  in	  vivo	  study	  
demonstrated	   a	   directional	   flow	   of	   magnesium	  
into	   the	   CNS	   (Allsop	   and	   Pauli,	   1985).	   In	   normal	  
cows	   the	   magnesium	   concentration	   in	   the	  
ventricular	   CSF	   was	   found	   to	   be	   higher	   than	   its	  
concentration	  in	  the	  lumbar	  CSF	  (Allsop	  and	  Pauli,	  
1985).	   Under	   hypomagnesemic	   conditions,	  
magnesium	   concentration	   in	   the	   ventricle	  
decreased	  more	   rapidly	   than	   that	   of	   the	   lumbar	  
CSF,	  while	  intravenous	  infusion	  of	  magnesium	  led	  
to	   increased	   magnesium	   in	   the	   ventricular	   CSF	  
before	   changes	   in	   the	   lumbar	   CSF	   (Allsop	   and	  
Pauli,	   1985).	   This	   study	   indicates	   that	   the	  access	  
of	   magnesium	   from	   the	   blood	   to	   the	   brain	   is	  
mainly	   via	   the	   choroid	   plexus	   to	   CSF,	   which	  
equilibrates	  with	  the	  CNS	  parenchyma.	  Transport	  
of	  magnesium	  in	  the	  choroid	  plexus	  is	  influenced	  
by	  other	  selective	  electrolytes.	  For	  example,	  high	  
levels	   of	   potassium	   in	   the	   perfusate	   of	   the	  
choroid	  plexus	  leads	  to	  a	  reduction	  in	  the	  transfer	  
rate	   of	  magnesium,	   but	   higher	   levels	   of	   calcium	  
does	  not	  have	  a	   similar	  effect	  on	   the	   transfer	  of	  
magnesium	  (Allsop,	  1986).	  
	  
A	   recent	   clinical	   trial	   on	   the	   protective	   role	   of	  
magnesium	   in	   traumatic	   brain	   injury	   (Temkin	   et	  
al.,	   2007)	   failed	   to	   replicate	   the	   improved	  
outcome	   detected	   in	   experimental	   studies	   on	  
rodents	   (Temkin	   et	   al.,	   2007;	   Vink	   and	   Cernak,	  
2000).	  In	  this	  clinical	  trial,	  plasma	  magnesium	  was	  
maintained	   at	   higher	   levels	   compared	   to	   the	  
placebo	   group	   and	   normal	   plasma	   level,	   to	  
counteract	   the	   reported	   decline	   in	   Mg2+	   in	   TBI	  
patients	   (Kahraman	   et	   al.,	   2003).	   Since	   under	  
normal	   conditions	   choroidal	   epithelial	   cells	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actively	   transport	   magnesium	   into	   the	   CSF,	   it	   is	  
likely	  that	  such	  activity	  was	  disrupted	  in	  TBI	  cases	  
in	   humans	   leading	   and	   failure	   of	   magnesium	  
entry	  to	  the	  CNS.	  It	   is	  relevant	  here	  to	  state	  that	  
in	   the	   rat,	   TBI	   induces	   severe	   morphological	  
changes	   in	   choroidal	   epithelial	   cells	   detected	   by	  
scanning	   and	   transmission	   electron	   microscopy	  
that	   were	   still	   evident	   4	   weeks	   after	   trauma	  
(Ghabriel	  et	  al.,	  2010).	  
	  
Although	   one	   cannot	   dismiss	   the	   possibility	   that	  
new	  channels	  may	  be	  involved	  in	  the	  transport	  of	  
magnesium	  at	  the	  choroid	  plexus,	   it	   is	  natural	  to	  
look	   at	   other	   systems	   for	   similar	   magnesium	  
transport	   mechanisms.	   As	   stated	   above	   the	  
strongest	  evidence	  for	  magnesium	  transport	  was	  
obtained	   from	   genetic	   studies	   in	   familial	  
hypomagnesemia,	   positional	   cloning	   and	  
knockout	  mice	  investigations	  (Konrad	  et	  al.,	  2006;	  
Schlingmann	   et	   al.,	   2005;	   Schlingmann	   et	   al.,	  
2007;	   Simon	   et	   al.,	   1999;	   Walder	   et	   al.,	   2002)	  
which	   identified	   TRPM6	   and	   TRPM7	   as	  
candidates	   for	   transcellular	   transport,	   and	  
Claudin16	  (Efrati	  et	  al.,	  2005;	  Simon	  et	  al.,	  1999)	  
for	  paracellular	   transport	   in	   the	  kidney.	  Recently	  
TRPM7	  has	  also	  been	  identified	  in	  smooth	  muscle	  
cells	   in	   the	   vasculature	   (Callera	   et	   al.,	   2009).	  
Although	   TRPM6	   and	   TRPM7	   were	   detected	   in	  
the	   brain	   using	   RT-­‐PCR	   it	   is	   not	   clear	   if	   these	  
channels	   are	   expressed	   in	   choroidal	   epithelial	  
cells.	   The	   role	   of	   claudin-­‐16	   and	   claudin-­‐19	   in	  
magnesium	  reabsorption	  from	  the	  kidney	  filtrate	  
has	  been	  discussed	   in	  previous	  sections,	  and	  the	  
role	  of	   claudins	  as	   selective	   conductance	   to	   ions	  
through	   tight	   junction	   has	   been	   stated.	   The	  
choroidal	   epithelial	   cells	   show	   selective	  
expression	  of	  claudin-­‐1,	   -­‐2	  and	   -­‐5	  at	  and	  near	   to	  
their	   tight	   junctions.	   Also	   the	   endothelial	   cells	  
within	   the	   choroid	   plexus	   show	   stronger	  
expression	   of	   claudin-­‐5	   than	   claudin-­‐1	   and	   -­‐2	  
(Lippoldt	   et	   al.,	   2000).	   However,	   claudin-­‐16	   and	  
claudin-­‐19	  have	  not	  been	  reported	  in	  the	  choroid	  
plexus.	   Whether	   other	   claudin	   members	   may	  
contribute	   to	   magnesium	   conductance	   in	   the	  
choroid	  plexus	  is	  speculative.	  Thus	  it	  appears	  that	  
the	   channels	   for	   magnesium	   transport	   in	   the	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Intracellular	  free	  Mg2+	  and	  MgATP2-­‐	  in	  coordinate	  control	  of	  	  










Specific	  and	  non-­‐specific	  mitogens	  stimulate	  the	  proliferation	  of	  cultured	  fibroblasts.	  	  They	  also	  stimulate	  
other	   responses	   that	   are	   part	   of	   a	   coordinate	   response,	   some	   members	   of	   which	   are	   essential	   for	  
proliferation	  and	  others	  that	  are	  not.	   	  The	  synthesis	  of	  protein	  is	  an	  early	  response	  to	  mitogens	  and	  its	  
continuation	  through	  the	  G1	  period	  drives	  the	  accumulation	  of	  protein	  which	  is	  required	  for	  the	  initiation	  
of	  DNA	  synthesis	  hours	  later.	  The	  parabola-­‐like	  curve	  for	  dependence	  of	  protein	  synthesis	  on	  intracellular	  
Mg2+	   concentration	   is	   similar	   to	   that	   of	   cell-­‐free	   ribosome	   preparations,	   and	   is	   later	   reflected	   in	   the	  
initiation	  of	  DNA	  synthesis.	  	  Hence,	  DNA	  synthesis	  is	  dependent	  on	  the	  rate	  of	  protein	  synthesis	  which	  is	  
regulated	  by	  the	  concentration	  of	  intracellular	  Mg2+.	  Presumably	  free	  Mg2+	  is	  an	  indicator	  of	  the	  fraction	  
of	  ATP4-­‐	  that	  is	  complexed	  with	  Mg2+	  as	  MgATP2-­‐,	  which	  is	  the	  immediate	  regulatory	  form.	  Uridine	  uptake	  
is	   determined	   by	   its	   phosphorylation,	  which	   is	   also	   dependent	   on	   intracellular	  Mg2+	   in	   the	   coordinate	  
response,	  but	  unlike	  protein	  synthesis,	  neither	  influences	  DNA	  synthesis	  nor	  exhibits	  downturn	  at	  a	  high	  
Mg2+	   concentration.	   Intracellular	   free	  Mg2+	   determines	   the	  onset	  of	   protein	   synthesis	   in	   activated	   frog	  
oocytes	  and	   its	  rate	   in	   lymphocytes.	  Mg2+	  regulation	  of	  protein	  synthesis	   is	  effected	  through	  the	  PI	  3-­‐K	  
pathway	  at	  mTOR	  phosphorylation	  of	  two	  translation-­‐regulating	  proteins.	  Regulation	  of	  proliferation	  by	  
Mg2+	   is	   lost	   in	   transformed	   cells.	  Mg2+	   and	  MgATP2-­‐	   apparently	   play	   a	   central	   role	   in	   the	   regulation	  of	  




The	   study	   of	   the	   regulation	   of	   cell	   proliferation	  
was	  greatly	  facilitated	  in	  the	  1960s	  and	  1970s	  by	  
the	   development	   of	  monolayer	   cell	   culture.	   This	  
permitted	  direct	  microscopic	   examination	  of	   cell	  
populations	   including	   cellular	   morphology	   and	  
behaviour.	   Techniques	   were	   also	   developed	   for	  
suspending	   and	   accurately	   counting	   the	   cells.	   It	  
was	  also	  possible	  to	  vary	  the	  cell	  population	  size,	  
change	   the	   constituents	   of	   the	   medium,	   and	  
uniformly	   label	   the	   cells	   with	   radioactive	  
chemicals	   to	   study	   their	   metabolism.	   Some	  
general	   features	   of	   cell	   growth	   stimulation	   have	  
to	  be	  considered	  before	  delving	  into	  the	  possible	  
mechanism(s)	   of	   its	   control.	   Most	   of	   the	  
experiments	  to	  be	  described	  here	  were	  conducted	  
in	   cell	   culture	   with	   fibroblasts	   obtained	   directly	  
from	   chicken	   embryos,	   or	   with	   established	   lines	  
of	   mouse	   fibroblasts.	   In	   most	   cases	   they	   were	  
allowed	   to	   grow	   into	   confluent	   sheets	   to	  
establish	   contact	   inhibition	   with	   low	   levels	   of	  
DNA	   synthesis	   that	   represented	   the	   small	  
proportion	   of	   cells	   in	   the	   S-­‐period,	   and	   no	   net	  
proliferation.	  Fresh	  medium	  containing	  serum	  or	  
other	  growth	  stimulants	  was	  added	  and	  measure-­‐
ments	  of	  various	  cellular	  parameters	  were	  made	  
at	  intervals	  thereafter.	  	  
	  
After	   application	   of	   a	   stimulus	   to	   a	   growth-­‐
inhibited	   culture,	   increase	   in	   DNA	   synthesis,	  
representing	   the	   increased	  proportion	  of	   cells	   in	  
the	  S-­‐period,	  does	  not	  begin	  for	  4	  hours	  in	  ex	  vivo	  
chicken	  embryo	  cells	  (Rubin	  and	  Steiner,	  1975)	  or	  
10	   hours	   in	   an	   established	   line	   of	   mouse	   cells	  
(Rubin	   et	   al.,	   1978).	   This	   indicates	   that	  multiple	  
metabolic	  processes	  are	  required	  to	  produce	  that	  
response.	  These	   include	   increases	   in	  the	  rates	  of	  
uptake	  of	  glucose	  analogues,	  and	  uridine	  prior	  to	  
its	   incorporation	   into	   RNA	   (Rubin,	   1975b).	  
Although	   neither	   of	   these	   responses	   is	   required	  
for	   the	   increased	  DNA	  synthesis,	   they	  are	  clearly	  
part	  of	  a	   coordinate	   response	  of	   the	  cells	   to	   the	  
growth	   stimulants,	   and	   have	   to	   be	   taken	   into	  
account	   in	   understanding	   the	   intracellular	  
mechanism	   of	   growth	   regulation.	   Most	  
significant,	   there	   is	   also	   a	   fractional	   increase	   in	  
the	   rate	   of	   protein	   synthesis	   that	   must	   be	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maintained	  throughout	  the	  period	  preceding	  DNA	  
synthesis,	  and	  is	  essential	  for	  its	  initiation	  (Rubin,	  
2005).	   Small	   decreases	   of	   protein	   synthesis	   in	  
cells	   treated	   with	   a	   specific	   inhibitor	   of	   protein	  
synthesis	  result	   in	   large	  decreases	  in	  the	  fraction	  
of	   cells	   that	   later	   initiate	  DNA	  synthesis	   (Brooks,	  
1977;	  and	  Figure	  1).	  	  
	  
Another	   aspect	   of	   growth	   stimulation	   concerns	  
treatments	  other	  than	  serum	  growth	  factors	  that	  
produce	   the	   same	   constellation	   of	   responses.	  
Certain	   hormones	   such	   as	   insulin	   produce	   the	  
coordinate	  response	  in	  some	  cell	  types,	  indicating	  
that	   a	   specific	   interaction	   between	   proteins	   and	  
their	  receptors	  at	  the	  cell	  surface	  can	  initiate	  the	  
coordinate	   response.	  However,	   the	   same	  effects	  
are	  produced	  by	  removing	  a	  strip	  of	  cells	   from	  a	  
confluent	  monolayer,	  which	  allows	  migration	  and	  
multiplication	   of	   the	   cells	   at	   the	   margin.	   This	  
indicates	   that	   the	   coordinate	   response	   is	   not	  
limited	  to	  specific	  receptors.	  A	  similar	  conclusion	  
is	   suggested	   by	   the	   finding	   that	   subtoxic	  
concentrations	   of	   heavy	   metals	   including	   zinc,	  
cadmium,	   and	   mercury	   initiate	   the	   coordinate	  
response	   in	   chick	   embryo	   fibroblasts	   (Rubin,	  
1975b).	   Lead	   stimulated	   DNA	   synthesis	   in	   some	  
experiments,	   and	   in	   other	   experiments	   did	   not	  
(Sanui	  and	  Rubin,	  1984).	  Those	  cultures	   in	  which	  
DNA	   was	   not	   stimulated	   showed	   no	   increase	   in	  
cellular	  Mg2+,	  whereas	  those	  that	  were	  significantly	  
stimulated	   exhibited	   a	   10	   -­‐	   13%	   increase	   in	  
intracellular	   Mg2+.	   Stimulation	   of	   DNA	   synthesis	  
by	   lead	   coincided	   with	   the	   formation	   of	   lead	  
precipitate	  in	  the	  medium.	  	  
	  
	  A	  striking	  finding	  made	  with	  a	  permanent	  line	  of	  
cells	   originating	   from	  mouse	   embryo	   fibroblasts	  
was	   that	   increasing	   concentrations	   of	   inorganic	  
pyrophosphate	   initiated	  the	  coordinate	  response	  
at	   precisely	   the	   concentration	   (about	   0.2	  mM	   in	  
standard	   medium)	   at	   which	   it	   first	   formed	   a	  
flocculent	   precipitate	   with	   calcium	   (Rubin	   and	  
Sanui,	  1977).	  The	  stimulation	  required	  contact	  of	  
the	  precipitate	  with	  the	  cell	  surface	  as	  shown	  by	  
the	   failure	   of	   stimulation	   when	   the	   culture	   dish	  
was	   inverted	   so	   that	   the	   precipitate	   did	   not	  
contact	   the	  cells	   (Bowen-­‐Pope	  and	  Rubin,	  1983).	  
The	   stimulation	  was	   terminated	  when	   the	  pH	  of	  
the	   medium	   was	   slightly	   lowered	   and	   the	  
precipitate	   dissolved,	   showing	   that	   the	   effect	  
required	   the	   precipitate	   and	  was	   exerted	   at	   the	  
surface	  of	  the	  cell.	  	  
	  
	  
Figure	   1.	   Inhibition	   of	   protein	   synthesis	   by	  
cycloheximide	   and	   its	   effect	   on	   the	   initiation	   of	  
DNA	  synthesis	  in	  mouse	  3T3	  cells.	  Quiescent	  cells	  
were	   stimulated	   with	   serum	   in	   the	   presence	   of	  
the	   indicated	   concentrations	   of	   cycloheximide.	  	  
Cultures	  were	  pulse-­‐labelled	  for	  protein	  synthesis	  
with	   3H-­‐leucine	   at	   2	   hours	   (●)	   and	   continuously	  
labelled	   with	   3H-­‐thymidine	   for	   24	   hours	   (O).	  	  
Ordinate:	   radioactivity	   incorporated	   as	   percentage	  
of	  control	  (no	  cycloheximide)	  (Brooks,	  1977).	  	  
	  
	  
In	   the	   absence	   of	   pyrophosphate,	   supranormal	  
concentrations	   of	   either	   Ca2+	   or	   orthophosphate	  
caused	  graded	  increases	   in	  DNA	  synthesis	  (Rubin	  
and	  Sanui,	  1977).	  The	  effect	  of	  supranormal	  Ca2+	  
depended	  on	  orthophosphate	  and	  vice	  versa.	  The	  
stimulation	   was	   associated	   with	   increasing	  
turbidity	   of	   the	   medium,	   consistent	   with	   the	  
involvement	  of	  a	  precipitate	   interacting	  with	   the	  
cell	   membrane.	   Several	   other	   non-­‐physiological,	  
non-­‐specific	   treatments	   could	   initiate	   the	  
coordinate	   response,	   although	   most	   of	   them	  
could	   not	   maintain	   multiple	   rounds	   of	   cell	  
multiplication.	   One	   exception	   was	   the	   wound-­‐
healing	  experiment,	  which	  allowed	  continued	  cell	  
multiplication	   until	   the	   cleared	   strip	   was	  
completely	   covered	   with	   cells.	   The	   sum	   total	   of	  
these	  experiments	   indicates	   that	  perturbation	  of	  
the	   cell	   membrane,	   which	   could	   be	   brought	  
about	   by	   specific	   or	   non-­‐specific	   means,	   is	  
involved	   in	   growth	   stimulation,	   and	   raises	   the	  
question	   of	   what	   intracellular	   response(s)	   or	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second	   messenger(s)	   mediate	   the	   diverse	  
reactions	  of	  the	  coordinate	  response.	  
	  
Variations	  of	   intracellular	  K+,	  Na+	  or	  Ca+	   failed	   to	  
reproduce	  the	  coordinate	  response	  in	  a	  balanced	  
manner	   (Moscatelli	  et	  al.,	  1979)	  nor	  did	  changes	  
in	   the	   pH	   of	   the	   medium	   (Rubin,	   2005).	   Intra-­‐
cellular	  Mg2+	  was	   considered	   a	   logical	   candidate	  
as	   a	   second	   messenger	   for	   regulating	   the	  
coordinate	   response	   to	   membrane	   perturbation	  
because	   it	   is	   required	   for	   every	   phosphoryl	  
transfer	   in	   the	   cell.	   Drastic	   reduction	   in	   Mg2+	  
concentration	   in	   the	   medium	   reduced	   the	  
number	  of	   cells	   in	   the	   S-­‐period	  of	   the	   cell	   cycle,	  
but	   the	   effect	   was	   erratic	   (Rubin,	   1975a).	  
Phosphorylated	  compounds	   that	  bind	  Mg2+	  were	  
more	   reproducible,	   especially	   inorganic	   pyro-­‐
phosphate	   in	   concentrations	   that	   exceeded	   the	  
concentration	  of	  Mg2+	   in	  the	  medium.	  Unlike	  the	  
very	   low	   concentrations	   of	   pyrophosphate	   that	  
stimulated	   mouse	   fibroblasts	   via	   a	   precipitate	  
with	   Ca2+	   (Bowen-­‐Pope	   and	   Rubin,	   1983),	   the	  
inhibition	  of	  fibroblast	  growth	  was	  most	  efficient	  
in	   low	  concentrations	  of	  Ca2+	   in	  which	  there	  was	  
no	  precipitate.	  Mg2+	  deprivation,	  further	  lowered	  
by	  its	  binding	  with	  pyrophosphate,	  suppressed	  all	  
elements	   of	   the	   coordinate	   response	   in	   a	  
balanced	  manner	  (Rubin,	  1975a).	  
	  
Changes	  in	  total	  and	  free	  Mg2+	  after	  stimulation	  
of	  cells	  with	  mitogens	  
	  
The	   major	   cellular	   cations	   were	   measured	   in	  
confluent	  chick	  embryo	  fibroblasts	  16	  hours	  after	  
a	  fresh	  change	  of	  medium	  with	  insulin	  substituting	  
for	   serum	   (Sanui	   and	   Rubin,	   1978).	   There	   was	  
more	  than	  a	  16-­‐fold	  increase	  in	  the	  overall	  rate	  of	  
DNA	   synthesis	   in	   the	   optimal	   concentration	   of	  
insulin,	  with	   a	   22%	   increase	   in	   total	  Mg2+	   of	   the	  
cells	   as	  measured	  by	   atomic	   absorption	   spectro-­‐
photometry.	   There	   was	   no	   change	   in	   total	   cell	  
Ca2+,	  negligible	  change	  in	  Na+	  and	  a	  14%	  increase	  
in	   K+,	   an	   element	   that	   plays	   an	   adjunct	   role	   to	  
Mg2+	   in	   the	   synthesis	   of	   protein	   in	   cell-­‐free	  
systems	   (Schreier	   and	   Staehelin,	   1973).	   In	   an	  
experiment	  with	  a	  contact	  –inhibited	  and	  serum-­‐
limited	   line	  of	  mouse	   fibroblasts,	   the	  addition	  of	  
fresh	  medium	  containing	  serum	  induced	  a	  15-­‐fold	  
increase	  of	  DNA	  synthesis	  at	  17	  hours,	  associated	  
with	   a	   15%	   increase	   in	   total	   Mg2+	   (Sanui	   and	  
Rubin,	  1982).	  There	  was	  only	  a	  marginal	  increase	  
in	  K+,	  and	  decreases	  in	  Na+	  and	  Ca2+.	  These	  results	  
were	   consistent	   with	   a	   central	   role	   for	   Mg2+	   in	  
supporting	  cell	  proliferation.	  
	  
It	  seemed	  likely	  to	  us	  that	   intracellular	  free	  Mg2+	  
combined	   with	   ATP4-­‐	   is	   its	   regulatory	   form,	  
possibly	  made	  available	  by	  cation	  exchange	  with	  
intracellular	  K+	  that	  releases	  bound	  Mg2+	  from	  the	  
inner	  surface	  of	  the	  cell	  membrane	  (Rubin,	  1976;	  
Sanui	   and	   Rubin,	   1978).	   The	   free	   Mg2+	   would	  
combine	   with	   ATP4-­‐	   to	   form	   MgATP2-­‐,	   which	  
would	   stimulate	   phosphoryl	   transfer	   reactions	  
throughout	   the	   cell,	   and	   reduce	   the	   inhibitory	  
KATP3-­‐	   form.	   However,	   we	   did	   not	   have	   an	  
efficient	   means	   at	   the	   time	   of	   measuring	   free	  
Mg2+	   in	   the	   cell.	   The	   development	   of	   a	   Mg2+-­‐
sensitive	   fluorescent	   dye,	   mag-­‐fura-­‐2,	   made	   it	  
possible	   to	   quantify	   intracellular	   free	   Mg2+	  
(Murphy	   et	   al.,	   1989;	   Raju	   et	   al.,	   1989).	   It	   was	  
used	   to	   monitor	   free	   Mg2+	   in	   a	   quiescent,	  
confluent	  line	  of	  mouse	  fibroblasts	  stimulated	  by	  
insulin	   or	   by	   insulin	   combined	   with	   epidermal	  
growth	   factor	   (Ishijima	   et	   al.,	   1991).	   The	  
combination	   of	   the	   two	   growth	   factors	   led	   to	   a	  
significant	  increase	  of	  intracellular	  free	  Mg2+	  from	  
a	   basal	   level	   of	   0.22	   mM	   to	   0.29	   mM	   at	   30	  
minutes,	  and	  to	  0.35	  mM	  at	  60	  minutes.	  After	  60	  
minutes	   the	   free	  Mg2+	   levels	   seemed	   to	   decline,	  
but	   the	   measurements	   were	   no	   longer	   reliable	  
because	  of	  leakage	  of	  the	  dye.	  Epidermal	  growth	  
factor	   produced	   a	   50-­‐fold	   increase	   in	   DNA	  
synthesis	  when	  added	  to	  a	  serum-­‐starved	   line	  of	  
differentiated	   myocytes	   (Grubbs,	   1991).	   Free	  
Mg2+	  increased	  after	  a	  5-­‐	  minute	  lag	  period,	  rising	  
gradually	  from	  an	  initial	  0.32	  mM	  to	  as	  high	  as	  1.4	  
mM	   at	   20	  minutes,	   and	   then	   levelled	   off.	   There	  
was	   no	   change	   in	   the	   cellular	   pH	   or	   free	   Ca2+	  
during	   the	  20-­‐minute	  period.	   The	  dose-­‐response	  
to	  epidermal	  growth	  factor	  was	  the	  same	  for	  free	  
Mg2+	  and	  the	  synthesis	  of	  DNA,	  strengthening	  the	  
case	   for	   the	   dependence	   of	   the	   proliferative	  
response	  on	  the	  rise	  of	  free	  Mg2+.	  
	  
Correlations	  between	  cellular	  Mg2+,	  protein	  
synthesis	  and	  the	  onset	  of	  DNA	  synthesis	  
	  
A	  series	  of	  experiments	  was	  carried	  out	   in	  which	  
external	  Mg2+	  was	  varied	  over	  a	  wide	  range	  (1-­‐48	  
mM)	   in	   a	   medium	   containing	   only	   0.02	   Ca2+	  
(Rubin	   et	   al	   1979).	   The	   low	   Ca2+	   concentration	  
increased	   the	   permeability	   of	   the	   cells	   for	   entry	  
of	  Mg2+.	  Intracellular	  Mg2+	  content	  and	  the	  rate	  of	  
protein	   synthesis	   were	   measured	   at	   3	   and	   17	  
hours	  and	  the	  rate	  of	  DNA	  synthesis	  at	  17	  hours.	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The	   results	   showed	   that	   the	   intracellular	   Mg2+	  
concentration	   increased	   as	   the	   external	   Mg2+	  
concentration	   was	   increased,	   but	   the	   rate	   of	  
protein	   synthesis	   at	   3	   hours	   peaked	   at	   20	   mM	  
external	   Mg2+	   concentration,	   and	   declined	   with	  
higher	  (30	  –	  48	  mM)	  Mg2+	  concentrations	  (Figure	  
2A,	   B).	   The	   rate	   of	   DNA	   synthesis	   at	   17	   hours	  
peaked	   at	   the	   same	   Mg2+	   concentration	   as	  
protein	   synthesis	   at	   3	   hours	   (Figure	   2A),	  
consistent	   with	   the	   dependence	   of	   the	   onset	   of	  
the	   S-­‐period	   on	   the	   rate	   of	   protein	   synthesis	  




Figure	   2.	   Effects	   of	   extracellular	   Mg2+	   on	  
intracellular	   Mg2+	   and	   on	   protein	   and	   DNA	  
synthesis.	   Quiescent	   mouse	   3T3	   cells	   were	  
stimulated	   with	   10%	   dialyzed	   serum	   in	   Ca2+-­‐
deprived	  medium	  with	  varying	  concentrations	  of	  
Mg2+.	   At	   3	   hours	   some	   of	   the	   cultures	   were	   A)	  
labelled	  with	  3H-­‐leucine;	  and	  at	  17	  hours	  with	  3H-­‐
leucine	   or	   3H-­‐thymidine;	   B)	   processed	   for	  
measurement	   of	   intracellular	   Mg2+	   at	   3	   and	   17	  
hours	  (Rubin	  et	  al.,	  1979).	  	  
	  
	  
Protein	   synthesis	   at	   17	   hours	   showed	   a	  
stimulation	   at	   30	   mM	   external	   Mg2+	   which	   had	  
first	   inhibited	   protein	   synthesis	   at	   3	   hours,	   and	  
consequently	  reduced	  DNA	  synthesis	  at	  17	  hours	  
(Figure	  2A).	  The	  increased	  protein	  synthesis	  at	  17	  
hours	  was	  associated	  with	  a	  decrease	  of	   cellular	  
Mg2+	   from	   its	   inhibitory	   level	   at	   3	   hours	   to	   a	  
physiological	  stimulatory	  level	  at	  17	  hours	  (Figure	  
2A,	   B),	   indicating	   the	   cells	   were	   able	   to	   reduce	  
Mg2+	   content	   to	   functional	   levels.	   If	   the	  external	  
Mg2+	   levels	  were	   carried	   to	  even	  higher	  external	  
levels	  (48	  mM),	  the	  cellular	  Mg2+	  rose	  to	  very	  high	  
levels	   at	   17	   hours	   and	   both	   protein	   and	   DNA	  
synthesis	  remained	  close	  to	  zero,	  indicating	  toxic	  
damage	  of	  the	  cells.	  The	  overall	   results	  provided	  
strong	   evidence	   of	  Mg2+	   as	   an	   indirect	   regulator	  
of	   the	   onset	   of	  DNA	   synthesis	   through	   its	   direct	  
effect	  on	  the	  rate	  of	  preceding	  protein	  synthesis.	  
It	  should	  be	  recalled	  however	  that	  the	  free	  Mg2+	  
level	  is	  an	  indicator	  of	  the	  fraction	  of	  ATP4-­‐	  that	  is	  
complexed	   to	  Mg2+	  as	  MgATP2-­‐	  which	   is	   the	   true	  
regulator	  (Rubin,	  2005).	  
	  
Figure	   3	   plots	   the	   rate	   of	   protein	   synthesis	   at	   3	  
hours	   against	   the	   intracellular	   concentration	   of	  
Mg2+,	   showing	   the	   sharp	   increase	   in	   protein	  
synthesis	   with	   small	   increases	   of	   intracellular	  
Mg2+	   in	   the	   physiological	   range	   (0.05	   –	   0.08	  
µmole/mg	   protein).	   At	   high	   concentrations	   of	  
Mg2+,	   protein	   synthesis	   is	   reduced	   both	   in	  
cultured	   cells	   and	   in	   cell	   free	   systems	   (Schreier	  
and	   Staehelin,	   1973;	   and	   Figure	   4).	   The	   same	  
concentration	   dependence	   is	   exhibited	   by	   DNA	  
synthesis	   in	  cells	  at	  17	  hours	   (Rubin	  et	  al.,	  1978,	  
and	   Figure	   5),	   which	   is	   consistent	   with	   the	  
dependence	   of	   DNA	   synthesis	   on	   prior	   protein	  
synthesis.	   The	   increase	  of	  protein	   synthesis	  with	  
ascending	   Mg2+	   at	   physiological	   intracellular	  
levels	   has	   to	   be	   maintained	   through	   the	   G-­‐1	  





Figure	  3.	  Relationship	  between	  intracellular	  Mg2+	  
and	   protein	   synthesis.	   Quiescent	   mouse	   3T3	  
cultures	   were	   stimulated	   with	   10%	   dialyzed	  
serum	   in	   Ca2+-­‐deprived	   medium	   and	   varying	  
concentrations	   of	  Mg2+.	   At	   3	   hours	   some	   of	   the	  
cultures	   were	   labelled	   with	   3H-­‐leucine,	   or	  
processed	   for	  measurement	  of	   intracellular	  Mg2+	  
(Rubin	  et	  al.,	  1979).	  




Figure	  4.	  Mg2+dependency	  of	  globin	  synthesis	  by	  
mouse	  liver	  polysomes	  in	  a	  cell-­‐free	  system,	  with	  
labelling	   by	   14C-­‐leucine.	   	   After	   correction	   for	  
chelation	   of	  Mg2+	   by	   ATP	   and	  GTP,	   the	   effective	  
Mg2+	   concentration	   is	   1.4	   mM	   lower	   than	   that	  
indicated	   (Schreier	   and	   Staehelin,	   1973).	   	   The	  
correction	  does	  not	  take	  into	  account	  that	  32%	  of	  
cytosolic	   Mg2+	   is	   bound	   to	   low	   affinity,	   non-­‐
diffusible	   sites	   (Corkey	   et	   al.,	   1986).	   	   Note	   the	  
steep	   increase	   in	   globin	   synthesis	   with	   Mg2+	   at	  
lower	   levels,	   closer	   to	   an	   estimated	   intracellular	  




synthesis.	  The	  high	  concentration	  of	  total	  Mg2+	  in	  
cells,	   and	   the	   low	   affinity	   of	   Mg2+	   binding	   sites,	  
results	   in	   rather	   large	   changes	  of	   free	  Mg2+	  with	  
small	   variations	   in	   total	   cell	   Mg2+.	   This	   makes	  
Mg2+	   an	   unlikely	   short-­‐term	   regulatory	  molecule	  
like	   Ca2+,	   but	   long	   term	   change	   in	   total	  Mg2+,	   as	  
exhibited	   in	   mitogen	   stimulation,	   may	   have	  
profound	   effects	   on	   metabolic	   regulation	   given	  
the	  sensitivity	  of	   free	  Mg2+	  to	  alterations	   in	  total	  
Mg2+	  (Corkey	  et	  al.,	  1986).	  
	  
Response	  of	  protein	  synthesis	  in	  frog	  oocytes	  to	  
injection	  of	  Mg2+	  resembles	  that	  of	  stimulation	  
by	  gonadotropin	  
	  
Frog	   oocytes	   are	   large	   enough	   (850-­‐950	  
micrometres	  in	  diameter)	  to	  allow	  microinjection	  
of	  materials,	  and	  to	  measure	  cations	  and	  protein	  
synthesis	  in	  single	  cells	  (Horowitz	  and	  Lau,	  1988).	  
When	  stimulated	  by	  gonadotropin	  these	  quiescent	  
cells	  begin	  to	  synthesize	  protein	  that	  drives	  their	  
	  
	  
Figure	   5.	   	  DNA	   synthesis	   as	   a	   function	   of	   extra-­‐
cellular	   Mg2+.	   Quiescent	   mouse	   3T3	   cells	   were	  
stimulated	   with	   10%	   dialyzed	   serum	   in	   Ca2+-­‐
deprived	  medium	  with	  varying	  concentrations	  of	  
Mg2+.	  	  At	  17	  hours	  the	  cultures	  were	  labelled	  with	  
3H-­‐thymidine.	   	   The	   asterisks	   associated	  with	   the	  
two	   highest	   concentrations	   of	   Mg2+	   in	   the	  
medium	   and	   greatly	   reduced	   incorporation	   in	  
DNA	   indicate	   many	   foci	   of	   degenerated	   cells	  






growth	   and	   maturation	   into	   eggs.	   Exposing	  
oocytes	   in	   saline	   to	   gonadotropin	   that	   acts	   via	  
cell	   surface	   receptors	   increases	   cytoplasmic	   K+	  
activity	  and	  protein	  synthesis	  for	  at	  least	  10	  days	  
(Lau	  et	  al.,	  1988).	  These	  effects	  are	  mimicked	  by	  
microinjection	   of	   K+	   into	   oocytes	   immersed	   in	  
paraffin	   oil	   to	   prevent	   contributions	   from	  
external	   sources.	   The	   results	   suggested	   that	   K+	  
activity	   is	   critical	   to	   activate	   and	   perpetuate	  
protein	  synthesis.	  
	  
Further	  analysis	  of	  the	  results	  showed	  that	  there	  
was	   a	   greater	   effect	   of	   K+	   on	   translation	   in	   the	  
oocytes	  than	  expected	  from	  its	  effect	  on	  cell-­‐free	  
translation	   (Horowitz	   and	   Tluczek,	   1989).	   Also,	  
injection	   of	   Na+	   into	   the	   oocytes	   stimulated	  
protein	   synthesis	   to	   the	   same	   extent	   as	   K+,	  
despite	  the	  fact	  that	  Na+	  has	  no	  effect	  on	  cell-­‐free	  
translation	   systems.	   These	   results	   indicated	   that	  
Na+	   and	  K+	   compete	  with	  each	  other	   for	  binding	  
to	  high	  affinity	  anions	  such	  as	  phosphate	  groups	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on	   membranes.	   Ca2+	   was	   ruled	   out	   as	   the	  
displaced	   cation,	   but	   Mg2+	   stimulated	   protein	  
synthesis	   at	   much	   lower	   and	   narrower	  
concentrations	  than	  did	  K+.	  It	  was	  concluded	  that	  
Mg2+,	   presumably	   as	   MgATP2-­‐,	   is	   the	   effector	  
directly	   controlling	   translation	   rates	   in	   oocytes.	  
There	  was	   also	   evidence	   that	   stimulation	   of	   the	  
oocytes	   by	   gonadotropin,	   which	   was	   necessarily	  
done	   in	   saline	   medium	   containing	   Mg2+,	   added	  
extracellular	   Mg2+	   to	   that	   contributed	   by	  
intracellular	   cation	   exchange	   (Horowitz	   and	  
Tluczek,	  1989).	  	  
	  
Role	  of	  Mg2+	  in	  regulating	  uridine	  uptake	  
	  
The	   uptake	   rate	   of	   uridine	   into	   the	   acid	   soluble	  
fraction	   of	   the	   cytoplasm	   increases	   several	   fold	  
within	  a	   few	  minutes	  after	   stimulating	   cells	  with	  
serum	   (Bowen-­‐Pope	   and	   Rubin,	   1977),	   and	   is	  
sensitive	   to	   the	   concentration	   of	   Mg2+	   in	   the	  
medium	   (Rubin,	   1976).	   External	   uridine	   is	   not	  
required	  for	  growth	  of	  the	  cells,	  and	  its	  increased	  
uptake	   does	   not	   require	   protein	   synthesis	  
(Bowen-­‐Pope	  and	  Rubin,	  1977).	  The	  regulation	  of	  
uridine	   uptake	   by	   Mg2+	   occurs	   at	   its	  
phosphorylation,	  which	  is	  the	  same	  step	  at	  which	  
serum	   modulates	   uridine	   uptake	   (Vidair	   and	  
Rubin,	  1981).	  	  
	  
Phosphorylation	  of	  uridine	  is	  catalysed	  by	  uridine	  
kinase,	   which	   responds	   to	   Mg2+	   in	   cell-­‐free	  
systems	   in	  a	  manner	  similar	   to	   that	  exhibited	  by	  
uridine	   uptake	   in	   living	   cells.	   Unlike	   protein	  
synthesis,	  uridine	  uptake	   is	  not	   inhibited	  by	  high	  
concentrations	   of	   Mg2+	   in	   the	   cells,	   which	   is	  
consistent	  with	   its	   simpler	  dependence	  on	   initial	  
phosphorylation	  vs	   the	  many	   steps	   at	  which	  net	  
protein	   synthesis	   may	   be	   affected	   by	   Mg2+	  
(Bowen-­‐Pope	   et	   al.,	   1979).	   Thymidine	   uptake	  
does	   not	   respond	   to	   mitogenic	   stimulation,	   nor	  
does	   it	   require	   Mg2+	   at	   the	   concentrations	  
required	  by	  uridine	  (Vidair	  and	  Rubin,	  1981).	  This	  
is	   presumably	   because	   the	   Km	   of	   uridine	   kinase	  
for	  Mg2+	   is	   higher	   than	   that	   of	   thymidine	   kinase	  
and	  within	  the	  normal	  range	  of	  intracellular	  Mg2+	  
variation	   (Vidair	   and	   Rubin,	   2005).	   The	   divalent	  
cation	   ionophore	   A23187	   facilitates	   the	  
manipulation	   of	   intracellular	  Mg2+	   concentration	  
without	   increasing	   the	   generalized	   permeability	  
of	  the	  cell.	  In	  high	  concentrations	  of	  extracellular	  
Mg2+,	  the	  ionophore-­‐treated	  cells	  take	  up	  uridine	  
in	   the	   absence	   of	   protein	   growth	   factors	   at	   the	  
same	   high	   rate	   as	   in	   their	   presence.	   The	   results	  
support	   the	   thesis	   that	   increased	  uridine	   uptake	  
in	  cells	  treated	  with	  growth	  factors	  is	  determined	  
by	  a	  membrane-­‐activated	  increase	  in	  intracellular	  
free	  Mg2+.	  	  
	  
Molecular	  studies	  of	  Mg2+	  regulation	  in	  
lymphocytes	  
	  
TRPM7	   is	   a	  membrane	   protein	  with	   intrinsic	   ion	  
channel	   and	   protein	   kinase	   domains	   (Schmitz	   et	  
al.,	   2003).	   An	   established	   line	   of	   chicken	  
lymphocytes	   deficient	   in	   TRPM7	   entered	   a	  
quiescent	   phase	   when	   cultured	   in	   standard	  
concentrations	   (0.4	  mM)	   of	  Mg2+	   similar	   to	   that	  
of	  lymphocytes	  in	  the	  organism.	  Raising	  the	  Mg2+	  
concentration	   in	  the	  medium	  to	  15	  mM	  resulted	  
in	   an	   increase	   in	   both	   the	   viability	   and	  
proliferation	   of	   the	   cells,	   implying	   increased	  
protein	   accumulation	   accompanying	   progress	  
through	   the	   cell	   cycle.	   This	   activation	   indicated	  
that	   TRPM7	   has	   an	   essential	   role	   in	   regulating	  
physiological	  concentrations	  of	  Mg2+	  by	  an	  uptake	  
pathway	   with	   functional	   coupling	   between	   its	  
channel	  and	  kinase	  domains.	  TRPM7	  channels	  are	  
required	  for	  PI	  3-­‐K	  function	  as	  a	  central	  regulator	  
of	   growth	   in	   lymphocytes	   (Sahni	   and	  
Scharenberg,	   2008),	   as	   had	   been	   hypothesized	  
from	   studies	   of	   Mg2+	   regulation	   in	   fibroblasts	  
(Rubin,	  2005).	  The	  PI	  3-­‐K	  pathway	  leads	  through	  a	  
protein	  kinase	  cascade	  to	  mTOR	  kinase	  which	  is	  a	  
central	   regulator	   of	   protein	   synthesis	   (Schmelzle	  
and	  Hall,	   2000).	  mTOR	  accomplishes	   this	   role	  by	  
phosphorylating	   serines	   and	   threonines	   on	   two	  
proteins	   which	   drive	   further	   steps	   that	   initiate	  
translation	   (Terada	   et	   al.,	   1994;	   Sahni	   and	  
Scharenberg,	  2008).	  The	  mTOR	  phosphorylations	  
have	   a	   high	   Km	   for	   MgATP2-­‐,	   which	   is	   in	   the	  
physiological	  range	  of	  free	  Mg2+.	  Total	  Mg2+	  in	  the	  
TRPM7-­‐deficient	   lymphocytes	   in	   standard	  
medium	  underwent	  a	  significant	  decrease,	  but	  no	  
change	   in	   free	   Mg2+	   was	   detected,	   which	  
contrasts	   with	   the	   increase	   in	   free	   Mg2+	   in	  
mitogen-­‐stimulated	   fibroblasts	   (Ishijima	   et	   al.,	  
1991)	  and	  in	  myocytes	  (Grubbs,	  1991).	  
	  
A	  number	  of	   the	  known	  properties	  of	  quiescent,	  
ex-­‐vivo	   lymphocytes	   were	   also	   measured	   in	   the	  
TRPM7-­‐deficient	   lymphocytes	   in	   standard	  
medium	   containing	   0.4	   mM	   Mg2+	   (Sahni	   et	   al.,	  
2010).	  The	  DNA	  content	  and	   size	  of	   the	   two	  cell	  
sources	  were	  similar,	  and	  suggested	   that	  TRPM7	  
and	  Mg2+	  are	  involved	  in	  the	  activation	  of	  normal	  
quiescent	   lymphocytes.	   The	   TRPM7-­‐deficient	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lymphocytes	   increased	   in	   size	   and	  entered	   rapid	  
proliferation	   when	   the	   concentration	   of	  Mg2+	   in	  
the	  medium	  was	  increased.	  The	  key	  cell	  regulator	  
p27	   was	   elevated	   in	   both	   normal,	   quiescent	  
lymphocytes	   and	   in	   TRPM7-­‐deficient	   cells	   in	  
standard	   medium.	   A	   reduction	   in	   RNA,	   store-­‐
operated	   Ca2+	   entry	   and	   altered	   energy	  
metabolism	  was	   found	   in	   the	   quiescent	   TRPM7-­‐
deficient	   cells	   and	   in	   normal	   quiescent	  
lymphocytes.	  The	  addition	  of	  excess	  Mg2+	   to	   the	  
deficient	   cells	   altered	   all	   these	   processes	   in	   a	  
characteristic	   manner	   of	   activation	   of	   normal	  
lymphocytes,	   just	   as	   it	   activated	   the	   coordinate	  
response	   of	   fibroblasts	   in	   Ca2+-­‐deficient	  medium	  
(Rubin	  et	  al.,	  1979).	  The	  implication	  of	  these	  and	  
foregoing	   results	   is	   that	   cytosolic	   free	  Mg2+	   and	  
MgATP2-­‐	  play	  a	  central	  role	  in	  the	  regulation	  of	  all	  
cell	   types	   and	   stages	   of	   development	   across	   the	  
animal	  kingdom.	  
	  
Loss	  of	  Mg2+	  regulation	  in	  neoplastically	  
transformed	  cells	  
	  
Neoplastically	   transformed	   cells	   have	   the	  
capacity	  to	  proliferate	  in	  lower	  concentrations	  of	  
serum	   and	   to	   higher	   saturation	   densities	   than	  
non-­‐transformed	   cells	   (Rubin,	   1981).	   Cell	  
transformation	   causes	   a	   selective	   loss	   of	   the	  
regulatory	   role	   of	  Mg2+	   in	   cellular	   multiplication	  
(McKeehan	  and	  Ham,	  1978).	  Deprivation	  of	  Mg2+	  
caused	   transformed	   cells	   to	   flatten	   and	   to	  
assume	   a	   regularly	   patterned,	   non-­‐overlapping	  
relationship	   to	   one	   another	   (Rubin	   et	   al.,	   1981).	  
After	  3	  days	  of	  Mg2+	  deprivation,	  the	  rate	  of	  DNA	  
synthesis	   became	   highly	   dependent	   on	   both	  
serum	   concentration	   and	   population	   density,	  
thus	   resembling	   the	   growth	   behaviour	   of	   non-­‐
transformed	  cells.	  The	  capacity	  of	  the	  normalized	  
transformed	   cells	   to	   produce	   colonies	   in	   agar	   in	  
normal	   Mg2+	   is	   greatly	   reduced	   after	   7	   days	   of	  
Mg2+	  deprivation	  in	  monolayer	  culture	  (Rubin	  and	  
Chu,	  1982).	  	  
	  
The	  Ca2+	  content	  of	  transformed	  cells	  is	  only	  one-­‐
third	   that	   of	   non-­‐transformed	   cells,	   but	   it	  
increases	   to	   that	  of	   the	  non-­‐transformed	  cells	   in	  
Mg2+-­‐deprived	  medium	   (Rubin	   et	   al.,	   1981).	   The	  
normalization	   of	   these	   parameters	   in	   Mg2+-­‐
deprived	  transformed	  cells	  is	  reversed	  a	  few	  days	  
after	  their	  subculture	   in	  Mg2+-­‐adequate	  medium.	  
The	   results	   support	   the	   suggestion	   that	   a	   defect	  
in	   Mg2+	   regulation	   of	   the	   multiplication	   of	  
transformed	  cells	   is	  a	  basic	   feature	  of	  neoplastic	  
transformation	   (McKeehan	   and	   Ham,	   1978)	  
which	   could	   be	   exerted	   at	   the	   level	   of	   protein	  
synthesis	   (Rubin,	   2005;	   Sahni	   and	   Scharenberg,	  
2008).	   Nothing	   has	   been	   established	   about	   the	  
cause	   of	   the	   postulated	   loss	   of	   Mg2+	   control	   in	  
transformed	   cells	   but	   one	   possibility	   has	   to	   do	  
with	   their	   actively	   moving	   surface	   membranes	  
(Abercrombie	   and	   Ambrose,	   1958),	   which	   could	  
result	   in	   lowering	   of	   the	   binding	   of	   Mg2+	   to	  
anionic	   groups	   on	   their	   internal	   surface,	   and	   its	  
release	   into	   the	   cytosol	   (Rubin,	   2005).	   This,	   of	  
course,	  would	   shift	   the	   question	   to	  what	   causes	  
the	  excessive	  membrane	  activity,	  which	  gets	  into	  
the	   somatic	   cell	   genetics	   of	   neoplastic	  





There	   were	   several	   lines	   of	   thought	   that	   led	   to	  
the	   suspicion	   that	   Mg2+	   plays	   a	   central	   role	   in	  
regulation	   of	   growth	   and	   replication.	   Among	  
them	   were	   the	   observations	   that	   a	   variety	   of	  
unrelated	   and	   non-­‐specific	   substances	   could	  
initiate	   at	   least	  one	   round	  of	  DNA	   synthesis	   and	  
cell	   replication	   (Rubin,	   1975b;	   Rubin	   and	   Sanui,	  
1977).	   Another	   was	   that	   a	   number	   of	   reactions	  
were	   activated	   by	   mitogenic	   substances	   that	  
were	  essential	  for	  cell	  replication	  and	  others	  that	  
were	   not,	   but	   all	   responded	   directly	   to	   the	  
mitogens	  hours	  before	  the	  synthesis	  of	  DNA	  was	  
initiated	   (Bowen-­‐Pope	   and	   Rubin,	   1977).	   These	  
early	   responses	   were	   considered	   part	   of	   a	  
coordinate	   response	   and	   drove	   a	   search	   for	   a	  
second	   messenger	   that	   could	   regulate	   all	  
members	   of	   that	   response.	   That	   search	   was	  
pursued	  by	  depriving	  confluent,	  contact-­‐inhibited	  
cultures	   of	   each	   extracellular	   candidate	   in	   turn,	  
and	   determining	   the	   capacity	   of	   its	   removal	   to	  
inhibit	   both	   the	   early	   responses	   and	   later	  
increases	   in	   DNA	   synthesis	   of	   freshly	   stimulated	  
cultures	   (Rubin,	   1976;	   Rubin	   et	   al.,	   1979).	   The	  
most	   significant	   early	   response	   of	   the	   cells	   for	  
controlling	  later	  DNA	  synthesis	  was	  the	  synthesis	  
of	   proteins,	   and	   the	   only	   measured	   cation	   that	  
correlated	  quantitatively	  with	  both	  reactions	  was	  
total	   intracellular	   Mg2+	   concentration	   produced	  
by	   variation	   in	   extracellular	   Mg2+.	   In	   order	   to	  
reliably	   produce	   a	   change	   of	   intracellular	   Mg2+	  
over	  a	  wide	  range,	  it	  was	  necessary	  to	  drastically	  
lower	   the	   concentration	   of	   Ca2+	   in	   the	   medium	  
while	   varying	   the	   extracellular	   concentration	   of	  
Mg2+.	   The	   deprivation	   of	   Ca2+	   increased	   the	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permeability	   of	   the	   cells	   for	  Mg2+	   as	   well	   as	   for	  
other	  small	  molecules.	   It	  was	  concluded	  that	  the	  
concentration	   of	   free	   Mg2+	   in	   the	   cells	  
determined	  the	  level	  of	  the	  coordinate	  response,	  
and	  most	  significantly	  of	  protein	  synthesis.	  
	  
This	   conclusion	   was	   in	   part	   based	   on	   small	  
increases	   in	  total	  Mg2+	  assuming	  that	  there	  were	  
accompanying	   increases	   in	  free	  Mg2+.	  Supporting	  
evidence	   for	   this	   conclusion	   was	   provided	   by	  
experiments	   in	   Xenopus	   oocytes	   which	   allowed	  
direct	   injection	   and	   measurement	   of	   free	   Mg2+	  
(Horowitz	   and	   Tluczek,	   1989).	   However,	   there	  
was	  a	   failure	   to	  demonstrate	  an	   increase	   in	   free	  
Mg2+	   by	   indicator	   measurements	   in	   activated	  
lymphocytes	   (Rink	   et	   al.,	   1982),	   despite	   the	  
reported	   increase	   in	   total	   Mg2+	   (Sahni	   et	   al.,	  
2010).	  It	  should	  be	  noted	  that	  although	  Mg2+	  is	  a	  
co-­‐factor	   in	   all	   phosphoryl	   transfers	   in	   cells,	   the	  
actual	   regulatory	   substrate	   is	   MgATP2-­‐	   in	   which	  
the	   Mg2+	   is	   chelated	   by	   ATP4-­‐,	   and	   therefore	  
would	   not	   be	   registered	   by	   indicators	   of	   free	  
Mg2+.	  
	  
The	  PI	  3-­‐K	  pathway	  is	  essential	  for	  the	  regulation	  
of	   protein	   synthesis	   (Richardson	   et	   al.,	   2004).	   It	  
leads	   through	  a	  protein	  kinase	  cascade	   to	  mTOR	  
kinase,	  which	  is	  considered	  a	  central	  regulator	  of	  
protein	   synthesis	   (Schmelzle	   and	   Hall,	   2000).	  
mTOR	  accomplishes	   this	   role	  by	  phosphorylating	  
serines	  and	  threonines	  on	  two	  protein	  substrates	  
which	   regulate	   the	   initiation	   of	   translation,	  
mainly	   of	   ribosomal	   proteins	   and	   elongation	  
factors	   (Terada	   et	   al.,	   1994).	   The	   mTOR	  
phosphorylations	   have	   a	   high	   Km	   for	   MgATP2-­‐	  
(Dennis	  et	  al.,	  2001;	  Jaeschke	  et	  al.,	  2004).	  It	  may	  
be	   significant	   for	   the	   coordination	   of	   protein	  
synthesis	  with	  energy	  production	  that	  the	  kinases	  	  
of	   carbohydrate	   metabolism	   which	   phosphorylate	  
low	  molecular	  substrates	  have	  a	  Km	  for	  MgATP2-­‐	  
similar	   to	   that	   of	   mTOR	   (Edelman	   et	   al.,	   1987;	  
Garner	   and	   Rosett,	   1973).	   Hence	   MgATP2-­‐	   may	  
have	   as	   important	   a	   role	   in	   regulating	   energy	  
production	   as	   it	   does	   in	   regulating	   protein	   and	  
DNA	  synthesis.	  
	  
One	   aspect	   of	  Mg2+	   regulation	   that	   needs	  more	  
investigation	  is	  the	  putative	  role	  of	  the	  loss	  of	  its	  
function	   in	   cell	   transformation	   (McKeehan	   and	  
Ham,	  1978;	  Rubin	  et	  al.,	  1981).	  A	  major	  target	  for	  
mTOR	  phosphorylation	  is	  the	  eukaryotic	  initiation	  
factor	   4E	   (eIF4E).	   Enhanced	   phosphorylation	   of	  
eIF4E	  up-­‐regulates	   several	  proteins	   implicated	   in	  
tumorigenesis	   (Furic	   et	  al.,	   2010).	   Since	  mTOR	   is	  
itself	   regulated	   by	   MgATP2-­‐	   (Rubin,	   2005;	   Sahni	  
and	  Scharenberg,	  2008),	  the	  loss	  of	  regulation	  by	  
Mg2+	   in	   tumorigenesis,	   if	   confirmed,	   should	   lead	  
to	   increased	   activity	   of	   eIF4E	   and	   could	   account	  
for	   its	   frequent	   involvement	   in	   human	   cancer	  
(Hay,	   2010).	   Hence,	   the	   measurement	   of	   free	  
Mg2+	   in	   neoplastic	   transformation	   would	   be	   a	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Apoptosis	   is	   a	   distinctive	   feature	   in	   the	   physiology	   of	   the	   developing	   brain,	   but	   also	   a	   key	   event	   in	  
pathological	  conditions	  of	   the	  adult	  brain.	  The	  basic	  mechanisms	  executing	  cell	  death	  by	  apoptosis	  are	  
conserved	  among	  different	  tissues	  and	  in	  different	  conditions,	  while	  the	  initiating	  event(s)	  may	  be	  more	  
specific.	  Magnesium	  appears	   to	  be	  an	   important	  player	   in	   the	  process,	   though	   it	  might	  exert	  opposite	  
actions	   depending	   on	   extra/intracellular	   availability.	   Extracellular	   magnesium	   deficiency	   induces	  
apoptosis,	  mainly	   through	   increased	   oxidative	   stress,	  while	   intracellular	  magnesium	  mobilization	   from	  
intracellular	   stores	   and	   consequent	   increase	   of	   cytosolic	   free	   magnesium	   seem	   to	   act	   in	   the	   effector	  
phase.	   The	  molecular	  mechanism	  and	   the	  physio-­‐pathological	  meaning	  of	   these	   findings	   await	   further	  
characterization.	   The	   issue	   is	   even	  more	   complex	   in	   the	   context	   of	   the	   brain,	  where	  many	   concurring	  
factors	  may	   determine	   a	   pro-­‐	   or	   anti-­‐apoptotic	   environment.	   A	   deeper	   understanding	   of	   the	   yin-­‐yang	  
role	   of	   magnesium	   in	   apoptosis	   may	   cast	   light	   on	   the	   basic	   processes	   that	   regulate	   cell	   fate,	   and	  
consequently	   may	   open	   up	   novel	   opportunities	   for	   a	   successful	   therapeutic	   intervention	   for	   all	   the	  
pathological	  conditions	  where	  excessive	  and	  undue	  apoptosis	  takes	  place.	  	  
	  
Cell	  death	  by	  apoptosis	  
	  
Multicellular	   organisms	   maintain	   their	   homeo-­‐
stasis	   thanks	   to	   a	   tightly	   regulated	  mode	   of	   cell	  
death.	  Programmed	  cell	  death,	  or	  apoptosis,	  is	  an	  
internally	  controlled	  suicide	  program	  consisting	  in	  
a	   stereotyped	   sequence	   of	   biochemical	   and	  
morphological	   changes	   that	   allow	   the	   cell	   to	   die	  
without	   adversely	   affecting	   its	   neighbours,	   i.e.	  
without	  causing	  inflammation.	  As	  such,	  apoptosis	  
is	   distinct	   from	   necrosis,	   the	   traumatic	   form	   of	  
cell	   death	   whereby	   massive	   disruption	   of	   the	  
surrounding	   tissue	   takes	   place.	   A	   cell	   may	   be	  
doomed	   to	   die	   either	   by	   apoptosis	   or	   necrosis	  
depending	   on	   the	   intensity	   and	   duration	   of	   the	  
stimulus,	   the	   rapidity	   of	   the	   death	   process,	   and	  
the	  extent	  of	  ATP	  depletion	  suffered	  by	  the	  cell.	  	  
	  
Apoptosis	   occurs	   in	   numerous	   physiological,	  
adaptive	   and	   pathological	   events:	   1)	   during	  
development;	  2)	  as	  a	  homeostatic	  mechanism	  to	  
maintain	   cell	  populations	   in	  proliferating	   tissues;	  
3)	   as	   a	   defence	   mechanism	   such	   as	   in	   immune	  
reactions;	   4)	   following	   cell	   injury	   from	   various	  
agents;	   and	   5)	   in	   aging.	   There	   is	   general	  
agreement	   that	   this	   form	   of	   cell	   death	   is	   an	  
energy-­‐dependent	   cascade	   of	   molecular	   events	  
leading	   to	   cell	   shrinkage	   with	   maintenance	   of	  
organelle	   integrity;	   long-­‐recognized	   features	   of	  
apoptosis	   are	  protein	   cleavage	  and	   cross-­‐linking,	  
chromatin	   condensation,	   DNA	   fragmentation	  
and,	   ultimately,	   phagocytic	   recognition	   and	  
engulfment	   of	   the	   dying	   cell.	   The	   process	   of	  
apoptosis	   is	   triggered	   by	   a	   diverse	   range	   of	   cell	  
signals,	  which	  may	  originate	  either	  extracellularly	  
(i.e.	   death	   receptor	   ligation	   with	   their	   cognate	  
ligands,	   extrinsic	   pathway)	   or	   intracellularly	   (e.g.	  
DNA	   damage	   or	   organelle	   dysfunction,	   intrinsic	  
pathway).	  	  
	  
The	   apoptotic	   cascade	   consists	   of	   three	   parts:	  
first,	   cells	   process	   the	   receptor-­‐mediated	   death	  
signal	   (initiation	   phase,	   somewhat	   more	   cell-­‐
specific),	   then	  get	   ready	   to	   implement	  apoptosis	  
(effector	  phase,	  more	  conserved	  among	  different	  
tissues)	   and	   finally	   commit	   suicide	   (degradation	  
phase).	  During	  the	  initiation	  phase,	  the	  receptor-­‐
mediated	   death	   signal	   activates	   an	   intracellular	  
cascade	   of	   events	   including:	   1)	   activation	   of	  
initiator	   caspases	   (caspase-­‐8,	   for	   example),	   that	  
can	  act	  early	   in	  the	  cell	  death	  process	  before,	  or	  
independently	   of,	   mitochondrial	   changes;	   2)	  
increase	   in	   levels	   of	   oxyradicals	   and	   Ca2+;	   3)	  
transcription	   and	   translocation	   of	   pro-­‐apoptotic	  
Bcl-­‐2	   family	   members	   (Bax	   and	   Bad)	   to	   the	  
mitochondrial	   membrane.	   The	   execution	   phase	  
involves:	   1)	   increased	   mitochondrial	   Ca2+	   and	  
oxyradical	   levels;	   2)	   opening	   of	   permeability	  
Mg	  and	  apoptosis	   	   Chapter	  5	  
 
 86	  
transition	   pores	   (PTP)	   in	   the	   mitochondrial	  
membrane;	  3)	  release	  of	  cytochrome	  c	  and	  many	  
other	   apoptosis-­‐inducing	   factors	   from	   the	  
mitochondrial	   matrix	   into	   the	   cytosol;	   4)	  
formation	   of	   a	   molecular	   complex	   (the	   apopto-­‐
some)	   between	   cytochrome	   c	   and	   apoptotic	  
protease-­‐activating	  factor	  1	  (Apaf-­‐1),	  that	  recruits	  
and	  activates	  pro-­‐caspase-­‐9.	  Activated	  caspase-­‐9,	  
in	   turn,	   activates	   caspase-­‐3,	   which	   begins	   the	  
degradation	   phase:	   proteins	   are	   cleaved	   by	  
various	   caspases	   and	   packed	   by	   trans-­‐
glutaminases,	  while	   nucleic	   acids	   are	   cleaved	   by	  
activated	  Ca2+/Mg2+	  endonucleases,	  which	  results	  
in	   the	   formation	   of	   apoptotic	   bodies	   and	  
subsequent	   phagocytosis	   by	   elicited	   macro-­‐
phages	   or	   neighbouring	   cells.	   It	   is	   interesting	   to	  
underline	   the	   role	   of	   mitochondria	   in	   triggering	  
apoptosis.	   Whether	   or	   not	   a	   direct	   injury	  
jeopardizing	   the	   efficiency	   of	   these	   energy	  
producing	  organelles	  occurs,	  mitochondria	  play	  a	  
pivotal	   role	   in	   the	   cell	   death	   decision,	   as	  
apoptotic	   factors	   are	   released	   by	   active	  
mechanisms,	   which	   can	   be	   unrelated	   to	  
mitochondrial	  damage	  (Tait	  and	  Green,	  2010).	  	  
	  
Role	  of	  Magnesium	  in	  Apoptosis	  
	  
In	   the	   attempt	   to	   review	   the	   role	  of	  magnesium	  
in	  apoptosis,	  one	  should	   first	  of	  all	  keep	   in	  mind	  
that	   the	   effects	   of	   extracellular	   magnesium	  
availability	   may	   differ	   from	   those	   due	   to	  
intracellular	  magnesium	  fluxes	  or	  mobilization.	  In	  
fact,	   decreased	   extracellular	   magnesium	  
availability	   does	   not	   necessarily	   reflect	   an	  
intracellular	   depletion,	   as	   demonstrated	   by	   the	  
fact	  that	   in	  vivo	  serum	  magnesium	  levels	  are	  not	  
a	   reliable	   marker	   of	   pathological	   hypo-­‐
magnesemia.	   Sensitivity	   to	   extracellular	  
magnesium	   availability	   is	   highly	   tissue-­‐specific,	  
and	   can	   be	   translated	   in	   molecular	   terms	   by	  
considering	   the	   expression	   and	   activity	   of	  
magnesium-­‐specific	   cation	   channels,	   such	   as	   the	  
transient	  receptor	  potential	  melastatin	  (TRPM)	  -­‐6	  
and	   -­‐7	   channels,	   which,	   by	   modulating	   trans-­‐
membrane	   cation	   fluxes,	   regulate	   the	  
intracellular	   ion	   concentration	   (Schlingmann	   et	  
al.,	   2007).	   Furthermore,	   intracellular	  magnesium	  
is	   tightly	   buffered	   to	   meet	   specific	   metabolic	  
requirements.	   As	   discussed	   elsewhere	   in	   this	  
book,	  large	  changes	  in	  total	  cell	  magnesium	  occur	  
with	   little	   or	   no	   change	   in	   cytosolic	   free	  
magnesium,	   suggesting	   that	   the	   changes	   in	   total	  
magnesium	   are	   due	   to	   changes	   in	   bound	   or	  
sequestered	   magnesium	   (Murphy,	   2000).	   ATP	   is	  
the	   most	   important	   intracellular	   magnesium	  
buffer.	   Following	   massive	   ATP	   hydrolysis	   intra-­‐
cellular	  free	  magnesium	  transiently	  increases	  and	  
is	   subsequently	   released	   into	   the	   extracellular	  
environment.	  As	  a	  consequence,	  in	  a	  dying	  cell	  an	  
increase	  in	  ionized	  magnesium	  occurs.	  Therefore,	  
caution	   should	   be	   used	   also	   when	   investigating	  
the	  role	  of	  intracellular	  magnesium	  as	  a	  player	  in	  
the	   apoptotic	   program,	   in	   order	   to	   discriminate	  
coincidental	  from	  causative	  events.	  
	  
In	   conclusion,	   whether	   considering	   extracellular	  
magnesium	  availability	  or	  intracellular	  magnesium	  
concentration,	   the	   story	   is	   more	   complicated	  
than	  it	  appears	  at	  first	  glance.	  We	  will	  attempt	  to	  
discuss	  the	  issue	  by	  reviewing	  the	  latest	  available	  
data	  in	  view	  of	  the	  complex	  cellular	  physiology	  of	  
magnesium.	  
	  
Extracellular	  magnesium	  and	  apoptosis	  
Several	   important	   aspects	   of	   magnesium	  
biochemistry	   and	   physiology	   point	   to	   a	   possible	  
role	   for	   this	   cation	   in	   the	   apoptotic	   process.	   As	  
discussed	   in	   other	   chapters	   of	   this	   book,	  
magnesium	   is	  a	  key	  modulator	  of	  cell	  proliferation	  
and	  metabolism	  and,	  most	  importantly,	  magnesium	  
availability	   appears	   to	   affect	   the	   occurrence	   of	  
oxidative	  stress.	  Many	  studies	  are	  available	  in	  the	  
literature	  on	  the	  subject,	  but	  the	  most	  convincing	  
ones	   investigate	   the	   effects	   of	   hypomagnesemia	  
in	   vivo.	   In	   these	   circumstances,	   however,	   other	  
factors,	   including	   inflammation,	   cytokine	  
production	  and	  activation	  of	  phagocyte	  oxidative	  
burst,	   concur	   to	   what	   is	   referred	   to	   as	   the	   pro-­‐
oxidant	  effect	  of	  hypomagnesemia	  (Mazur	  et	  al.,	  
2007).	   Induction	   of	   apoptosis	   mediated	   by	  
oxidative	  stress	  following	  magnesium	  deprivation	  
has	   been	   documented	   in	   several	   tissues.	  
Accelerated	   thymus	   involution,	   a	   classical	  
example	  of	   apoptosis,	  was	   found	   in	  magnesium-­‐
deficient	   rats	   (Malpuech-­‐Brugère	   et	   al.,	   1999).	  
Dietary	   magnesium	   deficiency	   also	   induced	  
apoptosis	   in	   cardiovascular	   tissues	   (Altura	  et	   al.,	  
2009;	   Tejero-­‐Taldo	   et	   al.,	   2007)	   and	   in	   the	   liver	  
(Martin	   et	   al.,	   2003;	   Martin	   et	   al.,	   2008).	   In	  
addition	   to	   the	   induction	   of	   reactive	   oxygen	  
species,	   low	   magnesium	   availability	   could	   in	  
principle	   trigger	   apoptosis	   by	   affecting	   DNA	  
structure.	   This	   occurs	   not	   only	   by	   promoting	  
oxidative	   DNA	   damage,	   but	   also	   by	   impairing	  
DNA	   repair	   mechanisms,	   since	   magnesium	   is	  
required	   for	   several	   crucial	   DNA	   repair	   enzyme	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activities,	   e.g.	   endonucleases,	   ligases,	   topo-­‐
isomerases	  (Hartwig,	  2001).	  	  
	  
Intracellular	  magnesium	  and	  apoptosis	  
As	  to	   intracellular	  events,	  several	   in	  vitro	   studies	  
have	  suggested	  a	  promoting	   role	   for	  magnesium	  
in	   apoptosis.	   An	   early	   increase	   in	   intracellular	  
magnesium	   seems	   to	   follow	   both	   extrinsic	   and	  
intrinsic	  induction	  of	  apoptosis	  (Patel	  et	  al.,	  1994;	  
Chien	  et	  al.,	  1999;	  Zhang	  et	  al.,	  2005).	  The	  most	  
straightforward	   explanation	   is	   that	   the	   increase	  
in	   intracellular	   magnesium	   concentration	   is	  
necessary	   for	   stimulating	   the	   activity	   of	   Ca2+/	  
Mg2+dependent	   endonucleases,	   which	   perform	  
the	   apoptotic	   event	   par	   excellence,	   i.e.	  
nucleosomal	   DNA	   fragmentation.	   Interestingly,	  
however,	   the	   source	   of	   intracellular	   magnesium	  
was	   hypothesized	   to	   be	   in	   the	   mitochondria	  
(Chien	  et	  al.,	  1999),	  which	  is	  particularly	  appealing,	  
as	   it	   is	  well	  established	   that	  mitochondria	  play	  a	  
central	   role	   in	   the	   onset	   of	   the	   apoptotic	  
program.	   Other	   lines	   of	   evidence	   point	   to	   the	  
same	   direction.	   While	   the	   opening	   of	   the	  
permeability	   transition	   pores	   appears	   to	   be	  
dispensable	  for	  the	  release	  of	  cytochrome	  c,	  this	  
is	   not	   the	   case	   for	   the	   presence	   of	   magnesium,	  
which	   instead	   seems	   an	   absolute	   requirement	  
(Eskes	   et	   al.,	   1998;	   Kim	   et	   al.,	   2000).	   Another	  
study	   (Salvi	   et	   al.,	   2004)	   indicated	   that	   an	  
apoptotic	   compound,	   gliotoxin,	   can	   specifically	  
activate	   a	   magnesium	   efflux	   system	   from	  
mitochondria	   in	   conditions	   of	   preserved	  
mitochondrial	   integrity	   (i.e.	   high	   membrane	  
potential,	   no	   swelling	   and	   retention	   of	   other	  
ions).	  Most	   importantly,	   it	  has	  been	   shown	   that	  
mitochondria	  act	  in	  fact	  as	  magnesium	  stores,	  	  
	  
and	   that	   Mg2+	   release	   can	   occur	   following	   Ca2+	  
release	  and	  prior	  to	  ATP	  hydrolysis	  (Kubota	  et	  al.,	  
2005).	   It	   is	   noteworthy	   that	   the	   same	   Authors	  
have	   recently	   demonstrated	   that	   glutamate	  
administration	   to	   rat	   hippocampal	   neurons	  
triggers	   the	   same	   pathway,	   whereby	   Ca2+	  
accumulation	   in	   the	  mitochondria	   is	   required	  for	  
Mg2+	   release	   from	   the	   organelles	   (Shindo	   et	   al.,	  
2010).	   The	   presence	   of	   a	   specific	   mitochondrial	  
channel	   for	   magnesium,	   Mrs2,	   (Kolisek	   et	   al.,	  
2003)	  corroborates	  these	  findings.	  As	  the	  activity	  
of	  Mrs2	   is	  dependent	   from	  membrane	  potential,	  
it	   can	   be	   speculated	   that	   stored	   magnesium	  
might	   be	   released	   through	   the	   channel	   upon	  
depolarization.	   Intriguingly,	   in	   a	   recent	   paper	  
Mrs2	   expression	   has	   been	   associated	   with	  
resistance	   to	   drug-­‐induced	   apoptosis	   in	   cancer	  
cells	   (Chen	   et	   al.,	   2009):	   by	   upregulating	  
magnesium	   uptake	   into	   mitochondria,	   Mrs2	  
might	   counteract	   the	   increase	   in	   cytosolic	  
magnesium	   that	   seems	   to	   be	   necessary	   for	   the	  
execution	   of	   the	   apoptotic	   program	   via	   the	  
mitochondrial	  pathway	  (Wolf	  and	  Trapani,	  2009).	  
In	  conclusion,	   the	   latest	   findings	   seem	  to	  concur	  
to	   suggest	   a	   finer	   involvement	   of	  magnesium	   in	  
the	   apoptotic	   cascade:	   not	   just	   a	   biochemical	  
factor,	  but	  rather	  a	  crucial	  control	  element	  in	  life	  
vs	   death	   decisions	   (see	   Table	   1	   for	   a	   summary).	  
At	  present,	  these	  are	  only	  attractive	  speculations;	  
most	   importantly,	   it	   has	   to	   be	   clarified	   whether	  
the	  increase	  in	  intracellular	  magnesium	  occurring	  
following	   an	   apoptotic	   stimulus	   is	   just	   a	   coin-­‐
cidental	  event	  (for	  example,	  due	  to	  mitochondrial	  
depolarization)	  or	  rather	  a	  causative	  determinant	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In	   contrast	   to	   the	   rapid	   turnover	   of	   cells	   in	  
proliferative/renewing	   tissues,	   neurons	   commonly	  
survive	  for	  the	  entire	   lifetime	  of	  the	  organism	  —	  
this	   enduring	   nature	   of	   neurons	   is	   necessary	   for	  
maintaining	   the	   function	   of	   those	   cells	   within	  
neuronal	   circuits.	   However,	   during	   development	  
of	   the	   central	   and	   peripheral	   nervous	   systems,	  
many	   neurons	   undergo	   apoptosis	   during	   a	   time	  
window	   that	   coincides	   with	   the	   process	   of	  
synaptogenesis	   (Oppenheim,	   1991).	   Initial	  
overproduction	  of	  neurons,	  followed	  by	  death	  of	  
some,	   is	   probably	   an	   adaptive	   process	   that	  
provides	   enough	   neurons	   to	   form	   nerve	   cell	  
circuits	   that	   are	   precisely	   matched	   to	   their	  
functional	   specifications.	  However,	   the	  persistence	  
of	   neurons	   throughout	   life	   to	   preserve	   brain	  
function	  implies	  that	  a	  considerable	  evolutionary	  
pressure	   was	   placed	   on	   the	   development	   of	  
mechanisms	  that	  guarded	  against	  neuronal	  death	  
and/or	  promoted	  neuronal	  survival	  and	  plasticity.	  	  
	  
Trophic	  factors	  
Like	   all	   cells,	   neuronal	   survival	   requires	   trophic	  
support.	   Viktor	   Hamburger	   and	   Rita	   Levi-­‐
Montalcini	  described	   in	  a	  seminal	  paper	  that	  the	  
survival	  of	  developing	  neurons	   is	  directly	   related	  
to	   the	   availability	   of	   their	   innervating	   targets	  
(Hamburger	  and	  Levi-­‐Montalcini,	  1949).	  This	   laid	  
the	   foundation	   for	   the	   neurotrophin	   hypothesis,	  
which	  proposed	  that	  immature	  neurons	  compete	  
for	   target-­‐derived	   trophic	   factors	   that	   are	   in	  
limited	   supply.	   Neurotrophins,	   which	   include	  
nerve	   growth	   factor	   (NGF),	   brain-­‐derived	  
neurotrophic	  factor	  (BDNF),	  and	  neurotrophins	  3	  
and	   4/5	   (Lewin	   and	   Barde,	   1996),	   generally	  
activate	   and	   ligate	   the	   Trk	   receptors	   (TrkA,	   TrkB	  
and	   TrkC),	   which	   are	   cell-­‐surface	   receptors	   with	  
intrinsic	   tyrosine	   kinase	   activity.	   They	   can	  
autophosphorylate;	   for	   instance,	   after	   the	  
binding	   of	   NGF	   to	   TrkA,	   the	   receptor	  
phosphorylates	   several	   tyrosine	   residues	   within	  
its	  own	  cytoplasmic	  tail.	  These	  phosphotyrosines	  
in	  turn	  serve	  as	  docking	  sites	  for	  other	  molecules	  
such	   as	   phospholipase	   Cg,	   phosphoinositide	   3-­‐
kinase	  (PI(3)K)	  and	  adaptor	  proteins	  such	  as	  Shc,	  
and	   these	   signal	   transduction	   molecules	  
coordinate	  neuronal	  survival	  through	  the	  Akt	  and	  
MAP	  kinase	  signalling	  pathways	  (Hennigan	  et	  al.,	  
2007).	  Several	  neurotrophic	  factors	  and	  cytokines	  
use	  a	  survival	  pathway	  involving	  the	  transcription	  
factor	   NF-­‐κB	   (Mattson	   and	   Camandola,	   2000).	  
The	   neurotrophin	   hypothesis	   predicts	   correctly	  
that	  neuronal	  survival	  requires	  a	  positive	  survival	  
signal.	   It	   does	   not,	   however,	   provide	   a	   concrete	  
hypothesis	  as	  to	  how	  neurons	  die	  in	  the	  absence	  
of	   trophic	   support;	   it	  was	  assumed	   that	  neurons	  
die	   simply	   of	   passive	   starvation.	   In	   1988,	   using	  
cultured	  sympathetic	  neurons	  as	  a	  model	  system,	  
Johnson	  and	  colleagues	  showed	  that	  inhibition	  of	  
RNA	   and	   protein	   synthesis	   blocked	   sympathetic	  
neuronal	   cell	   death	   induced	   by	   nerve	   growth	  
factor	   (NGF)	   deprivation	   (Martin	   et	   al.,	   1988),	  
providing	  the	  first	  tangible	  evidence	  that	  neurons	  
might	  actually	  actively	  instigate	  their	  own	  demise.	  
	  
Glutamate	  receptors	  
Lack	   of	   neurotrophic	   support	   is	   undeniably	   the	  
best-­‐studied	   signal	   that	   may	   trigger	   apoptosis	  
during	   development	   of	   the	   nervous	   system.	  
However,	   most	   neurons	   in	   the	   mammalian	  
central	   nervous	   system	   possess	   receptors	   for	  
another	  trigger	  of	  apoptosis,	  glutamate.	  	  
	  
Glutamate	  is	  a	  major	  excitatory	  neurotransmitter	  
with	   a	   crucial	   role	   in	   neural	   development,	  
synaptic	   plasticity,	   and	   learning	   and	   memory	  
under	   physiological	   conditions	   (Riedel	   et	   al.,	  
2003).	   Glutamate	   receptors	   are	   classified	   into	  
several	   classes.	   In	   this	   context,	   we	   will	   go	   into	  
some	   detail	   only	   for	   N-­‐methyl-­‐D-­‐aspartate	  
(NMDA)	   receptors.	   NMDA	   receptors	   are	   tetra-­‐
heteromeric	   ligand-­‐gated	   ion	  channels	  that	  open	  
upon	  the	  binding	  of	  glutamate.	  Magnesium	  binds	  
the	  channel	  pore	  in	  a	  voltage-­‐dependent	  manner;	  
thus,	   at	   normal	   physiological	   resting	   membrane	  
potential,	  the	  NMDA	  receptor	  is	  blocked	  by	  Mg2+.	  
Synaptic	   release	   of	   glutamate	   causes	   Na+	   influx	  
through	   α-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazole-­‐
propionate	  (AMPA)	  receptors	  in	  the	  postsynaptic	  
cell,	  resulting	  in	  partial	  membrane	  depolarization	  
sufficient	   to	   lift	   the	  Mg2+	   block	   and	   activate	   the	  
channel.	   The	   activated	   NMDA	   receptor	   is	  
permeable	  to	  Na+	  but,	  crucially,	  also	  to	  Ca2+.	  This	  
Ca2+	   influx	   mediates	   most	   of	   the	   physiological	  
effects	   of	   NMDA	   receptor	   activity,	   leading	   to	  
postsynaptic	   depolarization	   and	   action	   potential	  
in	  the	  postsynaptic	  neuron.	  	  
	  
Physiological	   levels	   of	   synaptic	   NMDA	   receptor	  
activity	   are	   essential	   for	   neuronal	   survival	  
(Hetman	   and	   Kharebava,	   2006).	   However,	  
regulation	   of	   glutamatergic	   neurotransmission	   is	  
critical,	   as	   improper	   management	   of	   glutamate	  
levels	  and	  glutamate	  receptor	  activity	  may	  impair	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not	  only	   its	  signalling	  properties,	  but	  can	   lead	  to	  
cell	  death.	  The	  concept	  of	  excitotoxicity	  was	  first	  
proposed	  by	  John	  Olney	  in	  1969	  as	  a	  toxic	  effect	  
of	  excessive	  or	  prolonged	  activation	  of	  receptors	  
by	  excitatory	  amino	  acids	  (Olney,	  1969).	  Although	  
the	  molecular	  pathways	  involved	  in	  excitotoxicity	  
are	  still	  not	  fully	  understood	  at	  the	  present,	  there	  
is	   a	   wealth	   of	   evidence	   suggesting	   that	   over-­‐
stimulation	   of	   glutamate	   receptors	   produces	  
multiple	   adverse	  effects	   including	   impairment	  of	  
intracellular	   calcium	  homeostasis,	   dysfunction	  of	  
mitochondria	   and	   endoplasmic	   reticulum,	  
increase	   in	  nitric	  oxide	   (NO)	  production	  and	   free	  
radicals,	   persistent	   activation	   of	   proteases	   and	  
kinases,	   increases	   in	   expression	   of	   pro-­‐death	  
transcription	   factors	   and	   immediate	   early	   genes	  
(IEGs),	  ultimately	  leading	  to	  apoptosis	  (Wang	  and	  
Qin,	  2010).	  Excitotoxicity	  might	  mediate	  neuronal	  
damage	   in	   various	   neurological	   disorders	  
including	   ischemia	   and	   traumatic	   brain	   injury	  
(Arundine	  and	  Tymianski,	  2004)	  and	  neurodegen-­‐
erative	   diseases	   (Lipton	   and	   Rosenberg,	   1994;	  
Rego	  and	  Oliveira,	  2003);	  it	  has	  also	  been	  implicated	  
in	   neonatal	   brain	   injury	   (Johnston,	   2005).	   NMDA	  
receptors	  are	   important	  mediators	  of	  glutamate-­‐
induced	   excitotoxicity,	   as	   calcium	   entering	  
through	   over-­‐activated	   NMDA	   receptors	   results	  
in	  more	  cell	  death	  as	  opposed	  to	  calcium	  entering	  
through	   non-­‐NMDA	   glutamate	   receptors	   or	  
voltage-­‐gated	   calcium	   channels	   (Cristofanilli	   and	  
Akopian,	  2006),	  which	  maybe	  due	  in	  part	  to	  their	  
high	   permeability	   to	   Ca2+	   and	   incomplete	  
desensitization.	  	  
	  
Thus,	  responses	  to	  NMDA	  receptor	  activity	  follow	  
a	   classical	   hormetic	   dose-­‐response	   curve:	   both	  
too	   much	   and	   too	   little	   can	   be	   harmful	  
(Hardingham,	  2009).	  	  
	  
Pathological	  stimuli	  
Another	   trigger	   of	   neuronal	   death	   is	   increased	  
oxidative	   stress,	   whereby	   free	   radicals	   (such	   as	  
the	   superoxide	   anion	   radical	   and	   the	   hydroxyl	  
radical)	   damage	   cellular	   lipids,	   proteins	   and	  
nucleic	   acids	   by	   disrupting	   chemical	   bonds	   in	  
those	  molecules.	  Metabolic	  stress,	  in	  which	  levels	  
of	  glucose,	  oxygen	  and	  other	  molecules	  required	  
for	   ATP	   (energy)	   production	   are	   decreased,	   and	  
environmental	   toxins	   may	   also	   initiate	   neuronal	  
apoptosis	   (Mattson,	   2000).	   These	   stimuli	   are	  
mostly	   involved	   in	   aging	   and	   pathological	  
conditions,	   such	   as	   acute	   or	   chronic	   neuro-­‐
degenerative	   diseases.	   The	   classical	   and	   most	  
studied	   pathway	   of	   oxidation-­‐induced	   apoptosis	  
consists	  in	  cell-­‐damage	  triggered	  phosphorylation	  
of	  p53	  and	  transcription	  of	  pro-­‐apoptotic	   factors	  
like	   Bid	   or	   Bad	   leading	   to	   mitochondrial-­‐
dependent	  activation	  of	  caspase	  9.	  
	  
The	   genetic	   and	   environmental	   factors	   that	  
trigger	   neuronal	   apoptosis	   may	   be	   different	   in	  
various	   physiological	   and	   pathological	   settings	  
and	   can	   vary	   from	   those	   active	   in	   other	   tissues,	  
but	   most	   of	   the	   subsequent	   biochemical	   events	  
that	   execute	   the	   cell	   death	   process	   are	   highly	  
conserved	   and	   shared	   with	   all	   other	   cell	   types.	  
Thus,	   the	   key	   components	   of	   the	   apoptosis	  
program	  in	  neurons,	   like	  that	  of	  other	  cell	  types,	  
are	  Apaf-­‐1	  and	  proteins	   in	  the	  Bcl-­‐2	  and	  caspase	  
families.	  Nevertheless,	  different	  types	  of	  neurons,	  
and	   neurons	   at	   different	   developmental	   stages,	  
express	   different	   combinations	   of	   Bcl-­‐2	   and	  
caspase	   family	   members,	   which	   is	   one	   way	   of	  
providing	   the	   specificity	   of	   regulation	   (Yuan	   and	  
Yankner,	  2000).	  	  
	  
Tissue	  specific	  factors	  
An	   alternative	   way	   to	   control	   cell	   death	   or	  
survival	   is	   through	   the	   expression	   of	   tissue-­‐
specific	   proteins	   that	   affect	   signal	   transduction	  
reactions	  and	  may	  be	  either	  pro-­‐apoptotic	  or	  pro-­‐
survival.	  
	  
The	  prostate	  apoptosis	  response-­‐4	  (Par-­‐4)	  protein	  
was	   identified	   as	   being	   upregulated	   in	   prostate	  
tumour	   cells	   undergoing	   apoptosis,	   but	   is	   now	  
known	   to	   be	   essential	   in	   developmental	   and	  
pathological	   neuronal	   death	   (Guo	   et	   al.,	   1998).	  
Levels	   of	   Par-­‐4	   increase	   rapidly	   in	   response	   to	  
various	   apoptotic	   stimuli	   through	   enhanced	  
translation	  of	  Par-­‐4	  messenger	  RNA.	  Par-­‐4	  acts	  at	  
an	   early	   stage	   of	   the	   apoptotic	   cascade	   prior	   to	  
caspase	   activation	   and	   mitochondrial	   dys-­‐
function,	   by	   a	   mechanism	   that	   may	   involve	  
inhibition	   of	   the	   antiapoptotic	   transcription	  
factor	  NF-­‐kβ	  and	  suppression	  of	  Bcl-­‐2	  expression	  
and/or	  function	  (Mattson	  et	  al.,	  1999).	  
	  
Rai	   is	   an	   Shc-­‐related	   adaptor	   protein	   whose	  
expression	  is	  exclusively	  restricted	  to	  the	  nervous	  
system.	   It	   exerts	   a	   prosurvival	   function	   in	  
neuronal	   cells	   by	   activating	   the	   PI3K/Akt	  
signalling	  pathway	  (Pelicci	  et	  al.,	  2002).	  
	  
A	   neuron-­‐specific	   splice	   variant	   of	   the	   variable	  
subunit	   Bβ	   was	   characterized,	   which	   is	   induced	  
Mg	  and	  apoptosis	   	   Chapter	  5	  
 
 90	  
upon	   neuronal	   differentiation,	   targets	   protein	  
phosphatase	  2A	  to	  mitochondria	  and	  accelerates	  
neuronal	   cell	   apoptosis	   after	   survival	   factor	  
deprivation	  (Dagda	  et	  al.,	  2003).	  
	  
Lately,	   a	   brain-­‐specific	   isoform	   of	   mitochondrial	  
apoptosis-­‐inducing	  factor,	  AIF2,	  has	  been	  isolated	  
(Hangen	   et	   al.,	   2010).	   AIF2	   dimerizes	   with	   AIF1	  
and	   has	   a	   stronger	   membrane	   anchorage.	  
Therefore	   it	   is	   conceivable	   the	   neuron-­‐specific	  
AIF2	  may	  have	  been	   ‘designed’	   to	  be	  retained	   in	  
mitochondria	   and	   to	   minimize	   its	   potential	  
neurotoxic	  activity.	  
	  
In	   conclusion,	   although	   mature	   neurons	   are	  
among	   the	   most	   long-­‐lived	   cell	   types	   in	  
mammals,	   immature	   neurons	   die	   in	   large	  
numbers	   and	   the	   regulation	   of	   apoptosis	   has	   a	  
major	   role	   in	   sculpting	   the	   developing	   brain.	  
Furthermore,	   not	   only	   is	   apoptosis	   important	   in	  
regulating	   neuronal	   development,	   but	   it	   might	  
also	   be	   a	   cardinal	   feature	   in	   the	   adult	   brain	   in	  
several	   pathological	   conditions	   that	   will	   be	  
detailed	   in	   the	   section	   on	   neurodegenerative	  
diseases.	  
	  
Role	  of	  Magnesium	  in	  Neuronal	  Apoptosis	  
	  
Deciphering	   the	   role	   of	   magnesium	   in	   the	  
apoptotic	   process	   is	   further	   complicated	   in	   the	  
nervous	   system,	   as	   the	   blood	   brain	   barrier	   may	  
restrain	  serum	  magnesium	  availability	  within	  the	  
CNS.	   Indeed,	   this	   has	   been	   advocated	   as	   the	  
cause	   for	   the	   failure	   of	   clinical	   trials	   assessing	  
magnesium	   therapy	   in	   acute	   and	   chronic	   brain	  
injury	  (Vink	  et	  al.,	  2009).	  
	  
A	   significant	  part	  of	   the	   literature	  on	   the	  effects	  
of	  magnesium	  on	  apoptosis	  in	  the	  brain	  is	  related	  
to	  perinatal	  brain,	  as	  magnesium	  is	  often	  used	  as	  
a	   treatment	   for	   pre-­‐eclampsia/eclampsia	   and	  
preterm	  labour.	  The	  basis	  for	  its	  use	  as	  a	  tocolytic	  
is	   due	   to	   its	   observed	   effects	   in	   reducing	  
myometrial	   contractility	   through	   extra-­‐	   and	  
intracellular	  mechanisms	  of	   action	   (Fomin	  et	   al.,	  
2006).	  However,	   the	  use	  of	  magnesium	  sulphate	  
as	  a	  drug	  in	  obstetrical	  medicine	  for	  both	  mother	  
and	   fetus	   is	   highly	   controversial.	   A	   recent	  meta-­‐
analysis	  of	  all	  trials	  has	  recommended	  the	  use	  of	  
magnesium	   for	   neuroprotection	   in	   the	   preterm	  
fetus,	  as	   it	  was	  both	  safe	  and	  effective	   (Doyle	  et	  
al.,	   2009).	   Nevertheless,	   some	   caution	   is	  
mandatory,	   as	   several	   reports	   point	   to	  
detrimental	   effects	   of	   magnesium	   for	   the	   fetal	  
brain,	   depending	  on	   the	  dose	   (Mittendorf	  et	   al.,	  
2006;	   Dribben	   et	   al.,	   2009),	   on	   the	   period	   of	  
neurodevelopment	  when	   the	   exposure	   occurred	  
(Dribben	   et	   al.,	   2009)	   or	   on	   the	   level	   of	   stress	  
experienced	   (Krueger	   et	   al.,	   2001).	   In	   addition,	  
some	   papers	   report	   a	   pro-­‐apoptotic	   action	   of	  
magnesium	   in	   placental	   tissues	   (Black	   et	   al.,	  
2001;	   Gude	   et	   al.,	   2000).	   The	   major	   hurdle	   to	  
establishing	   protective	   or	   deleterious	   effects	   of	  
tocolytic	   magnesium	   to	   the	   developing	   brain	   is	  
that	   magnesium’s	   effects	   on	   preterm	   infant’s	  
brains,	  and	  the	  mechanisms	  of	  those	  effects,	  are	  
not	  understood.	  	  
	  
As	   discussed	   earlier,	   neuronal	   apoptosis	   can	   be	  
triggered	   by	   three	   main	   mechanisms:	   1)	   lack	   of	  
growth	   factors;	   2)	   overstimulation	   of	   glutamate	  
receptors;	   and	   3)	   oxidative	   stress.	   Magnesium	  
could	   play	   a	   (different)	   role	   in	   each	   of	   these	  
signalling	  pathways.	  
	  
First,	  most	  growth	  factors	  work	  through	  receptor	  
tyrosine	   kinases	   (RTKs)	   which	   require	   two	  
magnesium	   ions	   for	   maximal	   activity.	   Kinases	  
downstream	  of	  these	  RTKs,	  such	  as	  PI	  -­‐kinase	  and	  
the	  anti-­‐apoptotic	  kinase	  Akt	  require	  magnesium	  
both	   for	   their	   activation	   and	   activity.	   Therefore,	  
extracellular	   magnesium	   could	   modulate	   the	  
effect	  of	  growth	  factors	  on	  CNS	  cells,	  or	  activate	  
their	   second	   messenger	   systems	   directly,	  
ultimately	   affecting	   viability,	   proliferation,	   and	  
apoptosis	  in	  these	  cells.	  
	  
Secondly,	  under	  conditions	  of	  normal	  membrane	  
polarization	   magnesium	   is	   known	   to	   block	   the	  
NMDA	   glutamate	   receptor	   and	   prevent	   ion	   flow	  
through	   the	   channel.	   Therefore,	   in	   principle,	  
magnesium	  should	  protect	  against	  excitotoxicity-­‐
induced	   apoptosis.	   Nevertheless,	   as	   already	  
discussed,	   normal	   physiological	   patterns	   of	  
NMDA	  receptor	  activity	  promote	  neuroprotection	  
against	   both	   apoptotic	   and	   excitotoxic	   insults;	  
vice	  versa,	  NMDA	  receptor	  blockade	  can	  promote	  
neuronal	   death	   outright	   or	   render	   neurons	  
vulnerable	   to	   secondary	   trauma	   (Hardingham,	  
2009).	   Indeed,	   most	   NMDA	   antagonists	   have	  
failed	   miserably	   as	   neuroprotective	   agents	   in	  
clinical	   trials,	   in	   large	  part	  because	  of	   intolerable	  
side	  effects	  (Lipton,	  2006).	  Moreover,	  it	  has	  been	  
shown	   that	   various	   drugs	   that	   inhibit	   neuronal	  
activity,	   including	   NMDA	   antagonists,	   trigger	  
widespread	   apoptotic	   neurodegeneration	   in	   the	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developing	   brain	   and	   cause	   long-­‐term	  
neurobehavioral	   deficits;	   in	   the	   infant	   rodent	  
brain,	  peak	  sensitivity	  to	  this	  effect	  is	  in	  the	  P3	  to	  
P7	   period	   (Ikonomidou	   et	   al.,	   1999).	   Thus,	  
although	   other	   mechanisms	   may	   play	   a	   role,	   it	  
seems	   likely	   that	   the	   neuroapoptogenic	   action	  
demonstrated	   for	   magnesium	   in	   some	   studies	  
could	  be	  mediated	  by	  its	  action	  at	  NMDA	  receptors.	  
	  
Third,	   as	   mentioned	   earlier,	   magnesium	  
deprivation	   may	   induce	   or	   exacerbate	   oxidative	  
stress,	   another	   trigger	   of	   neuronal	   death,	  
especially	   in	   pathological	   conditions.	   In	   this	  
regard,	   magnesium	   supplementation	   might	   well	  
have	  a	  neuroprotective	  action.	  
	  
Apoptosis	  in	  neurodegenerative	  diseases	  
	  
As	   already	   mentioned,	   neuronal	   death	   by	  
apoptosis	   is	   a	  distinctive	  physiological	   feature	  of	  
the	   developing	   brain;	   once	   synaptogenesis	   is	  
over,	   the	   remaining	   neurons	   will	   usually	   survive	  
throughout	   life	   to	   preserve	   brain	   function.	  
Unfortunately,	  however,	  many	  people	  experience	  
excessive	   death	   of	   specific	   neuronal	   sub-­‐
populations	   as	   a	   result	   of	   chronic	   diseases	  
including	   Alzheimer’s	   disease,	   Parkinson’s	  
disease,	   Huntington’s	   disease	   and	   amyotrophic	  
lateral	   sclerosis.	   Neuronal	   death	  may	   also	   occur	  
as	   a	   consequence	   of	   acute	   conditions,	   such	   as	  
stroke	   or	   traumatic	   brain	   and	   spinal	   cord	   injury.	  
For	   each	   of	   these	   disorders,	   apoptosis	   has	   been	  
implicated	  as	  the	  main	  form	  of	  cell	  death,	  though	  
it	   is	   very	   difficult	   to	   demonstrate	   it	   for	   both	  
technical	   and	   ethical	   reasons.	   Much	   of	   the	  
evidence	   supporting	   an	   apoptotic	   mode	   of	  
neuronal	  death	  comes	  from	  studies	  of	  animal	  and	  
cell-­‐culture	   models	   of	   neurodegenerative	  
disorders	  (Mattson,	  2000).	  
	  
Physiological	   apoptosis	   in	   the	   developing	   brain	  
and	   pathological	   apoptosis	   in	   the	   adult	   brain	  
share	   similar	   molecular	   mechanisms	   in	   the	  
effector	   phase,	   but	   may	   differ	   in	   the	   initiation.	  
Whereas	   trophic	   factor	   withdrawal	   has	   a	  
prominent	  role	  in	  apoptosis	  during	  development,	  
toxic	  insults	  resulting	  from	  biochemical	  or	  genetic	  
accidents	   seem	   to	   be	   the	   triggering	   event	   in	  
neurodegenerative	   disorders.	   An	   emerging	  
theme	   is	   the	   toxicity	   of	   abnormal	   protein	  
structures	   or	   aggregates	   (Yuan	   and	   Yankner,	  
2000).	   Indeed,	   a	   defining	   feature	   of	   Alzheimer’s	  
disease	   is	   accumulation	   of	   amyloid	   plaques	  
formed	  by	  aggregates	  of	  amyloid-­‐β	  peptide	  (Aβ).	  
Parkinson’s	   disease	   is	   characterized	   by	   the	  
appearance	  of	  α-­‐synuclein	  oligomers.	  Huntington’s	  
disease	  is	  caused	  by	  expansions	  of	  a	  trinucleotide	  
(CAG)	  sequence	  in	  the	  huntingtin	  gene	  producing	  
a	   protein	   containing	   increased	   polyglutamine	  
repeats.	   The	   neuropathological	   signature	   of	  
amyotrophic	   lateral	   sclerosis	   (ALS)	   is	   the	  
presence	   of	   ubiquitinated	   inclusions	   immuno-­‐
reactive	   for	   the	  proteins	   TDP-­‐43	   and/or	   FUS/TLS	  
in	   the	   cytoplasm	   of	   motor	   neurons.	   Moreover,	  
mutations	   in	   specific	   genes	   may	   predispose	   to	  
neuronal	   degeneration,	   e.g.	   presenilin	   in	  
Alzheimer's	  disease,	  parkin	  in	  Parkinson's	  disease,	  
huntingtin	   in	   Huntington's	   disease,	   and	   Cu/Zn-­‐
superoxide	   dismutase	   (SOD)	   in	   ALS	   (please	   refer	  
to	  the	  dedicated	  chapters	  in	  this	  book	  for	  further	  
details).	  
	  
The	   identification	   of	   specific	   genetic	   and	  
environmental	   factors	   responsible	   for	   chronic	  
neurodegenerative	   disorders	   has	   bolstered	  
evidence	   for	   a	   shared	   pathway	   of	   neuronal	  
apoptosis	   involving	   oxidative	   stress,	   perturbed	  
calcium	   homeostasis	   and	   mitochondrial	  
dysfunction	   ultimately	   converging	   on	   caspase	  
activation	   (Zündorf	   and	   Reiser,	   2010;	   Gibson	   et	  
al.,	  2010).	  
	  
In	   Alzheimer's	   disease,	   toxic	   forms	   of	   Aβ	   may	  
induce	  Ca2+	  influx	  into	  neurons	  by	  formation	  of	  an	  
oligomeric	   pore	   in	   the	   plasma	   membrane,	  
thereby	   rendering	   neurons	   vulnerable	   to	  
excitotoxicity	   and	   apoptosis	   (Supnet	   and	  
Bezprozvanny,	  2010).	  Aβ	  also	  generates	  hydrogen	  
peroxide	   and	   hydroxyl	   radicals,	   producing	  
membrane	   lipid	   peroxidation	   and	   consequently	  
membrane	   depolarization	   and	   excitotoxicity	  
through	   NMDA	   receptor	   channels	   and	   voltage-­‐
gated	   Ca2+	   channels	   (Sultana	   and	   Butterfield,	  
2010;	   Butterfield	   et	   al.,	   2010).	   In	   addition,	   Aβ	  
accumulates	  in	  mitochondria,	  impairs	  the	  activity	  
of	   complexes	   III	   and	   IV	   of	   the	   respiratory	   chain,	  
causes	   elevated	   cytoplasmic	   Ca2+	   levels	   and	  
oxidative	   stress,	   and	   reduces	   ATP	   synthesis,	  
further	   increasing	   Ca2+	   overload	   and	   oxidative	  
stress	  (Moreira	  et	  al.,	  2010).	  
	  
Mitochondrial	   dysfunction	   is	   a	   defect	   occurring	  
early	   in	   the	   pathogenesis	   of	   both	   sporadic	   and	  
familial	   Parkinson's	   disease.	   Mitochondrial	  
association	   of	   α-­‐synuclein	   in	   cells	   was	   linked	   to	  
impairment	   of	   respiratory	   complex	   I	   activity,	  
Mg	  and	  apoptosis	   	   Chapter	  5	  
 
 92	  
oxidative	  modification	  of	  mitochondrial	  proteins,	  
and	   increased	   levels	   of	   Ca2+	   and	   nitric	   oxide	  
(Navarro	  and	  Boveris,	  2009).	  
	  
Mitochondrial	   Ca2+	   overload	   is	   also	   a	   decisive	  
commitment	   step	   for	   Huntington's	   disease.	  
Mutant	  huntingtin	   facilitates	  opening	  of	   the	  PTP	  
and	   directly	   impairs	   the	   mitochondrial	   function.	  
Furthermore,	  huntingtin	  forms	  a	  ternary	  complex	  
with	   other	   proteins,	   which	   causes	   Ca2+	   release	  
from	  the	  ER	  and	  renders	  neurons	  more	  sensitive	  
to	   Ca2+-­‐mediated	   cellular	   dysfunction	   (Damiano	  
et	  al.,	  2010).	  
	  
The	  mutations	  in	  SOD	  responsible	  for	  ALS	  do	  not	  
decrease	   antioxidant	   activity	   of	   the	   enzyme,	   but	  
result	   in	   the	   gain	   of	   an	   adverse	   pro-­‐apoptotic	  
activity	   that	   may	   involve	   increased	   peroxidase	  
activity.	   Through	   interactions	   with	   hydrogen	  
peroxide	   or	   superoxide	   anion,	   the	   mutant	  
enzyme	   may	   induce	   oxidative	   damage	   to	  
membranes	   and	   disturbances	   in	   mitochondrial	  
function	   that	   make	   neurons	   vulnerable	   to	  
excitotoxic	   apoptosis	   (Vucic	   and	   Kiernan,	   2009).	  
Also,	   stroke	   and	   trauma,	   and	   the	   consequent	  
brain	   ischemia,	   initiate	   biochemical	   and	  
molecular	   events	   involving	   many	   of	   the	   same	  
neurodegenerative	   cascades	   that	   occur	   in	   the	  
chronic	   neurodegenerative	   diseases	   described	  
above,	   namely	   excitotoxicity,	   calcium	   overload	  
and	   oxidative	   stress	   (Arundine	   and	   Tymianski,	  
2004).	  
	  
In	  conclusion,	  despite	  the	  concurrence	  of	  diverse	  
genetic	   and	  environmental	   factors	   for	   acute	  and	  
chronic	   neurodegenerative	   disorders,	   such	  
conditions	  possess	  a	  common	  denominator	  as	  to	  
the	   ultimate	   mechanisms	   executing	   neuronal	  
death,	   which	   are	   identical	   to	   those	   involved	   in	  
normal	   brain	   development	   and	   all	   converge	   to	  
mitochondrial	   dysfunction.	   On	   one	   hand,	   these	  
findings	   testify	   the	   evolutionary	   importance	   of	  
conserving	   fundamental	  processes.	  On	   the	  other	  
hand,	  they	  call	  for	  further	  research	  to	  understand	  
the	   basic	  mechanisms	   and	   the	   key	   regulators	   of	  
neuronal	  fate,	  as	  novel	  opportunities	  for	  targeted	  
therapeutic	  intervention	  may	  arise.	  
	  
Role	  of	  magnesium	  in	  neurodegenerative	  
diseases	  
	  
As	   detailed	   above,	   there	   is	   increasing	   evidence	  
that	   neuronal	   death	   by	   apoptosis	   is	   associated	  
with	   both	   acute	   and	   chronic	   neurodegenerative	  
disorders.	   Interestingly,	   brain	   free	   magnesium	  
levels	  have	  been	  shown	  to	  decline	  in	  a	  number	  of	  
such	   pathologies	   (Vink	   et	   al.,	   2009).	   As	   a	  
consequence,	   a	   considerable	   research	   effort	   has	  
been	  directed	  toward	  establishing	  the	  mechanisms	  
of	  such	  decline	  and	  the	  potential	   for	  magnesium	  
administration	  as	  a	  neuroprotective	  agent.	  	  
	  
Brain	  magnesium	  decline	   is	   a	   ubiquitous	   feature	  
of	   traumatic	   brain	   injury	   and	   is	   associated	   with	  
the	  development	  of	  motor	  and	  cognitive	  deficits.	  
Experimentally,	   parenteral	   administration	   of	  
magnesium	  up	  to	  12	  h	  post-­‐trauma	  restores	  brain	  
magnesium	   homeostasis	   and	   profoundly	  
improves	   both	   motor	   and	   cognitive	   outcome.	  
Although	   the	   mechanism	   of	   action	   is	   unclear,	  
magnesium	   has	   been	   shown	   to	   attenuate	   a	  
variety	   of	   secondary	   injury	   factors,	   including	  
brain	   edema,	   cerebral	   vasospasms,	   glutamate	  
excitotoxicity,	  calcium-­‐mediated	  events,	  lipid	  per-­‐
oxidation,	   mitochondrial	   permeability	   transition,	  
and	   apoptosis.	   Disappointingly,	   magnesium	  
therapy	   has	   failed	   in	   clinical	   trials.	   Increase	   in	  
brain	  free	  magnesium	  concentration	  seems	  to	  be	  
essential	   to	   confer	   neuroprotection,	   and	  
intravenous	   magnesium	   administration	   only	  
marginally	  increases	  CSF	  magnesium	  concentration,	  
which	   suggests	   that	   the	   integrity	   of	   the	   blood-­‐
brain	  barrier	  and	  the	  regulation	  of	  magnesium	  in	  
the	   cerebrospinal	   fluid	   are	   largely	   maintained	  
following	  acute	  brain	  injury	  and	  limit	  magnesium	  
bioavailability	   in	   the	   brain	   (Vink	   and	   Nimmo,	  
2009).	  
	  
Magnesium	   therapy	   has	   also	   been	   described	   in	  
the	  clinical	  stroke	  literature,	  with	  similar	  negative	  
results,	   though	   magnesium	   was	   shown	   to	   be	  
beneficial	   in	   a	   subgroup	   of	   patients	   with	  
noncortical,	  or	   lacunar,	   strokes	   (Ginsberg,	  2008).	  
Magnesium	  may	  protect	   via	  multiple	  mechanisms,	  
including	  NMDA	   receptor	   blockade,	   inhibition	   of	  
excitatory	   neurotransmitter	   release,	   blockade	   of	  
calcium	   channels,	   as	   well	   as	   vascular	   smooth	  
muscle	  relaxation,	  and	  may	  be	  more	  bioavailable,	  
as	   it	   is	   well	   known	   that	   the	   blood	   brain	   barrier	  
around	  infarcted	  tissue	   is	  highly	  permeable,	  thus	  
potentially	   facilitating	   local	   magnesium	   entry	   to	  
the	  injured	  tissues.	  
	  
Intriguingly,	   the	   cation	   channel	   TRPM7,	  which	   is	  
crucial	   for	   Mg2+	   homeostasis	   and	   cell	   survival	  
(Schmitz	   et	   al.,	   2003),	   seems	   to	   be	   a	   critical	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mediator	   of	   anoxic	   cell	   death.	   It	   appears	   that	  
TRPM7	   gating	   lies	   downstream	   of	   NMDA	  
receptor-­‐mediated	  NO	  free-­‐radical	  production.	  In	  
this	  paradigm,	  excitotoxicity	  is	  likely	  the	  initiating	  
signal	   in	  a	  cell	  death	  cascade	  that	   involves	  nNOS	  
activation	   with	   subsequent	   peroxynitrite	  
production,	   which	   in	   turn	   activates	   TRPM7	  
channels.	   Calcium	   influx	   through	   TRPM7	   then	  
creates	   a	   positive	   feedback	   loop	   of	   ROS	  
production,	  which	   eventually	   kills	   the	   cell	   (Aarts	  
and	   Tymianski,	   2005).	   TRPM7	   suppression	  made	  
neurons	   resistant	   to	   ischemic	   death	   after	   brain	  
ischemia	   and	   preserved	   neuronal	   morphology	  
and	  function;	  also,	  it	  prevented	  ischemia-­‐induced	  
deficits	   in	   long-­‐term	   potentiation	   and	   preserved	  
performance	   in	  memory	   tasks	   (Sun	  et	  al.,	   2009).	  
The	   role	   of	   the	   magnesium-­‐specific	   channel	  
TRPM6	   in	   these	   processes	   is	   currently	   unclear,	  
but,	   given	   its	   localization	   in	   the	   brain,	   its	  
permeability	  to	  Mg2+	  and	  its	  functional	  interaction	  
with	   TRPM7,	   it	   may	   be	   involved	   in	   neuronal	  
death	  as	  well	   (Cook	  et	  al.,	  2009).	  At	  present,	  the	  
role	   of	   TRPM6/7	   channels	   in	   magnesium	  
transport	   seems	   less	   important	   than	   their	  
facilitation	  of	  other	  cation	  fluxes,	  but	  it	  cannot	  be	  
ruled	   out,	   especially	   considering	   the	   known	  
involvement	   of	   magnesium	   in	   excitotoxicity	   and	  
oxidative	  stress,	  as	  discussed	  earlier.	  
	  
With	   respect	   to	   chronic	   brain	   degeneration,	   the	  
first	   connection	   between	   magnesium	   and	   three	  
apparently	   dissimilar	   neurodegenerative	   dis-­‐
orders	   (ALS,	   Parkinson's	   and	   Alzheimer's	  
diseases)	   came	   from	   the	   observation	   that	   those	  
conditions	   occurred	   at	   extraordinarily	   high	   rates	  
in	   geographically	   separate	   foci	   among	   three	  
genetically	   different,	   homogenous	   western	  
Pacific	   populations	   (Durlach	   et	   al.,	   1997).	  
Intensive	   research	   conducted	   over	   the	   years	   led	  
to	   the	   identification	   of	   two	   candidate	  
environmental	   factors:	   1)	   severely	   low	   levels	   of	  
Ca2+	   and	   Mg2+	   in	   the	   soil	   and	   drinking	   water	  
coupled	  with	  abnormal	  mineral	  metabolism;	  and	  
2)	   the	   putative	   neurotoxin	   β-­‐methylamino-­‐L-­‐
alanine	  (L-­‐BMAA),	  derived	  from	  the	  cycad	  plant,	  a	  
traditional	   food	   source	   in	   Guam.	   Experimental	  
findings	   supported	   this	   hypothesis:	   animals	   fed	  
diets	   that	  mimic	   the	  mineral	   composition	   in	   the	  
disease	   foci	   environment	   showed	   signs	   of	  
neuronal	  damage;	  of	  the	  various	  combinations	  of	  
Ca2+	   and	  Mg2+	   contents	   tested,	   exposure	   to	   low	  
Mg2+	   (one-­‐fifth	   of	   the	   normal	   level)	   was	   more	  
deleterious,	   causing	   significant	   loss	   of	  
dopaminergic	   neurons	   in	   the	   substantia	   nigra	  
(Oyanagi	   et	   al.,	   2006).	   Furthermore,	   motor	  
neurons	   are	   selectively	   more	   vulnerable	   to	   L-­‐
BMAA	   toxicity,	   and	   these	   toxic	   effects	   are	  
mediated	   through	   [Ca2+]i	   rises	   via	   Ca-­‐A/K	  
channels	   and	   other	   pathways,	   and	   subsequent	  
reactive	   oxygen	   species	   generation	   (Rao	   et	   al.,	  
2006).	  
	  
In	   the	  hyperendemic	   foci	   in	   the	  Western	  Pacific,	  
the	   unique	   mineral	   composition	   of	   the	  
environment	   creates	   a	   condition	   of	   increased	  
oxidative	   stress	   because	   low	   Mg2+	   levels	   cause	  
lipid	   peroxidation	   while	   transition	   metals	   act	   as	  
redox	   catalysts	   causing	   increased	   ROS	  
production.	  Therefore,	  the	  genes	  whose	  function	  
is	   most	   likely	   to	   be	   affected	   are	   ion	   channels	  
expressed	  in	  the	  CNS	  and	  modulated	  by	  oxidative	  
stress.	  TRPM7	  and	  TRPM2	  fulfil	  these	  conditions;	  
their	   functional	   properties	   are	   interconnected	  
with	   calcium	   and	   magnesium	   homeostasis,	  
oxidative	   stress,	   mitochondrial	   dysfunction,	   and	  
immune	   mechanisms,	   all	   principal	   suspects	   in	  
neurodegeneration	   (Hermosura	   and	   Garruto,	  
2007).	   Indeed,	  variants	  of	  both	  genes	  have	  been	  
found	   in	   Guamanian	   neurodegenerative	  
disorders	   and	   may	   contribute	   to	   their	  
pathogenesis	  (Hermosura	  et	  al.,	  2008;	  Hermosura	  
et	  al.,	  2005).	  	  
	  
Despite	   the	   evidence	   implicating	   magnesium	   in	  
the	  aetiology	  of	  neurodegenerative	  diseases,	   the	  
therapeutic	   effects	   of	   magnesium	  
supplementation	   are	   not	   well	   documented.	  
Magnesium	   administration	   proved	   beneficial	   in	  
an	  in	  vitro	  model	  of	  Parkinson's	  disease,	  where	  in	  
particular	   magnesium	   concentration	   seems	  
critical	   in	  the	  onset	  of	  the	  disease	  (Hashimoto	  et	  
al.,	   2008),	   but	   there	   is	   still	   much	   to	   be	   done	   to	  





An	   extensive	   and	   up-­‐to-­‐date	   review	   of	   the	  
literature	   shows	   that	   drawing	   a	   clear-­‐cut	  
conclusion	   on	   the	   role	   of	   magnesium	   in	  
neuroapoptosis	   is	   not	   an	   easy	   task.	   Magnesium	  
may	   play	   pleiotropic	   roles	   in	   different	   stages	   of	  










the	   apoptotic	   process,	   that	   range	   from	  
modulating	   growth	   factor-­‐	   and	   Ca2+-­‐dependent	  
signal	   transduction	   to	   affecting	   oxidative	   stress-­‐
related	   reactions.	   From	   this	   point	   of	   view,	  
increased	   extracellular	   magnesium	   availability	  
should	   in	   principle	   be	   considered	   anti-­‐
apoptogenic.	   On	   the	   other	   hand,	   an	   increase	   in	  
cytosolic	   free	   magnesium,	   which	   seems	   to	   be	  
released	   from	   mitochondrial	   stores,	   appears	   to	  
accompany	   the	   intrinsic	   apoptotic	   process.	   The	  
pathophysiological	  meaning	  of	  this	  occurrence	  in	  
the	   context	   of	   apoptosis	   induction/execution	  
awaits	  to	  be	  defined	  (see	  Figure	  1	  for	  a	  summary).	  
	  
In	   a	   more	   physiological	   basis,	   magnesium	  
availability	   in	   the	   brain	   should	   be	   considered	  
within	   a	   more	   complex	   and	   interconnected	  
picture,	   where	   other	   conditions,	   such	   as	  
developmental	  stage,	  inflammation,	  acute	  or	  	  
	  
	  
chronic	  injuries,	  blood	  brain	  barrier	  integrity,	  and	  
so	   on,	  may	   concur	   in	   determining	   a	   pro	   or	   anti-­‐
apoptotic	  environment.	  	  
	  
We	  believe	  that	  further	  investigation	  into	  the	  role	  
of	   magnesium	   in	   the	   molecular	   mechanisms	   of	  
apoptosis	   is	   warranted	   for	   a	   deeper	  
understanding	   of	   the	   basic	   processes	   that	  
regulate	  cell	   fate,	  and	  ultimately	   for	  a	  successful	  
therapeutic	   intervention	   when	   these	   processes	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In	   the	   general	   deterioration	   of	   physiological	   functions	   that	   takes	   place	   in	   aging,	   the	   prevalence	   of	  
cognitive	  impairments,	  and	  particularly	  of	  those	  related	  to	  learning	  and	  memory,	  makes	  these	  deficits	  a	  
major	  concern	  of	  public	  health.	  Although	  the	  exact	  nature	  of	  cellular	  and	  molecular	  substrates	  underlying	  
learning	  and	  memory	  still	  remains	  an	  open	  issue	  for	  the	  neurobiologist,	  the	  current	  hypothesis	  assumes	  
that	  it	  is	  determined	  by	  the	  capacity	  of	  brain	  neuronal	  networks	  to	  express	  short-­‐	  and	  long-­‐term	  changes	  
in	   synaptic	   strength.	   Accordingly,	   the	   capacity	   of	   functional	   plasticity	   is	   impaired	   in	   the	   brain	   of	   aged	  
memory-­‐deficient	   animals.	   Short-­‐term	   changes	   in	   synaptic	   transmission	   closely	   depend	   on	   transmitter	  
release	  and	  neuronal	   excitability	  while	   long-­‐term	  modifications	  are	  mainly	   related	   to	   the	  activation	  of	  
the	   N-­‐methyl-­‐D-­‐aspartate	   receptor	   (NMDA-­‐R),	   a	   subtype	   of	   glutamate	   receptors.	   Because	   transmitter	  
release,	  neuronal	  excitability	  and	  NMDA-­‐R	  activation	  are	  modulated	  by	  magnesium	  (Mg2+),	  a	  change	   in	  
brain	  Mg2+	  homeostasis	  could	  affect	  synaptic	  strength	  and	  plasticity	  in	  neuronal	  networks	  and	  consequently	  
could	  alter	  memory	  capacities.	  In	  addition,	  alteration	  of	  brain	  Mg2+	  levels	  could	  be	  regarded	  as	  a	  possible	  
mechanism	   contributing	   to	   cognitive	   aging.	   According	   to	   these	   postulates,	   long-­‐term	   increase	   in	  Mg2+	  
levels	  facilitates	  the	  conversion	  of	  synapses	  to	  a	  plastic	  state	  while	  learning	  and	  memory	  capacities	  are	  
enhanced	   in	   adult	   animals	   fed	  with	   a	   diet	   enriched	   in	  Mg2+-­‐L-­‐threonate,	   a	   treatment	   that	   significantly	  
elevates	   brain	   Mg2+	   levels.	   Because	   Mg2+-­‐L-­‐threonate	   also	   improves	   learning	   and	   memory	   in	   aged	  
animals,	  the	  regulation	  of	  brain	  Mg2+	  homeostasis	  may	  therefore	  be	  regarded	  as	  a	  relevant	  target	  for	  the	  





Alterations	   in	   brain	   anatomy	   and	   physiology	   are	  
frequent	  features	  that	  gradually	  take	  place	  in	  the	  
course	   of	   aging,	   to	   finally	   impair	   cognitive	  
functions,	   such	   as	   learning	   and	   memory.	   In	   the	  
last	   decades,	   extensive	   behavioural	   experiments	  
performed	  in	  animal	  models	  of	  aging	  confirm	  that	  
the	   efficient	   learning	   and	   memory	   in	   young	  
individuals	   is	   slowed	   down	   with	   age,	   while	  
forgetfulness	   is	   accelerated	   (Barnes	   and	  
McNaughton,	   1985;	   Gallagher	   and	   Rapp,	   1997;	  
Lanahan	   et	   al.,	   1997;	   Norris	   and	   Foster,	   1999;	  
Ward	   et	   al.,	   1999),	   and,	   like	   in	   humans,	   deficits	  
concern	   several	   forms	   of	   memory,	   including	  
spatial,	   associative	   and	   long-­‐term	   memory	  
(Clayton	  et	  al.,	  2002;	  Gruart	  et	  al.,	  2008;	  Houston	  
et	   al.,	   1999;	   Rosenzweig	   and	   Barnes,	   2003;	  
Sykova	   et	   al.,	   2002;	   Winocur	   and	   Moscovitch,	  
1990;	   Zornetzer	   et	   al.,	   1982).	   Neuronal	   or	  
synaptic	   loss	   is	   unlikely	   to	   significantly	   account	  
for	   the	   senescent-­‐associated	   cognitive	   deficits	  
(Eriksen	   et	   al.,	   2009;	   Geinisman	   et	   al.,	   2004;	  
Luebke	   et	   al.,	   2010;	   Morrison	   and	   Hof,	   2007;	  
Rapp	   and	  Gallagher,	   1996)	   and	   a	  wealth	   of	   data	  
now	   rather	   indicate	   that	   changes	   in	   functional	  
properties	   within	   neuronal	   networks	   are	   mainly	  
concerned	  (Billard	  2006;	  Burke	  and	  Barnes,	  2006;	  
Craik	  and	  Bialystok,	  2006;	  Disterhoft	  et	  al.,	  1994;	  
Driscoll	   et	   al.,	   2003;	   Erickson	   and	   Barnes,	   2003;	  
Foster,	   2007;	   Grady	   and	   Craik,	   2000;	   Hsu	   et	   al.,	  
2002;	  Kelly	   et	  al.,	  2006;	   Lister	  and	  Barnes,	  2009;	  
Magnusson,	  1998;	  Mora	  et	  al.,	  2007;	  Sykov	  et	  al.,	  
1998;	   Toescu	   and	   Verkhratsky,	   2004).	   In	  
particular,	  studies	  of	  long-­‐lasting	  modifications	  of	  
glutamatergic	   neurotransmission,	   such	   as	   long-­‐
term	  potentiation	  (LTP)	  and	  long-­‐term	  depression	  
(LTD)	   of	   synaptic	   strength,	   now	   considered	   as	  
functional	   substrates	   of	  memory	   encoding	   (Bear	  
and	  Malenka,	  1994;	  Bliss,	   1990;	  Collingridge	  and	  
Bliss,	   1995;	   Eichenbaum,	   1996;	   Izquierdo,	   1991;	  
Kim	   and	   Linden,	   2007;	   Lisman	   and	   McIntyre,	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2001;	   Martin	   et	   al.,	   2000;	   Teyler	   and	   DiScenna,	  
1987),	   show	   substantial	   changes	   with	   age	  
(Barnes,	   2003;	   Billard,	   2006;	   Burke	   and	   Barnes,	  
2006;	   Foster,	   2006;	   Norris	   et	   al.,	   1996).	   Among	  
the	   different	   mechanisms	   that	   may	   account	   for	  
these	   age-­‐associated	   impairments	   of	   synaptic	  
plasticity	   (Foster,	   2007;	   Rosenzweig	   and	   Barnes	  
2003),	  the	  activation	  of	  the	  N-­‐methyl-­‐D-­‐aspartate	  
subtype	   of	   glutamate	   receptors	   (NMDA-­‐R)	   has	  
received	   particular	   attention.	   Indeed,	   these	  
receptors	  are	  pivotal	   for	   the	  regulation	  of	  synaptic	  
strength,	   by	  means	  of	   their	   high	  permeability	   to	  
calcium	   (Ca2+),	   which	   triggers	   the	   activation	   of	  
specific	   intracellular	   protein	   kinases	   and	  
phosphatases	   (Wang	   et	   al.,	   1997).	   Although	   it	   is	  
obvious	   that	   NMDA-­‐R	   activation	   is	   impaired	   in	  
aging	   (Barnes	   et	   al.,	   1997;	   Junjaud	   et	   al.,	   2006;	  
Potier	   et	   al.,	   2000),	   all	   of	   the	   underlying	   mech-­‐
anisms	  have	  yet	  to	  be	  definitely	  characterized	  and	  
it	  remains	  to	  be	  determined	  to	  what	  extent	  they	  
are	   involved	   in	   age-­‐related	   deficits	   in	   synaptic	  
plasticity	  and	  of	  memory	  capacities.	  	  
	  
Among	  the	  different	  mechanisms	  possibly	  involved	  
in	  cognitive	  aging	   is	  a	  change	   in	   ion	  homeostasis	  
(Roberts,	  1999)	  since	  transmitter	  release,	  cellular	  
excitability	   and	   expression	   of	   synaptic	   plasticity	  
closely	   depend	   on	   ion	   flux	   across	   neuronal	  
membranes.	  Although	  Ca2+	  regulation	  has	  initially	  
gathered	   the	   largest	   interest	   in	   aging	   studies	  
(Thibault	   et	   al.,	   2007;	   Toescu	   et	   al.,	   2004;	  
Verkhratsky	   and	   Toescu,	   1998),	   the	   role	   of	  
magnesium	   (Mg2+),	   which	   is	   found	   in	   a	   relative	  
large	  concentration	  in	  the	  central	  nervous	  system	  
(CNS)	   (Chutkow,	   1974;	   Poenaru	   et	   al.,	   1997),	   is	  
now	   much	   more	   considered.	   Indeed,	   aging	   is	   a	  
risk	   factor	   for	  Mg2+	  deficit	   (Wakimoto	  and	  Block,	  
2001)	  [for	  a	  review	  see	  (Durlach	  et	  al.,	  1998)]	  and	  
brain	  Mg2+	  levels	  are	  significantly	  reduced	  in	  age-­‐
associated	   neurodegenerative	   diseases	   (Andrasi	  
et	   al.,	   2000;	   Andrasi	   et	   al.,	   2005;	   Basun	   et	   al.,	  
1991).	   On	   the	   other	   hand,	   the	   well-­‐known	  
regulation	  of	  NMDA-­‐R	  activation	  by	  Mg2+	  (Mayer	  
and	   Westbrook,	   1987;	   Nowak	   et	   al.,	   1984)	   and	  
the	   fact	   that	   altered	  Mg2+	   levels	   impair	  memory	  
functions	   (Bardgett	   et	   al.,	   2005;	   Bardgett	   et	   al.,	  
2007;	   Landfield	   and	   Morgan,	   1984),	   strongly	  
suggest	  that	  a	  change	  in	  Mg2+	  homeostasis	  could	  
contribute	   to	   the	   physiopathology	   of	   cognitive	  
aging.	  
	  
After	  reviewing	  the	  different	  roles	  of	  Mg2+	   in	  the	  
regulation	   of	   synaptic	   mechanisms	   at	   glutamat-­‐
ergic	   synapses,	   the	   present	   report	   will	   consider	  
whether	   Mg2+	   could	   be	   involved	   in	   deficits	   of	  
these	  mechanisms	   that	   occur	   in	   the	   aging	  brain,	  
and,	   finally,	   recent	   data	   will	   be	   presented	  
suggesting	  Mg2+	  as	  a	  relevant	  dietary	  component	  




The	  impact	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  brain	  Mg2+	  levels	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  synaptic	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  contributing	  to	  cognitive	  functions	  
	  
Although	   Mg2+	   is	   the	   second	   most	   abundant	  
intracellular	   mineral	   after	   potassium	   and	   is	  
present	  at	  large	  amount	  in	  the	  cerebrospinal	  fluid	  
of	   both	   rodents	   (0.8	   mM)	   (Chutkow,	   1974)	   and	  
humans	   (1.0	   to	   1.2	   mM)	   (Basun	   et	   al.,	   1991;	  
Kapaki	  et	  al.,	  1989),	  its	  role	  on	  neural	  activity	  and	  
synaptic	  plasticity	  has	  been	  much	  less	  considered	  
compared	   to	   other	   divalent	   cations	   such	   as	  
calcium	   (Ca2+).	   This	   is	   rather	   surprising	  
considering	  that	  Mg2+	  is	  a	  cofactor	  for	  more	  than	  
300	   enzymes	   and	   also	   tightly	   interacts	   with	  
phospholipids	   and	  nucleic	   acids	   (Hofmann	   et	   al.,	  
2000;	  Wolf	   and	   Cittadini,	   2003),	   suggesting	   that	  
the	   mineral	   should	   be	   able	   to	   modulate	   brain	  
activity	  on	  a	  broad	  scale.	  Initially,	  the	  role	  of	  Mg2+	  
has	   mainly	   been	   evaluated	   in	   vitro	   by	   lowering	  
extracellular	   levels	   ([Mg2+]e),	   a	   procedure	   that	  
increases	   spontaneous	   firing	   rate	   of	   neurons	  
through	   membrane	   depolarization	   (Furukawa	   et	  
al.,	   2009;	   Stone	   et	   al.,	   1992).	   This	   decrease	   in	  
[Mg2+]e	   can	   lead	   to	   paroxysmal	   events	   in	   slice	  
preparations	   from	   both	   animals	   and	   humans,	  
which	   resemble	   abnormal	   activities	   occurring	  
during	   sustained	   seizures	   in	   vivo	   (Armand	   et	   al.,	  
1998;	  Jones	  and	  Heinemann,	  1988;	  Stanton	  et	  al.,	  
1987).	   Using	   high	   performance	   liquid	   chroma-­‐
tography,	   quantification	  of	   basal	   efflux	   of	   amino	  
acids	   indicates	   that	  only	   levels	  of	  glutamate,	   the	  
neurotransmitter	   involved	   in	   most	   of	   excitatory	  
synapses	  in	  the	  CNS,	  are	  significantly	  enhanced	  in	  
low	   [Mg2+]e	   medium	   (Furukawa	   et	   al.,	   2009;	  
Smith	   et	   al.,	   1989).	   These	   data	   point	   out	   a	   first	  
contribution	   of	   Mg2+	   regarding	   the	   activity	   of	  
excitatory	   synapses	   in	   the	   brain,	   that	   is,	   the	  
regulation	   of	   the	   probability	   of	   transmitter	  
release	  (Figure	  1,	  left),	  as	  initially	  characterized	  at	  
neuromuscular	   junctions	   (Kelly	   and	   Robbins,	  
1983;	   Kuno	   and	   Takahashi,	   1986).	   But	   several	  
lines	  of	  evidence	  show	  that	  beside	  this	  ubiquitous	  
control	  on	  the	  probability	  of	  glutamate	  release	  at	  
presynaptic	  terminals,	  Mg2+is	  also	  able	  to	  influence	  	  




Figure	  1.	  Schematic	  representation	  of	  the	  positive	  and	  negative	  effects	  of	  short-­‐term	  (left)	  and	  long-­‐term	  
(right)	  elevation	  of	  brain	  Mg2	  levels	  on	  neurotransmission	  and	  synaptic	  plasticity	  at	  an	  excitatory	  glutamat-­‐
ergic	  synapse.	  AMPAr: α-amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	  acid	  receptor;	  NMDAr:	  N-­‐methyl-­‐





synaptic	   activity	   by	   acting	   at	   postsynaptic	   level	  
(Figure	   1,	   left).	   For	   instance,	   frequency	  
potentiation	  (FP),	  which	  represents	  an	  increase	  in	  
synaptic	   strength	   rapidly	   developing	   during	  
repetitive	   activation	   of	   glutamatergic	   afferent	  
fibres	  (Anderson	  and	  Lomo,	  1966;	  Andreasen	  and	  
Lambert,	  1998),	   is	  greater	  after	  elevating	  [Mg2+]e	  
(Landfield	  and	  Morgan,	  1984).	  This	   is	  mainly	  due	  
to	   the	   ability	   of	   Mg2+	   to	   reduce	   the	   calcium-­‐
dependent	   post-­‐burst	   after	   hyper-­‐polarization	  
(AHP)	   of	  membrane	  potential,	  which	   is	   normally	  
induced	  in	  depolarized	  neurons	  to	  limit	  excessive	  
firing	   (Hotson	   and	   Prince,	   1980;	   Lorenzon	   and	  
Foehring,	  1992;	  Madison	  and	  Nicoll,	  1984).	  AHPs	  
are	   reversibly	   reduced	   by	   the	   acquisition	   of	  
learning-­‐dependent	   behavioural	   tasks	   such	   as	  
trace	  eye	  blink	  conditioning	  or	  spatial	  water	  maze	  
(Moyer	  et	  al.,	  2000;	  Thompson	  et	  al.,	  1996).	  Thus,	  
by	  controlling	  the	  initial	  postsynaptic	  depolarization	  
through	   the	   regulation	   of	   AHP	   amplitude	   and	  
duration,	   Mg2+	   is	   able	   to	   modulate	   synaptic	  
strength	   and	   to	   alter	   cognitive	   abilities	  
(Disterhoft	  and	  Oh,	  2006).	  
	  
Although	   there	   is	   no	   doubt	   that	   Mg2+	   may	   be	  
considered	  as	  firmly	  involved	  in	  the	  regulation	  of	  
synaptic	   activity	   through	   the	   pre-­‐	   and	   post-­‐
synaptic	   mechanisms	   described	   above,	   an	  
additional	   and	   essential	   role	   for	   the	  mineral	   has	  
emerged	   at	   the	   end	   of	   the	   1980s	   from	  
electrophysiological	   studies	   demonstrating	   that	  
Mg2+	  inhibits	  currents	  through	  channels	  associated	  
with	   the	  N-­‐methyl-­‐D-­‐aspartate	   subtype	   of	   gluta-­‐
mate	  receptors	  (NMDA-­‐R)	  by	  directly	  blocking	  the	  
ion	   pore	   (Bekkers	   and	   Stevens,	   1993;	   Jahr	   and	  
Stevens,	   1990;	   Mayer	   and	   Westbrook,	   1987;	  
Nowak	   et	   al.,	   1984).	   A	   transient	   rise	   in	   [Mg2+]e	  
within	   physiological	   range,	   i.e.	   from	   0.8	   to	   1.2	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mM,	   rapidly	   reduces	   the	   current	   amplitude	  
mediated	   by	   NMDA-­‐R	   by	   more	   than	   60%	   in	  
cultured	  neurons	  clamped	  at	  potentials	  below	  -­‐50	  
mV	   while	   further	   increase	   in	   [Mg2+]e	   is	  
significantly	   less	   effective	   (Slutsky	   et	   al.,	   2004).	  
Importantly,	  this	  depression	  effect	  does	  not	  occur	  
at	   depolarized	   potentials,	   revealing	   a	   voltage	  
dependency	   for	   the	   block	   of	   NMDA-­‐R	   by	   Mg2+,	  
which	  underlies	  the	  pivotal	  role	  of	  NMDA-­‐R	  in	  the	  
induction	  of	  synaptic	  plasticity	  such	  as	   long-­‐term	  
potentiation	   (LTP)	   and	   long-­‐term	   depression	  
(LTD).	  Indeed,	  following	  high-­‐frequency	  activation	  
of	   presynaptic	   terminals,	   the	   glutamate-­‐induced	  
depolarization	   of	   membrane	   potential	   releases	  
NMDA-­‐R	   from	  Mg2+	   block	   allowing	   Ca2+	   to	   enter	  
the	   cells	   (Figure	   1,	   left).	   As	   a	   consequence,	  
activation	   of	   specific	   kinases	   or	   phosphatases	   is	  
triggered,	   thus	   modifying	   synaptic	   strength	  
(Wang	   et	   al.,	   1997).	   Several	   lines	   of	   evidence	  
show	   effects	   of	   transient	   changes	   in	  Mg2+	   levels	  
on	   the	   induction	   of	   synaptic	   plasticity.	   For	  
instance,	   a	   rapid	   rise	   in	   [Mg2+]e	   selectively	  
antagonizes	   LTP	   by	   reducing	   the	   depolarization-­‐
induced	  Ca2+	   influx	   (Dunwiddie	  and	   Lynch,	  1979;	  
Malenka	  et	  al.,	  1992;	  Malenka	  and	  Nicoll,	  1993).	  
Interestedly,	   LTP	   is	   also	   suppressed	   in	   slices	  
bathed	   with	   a	   Mg2+-­‐free	   medium	   (Frankiewicz	  
and	   Parsons,	   1999;	   Jouvenceau	   et	   al.,	   2002),	   a	  
loss	   that	   is	   independent	   of	   NMDA-­‐R	   activation	  
but	   rather	   due	   to	   changes	   in	   signalling	   cascades	  
in	   post-­‐synaptic	   neurons	   that	   remain	   to	   be	  
characterized	   (Hsu	   et	   al.,	   2000).	   At	   intracellular	  
level,	   Mg2+	   also	   regulates	   the	   activity	   of	   Ca2+-­‐
dependent	   protein	   kinases	   governing	   NMDA-­‐
dependent	   LTP.	   For	   instance,	   it	   controls	   the	  
subcellular	   localization	  of	  protein	  kinase	  C	   (PKC),	  
which	   closely	   determines	   the	   function	   of	   the	  
enzyme	   (Tanimura	   et	   al.,	   2002)	   and	   stimulates	  
the	   dephosphorylation	   and	   deactivation	   of	  
Calmodulin	   Kinase	   II	   (CaMKII)	   (Easom	   et	   al.,	  
1998).	  
	  
Despite	  much	  of	  data	  underlining	  that	  a	  transient	  
increase	   in	   Mg2+	   levels	   unables	   synapses	   to	  
remain	   highly	   plastic,	   an	   unexpected	   opposite	  
result	   has	   been	   reported	   in	   vitro	   after	   studying	  
the	  effects	  of	   long-­‐term	  elevation	  of	   the	  mineral	  
(Figure	  1,	  right).	  Indeed,	  when	  [Mg2+]e	  is	  increased	  
within	   physiological	   range	   in	   neuronal	   cultures	  
for	  more	   than	   several	   hours,	   NMDA-­‐R-­‐mediated	  
currents	  are	  enhanced	  and	  the	  expression	  of	  LTP	  
significantly	   facilitated	   (Slutsky	   et	   al.,	   2004).	   In	  
the	   same	   conditions,	   synaptic	   strength	   is	   not	  
modified	   following	   a	   single	   action	   potential	   but	  
increased	  after	  a	  burst	  of	  inputs.	  These	  long-­‐term	  
facilitation	   effects	   of	  Mg2+	   on	   neurotransmission	  
and	   synaptic	   plasticity	   also	   occur	   in	   vivo	   since	  
they	   are	   found	   in	   young	   rats	   fed	   with	   a	   diet	  
enriched	   in	   Mg2+-­‐L-­‐threonate	   (Mg2+-­‐T),	   a	   new	  
highly	   bioavailable	   compound	   that	   enhances	  
loading	   of	   Mg2+	   into	   the	   brain	   (Slutsky	   et	   al.,	  
2010).	   The	   increase	   in	   the	   density	   of	   functional	  
presynaptic	  boutons	  (Slutsky	  et	  al.,	  2010)	  coupled	  
with	   the	   weaker	   glutamate	   release	   at	   synapses	  
found	  after	  chronic	  Mg2+	  elevation	  (Slutsky	  et	  al.,	  
2004)	   indicate	   that	   long-­‐lasting	   changes	   in	  Mg2+	  
homeostasis	   are	   able	   to	   modify	   the	   pattern	   of	  
synaptic	   assemblies	   within	   neuronal	   networks,	  
from	   a	   limited	   number	   of	   synapses	   with	   high	  
probability	  of	  release	  to	  a	  larger	  density	  with	  low	  
probability	  of	  release	  (Figure	  1,	  right).	  In	  addition,	  
both	   the	   increase	   in	   [Mg2+]e	   in	   vitro	   and	   the	  
elevation	   of	   brain	   Mg2+	   in	   vivo	   up-­‐regulate	   the	  
expression	   of	   NR2B-­‐containing	   NMDA-­‐R	   (Slutsky	  
et	   al.,	   2004;	   Slutsky	   et	   al.,	   2010).	   This	   increase,	  
proposed	  to	  counterbalance	  the	  higher	  blockade	  
of	   NMDA-­‐R	   opening	   associated	   with	   chronic	  
elevation	   of	   [Mg2+]e,	   contributes	   to	   the	   greater	  
capacity	  of	  synapses	  to	  be	  highly	  plastic.	  	  
	  
Because	   the	   pattern	   and	   strength	   of	   synaptic	  
transmission	  are	  widely	  believed	  to	  code	  memory	  
traces	   (Bear	   and	   Malenka,	   1994;	   Bliss,	   1990;	  
Collingridge	   and	   Bliss,	   1995;	   Eichenbaum,	   1996;	  
Izquierdo,	   1991;	   Kim	   and	   Linden,	   2007;	   Lisman	  
and	  McIntyre,	  2001;	  Martin	  et	  al.,	  2000;	  Neves	  et	  
al.,	   2008;	   Teyler	   and	   DiScenna,	   1987),	   their	  
susceptibility	   to	   short-­‐	   and	   long-­‐term	  changes	   in	  
Mg2+	   homeostasis	   described	   above	   predict	   that	  
cognitive	   abilities	   would	   also	   be	   modulated	   by	  
altering	  Mg2+	   levels.	  Accordingly,	  Mg2+	  deficiency	  
impairs	   fear-­‐conditioning	   (Bardgett	   et	   al.,	   2005;	  
Bardgett	   et	   al.,	   2007)	  while	   chronically	   elevating	  
plasma	  Mg2+	  over	  several	  days	   improves	  reversal	  
learning	   in	   the	   hippocampus-­‐dependent	   T-­‐maze	  
task	   (Landfield	   and	   Morgan,	   1984).	   However,	  
whether	   brain	   Mg2+	   levels	   are	   really	   altered	   in	  
these	   studies	   has	   been	   questioned	   considering	  
that	   Mg2+	   loading	   into	   the	   brain	   is	   tightly	  
regulated	   by	   active	   transport	   processes	   that	  
maintain	   a	   concentration	   gradient	   between	   the	  
cerebrospinal	   fluid	   (CSF)	  and	  the	  plasma.	   In	   fact,	  
Mg2+	   levels	  are	  poorly	  affected	   in	   the	  brain	  after	  
long-­‐lasting	   increase	   in	   plasma	  Mg2+	   induced	   by	  
intravenous	   injection	   of	   MgSO4	   both	   in	   animals	  
and	  humans	  (Kim	  et	  al.,	  1996;	  McKee	  et	  al.,	  2005).	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Nevertheless,	   this	   rigorous	   control	   of	   brain	  Mg2+	  
levels	   has	   recently	   been	   overcome	   using	   the	  
highly	   bioavailable	   compound	   Mg2+-­‐T,	   which	  
increases	  Mg2+	   concentrations	   in	   CSF	   by	   at	   least	  
15%	   (Slutsky	   et	   al.,	   2010).	   Behavioural	  
characterization	   of	   the	   Mg2+-­‐T-­‐treated	   rats	  
indicates	   significant	   improvements	   of	   learning	  
abilities,	   working	   memory	   as	   well	   as	   short-­‐	   and	  
long-­‐term	  memory	   compared	   to	   control	   animals	  
(Slutsky	   et	   al.,	   2010),	   confirming	   that	   even	  
moderate,	  changes	  in	  brain	  Mg2+	  homeostasis	  are	  
capable	  of	  altering	  cognitive	  performances.	  	  
	  
The	  impact	  of	  brain	  Mg2+	  levels	  on	  impaired	  
synaptic	  mechanisms	  underlying	  cognitive	  aging	  
	  
Although	  a	  link	  between	  Mg2+deficiency	  and	  cellular	  
senescence	   has	   been	   proposed	   for	   the	   age-­‐
related	   deterioration	   of	   a	   large	   range	   of	  
physiological	   functions	  (Killilea	  and	  Maier,	  2008),	  
a	  causal	  effect	  on	  deficits	  of	  cognitive	  functions	  is	  
still	   questioned.	   Even	   aging	   is	   thought	   of	   as	   a	  
general	  risk	  factor	  for	  Mg2+	  deficit	  (Durlach	  et	  al.,	  
1993;	   Wakimoto	   and	   Block,	   2001).	   In	   fact,	  
Mg2+concentrations	   determined	   in	   various	   brain	  
structures	  only	  slightly	  decrease	   in	  healthy	  aging	  
(Morita	   et	   al.,	   2001;	   Takahashi	   et	   al.,	   2001).	  
However,	   since	  even	  a	   very	   small	  disturbance	  of	  
[Mg2+]e	   is	   able	   to	   substantially	   modify	   synaptic	  
assemblies	  supporting	  cognitive	  performances	  as	  
reported	   above,	   it	   may	   be	   postulated	   that	   age-­‐
related	  changes	  in	  Mg2+	  levels,	  even	  of	  very	  weak	  
amplitude,	   could	   contribute	   to	   the	   physio-­‐
pathology	  of	  cognitive	  aging.	  	  
	  
Regarding	  the	  regulation	  of	  transmitter	  release	  at	  
presynaptic	   terminals,	   the	   increase	   in	   basal	  
release	   of	   glutamate	   determined	   in	   the	   brain	   of	  
aged	   rats	   and	   monkeys	   in	   vivo	   (Massieu	   and	  
Tapia,	   1997;	   Quintero	   et	   al.,	   2007)	   suggests	   a	  
possible	   role	   for	   Mg2+.	   According	   to	   this	  
postulate,	   spontaneous	   miniature	   end-­‐plate	  
potentials	   increase	   in	   amplitude	   at	   neuro-­‐
muscular	  junctions	  in	  aging,	  that	  has	  been	  shown	  
to	   reflect	  an	   impaired	   regulation	  of	   transmission	  
release	   by	   Mg2+	   (Kelly	   and	   Robbins,	   1983).	  
Nevertheless,	   whether	   a	   similar	   effect	   of	   Mg2+	  
also	  occurs	  at	  central	  synapses	  still	  remains	  to	  be	  
demonstrated.	  
	  
Age-­‐related	   decrease	   in	   neuronal	   excitability	   is	  
well	   documented,	   indicating	   that	   the	   amplitude	  
and	   duration	   of	   AHPs	   are	   enhanced	   with	   age	  
(Disterhoft	   and	   Oh,	   2006;	   Disterhoft	   and	   Oh,	  
2007;	   Power	   et	   al.,	   2002;	   Thibault	   et	   al.,	   2007).	  
AHP	   amplitude	   inversely	   correlates	   with	   both	  
acquisition	   and	   probe	   performance	   in	   learning	  
behaviours	   among	   aged	   animals	   (Tombaugh	   et	  
al.,	   2005)	   and	   pharmacological	   treatments	   that	  
rescue	   the	   age-­‐related	   alteration	   of	   AHPs,	   also	  
minimize	  memory	  deficits	  (Oh	  et	  al.,	  1999;	  Weiss	  
et	   al.,	   2000).	   These	   data	   strongly	   suggest	   that	   a	  
decrease	   in	   neuronal	   excitability	   is	   a	   potent	  
mechanism	   contributing	   to	   the	   physiopathology	  
of	   cognitive	   aging	   (Disterhoft	   and	   Oh,	   2006).	  
Although	   the	   involvement	   of	   Mg2+	   in	   this	  
functional	   deficit	   has	   not	   yet	   been	   formally	  
demonstrated,	   some	   indirect	   experimental	   data	  
suggest	  that	  this	   is	  probably	  the	  case.	  Frequency	  
potentiation,	   which	   is	   negatively	   correlated	   to	  
AHP	  magnitude	  (Thibault	  et	  al.,	  2001),	  is	  reduced	  
by	   age	   (Diana	   et	   al.,	   1994;	   Landfield	   and	   Lynch,	  
1977;	  Landfield	  et	  al.,	  1986;	  Thibault	  et	  al.,	  2001)	  
and	   this	   alteration	   is	   prevented	   by	   elevating	  
[Mg2+]e	  (Landfield	  and	  Morgan,	  1984;	  Landfield	  et	  
al.,	   1986).	   From	   these	   results,	   it	   may	   be	  
hypothesized	   that	   the	   age-­‐related	   facilitation	   of	  
Ca2+	  conductances	  supporting	  the	  increase	  in	  AHPs	  
is	   not	   only	   due	   to	   a	   greater	   density	   of	   Ca2+	  
channels	   on	   neuronal	   membranes	   (Campbell	   et	  
al.,	   1996;	   Thibault	   and	   Landfield,	   1996;	   Thibault	  
et	   al.,	   2001;	  Veng	   et	   al.,	   2003)	  but	   also	   to	   some	  
extent,	  to	  a	  weaker	  competition	  between	  cations	  
following	  Mg2+	  depletion.	  	  
	  
Regarding	  the	  expression	  of	   long-­‐lasting	  synaptic	  
plasticity,	   extensive	   electrophysiological	   studies	  
report	  age-­‐related	  deficits	  of	  both	  LTP	  and	  LTD	  in	  
aged	   memory-­‐impaired	   animals	   that	   reflects	   a	  
shift	   in	   Ca2+	   sources,	   with	   a	   weaker	   role	   for	  
NMDA-­‐R,	  and	  an	  increased	  contribution	  of	  voltage-­‐
gated	  Ca2+	   channels	   and	   intracellular	   stores	  with	  
different	   kinetic	   properties	   (Foster	   and	   Kumar,	  
2002;	   Gant	   et	   al.,	   2006;	   Junjaud	   et	   al.,	   2006;	  
Kumar	   and	   Foster,	   2005;	   Shankar	   et	   al.,	   1998;	  
Thibault	   et	   al.,	   2007).	   NMDA-­‐R	   activation	   is	  
impaired	   in	   aged	   animals	   (Barnes	   et	   al.,	   1997;	  
Burke	   and	   Barnes,	   2010;	   Clayton	   et	   al.,	   2002;	  
Eckles-­‐Smith	   et	   al.,	   2000;	   Fontan-­‐Lozano	   et	   al.,	  
2007;	  Kollen	  et	  al.,	  2010;	  Magnusson,	  1998;	  Ontl	  
et	  al.,	  2004;	  Potier	  et	  al.,	  2000),	  not	  because	  of	  a	  
reduced	  receptor	  density	  but	  rather	  to	  changes	  in	  
pharmacological	   properties	   of	   the	   glutamatergic	  
receptor	   (Billard	   and	   Rouaud,	   2007;	   Junjaud	   et	  
al.,	  2006;	  Kollen	  et	  al.,	  2010;	  Kuehl-­‐Kovarik	  et	  al.,	  
2003;	   Mothet	   et	   al.,	   2006;	   Turpin	   et	   al.,	   2009).	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Among	   the	   possible	   mechanisms	   affecting	  
NMDA-­‐R	   activation	   in	   aging,	   a	   role	   for	  Mg2+	   has	  
been	   evaluated.	   No	   significant	   alteration	   of	  
NMDA-­‐R	   susceptibility	   to	  Mg2+	   block	  occurs	  during	  
aging	   since	   the	   percent	   decrease	   in	   NMDA-­‐R-­‐
mediated	   synaptic	   potentials	   is	   comparable	   in	  
young	   and	   aged	   animals	   after	   transient	   [Mg2+]e	  
elevation	  (Barnes	  et	  al.,	  1997;	  Potier	  et	  al.,	  2000).	  
Also	   altering	   [Mg2+]e	   affects	   NMDA-­‐R-­‐dependent	  
LTP	  as	  well	   as	   short-­‐term	  potentiation	   (STP)	   in	  a	  
similar	   way	   in	   the	   two	   groups	   of	   animals	  
indicating	  that	  a	  change	  in	  Mg2+	  block	  of	  NMDA-­‐R	  
is	   unlikely	   to	   contribute	   to	   the	   age-­‐related	  
impairment	   of	   synaptic	   plasticity	   (Potier	   et	   al.,	  
2000).	   However,	   a	   role	   for	   Mg2+	   in	   LTP	   deficits	  
occurring	  in	  aged	  animals	  does	  not	  definitively	  be	  
discarded.	   For	   instance,	   a	   weaker	   activation	   of	  
NMDA-­‐R	   by	   its	   co-­‐agonist	   D-­‐serine	   has	   been	  
shown	   to	   underlie	   LTP	   impairment	   in	   aged	  
rodents,	  that	  is	  due	  to	  a	  weaker	  production	  of	  the	  
amino	   acid	   by	   its	   synthesizing	   enzyme	   serine	  
racemase	  (SR)	  (Junjaud	  et	  al.,	  2006;	  Mothet	  et	  al.,	  
2006;	   Potier	   et	   al.,	   2010;	   Turpin	   et	   al.,	   2009).	  
Because	   SR	   activity	   is	   potently	   stimulated	   by	  
Mg2+,	   which	   increases	   5-­‐	   to	   10-­‐fold	   the	   rate	   of	  
racemization	   of	   L-­‐	   to	   D-­‐serine,	   an	   impaired	  
activation	   of	   SR	   by	   Mg2+	   may	   therefore	   be	  
possibly	  regarded	  as	  a	  potent	  mechanism	   linking	  
lower	   brain	   Mg2+	   levels	   to	   deficits	   of	   NMDA-­‐R	  
activation	  and	  related	  synaptic	  plasticity	  in	  aging.	  
	  
Regarding	   the	  effects	  of	   long-­‐lasting	  elevation	  of	  
[Mg2+]e,	   functional	   improvements	   also	   occur	   at	  
synapses	  of	  the	  aging	  brain	  (Slutsky	  et	  al.,	  2010).	  
The	  density	  of	  synaptophysin-­‐	  and	  synaptobrevin-­‐
immunostained	   puncta	   is	   decreased	   in	   the	  
hippocampal	   dentate	   gyrus	   of	   aged	   animals	  
whereas	  synaptic	  loss	  in	  the	  stratum	  radiatum	  of	  
CA1	  subfield	  is	  less	  pronounced	  and	  even	  remains	  
controversial	  (Burke	  and	  Barnes,	  2006;	  Geinisman	  
et	  al.,	  2004;	  Smith	  et	  al.,	  2000).	  However,	  in	  aged	  
Mg2+-­‐T	   treated	   rats,	   the	   number	   of	   functional	  
synaptic	   connections	   is	   significantly	   increased	   in	  
both	  hippocampal	  areas	  compared	  to	  aged	  controls	  
(Slutsky	   et	   al.,	   2010).	   As	   in	   young	   animals,	   a	  
treatment	   with	   Mg2+-­‐T	   also	   up-­‐regulates	   NR2B-­‐
containing	   NMDA-­‐R,	   thus	   improving	   LTP	  
expression	  in	  slices	  from	  aged	  animals	  (Slutsky	  et	  
al.,	   2010).	   Interestingly,	   both	   the	   increase	   in	  
functional	   synaptic	   connections	   and	   the	  
facilitated	   induction	  of	   synaptic	   plasticity	   (Figure	  
2A)	   (see	   (Slutsky	   et	   al.,	   2010)).	   In	   addition,	   it	   is	  
worth	  noting	  in	  these	  aged	  treated	  animals	  that	  	  
	  
	  
Figure	  2.	  Elevation	  of	  brain	  Mg2	   levels	  by	  Mg2+-­‐T	  
improves	  memory	   in	   aged	   rats.	   (A).	  Mg2+-­‐T	   aged	  
treated	   rats	   show	   shorter	   escape	   time	   in	   the	  
water	   maze	   task	   indicating	   faster	   learning.	   (B).	  
Time	   course	   of	   the	   reversible	   benefit	   effect	   of	  
Mg2+-­‐T	   treatment	   on	   spatial	   working	  memory	   in	  
aged	  rats.	  Modified	  from	  (Slutsky	  et	  al.,	  2010).	  	  
	  
	  
the	   control	   level	   after	   the	   end	   of	   Mg2+-­‐T	  
supplementation	   and	   the	   time	   course	   of	   this	  
decrease	   matches	   that	   of	   the	   reinstallation	   of	  
impairment	  in	  memory	  scores	  (Figure	  2B).	  
	  
Other	   possible	   routes	   involving	   brain	   Mg2+	   in	  
cognitive	  aging	  
	  
The	  basal	  forebrain	  cholinergic	  complex	  including	  
the	  medial	  septum/diagonal	  band,	  the	  substantia	  
innominata,	   and	   the	   nucleus	   basalis	   of	  Meynert	  
of	   Broca,	   represents	   a	   second	   major	   excitatory	  
pathway	  of	  the	  CNS	  (Dutar	  et	  al.,	  1995;	  McKinney	  
et	   al.,	   1983;	   Mesulam	   et	   al.,	   1983;	   Mesulam	   et	  
al.,	  1984;	  Woolf	  et	  al.,	  1984).	  During	  the	  past	  fifty	  
years,	  many	  experiments	  were	  directed	  at	  testing	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whether	   this	   cholinergic	   pathway	   is	   involved	   in	  
aspects	   of	   cognition	   and	   a	   significant	   role	   in	  
learning	   and	   memory	   has	   been	   firmly	   debated	  
(see	   (McKinney	   and	   Jacksonville,	   2005)	   for	   a	  
review).	   Electrically-­‐induced	   release	   of	   acetyl-­‐
choline	   generates	   slow	   and	   long-­‐lasting	  
excitatory	   postsynaptic	   potentials	   involving	   the	  
activation	   of	   muscarinic	   receptors	   (Dutar	   and	  
Nicoll,	   1988;	   Misgeld	   et	   al.,	   1989;	   Muller	   and	  
Misgeld,	   1986).	   These	   responses	   are	   impaired	   in	  
aging	  (Lippa	  et	  al.,	  1985;	  Potier	  et	  al.,	  1993;	  Segal,	  
1982;	  Shen	  and	  Barnes,	  1996;	  Taylor	  and	  Griffith,	  
1993),	   that	   reflects	   a	   decreased	   transmitter	  
release	   from	  cholinergic	   terminals	   (Aubert	  et	  al.,	  
1995;	   Birthelmer	   et	   al.,	   2003;	   Scali	   et	   al.,	   1994;	  
Takei	  et	  al.,	  1989;	  Vannucchi	  et	  al.,	  1997)	  but	  also	  
a	   weaker	   activation	   of	   postsynaptic	   receptors	  
(Calhoun	  et	  al.,	  2004;	  Lippa	  et	  al.,	  1985;	  Potier	  et	  
al.,	   1992;	   Potier	   et	   al.,	   1993;	   Segal,	   1982;	  
Vannucchi	   et	   al.,	   1997).	   However,	   it	   is	   worth	  
noting	   that	   the	   degree	   of	   memory	   deficit	   does	  
not	   appear	   to	   closely	   correlate	   with	   changes	   in	  
cholinergic	  synaptic	  activity	  (Calhoun	  et	  al.,	  2004;	  
Potier	   et	   al.,	   1993;	   Shen	   and	   Barnes,	   1996),	  
suggesting	   that	   acetylcholine	   should	   not	   play	   a	  
critical	  role	  in	  cognitive	  aging	  as	  initially	  proposed	  
(Bartus	   et	   al.,	   1982;	   Bartus	   et	   al.,	   1985;	   Pepeu,	  
1988).	  
	  
In	   addition	   to	   reducing	   acetylcholine	   release	  
(Jope,	   1981;	   Vickroy	   and	   Schneider,	   1991),	  Mg2+	  
also	   acts	   on	   postsynaptic	   muscarinic	   receptors	  
through	   several	   distinct	  mechanisms.	   First,	  Mg2+	  
is	  able	   to	  bind	  to	   the	  allosteric	   region	  of	   the	  M2	  
subtype	   of	   receptors,	   decreasing	   the	   inhibitory	  
effects	  of	  some	  modulators	  on	  the	  dissociation	  of	  
orthosteric	   ligands	   (Burgmer	   et	   al.,	   1998).	  
Second,	   Mg2+	   reduces	   a	   non-­‐selective	   cationic	  
conductance	   activated	   by	   muscarinic	   agonists
(Guerineau	  et	  al.,	  1995),	  and,	  finally,	  the	  cation	  is	  
necessary	   for	   activating	   G-­‐proteins	   coupled	   to	  
muscarinic	  receptors	  (Cladman	  and	  Chidiac,	  2002;	  
Shiozaki	   and	   Haga,	   1992;	   Zhang	   et	   al.,	   2004).	  
Regarding	   these	   multiple	   interactions,	   it	   is	  
obvious	   that	   changes	   in	  Mg2+	   levels	   are	   likely	   to	  
contribute	   to	   the	   alteration	   of	   cholinergic	  
neurotransmission	  that	  occurs	  in	  aging.	  Although	  
direct	  evidence	  is	  still	  lacking,	  several	  data	  of	  the	  
literature	  argue	  for	  the	  possibility	  that	  changes	  in	  
brain	  Mg2+	  may	  contribute	   to	   the	  age-­‐associated	  
impairment	   of	   acetylcholine-­‐dependent	   synaptic	  
activity.	   For	   instance,	   hypomagnesia	   significantly	  
weakens	   responses	   of	   cortical	   neurons	   to	   ion-­‐
tophoretically	   applied	   acetylcholine	   (El-­‐Beheiry	  
and	  Puil,	   1990)	  while	   the	  high-­‐affinity	  binding	  at	  
the	  muscarinic	   receptor	   in	  Alzheimer’s	  disease	   is	  
closely	  regulated	  by	  Mg2+	  (Ladner	  and	  Lee,	  1999).	  
Conclusion	  
	  
Although	   it	   is	  obvious	   that	  additional	  studies	  are	  
necessary	  to	  unravel	  the	  mechanisms	  connecting	  
brain	   Mg2+	   homeostasis	   and	   cognitive	   aging,	  
experimental	  data	  has	  progressively	  accumulated	  
showing	   that	   even	   moderate	   changes	   in	   the	  
concentration	   of	   the	   mineral	   are	   able	   to	  
significantly	  affect	  the	  assembly	  and	  functionality	  
of	   neuronal	   networks	   involved	   in	   cognition.	  
Recently,	  the	  World	  Health	  Organization	  reached	  
consensus	   that	   in	   a	   majority	   of	   the	   world's	  
population,	  the	  dietary	  Mg2+	   intake	  is	   lower	  than	  
recommended,	  especially	  in	  the	  aging	  population	  
(see	  also	  (Ford	  and	  Mokdad,	  2003;	  Galan,	  1997).	  
Based	   on	   the	   results	   summarized	   in	   the	   present	  
review,	   there	   is	   no	   doubt	   that	   elevating	   Mg2+	  
levels	  in	  the	  brain	  of	  the	  elderly	  could	  represent	  a	  
promising	   strategy	   to	   minimize	   or	   even	   prevent	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The	  old	   saying	  “you	  are	  what	  you	  eat”	   is	  becoming	   increasingly	   important	   in	   the	   field	  of	  neuroscience	  
these	   days.	   There	   is	  mounting	   evidence	   that	   nutritional	   factors	   are	   beginning	   to	   play	   a	  major	   role	   in	  
cognitive	   status,	   or	   cognitive	  wellbeing.	  One	  of	   these	  emerging	   factors	   is	  magnesium	   (Mg2+).	  Although	  
the	  physiological	  investigation	  of	  Mg2+	  has	  a	  long	  history,	  its	  role	  in	  cognitive	  function	  is	  just	  starting	  to	  
emerge.	  The	  focus	  of	  this	  chapter	  is	  to	  review	  the	  available	  literature	  on	  the	  effects	  of	  Mg2+	  on	  cognitive	  
function	   in	   the	   healthy	   and	   diseased/injured	   brain.	   In	   addition,	   data	   from	   our	   laboratory	   will	   be	  
presented	   that	   has	   investigated	   the	   effects	   of	   Mg2+	   manipulation	   on	   learning	   and	   memory	   tasks	   in	  




The	  purpose	  of	  this	  chapter	  is	  to	  provide	  a	  review	  
of	   the	   literature	  on	   the	   role	  of	  Mg2+	   in	   cognitive	  
function.	   Although	   the	   research	   on	   this	   topic	   is	  
generally	   sparse,	   there	   is	   an	   accumulating	   body	  
of	   evidence	   suggesting	   that	   Mg2+	   is	   vitally	  
important.	   The	   role	   that	   micronutrients	   play	   in	  
maintaining	   and	   promoting	   cognitive	   ability	   and	  
neural	   plasticity	   has	   started	   to	   receive	   a	   good	  
deal	  of	  attention.	  A	  recent	  paper	  has	  provided	  an	  
excellent	   review	   on	   how	   various	   nutrients	  
promote	   cognitive	   performance	   and	   neural	  
plasticity	   (Gómez-­‐Pinilla,	   2008).	   Although	   this	  
review	   does	   not	   specifically	   discuss	   the	   role	   of	  
Mg2+,	  it	  is	  clear	  that	  this	  is	  a	  rapidly	  evolving	  area	  
of	   research.	   Another	   review	   does	   address	   the	  
role	   of	   Mg2+	   and	   its	   relationship	   with	   other	  
micronutrients	   on	   cognitive	   function	   and	  
performance.	   It	   especially	   highlights	   the	  
important	   role	   that	  Mg2+	   has	   in	   interacting	  with	  
other	   micronutrients	   (Huskisson	   	   et	   al.,	   2007).	  
Recent	  evidence	  also	  suggests	  that	  Mg2+	  plays	  an	  
important	   role	   in	   age-­‐related	   deficits	   in	  
neurotransmitter	   release,	   neuronal	   excitability	  
and	   synaptic	   plasticity	   related	   to	   cognition	  
(Billard,	  2006),	  and	  these	  topics	  will	  be	  reviewed	  
in	  Chapter	  6.	  
	  
Additionally,	   there	   is	   ample	   evidence	   that	   Mg2+	  
plays	  an	  important	  role	  in	  the	  pathophysiological	  
processes	   following	   traumatic	   brain	   injury	   (TBI)	  
and	   that	   Mg2+	   therapy	   is	   effective	   in	   promoting	  
functional	  recovery	  in	  a	  variety	  of	  animal	  models	  
(Hoane	   and	   Barth,	   2001;	   Hoane,	   2004;	   Sen	   and	  
Gulati,	  2010;	  van	  den	  Heuvel	  and	  Vink,	  2004;	  Vink	  	  
et	   al.,	   2009).	   Specifically,	   this	   chapter	   will	   focus	  
on	  reviewing	  the	  literature	  on	  Mg2+	  and	  cognitive	  
function	  and	  review	  a	  series	  of	  studies	  conducted	  
in	   our	   laboratory	   that	   have	   investigated	   the	  
ability	  of	  Mg2+	  therapy	  to	  alter	  cognitive	  function	  
and	  to	  improve	  cognitive	  recovery	  following	  focal	  
and	  traumatic	  brain	  injuries	  in	  the	  rat.	  	  
	  
Introduction	  to	  rodent	  cognitive	  assessment	  
	  
The	  Morris	  water	  maze	  (MWM)	  is	  a	  standard	  task	  
for	   measuring	   cognitive/spatial	   performance	   in	  
rodents.	  This	   task	  uses	  a	  water-­‐filled	  tank	  with	  a	  
submerged	   escape	   platform	   and	   many	   different	  
aspects	   of	   memory	   can	   be	   assessed	   (Hoane	   	   et	  
al.,	   2003;	   Hoane,	   2005;	   Hoane	   	   et	   al.,	   2009;	  
Kaufman	   	  et	  al.,	  2010;	  Lindner,	  1997;	  Lindner	   	  et	  
al.,	   1998;	   Quigley	   	   et	   al.,	   2009).	   Briefly,	   a	  
reference	  memory	  trial	  consists	  of	  placing	  the	  rat	  
into	  the	  water	  at	  one	  of	  4	  randomly	  chosen	  start	  
locations.	   A	   computer-­‐assisted	   video	   tracking	  
system	  is	  used	  to	  measure	  the	  swim	  latency	  and	  
distance	   to	   the	   submerged	   escape	   platform.	   On	  
trials	   designed	   to	  measure	  working	  memory	   the	  
escape	  platform	  is	  relocated	  to	  a	  new	  position	  in	  
the	   tank	   every	   day.	   The	   first	   trial	   (in	   the	   new	  
location)	   is	   considered	   an	   information	   trial	   and	  
the	   subsequent	   3	   trials	   are	   test	   trials	   and	   are	  
averaged	   to	   form	   the	   dependent	   variable.	  
Additional	   paradigms	   can	   be	   used	   that	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incorporate	   various	   mazes	   or	   dividers	   that	   are	  
placed	  into	  the	  tank	  that	  can	  test	  other	  aspects	  of	  
learning	  and	  memory	  in	  the	  rodent.	  	  
	  
Additionally,	   the	   Barnes	   spatial	   maze,	   a	   dry	  
version	  of	   the	  MWM,	  can	  also	  be	  used	  to	  assess	  
cognitive/spatial	  performance	  (Vink	  	  et	  al.,	  2003).	  
Rats	   are	   placed	   on	   an	   elevated	   1.2	   m	   circular	  
tabletop	  with	  19	  holes	  cut	  around	  the	  periphery.	  
The	  rat	   learns	  the	  location	  of	  the	  hole	  that	   leads	  
to	   an	   escape	   tunnel.	   The	   latency	   to	   find	   the	  
correct	  hole	   is	   then	  analysed.	  Operant	  chambers	  
(Skinner	  boxes)	   can	  be	  used	   to	  assess	   appetitive	  
conditioning	   of	   learning	   ratios	   under	   various	  
conditions.	   In	   general,	   rats	   are	   shaped	   to	   bar-­‐
press	   for	   a	   reinforcer	   and	   then	   are	   shifted	   to	  
more	  complicated	  reward	  paradigms.	  Thus,	  there	  
are	   many	   ways	   in	   which	   rodent	   cognitive	  
assessments	   can	   be	   made	   and	   many	   of	   these	  
have	  been	  utilized	  to	  examine	  the	  role	  of	  Mg2+	  in	  
cognition.	  
	  
Role	  of	  Mg2+	  in	  health	  and	  cognition	  
	  
The	   importance	   of	   Mg2+	   in	   normal	   cellular	  
functioning	  has	  been	  well	  documented,	  as	  has	  its	  
importance	   in	   the	   pathophysiology	   following	  
injury.	   Previously,	   several	   reviews	   have	   been	  
written	   that	   address	   these	   issues	   (Hoane	   and	  
Barth,	   2001;	   Hoane,	   2004;	   van	   den	   Heuvel	   and	  
Vink,	   2004)	   so	   only	   a	   brief	   synopsis	   will	   be	  
provided	   in	   this	   paper.	  Mg2+	   is	   involved	   in	  many	  
critical	   cellular	   processes	   including	   cellular	  
respiration,	  protein	  synthesis,	  membrane	  stability	  
and	  regulation	  of	  vascular	   tone.	  A	  more	  detailed	  
discussion	  on	  the	  physiology	  of	  Mg2+	  is	  presented	  
in	  several	  chapters	  within	  Section	  1	  of	  this	  book.	  	  
	  
Although	   the	   main	   focus	   of	   this	   chapter	   is	   on	  
animal	   models,	   there	   are	   some	   interesting	  
human	   studies	   that	   have	   examined	   the	   role	   of	  
Mg2+	  in	  cognitive	  ability.	  A	  recent	  study	  examined	  
the	   correlation	   between	   levels	   of	   several	   trace	  
minerals	   (iron,	  Mg2+,	   potassium	   and	   zinc)	   in	   the	  
hair	   of	   adolescent	   girls	   and	   their	   academic	  
record.	   Although	   care	   must	   be	   taken	   with	   the	  
interpretation	   of	   correlational	   studies	   of	   this	  
nature,	   there	   was	   evidence	   that	   some	   trace	  
minerals	   correlated	   more	   highly	   with	   increased	  
academic	  performance.	  Specifically,	   it	  was	   found	  
that	   Mg2+	   and	   zinc	   demonstrated	   a	   strong	  
positive	   correlation	   with	   academic	   performance	  
(Wang	   	  et	  al.,	  2008).	  Furthermore,	  a	   recent	  case	  
report	   of	   a	   patient	   presenting	   with	   anorexia	  
nervosa	   and	   Wernicke-­‐Korsakoff	   syndrome	   was	  
found	   to	   have	   a	   low	   serum	  Mg2+	   level	   (Saad	   	   et	  
al.,	   2010).	   Although	   the	   main	   cause	   of	   this	  
condition	   was	   thiamine	   deficiency,	   a	   major	  
adjunct	   factor	   was	   believed	   to	   be	   Mg2+	  
deficiency.	   The	   results	   from	   this	   case	   study	   are	  
supported	   by	   a	   review	   article	   on	  micronutrients	  
and	  cognitive	  performance	  that	  details	  the	   inter-­‐
relationships	   between	   Mg2+	   and	   other	  
micronutrients	  such	  as	   the	  B-­‐group	  vitamins	  and	  
how	   deficiencies	   in	   these	   nutrients	   interact	   to	  
produce	   cognitive	   deficits	   (Huskisson	   	   et	   al.,	  
2007).	  Thus,	  there	  is	  an	  expanding	  literature	  that	  
suggests	  that	  Mg2+	  status	  plays	  an	  important	  role	  
in	  cognitive	  performance.	  
	  
A	   unique	   condition	   in	   which	   Mg2+	   has	   been	  
implicated	   is	   TBI.	  McIntosh	   and	   colleagues	   have	  
shown	   that	   Mg2+	   homeostasis	   is	   disrupted	  
following	  CNS	  injury	  (McIntosh	   	  et	  al.,	  1988;	  Vink	  	  
et	   al.,	   1988).	   Fluid	   percussion	   injury	   (FPI)	  
produced	  a	  rapid	  and	  severe	  decline	  in	  intra-­‐	  and	  
extracellular	   Mg2+	   levels,	   which	   correlated	  
significantly	  with	   the	   severity	   of	   the	   behavioural	  
deficits	   observed	   following	   injury	   (McIntosh	   	   et	  
al.,	  1988;	  Vink	   	  et	  al.,	  1988).	  Additional	   research	  
on	  the	  role	  of	  Mg2+	  and	  neurological	  diseases	  will	  
be	  presented	  in	  Section	  2	  of	  this	  book,	  while	  Mg2+	  
in	   cognitive	   function	   following	   TBI	   is	   addressed	  
later	   in	   this	   chapter.	   These	   findings	   suggest	   that	  
Mg2+	   plays	   an	   important	   role	   in	   normal	  
physiology	   and	   in	   the	   pathophysiological	   events	  
that	  occur	  following	  injury	  to	  the	  nervous	  system.	  	  
	  
Recent	  laboratory	  data	  
	  
Mg2+	  therapy	  and	  learning	  
From	   a	   purely	   pharmacological	   standpoint,	  
administration	   of	  Mg2+	   immediately	   prior	   to	   the	  
acquisition	   of	   a	   learning	   task	   should	   have	   a	  
detrimental	   effect	   on	   that	   task	   given	   the	   non-­‐
competitive	  antagonistic	  properties	  of	  Mg2+	  at	  the	  
NMDA	   receptor.	   It	   has	   been	   shown	   that	  
administration	   of	   other	   NMDA	   antagonists	   such	  
as	  MK-­‐801	  and	  PCP	  have	  been	   shown	   to	  disrupt	  
spatial	   learning	   in	   rodents	   (Kesner	   	   et	   al.,	   1993;	  
McLamb	   	  et	  al.,	  1990;	  Murray	  and	  Ridley,	  1997);	  
however,	  in	  some	  cases	  a	  facilitative	  effect	  can	  be	  
shown	   (Pussinen	   and	   Sirvio,	   1999).	   In	   order	   to	  
examine	   the	   biological	   activity	   of	   Mg2+	  
administration	   on	   the	   acquisition	   of	   learning,	   a	  
MgCl2	  solution	  was	  administered	  (1	  mmol/kg	  or	  2	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mmol/kg,	  i.p.)	  prior	  to	  the	  acquisition	  of	  learning	  
a	   reference	   memory	   task	   in	   the	   MWM	   (Hoane,	  
2007).	   Intact	   rats	   received	   daily	   injections	   of	  
MgCl2,	   30	   min	   prior	   to	   the	   start	   of	   their	   MWM	  
session	   and	   were	   tested	   for	   5	   consecutive	   days	  
for	  4	  trials	  per	  day	  with	  an	  intertrial	   interval	  (ITI)	  
of	   15	   min.	   The	   reference	   memory	   acquisition	  
paradigm	   was	   used	   in	   the	   MWM.	   In	   this	  
paradigm,	  the	  submerged	  escape	  platform	  stayed	  
in	   the	   same	   location	   for	   every	   trial	   and	   the	  
animals	   were	   released	   from	   1	   of	   4	   different	  
starting	   points	   in	   the	   maze.	   As	   can	   be	   seen	   in	  
Figure	   1,	   the	   vehicle-­‐treated	   (0.9%	   saline,	   i.p.)	  
group	   showed	   steady	   acquisition	   of	   the	   task.	   In	  
comparison,	  the	  MgCl2-­‐treated	  animals	  showed	  a	  
more	   varied	   response.	   The	   initial	   acquisition	   of	  
the	  2	  mmol	  group	  was	  slightly	  lengthened	  on	  day	  
1	  compared	  to	  the	  other	  groups.	  On	  day	  4,	  both	  
groups	  of	  MgCl2-­‐treated	  animals	  started	  to	  show	  
a	  lengthening	  of	  their	  escape	  latencies	  compared	  
to	  vehicle-­‐treated	  animals.	  On	  the	  last	  2	  test	  days	  
the	  comparison	  of	  swim	  latencies	  between	  the	  2	  
mmol	  and	  saline	  group	  was	  significantly	  different	  
(p	   <	   0.01)	   indicating	   a	   possible	   learning	   impair-­‐
ment	  on	  the	  task.	  	  
	  
Thus,	  it	  appears	  that	  daily	  dosing	  with	  the	  higher	  
dose	   of	   MgCl2	   produced	   a	   significant	   degree	   of	  
amnesia	  after	  3	  days.	  Unfortunately,	   testing	  was	  
terminated	   after	   5	   days	   so	   it	   is	   unknown	   if	   this	  
effect	   would	   have	   persisted	   or	   worsened	   with	  
additional	   testing.	   It	   should	   be	   noted	   that,	   in	  
general,	   the	  NMDA	  antagonists	   that	  work	  at	   the	  
PCP	  site	  on	  the	  NMDA	  receptor	  (i.e.,	  MK-­‐801	  and	  
PCP)	  seem	  to	  have	  a	  greater	  amnesic	  effect	  than	  
MgCl2.	   This	   may	   raise	   some	   concerns	   for	  
continued	   dosing	   regimens	   of	   Mg2+	   therapy	  
lasting	   more	   than	   a	   couple	   days.	   However,	   a	  
longer	  window	   of	   time	   between	   administrations	  
and	  testing	  may	  reveal	  different	  findings,	  because	  
this	   effect	   is	   perceived	   to	   be	   state	   dependent.	  
Thus,	   given	   these	   behavioural	   results	   it	   is	   clear	  
that	  systemic	  injections	  of	  MgCl2	  did	  indeed	  exert	  
behavioural	   effects	   in	   uninjured	   animals	  with	   an	  
intact	   blood-­‐brain	   barrier	   (BBB),	   and	   therefore	  
give	   support	   to	   the	   ability	   of	  MgCl2	   to	   cross	   the	  
BBB.	  This	  finding	  supports	  earlier	  research	  to	  this	  
fact	  (Hallack	  	  et	  al.,	  1992).	  
	  
We	   have	   also	   recently	   investigated	   the	   effect	   of	  
dietary	  Mg2+	  deficiency	  on	  learning	  acquisition	  in	  
the	  MWM.	  Rats	  were	  placed	  on	  either	  a	  standard	  




Figure	   1.	   The	   effects	   of	   repeated	   pre-­‐testing	  
administration	  of	  MgCl2	   (1	  or	  2	  mmol/kg)	  on	  the	  
acquisition	   of	   a	   reference	   memory	   task	   in	   the	  
MWM.	   Plotted	   are	   the	   mean	   (±	   SEM)	   swim	  
latencies	  to	  find	  the	  submerged	  escape	  platform.	  
The	  2	  mmol	  dose	  of	  MgCl2	   significantly	   impaired	  
swim	  latencies	  starting	  on	  the	  4th	  day	  of	  testing	  (*	  
=	  p	  <	  0.05).	  
	  
	  
deficient	  diet	  for	  14	  days.	  Peripheral	  blood	  collect-­‐	  
ions	  were	  performed	  for	  determination	  of	  serum	  
Mg2+	   levels	   and	   all	   animals	  were	  placed	  back	  on	  
to	  the	  standard	  diet.	  The	  serum	  analysis	  indicated	  
a	   significant	   loss	   in	   serum	  Mg2+	   in	   the	  deficiency	  
group	   (p	   <	   0.05).	   One	   week	   later,	   animals	   were	  
tested	  for	  the	  acquisition	  of	  a	  reference	  memory	  
task	  over	  4	  days	   (4	  trials	  per	  day,	  15	  min	   ITI).	  As	  
can	   be	   seen	   in	   Figure	   2A,	   the	   14	   days	   of	   Mg2+	  
deficiency	   significantly	   impaired	   the	   initial	  
acquisition	   of	   the	   task	   on	   the	   first	   day	   (p<0.05).	  
The	   animals	   were	   then	   switched	   to	   a	   more	  
challenging	   working	   memory	   assessment	   in	   the	  
MWM.	  As	   can	  be	   seen	   in	   Figure	  2B,	   the	  animals	  
that	   experienced	   Mg2+	   deficiency	   showed	  
impaired	   learning	   on	   the	   task	   (p<0.05).	  
Additionally,	   animals	   were	   trained	   to	   acquire	   a	  
fixed	  ration	  (FR-­‐10)	  schedule	  of	  reinforcement	   in	  
an	   operant	   chamber.	   The	   total	   number	   of	   bar	  
presses	  is	  shown	  in	  Figure	  2C.	  The	  higher	  number	  
of	   responses	   results	   in	   a	   greater	   number	   of	  
reinforcers	   being	   delivered	   and	   can	   be	   equated	  
to	   the	   learning	   of	   the	   reinforcement	   schedule.	  
Animals	  on	   the	  Mg2+-­‐deficient	  diet	   responded	  at	  
a	   significantly	   lower	   level	   (p<0.05)	   than	   those	  
animals	   on	   the	   Mg2+-­‐normal	   diet,	   suggesting	   a	  
learning	   impairment.	   A	   somewhat	   similar	   finding	  
has	  been	  shown	  in	  mice	  exposed	  to	  a	  Mg2+-­‐deficient	  	  




Figure	  2.	  The	  effects	  of	  dietary	  restriction	  of	  Mg2+	  on	  cognitive	  performance	  in	  the	  MWM.	  Plotted	  are	  the	  
mean	  swim	   latencies	   (±	  SEM)	  on	  the	  acquisition	  of	   reference	  memory	  task	   (A),	  working	  memory	   (B),	  and	  
the	  acquisition	  of	  a	  FR-­‐10	  reinforcement	  schedule	  in	  an	  operant	  chamber	  (C).	  A	  two-­‐week	  period	  of	  dietary	  
Mg2+	  deficiency,	  followed	  by	  reinstatement	  back	  to	  a	  Mg2+-­‐normal	  diet	  resulted	  in	  significant	  impairments	  
in	  cognitive	  performance	  on	  all	  measures	  (*	  =	  p	  <	  0.05). 	  
	  
	  
diet	  (Bardgett	  	  et	  al.,	  2005;	  Bardgett	  	  et	  al.,	  2007).	  In	  
this	  study,	  10	  days	  of	  Mg2+	  deficiency	  resulted	   in	  
impaired	   learning	   of	   a	   conditioned	   fear	   task.	  
However,	   maze	   performance	   in	   the	   MWM	   was	  
not	  impaired.	  Thus,	  these	  data	  suggest	  that	  even	  
temporary	   Mg2+	   deficiency	   may	   interfere	   with	  
learning.	  
	  
A	  newly	   formulated	   form	  of	  Mg2+,	  magnesium-­‐L-­‐
threonate	   (MgT)	   has	   been	   shown	   to	   increase	  
cerebrospinal	   fluid	   levels	   of	   Mg2+	   to	   a	   much	  
greater	  degree	  than	  other	  Mg2+	  preparations	  (e.g.	  
MgCl2)	   (Slutsky	   	   et	   al.,	   2010).	   Administration	   of	  
MgT	   has	   also	   been	   shown	   to	   result	   in	   an	  
enhancement	   of	   various	   forms	   of	   cognitive/	  
learning	   ability	   in	   rodents,	   including	   working	  
memory.	  This	  effect	  was	  also	  evident	  in	  aged	  rats	  
following	  which	  cognitive	  abilities	  were	  generally	  
reduced.	  The	  beneficial	  behavioural	  effects	  were	  
thought	   to	   be	   caused	   by	   beneficial	   changes	   in	  
synaptic	   plasticity	   within	   the	   hippocampus	  
(Slutsky	  	  et	  al.,	  2010).	  	  
	  
Effects	   of	   Mg2+	   therapy	   on	   cognitive	   function	  
following	  brain	  injury	  
Several	   studies	   have	   investigated	   the	   ability	   of	  
Mg2+	   to	   improve	   acute	   cognitive	   function	   in	  
animal	   models	   of	   TBI.	   It	   has	   been	   shown	   that	  
administration	   of	   MgCl2	   following	   FPI	   improved	  
cognitive	   outcome	   by	   reducing	   memory	   loss	  
following	   injury	   (Smith	   	   et	   al.,	   1993).	   However,	  
administration	   of	   MgCl2	   failed	   to	   improve	   the	  
acquisition	   of	   a	   reference	   memory	   task	   in	   the	  
MWM	   following	   injury	   (Bareyre	   	   et	   al.,	   1999).	   It	  
has	  also	  been	  recently	  shown	  that	  administration	  
of	   MgSO4	   (250	   μmol/kg,	   i.v.),	   30	   min	   following	  
diffuse	   axonal	   injury	   improved	   recovery	   of	   a	  
spatial	  memory	  task	  on	  the	  Barnes	  maze	  (Vink	  	  et	  
al.,	   2003).	   In	   addition,	   administration	   of	   an	  
intravenous	  solution	  of	  MgCl2	  (150	  μmol)	  prior	  to	  
FPI	   prevented	   the	   occurrence	   of	   injury-­‐induced	  
impairments	   on	   working	   and	   reference	  memory	  
tasks	  in	  a	  radial	  maze	  (Enomoto	  	  et	  al.,	  2005).	  	  
	  
There	   have	   been	   very	   few	   attempts	   to	   examine	  
the	   ability	   of	  Mg2+	   therapy	   to	   resolve	   long-­‐term	  
cognitive	  dysfunction.	  A	   recent	   study	  has	   shown	  
severe	   cognitive	   deficits	   in	   the	   acquisition	   of	   a	  
reference	  memory	  task	  in	  the	  MWM	  when	  tested	  
8	   months	   post-­‐FPI	   (Browne	   	   et	   al.,	   2004).	   The	  
administration	   of	  MgSO4	   (125	   μmol,	   i.v.)	   or	   NPS	  
1506	  (an	  NMDA	  antagonist)	  failed	  to	  improve	  the	  
acquisition	   of	   the	   reference	   memory	   task	  
compared	   to	   vehicle	   controls.	   However,	   it	   was	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found	   that	   MgSO4	   did	   reduce	   the	   amount	   of	  
ipsilateral	   hippocampal	   cell	   loss.	   Thus,	   preserv-­‐
ation	   of	   the	   hippocampus	   failed	   to	   result	   in	  
significant	  cognitive	  improvement	  (Browne	  	  et	  al.,	  
2004).	   Given	   the	   limited	   number	   of	   studies	   and	  
their	   mixed	   results,	   it	   is	   important	   to	   further	  
investigate	   the	   effect	   of	   Mg2+	   therapy	   on	   the	  
recovery	  of	  cognitive	  function	  following	  injury.	  
	  
Examination	   of	   Mg2+	   therapy	   following	   focal	  
injury	  
In	  our	   laboratory	  we	  have	  examined	   recovery	  of	  
cognitive	   function	   in	   a	   bilateral	   focal	   cortical	  
ablation	   model.	   Rats	   were	   given	   small	   (4	   mm2)	  
electrolytic	  lesions	  aimed	  at	  the	  bilateral	  anterior	  
medial	  cortex	  (bAMC)	  of	  the	  frontal	   lobe	   (Hoane	  	  
et	   al.,	   2003).	   Administration	   of	   Mg2+	   therapy	  
occurred	   15	   min	   following	   injury	   with	   rats	  
receiving	   either	   injections	   of	   MgCl2	   (1	   or	   2	  
mmol/kg,	   i.p.)	   or	   saline	   (1	   ml/kg).	   This	   regimen	  
was	   repeated	   again	   24	   and	   72	   hrs	   later,	   so	   that	  
each	   rat	   received	  3	   injections	  within	   the	   first	   72	  
hrs	   following	   injury.	  Behavioural	   testing	  began	  5	  
days	  after	   injury	  and	   included	  the	  assessment	  of	  
cognitive	   function.	   The	   MWM	   was	   used	   to	  
investigate	   the	   acquisition	   of	   reference	   and	  
working	  memory.	  In	  addition,	  the	  MWM	  tank	  was	  
also	   used	   to	   examine	   spatial	   ability	   using	   a	  
delayed	  matching-­‐to-­‐sample	   (DMTS)	   task,	   a	   very	  
sensitive	  measure	  of	  spatial	  working	  memory.	   	  
	  
As	   can	  be	   seen	   in	  Figure	  3A	  &	  3B,	   the	   results	  of	  
the	   behavioural	   testing	   indicated	   that	   bAMC	  
lesions	   produced	   severe	   deficits	   in	   cognitive	  
function	   on	   both	   the	   reference	   and	   working	  
memory	   tasks	   in	   the	   MWM.	   Mg2+	   therapy	   with	  
either	  the	  1	  or	  2	  mmol	  dose	  did	  not	  significantly	  
facilitate	   the	  acquisition	  of	   reference	  memory	   in	  
the	  MWM.	  However,	  the	  mean	  swim	  latencies	  for	  
both	   MgCl2	   groups	   were	   greatly	   improved	  
compared	   to	   saline	   in	   the	   last	   2	   blocks	   of	   trials.	  
Although	   Mg2+	   therapy	   did	   not	   demonstrate	   a	  
statistically	  significant	  improvement	  on	  reference	  
memory	  performance	  in	  the	  present	  study,	  it	  did	  
improve	   working	   memory	   performance	   in	   the	  
MWM.	   Administration	   of	   the	   2	   mmol	   dose	   of	  
MgCl2	   significantly	   reduced	   the	  working	  memory	  
deficit	  compared	  to	  saline	  treatment	  on	  the	   first	  
2	  days	  of	  testing.	  The	  1	  mmol	  dose	  of	  MgCl2	  also	  
reduced	   the	   working	   memory	   impairments	   on	  
the	  first	  day	  of	  testing	  and	  significantly	  improved	  
working	  memory	  performance	  on	  day	  2	  of	  testing.	  
Severe	   cognitive	   impairments	   were	   also	   seen	   on	  
the	   DMTS	   spatial	   memory	   test	   following	   injury.	  
The	   2	  mmol	   dose	   of	  MgCl2	   significantly	   reduced	  
the	  number	  of	  trials	  needed	  to	  reach	  the	  criterion	  
of	   80%	   correct	   choices	   compared	   to	   saline-­‐
treated	  rats,	  while	  the	  1	  mmol	  dose	  of	  MgCl2	  did	  
not,	   although	   the	   number	   of	   trials	   was	   greatly	  
reduced.	   Thus,	   Mg2+	   therapy	   was	   effective	   in	   a	  
task	  and	  dose-­‐dependent	  manner	  in	  this	  study.	  
	  
Mg2+	  therapy	  in	  the	  traumatically	  injured	  brain	  
To	  examine	  the	  ability	  of	  Mg2+	   therapy	   following	  
TBI,	  groups	  of	  rats	  were	  prepared	  with	  a	  cortical	  
contusion	   injury	   (CCI)	   or	   sham	   procedure	   and	  
then	  assigned	  to	  either	  MgCl2	  (1.0	  mmol/kg,	   i.p.)	  
or	   saline	   treatment	   conditions	   (Hoane,	   2005).	  
Mg2+	  therapy	  was	  administered	  15	  min	  and	  24	  hr	  
following	   injury.	   Rats	   were	   then	   examined	   for	  
cognitive/spatial	   performance	   in	   the	   MWM,	  
investigating	   the	   acquisition	   of	   reference	   and	  
working	   memory.	   Administration	   of	   MgCl2	  
following	   CCI	   significantly	   reduced	   some	   of	   the	  
behavioural	   impairments	   observed	   following	  
injury	   (see	   Figure	   3C	   &	   3D).	   The	   acquisition	   of	  
reference	  memory	  in	  the	  MWM	  was	  significantly	  
improved	   compared	   to	   saline-­‐treated	   rats.	   In	  
contrast,	  MgCl2	  did	  not	  improve	  working	  memory	  
performance.	  	  
	  
In	  a	   second	   study,	   the	  ability	  of	  Mg2+	   therapy	   to	  
improve	   cognitive/spatial	   performance	   following	  
unilateral	  CCI	  was	  examined.	  Groups	  of	  rats	  were	  
given	  unilateral	  CCIs	  or	  sham	  surgeries	  of	  the	  left	  
sensorimotor	   motor/frontal	   cortex.	   One	   hr	  
following	   injury,	   rats	  were	   administered	   1	  mmol	  
/kg	   MgCl2	   or	   saline.	   They	   were	   then	   tested	   for	  
their	   ability	   to	   acquire	   a	   reference	  memory	   task	  
in	  the	  MWM	  on	  4	  consecutive	  days	  (4	  trials/day)	  
starting	  11	  days	  after	  CCI.	  Their	  working	  memory	  
performance	  was	  measured	  on	  days	  16	  and	  17.	  It	  
was	   found	   that	   the	   single	   1	   mmol/kg	   dose	   of	  
MgCl2	  effectively	  facilitated	  the	  acquisition	  of	  the	  
reference	   memory	   task	   compared	   to	   treatment	  
with	  saline	  (see	  Figure	  4).	  In	  a	  similar	  manner,	  the	  
working	   memory	   performance	   was	   greatly	  
enhanced	   following	   CCI	   in	   the	  Mg2+-­‐treated	   rats	  
compared	   to	   the	   saline-­‐treated	   rats.	   In	   fact,	   the	  
working	   memory	   performance	   of	   the	   Mg2+-­‐
treated	   rats	   could	  not	  be	  distinguished	   from	   the	  
sham	  controls	  on	  either	  day	  of	  working	  memory	  
testing	   (see	  working	  memory	   graph	   in	   Figure	   4).	  
Mg2+	   treatment	  appeared	  to	  have	  prevented	  the	  
occurrence	   of	   the	   working	   memory	   deficit	  
following	  unilateral	  frontal	  injury.	  




Figure	  3.	  	  The	  effects	  of	  a	  regimen	  of	  MgCl2	  (1	  or	  2	  mmol/kg)	  administered	  following	  bAMC	  focal	  lesions	  on	  
cognitive	  performance	   in	   the	  MWM.	  Plotted	  are	   the	  mean	  swim	   latencies	   (±	  SEM)	  during	   the	  acquisition	  
phase	   of	   a	  working	  memory	   task	   (A)	   and	   the	  mean	   number	   of	   trials	   to	   criterion	   in	   the	  DMTS	   test	   (B)	   is	  
presented.	   There	   was	   a	   dose	   and	   task-­‐dependent	   effect	   on	   recovery.	   The	   2	   mmol	   dose	   provided	   the	  
greatest	   improvement	   on	  both	  measures	   of	  working	  memory	   (*	   =	   p	   <	   0.05	   comparing	   2	  mmol	  MgCl2	   to	  
saline;	  ^	  =	  p	  <	  0.05	  comparing	  1	  mmol	  MgCl2	  to	  saline).	  Adapted	  from	  Hoane	  	  et	  al.,	  (2003).	  The	  effects	  of	  a	  
regimen	  of	  MgCl2	  (1	  mmol/kg)	  administered	  15	  min	  following	  bilateral	  CCI	  of	  the	  frontal	  cortex.	  Plotted	  are	  
the	  mean	  swim	  latencies	  (+SEM)	  on	  the	  acquisition	  of	  reference	  memory	  (C)	  and	  working	  memory	  (D)	  tasks	  
in	   the	  MWM.	  Administration	  of	  MgCl2	  significantly	   improved	  the	  acquisition	  of	  a	  reference	  memory	  task,	  
but	  not	  working	  memory	  following	  CCI	  (*	  =	  p	  <	  0.05).	  Adapted	  from	  Hoane	  	  et	  al.,	  (2005).	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Figure	   4.	   The	   effects	   of	   MgCl2	   (1	   mmol/kg)	   administration	   1	   hr	   following	   unilateral	   CCI	   of	   the	  
sensorimotor/frontal	  cortex.	  Plotted	  are	  the	  mean	  swim	  latencies	  (±	  SEM)	  on	  the	  acquisition	  of	  reference	  
memory	   and	   working	   memory	   tasks	   in	   the	   MWM.	   Administration	   of	   MgCl2	   significantly	   improved	   the	  





The	  results	  of	  these	  studies	  have	  demonstrated	  a	  
wide	   range	   of	   conditions	   in	   which	  Mg2+	   therapy	  
regulates	   cognitive	   function.	   It	   was	   first	   shown	  
that	   daily	   injections	   of	   MgCl2	   administered	   30	  
mins	   prior	   to	   training	   on	   the	   task	   worsened	  
acquisition	  of	   the	  reference	  memory	  task.	   It	  was	  
also	   demonstrated	   that	   a	   two-­‐week	   regimen	   of	  
dietary	   Mg2+	   deficiency	   impaired	   learning	   on	   3	  
different	  cognitive	  tasks.	  This	  finding	  is	  especially	  
interesting	  because	  the	  animals	  had	  been	  placed	  
back	   onto	   a	   normal	   laboratory	   diet	   prior	   to	   the	  
assessment	  phase	  of	  the	  study.	  	  
	  
Mg2+	   therapy	   in	   several	   models	   of	   cortical	  
ablation	   and	   TBI	   have	   demonstrated	   positive	  
effects	   on	   cognitive	   recovery.	   However,	   these	  
effects	   occurred	   in	   a	   task	   and	   dose-­‐dependent	  
manner.	   Following	   focal	   ablation	   of	   the	   bAMC,	  
MgCl2	   improved	   working	   memory	   performance	  
on	   several	   measures	   and	   slightly	   improved	  
reference	  memory	  performance.	  The	  CCI	   studies	  
performed	   in	   our	   laboratory	   have	   shown	   that	  
MgCl2	   administration	   following	   injury	   improved	  
cognitive	   performance	   in	   a	   task-­‐dependent	  
manner.	  Previous	  studies	  that	  have	  examined	  the	  
ability	   of	   Mg2+	   therapy	   to	   improve	   cognitive	  
performance	   following	   injury	   have	   shown	  mixed	  
results.	   For	   example,	   administration	   of	   MgCl2	  
following	   FPI	   has	   been	   shown	   to	   improve	  
cognitive	   outcome	   by	   reducing	   memory	   loss	   in	  
the	  MWM	  (Smith	  et	  al.,	  1993),	  but	  administration	  
of	   MgCl2	   failed	   to	   improve	   the	   acquisition	   of	   a	  
reference	   memory	   task	   in	   the	   MWM	   following	  
injury	   (Bareyre	   	   et	   al.,	   1999).	   Thus,	   in	   a	   similar	  
manner	   the	   current	   series	   of	   studies	   has	   shown	  
similar	   mixed	   results.	   That	   is,	   significant	   effects	  
were	   seen	   in	   some	   cases	   and	   non-­‐significant	  
effects	  were	  seen	   in	  others.	  However,	   in	  general	  
we	   saw	   significant	   improvements	   in	   cognitive	  
function	   by	   MgCl2	   in	   each	   of	   our	   studies.	   The	  
discrepant	   results	   mainly	   varied	   based	   on	   dose	  
and	  task-­‐dependent	  properties	  of	  the	  studies.	  	  
	  
From	  a	  mechanistic	  standpoint,	  Mg2+	  therapy	  has	  
multiple	   routes	   by	   which	   it	   can	   disrupt	   the	  
pathophysiological	  processes	  that	  occur	  following	  
injury	   and	   enhance	   cognitive	   recovery.	   In	  
addition	   to	   offsetting	   injury-­‐induced	   Mg2+	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depletion	   (McIntosh	   	   et	   al.,	   1988;	   Vink	   	   et	   al.,	  
1988)	  and	  preventing	  excitotoxic	  neuronal	  death	  
(Nowak	   	   et	   al.,	   1984)	   mediated	   by	   the	   NMDA	  
receptor,	   Mg2+	   has	   been	   shown	   to	   have	   several	  
other	   effects.	   For	   instance,	   administration	   of	  
MgSO4	  has	  been	  shown	  to	  limit	  the	  generation	  of	  
injury-­‐induced	   edema	   following	   closed-­‐head	  
injury	   (Feldman	   	   et	   al.,	   1996)	   and	   it	   has	   been	  
more	   recently	   shown	   that	   MgSO4	   (30	   mg/kg)	  
reduced	   aquaporin-­‐4	   immunoreactivity,	   thus	  
contributing	   to	  edema	  reduction	   following	   injury	  
(Ghabriel	   	   et	   al.,	   2006).	   Administration	   of	  MgCl2	  
has	  also	  been	  shown	  to	  reduce	  the	  expression	  of	  
p53	  mRNA,	  a	  gene	  associated	  with	  the	   induction	  
of	   cell	   death,	   following	   lateral	   FPI	   (Muir	   	   et	   al.,	  
1999).	  In	  this	  study	  it	  was	  found	  that	  750	  μmol/kg	  
of	  MgCl2	  reduced	  the	  expression	  of	  p53	  mRNA	  in	  
the	   injured	   cortex	   compared	   to	   saline-­‐treated	  
controls	  (Muir	   	  et	  al.,	  1999).	  High	  concentrations	  
of	  Mg2+	   (3	  mM)	  have	  been	  shown	  to	   inhibit	   lipid	  
peroxidation	   (Regan	   	  et	   al.,	   1998).	   Regardless	   of	  
the	  mechanisms	  of	  action,	   the	  data	  presented	   in	  
this	   review	   has	   shown	   that	   MgCl2	   has	   strong	  
biological	  activity,	  appears	   to	  cross	   the	  BBB,	  and	  
can	   improve	   cognitive	   performance	   following	  




The	   studies	  presented	   in	   this	  book	   chapter	  have	  
demonstrated	  a	  wide	  range	  of	  activities	  for	  Mg2+	  
therapy	   in	   relationship	   to	   cognitive	   function	   in	  
the	  rodent.	  Daily	   injections	  of	  MgCl2	  prior	   to	   the	  
acquisition	   of	   a	   learning	   task	   blocked	   the	  
acquisition	   of	   a	   reference	   memory	   task	   and	  
dietary	  deficiency	  of	  Mg2+	  impaired	  learning	  on	  a	  
number	   of	   different	   tasks.	   Using	   the	   damaged	  
brain	   as	   a	  model	   to	   examine	   the	   ability	   of	  Mg2+	  
therapy	   to	   improve	   cognitive	   performance	   also	  
demonstrated	   significant	   advantages	   with	   the	  
therapy.	   Thus,	   it	   does	   appear	   that	   Mg2+	   status	  
and	   therapy	  have	   significant	  effects	  on	  cognitive	  
performance	   in	   the	   brain	   and	   that	   further	  
research	   is	   warranted.	   In	   addition,	   an	  
accumulating	  body	  of	  research	  suggests	  that	  Mg2+	  
also	   plays	   an	   important	   role	   in	   human	   cognitive	  
performance.	   Given	   the	   reported	   rates	   of	  
magnesium	  deficiency	   in	   humans	   it	   is	   likely	   that	  
this	   could	   impair	   cognitive	   performance	  
(Barbagallo	  and	  Dominguez,	  2010;	  Elin,	  2010).	   In	  
addition,	   the	   most	   intriguing	   factor	   related	   to	  
Mg2+	   therapy	   for	   cognitive	  wellbeing	  may	   reside	  
in	  the	  use	  of	  Mg2+	  as	  a	  co-­‐therapy	  with	  other	  vital	  







A	  special	  thanks	  is	  given	  to	  Alicia	  Swan	  for	  critical	  
reading	  of	  an	  earlier	  draft	  of	  this	  chapter.	  Partial	  











Barbagallo	  M,	  Dominguez	  LJ	  (2010)	  Magnesium	  and	  
aging.	  Curr	  Pharm	  Des	  16:832-­‐9.	  
	  
Bardgett	  ME,	  Schultheis	  PJ,	  McGill	  DL,	  Richmond	  RE,	  
Wagge	  JR	  (2005)	  Magnesium	  deficiency	  impairs	  fear	  
conditioning	  in	  mice.	  Brain	  Res	  1038:100-­‐6.	  
	  
Bardgett	  ME,	  Schultheis	  PJ,	  Muzny	  A,	  Riddle	  MD,	  
Wagge	  JR	  (2007)	  Magnesium	  deficiency	  reduces	  fear-­‐
induced	  conditional	  lick	  suppression	  in	  mice.	  Magnes	  
Res	  20:58-­‐65.	  
	  
Bareyre	  FM,	  Saatman	  KE,	  Helfaer	  MA,	  Sinson	  GP,	  
Weisser	  JD,	  Brown	  AL,	  McIntosh	  TK	  (1999)	  Alterations	  




experimental	  traumatic	  brain	  injury:	  Relationship	  to	  
neurobehavioral	  outcome	  and	  neuroprotective	  
efficacy	  of	  magnesium	  chloride.	  J	  Neurochem	  73:271-­‐
80.	  
	  
Billard	  JM	  (2006)	  Ageing,	  hippocampal	  synaptic	  
activity	  and	  magnesium.	  Magnes	  Res	  19:199-­‐215.	  
	  
Browne	  KD,	  Leoni	  MJ,	  Iwata	  A,	  Chen	  XH,	  Smith	  DH	  
(2004)	  Acute	  treatment	  with	  MgSO4	  attenuates	  long-­‐
term	  hippocampal	  tissue	  loss	  after	  brain	  trauma	  in	  the	  
rat.	  J	  Neurosci	  Res	  77:878-­‐83.	  
	  
Elin	  RJ	  (2010)	  Assessment	  of	  magnesium	  status	  for	  
diagnosis	  and	  therapy.	  Magnes	  Res.	  23:194-­‐8.	  
	  
Magnesium	  in	  the	  Central	  Nervous	  System	   	   Chapter	  7	  
 123	  
Enomoto	  T,	  Osugi	  T,	  Satoh	  H,	  McIntosh	  TK,	  Nabeshima	  
T	  (2005)	  Pre-­‐Injury	  magnesium	  treatment	  prevents	  
traumatic	  brain	  injury-­‐induced	  hippocampal	  ERK	  
activation,	  neuronal	  loss,	  and	  cognitive	  dysfunction	  in	  
the	  radial-­‐arm	  maze	  test.	  J	  Neurotrauma	  22:783-­‐92.	  
	  
Feldman	  Z,	  Gurevitch	  B,	  Artru	  AA,	  Oppenheim	  A,	  
Shohami	  E,	  Reichenthal	  E,	  Shapira	  Y	  (1996)	  Effect	  of	  
magnesium	  given	  1	  hour	  after	  head	  trauma	  on	  brain	  
edema	  and	  neurological	  outcome.	  J	  Neurosurg	  85:131-­‐
7.	  
	  
Ghabriel	  MN,	  Thomas	  A,	  Vink	  R	  (2006)	  Magnesium	  
restores	  altered	  aquaporin-­‐4	  immunoreactivity	  
following	  traumatic	  brain	  injury	  to	  a	  pre-­‐injury	  state.	  
Acta	  Neurochir	  Suppl	  96:402-­‐6.	  
	  
Gómez-­‐Pinilla	  F	  (2008)	  Brain	  foods:	  The	  effects	  of	  
nutrients	  on	  brain	  function.	  Nat	  Rev	  Neurosci	  9:568-­‐
78.	  
	  
Hallack	  M,	  Berman	  RF,	  Ortemkauf	  SM,	  Evans	  MI,	  
Cotton	  DB	  (1992)	  Peripheral	  magnesium	  sulfate	  enters	  
the	  brain	  and	  increases	  the	  threshold	  for	  hippocampal	  
seizures	  in	  rats.	  Am	  J	  Obstet	  Gynecol	  167,	  1605-­‐10.	  
	  
Hoane	  MR	  (2004)	  Magnesium	  therapy	  and	  recovery	  of	  
function	  in	  experimental	  models	  of	  brain	  injury	  and	  
neurodegenerative	  disease.	  Clin	  Calcium	  14:65-­‐70.	  
	  
Hoane	  MR	  (2005)	  Treatment	  with	  magnesium	  
improves	  reference	  memory	  but	  not	  working	  memory	  
while	  reducing	  GFAP	  expression	  following	  traumatic	  
brain	  injury.	  Restor	  Neurol	  Neurosci	  23:67-­‐77.	  
	  
Hoane	  MR	  (2007)	  Assessment	  of	  cognitive	  function	  
following	  magnesium	  therapy	  in	  the	  traumatically	  
injured	  brain.	  Magnes	  Res	  20:229-­‐36.	  
	  
Hoane	  MR,	  Barth	  TM	  (2001)	  The	  behavioral	  and	  
anatomical	  effects	  of	  MgCl2	  therapy	  in	  an	  electrolytic	  
lesion	  model	  of	  cortical	  injury	  in	  the	  rat.	  Magnes	  Res	  
14:51-­‐63.	  
	  
Hoane	  MR,	  Kaufman	  NA,	  Vitek	  MP,	  McKenna	  SE	  
(2009)	  COG1410	  improves	  cognitive	  performance	  and	  
reduces	  cortical	  neuronal	  loss	  in	  the	  traumatically	  
injured	  brain.	  J	  Neurotrauma	  26:1-­‐10.	  
	  
Hoane	  MR,	  Knotts	  AA,	  Akstulewicz	  SL,	  Aquilano	  M,	  
Means	  LW	  (2003)	  The	  behavioral	  effects	  of	  
magnesium	  therapy	  on	  recovery	  of	  function	  following	  
bilateral	  anterior	  medial	  cortex	  lesions	  in	  the	  rat.	  Brain	  
Res	  Bull	  60:105-­‐14.	  
	  
Hoane	  MR,	  Wolyniak	  J,	  Akstulewicz	  SL	  (2005)	  
Administration	  of	  riboflavin	  improves	  behavioral	  
outcome	  and	  reduces	  edema	  formation	  and	  GFAP	  
expression	  following	  traumatic	  brain	  injury.	  J	  
Neurotrauma	  22:1112-­‐22.	  
	  
Huskisson	  E,	  Maggini	  S,	  Ruf	  M	  (2007)	  The	  influence	  of	  
micronutrients	  on	  cognitive	  function	  and	  
performance.	  J	  Int	  Med	  Res	  35:1-­‐19.	  
	  
Kaufman	  NA,	  Beare	  JE,	  Tan	  AA,	  Vitek	  MP,	  McKenna	  SE,	  
Hoane	  MR	  (2010)	  COG1410,	  an	  apolipoprotein	  E-­‐
based	  peptide,	  improves	  cognitive	  performance	  and	  
reduces	  cortical	  loss	  following	  moderate	  fluid	  
percussion	  injury	  in	  the	  rat.	  Behav	  Brain	  Res	  214:395-­‐
401.	  
	  
Kesner	  RP,	  Dakis	  M,	  Bolland	  BL	  (1993)	  Phencyclidine	  
disrupts	  long-­‐	  but	  not	  short-­‐term	  memory	  within	  a	  
spatial	  learning	  task.	  Psychopharmacology	  111:85-­‐90.	  
	  
Lindner	  MD	  (1997)	  Reliability,	  distribution,	  and	  validity	  
of	  age-­‐related	  cognitive	  deficits	  in	  the	  Morris	  water	  
maze.	  Neurobiol	  Learn	  Mem	  68:203-­‐20.	  
	  
Lindner	  MD,	  Plone	  MA,	  Cain	  CK,	  Frydel	  BR,	  Francis	  JM,	  
Emerich	  DF,	  Sutton	  RL	  (1998)	  Dissociable	  long-­‐term	  
cognitive	  deficits	  after	  frontal	  versus	  sensorimotor	  
cortical	  contusions.	  J	  Neurotrauma	  15:199-­‐216.	  
	  
McIntosh	  TK,	  Faden	  AI,	  Yamakami	  I,	  Vink	  R	  (1988)	  
Magnesium	  deficiency	  exacerbates	  and	  pretreatment	  
improves	  outcome	  following	  traumatic	  brain	  injury	  in	  
rats:	  31P	  magnetic	  resonance	  spectroscopy	  and	  
behavioral	  studies.	  J	  Neurotrauma	  5:17-­‐31.	  
	  
McLamb	  RL,	  Williams	  LR,	  Nanry	  KP,	  Wilson	  WA,	  Tilson	  
HA	  (1990)	  MK-­‐801	  impedes	  the	  acquisition	  of	  a	  spatial	  
memory	  task	  in	  rats.	  Pharmacol	  Biochem	  Behav	  37:41-­‐
5.	  
	  
Muir	  JK,	  Raghupathi	  R,	  Emery	  DL,	  Bareyre	  FM,	  
McIntosh	  TK	  (1999)	  Postinjury	  magnesium	  treatment	  
attenuates	  traumatic	  brain	  injury-­‐induced	  cortical	  
induction	  of	  p53	  mRNA	  in	  rats.	  Exp	  Neurol	  159:584-­‐93.	  
	  
Murray	  TK,	  Ridley	  RM	  (1997)	  The	  effect	  of	  dizocilpine	  
(MK-­‐801)	  on	  conditional	  discrimination	  learning	  in	  the	  
rat.	  Behav	  Pharmacol	  8:383-­‐8.	  
	  
Nowak	  L,	  Bregestovski	  P,	  Ascher	  P,	  Herbert	  A,	  
Prochiantz	  A	  (1984)	  Magnesium	  gates	  glutamate	  
activated	  channels	  in	  mouse	  central	  neurones.	  Nature	  
307:462-­‐5.	  
	  
Pussinen	  R,	  Sirvio	  J	  (1999)	  Effects	  of	  D-­‐cycloserine,	  a	  
positive	  modulator	  of	  N-­‐methyl-­‐D-­‐aspartate	  receptors,	  
and	  ST	  587,	  a	  putative	  alpha-­‐1	  adrenergic	  agonist,	  
individually	  and	  in	  combination,	  on	  the	  non-­‐delayed	  
and	  delayed	  foraging	  behaviour	  of	  rats	  assessed	  in	  the	  
radial	  arm	  maze.	  J	  Psychopharmacol	  13:171-­‐9.	  
Mg	  and	  cognition	   	   Chapter	  7	  
 
 124	  
Quigley	  A,	  Tan	  AA,	  Hoane	  MR	  (2009)	  The	  effects	  of	  
hypertonic	  saline	  and	  nicotinamide	  on	  sensorimotor	  
and	  cognitive	  function	  following	  cortical	  contusion	  
injury	  in	  the	  rat.	  Brain	  Res	  1304:138-­‐48.	  
	  
Regan	  RF,	  Jasper	  E,	  Guo	  Y,	  Panter	  SS	  (1998)	  The	  effect	  
of	  magnesium	  on	  oxidative	  neuronal	  injury	  in	  vitro.	  J	  
Neurochem	  70:77-­‐85.	  
	  
Saad	  L,	  Silva	  L,	  Banzato	  C,	  Dantas	  C,	  Garcia	  C	  (2010)	  
Anorexia	  nervosa	  and	  Wernicke-­‐Korsakoff	  syndrome:	  
a	  case	  report.	  J	  Med	  Case	  Reports	  4:1-­‐5.	  
	  
Sen	  AP,	  Gulati	  A	  (2010)	  Use	  of	  magnesium	  in	  traumatic	  
brain	  injury.	  Neurotherapeutics	  7:91-­‐9.	  
	  
Slutsky	  I,	  Abumaria	  N,	  Wu	  LJ,	  Huang	  C,	  Zhang	  L,	  Li	  B,	  
Zhao	  X,	  Govindarajan	  A,	  Zhao	  MG,	  Zhuo	  M,	  Tonegawa	  
S,	  Liu	  G	  (2010)	  Enhancement	  of	  learning	  and	  memory	  
by	  elevating	  brain	  magnesium.	  Neuron	  65:165-­‐77.	  
	  
Smith	  DH,	  Okiyama	  K,	  Gennarelli	  TA,	  McIntosh	  TK	  
(1993)	  Magnesium	  and	  ketamine	  attenuate	  cognitive	  
dysfunction	  following	  experimental	  brain	  injury.	  







Van	  Den	  Heuvel	  C,	  Vink	  R	  (2004)	  The	  role	  of	  
magnesium	  in	  traumatic	  brain	  injury.	  Clin	  Calcium	  
14:9-­‐14.	  
	  
Vink	  R,	  Cook	  NL,	  van	  de	  Heuvel	  C	  (2009)	  Magnesium	  in	  
acute	  and	  chronic	  brain	  injury:	  an	  update.	  Magnes	  Res	  
22:158S-­‐62S.	  
	  
Vink	  R,	  McIntosh	  TK,	  Demediuk	  P,	  Weiner	  MW,	  Faden	  
AI	  (1988)	  Decline	  in	  intracellular	  free	  Mg2+	  is	  
associated	  with	  irreversible	  tissue	  injury	  after	  brain	  
trauma.	  J	  Biol	  Chem	  263:757-­‐61.	  
	  
Vink	  R,	  O'Connor	  CA,	  Nimmo	  AJ,	  Heath	  DL	  (2003)	  
Magnesium	  attenuates	  persistent	  functional	  deficits	  
following	  diffuse	  traumatic	  brain	  injury	  in	  rats.	  
Neurosci	  Lett	  336:41-­‐4.	  
	  
Wang	  C-­‐T,	  Li	  Y,	  Wang	  F-­‐J,	  Shi	  Y-­‐M,	  Lee	  B-­‐T	  (2008)	  
Correlation	  between	  iron,	  magnesium,	  potassium	  and	  
zinc	  content	  in	  adolescent	  girl's	  hair	  and	  their	  











Magnesium	  in	  the	  Central	  Nervous	  System	   	   Chapter	  8	  
 125	  
Magnesium	  in	  headache	  	  
	  
Lisa	  A.	  Yablon*	  and	  Alexander	  Mauskop 	  






Magnesium's	   role	   in	   migraine	   pathogenesis	   is	   well-­‐described,	   with	   deficiencies	   known	   to	   promote	  
cortical	  spreading	  depression,	  alter	  nociceptive	  processing	  and	  neurotransmitter	  release,	  and	  encourage	  
the	  hyperaggregation	  of	  platelets,	  all	  major	  elements	  of	  migraine	  development.	  Research	  on	  magnesium	  
has	   found	   it	   to	   be	   a	   potentially	   well-­‐tolerated,	   safe	   and	   inexpensive	   option	   for	   migraine	   prevention,	  
while	  it	  may	  also	  be	  effective	  as	  an	  acute	  treatment	  option	  for	  headaches	  including	  migraines,	  tension-­‐
type	  headaches	   and	   cluster	  headaches,	   particularly	   in	   certain	  patient	   subsets.	   This	   chapter	  will	   review	  
the	  various	  aspects	  of	  migraine	  in	  which	  magnesium	  plays	  a	  part,	  as	  well	  as	  numerous	  studies	  on	  the	  use	  
of	   magnesium	   in	   both	   headache	   prophylaxis	   and	   in	   the	   acute	   treatment	   of	   headaches,	   offering	  
recommendations	  in	  its	  use	  in	  clinical	  practice.	  
	  
Magnesium	  in	  the	  Body	  
	  
Magnesium	   (Mg),	   the	   second	   most	   abundant	  
intracellular	  divalent	  cation,	  is	  a	  cofactor	  of	  many	  
enzymes	  and	   is	   involved	   in	  a	  plethora	  of	   cellular	  
functions.	   It	   plays	   a	   central	   role	   in	   both	   glucose	  
metabolism	   and	   in	   ATP	   function.	   Over	   300	  
enzymes	  require	  the	  presence	  of	  magnesium	  ions	  
for	   their	   catalytic	   action,	   including	   all	   enzymes	  
utilizing	   or	   synthesizing	   ATP,	   or	   those	   that	   use	  
other	   nucleotides	   to	   synthesize	   DNA	   and	   RNA.	  
ATP	   exists	   in	   cells	   as	   a	   chelate	   of	   ATP	   and	   a	  
magnesium	   ion.	   Because	   of	   the	   important	  
interaction	   between	   phosphate	   and	   magnesium	  
ions,	   magnesium	   ions	   are	   essential	   to	   the	   basic	  
nucleic	   acid	   chemistry	   of	   life,	   and	   thus	   are	  
essential	  to	  all	  cells	  of	  all	  known	  living	  organisms.	  
	  
Magnesium	   is	   involved	   in	   the	   formation	   of	  
phospholipids	   and	   the	   insertion	   of	   proteins	   into	  
the	   phospholipid	   membrane,	   and	   is	   therefore	  
critical	  to	  membrane	  stabilization	  (Durlach	  et	  al.,	  
1987).	   It	   also	   contributes	   to	   contraction	   of	   the	  
cytoskeleton	  at	  the	  myoneural	  junction,	  playing	  a	  
vital	  role	   in	  the	  function	  of	  both	  skeletal,	  cardiac	  
and	  other	  smooth	  muscles.	  
	  
Magnesium	   is	   absorbed	   in	   the	   gastrointestinal	  
tract,	   via	   intestinal	   epithelial	   channels	   in	   the	  
ileum	   as	   well	   as	   by	   the	   renal	   system’s	   thick	  
ascending	   limb,	   distal	   tubule,	   and	   loop	   of	   Henle	  
of	   the	   nephron	   (Wagner,	   2007).	   It	   facilitates	  
calcium	   absorption	   via	   the	   thick	   ascending	   limb,	  
and	   the	   absorption	   of	   both	   ions	   is	   regulated	   by	  
the	  parathyroid	  hormone	  (PTH)	  secreting	  cells	  of	  
the	   parathyroid	   gland	   (Bapty	   et	   al.,	   1998).	   The	  
calcium/magnesium	   sensing	   receptor	   within	   the	  
parathyroid	   gland	   regulates	   absorption	   of	   both	  
ions	  by	  detecting	  their	  levels	  in	  ionized	  form,	  and	  
then	  controlling	  PTH	  secretion,	  thereby	  maintain-­‐
ing	   calcium	   homeostasis	   (Brown	   et	   al.,	   1993).	  
Dietarily,	  absorption	  is	  affected	  by	  protein	  intake	  
as	  well	   as	  phosphate,	  phytate	  and	   fat.	  Absorbed	  
dietary	   magnesium	   is	   largely	   excreted	   through	  
the	   urine,	   although	   most	   iatrogenically	   admin-­‐
istered	   oral	   magnesium	   is	   excreted	   through	   the	  
faeces.	  
	  
Adult	   human	   bodies	   contain	   approximately	  
24	  grams	  of	  magnesium,	  with	  67%	  located	  in	  the	  
skeleton,	   31%	   intracellularly	   (20%	   in	   skeletal	  
muscle),	   and	   only	   1-­‐2%	   extracellularly.	   Of	   this	  
amount,	  one	  half	  is	  ionized,	  and	  25-­‐30%	  is	  protein	  
bound.	  As	  a	   result,	   levels	   found	  on	   routine	   serum	  
testing,	   which	   only	   reflects	   that	   magnesium	  
found	  in	  the	  extracellular	  space,	  is	  not	  represent-­‐
ative	  of	  true	  total	  body	  magnesium	  stores	  (Moe,	  
2008).	  
	  
Serum	  levels	  are	  typically	  0.7–1.0	  mmol/L	  or	  1.8–
2.4	  mEq/L.	  Serum	  magnesium	   levels	  may	  appear	  
normal	   even	   in	   cases	   of	   underlying	   intracellular	  
deficiency,	   and	   true	   hypomagnesemia	   is	  
common,	   possibly	   due	   to	   decreased	   intake	   or	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absorption,	   increased	   loss	   via	   the	   urine	   or	  
diarrhea,	  or	  genetic	  factors	  (Henrotte,	  1982).	  	  
	  
Primary	  and	  Secondary	  Hypomagnesemia	  
	  
Familial	   hypomagnesemia	   with	   secondary	   hypo-­‐
calcemia	   has	   been	   studied	   in	   various	   kindreds,	  
and	   heredity	   has	   been	   found	   to	   be	   X	   linked	   in	  
some	  families,	  and	  autosomal	  recessive	  in	  others	  
(Walder	   et	   al.,	   1997).	   There	   are	   currently	   more	  
than	  30	  known	  mutations	  in	  the	  TRPM6	  gene	  that	  
are	  associated	  with	  familial	  hypomagnesemia	  and	  
hypocalcemia.	  Another	  hereditary	   form	  of	   hypo-­‐
magnesemia,	   tubular	   hypomagnesemia/hypo-­‐
kalemia	   with	   hypocalciuria	   (Gitelman's	   synd-­‐
rome),	  is	  hypothesized	  to	  be	  due	  to	  two	  different	  
types	   of	   genetic	   transmission,	   one	   autosomal	  
recessive	  and	  one	  autosomal	  dominant	  with	  high	  
phenotype	  variability	  (Bettinelli	  et	  al.,	  1995).	  
	  
A	   population	   study	   in	   Germany	   found	   the	  
prevalence	   of	   serum	   hypomagnesemia	   to	   be	  
14.5%,	   with	   even	   higher	   frequencies	   in	   females	  
(Schimatschek	   and	   Rempis,	   2001).	   Additionally,	  
chronic	   disease	   is	   associated	   with	   hypo-­‐
magnesemia,	   including	  diabetes,	   asthma,	   cardio-­‐
vascular	   disease,	   sickle	   cell	   anaemia,	   pre-­‐
eclampsia	  and	  eclampsia	  (Laires	  et	  al.,	  2004).	  10-­‐
20%	   of	   hospitalized	   patients	   are	   deficient	   in	  
magnesium,	   and	   up	   to	   65%	   of	   patients	   in	  
intensive	   care	   units	   are	   hypomagnesemic.	  
Alcoholism	   is	   also	   associated	   with	   inadequate	  
magnesium	   levels,	   in	   part	   due	   to	   poor	   nutrition	  
(Bohmer	  and	  Mathiesen,	   1982).	   It	   has	   also	  been	  
implicated	   in	   patients	   with	   end-­‐stage	   renal	  
disease	   suffering	   from	   hemodialysis	   headache	  
(Goksel	   et	   al.,	   2006),	   and	   is	   often	   seen	   in	  
conjunction	   with	   electrolyte	   abnormalities	  
including	   hypokalemia,	   hyponatremia,	   hypo-­‐
calcemia	   and	   hypophosphatemia	   (Whang	   et	   al.,	  
1985).	  A	  number	  of	  medications	  such	  as	  diuretics,	  
aminoglycosides	   and	  digoxin	   are	   associated	  with	  
hypomagnesemia,	   and	   patients	   with	   refractory	  
hypocalcemia	   and	   hypokalemia	   should	   be	  




Clinical	   symptoms	   of	   hypomagnesemia	   include	  
hallucinations,	   depression,	   delirium,	   lethargy,	  
weakness,	   paresthesias,	   tremors,	   premenstrual	  
syndrome,	  cold	  extremities,	  leg	  or	  foot	  cramps,	  	  
seizures,	   ventricular	   arrhythmias	   and	   congestive	  
heart	   failure	   (Douban	   et	   al.,	   1996).	   However,	  
since	   total	   body	   stores	   are	   not	   accurately	  
represented	   by	   serum	   levels,	   routine	   blood	  
testing	   and	   even	   erythrocyte	  Mg	   concentrations	  
may	  reveal	  normal	   levels,	  particularly	   in	  patients	  
with	   low	   free	   (ionized)	  magnesium	   levels.	   Urinary	  
fractional	   excretion	   or	   the	   oral	   magnesium	   load	  
test	   can	   estimate	   the	   total	   body	   magnesium	  
status.	   Intravenous	  magnesium	   loading	   tests	   are	  
likely	   the	   most	   accurate	   and	   practical	  
assessment,	   whereby	   total	   excretion	   of	   urinary	  
magnesium	   is	   calculated	   over	   a	   24	   hour	   period,	  
following	   administration	   of	   a	   loading	   dose;	   a	  
retention	   of	   20%	   or	   more	   indicates	   deficiency	  
(Arnaud,	  2008).	  
	  
Hypermagnesemia,	   on	   the	   other	   hand,	   is	   a	   rare	  
condition	  due	  to	  the	  nephron’s	  rapid	  response	  to	  
increased	   levels.	   It	   usually	   develops	   only	   in	  
people	   with	   kidney	   failure	   who	   are	   given	  
magnesium	  salts	  or	  who	   take	  drugs	   that	   contain	  
magnesium	  such	  as	   laxatives	  or	  antacids.	  Clinical	  
symptoms	   include	   nausea,	   muscle	   weakness,	  
lethargy,	  confusion,	  hypotension	  and	  arrhythmias.	  
In	   mild	   cases,	   withdrawing	   magnesium	   supple-­‐
mentation	   is	   often	   sufficient.	   In	   more	   severe	  
cases,	   intravenous	   calcium	   gluconate	   and	  
diuretics	  or	  dialysis	  may	  be	  required.	  
	  
Magnesium	  Levels	  in	  Migraineurs	  
	  
For	   many	   decades,	   it	   was	   postulated	   that	  
magnesium	   deficiency	   played	   a	   role	   in	   migraine	  
pathogenesis.	   However,	   the	   lack	   of	   simple	   and	  
reliable	  measures	  of	  magnesium	  levels	  prevented	  
further	   research	   to	  prove	   this	   theory.	  While	   low	  
serum,	   cerebrospinal	   fluid	   and	   cerebral	   tissue	  
levels	  of	  magnesium	  have	  been	   found	   to	  be	   low	  
in	   patients	   with	   migraine	   (Jain	   et	   al.,	   1985;	  
Ramadan	   et	   al.,	   1989;	   Schoenen	   et	   al.,	   1991),	  
these	   results	   have	   been	   inconsistent,	   with	   both	  
normal	   and	   low	   levels	   detected	   in	   the	   same	  
tissues	  of	  some	  patients.	  The	  variability	  of	  results	  
may	   be	   due	   to	   the	   need	   to	   measure	   ionized	  
magnesium	   as	   a	   true	   reflection	   of	   magnesium	  
metabolism,	   and	   the	   development	   of	   an	   ion	  
selective	   electrode	   for	   ionized	   magnesium	   in	  
whole	   blood,	   serum,	   plasma	   and	   aqueous	  
samples	   has	   made	   an	   accurate	   and	   rapid	  
measurement	   of	   ionized	   magnesium	   levels	  
possible	  (Altura	  et	  al.,	  1992).	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A	   study	   measuring	   ionized	   magnesium	   levels	   in	  
40	   patients	   during	   an	   acute	   migraine	   attack	  
found	   that	   50%	   had	   levels	   below	   0.54	   mmol/l	  
(normal	  adult	  range	  0.54-­‐0.65	  mmol/l)	  (Mauskop	  
et	  al.,	  1995),	  with	  all	  subjects	  having	  total	  serum	  
magnesium	   levels	   within	   normal	   limits.	  
Intravenous	   administration	   of	   1g	   of	   magnesium	  
sulfate	   was	   most	   effective	   in	   those	   with	   low	  
ionized	   magnesium,	   with	   86%	   of	   patients	  
reporting	   sustained	   pain	   relief	   over	   24	   hours	   in	  
those	   found	   to	   have	   low	   serum	   ionized	  
magnesium,	  while	   this	  was	   the	   case	   in	  only	  16%	  
of	   patients	   with	   normal	   levels.	   This	   finding	   was	  
extended	   to	   patients	   with	   various	   headache	  
types,	   including	   migraine	   without	   aura,	   cluster	  
head-­‐ache,	   chronic	  migraine	  and	  chronic	   tension	  
type	  headache	  (Mauskop	  et	  al.,	  1996),	  with	  most	  
patients	   demonstrating	   low	   ionized	   magnesium	  
levels.	   In	  addition,	  high	  serum	  ionized	  calcium	  to	  
magnesium	   ratios	   were	   found	   in	   all	   headache	  
types	   except	   for	   in	   those	   patients	   with	   chronic	  
tension-­‐type	  headaches.	  Based	  on	  these	  findings,	  
it	  has	  been	  suggested	  that	  tension	  type	  headache	  
may	   possibly	   be	   discriminated	   from	   chronic	  
migraine	   based	   on	   serum	   ionized	   magnesium	  




Migraine	   is	   the	  most	   common	   form	   of	   disabling	  
primary	  headache	   that	  afflicts	  patients,	  affecting	  
approximately	   12%	   of	   Western	   populations	  
(Lipton	   et	   al.,	   2007).	   It	   is	   clear	   that	   there	   is	  
genetic	   transmission	   of	   the	   disorder,	   although	  
specific	   genes	   for	   most	   forms	   of	   migraine	   have	  
not	   yet	   been	   identified.	   Additionally,	   although	  
the	  exact	  etiology	  remains	  to	  be	  defined,	  current	  
theories	  centre	  on	  hyperexcitability	  of	  the	  cortex	  
and	   trigeminovascular	   complex.	   In	   migraineurs,	  
headache	   triggers	   stimulate	   the	   release	   of	  
neuropeptides	  from	  the	  trigeminovascular	  neurons,	  
including	   calcitonin	   gene-­‐related	   peptide	   and	  
substance	   P.	   Additionally,	   stimulation	   of	   the	  
trigeminal	  ganglion	  increases	  cerebral	  blood	  flow	  
due	   to	   the	   release	   of	   vasoactive	   intestinal	  
peptide	   by	   the	   facial	   nerve	   (Goadsby	   and	  
Macdonald,	  1985).	  The	  vasodilation	  is	  accompanied	  
by	   mast	   cell	   degranulation,	   blood	   vessel	   edema	  
and	   increased	   vascular	   permeability,	   resulting	   in	  
meningeal	  neurogenic	  inflammation.	  
	  
The	   trigeminal	   nerve	   transmits	   this	   information	  
to	  the	  brainstem	  trigeminal	  nucleus	  caudalis,	  and	  
then	   on	   to	   the	   thalamic	   nuclei	   and	   the	   cortex,	  
where	   the	   pain	   is	   ultimately	   perceived	  
(Moskowitz,	   1984).	   Other	   structures,	   including	  
the	   periaqueductal	   gray	   matter	   and	   the	   locus	  
coeruleus	  and	   the	  dorsal	   raphe	  nuclei,	  modulate	  
pain	   transmission	   and	   therefore	   its	   perception	  
(Martin	  and	  Behbehani,	  2001).	  
	  
Recent	  research	  has	  elucidated	  the	  aura	  phase	  of	  
migraine,	   which	   affects	   up	   to	   5%	   of	   the	   adult	  
population	   (Agostini	   and	   Aliprandi,	   2006).	  
Migraine	   aura	   is	   the	   presentation	   of	   charac-­‐
teristic	  neurological	  symptoms	  usually	  developing	  
prior	   to	   the	   onset	   of	   the	   painful	   phase	   of	   a	  
migraine	   headache,	   believed	   to	   be	   due	   to	   a	  
phenomenon	   known	   as	   cortical	   spreading	  
depression	  (CSD).	  CSD	  was	  originally	  described	  by	  
Leao	   (1944)	   and	   is	   an	   intense	   depolarization	   of	  
neuronal	  and	  glial	  membranes,	  with	  alterations	  in	  
membrane	   resistance	   and	   ion	   flow.	   There	   is	  
subsequent	   massive	   release	   of	   glutamate	   and	  
potassium	   as	   well	   as	   an	   increase	   in	   intracellular	  
sodium	  and	  calcium.	  This	  results	  in	  a	  strong	  wave	  
of	   depolarization	   that	   spreads	   across	   contiguous	  
neuronal	   tissue.	   It	   can	   be	   triggered	   by	  
depolarization	  of	  a	  small	  region	  of	  brain	  tissue	  or	  
by	   direct	   application	   of	   excitatory	   amino	   acids,	  
and	   activation	   of	   the	   N-­‐methyl-­‐D	   aspartate	  
(NMDA)	   receptor	   can	   evoke	   CSD	   (Gorji	   et	   al.,	  
2001).	   There	   are	   characteristic	   alterations	   in	  
cerebral	  blood	  flow,	  with	  an	   initial	  brief	  oligemia	  
followed	   by	   a	   profound	   hyperemia,	   and	   a	   mild,	  
long-­‐lasting	  oligemia	  (Otori	  et	  al.,	  2003).	  Precisely	  
how	   the	   aura	   phase	   of	   a	   migraine	   evolves	   into	  
the	   painful	   phase	   remains	   unknown,	   and	   it	   has	  
been	   theorized	   that	   it	   is	   due	   to	   the	   action	   of	   a	  
number	   of	   inflammatory	   proteins	   including	  
calcitonin	   gene-­‐related	   peptide	   (CGRP),	   nitric	  
oxide	   and	   vasoactive	   peptide	   (Goadsby	   et	   al.,	  
1990),	  which	   feed	   into	   the	   trigeminal	   nerve	   and	  
generate	   pial	   artery	   dilation	   and	   CSD,	   and,	  
ultimately,	  headache.	  	  	  	  
	  
Using	   phosphorus	   nuclear	   magnetic	   resonance	  
spectroscopy	   (MRS),	   low	   levels	   of	   magnesium	  
have	   been	   found	   in	   the	   cerebral	   tissue	   of	   some	  
migraineurs	   both	   during	   attacks	   and	   interictally	  
(Ramadan	  et	  al.,	  1989).	  Another	  study	  utilized	  the	  
same	   technology	   to	   assess	   the	   brain	   cytosolic	  
free	   magnesium	   concentration	   and	   free	   energy	  
released	   by	   the	   hydrolysis	   of	   adenosine	  
triphosphate,	  an	  index	  of	  cellular	  bioenergetics	  in	  
both	   migraineurs	   and	   patients	   with	   cluster	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headaches	   (Lodi	   et	   al.,	   2001).	   Cytosolic	   free	  
magnesium	  and	   the	   free	   energy	   released	  by	   the	  
reaction	   of	   ATP	   hydrolysis	   were	   significantly	  
reduced	  in	  the	  occipital	   lobes	  of	  patients	  with	  all	  
types	   of	  migraine	   as	  well	   as	   in	   cluster	   headache	  
patients.	   The	   authors	   of	   this	   study	   took	   these	  
results	   to	   lend	   support	   to	   their	   hypothesis	   that	  
the	   reduction	   of	   free	   magnesium	   in	   tissue	   with	  
mitochondrial	   dysfunction	   is	   due	   to	   a	  
bioenergetics	   deficit,	   as	   magnesium	   is	   essential	  
for	   mitochondrial	   membrane	   stability	   and	   the	  
coupling	  of	   oxidative	  phosphorylation.	   Phosphorus	  
nuclear	  MRS	   demonstrated	   reduced	  magnesium	  
in	   the	   occipital	   cortices	   of	   patients	   with	  
hemiplegic	   migraine,	   with	   decreases	   correlating	  
with	   the	   severity	   of	   neurological	   complaints	  
(Boska	  et	  al.,	  2002).	   Interestingly,	   this	   study	  also	  
found	   increased	   magnesium	   in	   the	   brains	   of	  
patients	   with	   migraine	   without	   aura,	   which	   the	  
authors	   attributed	   to	   a	   possible	   decrease	   in	  
intracellular	   potassium,	   which	   may	   occur	   in	  
neuronal	  tissue	  prone	  to	  hyper-­‐excitability.	  
	  
Various	   hypotheses	   abound	   as	   to	   the	   reason	  
behind	   the	   hypomagnesemia	   observed	   in	  
migraineurs.	  Some	  suggest	  that	  during	  a	  migraine	  
headache,	   excessive	   amounts	   of	  magnesium	   are	  
excreted	  due	  to	  stress.	  Others	  propose	  that	  stress	  
triggers	  excretion	  of	  magnesium,	  with	  secondary	  
hypomagnesemia	   causing	   a	   migraine	   (Durlach,	  
1976).	   During	   attacks	   as	   well	   as	   interictally,	  
magnesium	   levels	   in	   both	   serum	   and	   saliva	   are	  
decreased	   (Gallai	   et	   al.,	   1992),	   perhaps	   an	  
indicator	   of	   low	   cerebral	   magnesium	   levels	   and	  
therefore	   a	   decreased	   threshold	   for	   migraine	  
development	   (Ramadan	   et	   al.,	   1989).	   Interictal	  
studies	   on	   intracellular	   and	   serum	   levels	   in	  
patients	   with	   migraines	   and	   tension-­‐type	  
headaches	   have	   shown	   inconsistent	   results.	  
However	   a	   study	   of	   migraineurs	   utilizing	   the	  
magnesium	   load	   test	   found	   that	   after	   loading	  
with	  magnesium	   lactate,	   there	   was	   retention	   of	  
the	  magnesium,	  suggesting	  a	  systemic	  deficiency.	  
Further,	   interictal	   levels	   of	   erythrocyte	  
magnesium	  are	  lower	  in	  both	  adult	  (Schoenen	  et	  
al.,	   1991)	   and	   juvenile	   migraineurs	   with	   and	  
without	   aura	   (Soriani	  et	  al.,	   1995).	   In	   support	  of	  
these	  studies,	  one	  in	  which	  migraineurs	  with	  low	  
erythrocyte	   magnesium	   levels	   as	   well	   as	  
decreased	  ionized	  lymphoycyte	  magnesium	  levels	  
were	  given	  mineral	  water	  containing	  magnesium	  
over	   a	   two-­‐week	   period.	   Both	   erythrocyte	   and	  
lymphocyte	   magnesium	   levels	   rose	   (Thomas	   et	  
al.,	   2000).	   These	   suggest	   that	   assays	   of	  
erythrocyte	   magnesium	   may	   be	   a	   useful	   and	  
easily	   available	   tool	   to	   assess	   magnesium	  
deficiency	  in	  migraineurs.	  
	  
Magnesium	  in	  Migraine	  Pathogenesis	  
	  
Magnesium	   is	   believed	   to	   be	   involved	   in	   a	  
number	   of	   the	   aspects	   of	   migraine	   patho-­‐
physiology,	   and	   deficiency	   has	   been	   linked	   to	  
cortical	  spreading	  depression	  (Mody	  et	  al.,	  1987),	  
platelet	   aggregation	   (Baudouin-­‐Legros	   et	   al.,	  
1986),	   release	   of	   substance	   P	   (Weglicki	   and	  
Phillips,	   1992),	   neurotransmitter	   release	   (Coan	  
and	   Collingridge,	   1985)	   and	   vasoconstriction	  
(Altura	  and	  Altura,	  1982).	  
	  
NMDA	  receptors	  are	  associated	  with	  nociception	  
and	   the	   resulting	   neuroplastic	   changes	   in	   the	  
trigeminal	   nociceptive	   neurons,	   as	   well	   as	   with	  
regulation	   of	   cerebral	   blood	   flow	   (Foster	   and	  
Fagg,	   1987).	   Magnesium	   ions	   may	   block	   the	  
NMDA	  receptor,	  thereby	  preventing	  calcium	  ions	  
from	   moving	   intracellularly,	   and	   stopping	   the	  
calcium's	   effects	   on	   neurons	   and	   cerebral	  
vasculature	   (Coan	   and	   Collingridge,	   1985).	  
Decreased	   magnesium	   levels	   therefore	   facilitate	  
the	  NMDA	  receptor,	  increasing	  its	  effects	  on	  CSD,	  
as	  well	   as	   the	  effect	  of	   glutamate	  on	   the	  NMDA	  
receptor.	  The	  NMDA	  receptor	  has	  been	  shown	  to	  
have	   a	   part	   in	   both	   the	   initiation	   and	   spread	   of	  
cortical	   depression	   (Ferrari,	   1992).	   Magnesium	  
has	   been	   shown	   to	   block	   CSD	   induced	   by	  
glutamate,	   and	   CSD	   is	  more	   easily	   initiated	  with	  
decreased	  magnesium	  levels	  (Mody	  et	  al.,	  1987).	  
	  
Nitric	   oxide	   (NO)	   plays	   a	   role	   as	   a	   synaptic	  
modulator,	   affecting	   nociceptive	   processing	  
(Meller	   and	   Gebhart,	   1993)	   in	   addition	   to	   its	  
involvement	  in	  the	  regulation	  of	  blood	  flow	  both	  
intracranially	   and	   extracranially.	   It	   augments	   the	  
NMDA	   receptor-­‐evoked	   currents,	   thereby	   facilit-­‐
ating	   glutaminergic	   transmission	   (Choi	   and	  
Lipton,	  2000),	  which,	  as	  previously	  discussed,	  can	  
be	  inhibited	  by	  magnesium.	  Production	  of	  NO	  can	  
be	  inhibited	  by	  decreased	  magnesium	  levels.	  
	  
CGRP,	  a	  neuropeptide,	  is	  released	  from	  activated	  
trigeminal	   sensory	   nerves,	   is	   involved	   in	   the	  
dilation	  of	  intracranial	  blood	  vessels	  and	  may	  also	  
increase	   nociceptive	   transmission	   in	   the	   brain-­‐
stem	   and	   spinal	   cord.	   It	   is	   therefore	   believed	   to	  
play	   a	   central	   part	   in	   the	   development	   of	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migraines.	   A	   positive	   correlation	   has	   been	  
demonstrated	   between	   migraines	   and	   serum	  
CGRP	   levels,	   and	   after	   the	   pain	   of	   a	   migraine	  
subsides,	  levels	  are	  observed	  to	  return	  to	  normal	  
(Coderre	   et	   al.,	   1993).	   It	   has	   hence	   been	  
hypothesized	   that	   inhibition	   of	   the	   release	   of	  
CGRP	   either	   centrally	   or	   from	   the	   trigeminal	  
nerve,	   may	   inhibit	   intracranial	   vasodilation	  
thereby	   aborting	   migraine	   attacks.	   CGRP	  
antagonists	   lack	   vasoconstrictive	   properties	   and	  
have	   an	   advantage	   over	   current	   acute	   migraine	  
treatment,	   triptans,	  which	  are	  contraindicated	   in	  
patients	   with	   cardiovascular	   risk	   factors	   due	   to	  
their	  vasoconstrictive	  effects.	  
	  
Circulating	   CGRP	   levels	   have	   been	   shown	   to	   be	  
decreased	  by	  the	  administration	  of	  magnesium	  in	  
patients	   with	   primary	   Raynaud’s	   phenomenon	  
(PRP).	  A	  study	  followed	  CGRP	  levels	  in	  12	  women	  
with	   PRP	   and	   12	   controls	   before	   and	   after	   the	  
administration	  of	  intravenous	  magnesium	  sulfate.	  
While	   there	   was	   no	   significant	   difference	  
between	   baseline	   circulating	   CGRP	   in	   the	   two	  
groups,	   following	   the	   infusion	   of	   magnesium	  
sulfate	  there	  was	  a	  significant	  reduction	   in	  CGRP	  
levels	   in	   the	   women	  with	   PRP	   only	   as	   well	   as	   a	  
significant	   increase	   in	   RBC	   magnesium	   levels	   in	  
the	   women	   with	   PRP	   but	   not	   in	   the	   control	  
subjects	  (Myrdal	  et	  al.,	  1994).	  
	  
Serotonin,	   released	   from	   platelets	   during	  
migraines,	  promotes	  cerebral	  vasoconstriction	  as	  
well	   as	   triggering	   nausea	   and	   vomiting.	   Cerebral	  
vascular	  muscle	  serotonin	  receptors	  may	  develop	  
increased	   affinity	   if	   serum	   ionized	   magnesium	  
falls	   and	   the	   ratio	   of	   serum	   ionized	   calcium	   to	  
magnesium	   increases.	   This	   may	   lead	   to	   further	  
cerebral	   vasoconstriction	   and	   facilitates	   the	  
release	  of	   serotonin	   from	  neuronal	   storage	   sites	  
(Altura	   and	   Turlapaty,	   1982).	   Pretreatment	   with	  
magnesium	  has	  been	  shown	  to	  reduce	  serotonin-­‐
induced	   vasoconstriction	   (Goldstein	   and	   Zsoter,	  
1978).	  
	  
Oral	  Magnesium	  Supplementation	  
	  
A	   double-­‐blind	   placebo-­‐controlled	   study	   was	  
performed	  in	  which	  24	  women	  with	  menstrually-­‐
related	   migraine	   were	   given	   supplementation	  
with	   360	   mg	   of	   magnesium	   pyrrolidone	   carbox-­‐
ylic	  acid,	  divided	  into	  3	  divided	  daily	  doses	  taken	  
from	  ovulation	  to	  the	  first	  day	  of	  menstrual	  flow	  
(Facchinetti	  et	  al.,	  1991).	  The	  treatment	  was	  well	  
tolerated,	  with	  only	  one	  patient	  dropping	  out	  of	  
the	   study	   due	   to	   side	   effects	   (magnesium-­‐
induced	   diarrhoea),	   and	   significant	   reductions	  
were	   observed	   in	   number	   of	   days	   of	   headache,	  
total	   pain	   index	   and	   in	   Menstrual	   Distress	  
Questionnaire	  score.	  
	  
A	   larger	   double-­‐blind,	   placebo-­‐controlled,	   rand-­‐
omized	  study	  on	  81	  migraineurs	  receiving	  600	  mg	  
of	   trimagnesium	   dicitrate	   taken	   once	   daily,	  
showed	   attack	   frequency	   reduction	   of	   41.6%	   in	  
the	   magnesium	   group	   and	   15.8%	   in	   controls.	  
Three	   patients	   dropped	   out	   of	   the	   study	   due	   to	  
side	   effects,	   18.6%	   of	   patients	   complained	   of	  
diarrhoea	  and	  4.7%	  of	  gastric	  irritation	  (Peikert	  et	  
al.,	  1996).	  
	  
A	   third	   placebo-­‐controlled	   double-­‐blind	   trial	  
showed	   no	   effect	   of	   magnesium	   on	   migraine	  
(Pfaffenrath	  et	  al.,	  1996),	  possibly	  attributable	  to	  
the	   use	   of	   poorly-­‐absorbed	   magnesium	   salt,	   as	  
almost	  half	  of	  the	  treatment	  group	  complained	  of	  
diarrhoea.	  
	  
A	   recent	   double-­‐blind	   placebo-­‐controlled,	  
randomized	  study	  investigated	  the	  effects	  of	  600	  
mg	   of	   magnesium	   citrate	   supplementation	   per	  
day	   in	   patients	   with	   migraine	   without	   aura.	   A	  
combination	   of	   clinical	   assessments,	   visual-­‐
evoked	  potentials	  (VEPs)	  and	  brain	  single-­‐photon	  
emission	  computerized	  tomography	  (SPECT)	  were	  
performed	   to	   assess	   neurogenic	   and	   vascular	  
mechanisms	   of	   action	   (Koseoglu	   et	   al.,	   2008).	  
Supplementation	  was	   associated	  with	   significant	  
decrease	   in	   migraine	   attack	   frequency	   and	  
severity,	   as	   well	   as	   decreased	   P1	   amplitude	   on	  
VEPs,	   and	   increased	   cortical	   blood	   flow	   to	   the	  
inferolateral	   temporal,	   inferofrontal	   and	   insular	  
regions	   seen	   on	   SPECT.	   The	   authors	   suggested	  
that	   magnesium	   may	   interfere	   with	   both	  
neurogenic	  and	  vascular	  mechanisms	  of	  migraine	  
and	   may	   hence	   be	   an	   effective	   prophylactic	  
treatment.	  Other	  studies	  using	  SPECT	  have	  shown	  
conflicting	   results	   (Ramadan	  et	   al.,	   1991;	   Ferrari	  
et	  al.,	  1995;	  Olesen	  et	  al.,	  1982).	  
	  
Women	   with	   menstrually-­‐related	   migraine	  
(MRM)	  may	   be	   particularly	   prone	   to	   developing	  
magnesium	   deficiency.	   A	   prospective	   study	  
involving	   270	   women,	   61	   of	   whom	   had	   MRM,	  
showed	   that	   45%	   had	   ionized	   magnesium	  
deficiency	  during	  MRM	  attacks,	  15%	  during	  non-­‐
menstrual	   attacks,	   14%	   during	   menstruation	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without	  migraine	  and	  15%	  between	  menstruation	  
without	  migraine	   (Mauskop	   et	   al.,	   2002).	   Serum	  
ionized	  calcium/magnesium	   levels	  were	  elevated	  
in	  MRM,	  with	  normal	  ionized	  calcium	  levels.	  
	  
Magnesium	   deficiency	   has	   also	   been	   found	   in	  
paediatric	   migraine,	   with	   decreased	   levels	   of	  
serum,	   RBC	   and	   mononuclear	   blood	   cell	  
magnesium	   found	   in	  paediatric	  migraineurs	  with	  
or	   without	   aura	   compared	   with	   patients	   with	  
tension	   type	   headache	   and	   controls	   (Soriani	   et	  
al.,	   1995;	   Mazzotta	   et	   al.,	   1999).	   Magnesium	  
supplementation	   may	   be	   a	   safe	   and	   well-­‐
tolerated	   option	   for	  migraine	   prophylaxis	   in	   the	  
prevention	   of	   paediatric	   migraine.	   However,	  
while	   a	   double-­‐blind	   placebo-­‐controlled,	  
randomized	   trial	   of	   patients	   aged	   3	   to	   17	   years	  
found	  a	  statistically	  significant	  downward	  trend	  in	  
headache	   frequency	   in	   those	   treated	   with	  
magnesium	  oxide,	  the	  difference	  in	  the	  slopes	  of	  
the	   two	   lines	   was	   not	   statistically	   significant	  
(Wang	   et	   al.,	   2003).	   It	   could	   therefore	   not	   be	  
determined	   if	   oral	   magnesium	   was	   superior	   to	  
placebo	   in	   preventing	   frequent	   migraines	   in	  
children	  and	  adolescents.	  
	  
While	  oral	  magnesium	  is	  generally	  well	  tolerated,	  
the	   most	   prominent	   side-­‐effect	   is	   diarrhoea.	  
Magnesium	  toxicity	   leads	  to	   loss	  of	  deep	  tendon	  
reflexes	  as	  well	  as	  generalized	  muscle	  weakness.	  
Severe	   toxicity	   can	   manifest	   as	   cardiac	   muscle	  
weakness,	   respiratory	   paralysis	   and	   death,	   and	  
patients	  with	  renal	  disease	  are	  at	  greater	  risk	  for	  
developing	  toxicity.	  Although	  the	  diarrhoea	   itself	  
may	   prevent	   the	   development	   of	   toxicity,	  






Studies	   examining	   the	   use	   of	   intravenous	  
magnesium	   in	   the	   treatment	   of	   acute	   migraine	  
have	  been	  conflicting.	  A	  study	  on	  40	  patients	  with	  
acute	   migraine	   attacks	   showed	   an	   85%	  
correlation	   between	   levels	   of	   serum	   ionized	  
magnesium	   (measured	   during	   an	   attack)	   and	  
clinical	  response	  to	  1g	  of	  intravenous	  magnesium	  
sulphate	   (Mauskop	   et	   al.,	   1995).	   Although	   the	  
study	   was	   neither	   double-­‐blinded	   nor	   placebo-­‐
controlled,	   both	   researchers	   and	   subjects	   were	  
blinded	   to	   ionized	   magnesium	   levels.	   A	   further	  
study	   on	   various	   headache	   types	   found	   1g	   of	  
magnesium	   sulphate	   to	   provide	   rapid	   relief	   in	  
patients	   with	   low	   serum	   ionized	   magnesium	  
levels	  (Mauskop	  et	  al.,	  1996).	  
	  
A	   single-­‐blind	   placebo-­‐controlled,	   randomized	  
trial	   involved	   30	   patients	   with	   migraines	   who	  
were	   randomized	   to	   receive	   either	   magnesium	  
sulphate	   1g	  or	   placebo	   (Demirkaya	  et	   al.,	   2001).	  
After	   30	  minutes,	   patients	   in	   the	   placebo	   group	  
who	  had	  ongoing	  pain,	  nausea	  or	  vomiting	  were	  
given	   magnesium	   sulphate	   1g.	   Treatment	   was	  
superior	   to	   placebo	   in	   terms	   of	   both	   response	  
rate	   (100%	   for	   magnesium	   sulphate	   vs	   7%	   for	  
placebo)	  and	  pain-­‐free	   rate	   (87%	  for	  magnesium	  
sulphate	  vs	  0%	  for	  placebo)	  and	  those	  treated	  did	  
not	   experience	   headache	   recurrence	   within	   24	  
hours.	   87%	   complained	   of	   flushing	   or	   a	   burning	  
sensation	  in	  the	  face	  and	  neck.	  
	  
A	   double-­‐blind	   placebo-­‐controlled,	   randomized	  
study	   evaluated	   the	   efficacy	   of	   magnesium	  
sulphate	  1g	  on	  the	  pain	  and	  associated	  symptoms	  
of	   migraine	   with	   and	   without	   aura	   (Bigal	   et	   al.,	  
2002).	   In	   subjects	   with	   migraine	   without	   aura,	  
although	   there	  was	   a	   significant	   decrease	   in	   the	  
intensity	   of	   photophobia	   and	   phonophobia,	   no	  
significant	   differences	   were	   observed	   in	   pain	  
relief	  or	  nausea.	  However	  subjects	  with	  migraine	  
with	   aura	   had	   significant	   improvement	   in	   pain	  
and	  all	  associated	  symptoms.	  
	  
An	  emergency	  room-­‐based	  double-­‐blind	  placebo-­‐
controlled,	  randomized	  study	  of	  44	  subjects	  with	  
acute	   migraines	   tested	   a	   combination	   of	  
magnesium	   sulphate	   2g	   and	   metoclopramide	  
20mg	   versus	  metoclopramide	   20mg	   alone	   at	   15	  
minute	   intervals	   for	   up	   to	   3	   doses,	   or	   until	   pain	  
relief	  occurred	  (Corbo	  et	  al.,	  2001).	  Pain	  intensity	  
was	   recorded	   using	   a	   standard	   visual	   analogue	  
scale	   (VAS).	   Although	   both	   groups	   experienced	  
more	  than	  50mm	  improvement	  in	  the	  VAS	  score,	  
improvement	   was	   smaller	   in	   the	   magnesium	  
group,	  both	   comparing	  VAS	   score	   improvements	  
and	   evaluating	   normal	   functional	   status.	   The	  
authors	  suggested	  that	  magnesium	  may	  diminish	  
the	   efficacy	   of	   metoclopramide	   in	   decreasing	  
migraine	  pain.	  
	  
A	   study	   involving	   22	   patients	   with	   cluster	  
headaches	   who	   were	   treated	   with	   magnesium	  
sulphate	  1g	   found	  that	  41%	  of	  patients	   reported	  
'meaningful	  relief'	  (defined	  as	  complete	  cessation	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of	   attacks	   or	   relief	   for	   more	   than	   3	   days)	   after	  




Magnesium	   is	   central	   to	   numerous	   physiological	  
functions,	   and	   the	   role	   it	   plays	   in	   the	   various	  
aspects	   of	   migraine	   pathogenesis	   is	   well	  
described.	  Although	  some	  studies	  have	  shown	  an	  
association	   between	   migraines	   and	   magnesium	  
deficiency,	  it	  is	  difficult	  to	  assess	  this	  with	  routine	  
blood	  testing	  and	  serum	  magnesium	   levels	  are	  a	  
poor	   reflection	   of	   body	   stores	   of	   the	   cation.	  
Therefore,	  treatment	  should	  be	  based	  on	  clinical	  
suspicion,	   with	   both	   oral	   and	   intravenous	  
magnesium	  available	  as	  simple,	  safe,	  inexpensive	  
and	   well-­‐tolerated	   options	   for	   the	   management	  
of	   migraines.	   In	   patients	   with	   symptoms	  
suggestive	   of	   hypomagnesemia	   such	   as	   pre-­‐
menstrual	  syndrome,	  cold	  extremities	  and	  foot	  or	  
leg	   cramps,	   we	   suggest	   daily	   magnesium	  
supplementation	   with	   400mg	   of	   chelated	  
magnesium,	   magnesium	   oxide	   or	   slow-­‐release	  
magnesium.	   While	   some	   patients	   may	   require	  
doses	  of	  up	  to	  1000mg,	  diarrhoea	  and	  abdominal	  
pain	   may	   be	   limiting	   factors.	   Intravenous	  
magnesium	   may	   be	   used	   in	   patients	   who	   are	  
unable	   to	   tolerate	   or	   absorb	   oral	  magnesium	   or	  
who	  are	  non-­‐compliant	  with	  daily	  dosing.	   It	  may	  
also	   be	   used	   for	   the	   treatment	   of	   acute	  
migraines,	  or	  as	  a	  monthly	  prophylactic	   infusion,	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The	   blood-­‐brain	   barrier	   (BBB)	   is	   constituted	   primarily	   of	   brain	   capillary	   endothelial	   cells	   and	   is	   a	   pre-­‐
requisite	  for	  the	  maintenance	  of	  brain	  homeostasis	  that	  is	  essential	  for	  optimal	  brain	  function.	  However,	  
a	   variety	   of	   pathological	   conditions,	   such	   as	   sepsis,	   multiple	   sclerosis	   and	   epilepsia	   disrupt	   the	   BBB	  
integrity	   and	   lead	   to	   the	  development	  of	   brain	   edema.	   Ionized	  magnesium	   (Mg2+)	   is	   a	   crucial	   cofactor	  
that	  plays	  an	  essential	   role	  within	  the	  cell	  and	  regulates	  a	  variety	  of	  biochemical	   reactions.	  Changes	   in	  
intra-­‐	  and	  extracellular	  Mg2+	  concentrations	  influence	  the	  functions	  of	  cells	  and	  tissues.	  A	  growing	  body	  
of	   evidence	   suggests	   that	   Mg2+	   plays	   a	   pivotal	   role	   in	   ameliorating	   BBB	   disruption	   via	   a	   number	   of	  
mechanisms	  during	  certain	  neurological	  diseases.	  Systemic	  delivery	  of	  Mg2+	  may	  constitute	  an	  alternative	  
approach	   in	   the	   future,	  both	   to	   improve	  BBB	   integrity	  and	   to	  decrease	  brain	  edema	   in	   the	  course	  of	  a	  




The	  blood-­‐brain	  barrier	  (BBB)	  is	  composed	  mainly	  
of	  brain	  capillary	  endothelial	  cells	  and	  represents	  
a	  dynamic	  structure	  that	  regulates	  the	  trafficking	  
of	  molecules	  between	  blood	  and	  brain	  tissue.	  The	  
passage	  of	  many	  circulating	  substances	   from	  the	  
capillary	  bed	  into	  the	  brain	  parenchyma	  is	  tightly	  
controlled	   by	   physical	   and	   enzymatic	   barriers	  
provided	  by	   the	  endothelial	   cells	  of	   capillaries	   in	  
the	   brain	   parenchyma	   (Abbott	   et	   al.,	   2010;	  
Cardoso	   et	   al.,	   2010).	   In	   this	   way,	   the	   BBB	   is	  
equipped	  with	   regulating	  means	   that	   enable	   the	  
maintenance	  of	  neuronal	  homeostasis.	  In	  addition,	  
the	   BBB	   harbours	   transport	   mechanisms	   that	  
provide	   bidirectional	   control	   of	   exchange	   of	  
nutrients,	  electrolytes	  and	  neurotoxins,	  and	   thus	  
establishes	   an	   optimum	   milieu	   that	   is	   strictly	  
essential	   to	   neuronal	   survival.	   Although	   the	   BBB	  
appears	   to	   possess	   a	   static	   structure,	   it	   has	   the	  
ability	  to	  adapt	  readily	  to	  sudden	  changes.	  
	  
About	   95%	   of	   the	   microvessels	   in	   the	   brain	  
display	  BBB	  properties,	  and	  almost	  every	  neuron	  
is	  estimated	  to	  be	  nourished	  by	  a	  distinct	  capillary	  
vessel	  (Pardridge,	  2005).	  When	  regulating	  its	  own	  
activities,	   the	  mature	  BBB	   receives	   support	   from	  
at	   least	   three	   different	   cell	   types:	   1)	   pericytes	  
which	  share	  the	  same	  basement	  membrane	  with	  
endothelial	   cells;	   2)	   astrocytes	   which	   envelope	  
99%	   of	   the	   abluminal	   face	   of	   endothelial	   cells;	  
and	  3)	  neurons	   (Guo	  and	  Lo,	  2009;	  Correale	  and	  
Villa,	  2009).	  Nevertheless,	  under	  normal	  conditions,	  
BBB	   function	   is	   regulated	   primarily	   by	   capillary	  
endothelial	   cells	   (Fisher,	   2009;	   Abbott	   et	   al.,	  
2010).	  
	  
In	   brain	   tissue,	   the	   barrier-­‐type	   endothelial	   cells	  
have	   a	   continuous	   basal	   membrane	   and	   do	   not	  
exhibit	   fenestrations.	   These	   cells	   contain	   many	  
mitochondria,	   but	   harbour	   very	   few	   caveola	  
(pinocytotic	   vesicles)	   in	   their	   luminal	   surfaces.	  
Tight	   junctions	   (TJs)	   between	   adjacent	   brain	  
capillary	   endothelial	   cells	   possess	   occludin	   and	  
claudin	  proteins	  that	  serve	  to	  preserve	  junctional	  
integrity.	   Meanwhile,	   zonula	   occludens	   (ZO)-­‐1	  
and	   ZO-­‐2,	   cingulin,	   cadherin,	   cathenin,	   vinculin	  
and	  actin	  constitute	  accessory	  proteins	  that	  aid	  in	  
the	  assembly	  of	  TJs.	  	  	  
	  
Passive	  diffusion	  across	   the	  BBB	  mainly	  depends	  
on	   the	   lipid	   solubility	   and	   molecular	   weight	   of	  
molecules.	   Lipophilic	   substances	   with	   molecular	  
weights	   less	   than	   400-­‐600	   Da	   can	   pass	   readily	  
into	   the	   brain	   tissue	   by	   passive	   diffusion.	   In	   the	  
normally	   functioning	   BBB,	   oxygen,	   carbon	  
dioxide,	   nicotine,	   ethanol,	   lipid-­‐soluble	  
substances	  such	  as	  heroin,	  and	  amphiphilic	  drugs	  
(containing	   both	   hydrophobic	   and	   hydrophilic	  
moieties)	  are	  carried	  by	  this	  route.	   In	  addition,	  a	  
number	  of	  molecules	   are	   transported	  across	   the	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BBB	   by	   other	  mechanisms	   including	   carrier-­‐	   and	  
receptor-­‐mediated	  transport,	  adsorptive-­‐mediated	  
endocytosis	   and	   fluid	   phase-­‐mediated	   endo-­‐
cytosis	   (Loscher	   and	   Potschka,	   2005;	   Pardridge,	  
2007).	   However,	   many	   pathological	   conditions	  
alter	   the	   functional	  and	  structural	  characteristics	  




Magnesium	   ion	   (Mg2+),	   the	   most	   abundant	  
divalent	  cation	  in	  living	  cells,	  exists	  not	  only	  in	  the	  
intracellular	   compartment	   but	   also	   in	   circulation	  
and	   cerebrospinal	   fluid	   (CSF).	   Serum	   Mg2+	  
concentration	   normally	   ranges	   between	   1.7-­‐2.3	  
mEq/L	   in	   humans	   and	   may	   decrease	   during	  
several	   pathological	   conditions	   (Romani	   and	  
Scarpa,	   2000;	   Musso,	   2009).	   	   Cell	   membranes	  
have	  a	  particularly	   low	  permeability	   to	  Mg2+	  and	  
hence	  the	  ion	  moves	  slowly	  between	  intracellular	  
and	   interstitial	   compartments.	   Under	   physiol-­‐
ogical	   conditions,	   the	  Mg2+	   concentration	   within	  
the	  cell	  is	  maintained	  in	  a	  relatively	  narrow	  range	  
between	  0.5	  and	  1	  mM	  (Dai	  and	  Quamme,	  1991;	  
Romani	   and	   Scarpa,	   2000).	   Mg2+	   acts	   as	   a	  
regulatory	   cation	   at	   the	   systemic	   and	   cellular	  
levels,	  and	  participates	  in	  almost	  all	  anabolic	  and	  
catabolic	   processes	   in	   the	   body.	   It	   plays	   a	  
fundamental	   role	   in	   a	   wide	   range	   of	   cellular	  
events,	   biochemical	   reactions	   and	   physiological	  
functions,	   by	   activating	   over	   325	   enzyme	  
systems,	   including	   those	   involved	   in	   ATP	  
synthesis,	   carbohydrate	  metabolism,	   K+	   and	  Ca2+	  
transport,	   cell	   proliferation	   and	   membrane	  
stability	  and	  function	  (Grubbs	  and	  Maguire,	  1987;	  
Saris	   et	   al.,	   2000;	   Wolf	   and	   Trapani,	   2008;	  
Barbagallo	  and	  Dominguez,	  2010).	  	  
	  
During	   normal	   physiological	   processes,	   Mg2+	  
works	   as	   a	   voltage	   dependent	   antagonist	   and	   a	  
noncompetitive	   inhibitor	   of	   the	   N-­‐methyl-­‐D-­‐
aspartic	  acid	  (NMDA)	  receptors	  and	  ion	  channels	  
in	   the	   brain.	   Although	   pharmacokinetic	   and	  
pharmacodynamic	   studies	   in	   rats	   have	   shown	  
Mg2+	  entry	  into	  the	  brain	  upon	  systemic	  treatment	  
(Hallak	   et	   al.,	   1992;	   Hoane,	   2007),	   no	  
concomitant	   rise	   of	   Mg2+	   in	   CSF	   was	   noted	  
following	   parenteral	   administration	   in	   humans	  
with	  brain	  insults	  (McKee	  et	  al.,	  2005).	  
	  
A	   reduction	   of	   Mg2+	   level	   within	   the	   cell	   in	  
pathological	  states	  can	  be	  considered	  as	  an	  injury	  
factor	   in	   the	   brain	   and	   may	   lead	   to	   serious	  
biological	   and	   metabolic	   dysfunction.	   Decline	   in	  
intracellular	  free	  Mg2+	  concentration	  reduces	  ATP	  
synthesis,	   and	   utilization	   in	   the	   maintenance	   of	  
ion	  gradients	   via	   the	  Na+-­‐K+	  ATPase	   (Grubbs	  and	  
Maguire,	   1987).	   Also,	   the	   reduction	   in	   Mg2+	  
concentration	   within	   the	   cell	   results	   in	   an	  
impairment	   of	  membrane	   stability	   by	   promoting	  
free	  radical	  production	   (Ebel	  and	  Gunther,	  1980;	  
Bara	   and	   Guiet-­‐Bara,	   1984).	   Among	   the	   other	  
events	   associated	   with	   Mg2+	   deficiency	   in	   brain	  
are	   opening	   of	   Ca2+	   channels,	   cellular	   entry	   of	  
Ca2+,	   release	   of	   certain	   neurotransmitters,	   activ-­‐
ation	   of	   NMDA	   receptors,	   membrane	   oxidation	  
and	   activation	   of	   nuclear	   factor	   kappa	   B	   (NFKB)	  
(Weglicki	  et	  al.,	  1994;	  Altura	  et	  al.,	  2003;	  Billard,	  
2006;	   Rayssiguier	   et	   al.,	   2010).	   On	   the	   other	  
hand,	   beneficial	   effects	   of	   magnesium	  
supplementation	   have	   been	   shown	   in	  
experimental	   models,	   and	   a	   variety	   of	  
mechanistic	   pathways	   have	   been	   put	   forward	  
including	   decrease	   in	   intracellular	   Ca2+	  
concentration,	   increase	   in	   antioxidant	   capacity	  
and	   induction	   of	   endothelial	   cell	   proliferation	  
(Kaya	  et	  al.,	  2001;	  2004;	  Esen	  et	  al.,	  2005;	  Euser	  
et	  al.,	  2008;	  Wolf	  et	  al.,	  2008;	  2009).	  	  
	  
Brain	  edema	  and	  magnesium	  
Two	   major	   types	   of	   brain	   edema,	   termed	  
cytotoxic	   and	   vasogenic	   edema,	   were	   described	  
by	   Klatzo	   in	   the	   late	   1960s,	   and	   later	   two	  more	  
types	   were	   added	   to	   the	   classification	   (Klatzo,	  
1967;	   Marmarou,	   2004;	   Nag	   et	   al.,	   2009).	  
Cytotoxic	   brain	   edema	   is	   characterized	   by	  
sustained	   intracellular	   water	   accumulation,	  
causing	   cellular	   injury	   in	   the	   absence	   of	   BBB	  
damage	   and	   involving	  mainly	   astrocytes.	   On	   the	  
other	   hand,	   vasogenic	   edema	   results	   in	  
extracellular	   water	   accumulation	   in	   brain	  
parenchyma	   through	   BBB	   disruption.	   The	   other	  
types	   of	   edema	   are	   interstitial	   edema,	   which	   is	  
observed	   in	   patients	   with	   hydrocephalus,	   and	  
osmotic	   edema	   caused	   by	   imbalances	   of	  
osmotically	   active	   substances,	   promoting	   water	  
influx	  into	  cells.	  
	  
Energy	  depletion	  followed	  by	  a	  failure	  of	  the	  Na+-­‐
K+	  ATPase	  plays	  a	  major	  role	   in	  the	  pathogenesis	  
of	   cytotoxic	   brain	   edema,	   and	   increased	   uptake	  
of	  Na+	  into	  the	  cell	  cannot	  be	  equilibrated	  by	  the	  
defective	   pump.	   Under	   certain	   pathological	  
conditions,	   such	   as	   traumatic	   brain	   injury	   (TBI),	  
cerebral	   ischemia	   and	   acute	   hypertension,	   the	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brain	  edema,	  which	  is	   initially	  cytotoxic,	  acquires	  
a	   vasogenic	   character	   in	   the	   following	   stages.	  
Brain	   edema	   caused	   by	   trauma	   has	   also	   been	  
proposed	  to	  be	  mainly	  vasogenic	  in	  nature	  due	  to	  
the	   opening	   of	   TJs	   in	   the	   BBB	   (Unterberg	   et	   al.,	  
2004).	   Magnesium	   supplementation	   has	   been	  
reported	   to	  decrease	   regional	  brain	   tissue	  water	  
content	   and	   attenuate	   brain	   edema	   formation	  
after	   experimental	   TBI	   (Okiyama	   et	   al.,	   1995;	  
Feldman	   et	   al.,	   1996).	   In	   addition,	   magnesium	  
treatment	  protects	  the	  blood-­‐spinal	  cord	  barrier,	  
improves	  clinical	   recovery,	  and	  preserves	  normal	  
spinal	   cord	   ultrastructure	   in	   experimental	   spinal	  
cord	  injury	  in	  rats	  (Kaptanoglu	  et	  al.,	  2003).	  	  
	  
Aquaporin	   (AQP)-­‐4,	  a	  bidirectional	   transmembrane	  
water	  channel	  expressed	  mainly	  in	  astrocytes	  and	  
to	   a	   lesser	   extent	   in	   barrier	   type	   of	   endothelial	  
cells	  and	  pial	  membranes,	  may	  play	  a	  crucial	  role	  
in	   the	   pathogenesis	   of	   cytotoxic	   and	   vasogenic	  
brain	   edema	   and	   aggravation/resolution	   of	  
ischemic	   and	   traumatic	   brain	   edema	   (Amiry-­‐
Moghaddam	   et	   al.,	   2003;	   Zador	   et	   al.,	   2009).	  
Experimental	   studies	   focusing	   on	   the	   treatment	  
of	   brain	   edema	   showed	   beneficial	   effects	   of	  
magnesium	   administered	   in	   combination	   with	  
various	   pharmacological	   drugs	   in	   animal	  models	  
(Royo	  et	  al.,	  2003;	  Sen	  and	  Gulati,	  2010).	  Upreg-­‐
ulation	   of	   AQP-­‐4	   in	   brain	   injury	   leads	   to	   an	  
increase	  in	  brain	  water	  content,	  resulting	  in	  brain	  
edema	  (Taniguchi	  et	  al.,	  2000;	  Papadopoulos	  and	  
Verkman,	   2005)	   and	   treatment	  with	  magnesium	  
causes	  the	  down-­‐regulation	  of	  AQP-­‐4	  (Ghabriel	  et	  
al.,	   2006)	   and	   thereby	   attenuates	   brain	   edema	  
(Okiyama	  et	  al.,	  1995).	  	  
	  
It	   has	   been	   reported	   that	   Mg2+	   exerts	  
neuroprotective	   effects	   in	   an	   anoxic	   insult	   by	  
improving	   the	   recovery	   of	   synaptic	   transmission	  
and	   blocking	   the	   loss	   of	   protein	   kinase	   C	   (PKC)	  
(Libien	   et	   al.,	   2005).	   These	   data	   are	  
mechanistically	   consistent	   with	   the	   observation	  
that	   the	   treatment	   of	   the	   astrocytes	  with	   a	   PKC	  
activator	  caused	  a	  rapid	  decrease	  in	  AQP-­‐4	  mRNA	  
and	   that	   this	   effect	   was	   inhibited	   by	   a	   specific	  
PKC	  inhibitor	  (Nakahama	  et	  al.,	  1999).	  Among	  the	  
other	  mechanisms	  put	   forward	  for	  the	  beneficial	  
effects	   of	   Mg2+	   in	   decreasing	   brain	   edema	   are	  
restriction	   of	   the	   opening	   of	   paracellular	  
pathways	  through	  Ca2+	  antagonism,	  alleviation	  of	  
the	   oxidative	   stress,	   and	   prevention	   of	  
hypertensive	   encephalopathy	   through	   reduction	  
in	   cerebral	   perfusion	   pressure	   (Belfort	   et	   al.,	  
2008;	  Euser	  and	  Cipolla	  2009).	  Mg2+	  has	  also	  been	  
shown	   to	   reduce	  brain	  edema	  and	  protect	  brain	  
morphology	   in	   experimental	   cold-­‐injury	   by	  
inhibition	   of	   lipid	   peroxidation	   (Turkoglu	   et	   al.,	  
2008).	  	  
	  
Blood-­‐brain	  barrier	  and	  magnesium	  
	  
Mg2+	  is	  slowly	  transported	  across	  the	  BBB	  into	  the	  
brain	   by	   transporters	   and	   exchangers	   located	   in	  
endothelial	   cell	   membranes,	   including	   the	  
Na+/Mg2+	   exchanger,	   the	   Mg2+/Ca2+	   exchanger	  
and	   cation	   channels.	   Following	   systemic	  
administration,	   regional	   increases	   in	   Mg2+	   has	  
been	   detected	   in	   the	   cerebral	   cortex	   and	  
hippocampus	  in	  rats	  with	  an	  intact	  BBB	  (Hallak	  et	  
al.,	  1992;	  Touyz,	  2008).	  In	  both	  physiological	  and	  
pathological	   conditions,	   Mg2+	   can	   directly	  
influence	  BBB	  properties.	  Low	  Mg2+	  concentration	  
in	   the	   circulation	   is	   associated	   with	   increase	   in	  
endothelial	   permeability,	   decrease	   in	   vasodilator	  
capacity	   and	   an	   increase	   in	   the	   production	   of	  
vasoconstrictor	   substances,	   cytokines	   and	  
oxidative	   products	   (Touyz,	   2003;	   Maier	   et	   al.,	  
2004).	   In	   pathological	   conditions	   with	   BBB	  
impairment,	   Mg2+	   passes	   into	   the	   extracellular	  
compartment	   of	   the	   brain	   in	   significantly	   higher	  
concentrations	  and	  plays	  an	  important	  role	  in	  the	  
pathophysiological	   processes	   that	   follow	   BBB	  
disruption.	   An	   elevation	   in	   free	   Mg2+	  
concentration	   in	   capillary	   endothelial	   cells	  
increases	   the	   proliferation	   of	   endothelial	   cells,	  
restores	   the	   cell's	   ability	   to	   generate	   and	   utilize	  
ATP	  for	  cellular	  repair	  mechanisms,	  and	  improves	  
disrupted	  BBB	   integrity	   in	   a	   variety	   of	   insults.	   In	  
addition	   to	   the	   stimulatory	   effect	   of	   Mg2+	   on	  
endothelial	   cell	   migration	   and	   proliferation,	   the	  
observation	   that	   high	   Mg2+	   concentration	  
facilitates	   the	   re-­‐endothelialization	   of	   vascular	  
injuries	   may	   also	   provide	   new	   insights	   into	   the	  
role	  of	  Mg2+	  in	  angiogenesis	  (Maier	  et	  al.,	  2004).	  
	  
	  A	   decrease	   in	  Mg2+	   level	   in	   the	  microcirculation	  
of	   the	   cortical	   structures	   causes	   a	   rapid	   and	  
progressive	   damage	   to	   microvessels,	   leading	   to	  
focal	   haemorrhages	   and	   brain	   edema	   (Altura	   et	  
al.,	   1991).	   Increasing	   brain	   bioavailability	   of	  
parenterally	  administered	  magnesium	  by	  artificial	  
BBB	   disruption	   has	   been	   considered	   as	   a	  
necessary	   step	   in	   assessing	   the	   therapeutic	  
benefits	  of	  magnesium	  supplementation	  after	  TBI	  
(Sen	   and	   Gulati,	   2010).	   Magnesium	   therapy	   has	  
been	   shown	   to	   be	   effective	   in	   a	   variety	   of	   animal	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models	   of	   experimental	   BBB	   disruption.	  
Accumulated	   data	   indicate	   that	   magnesium	  
administration	   improves	   functional	   outcome	  
following	   BBB	   disruption	   and	   decreases	   brain	  
edema	   (Okiyama	   et	   al.,	   1995;	   Feldman	   et	   al.,	  
1996;	  Kaya	  et	  al.,	  2004;	  Esen	  et	  al.,	  2005;	  Euser	  et	  
al.,	   2008).	   Treatment	   with	   magnesium	   and	   MK-­‐
801	   (dizocilpine),	   a	   noncompetitive	   NMDA	  
receptor	   antagonist,	   either	   alone	   or	   in	  
combination,	   can	   reduce	   brain	   edema	  
development	   and	   help	   to	   restore	   BBB	  
permeability	   after	   experimental	   diffuse	   brain	  
injury	  (Feng	  et	  al.,	  2004;	  Imer	  et	  al.,	  2009).	  	  
	  
One	  of	  the	  major	  mechanisms	  responsible	  for	  the	  
pharmacological	   action	   of	   Mg2+	   is	   blockage	   of	  
NMDA	   or	   alpha-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl	  
isoxazole-­‐4-­‐proprionic	   acid	   (AMPA)	   channels/	  
receptors	   in	   cerebral	   vascular	   system	   as	   well	   as	  
brain	   parenchyma	   (Huang	   et	   al.,	   1994).	   The	  
observation	   that	   blockade	   of	   NMDA	   or	   AMPA	  
receptors	  could	  attenuate	  BBB	  disruption	  in	  focal	  
cerebral	   ischemia	   suggest	   that	   ionotropic	  
glutamate	  receptors	  are	   involved,	  at	   least	  partly,	  
in	   BBB	   disruption	   (Liu	   et	   al.,	   2010).	   Magnesium	  
can	   modulate	   hypoxic-­‐ischemic	   events	   in	   the	  
cerebral	   cortex	   by	   blocking	   the	   action	   of	   local	  
putative	  excitatory	  amino	  acid	  neurotransmitters	  
and	   consequently,	   high	   extracellular	   Mg2+	   has	  
been	   shown	   to	   be	   effective	   in	   blocking	   the	  
pathophysiological	   mechanisms	   of	   rupture	   and	  
spasm	   in	   the	   brain	   microvasculature	   (Huang	   et	  
al.,	   1994;	   Chaon	   et	   al.,	   2006).	   Other	   possible	  
mechanisms	   of	   action	   of	   Mg2+	   in	   regulating	  
vascular	   function	   involve	   its	   antioxidant,	   anti-­‐
inflammatory,	   and	   growth	   regulatory	   properties	  
via	   which	   burden	   of	   oxidative	   stress	   and	  
inflammation	   in	   the	   endothelial	   cells	   of	  
microvessels	   are	   attenuated	   (Weglicki	   et	   al.,	  
1996;	  Mazur	  et	  al.,	  2007).	   In	  addition,	   treatment	  
of	   human	   endothelial	   cells	   with	   magnesium	   has	  
induced	   reduction	   of	   cellular	   pro-­‐oxidant	   levels	  
and	   diminished	   the	   release	   of	   pro-­‐inflammatory	  
cytokines	  (Wolf	  et	  al.,	  2008).	  	  
	  
Although	   the	   effects	   of	   magnesium	   on	   BBB	  
characteristics	  and	  the	  formation	  of	  brain	  edema	  
in	   various	   pathophysiological	   conditions	   has	   not	  
been	   thoroughly	   elucidated,	   the	   studies	  
mentioned	   above	   suggest	   that	   magnesium	  
provides	   protective	   effects	   on	   BBB	   integrity	   and	  
reduces	   brain	   edema	   by	   more	   than	   one	  
mechanism	  (Figure	  1).	  Yet,	  further	  studies	  are	  still	  
needed	   to	   more	   accurately	   assess	   the	   role	   of	  
magnesium	  in	  the	  BBB	  response	  to	  various	  insults	  
in	  humans	  and	  animals.	  	  
	  
Figure	  1.	  	  Effects	  of	  magnesium	  on	  BBB	  integrity.	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Blood-­‐brain	  barrier,	  magnesium	  and	  traumatic	  
brain	  injury	  
BBB	   disruption	   commonly	   occurs	   shortly	   after	  
experimental	   and	   clinical	   TBI.	   Brain	   intracellular	  
and	  extracellular	  Mg2+	   concentrations,	  as	  well	   as	  
serum	   Mg2+	   levels,	   are	   decreased	   following	  
central	   nervous	   system	   injury	   and	   a	   decline	   of	  
Mg2+	   concentration	   in	  brain	   can	   further	   increase	  
the	   severity	   of	   BBB	   disruption	   and	   be	   a	   critical	  
factor	   in	   the	   development	   of	   irreversible	   tissue	  
damage	  (Vink	  et	  al.,	  1987;	  Vink	  and	  Cernak,	  2000;	  
Vink	  et	  al.,	  2009).	  Reduction	  in	  brain	  intracellular	  
free	   Mg2+	   is	   also	   associated	   with	   brain	  
intracellular	  acidosis	  and	  a	  concomitant	  reduction	  
of	  brain	  energy	  stores	  (Vink	  et	  al.,	  1988;	  Altura	  et	  
al.,	  1995).	  
	  
Magnesium	   salts,	   such	   as	   magnesium	   sulphate	  
(MgSO4)	   or	   magnesium	   chloride	   were	   shown	   to	  
penetrate	   the	   BBB	   and	   cause	   enhancement	   of	  
brain	   intracellular	   free	   Mg2+	   concentration	  
following	   TBI	   (Heath	   and	   Vink,	   1999).	  
Accumulated	   data	   from	   animal	  models	   indicates	  
that	   administration	   of	   magnesium	   salts	   into	   the	  
circulation	   or	   extracellular	   brain	   compartments	  
can	  provide	  an	  effective	  therapy	  for	  TBI	  (Vink	  and	  
Cernak,	  2000;	  Saatman	  et	  al.,	  2001;	  Hoane,	  2007)	  
by	   improving	   BBB	   integrity	   and	   decreasing	   brain	  
edema	   (Esen	   et	   al.,	   2003).	   In	   contrast	   to	   the	  
animal	   studies	   mentioned	   above,	   McKee	   and	  
colleagues	   (McKee	   et	   al.,	   2005)	   described	   the	  
functional	   characteristics	   of	   the	   BBB	   in	   patients	  
with	  TBI	  by	  using	  MgSO4	   infusions	   initiated	  at	  an	  
average	   of	   5	   days	   after	   injury.	   The	   authors	  
showed	   that	   the	   increased	   serum	   Mg2+	  
concentrations	   yielded	   only	   a	   marginal	   increase	  
of	   total	   and	   ionized	   Mg2+	   in	   CSF	   and	   they	  
concluded	   that	   the	   regulation	   of	   magnesium	   by	  
the	  constituents	  of	  the	  BBB	  remains	  largely	  intact	  
following	  brain	   injuries.	  Meanwhile,	   in	  a	  double-­‐
blinded	   trial	   conducted	   to	   check	   the	   validity	   of	  
animal	   data	   in	   humans,	   and	   to	   explore	  whether	  
magnesium	   infusion	   initiated	   within	   8	   hours	   of	  
major	  head	  injury	  and	  continued	  for	  5	  days	  would	  
decrease	   mortality	   and	   improve	   the	   functional	  
outcome	  in	  head-­‐injured	  patients,	  it	  was	  reported	  
that	   there	   was	   no	   clinical	   suggestion	   of	   a	  
beneficial	   effect	   of	   the	   magnesium	   regimen	   in	  
these	  patients	  (Temkin	  et	  al.,	  2007).	  
	  
Based	   on	   the	   above-­‐mentioned	   data,	   it	   can	   be	  
concluded	   that	   although	   there	   has	   not	   been	   a	  
consensus	   between	   animal	   and	   human	   studies	  
regarding	   the	   efficiency	   of	   magnesium	  
administration	   in	   TBI,	   it	   can	   be	   effective	   in	   the	  
recovery	   of	   BBB	   damage	   at	   least	   in	   animal	  
models.	  
	  
Blood-­‐brain	  barrier,	  magnesium	  and	  seizures	  
Eclampsia	   is	   a	   serious	   hypertensive	   disorder	   of	  
pregnancy	   with	   seizures	   and	   associated	   BBB	  
disruption	  and	  vasogenic	  edema	  in	  a	  similar	  manner	  
to	  that	  observed	  in	  hypertensive	  encephalopathy	  
(Schwartz	  et	  al.,	  2000;	  Euser	  and	  Cipolla,	  2009).	  In	  
animal	   models,	   magnesium	   treatment	   has	   been	  
shown	  to	  contribute	  to	  the	  protection	  of	  the	  BBB	  
during	  eclampsia,	   to	  decrease	   the	   increased	  BBB	  
permeability,	  and	  to	  prevent	  the	  development	  of	  
brain	   edema	   in	   certain	   experimental	   settings,	  
including	   acute	   hypertension	   and	   hypoglycemia-­‐
induced	   seizures	   (Kaya	   et	   al.,	   2001	   and	   2004;	  
Euser	   et	   al.,	   2008).	   The	   above-­‐mentioned	  
beneficial	   effects	  of	  magnesium	  on	  BBB	   integrity	  
may	   be	   related	   to	   its	   ability	   to	   scavenge	   free	  
radicals.	  The	  antioxidant	  action	  of	  magnesium	  has	  
been	  reported	  in	  two	  recent	  studies	  (Ariza	  et	  al.,	  
2005;	   Turkoglu	   et	   al.,	   2008),	   suggesting	   that	   it	  
could	   protect	   against	   free	   radical	   surge	  
associated	   with	   epileptic	   seizures.	   However,	   the	  
exact	   mechanism/s	   of	   action	   of	   magnesium	  
treatment	  in	  the	  improvement	  of	  BBB	  integrity	  in	  
eclampsia	  still	  remains	  to	  be	  elucidated.	  
	  
Blood-­‐brain	  barrier,	  magnesium	  and	  sepsis	  
Magnesium	   supplementation	   is	   one	   of	   the	  
experimental	   methods	   and	   pharmacological	  
approaches	   developed	   for	   the	   treatment	   of	   BBB	  
disruption	   and	   brain	   edema	   caused	   by	   septic	  
encephalopathy.	  The	  impairment	  of	  BBB	  integrity	  
during	   sepsis	  has	  been	  shown	   in	   several	   studies,	  
and	  magnesium	  administration	  in	  the	  early	  stages	  
of	   sepsis	   reduced	   BBB	   permeability	   and	   brain	  
edema	   (Papadopoulos	   et	   al.,	   2005;	   Esen	   et	   al.,	  
2005).	   Magnesium	   deficiency	   leads	   to	   an	  
elevation	   in	   plasma	   inflammatory	   cytokines	   and	  
excessive	   production	   of	   free	   radicals,	   and	  
aggravates	  endotoxic	  shock	  (Weglicki	  et	  al.,	  1994;	  
Matsui	  et	  al.,	  2007).	  	  Treatment	  with	  magnesium	  
decreases	   the	   concentration	   of	   inflammatory	  
cytokines	   and	   free	   radicals	   and	   increases	  
antioxidant	   capacity	   and	   survival	   rate	   in	   rats	  
(Salem	   et	   al.,	   1995).	   Finally,	   alterations	   in	  
endothelial	   cells,	   which	   are	   protagonists	   in	   the	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vascular	   changes	   during	   inflammation,	   are	  
reversible	   upon	   magnesium	   supplementation	  
(Mazur	   et	   al.,	   2007).	   Although	   the	   above-­‐
mentioned	   studies	   suggest	   that	   magnesium	   is	  
involved	   in	   the	   protection	   of	   the	   BBB	   and	   brain	  
edema	   in	   sepsis,	   the	   literature	   data	   is	   quite	  
limited	   at	   present	   and	   additional	   studies	   are	  
needed	   to	   explain	   the	   pathophysiologic	  
mechanisms	  involved	  in	  this	  protection.	  
	  
Blood-­‐brain	  barrier,	  magnesium	  and	  brain	  
hypoxia/ischemia	  	  
Cerebral	   hypoxia/ischemia	   is	   known	   to	   cause	  
disruption	   of	   BBB	   integrity,	   thereby	   increasing	  
the	   permeability	   of	   the	   BBB	   and	   leading	   to	   the	  
development	   of	   brain	   edema.	   Extracellular	  Mg2+	  
concentration	   has	   been	   shown	   to	   significantly	  
decrease	  to	  approximately	  60%	  of	  basal	  values	  in	  
the	   ipsilateral	   cortex	   in	  hypoxia-­‐ischemia	   (Lee	  et	  
al.,	   2002).	  Meanwhile,	   magnesium	   deficient	   rats	  
are	   more	   susceptible	   to	   cerebral	   hypoxia/	  
ischemia	   than	   rats	   fed	   with	   a	   normal	   or	   high	  
magnesium	   diet	   (Demougeot	   et	   al.,	   2004).	  
Magnesium	  administration	  significantly	  attenuates	  
the	   hypoxia-­‐induced	   increase	   in	   reactive	   oxygen	  
species	   and	   contributes	   to	   the	   repair	   of	   the	  
disrupted	   BBB	   in	   hypoxia/ischemia	   (Ravishankar	  
et	   al.,	   2001;	   Goñi-­‐de-­‐Cerio	   et	   al.,	   2009).	   The	  
protection	   of	   the	   BBB	   by	  magnesium	   in	   hypoxic	  
conditions	  could	  be	  multifactorial	  and,	  in	  addition	  
to	   the	   above	   mentioned	   effects,	   may	   involve	  
other	   factors	  such	  as	  decrease	   in	   the	  production	  
of	   cytokines,	   increase	   in	   antioxidative	   products	  
and	   blockade	   of	   NMDA	   or	   AMPA	   channels/	  
receptors.	   There	   is	   at	   present	   only	   limited	  
knowledge	  about	   the	   role	  of	  magnesium	  on	  BBB	  
integrity	   and	   brain	   edema	   in	   hypoxia/ischemia	  
and	   future	   research	   is	   needed	   to	   determine	   the	  
possible	  mechanisms	  of	  magnesium	  supplement-­‐
ation	  in	  improving	  the	  functions	  of	  BBB.	  	  
	  
Blood-­‐brain	  barrier,	  magnesium	  and	  ethanol	  
Acute	  and	  chronic	  ethanol	  treatment	  gives	  rise	  to	  
significant	   increases	   in	   BBB	   permeability	   to	   a	  
variety	   of	   molecules	   that	   do	   not	   normally	   cross	  
the	  BBB.	  Increase	  in	  free	  radical	  concentration	  in	  
ethanol-­‐treated	   endothelial	   cells	   leads	   to	  
phosphorylation	   of	   TJ	   proteins,	   activation	   of	  
paracellular	   pathway	   and	   thus	   disruption	   of	   the	  
BBB	   (Haorah	   et	   al.,	   2005).	   A	   number	   of	   studies	  
have	   provided	   evidence	   for	   the	   alterations	   in	  
serum	   Mg2+	   levels	   in	   acute	   and	   chronic	   ethanol	  
treatments.	   A	   single	   dose	   of	   ethanol	   (2	   g/kg)	  
injected	   to	   mice	   significantly	   decreased	   total	  
Mg2+	  concentration	  in	  serum	  (Papierkowski	  et	  al.,	  
1998).	   Furthermore,	   acute	   or	   chronic	   alcohol	  
consumption	   impairs	   Mg2+	   transport	   and	  
homeostasis	   at	   the	   capillary	   level	   in	   the	   brain	  
(Romani,	   2008).	   However,	   little	   is	   known	   about	  
whether	  any	  improvement	  in	  BBB	  integrity	  can	  be	  
achieved	   by	   magnesium	   treatment	   in	   acute	   or	  
chronic	   ethanol	   intake.	   Therefore,	   this	   lack	   of	  
basic	   knowledge	   compounds	   the	   difficulty	   we	  
face	  when	   interpreting	  the	   importance	  of	  efforts	  
of	   increasing	   serum	   Mg2+	   levels	   under	   these	  
conditions.	  	  
	  
Blood-­‐brain	  barrier,	  magnesium	  and	  
hydrocephalus	  
Human	   and	   animal	   studies	   have	   indicated	   that	  
hydrocephalus	  leads	  to	  disruption	  of	  the	  BBB.	  In	  a	  
study	  involving	  a	  total	  of	  21	  patients	  with	  normal-­‐
pressure	   hydrocephalus,	   a	   slight	   plasma-­‐like	  
protein	  pattern	  has	  been	  demonstrated	  in	  CSF	  in	  
38%	  of	  the	  patients	  prior	  to	  surgical	  intervention,	  
indicating	   BBB	   dysfunction	   (Wikkelsø	   and	  
Blomstrand,	  1982).	  There	  is	  only	  one	  study	  in	  the	  
current	   literature	   that	   evaluates	   the	   effects	   of	  
magnesium	   in	   hydrocephalus,	   and	   a	   mild	  
protection	  against	  brain	  damage	  was	  shown	  using	  
MgSO4	  therapy	  in	  a	  rat	  model	  of	  childhood-­‐onset	  
hydrocephalus	  (Khan	  et	  al.,	  2003).	  Further	  studies	  
are	   necessary	   to	   increase	   our	   understanding	   of	  
the	   effects	   of	   deficiency	   or	   supplementation	   of	  
magnesium	   on	   the	   functional	   and	   structural	  
characteristics	   of	   the	   BBB	   during	   hydrocephalus	  
in	  both	  animal	  and	  human	  studies.	  
	  
Conclusion	  
It	   is	   clear	   from	   the	   discussion	   above	   that	  
magnesium	   plays	   a	   variety	   of	   essential	   roles	  
within	  the	  cell	  by	  modulating	  the	  activity	  of	  more	  
than	  325	  enzymes	   as	   a	   cofactor.	   These	   enzymes	  
are	  important	  for	  the	  survival	  of	  various	  cell	  types	  
including	  endothelial	  cells	  of	  the	  BBB.	  Meanwhile,	  
magnesium	   deficiency	   leads	   to	   or	   worsens	   a	  
variety	  of	   central	  nervous	   system	  pathologies	  by	  
increasing	   inflammatory	   cytokines	   and	   reactive	  
oxygen	   species	   and	   disturbing	   the	   activity	   of	  
transporters	  in	  neurons,	  astrocytes,	  pericytes	  and	  
capillary	   endothelial	   cells,	   which	   together	  
constitute	   the	   neurovascular	   unit	   of	   the	   brain.	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Besides,	  the	  alterations	  in	  the	  Mg2+	  concentration	  
in	   intra-­‐	   and	   extracellular	   fluids	   are	   associated	  
with	   development	   or	   aggravation	   of	   BBB	  
disruption	   and	   brain	   edema	   in	   various	   clinical	  
disorders	  and	  experimental	  settings.	  On	  the	  other	  
hand,	   magnesium	   supplementation	   can	   play	  
multiple	   roles	   in	   protecting	   BBB	   integrity	   and	  
improving	   brain	   edema.	   However,	   owing	   to	   the	  
availability	   of	   limited	   knowledge,	   it	   is	   hard	   to	  
come	  to	  a	  full	  understanding	  of	  the	  highly	  specific	  
actions	  of	  magnesium	  on	  BBB	  integrity	  and	  brain	  
edema	   in	   the	   course	   of	   a	   variety	   of	  
pathophysiologies	   involving	   the	   BBB.	   For	   this	  
reason,	   research	   in	   this	   field	   should	   continue	   in	  
order	   to	   provide	   a	   thorough	   explanation	   of	   the	  
impact	   of	   magnesium	   on	   the	   BBB,	   brain	   edema	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Hearing	  loss	  is	  a	  major	  public	  health	  problem	  with	  a	  large	  number	  of	  causes.	  Among	  them,	  noise-­‐induced	  
hearing	  loss,	  drug	  ototoxicity	  and	  sudden	  sensorineural	  hearing	  loss	  have	  been	  proven	  to	  result,	  in	  part,	  
from	  metabolic	  disorders.	  Metabolic	  disorders	  have	  multiple	  origins	  such	  as	   ionic,	   ischemic,	  excitotoxic	  
and	   production	   of	   cochlear	   free	   radicals	   causing	   cell	   death,	   via	   necrosis	   or	   apoptosis.	   The	   efficacy	   of	  
magnesium,	   administered	   either	   to	   prevent	   or	   to	   treat	   hearing	   damage,	   has	   been	   demonstrated	   in	  
several	   studies	   in	   animals	   and	   in	   humans,	   particularly	   in	   noise-­‐induced	   hearing	   loss.	   The	   exact	  
mechanism	   by	   which	   Mg2+	   acts	   is	   not	   fully	   known.	   Different	   hypotheses	   exist	   including	   calcium	  
antagonism,	   vasodilatation,	   antioxidant	   and	   anti-­‐NMDA	   properties.	   Because	   it	   is	   a	   relatively	   safe	   and	  
well-­‐known	   treatment,	   magnesium	   therapy,	   alone	   or	   in	   association,	   could	   be	   of	   a	   great	   interest	   to	  




According	  to	  the	  World	  Health	  Organization,	  278	  
million	   people	   worldwide	   have	   moderate	   to	  
profound	   hearing	   loss	   in	   both	   ears.	   Besides	  
pathologies	   of	   unknown	   origin,	   such	   as	   sudden	  
hearing	   loss	   and	  Meniere’s	   disease,	   hearing	   loss	  
has	  so	  many	  known	  causes;	   it	  would	  be	  arduous	  
to	  list	  them	  all.	  Briefly,	  it	  can	  be	  due	  to	  the	  aging	  
process,	   exposure	   to	   loud	   noise,	   certain	  
medications,	   infections,	   head	   or	   ear	   trauma,	  
congenital	  or	  hereditary	  factors,	  diseases,	  as	  well	  
as	   a	   number	   of	   other	   causes.	   In	   noise-­‐induced	  
hearing	  loss	  (NIHL),	  sudden	  sensorineural	  hearing	  
loss	  (SSHL)	  or	  iatrogenic	  hearing	  loss	  (ototoxicity),	  
sensory	   cell	   death	   involves	  metabolic	   processes.	  
Pharmacological	   intervention	   to	   prevent	   or	  
ameliorate	   the	   evolution	   of	   these	   hearing	  
impairments,	   as	   well	   as	   susceptibility	   factors,	  
have	   been	   studied	   for	   a	   number	   of	   years	   in	  
animal	   models	   or	   in	   humans.	   Among	   them,	  
magnesium	   seems	   to	   play	   an	   important	   role.	  
Magnesium	  therapy	   is	  well	  documented	  because	  
it	   is	   usually	   prescribed	   in	   other	   pathologies.	   Its	  
side	  effects	   and	   contraindications	  are	   few	  and	   it	  
is	   cheap.	   Magnesium,	   which	   easily	   crosses	   the	  
hematocochlear	   barrier,	   presents	   neuro-­‐
protective	  and	  vasodilatory	  effects,	  and	  is	  able	  to	  
limit	   cochlear	   damage.	   These	   observations	   have	  
led	  to	  many	  investigations,	  the	  aim	  of	  them	  being	  
to	   evaluate	   the	   pertinence	   of	   magnesium	  
administration	  in	  prevention	  or	  treatment	  in	  such	  
a	  hearing	  impairment.	  This	  article	  presents	  some	  
arguments	   that	   emphasize	   the	   interest	   of	  
magnesium	   therapy	   in	   some	   forms	   of	   hearing	  
loss.	  	  	  	  
How	  can	  we	  hear?	  
 
Sound	  waves	  are	  transmitted	  via	  the	  bones	  of	  the	  
middle	  ear	   to	  the	   fluid	  environment	  of	   the	   inner	  
ear,	   where	   the	   sensory	   organ	   is	   in	   the	   cochlea.	  
The	   human	   cochlea	   is	   a	   30-­‐35	   mm	   long	   coiled	  
tube	   containing	   three	   parallel	   chambers	   (Figure	  
1A):	   the	   scala	   vestibuli	   and	   the	   scala	   tympani,	  
which	   both	   contain	   perilymph,	   and	   the	   scala	  
media,	  which	  contains	  endolymph.	   In	  contrast	  to	  
perilymph,	  which	  is	  similar	  to	  cerebrospinal	  fluid,	  
endolymph	  contains	  a	  large	  amount	  of	  potassium	  
(154	   mM)	   maintained	   by	   the	   cells	   of	   the	   stria	  
vascularis.	   The	   organ	   of	   Corti	   (Figure	   1B)	   is	  
composed	  of	  supporting	  cells	  and	  hair	  cells.	  Of	  all	  
the	   sensory	   organs,	   the	   organ	   of	   Corti	   functions	  
with	   the	   smallest	   number	   of	   sensory	   receptor	  
cells.	   The	   human	   cochlea	   only	   contains	   about	  
15,000	   hair	   cells,	   including	   approximately	   3,000	  
inner	  hair	  cells	   (IHCs)	  and	  12,000	  outer	  hair	  cells	  
(OHCs).	   The	   IHCs	   form	   one	   row	   (Figure	   2A)	   and	  
are	   the	   primary	   sensory	   receptors.	   OHCs	   are	  
organized	  into	  three	  (and	  sometimes	  four)	  rows	  	  





Figure	   1.	   Schematic	   representation	   of	   the	   inner	  
ear.	  A:	  section	  of	  the	  cochlea;	  B:	  organ	  of	  Corti.	  
	  
	  
along	   the	   outer	   edge	   of	   the	   organ	   of	   Corti.	   The	  
longer	   stereocilia	   of	   the	   OHCs	   are	   connected	   to	  
the	  tectorial	  membrane.	  	  
	  
In	   the	   hearing	   process,	   sound	   reaches	   the	   inner	  
ear	  and	  the	  basilar	  membrane	  supporting	  the	  hair	  
cells	   is	   displaced.	   When	   the	   hair	   bundle	   is	  
deflected,	  transduction	  channels	  are	  opened	  and	  
K+	  enters	  the	  hair	  cells.	  The	  depolarisation	  evoked	  
by	   this	   transduction	   current	   activates	   voltage-­‐
gated	   Ca2+channels	   and	   Ca2+	   influx.	   In	   IHCs,	  
increased	  intracellular	  Ca2+	  causes	  mobilization	  of	  
synaptic	   vesicles	   and	   exocytotic	   release	   of	  
glutamate	  at	  the	  base	  of	  the	  hair	  cells.	  Glutamate	  
release	   modulates	   the	   activity	   of	   the	   auditory	  
nerve	   fibres	   by	   activating	   specific	   receptors,	  
among	   them	   the	   glutamate	   ionotropic	   receptors	  
(AMPA,	   NMDA	   and	   Kainite)	   and	   the	   metabo-­‐
tropic	   receptors.	   The	   OHCs	   respond	   quite	  
differently	   to	   changes	   in	   membrane	   potential.	  
Their	   membranes	   include	   a	   protein	   (prestin),	  
which	   alters	   conformation	   with	   the	   membrane	  
potential	   and	   forces	   cell	   length	   changes	   at	  
acoustic	   frequencies.	   This	  mechanism	   is	   thought	  
to	  amplify	  and	  tune	  the	  mechanical	  responses	  of	  
the	  basilar	  membrane.	  This	   sensory	   system	   is	   so	  
efficient	   that,	   near	   auditory	   threshold,	   a	   sound	  
vibration	  of	  less	  than	  0.1	  nanometres	  is	  detected,	  
corresponding	   to	   a	   stereocilia	   displacement	  
10,000	  times	   lower	  than	   its	  diameter	  (about	  one	  
micrometre).	   However,	   exposure	   to	   loud	   noise	  
can	  weaken	  the	  system.	  	  
	  
Magnesium	  and	  noise-­‐induced	  hearing	  loss	  
(NIHL)	  
	  
Excessive	   noise	   is	   the	   predominant	   cause	   of	  
permanent	   sensorineural	   hearing	   loss.	   Reports	  
from	  WHO	  (2004)	  state	   that	  “worldwide,	  16%	  of	  
the	  disabling	  hearing	  loss	  in	  adults	  is	  attributed	  to	  
occupational	   noise,	   ranging	   from	   7%	   to	   21%	   in	  
the	   various	   subregions”.	   At	   least	   30	   million	  
people	  in	  the	  United	  States	  encounter	  hazardous	  
levels	  of	  noise	  at	  work,	  particularly	  in	  jobs	  such	  as	  
construction,	  mining,	   agriculture,	  manufacturing,	  
transportation	  and	  in	  the	  military.	  Moreover,	  the	  
incidence	   of	   NIHL	   continues	   to	   grow,	   partly	   due	  
to	   the	   growing	   popularity	   of	   portable	   music	  
players	  with	  highly	  efficient	  headphones	  (Zhao	  et	  
al.,	   2010).	   The	   hearing	   loss	   can	   be	   caused	   by	   a	  
single	   exposure	   to	   very	   loud	   sounds	   (impulse	  
noise)	  or	  by	  repeated	  exposure	  to	  louder	  sounds	  
over	   an	   extended	   period.	   It	   may	   be	   temporary	  
(temporary	   threshold	   shifts,	   TTS)	   or	   permanent	  
(permanent	  threshold	  shifts,	  PTS).	  It	  is	  frequently	  
associated	  with	  tinnitus.	  
	  
The	   mechanisms	   of	   damage	   are	   of	   dual	   origin,	  
mechanical	  and	  metabolic.	  Mechanical	  damage	  is	  
immediately	  developed	  when	   the	  movements	  of	  
the	   basilar	   membrane	   are	   excessive,	   thus	  
inducing	  detachment	  of	  the	  hairs	  of	  the	  tectorial	  
membrane,	   disconnection	   of	   the	   interciliary	  
bridges	   (Figure	   2D),	   or	   even	   rupture	   of	  
membranes.	  Modern	   research	  has	  provided	  new	  
insights	   into	   the	   biological	   mechanisms	   of	   NIHL	  
such	  as	  free	  radical	  production	  (oxidative	  stress),	  
glutamatergic	   excitotoxicity,	   and	   ionic	   and	  
ischemic	   disorders.	   They	   are	   responsible	   for	  
delayed	  hair	  cell	  death	  by	  necrosis	  and	  apoptosis.	  
	  
Oxidative	  stress	  	  
It	   has	   been	   demonstrated	   that	   an	   increase	   in	  
reactive	   oxygen	   and	   nitrogen	   species	   (ROS	   and	  
RNS,	   respectively)	   is	   involved	   in	   noise	   trauma	  
(see	   Henderson	   et	   al.,	   2006	   for	   review).	   The	  
superoxide	  radical	  anion,	  nitric	  oxide	  (NO)	  and	  its	  
redox-­‐related	   forms,	   in	   conjunction	   with	   an	  
imbalance	   of	   antioxidant	   defences,	   have	   been	  
demonstrated	  to	  play	  a	  significant	  role	  in	  NIHL	  as	  
they	   largely	   participate	   in	   cellular	   mechanisms	  
that	   underlie	   hair	   cell	   death.	   ROS	   ototoxicity	   is	  
believed	  to	  be	  associated	  with	  deleterious	  cellular	  




Figure	   2.	   A,	   B:	   normal	   aspect	   of	   the	   hair	   cells	   and	   their	   stereocilia,	   observed	   with	   scanning	   electron	  
microscopy.	  C	  and	  D:	  Organ	  of	  Corti	  after	  traumatizing	  noise	  exposure:	  OHCs	  are	  partially	  missing	  (C).	  The	  





effects	   at	   multiple	   sites,	   including	   lipid	  
peroxidation,	   DNA	   strand	   breaks,	   alteration	   in	  
carbohydrate	   and	   protein	   structures,	   and	   a	  
triggering	   of	   cell	   death	   gene	   expression,	   leading	  
to	   necrosis	   or	   apoptosis.	   Oxidants	   are	   also	  
initiators	   of	   intracellular	   cell	   death	   signalling	  
pathways	  that	  may	   lead	  to	  apoptosis.	  The	  noise-­‐
induced	  ROS	  formation	  may	  occur	  with	  a	  delay	  of	  
7-­‐10	  days	  following	  exposure	  to	  noise	  (Yamashita	  
et	  al.,	  2004).	  
	  	  
Excitotoxicity	  
Excitotoxicity	   is	   a	   phenomenon	   of	   biochemical	  
events,	   triggered	  by	   the	   interaction	  of	  excitatory	  
amino	   acids	   with	   ion	   channel-­‐bound	   receptor	  
complexes,	   that	   can	   lead	   to	   cell	   death.	   During	  
high-­‐level	   noise	   exposure,	   the	   IHCs	   are	   highly	  
active,	  leading	  to	  the	  release	  of	  large	  amounts	  of	  
glutamate	   into	   the	   synapses	   with	   the	   auditory	  
fibres.	  The	  level	  of	  glutamate	  in	  the	  synapses	  can	  
overstimulate	  the	  glutamate	  receptors,	  especially	  
the	   NMDA	   receptors,	   and	   result	   in	   high	  
intracellular	   Ca2+	   levels.	   The	   increase	   in	   cytosolic	  
Ca2+concentration	  is	  not	  only	  caused	  by	  an	  influx	  
of	   extracellular	   Ca2+,	   but	   also	   by	   the	   release	   of	  
calcium	  ions	  from	  intracellular	  stores	  such	  as	  the	  
endoplasmic	   reticulum	  or	  mitochondria.	  Dendritic	  
swelling	   and	   vacuolization	   are	   a	   result	   of	  
excessive	   postsynaptic	   ion	   influx	   into	   the	   VIIIth	  
nerve	   terminals	   at	   the	   inner	   hair	   cell	   synapse	  
(Pujol	  et	  al.,	  1990).	  	  
	  
Ionic	  disorders	  
High-­‐level	   noise	   stimulation	   results	   in	   a	  massive	  
entrance	   of	   potassium	   through	   the	   apical	  
channels	  of	  the	  stereocilia.	  Moreover,	  mechanical	  
damage	   with	   ruptures	   of	   the	   membranes	   lining	  
the	   endolymphatic	   spaces,	   could	   involve	   an	  
excessive	   influx	   of	   K+.	   This	   increased	   K+	  
concentration	   may	   be	   toxic	   for	   the	   hair	   cells	  
(Zenner,	   1986).	   The	   consecutive	   increase	   in	  
intracellular	   Ca2+	   over-­‐activates	   a	   series	   of	  
enzymes	   including	   phospholipases,	   proteases,	  
and	   endonucleases.	   The	   result	   is	   membrane	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breakdown,	   depolymerization	   of	   microtubules	  
and	  disruption	  of	  protein	  synthesis.	  	  
	  
Ischemic	  process	  
Unlike	   most	   tissues	   in	   which	   increased	  
metabolism	   increases	   blood	   flow	   to	   provide	  
additional	   oxygen	   to	   stressed	   cells,	   the	   cochlea	  
shows	   reduced	   blood	   vessel	   diameter	   and	   red	  
blood	  cell	  velocity	  (Quirk	  and	  Seidman,	  1995)	  and	  
decreased	   blood	   flow	   (Thorne	   and	  Nuttal,	   1987)	  
post-­‐noise.	  This	  noise-­‐induced	  vasoconstriction	  is	  
a	  direct	  consequence	  of	  noise-­‐induced	  formation	  
of	   8-­‐isoprostane-­‐F2a,	   a	   vasoactive	   by-­‐product	   of	  
free	   radicals	   (Miller	   et	   al.,	   2003).	   Cochlear	  
ischemia	   is	   aggravated	   in	   animals	  with	   low	  Mg2+	  
content	  (Scheibe	  et	  al.,	  2000a).	  	  	  
	  
These	   different	   mechanisms	   can	   lead	   to	   cell	  
death,	  which	  may	   be	  more	   or	   less	   rapid,	   due	   to	  
necrosis	   or	   apoptosis	   (Yang	  et	   al.,	   2004).	   Recent	  
studies	  have	  revealed	  that	  these	  two	  types	  of	  cell	  
death	   exist	   following	   exposure	   to	   intense	   noise	  
and	   that	   apoptosis	   appears	   extremely	   rapidly	  
after	  the	  noise	  stress.	  Apoptosis	  has	  been	  shown	  
to	  be	  the	  primary	  cell	  death	  pathway	   in	   the	   first	  
day	   following	   noise	   exposure	   (Hu	   et	   al.,	   2002;	  
2006).	  	  
	  
Contrary	   to	   birds	   or	   reptiles,	   a	   mammal’s	  
auditory	   hair	   cells	   do	   not	   regenerate	   if	   they	   are	  
destroyed.	   Thus,	   these	   new	   metabolic	   insights	  
bring	   hope	   for	   possible	   prevention	   or	   treatment	  
to	   limit	   oxidative	   stress,	   ischemia	   and	   the	  
apoptosis	  cascade.	  A	  large	  number	  of	  treatments	  
have	  been	  tested	  over	  the	   last	   few	  years	  (see	  Le	  
Prell	  et	  al.,	  2007a;	  Shibata	  and	  Raphael,	  2010	  for	  
reviews).	   Among	   them,	  magnesium	   has	   aroused	  
some	  interest.	  	  
	  
Over	   a	   number	   of	   years,	   researchers	   and	  
clinicians	   have	   demonstrated	   the	   influence	   of	  
magnesium	   in	   the	   susceptibility	   to	   recover	  
following	   acoustic	   trauma.	   NIHL	   of	   guinea	   pigs	  
was	   found	   to	   increase	   with	   decreasing	   Mg2+	  
content	   of	   the	   drinking	   water	   while	   the	   Mg2+	  
content	  of	  the	  food	  was	  low	  and	  constant.	  In	  Mg-­‐
deficient	  guinea	  pigs,	   the	  hearing	   threshold	   shift	  
after	   10	   days	   of	   continuous	   noise	   exposure	  was	  
negatively	   correlated	   to	   the	  Mg2+	   content	  of	   the	  
perilymph	   (Ising	   et	   al.,	   1982).	   Coherent	   results	  
were	   obtained	   in	   rats	   (Joachims	   et	   al.,	   1983).	  
Similarly,	   electrocochleographic	   measurements	  
of	   the	   auditory	   threshold	   shifts	   induced	   by	  
impulse	  noises	  (Devrière	  et	  al.,	  1991)	  showed	  that	  
Mg-­‐deficient	   animals	   are	   slightly	   more	  
susceptible	   to	   this	   type	   of	   noise.	   This	  
susceptibility	  is	  less	  pronounced	  than	  after	  a	  long	  
duration	   exposure	   to	   a	   continuous	   noise,	   as	  
observed	  in	  the	  previous	  experiments	  (Ising	  et	  al.,	  
1982).	  After	  exposure	  to	  continuous	  noise,	  up	  to	  
75%	  of	  the	  variance	  of	  PTS	  in	  guinea	  pigs	  could	  be	  
explained	   by	   the	   level	   of	   perilymph	   Mg2+	  
(Vormann	   and	   Günther,	   1993).	   The	   increased	  
susceptibility	   to	   NIHL	   with	   Mg2+	   deficit	   has	   not	  
only	   been	   demonstrated	   in	   animal	   experiments.	  
In	   a	   retrospective	   study	   in	   humans,	   subjective	  
thresholds	   across	   frequencies	   of	   3,	   4	   and	   5	   kHz	  
were	   negatively	   correlated	   with	   serum	  
magnesium	   (Joachims	   et	   al.,	   1987).	   This	   finding	  
was	  the	  first	   indication	  that	  magnesium	  status	  in	  
humans	   may	   be	   one	   of	   the	   factors	   determining	  
variations	   in	   sensitivity	   to	   noise-­‐induced	   hearing	  
loss.	   Günther	   et	   al.,	   (1989)	   reported	   that	   NIHL	  
observed	   in	   24	   air	   force	   pilots	   was	   negatively	  
correlated	   to	   serum	   Mg2+	   concentration.	  
However,	   Walden	   et	   al.,	   (2000),	   exploring	   the	  
susceptibility	   of	   soldiers	   to	   NIHL,	   failed	   to	  
demonstrate	   any	   correlation	   between	  
audiometric	  index	  and	  body	  magnesium.	  	  
	  
Because	   Mg2+	   deficiency	   increases	   the	  
susceptibility	   to	  NIHL,	   several	   studies	   have	   been	  
conducted	   in	   animals	   or	   in	   humans	   to	   point	   out	  
the	  possible	  prophylactic	  efficacy	  of	  magnesium.	  
Joachims	  et	  al.,	   (1983)	  observed	  that	  guinea	  pigs	  
with	   physiologically	   high	   Mg2+	   levels,	   when	  
exposed	   to	   a	   single	   shot	   impulse	   or	   a	   series	   of	  
impulses,	   had	   significantly	   smaller	   threshold	  
increases	   as	   compared	   to	   physiologically	   low	  
Mg2+	  animals.	  Scheibe	  et	  al.,	  (2000b)	  showed	  that	  
oral	   magnesium	   supplementation	   significantly	  
reduces	  TTS	  and	  PTS	  in	  guinea	  pigs	  subjected	  to	  a	  
series	   of	   impulses.	   The	   mean	   PTS	   was	   found	   to	  
correlate	   negatively	   with	   the	   total	   Mg2+	  
concentration	   of	   perilymph	   and	   plasma.	  
Conversely,	   they	   did	   not	   observe	   any	   significant	  
effect	   on	   PTS	   following	   exposure	   to	   a	   gunshot	  
noise.	   More	   recently,	   Attias	   et	   al.,	   (2003)	  
explored	   the	   activity	   of	   the	   outer	   hair	   cells	   in	  
guinea	   pigs	   by	   means	   of	   otoacoustic	   emission	  
after	   impulse	   noise	   exposure.	   In	   animals	  
supplemented	   with	   Mg2+,	   the	   thresholds	   were	  
less	   significantly	   affected	   by	   noise	   exposure	   and	  
the	   audition	   recovery	   was	   faster.	   In	   humans,	  
preventive	  administration	  of	  magnesium	  has	  also	  
been	   shown	   to	   be	   effective	   in	   noise-­‐related	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hearing	   loss.	   Attias	   et	   al.,	   (1994)	   tested	   the	  
prophylactic	   effect	   of	   magnesium	   in	   human	  
subjects	   exposed	   to	   hazardous	   noise.	   The	   study	  
was	   carried	   out	   in	   300	   young,	   normal-­‐hearing	  
recruits	   who	   underwent	   2	   months	   of	   basic	  
military	   training.	   This	   training	   included	   repeated	  
exposure	   to	   high	   levels	   of	   impulse	   noises	   while	  
using	   earplugs.	   The	   subjects	   received	   an	  
additional	   drink	   daily	   containing	   either	   167	   mg	  
magnesium	  aspartate	  or	  a	  placebo.	  The	  NIHL	  was	  
significantly	   more	   frequent	   and	   more	   severe	   in	  
the	   placebo	   group	   (28.5%)	   than	   in	   the	  
magnesium	   group	   (11.2%).	   Moreover,	   the	  
severity	  of	  the	  NIHL	  was	  negatively	  correlated	  to	  
the	  magnesium	  content	  of	   red	  and	  mononuclear	  
cells.	   This	   prophylactic	   effect	   in	   humans	   was	  
confirmed	   by	   Attias	   et	   al.,	   (2004)	   for	   temporary	  
threshold	   shifts.	   Subjects	   were	   exposed	   to	   a	  
traumatizing	   noise	   over	   10	   min	   in	   order	   to	  
produce	   TTS	   without	   PTS.	   Compared	   to	   a	  
placebo,	  the	  preventive	  oral	  intake	  of	  magnesium	  
(122	  mg	  Mg2+	  aspartate	  during	  10	  days)	  provided	  
significant	   protection	   against	   TTS.	   A	   negative	  
correlation	  between	  the	  blood	  magnesium	  levels	  
and	  the	  TTS	  was	  also	  noted.	  	  
	  
Whilst	  magnesium	   is	  well	  known	  as	  a	  preventive	  
treatment	  for	  sound	  trauma,	  it	  may	  also	  be	  useful	  
therapeutically.	   In	   animals	   submitted	   to	   a	   series	  
of	  sound	  impulses,	  the	  systemic	  administration	  of	  
magnesium	   significantly	   reduced	   hearing	   loss	  
after	   7	   days	   (Scheibe	   et	   al.,	   2001;	   2002).	   This	  
treatment	   was	   more	   effective	   if	   it	   was	   quickly	  
instigated.	  Threshold	  shift	   reduction	  7	  days	  after	  
acoustic	   trauma	   in	   guinea	   pigs	   was	   confirmed	  
using	   distortion	   product	   otoacoustic	   emissions	  
(DPOAE,	   a	   non	   invasive	   technique	   to	   test	   OHC	  
function)(Haupt	   et	   al.,	   2003).	   In	   another	   study	  
(Sendowski	  et	  al.,	  2006)	  it	  has	  been	  shown	  that	  a	  
7-­‐day	   post-­‐trauma	   magnesium	   treatment	  
reduced	  auditory	  threshold	  shift	  measured	  seven	  
days	  after	  gunshot	  noise	  exposure.	  However,	  this	  
improvement	   was	   temporary,	   suggesting	   that	   it	  
could	   be	   potentially	   beneficial	   to	   prolong	   the	  
magnesium	   administration.	   This	   hypothesis	   has	  
since	   been	   confirmed	   (Abaamrane	   et	   al.,	   2009).	  
The	   latter	   study	   compared	   4	   post-­‐NIHL	  
treatments	  –	  a	  7-­‐day	  magnesium	  treatment,	  a	  1-­‐
month	   magnesium	   treatment,	   conventional	  
therapy	  with	  methylprednisolone,	  or	  a	  placebo.	  It	  
was	   demonstrated	   that	   3	   months	   after	   an	  
impulse	   noise	   trauma,	   the	   1-­‐month	   Mg	  
treatment	   preserved	  more	   hair	   cells	   from	   death	  
(Figure	  3),	  but	  this	  preservation	  was	  found	  to	  be	  
partial.	   These	   observations	   suggest	   that	   post-­‐
NIHL	   treatments	   can	   be	   improved	   if	   continued	  
beyond	  the	  period	  of	  one	  week.	  	  
	  
Another	   track	   of	   research	   concerns	   combination	  
of	   different	   therapies,	   including	   magnesium.	  
Treatment	  with	  a	  combination	  of	  vitamins	  A,	  C,	  E	  
and	   magnesium,	   initiated	   1	   hour	   before	   noise	  
exposure,	   produced	   a	   compelling	   reduction	   in	  
NIHL	   and	   cell	   death,	   while	   effects	   of	   either	   the	  
antioxidant	   agents	   (vitamin	   A,	   C,	   or	   E)	   or	  
magnesium	  alone	  were	  small	  and	  not	  statistically	  
reliable	   (Le	   Prell	   et	   al.,	   2007b).	   Thus,	   the	  
combination	   of	   magnesium	   with	   other	   agents	  
could	  also	  be	  of	  great	  interest,	  and	  suggests	  that	  
they	  act	  at	  different	  and	  complementary	  levels	  of	  
the	  cellular	  death	  process.	  
	  
Magnesium	  and	  ototoxicity	  
	  
Various	  pharmaceuticals	  are	  known	  to	  impair	  the	  
auditory	  system.	  The	  best-­‐known	  substances	  are	  
the	  aminoglycoside	  antibiotics	  and	  cisplatin.	  Both	  
cause	  high	   frequency	   sensorineural	   hearing	   loss,	  
which	   is	   usually	   permanent	   and	   associated	   with	  
loss	   of	   outer	   hair	   cells	   in	   the	   basal	   turn	   of	   the	  
cochlea.	   Aminoglycoside	   antibiotics	   (such	   as	  
gentamicin,	   neomycin	   and	   kanamycin)	   are	   used	  
to	   treat	   bacteria	   not	   responsive	   to	   conventional	  
antibiotics.	   Their	   clinical	   use	   is	   limited	   by	   toxic	  
side	   effects	   that	   include	   cochlear	   toxicity,	  
vestibular	   toxicity	   and	   nephrotoxicity.	   Amino-­‐
glycoside	   antibiotics	   possibly	   cause	   formation	   of	  
free	   radicals	   by	   forming	   complexes	   with	   iron,	  
which	   is	   vital	   for	   normal	  mitochondrial	   function.	  
Free	   radicals	   can	   rapidly	   react	   with	   cell	  
constituents,	  including	  cell	  membranes	  and	  DNA.	  
The	   resulting	   oxidative	   stress	   can	   trigger	  
apoptotic	   cell	   death.	   The	   intrinsic	   apoptosis	  
pathway	   is	   the	   major	   pathway	   induced	   by	  
aminoglycosides	   in	   the	   cochlea	   (Rybak	   and	  
Withworth,	  2005).	  	  	  
	  
Vormann	  and	  Günther	  (1991)	  demonstrated	  that	  
Mg	   deficiency	   in	   growing	   rats	   aggravated	   the	  
ototoxic	  effects	  of	   the	  aminoglycoside	  antibiotic,	  
gentamicin.	  Administration	  of	  gentamicin	  to	  Mg2+	  
deficient	   pregnant	   rats	   from	   day	   16-­‐20	   of	  
gestation	   produced	   hearing	   threshold	   shifts	   in	  
the	   maternal	   rats	   as	   well	   in	   their	   offspring	  
(Vormann	  and	  Günther	  1991).	  These	  data	  suggest	  
that	   Mg2+	   deficiency	   is	   a	   relevant	   predisposing





Figure	  3.	  	  Global	  hair	  cells	  loss	  in	  guinea	  pigs,	  3	  months	  after	  an	  impulse	  noise	  exposure,	  for	  4	  treatments	  
groups:	   placebo	   (NaCl),	   a	   7-­‐day	   or	   1-­‐month	   magnesium	   treatment,	   and	   conventional	   therapy	   with	  
methylprednisolone.	  	  (*	  p<0.05;	  **p<0.01)	  (after	  Abaamrane	  et	  al.,	  2009).  
	  
	  
	   	  
risk	   factor	   for	   the	   development	   of	   ototoxicity	  
induced	   by	   some	   pharmaceuticals.	   Recently,	   it	  
has	   been	   shown,	   in	   the	   zebrafish	   model,	   that	  
extracellular	   magnesium	   or	   calcium	   ions	  
modulate	   hair	   cell	   death	   from	   neomycin	   and	  
gentamycin,	   but	   exert	   their	   protective	   effects	  
through	   different	   mechanisms	   (Coffin	   et	   al.,	  
2009).	   In	   mammals,	   preliminary	   injection	   of	  
magnesium	   solution,	   by	   means	   of	  
electrophoresis,	   reduced	   the	   ototoxic	   effect	   of	  
kanamicin	  (Spasov	  et	  al.,	  1999).	  
	  
Other	   well-­‐known	   ototoxic	   treatments	   are	  
platinum	   compounds.	   Cisplatin	   is	   a	   frequently	  
used	  chemotherapeutic	  agent	  in	  the	  treatment	  of	  
many	   types	  of	  neoplasias,	  especially	  of	   the	  head	  
and	   neck	   (Rybak	   and	   Withworth,	   2005).	   The	  
mechanism	  of	  antineoplastic	  action	   is	  associated	  
with	  the	  selective	  and	  persistent	  inhibition	  of	  the	  
deoxyribonucleic	   acid	   synthesis	   (Williams	   and	  
Whitehouse,	   1979).	   Its	   side	   effects	   include	  
ototoxicity,	  kidney	  toxicity,	  medullar	  suppression	  
and	  gastrointestinal	  disorders.	  The	  nephrotoxic	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effect	   of	   cisplatin	   is	   severe	   damage	   in	   the	   renal	  
proximal	   cells	  within	   the	   thick	  ascending	   loop	  of	  
Henle,	   manifested	   by	   hypomagnesemia.	   These	  
types	   of	   toxicity	   can	   impact	   treatment,	   as	   they	  
reduce	  the	  chemotherapy	  dosage,	  frequency	  and	  
duration	   for	   many	   patients.	   Some	   audiometric	  
studies	  have	  reported	  elevated	  hearing	  threshold	  
in	   75-­‐100%	   of	   patients	   treated	   with	   cisplatin	  
(McKeage,	  1995).	  
	  	  
The	   auditory	   lesions	   seem	   to	   result	   from	   free	  
radical-­‐induced	   damage	   to	   many	   tissues	   (Kopke	  
et	   al.,	   1997;	   Rybak	   et	   al.,	   1995;	   Dehne	   et	   al.,	  
2001).	   Oxygen	   reactive	   species	   are	   generated	   in	  
the	   cochlea	   after	   exposure	   to	   cisplatin	   (Clerici	  
and	   Yang,	   1996)	   and	   such	   oxidative	   stress	   can	  
cause	  cochlear	  cell	  death	  by	  apoptosis	  secondary	  
to	  the	  activation	  of	  caspase-­‐3	  (Garcia-­‐Berrocal	  et	  
al.,	   2007;	   De	   Freitas	   et	   al.,	   2009).	   Inner	   ear	   cell	  
apoptosis	   can	   be	   triggered	   by	   the	   formation	   of	  
complexes	  between	  cisplatin	  and	  the	  DNA	  of	  the	  
damaged	   cell,	   preventing	   the	   progression	   of	   the	  
cell	   cycle.	   Cevette	   et	   al.,	   (2000)	   observed	   a	  
significant	   increase	   in	   otoacoustic	   emission	  
amplitude	   (which	   provides	   frequency-­‐specific	  
information	  about	  OHC	  function)	   in	   two	  patients	  
undergoing	   cisplatin	   treatment	   supplemented	  
with	   magnesium.	   The	   authors	   of	   this	   study	  
concluded	  that	  Mg2+	  might	  be	  a	  promising	  agent	  
against	   cisplatin	   ototoxicity.	   However,	   the	   study	  
of	   Sahin	   et	   al.,	   (2006)	   showed	   that	   a	   Mg2+	   rich	  
diet	  prevented	  the	  severe	  hypomagnesemia	  that	  
cisplatin	   causes	   in	   guinea	   pigs,	   but	   failed	   to	  
provide	  any	  protection	  against	  its	  ototoxic	  effect.	  	  
	  
Magnesium	  and	  sudden	  sensorineural	  hearing	  
loss	  	  
	  
The	   US	   National	   Institute	   for	   Deafness	   and	  
Communication	   Disorders	   defines	   SSHL	   as	   the	  
idiopathic	  loss	  of	  hearing	  of	  at	  least	  30	  dB	  over	  at	  
least	   3	   contiguous	   test	   frequencies	   occurring	  
within	  3	  days.	   Estimates	  of	   the	  overall	   incidence	  
of	  SSHL	   range	   from	  5	   to	  20	  per	  100	  000	  persons	  
per	   year	   (Conlin	   and	   Parnes,	   2007).	   Many	  
etiologic	  causes	  of	  SSHL	  have	  been	  proposed,	  but	  
many	   remain	   unconfirmed.	   In	   the	   majority	   of	  
patients	   (71%),	   the	   aetiology	   remains	   idiopathic.	  
A	   wide	   range	   of	   disorders	   might	   lead	   to	   the	  
development	   of	   SSHL.	   The	   theorized	   major	  
causative	   factors	   can	   be	   broken	   down	   into	  
several	   categories:	   1)	   viral	   infection	   (13	   %);	   2)	  
vascular	   impairment;	   3)	   immune-­‐mediated	  
mechanisms;	   4)	   inner	   ear	   abnormalities;	   and	   5)	  
CNS	   abnormalities,	   including	   tumours,	   trauma,	  
haemorrhage,	   infarction	   and	   other	   pathologies	  
(Chau	  et	  al.,	  2010).	  The	   lack	  of	  understanding	  of	  
the	   mechanism	   of	   SSHL	   has	   rendered	   the	  
development	  of	  a	  specific	  treatment	  difficult,	  and	  
currently,	  empirical	  guidelines	  are	  used.	  Because	  
of	  the	  spontaneous	  recovery	  rates	  of	  32%	  to	  70%	  
(Colin	  and	  Parnes,	  2010),	   some	  otolaryngologists	  
choose	   not	   to	   treat	   SSHL.	   However	   the	   most	  
common	   approach	   to	   treatment	   of	   SSHL	   is	   with	  
systemic	   steroids	   in	  moderate	   doses.	   Nageris	   et	  
al.,	   (2004)	   evaluated	   the	   efficiency	   of	   two	  
treatments	   after	   SSHL	   in	   humans.	   The	   first	   one	  
consisted	   of	   corticosteroid	   and	  magnesium,	   and	  
the	   second	   one	   (control)	   in	   corticosteroid	   and	  
placebo.	   They	   observed	   that	   more	   patients	  
treated	   with	   magnesium	   experienced	   hearing	  
improvement,	   and	   at	   a	   larger	   magnitude,	   than	  
control	   subjects.	   Gordin	   and	   colleagues	   (2002)	  
reported	   a	   significantly	   greater	   recovery	   rate	  
among	   patients	   treated	   with	   magnesium	   and	  
carbogen	   vs	   patients	   treated	   with	   carbogen	  
alone.	  	  	  
	  
How	  does	  magnesium	  therapy	  work?	  
	  
Magnesium	   plays	   an	   essential	   role	   in	   the	  
regulation	  of	  most	  cellular	  functions.	  However,	  it	  
is	  recognized	  that	  magnesium	  status	  in	  humans	  is	  
often	   deficient.	   In	   the	   recent	   French	   SU.VI.MAX	  
study	   (the	   “supplementation	   en	   vitamines	   et	  
mineraux	   antioxidants”	   study)	   of	   5,448	   subjects,	  
it	   was	   shown	   that	   77%	   of	   women	   and	   72%	   of	  
men	   had	   dietary	  magnesium	   intakes	   lower	   than	  
the	   recommended	   dietary	   allowance	   (Galan	   et	  
al.,	   1997).	  The	  deficiency	   is	   increased	  by	  chronic	  
stress,	   loud	   noise	   exposure	   or	   chemotherapy	  
with	  platinum	  compounds	   (Galland,	  1991;	  Mocci	  
et	   al.,	   2001,	   Sahin	   et	   al.,	   2006).	   Scheibe	   et	   al.,	  
(1999)	   were	   the	   first	   to	   study	   the	   correlation	  
between	   the	   plasma,	   perilymph	   and	  
cerebrospinal	   magnesium	   contents	   in	   the	   same	  
animal.	   Contrary	   to	   the	   blood	   brain	   barrier,	   the	  
blood	   perilymph	   barrier	   is	   not	   able	   to	  
concentrate	  Mg2+	  taken	  up	  from	  plasma.	  Also,	  the	  
perilymph	   Mg2+	   concentration	   correlates	   well	  
with	   the	   plasma	   level,	   and	   a	   Mg2+	   deficiency	  
affects	  perilymph	  content.	  	  
	  
The	   exact	   manner	   by	   which	   Mg2+	   affects	   the	  
susceptibility	  to	  hearing	  loss	  is	  still	  unknown,	  but	  
several	   mechanisms	   could	   be	   evoked.	   By	   its	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nature,	   magnesium	   is	   a	   calcium	   antagonist	   and	  
therefore	  blocks	  the	  excessive	  release	  of	  calcium,	  
both	   in	   the	   hair	   cells	   and	   in	   the	   cochlear	  
vasculature,	   limiting	   cell	   energy	   depletion	   and	  
inducing	  the	  vasodilatation	  of	  arterioles.	  Through	  
these	   mechanisms,	   magnesium	   could	   limit	  
ischemia	   induced	  by	  acoustic	   trauma.	  Haupt	  and	  
Scheibe	  (2002)	  demonstrated	  that	  cochlear	  blood	  
flow	   as	   well	   as	   perilymphatic	   pO2	   levels	   were	  
significantly	   increased	   in	   noise-­‐traumatized	  
animals	   that	   received	   magnesium	   supplements.	  
Not	   only	   does	  magnesium	   combat	   ischemia,	   but	  
it	   is	   also	   thought	   to	  prevent	   cell	   damage	   caused	  
by	  hypoxia.	  Konig	  et	  al.,	  (2003)	  noted	  a	  protective	  
effect	  of	  magnesium	  on	  hypoxia-­‐induced	  hair	  cell	  
loss	   in	   vitro.	   In	   other	   models,	   high	   magnesium	  
concentration	   has	   been	   shown	   to	   attenuate	   the	  
hypoxia/ischemia-­‐induced	   disruption	   of	   the	  
mitochondrial	   membrane	   potential,	   a	   critical	  
event	   in	   triggering	   cell	   death	   (Sharikabad	   et	   al.,	  
2001).	   This	   mechanism	   is	   supported	   by	   the	  
observation	   that	   an	   increase	   in	   the	   extracellular	  
magnesium	   concentration	   led	   to	   a	   decrease	   in	  
hypoxia	   induced	   apoptosis	   by	   maintaining	   the	  
normal	   ratio	  of	  Bax	   to	  Bcl-­‐2	  proteins	   involved	   in	  
determining	   the	   survival	   of	   cells	   or	   their	   death	  
(Ravishankar,	  2001).	  	  
	  
Another	  potential	  mechanism	  explaining	  the	  Mg2+	  
efficiency	   in	  NIHL	  or	   in	  drug	  ototoxicity,	   involves	  
free	   radical	   production.	   Two	   mechanisms	   have	  
been	   suggested	   (Garcia	   et	   al.,	   1998).	   It	   may	  
directly	   inhibit	   free	   radical	  production,	  or	   it	  may	  
facilitate	  scavenging	  of	  free	  radicals.	  Afanas’ev	  et	  
al.,	   (1995)	   showed	   that	   Mg2+	   inhibits	   reduced	  
NADP	   oxidase,	   an	   enzyme	   that	   produces	  
superoxide	   radical.	   However,	   despite	   the	  
protective	  effect	  of	  magnesium	  against	  oxidative	  
stress,	   as	   demonstrated	   in	   different	   models	  
(Sharikabad	   et	   al.,	   2001,	   Bede	   et	   al.,	   2008),	   no	  
data	  are	  currently	  available	  about	  the	  cochlea.	  
	  
Lastly,	  Mg2+	  could	  act	  on	  glutamate	  excitotoxicity,	  
especially	   in	   NIHL.	   Magnesium	   apparently	  
enhances	   the	   survival	   capability	   of	   the	   cochlear	  
afferents,	   reducing	   the	   effect	   of	   glutamate-­‐
induced	  inner	  hair	  cell	  damage	  (Ehrenberger	  and	  	  
Felix,	   1995).	  Magnesium	   is	   able	   to	  modulate	   the	  
opening	   of	   Na+/Ca++	   channels	   of	   the	   NMDA	  
receptors	   (Mayer	   et	   al.,	   1984).	   The	   blockade	   of	  
the	   NMDA	   receptors	   by	   Mg2+	   is	   voltage-­‐
dependent,	   but	   extracellular	   Mg2+	   behaves	   as	   a	  
non-­‐competitive	   NMDA	   antagonist,	   without	   the	  
side	   effects	   presented	   by	   the	   other	   non-­‐
competitive	   NMDA	   antagonists.	   In	   the	   hearing	  
process,	   if	   Mg2+	   is	   low,	   an	   excess	   of	   Ca2+	   could	  
enter	   hair	   cells.	   In	   turn,	   more	   glutamate	   would	  
then	  be	  produced	   in	  response	  to	  this	  Ca2+	   influx.	  
Increased	   glutamate	  would	   also	   greatly	   increase	  
the	  activity	  of	   the	  NMDA	   receptor,	  which	   is	   also	  
operating	  with	   low	  magnesium.	  With	   the	  double	  
insult	  of	  high	  glutamate	  and	  low	  Mg2+,	  a	  flood	  of	  
Ca2+	   could	   go	   through	   the	   NMDA	   channels	   into	  
the	  nerve	  cell,	  and	  the	  energetic	  system	  could	  be	  
compromised.	  	  
	  
Conclusion	  	  	  
 
Hearing	  loss	  is	  a	  significant	  clinical	  issue.	  We	  now	  
know	  many	  of	  the	  molecular	  pathways	  leading	  to	  
apoptotic	   cell	   death	   that	   are	   triggered	   by	   noise	  
and	   other	   environmentally	   mediated	   traumas	  
such	   as	   aminoglycoside	   antibiotics	   and	   chemo-­‐
therapeutics.	   There	   is	   increasing	   evidence	   for	  
their	   similarity,	   since	   free	   radical	   formation	   and	  
apoptotic	   cascades	   have	   been	   implicated	   in	   all.	  
Interventions	  can	  be	  directed	  at	  preventing	  initial	  
ROS	   formation,	  maintaining	   cochlear	   blood	   flow	  
or	   blocking	   apoptosis.	   A	   large	   number	   of	  
therapeutics,	   including	   magnesium,	   have	   been	  
tested.	   Magnesium,	   by	   its	   neuroprotective	   and	  
vasodilatory	   effects,	   has	   the	   potency	   to	   prevent	  
as	  well	   as	   to	   limit	   hearing	   loss,	   particularly	   after	  
noise	   exposure	   or	   sudden	   sensorineural	   hearing	  
loss.	   Magnesium	   therapy	   at	   the	   recommended	  
dosage	   appears	   to	   be	   safe	   with	   few	  
contraindications	  (such	  as	  severe	  renal	  failure).	  In	  
contrast	   to	   other	   therapeutic	   agents	   (like	  
corticosteroids),	   it	   easily	   crosses	   the	   perilymph	  
blood	  barrier	  and	  reaches	  the	  organ	  of	  Corti.	  The	  
majority	   of	   studies	   have	   shown	   that	  magnesium	  
is	   partly	   effective.	   Using	   magnesium	   in	  
combination	   with	   other	   agents	   could	   improve	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Magnesium	  plays	  an	   important	  role	   in	  the	  prevention	  of	  central	  sensitization	  and	  in	  the	  attenuation	  of	  
established	   pain	   hypersensitivity,	   and	   its	   main	   mode	   of	   action	   appears	   to	   involve	   its	   voltage-­‐gated	  
antagonist	  action	  at	  N-­‐methyl-­‐D-­‐aspartate	  (NMDA)	  receptors.	  Given	  the	  putative	  function	  of	  the	  NMDA	  
receptor	  in	  pain	  transduction,	  magnesium	  has	  been	  investigated	  in	  various	  clinical	  conditions	  associated	  
with	  acute	  or	  chronic	  pain.	  The	  parenteral	  administration	  of	  magnesium,	  via	  an	  intravenous,	  intrathecal,	  
or	   epidural	   route,	  may	   reduce	  pain,	   and	   anaesthetic	   and	   analgesic	   requirements	   during	   the	   intra-­‐	   and	  
post-­‐operative	  periods.	  The	  beneficial	  effects	  of	  magnesium	  treatment	  have	  also	  been	  demonstrated	  in	  
patients	  suffering	  from	  neuropathic	  pain,	  such	  as	  in	  those	  with	  malignancy-­‐related	  neurologic	  symptoms,	  
postherpetic	   neuralgia,	   diabetic	   neuropathy,	   and	   chemotherapy-­‐induced	   peripheral	   neuropathy.	   In	  
addition,	  magnesium	   therapy	  has	  been	   shown	   to	  be	  effective	   in	   alleviating	  dysmenorrhea,	  headaches,	  
and	   acute	  migraine	   attacks.	  Magnesium	   is	   playing	   an	   evolving	   role	   in	   pain	  management,	   but	   a	   more	  
thorough	  understanding	  of	  the	  mechanisms	  underlying	   its	  antinociceptive	  action	  and	  additional	  clinical	  




The	  research	  interest	   in	  NMDA	  receptors	  has	   led	  
to	   an	   examination	   of	   the	   interactions	   between	  
NMDA	   receptors	   and	   the	   induction	   and	  
maintenance	   of	   central	   sensitization	   after	  
nociceptive	  stimuli	  (Woolf	  and	  Thompson,	  1991).	  
Ketamine	   and	   magnesium	   are	   representative	  
NMDA	   receptor	   antagonists,	   and	   in	   particular,	  
magnesium	  can	  regulate	  calcium	  access	  into	  cells	  
by	  antagonizing	  the	  NMDA	  receptor	  (Paoletti	  and	  
Neyton,	   2007),	   which	   has	   encouraged	  
investigations	   on	   the	   use	   of	   magnesium	   as	   an	  
analgesic	  adjuvant.	  Recent	  studies	  have	  proposed	  
a	   role	   for	   NMDA	   receptor	   antagonists	   in	   the	  
management	   of	   postoperative	   pain	   and	   in	   other	  
acute	   and	   chronic	   pain	   conditions.	   This	   chapter	  
describes	   the	   pharmacologic	   basis	   of	   pain	   relief	  
by	   the	   magnesium	   ion,	   and	   surveys	   various	  
clinical	   studies	   that	   have	   examined	   the	  
antinociceptive	  effects	  of	  magnesium.	  
	  
Mechanism	  of	  magnesium	  as	  an	  analgesic	  
adjuvant	  	  
	  
Although	   magnesium	   has	   no	   direct	   analgesic	  
effect,	   it	   inhibits	   calcium	   ions	   entering	   cells	   by	  
blocking	   NMDA	   receptors,	   which	   causes	   an	  
antinociceptive	   effect.	   Furthermore,	   this	  
antinociceptive	  effect	   is	  related	  to	   its	  prevention	  
of	   central	   sensitization	   caused	   by	   peripheral	  
tissue	   injury	   (Woolf	   and	   Thompson,	   1991).	  
Central	   sensitization	   is	   the	   result	   of	   the	  
enhancement	   of	   neuronal	   properties	   in	  
nociceptive	   pathways	   of	   the	   central	   nervous	  
system,	  and	  is	  triggered	  by	  repetitive	  nociceptive	  
afferent	   inputs,	   which	  manifests	   as	   a	   prolonged	  
reduction	   in	   the	   pain	   threshold.	   Central	  
sensitization	  produces	  pain	  hypersensitivity,	  such	  
as	   wind-­‐up	   or	   long-­‐term	   potentiation	   of	   pain,	  
that	   is,	   it	   causes	   pain	   even	   when	   peripheral	  
stimuli	   are	   not	   intense	   and	   continues	   to	   cause	  
pain	  after	  the	   initiating	  stimuli	  have	  disappeared	  
(Latremoliere	   and	   Woolf,	   2009;	   Woolf,	   1983;	  
Woolf	  and	  Salter,	  2000).	  	  
	  
Increased	   intracellular	   calcium	   levels	   seem	   to	  
play	   a	   major	   role	   in	   the	   initiation	   of	   central	  
sensitization	   (Pockett,	   1995;	   Woolf	   and	   Chong,	  
1993),	  and	  the	  build-­‐up	  of	  intracellular	  calcium	  is	  
associated	  with	  various	  receptors	  on	  postsynaptic	  
neurons	   of	   the	   spinal	   dorsal	   horn,	   such	   as,	  
NMDA,	   α-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazole	  
propionate	   (AMPA),	   kainate,	   and	   glutamate	  
receptors	   (Latremoliere	   and	   Woolf,	   2009).	   Of	  
these	   receptors,	   NMDA	   receptor	   activation	   has	  
been	   demonstrated	   to	   be	   essential	   for	   initiating	  
and	  maintaining	  central	  sensitization.	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The	  NMDA	   receptor	   is	   a	  membrane	   ion	   channel	  
expressed	   in	   the	   central	   nervous	   system.	   It	   is	   a	  
tetramer	   composed	   of	   four	   different	   subunits,	  
that	   is,	   two	  NR1	  and	   two	  NR2	   (Dingledine	   et	  al.,	  
1999).	   NMDA	   receptors	   regulate	   the	   cellular	  
inflows	   of	   Na+	   and	   Ca2+,	   and	   the	   outflow	   of	   K+.	  
This	   voltage-­‐dependent	   ion	   channel	   is	   blocked	  
non-­‐competitively	   in	   the	   resting	   state	   by	   the	  
magnesium	   ion	   and	   by	   ketamine	   (phencyclidine	  
site	   blockade),	   MK-­‐801,	   memantine,	   and	   others	  
(Felsby	   et	   al.,	   1996;	   Paoletti	   and	   Neyton,	   2007)	  
(Fig.	   1).	   On	   the	   other	   hand,	   the	  NMDA	   receptor	  
channel	   is	   opened	   by	   membrane	   depolarization	  
induced	   by	   the	   sustained	   release	   of	   glutamate	  
and	   neuropeptides,	   which	   include	   substance	   P	  
and	   calcitonin	   gene-­‐related	   peptide	   (CGRP)	  
(Baranauskas	   and	   Nistri,	   1998;	   Mayer	   et	   al.,	  
1984).	  
	  
Extracellular	   magnesium	   blocks	   the	   NMDA	  
receptor	   in	   a	   voltage-­‐dependent	  manner	   (Mayer	  
et	   al.,	   1984),	   and	   thus,	   can	   prevent	   the	  
establishment	  of	  central	  sensitization	  and	  abolish	  
existing	   hypersensitivity.	   Other	   noncompetitive	  
or	  competitive	  NMDA	  receptor	  antagonists,	  such	  
as	   MK801	   and	   D-­‐CPP,	   also	   prevent	   and	   reverse	  
the	   hyperexcitability	   of	   neurons	   produced	   by	  
nociceptive	  afferent	  inputs	  (Ma	  and	  Woolf,	  1995;	  




Many	  authors	  have	  investigated	  the	  adjuvant	  role	  
of	  magnesium	   in	   the	   context	   of	   intra-­‐	   and	   post-­‐
operative	  analgesia.	  Magnesium	  has	  been	  shown	  
to	   be	   effective	   for	   treating	   intra-­‐	   and	   post-­‐
operative	   pain	   and	   for	   blunting	   autonomic,	  
somatic,	   and	   endocrine	   reflexes	   to	   noxious	  
stimuli	   (Kara	   et	   al.,	   2002;	   Koinig	   et	   al.,	   1998;	  
Levaux	   et	   al.,	   2003).	   Usually,	   magnesium	   is	  
administered	   as	   an	   i.v.	   30-­‐50	   mg/kg	   bolus	   of	  
magnesium	   sulphate	   as	   a	   loading	   dose,	   and	  
maintained	   at	   6-­‐20	   mg/kg/h	   by	   continuous	  
infusion	   until	   the	   end	   of	   surgery	   (Koinig	   et	   al.,	  
1998;	   Ryu	   et	   al.,	   2008;	   Ryu	   et	   al.,	   2009;	  Wilder-­‐
Smith	  et	  al.,	  1997),	  or	  for	  4	  hours	  after	  the	  initial	  
bolus	  (Seyhan	  et	  al.,	  2006).	  
	  
Tramer	   et	   al.,	   (1996)	   conducted	   the	   first	  
prospective,	   randomized	   study	   on	   the	   effect	   of	  
magnesium	   on	   analgesic	   requirements,	   pain,	  
comfort,	   and	   quality	   of	   sleep	   during	   the	  
immediate	  postoperative	  period.	  	  They	  showed	  	  
	  
	  
Figure	   1.	   Scheme	   of	   the	  NMDA	   receptor	   and	   its	  
ligand	   binding	   sites.	   The	   NMDA	   receptor	   is	  
composed	   of	   four	   subunits	   (two	   NR1	   and	   two	  
NR2).	   In	   the	   extracellular	   region,	   there	   are	  
agonist-­‐binding	   sites	   for	   glutamate	   and	   glycine,	  
co-­‐agonists	   for	   the	   efficient	   opening	   of	   the	   ion	  
channel.	   The	   ion	   channel	   includes	   the	   binding	  
sites	   for	   the	   pore	   block,	   one	   of	  which	   is	   for	   the	  
Mg2+	   and	   the	   other	   is	   for	   ketamine,	   MK-­‐801,	  
memantine,	  and	  so	  on.	  
	  
	  
that	   magnesium	   sulphate	   reduces	   analgesic	  
requirements	   and	   discomfort,	   and	   improves	  
quality	  of	   sleep	  during	   the	  postoperative	  period,	  
and	   that	   it	   does	  not	   cause	  any	  adverse	  effect	   at	  
48	  h	  after	  surgery.	  Oguzhan	  et	  al.,	  (2008)	  studied	  
the	   effect	   of	   a	   magnesium	   sulphate	   infusion	   on	  
postoperative	   requirements	   for	   opioids,	  
intraoperative	   muscle	   relaxant,	   inhalational	  
anaesthetic	   consumption,	   and	   post-­‐operative	  
pain	   during	   and	   after	   lumbar	   disc	   surgery.	   Their	  
results	  suggested	  that	   intraoperative	  magnesium	  
administration	  significantly	  reduced	  intraoperative	  
muscle	  relaxant	  and	  opioid	  requirements,	  and	  also	  
reduced	  postoperative	  pain	  and	  opioid	  use.	  	  
	  
When	   used	   during	   a	   variety	   of	   surgeries,	  
magnesium	   was	   also	   found	   to	   reduce	   the	   need	  
for	   intraoperative	   anaesthetics	   and	   muscle	  
relaxants	  and	  to	  reduce	  the	  amount	  of	  morphine	  
required	   to	   treat	   postoperative	   pain.	   Ryu	   et	   al.,	  	  
(2009)	   compared	   remifentanil	   and	   magnesium	  
during	   middle	   ear	   surgery	   in	   terms	   of	  
postoperative	   pain	   and	   other	   complications.	   In	  
this	   study,	  magnesium	  or	   remifentanil	   combined	  
with	  sevoflurane	  provided	  adequate	  hypotensive	  
anaesthesia,	   but	   patients	   in	   the	   magnesium	  
group	   experienced	   a	   more	   comfortable	  
postoperative	   course	   with	   better	   analgesia,	   less	  
Magnesium	  in	  the	  Central	  Nervous	  System	   	   Chapter	  11	  
 159	  
shivering,	   and	   less	   postoperative	   nausea	   and	  
vomiting	   (PONV).	   Furthermore,	   the	   amount	   of	  
sevoflurane	   required	   to	   maintain	   surgical	  
anaesthesia	   was	   significantly	   lower	   in	   the	  
magnesium	  group	  than	  in	  the	  remifentanil	  group	  
(Ryu	  et	  al.,	  2009).	  	  
	  
The	   use	   of	   magnesium	   as	   an	   analgesic	   adjunct	  
has	   also	   been	   found	   to	   be	   beneficial	   in	   patients	  
on	   total	   intravenous	   anaesthesia	   (TIVA).	  
Significant	   reductions	   in	   intraoperative	   propofol,	  
atracurium,	   and	   postoperative	   morphine	  
consumption	   were	   observed	   in	   patients	  
undergoing	  gynaecological	  surgery	  (Seyhan	  et	  al.,	  
2006).	   In	  another	  study	  on	  gynaecologic	  patients	  
receiving	   TIVA,	   post-­‐operative	   pain	   scores,	  
cumulative	  analgesic	  consumption,	  and	  shivering	  
incidents	   were	   significantly	   lower	   in	   patients	  
treated	  with	  magnesium,	   to	   the	   extent	   that	   the	  
authors	   concluded	   magnesium	   sulphate	   during	  
TIVA	   improved	   the	   quality	   of	   postoperative	  
analgesia	  (Ryu	  et	  al.,	  2008).	  Furthermore,	  Choi	  et	  
al.,	   (2002)	   found	   that	   intravenous	   magnesium	  
sulphate	  reduced	  propofol	  infusion	  requirements	  
during	  the	  maintenance	  of	  propofol-­‐nitrous	  oxide	  
anaesthesia	   in	   patients	   undergoing	   total	  
abdominal	  hysterectomy.	  	  
	  
The	   usefulness	   of	   adjunctive	   magnesium	   for	  
postoperative	   pain	   control	   has	   also	   been	  
examined	   in	  the	  context	  of	  regional	  anaesthesia.	  
Recent	   studies	   have	   suggested	   that	   magnesium	  
may	   play	   a	   beneficial	   role	   in	   spinal	   anaesthesia.	  
For	   example,	   magnesium	   was	   found	   to	   prevent	  
the	   induction	   of	   central	   sensitization	   by	  
peripheral	  nociceptive	  stimulation	  at	  a	  spinal	  site	  
of	   action,	   by	   blocking	   NMDA	   receptors	   in	   a	  
voltage-­‐dependent	   fashion	   (Woolf	   and	  
Thompson,	  1991).	  Utilizing	  the	  same	  mechanism,	  
the	   addition	   of	   small	   doses	   of	   magnesium	  
sulphate	   to	   local	   anaesthetics	   for	   spinal	  
anaesthesia	   enhances	   the	   duration	   of	  
anaesthesia	  and	   reduces	  postoperative	  analgesic	  
requirements	  and	  the	  incidence	  of	  side	  effects	  of	  
high	   doses	   of	   local	   anaesthetics	   and	   opioids.	   In	  
animal	   studies,	   the	   intrathecal	   co-­‐administration	  
of	  magnesium	  sulphate	  during	  spinal	  anaesthesia	  
was	   found	   to	   significantly	   potentiate	   morphine	  
analgesia	   in	   normal	   rats	   and	   in	   a	   surgical	  model	  
of	   mechanical	   allodynia	   (Kroin	   et	   al.,	   2000).	   In	  
another	   experimental	   model,	   intrathecal	  
magnesium	   sulphate	   produced	   a	   state	   of	   spinal	  
anaesthesia	   and	   general	   sedation	   in	   rats	   that	  
lasted	   for	   around	   1	   h,	   and	   at	   6	   h	   post-­‐injection,	  
animals	   recovered	   and	   showed	   no	   evidence	   of	  
neurotoxicity	  (Bahar	  et	  al.,	  1996).	  Clinical	  studies	  
have	   also	   shown	   that	   intrathecal	   magnesium	  
sulphate	   added	   to	   fentanyl	   prolongs	   analgesia	  
without	   increasing	   side	   effects	   during	   labour	  
analgesia	   (Buvanendran	   et	   al.,	   2002;	   Ozalevli	   et	  
al.,	   2005).	   Furthermore,	   the	   i.v.	   infusion	   of	  
magnesium	   sulphate	   during	   spinal	   anaesthesia	  
was	   found	   to	   improve	   postoperative	   analgesia	  
and	   reduce	   the	   cumulative	   consumption	   of	  
analgesics	   after	   total	   hip	   replacement	  
arthroplasty	   (Hwang	   et	   al.,	   2010).	   Postoperative	  
adjunctive	   i.v.	   magnesium	   infusion	   was	   also	  
found	   to	   increase	   time	   to	   analgesic	   need	  and	   to	  
reduce	   total	   analgesia	   consumption	   after	   spinal	  
anaesthesia	  (Apan	  et	  al.,	  2004).	  
	  
Comparatively	   little	   is	   known	   of	   the	   effect	   of	  
epidural	   magnesium	   sulphate,	   whereas	  
intrathecal	   magnesium	   sulphate	   has	   been	  
investigated	  on	  many	  occasions.	   Caudal	   epidural	  
anaesthesia	   with	   lidocaine	   plus	   magnesium	  
sulphate	   was	   found	   to	   produce	   analgesia	   of	  
longer	  duration	  than	  lidocaine	  plus	  distilled	  water	  
in	  cattle	  (Dehghani	  and	  Bigham,	  2009).	  Arcioni	  et	  
al.,	   (2007)	   compared	   intrathecal,	   epidural,	  
combined	   intrathecal	   and	   epidural	   magnesium	  
sulphate,	  and	  spinal	  anaesthesia	  alone	   (controls)	  
in	   patients	   undergoing	   orthopaedic	   surgery	   to	  
investigate	   whether	   intrathecal	   and/or	   epidural	  
magnesium	  sulphate	   could	   reduce	  postoperative	  
analgesic	   requirements.	   The	   results	   obtained	  
suggested	  that	  combined	  intrathecal	  and	  epidural	  
magnesium	   sulphate	   significantly	   reduced	  
postoperative	   analgesic	   requirements	   (Arcioni	   et	  
al.,	  2007).	  
	  
However,	   not	   all	   investigations	   have	   reported	  
postoperative	   analgesic	   effects	   for	   magnesium	  
sulphate.	   For	   example,	   perioperative	   i.v.	  
magnesium	   infusion	   was	   not	   found	   to	   reduce	  
postoperative	   pain	   or	   analgesic	   consumption	   in	  
patients	  undergoing	  abdominal	  hysterectomy	  (Ko	  
et	   al.,	   2001)	   or	   caesarean	   delivery	   (Paech	   et	   al.,	  
2006).	  Furthermore,	   in	  a	   recent	   report	   issued	  by	  
Tramer	   and	   Glynn	   (2007),	   pretreatment	   with	  
magnesium	  sulphate	  was	  found	  to	  have	  no	  effect	  
on	  postoperative	  pain	  or	   analgesic	   requirements	  
over	  the	  first	  three	  postoperative	  days	  in	  patients	  
undergoing	   ambulatory	   ilioinguinal	   hernia	   repair	  
or	  varicose	  vein	  surgery.	  However,	  in	  this	  study,	  a	  
single	   dose	   (4	   g)	   of	   intravenous	   magnesium	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sulphate	  was	  used	  instead	  of	  a	  loading	  dose	  plus	  
continuous	  infusion.	  
	  	  
Although	  some	  debate	  exists	  concerning	  the	  role	  
of	  magnesium	  sulphate	  as	  an	  analgesic	  adjuvant,	  
the	  consensus	  is	  that	  magnesium	  sulphate	  acts	  to	  
support	   a	   neuromuscular	   blockade.	   Magnesium	  
acts	   as	   a	   calcium	   channel	   blocker	   at	   presynaptic	  
nerve	   terminals	   and	   reduces	   acetylcholine	  
release	  at	  the	  motor	  endplate	  (Fisher,	  1999).	  This	  
diminishes	   muscle	   fibre	   excitability	   and	   reduces	  
end	   plate	   potential	   amplitudes,	   which	   leads	   to	  
the	  potentiation	  of	  a	  neuromuscular	  blockade	  by	  
nondepolarizing	   neuromuscular	   blockers	   (Fisher,	  
1999).	   Some	  authors	  have	   focused	  on	   the	  direct	  
effect	  of	  magnesium	  on	  neuromuscular	  blockade	  
(Fuchs-­‐Buder	   et	   al.,	   1995;	   Fuchs-­‐Buder	   and	  
Tassonyi,	   1996;	   Kussman	   et	   al.,	   1997;	   Ross	   and	  
Baker,	   1996;	   Telci	   et	   al.,	   2002),	   whereas	   others	  
concluded	   that	   a	   perioperative	   adjuvant	  
magnesium	   infusion	   enhances	   neuromuscular	  
blockade	   (Lee	   and	   Kwon	   2009;	   Oguzhan	   et	   al.,	  
2008;	  Ryu	  et	  al.,	  2008;	  Ryu	  et	  al.,	  2009;	  Seyhan	  et	  
al.,	  2006).	  
	  
Controlled	   hypotension	   is	   sometimes	   required	  
during	  surgery	   to	  maintain	  a	  bloodless	  operative	  
field,	   and	   investigations	   on	   perioperative	  
magnesium	   infusion	   for	   the	   control	   of	  
hypotension	  during	  middle	  ear	  surgery	  decreased	  
the	   incidences	   of	   postoperative	   nausea	   and	  
vomiting	   (PONV)	   (Ryu	   et	   al.,	   2008;	   2009),	  which	  
could	   have	   been	   due	   to	   lower	   sevoflurane	  
consumption	  (Apfel	  et	  al.,	  2002;	  Ryu	  et	  al.,	  2009)	  
rather	   than	   any	   antiemetic	   effect	   of	   the	  
magnesium.	   Nevertheless,	   since	   PONV	   is	   one	   of	  
the	  most	   common	   and	   distressing	   complications	  
after	  surgery,	  this	  effect	  is	  interesting,	  because	  it	  
could	   be	   used	   to	   benefit,	   for	   example,	   patients	  
undergoing	  ambulatory	  surgery.	  Perioperative	  i.v.	  
magnesium	   infusion	   has	   another	   advantageous	  
effect,	   in	   that	   it	   decreases	   the	   incidence	   of	  
shivering	  by	  up	   to	  70-­‐90%	   (Ryu	   et	  al.,	   2008;	  Ryu	  
et	  al.,	  2009;	  Tramer	  and	  Glynn,	  2007).	  Shivering	  is	  
one	   of	   the	   leading	   causes	   of	   postoperative	  
discomfort	   (Alfonsi,	   2001),	   and	   increases	   oxygen	  
consumption	   (Alfonsi,	   2001).	   Thus,	   the	  
prevention	   of	   shivering	   is	   one	   of	   the	   most	  
obvious	   benefits	   of	   magnesium	   sulphate	  
administration	  in	  surgical	  patients.	  
	  
When	   mixed	   with	   local	   anaesthetic,	   magnesium	  
may	   also	   show	   beneficial	   effects	   in	   intravenous	  
regional	   anaesthesia.	   In	   one	   study,	   magnesium	  
was	   added	   to	   lidocaine	   for	   intravenous	   regional	  
anaesthesia,	  and	  was	  found	  to	  improve	  quality	  of	  
anaesthesia	   and	   analgesia,	   specifically,	   sensory	  
and	   motor	   block	   onset	   times	   were	   shorter	   and	  
postoperative	   analgesia	   was	   better	   with	  
magnesium	  (Turan	  et	  al.,	  2005).	  However,	   in	  this	  
study,	   recovery	   after	   intravenous	   regional	  
anaesthesia	   was	   prolonged	   in	   the	   magnesium	  
group	   (Turan	   et	   al.,	   2005).	   In	   contrast,	   i.v.	  
magnesium	   infusion	   during	   general	   anaesthesia	  
has	   not	   been	   found	   to	   delay	   recovery	   from	  
anaesthesia	   in	   most	   investigations	   (Lee	   and	  
Kwon,	  2009;	  Ozcan	  et	  al.,	  2007;	  Ryu	  et	  al.,	  2008).	  
Another	   consideration	   during	   magnesium	  
administration	   is	   that	   magnesium	   may	   cause	  
cardiovascular	   depression	  by	   acting	   as	   a	   calcium	  
channel	   blocker.	   The	   consequent	   inhibition	   of	  
catecholamine	   release	   lowers	   plasma	  
epinephrine	   and	   norepinephrine	   concentrations	  
after	   endotracheal	   intubation,	   and	   therefore	  
reduces	   hypertensive	   responses	   during	  
anaesthesia	   induction	   (James	   et	   al.,	   1989).	  
Accordingly,	   magnesium	   should	   be	   used	   with	  
caution	  in	  hypovolemic	  patients	  and	  in	  those	  with	  
limited	  cardiac	  capacity.	  	  
	  
Other	  pain	  conditions	  
	  
Numerous	   clinical	   studies	   have	   found	   that	  
magnesium	   has	   beneficial	   effects	   in	   patients	  
suffering	   from	   neuropathic	   pain,	   dysmenorrhea,	  
tension	   headache,	   acute	   migraine	   attack,	   and	  
others.	  These	  effects	  are	  considered	  to	  be	  due	  to	  
blockage	   of	   the	   NMDA	   receptor,	   attenuation	   of	  
central	  sensitization,	  and	  muscle	  relaxing	  effects.	  
	  
Neuropathic	  pain	  
Neuropathic	   pain	   is	   caused	   by	   damage	   to	   or	   by	  
the	  dysfunction	  of	  a	  component	  of	  the	  peripheral	  
or	  central	  nervous	  system	  (Backonja,	  2003).	  Thus,	  
the	   causes	   of	   neuropathic	   pain	   are	   various	   and	  
include	   spinal	   cord	   injury,	   multiple	   sclerosis,	  
diabetic	   neuropathy,	   radiation	   injury,	  
complications	   of	   chemotherapy,	   a	   malignancy-­‐
related	  neurologic	  symptom,	  amongst	  others.	   Its	  
common	   features	   include	   burning,	   a	   cold	  
sensation,	   numbness,	   itching,	   and	   a	   shooting	   or	  
abnormal	   sensation	   called	   dysesthesia	   in	   a	  
continuous	   or	   episodic	   manner.	   The	  mechanism	  
responsible	   for	   neuropathic	   pain	   remains	  
unknown,	   but	   peripheral	   or	   central	   sensitization	  
is	  a	  prime	  candidate	  (Bridges	  et	  al.,	  2001;	  Ossipov	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et	   al.,	   2000).	   Neuropathic	   pain	   is	   extremely	  
difficult	   to	   treat,	   and	   is	   only	   partially	   relieved	   in	  
some	   40-­‐60%	   of	   patients.	   Favoured	  
pharmacologic	   treatments	   are	   antidepressants,	  
anticonvulsants,	   opioids,	   and	   NMDA	   receptor	  
antagonists	   (O'Connor	   and	   Dworkin,	   2009).	  
Magnesium	   has	   been	   shown	   to	   have	   beneficial	  
effects	   on	   neuropathic	   pain	   in	   some	   clinical	   and	  
animal	  studies.	  When	  magnesium	  sulphate	  (bolus	  
doses	  of	  500	  mg	  or	  1	  g)	  was	  given	   intravenously	  
to	   patients	   with	   uncontrolled	   neuropathic	   pain	  
due	  to	  cancer	  infiltration,	  pain	  intensity	  and	  pain	  
relief	   scores	   improved	   (Crosby	   et	   al.,	   2000).	   In	  
another	   study,	   magnesium	   chloride	   (bolus	   0.16	  
mmol/kg	  over	  10	  minutes	  followed	  by	  continuous	  
infusion	   at	   0.16	  mmol/kg/h)	   reduced	   protracted	  
pain	  and	  regions	  of	  allodynia	  in	  patients	  suffering	  
from	   peripheral	   neuropathic	   pain	   (Felsby	   et	   al.,	  
1996).	   In	   addition,	   in	   an	   animal	   model	   of	  
neuropathic	   pain	   induced	   hyperalgesia	   subsided	  
after	   intraperitoneal	   magnesium	   therapy	   (total	  
150	  or	  200	  mg/kg	  for	  5	  days)	  (Begon	  et	  al.,	  2000).	  
	  
Postherpetic	  neuralgia	  	  
Postherpetic	   neuralgia	   (PHN),	   a	   type	   of	  
neuropathic	   pain,	   is	   characterized	   by	   chronic	  
persistent	   pain	   after	   an	   acute	   herpes	   zoster	  
attack	   (Rowbotham	   and	   Petersen,	   2001).	  
Typically,	   PHN	   causes	   a	   burning,	   aching,	   sharp,	  
and	   lancinating	   pain	   that	   occurs	   in	   a	   continuous	  
or	  paroxysmal	  pattern,	  and	  is	  often	  accompanied	  
by	   hyperalgesia	   and	   allodynia.	   Brill	  et	   al.,	   (2002)	  
showed	  that	  magnesium	  can	  relieve	  hyperalgesia	  
and	   allodynia	   in	   PHN.	   When	   they	   administered	  
i.v.	  magnesium	  sulphate	  at	  30	  mg/kg	  over	  30	  min	  
to	  patients	  with	  intractable	  PHN,	  pain	  was	  either	  




Diabetes	   mellitus	   is	   the	   most	   common	   etiologic	  
factor	   of	   peripheral	   neuropathy,	   and	   diabetic	  
neuropathy	   is	   often	   expressed	   as	   numbness,	   a	  
tingling	   sensation,	   and	   hypersensitivity	   to	   pain.	  
These	   symptoms	   are	   limited	   to	   the	   fingers	   and	  
toes	  during	  early	  disease,	  and	  then	  spread	  to	  the	  
proximal	   extremities	   to	   produce	   a	   characteristic	  
glove	   and	   stocking	   pattern	   (Head,	   2006).	  
Conventional	  treatments	  include	  antidepressants,	  
anticonvulsants,	  lidocaine	  patches,	  opioid	  or	  non-­‐
opioids	   analgesics,	   and	   various	   alternative	  
treatments	   (Head,	   2006).	   Recently,	   dietary	  
magnesium	   supplementation	   has	   been	   at	   the	  
focus	  of	  attention,	  and	  oral	  doses	  of	  magnesium	  
sulphate	   have	   been	   found	   to	   be	   effective	   at	  
reducing	   thermal	   pain	   thresholds	   in	   rats.	  
However,	   appropriate	   treatment	   dosages	   and	  
durations	  have	  not	  been	  established	  (Hasanein	  et	  
al.,	   2006).	   De	   Leeuw	   et	   al.,	   (2004)	   also	  
demonstrated	   that	   long-­‐term	   magnesium	  
supplementation	   (300	   mg	   daily	   for	   5	   years)	   can	  
favourably	   influence	   the	   progression	   of	   diabetic	  
polyneuropathy.	  
	  
Chemotherapy-­‐induced	  peripheral	  neuropathy	  
CIPN	   is	   one	   of	   the	  most	   common	   side	   effects	   in	  
cancer	   patients	   administered	   many	   chemo-­‐
therapeutic	   agents,	   such	   as	   cisplatin,	   5-­‐
fluorouracil,	   vinca	   alkaloids,	   taxoids,	   and	  
etoposide	  (Head,	  2006;	  Hildebrand,	  2006;	  Wolf	  et	  
al.,	   2008).	   The	   symptoms	  and	   signs	  of	  CIPN	  may	  
resolve	   completely	   or	   partially,	   but	   are	  
sometimes	   irreversible	   (Kannarkat	   et	   al.,	   2007).	  
Because	   the	   pathophysiology	   of	   CIPN	   has	   not	  
been	   fully	   elucidated,	   various	   agents	   have	   been	  
used	   to	   prevent	   or	   treat	   CIPN.	   Recently,	   it	   was	  
reported	   that	   a	   Ca2+/Mg2+	   infusion	   before	   and	  
after	   oxaliplatin	   could	   prevent	   the	   development	  
of	   CIPN	   (Gamelin	   et	   al.,	   2004),	   but	   the	   overall	  
benefit	   of	   this	   is	   uncertain	   because	   of	   the	  
different	   treatment	   efficacies	   of	   oxaliplatin	   and	  
Ca2+/Mg2+	  infusion	  combinations	  (Hochster	  et	  al.,	  
2007).	   Furthermore,	   oxaliplatin	   metabolites	   are	  
chelated	   by	   calcium	   and	   magnesium,	   and	   this	  
could	   explain	   the	   observed	   neuroprotective	  
effect.	  However,	  Bujalska	  et	  al.,	  (2009)	  found	  that	  
pretreatment	   with	   magnesium	   (30	   mg/kg,	   i.p.)	  
enhanced	   the	   analgesic	   effects	   of	   opioids	   in	   a	  
vincristine-­‐induced	   neuropathy	   model,	   and	   re-­‐
emphasized	   the	   antagonistic	   effect	   that	  
magnesium	  has	  on	  NMDA	  receptors.	  
	  
Dysmenorrhea	  
Dysmenorrhea	  refers	  to	  a	  gynaecological	  medical	  
complaint	   characterized	   by	   severe	   uterine	  
cramps	   associated	   with	   menstruation.	  
Dysmenorrhea	   may	   precede	   or	   co-­‐occur	   with	  
menstruation,	   and	   causes	   a	   dull,	   nauseating,	  
colicky	   to	   sharp	   or	   cramping	   pain.	   The	  
overproduction	   of	   uterine	   prostaglandins	   or	  
vasopressin,	   which	   stimulates	   myometrial	  
contraction	  of	  the	  uterus,	  has	  been	  identified	  as	  a	  
potential	   contributory	   factor	   (Stromberg	   et	   al.,	  
1984;	   Woolf	   and	   Chong,	   1993).	   When	  
dysmenorrhea	   is	   severe	   enough	   to	   restrict	   daily	  
activities,	   nonsteroidal	   anti-­‐inflammatory	   drugs	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or	  oral	  contraceptive	  pills	  are	  required	  to	  reduce	  
uterine	   contraction,	   and	   thus,	   relieve	   the	   pain	  
(Harel,	   2008).	   The	   benefits	   and	   safety	   of	  
magnesium	   for	   the	   treatment	   of	   primary	  
dysmenorrhea	   have	   also	   been	   reviewed	  
(Bettendorf	   et	   al.,	   2008;	   Proctor	   and	   Murphy	  
2001),	  but	  more	  research	  is	  required	  to	  verify	   its	  
efficacy.	   Briefly,	   oral	   magnesium	   on	   the	   day	  
before	   menstruation	   and	   during	   the	   first	   and	  
second	   days	   of	   the	   menstrual	   cycle	   for	   six	  
consecutive	   cycles,	   was	   found	   to	   have	   a	  
therapeutic	   effect	   on	   dysmenorrhea	   (Fontana-­‐
Klaiber	  and	  Hogg,	  1990).	  However,	   the	  optimum	  
treatment	  regimen	  has	  yet	  to	  be	  established	  and	  
the	   mechanism	   responsible	   has	   not	   been	  
determined.	   Nevertheless,	   it	   has	   been	  
hypothesized	   that	   magnesium	   inhibits	   the	  
biosynthesis	   of	   PGF2-­‐α,	   which	   alleviates	  
myometrial	  contraction	  and	  muscle	  relaxation	  by	  
competing	  with	  calcium	  for	  entry	  into	  myometrial	  
cells	   through	   voltage-­‐gated	   channels	   (Seifert	   et	  
al.,	  1989;	  Zahradnik	  and	  Breckwoldt,	  1988).	  
	  
Tension	  headache	  
Tension	  headaches	  are	  characterized	  by	  a	  diffuse,	  
gradual,	   and	   pressure-­‐like	   aching	   pain	   bilaterally	  
over	   the	   top	   sides	   of	   the	   cranium	   (Altura	   and	  
Altura,	  2001).	  Its	  prevalence	  has	  been	  reported	  to	  
range	   from	   around	   10%	   to	   nearly	   90%	  
(Rasmussen	   et	   al.,	   1991;	   Robbins	   and	   Lipton,	  
2010;	   Russell	   et	   al.,	   2006).	   Although	   the	   exact	  
aetiology	   of	   tension	   headaches	   is	   unknown,	  
several	   pathophysiologies	   have	   been	   suggested,	  
such	  as,	  muscle	   tension	   (Jensen	  and	  Rasmussen,	  
1996;	   Langemark	   and	   Olesen	   1987),	   increased	  
myofascial	   pain	   sensitivity	   (Pfaffenrath	   et	   al.,	  
1998),	   platelet	   aggregation	   (Mishima	   et	   al.,	  
1997),	   and	   others.	   Furthermore,	   in	   one	   study,	   it	  
was	   shown	   that	   the	   magnesium	   ion	   levels	   of	  
platelets	   were	   lower	   in	   patients	   with	   a	   tension	  
headache	   (Mishima	   et	   al.,	   1997),	   and	   that	  
magnesium	   supplementation	   appeared	   to	  
ameliorate	   headaches,	   including	   the	   tension	  





The	   postoperative	   analgesic	   adjuvant	   role	   of	  
magnesium	   and	   its	   use	   as	   an	   analgesic	   therapy	  
for	   the	   treatment	   of	   acute	   or	   chronic	   pain	   have	  
been	   suggested	   for	   decades.	   Its	   antinociceptive	  
effect	   has	   been	   suggested	   to	   be	   due	   to	   the	  
blocking	   of	   NMDA	   receptors,	   and	   thus,	   the	  
prevention	   of	   central	   sensitization.	   More	  
consistent	   and	   convincing	   evidence	   is	   required	  
before	  magnesium	  can	  be	  viewed	  as	  an	  effective	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Traumatic	  injury	  to	  the	  central	  nervous	  system	  (CNS)	  is	  a	  leading	  cause	  of	  morbidity	  and	  mortality,	  and	  
represents	   a	   significant	   public	   health	   issue.	   Despite	   intensive	   research,	   no	   effective	   neuroprotective	  
therapy	  exists,	  and	  survivors	  of	  CNS	   injury,	   including	  traumatic	  brain	   injury	   (TBI)	  and	  spinal	  cord	   injury	  
(SCI),	  can	  be	  left	  with	  severe	  disabilities	  that	  require	  long-­‐term	  rehabilitation.	  Much	  of	  the	  damage	  that	  
occurs	  after	  TBI	  and	  SCI	  develops	  over	  time	  with	  the	  primary	  injury	  initiating	  a	  secondary	  injury	  cascade	  
made	   up	   of	   deleterious	   biochemical	   and	   pathophysiological	   reactions.	   This	   delayed	   development	   of	  
secondary	   injury	   provides	   a	   vital	   opportunity	   for	   therapeutic	   intervention	   and	   considerable	   effort	   is	  
currently	  being	  directed	   toward	   identifying	   these	   injury	   factors	  and	  developing	   interventions	   that	  may	  
potentially	  prevent	  their	  actions.	  Magnesium	  (Mg2+)	  decline	  has	  been	  identified	  as	  playing	  a	  key	  role	  in	  
the	   secondary	   injury	  process,	   in	  part	  because	  of	   its	   central	   role	   in	   the	   regulation	  of	  a	   large	  number	  of	  
known	   injury	   factors	   and	   that	   its	   decline	   is	   associated	   with	   the	   development	   of	   motor	   and	   cognitive	  
deficits.	   Mg2+	   administration	   has	   been	   extensively	   investigated	   both	   preclinically	   in	   TBI	   and	   SCI	   and	  
clinically	  as	  a	  neuroprotectant	  in	  TBI	  with	  varied	  success.	  	  This	  chapter	  focuses	  on	  the	  role	  of	  Mg2+	  in	  TBI	  





A	  decline	  in	  Mg2+	  following	  TBI	  was	  first	  identified	  
using	   in	   vivo	   magnetic	   resonance	   spectroscopy	  
(Vink	   et	   al.,	   1988)	   and	   further	   declines	   have	  
subsequently	   been	   reported	   by	   numerous	  
laboratories	   following	   a	   variety	   of	   insults	   to	   the	  
CNS	  including	  TBI,	  SCI,	  stroke	  and	  drug	  intoxication.	  
It	   has	   been	   observed	   that	   a	   traumatic	   insult	   to	  
the	  CNS	   results	   in	  a	  decrease	   in	   the	   intracellular	  
free	   Mg2+	   concentration	   of	   between	   40-­‐60%,	  
while	   the	   total	   tissue	  Mg2+	   falls	   by	   between	   10-­‐
15%.	   This	  Mg2+	   decline	   is	   confined	   to	   the	   site	  of	  
injury	   and	   the	   decrease	   is	   associated	   with	   the	  
development	   of	   neurological	   dysfunction.	   Treat-­‐
ment	  with	  Mg2+	  has	  been	  shown	  to	  attenuate	  the	  
neurological	  changes	  experimentally	  following	  TBI	  
and	   SCI,	   however,	   clinical	   studies	   of	   Mg2+	   as	   a	  
neuroprotective	   agent	   show	   conflicting	   results	  
(Dhandapani	  et	  al.,	  2008;	  Temkin	  et	  al.,	  2007).	  	  
	  
Traumatic	  CNS	  injury	  
	  
Injuries	  to	  the	  CNS	  are	  a	  significant	  problem,	  with	  
TBI	   the	   leading	   cause	   of	   death	   and	   disability	   in	  
people	  under	  the	  age	  of	  40	  years	  (Fleminger	  and	  
Ponsford,	   2005).	   In	   the	   USA,	   approximately	   1.5	  
million	   people	   are	   affected	   by	   TBI	   annually.	   Of	  
these,	   230,000	   people	   are	   hospitalized	   and	  
survive,	   80,000	   people	   develop	   a	   TBI-­‐related	  
disability,	  and	  50,000	  people	  die	  (Pitkänen	  et	  al.,	  
2005).	   In	   addition,	   SCI	   affects	   around	   200,000	  
people	   in	   the	   USA	   with	   10,000	   new	   cases	   each	  
year	   (Anonymous,	   2008;	   Buechner	   et	   al.,	   2000)	  
with	  the	  cost	  of	  caring	  for	  patients	  with	  SCI	  in	  the	  
US	   estimated	   to	   be	   $9.73	   billion	   (Weaver	   et	   al.,	  
2000).	   Since	   no	   effective	   treatment	   is	   available,	  
survivors	   of	   TBI	   and	   SCI	   may	   be	   left	   with	  
debilitating	   neurological	   deficits	   that	   confer	  
social,	   financial	   and	   emotional	   burdens	   and	  
adversely	  affect	  their	  quality	  of	  life.	  	  
	  
The	  neurological	  damage	  resulting	  from	  traumatic	  
injuries	   to	   the	   CNS	   is	   due	   to	   both	   direct,	  
immediate	  biomechanical	  processes	  (the	  primary	  
injury)	   and	   indirect,	   delayed	   (secondary)	   injury	  
mechanisms	   (Morales	   et	   al.,	   2005)	   and	   the	  
neuronal	  death	   in	  TBI	  and	  SCI	   is	   likely	   to	   involve	  
both	  necrotic	  and	  apoptotic	  pathways	  (Liou	  et	  al.,	  
2003).	  The	  primary	  event	  is	  irreversible	  and	  in	  TBI	  
comprises	  contusions,	  lacerations,	  tissue	  shearing	  
and	   stretching	   of	   nerve	   fibres	   (Gentile	   and	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McIntosh,	   1993),	   whereas	   the	   most	   common	  
primary	   injuries	   to	   the	   spinal	   cord	   result	   from	  
fracture/dislocation	   or	   crush	   injury	   to	   the	  
vertebral	   column.	   In	   contrast,	   secondary	   injury	  
consists	   of	   a	   series	   of	   complex	   biochemical	  
changes	   that	   are	   triggered	  by	   the	  primary	   event	  
and	   evolve	   over	   the	   minutes	   to	   days	   and	   even	  
months	   after	   the	   insult	   (Vink	   and	   Van	   Den	  
Heuvel,	   2010).	   A	   number	   of	   secondary	   injury	  
factors	  have	  been	  identified,	   including	  disruption	  
to	   the	   blood-­‐brain	   barrier	   (BBB),	   edema,	  
ischemia,	   hypertension,	   inflammation,	   excito-­‐
toxicity,	   oxidative	   stress	   and	  Mg2+	   decline,	   all	   of	  
which	   can	   be	   deleterious	   to	   neuronal	   cells	  
(Barone	   and	   Kilgore,	   2006;	   Cormio	   et	   al.,	   1997;	  
Gentile	  and	  McIntosh	  1993;	  Golding,	  2002).	  	  
	  
Secondary	  injury	  factors	  
	  
As	  stated	  above,	  secondary	   injury	   involves	  series	  
of	   complex	   biochemical	   changes	   that	   are	  
triggered	  by	  the	  primary	  event	  and	  may	  continue	  
for	  days	  to	  weeks	  after	  the	  insult	  (Roth	  and	  Farls	  
2000).	   To	   provide	   an	   example	   of	   the	   secondary	  
injury	   cascade,	   shearing	   of	   nerve	   fibres	   at	   the	  
time	  of	   insult	  results	   in	  massive	  ion	  fluxes	  across	  
cell	  membranes,	  loss	  of	  membrane	  potential	  and	  
rapid	  release	  of	  neurotransmitters	  from	  damaged	  
neurons.	   This	  may	   result	   in	   excitotoxicity,	  which	  
can	   evoke	   an	   inflammatory	   response,	   thereby	  
stimulating	   further	   processes	   (such	   as	   the	  
changes	   described	   above),	   eventually	   leading	   to	  
cell	   death	   (Vink	   and	   Van	   Den	   Heuvel,	   2004).	  
Secondary	   injury	   is	   associated	   with	   significant	  
morbidity	   and	  mortality	   following	   traumatic	  CNS	  
injury	   (Gentile	   and	   McIntosh,	   1993),	   but	   given	  
that	   it	   manifests	   over	   time,	   this	   provides	   an	  
opportunity	   to	   administer	   a	   pharmacological	  
agent	   to	   impede	   or	   prevent	   further	   injury	   and	  
thus	   improve	   outcome.	   Several	   injury	   processes	  
relevant	   to	   traumatic	   CNS	   injury	   will	   now	   be	  
discussed	   including	   diffuse	   axonal	   injury	   (DAI),	  
edema,	  oxidative	  stress,	  mitochondrial	  dysfunction,	  
inflammation	  and	  lastly	  significant	  discussion	  will	  
be	  given	  to	  magnesium	  decline.	  
	  
Diffuse	  Axonal	  Injury	  
DAI	  is	  a	  principal	  cause	  of	  coma	  following	  TBI,	  and	  
significantly	   contributes	   to	   TBI-­‐related	  morbidity	  
and	  mortality	  (Li	  and	  Feng,	  2009).	  Classically,	  DAI	  
was	   categorized	   as	   a	   primary	   injury,	   whereby	  
axons	   are	   torn	   and	   rupture	   at	   the	   time	  of	   insult	  
(Adams	   et	   al.,	   1982).	   However,	   more	   recent	  
evidence	   suggests	   that	   DAI	   is	   triggered	   at	   the	  
time	   of	   injury	   by	   inertial	   forces	   and	  may	   evolve	  
over	  a	  period	  of	  hours	  to	  days,	  progressing	  from	  
focal	   disruptions	   to	   axons	   to	   impaired	   axonal	  
transport,	   axolemmal	   swelling	   and,	   ultimately,	  
axonal	  disconnection	  (Büki	  and	  Povlishock,	  2006;	  
Mazzeo	   et	   al.,	   2009;	   Stone	   et	   al.,	   2004).	   DAI	   is	  
generally	   diagnosed	   at	   post-­‐mortem	   by	  
immunostaining	   for	   β-­‐amyloid	   precursor	   protein	  
(APP)	   (Gentleman	   et	   al.,	   1993),	   although	   recent	  
imaging	   advances	   may	   allow	   its	   detection	   at	   an	  
earlier	  stage	  (Li	  and	  Feng,	  2009).	  
	  
Edema	  
Cerebral	   edema	   is	   defined	   as	   an	   abnormal	  
accumulation	   of	   fluid	   within	   the	   brain	  
parenchyma,	   resulting	   in	   a	   volumetric	   enlarge-­‐
ment	  (swelling)	  of	  brain	  tissue	  (Heo	  et	  al.,	  2005).	  
Swollen	   tissues	   may	   exert	   harmful	   effects	   by	  
increasing	   pressure	   in	   surrounding	   tissues,	  
leading	   to	   ischemia	   and	   additional	   edema	  
(Simard	   et	   al.,	   2007).	   Swelling	   has	   particularly	  
deleterious	  consequences	  in	  the	  brain,	  due	  to	  the	  
fact	   that	   the	   volume	   of	   the	   intracranial	   cavity	   is	  
fixed	  (Ayata	  and	  Ropper,	  2002).	  The	  resulting	  rise	  
in	  intracranial	  pressure	  (ICP)	  with	  cerebral	  edema	  
formation	  is	  a	  potentially	  lethal	  process	  (Kimelberg,	  
1995).	  Indeed,	  cerebral	  edema	  plays	  an	  important	  
role	   in	   the	   outcome	  of	   TBI	   victims:	   uncontrolled	  
brain	   swelling	  with	   the	  accompanying	   rise	   in	   ICP	  
is	   the	   leading	   cause	   of	   death	   in	   TBI	   patients	  
(Marmarou	  et	  al.,	  2000).	  
	  
Cerebral	   edema	   is	   classified	   as	   cytotoxic	   and	  
vasogenic,	   depending	   upon	  whether	   or	   not	   BBB	  
permeability	   is	   increased	   (Verlooy	   and	   Van	  
Reempts,	   2005).	   The	   BBB	   is	   composed	   of	   a	  
monolayer	   of	   endothelial	   cells	   forming	   tight	  
junctions	   that	   prevent	   the	   direct	   interaction	   of	  
the	   peripheral	   circulation	  with	   the	   CNS	   (Palmer,	  
2010).	   Cytotoxic	   edema	   refers	   to	   the	  movement	  
of	  water,	  Na+	  and	  Cl-­‐	  from	  the	  extracellular	  to	  the	  
intracellular	   space,	   which	   results	   in	   cell	   swelling	  
and	   predisposes	   cells	   to	   oncotic	   cell	   death.	  
However,	   cytotoxic	   edema	   does	   not	   involve	  
increases	   in	   BBB	   permeability,	   nor	   does	   it	  
contribute	   to	   the	   actual	   net	   increase	   in	   brain	  
water	   (Ayata	   and	   Ropper,	   2002;	   Simard	   et	   al.,	  
2007).	  Conversely,	  vasogenic	  edema	  is	  associated	  
with	   the	   degradation	   of	   tight	   junctions	   between	  
endothelial	   cells	   of	   the	   BBB	   (Heo	   et	   al.,	   2005).	  
Consequently,	  the	  BBB	  becomes	  more	  permeable	  
to	  macromolecules	  and	  permits	  the	  movement	  of	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fluid	   from	   capillaries	   to	   the	   extravascular	  
compartment	   (Heo	   et	   al.,	   2005;	   Simard	   et	   al.,	  
2007);	   hence	   vasogenic	   edema	   causes	   a	   net	  
increase	   in	   brain	   water	   content	   (Ayata	   and	  
Ropper,	   2002).	   In	   TBI,	   the	   increase	   in	   BBB	  
permeability	   may	   occur	   by	   mechanical	   injury,	  
autodestructive	  mediators	  or	  both	   (Unterberg	   et	  
al.,	  2004).	  However,	  despite	  the	  potentially	  lethal	  
consequences	  of	  edema	  in	  TBI,	  there	  is	  currently	  
no	   effective	   therapy	   to	   prevent	   its	   formation	   or	  
progression.	   Treatments	   such	   as	   mannitol,	  
corticosteroids,	   barbiturates,	   induction	   of	   hypo-­‐
thermia,	  drainage	  of	  the	  cerebrospinal	  fluid	  (CSF)	  
and	   surgical	   decompression	   (Ayata	   and	   Ropper,	  
2002;	   Clausen	   and	   Bullock,	   2001)	   have	   had	  
limited	  success	  in	  managing	  rises	  in	  ICP	  (Vink	  and	  
Van	  Den	  Heuvel,	  2004).	  
	  	  
Neurogenic	   inflammation	   is	  a	   local	   inflammatory	  
reaction	   of	   neurons	   in	   response	   to	   infection,	  
toxins	   or	   trauma,	   which	   is	   characterized	   by	  
vasodilation,	   plasma	   extravasation	   and	   edema	  
(Black,	  2002;	  Ro	  et	  al.,	  2005;	  Turner	  et	  al.,	  2006).	  
Studies	  from	  our	  laboratory	  (Nimmo	  et	  al.,	  2004;	  
Vink	   et	   al.,	   2003)	   have	   shown	   that	   neurogenic	  
inflammation	  may	  be	  involved	  in	  the	  formation	  of	  
vasogenic	   edema	   and	   the	   functional	   deficits	  
following	   diffuse	   TBI	   in	   rats,	   and	   that	   the	  
neuropeptide,	   substance	   P	   (SP),	   is	   a	   potent	  
initiator	   of	   neurogenic	   inflammation.	   Further	  
research	   from	   our	   laboratory	   (Donkin	   et	   al.,	  
2009)	   has	   demonstrated	   that	   a	   SP	   receptor	  
antagonist	   inhibits	   BBB	   breakdown	   and	   edema	  
formation,	   and	   significantly	   improves	   long-­‐term	  
functional	   outcome	   and	   motor	   deficits	   resulting	  
from	  TBI.	  These	   important	   results	  may	  provide	  a	  
novel	  pharmacological	  treatment	  for	  TBI.	  
	  
Oxidative	  Stress	  
Reactive	   oxygen	   species	   (ROS)	   comprise	   a	   range	  
of	   chemical	   entities,	   including	   hydroxyl	   radicals,	  
peroxynitrite,	   superoxide	   anions,	   hydrogen	  
peroxide,	   nitric	   oxide	   and	   singlet	   oxygen	   (Chong	  
et	   al.,	   2005;	   Ellis,	   2007).	   ROS	   are	   highly	   reactive	  
molecules,	   possessing	   one	   or	   more	   unpaired	  
electrons	   in	   their	   outer	   orbits	   (Halliwell,	   1992).	  
While	   some	   ROS	   are	   normal	   by-­‐products	   of	  
cellular	   metabolism	   (Yu,	   1994),	   their	   over-­‐
production	   can	   lead	   to	   cell	   injury	   and	   tissue	  
damage	   via	   reactions	   with	   proteins,	   lipids	   and	  
nucleic	   acids,	   and	   cellular	   activation	   by	   ROS	  
induces	   signalling	   cascades	   that	   lead	   to	   rises	   in	  
intracellular	   Ca2+	   concentrations	   (Alexandrova	  
and	   Bochev,	   2005;	  Massullo	   et	   al.,	   2006).	  When	  
ROS	   are	   generated	   in	   excess	   of	   endogenous	  
antioxidant	   mechanisms,	   the	   result	   is	   oxidative	  
stress	  (Finkel	  and	  Holbrook,	  2000).	  	  
	  
Brain	   tissue	   is	   highly	   susceptible	   to	   damage	   by	  
oxidative	   stress	   for	   a	   number	   of	   reasons.	   The	  
brain	   has	   a	   high	   rate	   of	   oxygen	   metabolism,	  
which	   increases	   the	   likelihood	   of	   excess	   ROS	  
production	   (Chong	   et	   al.,	   2005).	   Furthermore,	   it	  
contains	   high	   levels	   of	   polyunsaturated	   fatty	  
acids,	   which	   are	   particularly	   vulnerable	   to	  
damage	   by	   free	   radicals	   (Halliwell,	   1992).	  
Critically,	  the	  brain	  has	  relatively	   low	  antioxidant	  
and	  repair	  capacities	  compared	  with	  other	  organs	  
(Vink	   and	   Nimmo,	   2009).	   All	   of	   these	   factors	  
render	   brain	   tissue	   extremely	   sensitive	   to	  
increases	   in	   ROS,	   and	   oxidative	   stress	   is	   indeed	  
relevant	   to	   TBI.	   Studies	   demonstrate	   that	   the	  
production	  of	  ROS	  is	  enhanced	  following	  TBI,	  and	  
this	   is	   accompanied	   by	   an	   impairment	   of	  
antioxidant	  defences	  (Ansari	  et	  al.,	  2008;	  Lima	  et	  
al.,	   2008).	   TBI-­‐induced	   oxidative	   stress	   can	   lead	  
to	   cytoskeletal	   damage,	   mitochondrial	  
dysfunction	   and	   altered	   signal	   transduction,	  
which	   can	   be	   deleterious	   to	   neuronal	   and	  




Mitochondria	   are	   organelles	   that	   are	   present	   in	  
all	   cells	   and	   play	   a	   critical	   role	   in	   regulating	  
cellular	   energy	   production	   via	   the	   electron	  
transport	   chain	   (Bayir	   and	   Kagan,	   2008;	  Mazzeo	  
et	  al.,	  2009).	  Consequently,	  it	  would	  be	  expected	  
that	   disruption	   to	   mitochondrial	   function	   would	  
have	   serious	   adverse	   consequences	   to	   cells,	  
particularly	   those	   with	   a	   high-­‐energy	   demand,	  
such	  as	  neurons.	  Indeed,	  mitochondrial	  dysfunction	  
is	  an	  important	  factor	  in	  TBI	  pathophysiology	  that	  
can	  lead	  to	  energy	  depletion,	  free	  radical	  release	  
and	   apoptosis,	   or	   programmed	   cell	   death	   (Vink	  
and	   Nimmo,	   2009).	   In	   experimental	   TBI,	  
alterations	   in	   mitochondrial	   function	   have	   been	  
reported	   within	   hours	   of	   injury	   and	  may	   persist	  
for	   days	   (Robertson,	   2004).	   Furthermore,	   in	  
clinical	   TBI	   studies,	   patients	   with	   profound	  
mitochondrial	   dysfunction	   have	   a	   poor	   outcome	  
(Signoretti	  et	  al.,	  2008).	  
	  
As	   discussed,	   traumatic	   CNS	   injury	   leads	   to	  
conditions	   of	   oxidative	   stress.	   Oxidative	   stress	  
directly	  contributes	  to	  mitochondrial	  dysfunction,	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promoting	   the	  release	  of	  cytochrome	  c	   from	  the	  
inner	   membrane	   of	   the	   mitochondrion,	   which	  
triggers	   an	   apoptotic	   cascade	   involving	   caspases	  
and	   other	   pro-­‐apoptotic	   proteins	   (Bayir	   and	  
Kagan,	   2008;	   Chong	   et	   al.,	   2005).	   Mitochondria	  
also	   constitute	   an	   important	   intracellular	   source	  
of	  ROS,	  which	  are	  produced	  during	  the	  synthesis	  
of	  ATP	  (Kowaltowski	  et	  al.,	  2009).	  During	  states	  of	  
electron	   transport	   chain	   dysregulation,	   as	   may	  
occur	   following	   TBI,	   there	   is	   an	   increase	   in	   the	  
production	   of	   ROS	   (Bayir	   and	   Kagan,	   2008).	  
Mitochondria	   have	   also	   been	   implicated	   in	  
glutamate-­‐mediated	   excitotoxicity,	   by	   participating	  
in	   the	   release	   of	   glutamate,	   Ca2+	   sequestration	  




The	   inflammatory	   response	   represents	   another	  
important	   secondary	   injury	   process	   of	   traumatic	  
CNS	   injury.	   Injury-­‐induced	   inflammation	   may	   be	  
beneficial	   in	  the	  short	  term,	  by	  removing	  cellular	  
debris	   or	   promoting	   regeneration,	   however,	   in	  
excess,	   inflammatory	   responses	   can	  have	   severe	  
deleterious	   effects	   that	   lead	   to	   neuro-­‐
degeneration	   (Maas	   et	   al.,	   2008;	   Vink	   et	   al.,	  
2009).	   Inflammation	   can	  occur	  within	   the	  neural	  
tissue,	   where	   activated	  microglia	   and	   astrocytes	  
release	  cytokines,	   chemokines	  and	  ROS.	  There	   is	  
also	   evidence	   that	   the	   complement	   system	   is	  
activated	   following	   TBI	   (Stahel	   et	   al.,	   1998).	  
Furthermore,	   disruption	   to	   the	   BBB	   in	   response	  
to	   brain	   insult	   is	   associated	   with	   the	  
transmigration	   of	   leukocytes	   to	   the	   area	   of	  
damage,	   which	   themselves	   produce	   cytokines	  
(Jain,	   2008).	   Indeed,	   levels	   of	   the	   pro-­‐
inflammatory	   cytokines,	   tumour	   necrosis	   factor	  
(TNF)-­‐α	   and	   interleukin	   (IL)-­‐1β	   are	   elevated	  
following	  experimental	  TBI	   (Fan	  et	  al.,	  1995;	  Fan	  
et	   al.,	   1996),	   and	   may	   act	   synergistically	   to	  
exacerbate	  the	  neuroinflammatory	  response	  and	  
excitotoxicity	   (Morganti-­‐Kossmann	   et	   al.,	   2007).	  
On	   the	  other	   hand,	   anti-­‐inflammatory	   cytokines,	  
such	   as	   IL-­‐10	   and	   transforming	   growth	   factor	  
(TGF)-­‐β,	  may	  exert	  neuroprotective	  effects	  in	  TBI	  
(Knoblach	   and	   Faden,	   1998)	   by	   suppressing	   the	  
actions	   of	   TNF-­‐α	   and	   IL-­‐1β	   (Benveniste	   et	   al.,	  
1995).	   Finally,	   IL-­‐6	  may	  act	  either	   to	  promote	  or	  
inhibit	   inflammation	   in	   different	   situations,	  
exemplifying	   the	   complexity	   of	   the	   neuro-­‐
inflammatory	   pathways	   associated	   with	   TBI	  
(Morganti-­‐Kossmann	  et	  al.,	  2007).	  
	  
Mg2+	  depletion	  following	  traumatic	  CNS	  injury	  
	  
Mg2+	   depletion	   has	   been	   observed	   both	  
experimentally	   within	   the	   brain	   of	   animals	   and	  
clinically	   in	   the	   blood	   of	   humans	   following	  
traumatic	   CNS	   injuries.	   This	   depletion	   is	   an	  
important	   secondary	   injury	   factor	   that	   has	   been	  
associated	   with	   poor	   neurological	   outcome	   in	  
both	   humans	   and	   experimental	   animals.	   A	  
significant	   decline	   in	   serum	   ionized	   Mg2+	   levels	  
was	  measured	   in	  TBI	  patients,	  with	  the	  magnitude	  
of	   Mg2+	   decline	   linked	   to	   the	   severity	   of	   TBI	  
(Kahraman	   et	   al.,	   2003).	   Similarly	   Mg2+	   levels	  
decline	   following	   experimental	   SCI	   in	   the	   acute	  
phase,	  with	   levels	   significantly	   lower	   for	   up	   to	   3	  
days	   following	   injury,	   before	   gradually	   returning	  
to	   sham	   levels	   (Chanimov	   et	   al.,	   2006;	   Lemke	   et	  
al.,	  1987).	  Like	  TBI,	  the	  degree	  of	  reduction	  is	  also	  
dependent	  on	   injury	   severity	   (Lemke	  and	  Faden,	  
1990)	   suggesting	   a	   drop	   in	   Mg2+	   levels	   plays	   a	  
central	   role	   in	   the	   secondary	   injury	   cascade.	  
Indeed,	  following	  TBI	  in	  rats	  the	  decrease	  in	  brain	  
intracellular	   free	   Mg2+	   concentration	   observed	  
following	  injury	  was	  correlated	  with	  the	  develop-­‐
ment	   of	   neurological	   deficits	   (Heath	   and	   Vink,	  
1996;	   Vink	   et	   al.,	   1988).	   In	   a	   study	   investigating	  
the	  consequences	  of	  Mg2+	  deficiency	  prior	  to	  TBI	  
in	   rats,	   the	   Mg2+-­‐deficient	   group	   was	   shown	   to	  
have	   significantly	   greater	   cortical	   cell	   loss	  
compared	   to	   the	   vehicle	   group,	   as	   well	   as	  
cytoskeletal	   alterations	   in	   cortical	   and	  
hippocampal	  neurons	  (Saatman	  et	  al.,	  2001).	  	  
	  
Mechanisms	  of	  Mg2+	  neuroprotection	  
	  
Given	   the	   significance	   of	   Mg2+	   decline	   with	  
respect	   to	   neurological	   outcome	   following	   CNS	  
injury,	  Mg2+	  has	  been	   investigated	  as	  a	  potential	  
neuroprotective	   agent	   for	   CNS	   injury.	   Mg2+	  
represents	   an	   attractive	   interventional	   therapy	  
due	   to	   its	   low	   cost,	   ease	   of	   use,	   low	   risk	   of	  
adverse	   effects	   and	   its	   ability	   to	   penetrate	   the	  
BBB	  (Sacco	  et	  al.,	  2007).	  Furthermore,	  it	  is	  able	  to	  
modulate	   many	   processes	   relevant	   to	   both	   TBI	  
and	  SCI.	  
	  
Mg2+	   is	   crucial	   to	   many	   diverse	   biological	  
processes	   and	   is	   an	   essential	   co-­‐factor	   required	  
for	   the	   function	  of	  numerous	  enzymes	   (Ebel	  and	  
Günther,	  1980).	  Given	  its	  vital	  physiological	  roles,	  
a	  decline	  in	  Mg2+	  concentration	  is	  likely	  to	  have	  
an	  adverse	  	  effect	  	  on	  	  cellular	  	  functioning,	  the	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maintenance	   of	   membrane	   potential	   and	   the	  
capacity	   for	   cells	   to	   undergo	   repair	   (Vink	   and	  
Cernak,	   2000).	   Mg2+	   also	   blocks	   N-­‐methyl-­‐D-­‐
aspartate	  receptors	  (NMDAR),	  thereby	  regulating	  
Ca2+	   influx	   (Sen	  and	  Gulati,	  2010),	  with	  a	  decline	  
in	  Mg2+	  exacerbating	  excitotoxicity	  post-­‐injury.	  In	  
the	   absence	   of	   injury,	   Mg2+	   deficiency	   impairs	  
antioxidant	   defences	   (Blache	   et	   al.,	   2006),	   with	  
Mg2+	  inhibiting	  the	  production	  of	  reactive	  oxygen	  
species	   (Blache	   et	   al.,	   2006),	   reducing	   lipid	  
peroxidation	   (Regan	   et	   al.,	   1998;	   Suzer	   et	   al.,	  
1999),	  and	  ultimately	  decreasing	  oxidative	  stress	  
in	   TBI	   patients	   (Cernak	   et	   al.,	   2000).	   In	   addition	  
Mg2+	   has	   a	   positive	   effect	   on	   cerebral	   energy	  
state,	   preserving	   mitochondrial	   membrane	  
potential	   with	   an	   improvement	   in	   oxidative	  
phosphorylation	   and	   a	   decrease	   in	   lactic	   acid	  
production	   when	   administered	   post-­‐injury	  
(Feldman	  et	  al.,	  1996;	  Van	  Den	  Heuvel	  and	  Vink,	  
2004).	   The	   acute	   inflammatory	   response	   is	   also	  
modulated	   by	   Mg2+,	   with	   neutrophil	   invasion	  
reduced	   following	   SCI	   in	   animals	   treated	   with	  
MgSO4	   (Gok	   et	   al.,	   2007).	   This	   correlates	   with	  
studies	  that	  show	  that	  Mg2+	  deficiency	  evokes	  an	  
inflammatory	  response	  (Malpuech-­‐Brugère	  et	  al.,	  
2000),	   including	   the	   release	  of	  pro-­‐inflammatory	  
cytokines	  and	  SP	  (Mazur	  et	  al.,	  2006).	  
	  
Mg2+	  and	  Substance	  P	  
Within	   one	   week	   of	   Mg2+	   deficiency,	   plasma	   SP	  
concentration	   was	   elevated	   (Weglicki	   and	  
Phillips,	   1992)	   and	   this	   was	   associated	   with	   the	  
develop-­‐ment	   of	   neurogenic	   inflammation	  
(Weglicki	   et	  al.,	   1994).	   This	   is	   relevant	   to	  TBI,	   as	  
SP	   expression	   increases	   following	   experimental	  
TBI	   (Donkin	   et	   al.,	   2009),	   with	   administration	   of	  
SP	   receptor	   antagonists	   increasing	   levels	   of	   free	  
Mg2+	   in	   the	   brain,	   indicating	   that	   the	   decline	   in	  
Mg2+	  could	  be	  mediated,	  in	  part,	  by	  elevations	  in	  
SP	  (Vink	  et	  al.,	  2004).	  
	  
SP	   has	   a	   number	   of	   neuroinflammatory	   roles,	  
including	  stimulating	  the	  release	  of	  histamine	  and	  
serotonin	   (5HT)	   from	   mast	   cells,	   which	   can	  
compromise	  the	  BBB	  along	  with	  nitric	  oxide	  (NO)	  
and	   bradykinin.	   It	   is	   also	   a	   potent	   initiator	   of	  
neurogenic	   inflammation	   (vasodilation,	   plasma	  
protein	   extravasation	   and	   edema)	   (Harrison	   and	  
Geppetti,	   2001)	   with	   the	   resulting	   disruption	   to	  
the	   BBB	   resulting	   in	   the	   entry	   of	   toxins,	   metal	  
ions	   and	   inflammatory	   cells	   into	   the	   brain	   (see	  
Figure	   1).	   Furthermore,	   SP	   stimulates	   immune	  
cells	   to	   release	   pro-­‐inflammatory	   cytokines,	  
including	   TNF-­‐α	   and	   several	   interleukin	   family	  
members	  (IL-­‐1β,	  1L-­‐2	  and	  Il-­‐6)	  resulting	  in	  further	  
inflammation	  (Delgado	  et	  al.,	  2003).	  Additionally,	  
NK-­‐1R	   activation	   stimulates	   second	   messenger	  
pathways	   that	   increase	   Ca2+	   entry	   to	   neurons	  
(Suh	  and	  Hille,	  2005;	  Yang	  et	  al.,	  2003).	  Since	  SP	  
also	   activates	   NMDAR	   (Wu	   et	   al.,	   2004),	   Ca2+	  
influx	   through	   these	   channels	   may	   lead	   to	  
excitotoxicity	  and	  the	  production	  of	   free	  radicals	  
such	  as	  peroxynitrite,	  which	  can	  be	  highly	  toxic	  to	  
cellular	   macromolecules.	   This	   Ca2+	   influx	   is	  
facilitated	   by	   low	   Mg2+	   levels,	   as	   blockade	   of	  
NMDAR	  is	  reduced	  and	  members	  of	  the	  transient	  
receptor	  potential	  melastatin	  (TRPM)	  family	  may	  
be	  activated	  allowing	   further	  Ca2+	  entry	   (Schmitz	  
et	   al.,	   2003).	   The	   induction	   of	   this	   secondary	  
injury	  cascade	  by	  SP	  correlates	  with	  results	  which	  
show	  increased	  SP	  is	  deleterious	  following	  TBI,	  as	  
it	   is	  associated	  with	  the	  development	  of	  cerebral	  
edema	  and	  poorer	  neurological	  outcome	  (Donkin	  
et	  al.,	  2009).	  Taken	   together,	  SP	   release	  and	   the	  
associated	  Mg2+	   decline	   following	   TBI	   can	   result	  
in	   neuroinflammation,	   BBB	   disruption,	   excito-­‐
toxicity	   and	  oxidative	   stress,	  with	   restoring	  Mg2+	  
homeostasis	   a	   potential	   target	   to	   limit	   these	  
secondary	  injury	  factors	  and	  thus	  cell	  death.	  
	  
Mg2+	  and	  TRPM7	  channels	  
TRPM7	   is	   one	   of	   the	   few	   mammalian	   Mg2+	  
transporters	   described	   to	   date,	   playing	   an	  
important	  role	  in	  regulating	  Mg2+	  entry	  into	  cells.	  
It	  is	  ubiquitously	  expressed	  and	  consists	  of	  an	  ion	  
channel	   fused	   to	   a	   protein	   kinase	   domain	  
(Runnels	   et	   al.,	   2001),	   with	   the	   channel	  
permeable	   to	   a	   number	   of	   divalent	   cations	  
including	   Mg2+	   (Monteilh-­‐Zoller	   et	   al.,	   2003).	   Of	  
note	   TRPM7	   has	   been	   implicated	   in	   the	   anoxic	  
death	   of	   neuronal	   cells	   (Aarts	   et	   al.,	   2003),	   and	  
activation	   of	   TRPM7	   during	   ischemia	   has	   been	  
proposed	   as	   a	   key	   factor	   contributing	   to	  
excitotoxicity	   and	   other	   deleterious	   processes	  
(MacDonald	  et	  al.,	  2006).	  We	  have	  recently	  found	  
changes	   in	   TRPM7	   channel	   expression	   following	  
experimental	   TBI	   in	   rats	   (Cook	   et	   al.,	  
unpublished),	  suggesting	  a	  role	  for	  this	  protein	  in	  
traumatic	  CNS	  injury.	  	  
	  
TRPM7	  has	  been	  suggested	  to	  mediate	  cell	  death	  
via	   a	   positive	   feedback	   loop	  whereby	   Ca2+	   entry	  
into	   cells	   as	   a	   result	   of	   injury	   causes	   the	  
production	   of	   free	   radicals,	   which	   activate	  
TRPM7,	   leading	   to	   further	   Ca2+	   influx	   and	  
additional	   free	   radical	   production	   (Aarts	   and






Figure	  1.	  Potential	  mechanisms	  of	  neuronal	  damage	  resulting	  from	  Mg2+	  depletion	  and	  SP	  release	  in	  TBI.	  
Tymianski,	   2005).	   Importantly,	   a	   decline	   in	  
intracellular	   Mg2+	   concentration,	   such	   as	   that	  
observed	   following	   TBI	   and	   SCI,	   can	   lead	   to	   the	  
generation	   of	   reactive	   oxygen	   and	   nitrogen	  
species	   (Altura	   et	  al.,	   2003),	  which	   could	   further	  
activate	   TRPM7,	   thereby	   exacerbating	   inflam-­‐
mation,	  oxidative	  stress	  and	  cell	  death	  pathways	  
(see	   Figure	   1).	   Given	   that	   Mg2+	   levels	   remain	  
suppressed	   for	   several	   days	   following	   injury	  
(Heath	  and	  Vink	  1996),	  this	  is	  potentially	  a	  critical	  
and	  persistent	  pathway	  leading	  to	  cell	  death	  after	  
TBI	   and	   SCI.	   However,	   additional	   studies	   are	  
required	   to	   determine	   whether	   TRPM7	   directly	  
mediates	  cell	  death	  in	  traumatic	  CNS	  injury,	  and	  if	  
changes	   in	   TRPM7	   expression	   following	   TBI	   are	  
linked	  to	  the	  observed	  decline	  in	  Mg2+	  levels.	  	  
	  
Mg2+	  administration	  in	  traumatic	  CNS	  studies	  
	  
Experimental	  TBI	  Studies	  
A	   number	   of	   studies	   have	   investigated	   whether	  
this	   attenuation	   of	   secondary	   injury	   factors	   by	  
restoring	  Mg2+	   homeostasis	   after	   TBI	   is	   effective	  
in	   improving	   neurological	   and	   functional	   out-­‐
come.	   Substantial	   evidence	   from	   studies	   of	  
experimental	   TBI	   suggests	   that	   Mg2+	   admin-­‐
istration	  may	  be	  beneficial	   following	  head	  injury.	  
Mg2+	   significantly	   reduced	   cortical	   cell	   loss	  
(Saatman	   et	   al.,	   2001)	   and	   motor	   deficits	  
(Bareyre	  et	  al.,	  1999)	  in	  injured	  rats	  compared	  to	  
vehicle	  controls.	  A	  number	  of	  other	  studies	  have	  
also	   demonstrated	   a	   neuroprotective	   effect	   of	  
Mg2+	  	  following	  	  experimental	  TBI	  (Browne	  et	  al.,	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2004;	  Fromm	  et	  al.,	  2004;	  McIntosh	  et	  al.,	  1989;	  
Turner	  et	  al.,	  2004).	  Mg2+	  treatment	  following	  TBI	  
in	   rats	  has	  been	   shown	   to	   reduce	  apoptosis	   and	  
the	   expression	   of	   p53-­‐related	   (apoptosis-­‐
inducing)	   proteins	   (Lee	   et	   al.,	   2004)	   as	   well	   as	  
modulating	  levels	  of	  Bax	  and	  Bcl-­‐2,	  which	  are	  also	  
regulators	  of	  apoptosis	  (Ravishankar	  et	  al.,	  2001).	  	  
	  
Although	   Mg2+	   has	   been	   shown	   to	   improve	  
neurological	   outcome	   when	   administered	   up	   to	  
24	   hours	   after	   injury	   (Hoane	   and	   Barth,	   2002),	  
the	   best	   results	   have	   been	   achieved	   when	   the	  
therapeutic	   window	   is	   restricted	   to	   12	   hours	  
(Vink	   and	   Cernak,	   2000).	   Mg2+	   decline	   has	   been	  
shown	   to	   persist	   for	   at	   least	   4	   days	   after	   injury	  
(Heath	   and	   Vink,	   1996),	   however,	   the	  
concentration	   of	   Mg2+	   in	   CNS	   injury	   has	   been	  
shown	   never	   to	   fall	   below	   0.2	   mM	   (Vink	   et	   al.,	  
1988).	  Thus,	  it	  is	  likely	  that	  the	  length	  of	  time	  for	  
which	  free	  Mg2+	  concentration	  is	  reduced,	  rather	  
than	   the	  magnitude	  of	  decline,	   is	   the	  parameter	  
that	   influences	   neurological	   outcome	   (Vink	   and	  
Cernak,	   2000).	   In	   addition	   to	   the	   positive	   effect	  
seen	   with	   respect	   to	   motor	   performance,	   Mg2+	  
also	   significantly	   improves	   cognitive	   function	  
following	  TBI	  (reviewed	  in	  (Hoane,	  2007)).	  	  
	  
Experimental	  SCI	  Studies	  
In	   experimental	   SCI,	   administration	   of	   Mg2+	   has	  
been	   found	   to	   have	   beneficial	   effects	   when	  
administered	   to	   rats	   using	   both	   the	   clip	  
compression	   (Ditor	   et	   al.,	   2007;	   Suzer	   et	   al.,	  
1999)	  and	  weight	  drop	  models	  of	  SCI	  (Gok	  et	  al.,	  
2007;	  Kaptanoglu	  et	  al.,	  2003a;	  Kaptanoglu	  et	  al.,	  
2003b;	   Kwon	   et	   al.,	   2009)	   as	   well	   as	   when	  
administered	  to	  rabbits	  following	  SCI	  (Ozdemir	  et	  
al.,	   2005).	   	   The	   beneficial	   effect	   of	  Mg2+	   include	  
decreases	   in	   membrane	   damage	   (Kaptanoglu	   et	  
al.,	   2003a;	   Kaptanoglu	   et	   al.,	   2003b),	  
normalization	  of	   energy	  balance	   (Ozdemir	   et	   al.,	  
2005),	   protection	   against	   axonal	   damage	   (Suzer	  
et	  al.,	  1999),	  preservation	  of	  the	  BBB	  (Kaptanoglu	  
et	   al.,	   2003a;	   Kaptanoglu	   et	   al.,	   2003b)	   and	  
reduction	   in	   apoptosis	   as	   seen	  by	   a	   reduction	   in	  
activated	   caspase-­‐3	   (Solaroglu	   et	   al.,	   2005).	  
However,	   unlike	   TBI,	   the	   clinical	   window	   for	  
administration	   of	   Mg2+	   in	   SCI	   appears	   only	   to	  
extend	   to	   8	   hours,	   with	   no	   improvement	   in	  
outcome	   seen	   in	   animals	   treated	   at	   later	   time	  
points	  (Kwon	  et	  al.,	  2009;	  Wiseman	  et	  al.,	  2009).	  
In	  contrast,	  earlier	  treatment	  leads	  to	  a	  decrease	  
in	   lesion	   size	   with	   an	   associated	   significant	  
improve-­‐ment	   in	   motor	   outcome	   seen	   early,	   at	  
24	   hours	   following	   injury	   (Kaptanoglu	   et	   al.,	  
2003a;	   Kaptanoglu	   et	   al.,	   2003b;	   Suzer	   et	   al.,	  
1999),	   as	   well	   as	   later,	   at	   4	   weeks	   post-­‐injury	  
(Wiseman	  et	  al.,	  2009).	  	  
	  
Despite	   this	   evidence	   supporting	   a	   potential	  
therapeutic	   role	   of	   Mg2+	   in	   SCI,	   the	   neuro-­‐
protective	   effects	   were	   only	   demonstrated	  
following	   extremely	   high	   doses	   of	   MgSO4	   (600	  
mg/kg)	   and	   smaller	   doses	   were	   less	   effective	   at	  
providing	   significant	   histological	   or	   functional	  
benefit	   (Kaptanoglu	   et	   al.,	   2003a;	   Kaptanoglu	   et	  
al.,	  2003b;	  Suzer	  et	  al.,	  1999).	  Such	  a	  bolus	  dose	  
of	   600	   mg/kg	   far	   exceeds	   the	   2-­‐4	   g	   bolus	   dose	  
given	   to	   patients	   with	   emergencies	   such	   a	   pre-­‐
eclampsia	   or	   cardiac	   arrest	   (Gowda	   and	   Khan,	  
2004;	  Leeman	  and	  Fontaine	  2008).	  Given	  the	  high	  
doses	   necessary	   to	   see	   these	   clinical	   improve-­‐
ments,	   further	   studies	   investigated	   whether	  
combining	  Mg2+	  with	  polyethylene	  glycol	  (PEG),	  a	  
hydrophilic	   polymer	   used	   as	   an	   excipient	   for	  
many	  pharmacological	   agents,	  would	   reduce	   the	  
dosage	  needed.	   Indeed,	  by	  treating	  animals	  with	  
60	  mg/kg	  of	  MgSO4	   in	   a	  PEG	   formulation,	   lesion	  
volume	   was	   reduced	   to	   a	   greater	   extent	   than	  
seen	  in	  animals	  treated	  with	  MgSO4	  or	  PEG	  alone,	  
with	   only	   the	   MgSO4	   in	   PEG	   leading	   to	   a	  
significant	   improvement	   of	  motor	   outcome	   at	   6	  
weeks	   post-­‐injury	   (Kwon	   et	   al.,	   2009).	   Similarly	  
with	  a	  higher	  dose	  of	  Mg2+	  (300	  mg/kg),	  only	  the	  
combination	  of	  MgSO4	  in	  PEG	  led	  to	  a	  significant	  
reduction	   in	   lesion	   volume,	   tissue	   sparing	   at	   the	  
site	  of	  injury	  and	  modest	  BBB	  improvements	  at	  6	  
weeks	  post	   injury	   (Ditor	   et	  al.,	  2007).	  The	  ability	  
to	   reduce	   the	   necessary	   dosage	   for	   treating	   SCI	  
by	  placing	  Mg2+	  in	  PEG	  makes	  it	  more	  likely	  that	  a	  
clinical	  translation	  can	  be	  made,	  with	  the	  dosage	  
optimized	  so	  that	  beneficial	  effects	  are	  seen	  with	  
a	   comparable	   amount	   of	   Mg2+	   administered	   to	  
that	   shown	   to	  be	   safe	   in	  patients	   suffering	   from	  




Although	  Mg2+	  is	  a	  multifactorial	  pharmacological	  
intervention	   with	   a	   proven	   safety	   record	   in	  
previous	   clinical	   studies,	   it	   has	   yet	   to	   be	   used	  
clinically	   to	   treat	   SCI.	   Interestingly,	   experimental	  
data	  suggests	  that	  the	  Mg2+	  in	  PEG	  formulation	  is	  
more	  effective	  than	  methylprednisolone,	  the	  only	  
pharmacological	   treatment	   currently	   available	  
clinically	  for	  SCI	  (Bracken	  and	  Holford,	  2002).	  This	  
formulation	   reduced	   lesion	   volume	   by	   67%	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compared	   to	   34%	   following	   SCI,	   with	   an	  
associated	   significant	   improvement	   in	   motor	  
outcome	   at	   6	   weeks	   post-­‐injury	   in	   the	   animals	  
treated	   with	   Mg2+	   compared	   to	   the	   methyl-­‐
prednisolone	   group	   (Kwon	   et	   al.,	   2009).	   This	   is	  
important	  as	  treatment	  with	  methylprednisolone	  
remains	   controversial	   with	   only	   modest	  
improvements	   noted	   in	   motor	   and	   sensory	  
outcome	   of	   patients	   treated	   within	   8	   hours	  
(Bracken	  and	  Holford,	  2002),	  which	  are	  offset	  by	  
an	  increase	  in	  complications	  such	  as	  severe	  sepsis	  
and	   pneumonia	   (Hurlbert,	   2006).	   This	   highlights	  
the	  importance	  of	  finding	  new	  treatments	  for	  SCI,	  
with	  the	  Mg2+/PEG	  formulation	  soon	  poised	  to	  be	  
translated	   into	   human	   SCI	   clinical	   trials	   (as	  
reviewed	  by	  (Kwon	  et	  al.,	  2010).	  
	  	  
Despite	   the	   positive	   results	   obtained	   using	  Mg2+	  
as	   a	   therapy	   for	   TBI	   in	   animal	   models,	   a	   recent	  
Phase	   III	   clinical	   trial	   (Temkin	   et	  al.,	  2007)	   found	  
that	   MgSO4	   given	   to	   patients	   for	   5	   days	   after	  
injury	  was	  not	  neuroprotective	  and	  possibly	  even	  
had	  a	  negative	  effect	  on	  outcome.	  Given	  that	  all	  
patients	   (including	   the	   control	   group)	   received	  
Mg2+	  to	  restore	  depleted	  serum	  levels	  to	  normal,	  
it	   is	   unclear	   whether	   this	   restoration	   of	   serum	  
Mg2+	   level	  was	  sufficient	  to	  confer	  positive	  effect	  
in	   all	   patients	   irrespective	   of	   the	   treatment	  
group.	   This	   result	   was	   in	   marked	   contrast	   to	  
another	   clinical	   trial	   (Dhandapani	   et	   al.,	   2008)	  
which	   reported	   that	   acute	   Mg2+	   administration	  
(less	   than	   24	   hours)	   resulted	   in	   significant	  
improvements	   in	   neurological	   outcome,	   post-­‐
operative	   brain	   swelling	   and	   1-­‐month	   mortality.	  
The	  differences	  in	  trial	  results	  could	  be	  attributed	  
to	   possible	   limitations	   in	   central	   Mg2+	   transport	  
(McKee	   et	   al.,	   2005),	   and	   the	   recently	  described	  
Mg2+	   transporters	   from	   the	   TRPM	   family	   have	  
been	   suggested	   to	   be	   involved	   in	   this	   process	  
(Cook	  et	  al.,	  2009).	  However,	  as	  described	  in	  this	  
review,	   further	   investigation	   is	   warranted	   to	  
elucidate	   the	  exact	   role	  of	   these	  channels	   in	   the	  




Secondary	   injury	   factors	   involve	   numerous	  
pathological	   processes	   that	   account	   for	  
significant	   morbidity	   and	   mortality	   following	  
traumatic	  CNS	  injury.	  Deficits	  in	  intracellular	  Mg2+	  
concentration	  occurring	  following	  TBI	  and	  SCI	  are	  
associated	   with	   poor	   neurological	   outcome,	   but	  
despite	  promising	  experimental	  studies,	  Mg2+	  has	  
not	   been	   proven	   clinically	   effective.	   While	   it	   is	  
unlikely	   that	   targeting	   a	   single	   factor	   will	  
significantly	   improve	  neurological	  outcome,	  Mg2+	  
may	   still	   be	   a	   useful	   neuroprotective	   agent	   as	  
part	   of	   a	   combination	   treatment	   regime	   that	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The	   rationale	   for	   trialing	  magnesium	  as	   a	   neuroprotective	   agent	   following	   cerebral	   ischemia	   has	   been	  
based	  both	  on	  its	  role	  in	  maintaining	  brain	  tissue	  homeostasis	  and	  on	  its	  known	  cellular	  actions	  that	  are	  
likely	  to	  counteract	  damaging	  ischemic	  processes.	  A	  number	  of	  studies	  using	  animal	  models	  of	  cerebral	  
ischemia,	  seizure,	  perinatal	  hypoxia-­‐ischemia,	  subarachnoid	  hemorrhage	  and	  traumatic	  brain	  injury	  have	  
reported	  positive	  outcomes	  with	  magnesium	  therapy.	  However,	  scrutiny	  of	  the	  animal	  cerebral	  ischemia	  
data	   shows	   that	   about	   46%	   of	   studies	   have	   not	   shown	   a	   neuroprotective	   effect.	   Furthermore,	   the	  
IMAGES	   clinical	   trial	   found	  magnesium	   to	   be	   largely	   ineffective	   in	   treating	   strokes.	   In	   this	   review,	  we	  
present	   the	  majority	   of	   published	   cerebral	   ischemia	   animal	   studies	   (focal	   and	   global)	   that	   have	   used	  
magnesium	  as	  a	  neuroprotective	  therapy,	  and	  discuss	  the	  possible	  reasons	   for	   the	   inconsistent	  results.	  
Our	  examination	  suggests	  that,	  in	  the	  majority	  of	  experiments,	  post-­‐ischemic	  hypothermia	  has	  probably	  
been	  a	  confounding	  factor	  in	  producing	  the	  positive	  outcomes.	  In	  addition,	  experimental	  design	  has	  not	  
always	  been	  appropriate	  with	  respect	   to	  magnesium	  dosage,	  and	  to	  the	  time	  and	  route	  of	  magnesium	  
administration.	   Moreover,	   data	   from	   our	   own	   laboratory	   indicates	   that	   magnesium	   is	   only	  
neuroprotective	   when	   combined	   with	   post-­‐ischemic	   hypothermia.	   Finally,	   additional	   information	  
regarding	  the	  efficacy	  of	  magnesium	  as	  a	  stroke	  treatment	  will	  be	  available	  on	  completion	  of	  the	  FAST-­‐
Mag	   trial,	   but	   in	   the	  meantime	   the	  neuroprotective	  potential	  of	  magnesium	  should	  be	  explored	  when	  





More	   than	   any	   other	   organ,	   the	   brain	   is	  
dependent	  on	  the	  aerobic	  metabolism	  of	  glucose	  
for	   energy,	   making	   it	   exceedingly	   sensitive	   to	  
ischemic	   disease.	   Inadequate	   supply	   of	   oxygen-­‐
ated	   blood	   leads	   to	   a	   rapidly	   developing	   energy	  
crisis	  that,	  within	  minutes,	  results	  in	  the	  death	  of	  
cells	   comprising	   the	   neurovascular	   unit.	  
Restoration	   of	   blood	   supply,	   or	   the	   presence	   of	  
collateral	   circulation,	   may	   preserve	   some	   tissue	  
only	   for	   it	   to	   die	   over	   the	   hours	   or	   days	   that	  
follow	   an	   ischemic	   event.	   Such	   delayed	   death	  
may	   occur	   from	   one	   or	   more	   of	   a	   range	   of	  
pathological	   processes;	   glutamate	   excitotoxicity,	  
calcium	   dysregulation	   and	   overload,	   apoptosis,	  
autophagy,	   inflammation,	   oxygen	   free	   radical	  
generation	   and	  edema	  have	   all	   been	   implicated.	  
Consequently,	   interruption	   of	   these	   processes	  
presents	   an	   opportunity	   for	   therapeutic	  
intervention	   to	  protect	   the	  damaged	  cells	  within	  
the	   neurovascular	   unit	   after	   cerebral	   ischemia.	  
Many	   therapies	   have	   been	   found	   to	   offer	  
neuroprotection	   in	   experimental	   models	   of	  
cerebral	  ischemia,	  magnesium	  among	  them.	  	  
	  
Since	   magnesium	   is	   important	   in	   many	   normal	  
cellular	   processes	   such	   as	   protein	   synthesis,	  
energy	   metabolism,	   maintenance	   of	   ionic	  
gradients	   and	   vascular	   smooth	   muscle	   tone,	  
abnormalities	   in	   serum	   and	   CNS	   magnesium	  
status	  before,	  during	  and	  after	  cerebral	   ischemia	  
can	  be	  expected	  to	  have	  an	  effect	  on	  neurological	  
outcome.	   Indeed,	   clinical	   and	   experimental	  
studies	  have	  shown	  that	  subjects	  with	  low	  serum	  
or	   CSF	   magnesium	   have	   worsened	   neurological	  
outcomes	   following	   brain	   ischemia	   and	   trauma	  
(Lampl	  et	  al.,	  1998;	  McIntosh	  et	  al.,	  1988;	  Vink	  et	  
al.,	   1988).	   There	   is	   also	   ample	   evidence	   demon-­‐
strating	   that	   there	   are	   marked	   changes	   in	  
intracellular	   and	   extracellular	   free	   magnesium	  
concentrations	   in	  brain	   tissue	   following	   ischemic	  
and	  traumatic	  insults	  (Helpern	  et	  al.,	  1993;	  Vande	  
Linde	  and	  Chopp,	  1991;	  Vink	   et	  al.,	   1996;	   Lee	   et	  
al.,	   2002).	   As	   such,	   maintaining	   normal	   serum	  
magnesium	  concentration	  should	  be	  considered	  a	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part	  of	  standard	  supportive	  care	  in	  such	  patients.	  
On	   top	   of	   that,	   however,	   the	   Mg2+	   cation	   has	  
properties	   that	   may	   specifically	   counteract	   a	  
number	  of	  the	  damaging	  process	  associated	  with	  
cerebral	   ischemia.	   In	   particular,	   magnesium	   can	  
reduce	  synaptic	  glutamate	  release	  (Nowak	  et	  al.,	  
1984),	   decrease	   calcium	   influx	   via	   voltage	   gated	  
calcium	   channels	   (Iseri	   and	   French,	   1984),	  
stabilise	  mitochondria	   (Kowaltowski	   et	   al.,	   1998;	  
Xu	  et	  al.,	  2002),	  increase	  cerebral	  blood	  flow	  (Chi	  
et	   al.,	   1990)	   and	   reduce	   free	   radical	   production	  
(Garcia	  et	  al.,	  1998).	  
	  
For	   these	   reasons,	   restoration	   of	   magnesium	  
homeostasis	   and	   exploration	   of	   the	   potential	  
positive	   effects	   in	   the	   ischemic	   brain	   have	  
prompted	   the	   investigation	   of	   magnesium	   as	   a	  
neuroprotective	   agent	   following	   such	   disorders	  
as	   traumatic	   brain	   injury	   (Heath	   and	  Vink,	   1996;	  
Vink	   et	   al.,	   1988),	   seizure	   (Cotton	   et	   al.,	   1993),	  
subarachnoid	  hemorrhage	  (Van	  den	  Bergh	  et	  al.,	  
2002)	   and	   cerebral	   ischemia	   (Muir,	   1998).	   Here	  
we	   overview	   the	   experimental	   animal	   studies	  
that	   have	   to	   date	   tested	   magnesium	   as	   a	  
neuroprotectant	   in	   the	   major	   animal	   models	   of	  
cerebral	   ischemia,	   specifically	   focal	   (ischemic	  
stroke)	  and	  global	  (cardiac	  arrest)	  brain	   ischemia	  
models.	  	  
	  
This	   review	   will	   present	   experimental	   findings	  
from	   these	   studies,	   offer	   potential	   explanations	  
for	  conflicting	  or	  inconsistent	  results	  and	  consider	  
the	   future	   application	   of	  magnesium	   in	   cerebral	  
ischemia.	  	  
	  
Efficacy	  of	  magnesium	  treatment	  in	  models	  of	  
focal	  cerebral	  ischemia	  
	  	  
The	   results	   from	   16	   studies	   using	  magnesium	   in	  
animal	   models	   of	   focal	   cerebral	   ischemia	   are	  
summarized	   in	   Table	   1.	   As	   can	   be	   seen	   in	   this	  
table,	   there	   is	   considerable	   variability	   in	   study	  
design	   (stroke	   model,	   animal	   species	   used,	  
magnesium	   dose,	   route	   and	   timing	   of	   admin-­‐
istration,	   outcome	   measures),	   which	   precludes	  
direct	   comparison	   of	   outcomes.	   There	   were	   5	  
studies	  using	  permanent	  focal	  ischemia	  models,	  9	  
using	  transient	  models	  and	  single	  studies	  using	  an	  
embolic	   and	   an	   endothelin-­‐1	   (lacunar	   stroke)	  
model.	  As	  a	  broad	  summary,	  10	  of	  the	  16	  studies	  
reported	   a	   neuroprotective	   effect	   for	   magnesium	  
based	  on	  infarct	  volume	  reduction.	  Magnesium	  
treatment	   in	   the	   endothelin-­‐1	   model	   did	   not	  
reduce	   infarct	   volume,	   but	   did	   improve	   some	  
behavioral	   outcomes.	   Thus,	   there	   is	   slightly	  
better	   than	   equivocal	   support	   for	   the	   claim	   that	  
magnesium	  has	  a	  neuroprotective	  effect	  in	  these	  
models.	  	  
	  
Magnesium	  in	  Permanent	  Focal	  Cerebral	  
Ischemia	  
In	  the	  5	  studies	  using	  permanent	  middle	  cerebral	  
artery	   occlusion	   (MCAO),	   3	   reported	   positive	  
outcomes	  with	  magnesium	  treatment.	  Two	  of	  the	  
studies,	   1	   using	   rats	   (Izumi	   et	   al.,	   1991)	   and	   1	  
using	   mice	   (Roffe	   et	   al.,	   1996),	   were	   otherwise	  
similar	   in	   their	   experimental	   procedures,	   yet	  
reported	   contrasting	   results.	   Izumi	   et	   al.,	   (1991)	  
observed	   both	   a	   neuroprotective	   effect	   and	   a	  
hyperglycemia	   associated	  with	   administration	   of	  
magnesium	   chloride;	   if	   the	   hyperglycemia	   was	  
managed	   with	   insulin,	   there	   was	   a	   further	  
reduction	  of	   infarct	  volume.	   In	  contrast,	  Roffe	  et	  
al.,	   (1996)	  found	  no	  neuroprotection,	  and	   in	  fact	  
reported	   that	   magnesium	   chloride	   treatment	  
increased	   edema	   in	   the	   infarcted	   hemispheres.	  
While	   increased	   edema	   was	   not	   evident	   in	  
animals	  treated	  with	  magnesium	  and	  insulin,	  the	  
combined	   treatment	   did	   not	   reduce	   infarct	  
volume.	  	  
Two	  other	  studies	  (Lee	  et	  al.,	  1999;	  Chung	  et	  al.,	  
2004),	   which	   were	   similar	   with	   respect	   to	  
magnesium	   dose	   and	   timing	   of	   administration,	  
but	  different	  in	  animal	  species	  used	  and	  route	  of	  
administration,	  reported	  positive	  findings,	  while	  a	  
study	   from	   our	   laboratory	   was	   negative	  
(Campbell	  et	  al.,	  2008a).	  Among	  these,	  our	  study	  
was	   the	   only	   trial	   to	   use	   a	   dosing	   regimen	   (IV	  
loading	  dose	  and	  24	  hour	  infusion)	  similar	  to	  the	  
IMAGES	   human	   stroke	   trial.	   Furthermore,	   we	  
paid	  careful	  attention	  to	  body	  temperatures	  post-­‐
surgery	   to	   ensure	   that	   animals	   did	   not	   become	  
hypothermic	   during	   the	   recovery	   period	   or	  
thereafter.	   The	   possibility	   of	   post-­‐ischemic	  
hypothermia	   having	   confounded	   these	  
experimental	   results,	   especially	   in	   the	   earlier	  
animal	   studies,	   will	   be	   discussed	   in	   a	   later	  
section.	  
It	  is	  of	  interest	  that	  Lee	  et	  al.,	  (1999)	  commented	  
that,	   in	   unpublished	   experiments,	   if	   the	   intra-­‐
arterial	   route	   of	   magnesium	   administration	   was	  
changed	  to	  an	  intravenous	  route,	  magnesium	  was	  
no	  longer	  protective.	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TABLE	  1.	  	  Summary	  of	  animal	  studies	  using	  magnesium	  following	  focal	  cerebral	  ischemia	  
	  
Reference	   Animal	  model	   Mg	  salt	   Route	   Magnesium	  dose	   Time	  of	  treatment	   Post-­‐ischemic	  temperature	  monitoring	   Neuroprotection/Outcome	  
Permanent	  Model	   	   	   	   	   	   	   	  
Izumi	  et	  al.,	  1991	   pMCAO,	  rat	   MgCl2	   IP	   1	  mmol/kg	  x	  2	   Immediately	  &	  1h	  after	  MCAO	   Measured	  1.5,	  4,	  24	  &	  48h	  post	  MCAO	   Yes;	  reduced	  infarct	  volume	  at	  48h	  	  
	  
Roffe	  et	  al.,	  1996	   pMCAO,	  mouse	   MgCl2	   IP	   1	  mmol/kg	  x	  2	   Immediately	  &	  1h	  after	  MCAO	   No	   No;	  based	  on	  infarct	  volume	  at	  24h	  	  
	  




Chung	  et	  al.,	  2004	   pMCAO,	  gerbil	   MgSO4	   IP	   0.75	  mmol/kg	   10min	  before	  MCAO	   No	  	   Yes;	  reduced	  infarct	  volume	  at	  24h	  	  
	  
Campbell	  et	  al.,	  2008a	   pMCAO,	  rat	  	   MgSO4.	  
7H2O	  
IV	   0.36	  +	  0.12	  mmol/kg/h	  for	  
24h	  
2h	  after	  MCAO	   Yes,	  actively	  monitored	  &	  controlled	   No;	  based	  on	  infarct	  volume	  at	  48h	  	  
Transient	  Model	   	   	   	   	   	   	   	  
Marinov	  et	  al.,	  1996	   2	  or	  1.5h	  tMCAO,	  rat	  	   MgSO4	   IA	   0.25	  or	  0.75	  mmol/kg	   Immediately	  before	  MCAO	   Monitored	  for	  45min	  after	  ischemia	   Yes;	  reduced	  infarct	  volume	  at	  24h	  	  
	  
Schmid-­‐Elsaesser	  et	  al.,	  
1999	  
1.5h	  tMCAO,	  rat	   MgCl2	  
	  
IV	   1	  mmol/kg	  x	  2	   Before	  MCAO	  &	  at	  time	  of	  
reperfusion	  
Monitored	  for	  1h	  after	  ischaemia	  &	  rats	  
housed	  in	  warm	  cages	  for	  8h	  
No;	  (25%	  reduction	  infarct	  volume	  
at	  7	  days)	  	  
	  
Kinoshita	  et	  al.,	  2001	   2h	  tMCAO,	  rat	   MgSO4	   IV	   0.21	  mmol/kg	  over	  2h	   During	  MCAO	   No	   Yes;	  reduced	  infarct	  volume	  at	  24h	  	  
	  
Lin	  et	  al.,	  2002	   1h	  tMCAO,	  gerbil	   MgSO4	   IP	   0.75	  mmol/kg	   30min	  before	  ischaemia	   No	   Yes;	  reduced	  infarct	  volume	  at	  24h	  	  
	  
Westermaier	  et	  al.,	  
2003	  
	  
1.5h	  tMCAO,	  rat	   MgSO4	   IV	  &	  IA	   0.75	  mmol/kg	   Immediately	  before	  MCAO	   As	  for	  Schmid-­‐Elsaesser	  et	  al.,	  1999	   No;	  (25%	  reduction)	  based	  on	  
infarct	  volume	  at	  7	  days	  
	  
Zhu	  et	  al.,	  2004a	   1.	  	  45min	  tMCAO,	  
rat	  
	  








0.18,	  0.36	  or	  	  
0.72	  mmol/kg	  
	  
0.37	  or	  0.74	  mmol/kg	  
Immediately	  before	  MCAO	  
	  
	  
Immediately	  before	  MCAO	  




No;	  based	  on	  infarct	  volume	  at	  24h	  	  
	  
	  
No;	  based	  on	  infarct	  volume	  at	  72h	  	  
	  
Lee	  et	  al.,	  2005	   1.5h	  tMCAO,	  rat	  	   MgSO4	   IA	   0.75	  mmol/kg	   At	  time	  of	  reperfusion	   Yes	  warm	  environment	  4h	  post	  
reperfusion.	  Less	  hyperthermia	  in	  Mg	  
treated	  	  
	  
Yes;	  reduced	  infarct	  volume	  at	  72h	  
&	  improve	  functional	  outcomes	  
	  
Westermaier	  et	  al.,	  
2005	  
1.5h	  tMCAO,	  rat	  	   MgSO4	   IV	   0.75	  or	  2	  x	  1mmol/kg	  or	  1	  
mmol/kg	  +	  0.5	  mmol/kg/h	  
for	  ≈2.5h	  
Immediately	  before	  MCAO	   As	  for	  Schmid-­‐Elsaesser	  et	  al.,	  (1999)	   Yes;	  based	  on	  infarct	  volume	  at	  7	  
days.	  	  Note:	  31%	  reduction	  for	  0.75	  
mmol/kg	  dose	  was	  not	  significant	  
	  
Campbell	  et	  al.,	  2008b	   45min	  tMCAO,	  rat	  	   MgSO4.	  
7H2O	  
IV	   0.36	  or	  0.72	  mmol/kg	  
	  
Immediately	  before	  MCAO	  
	  
No,	  rats	  mildly	  hypothermic	  for	  1	  -­‐	  4h	  
post	  surgery	  
Yes;	  for	  0.36	  mmol	  at	  24h	  	  
	  
Other	  Models	   	   	   	   	   	   	   	  
Yang	  et	  al.,	  2000	   Embolic,	  rat	  	   MgSO4	   IV	   0.75	  mmol/kg	   2,	  6	  or	  8h	  after	  ischaemia	  
	  
No	   Yes;	  reduced	  infarct	  volume	  at	  72h	  	  
	  
Lecrux	  et	  al.,	  2008	   ET-­‐1	  injection,	  rat	   MgSO4	   SC	   2.5	  mmol/kg	  +	  	  
1.66	  mmol/kg	  x	  4	  
30min	  before	  ET-­‐1	  injection	  &	  
every	  h	  for	  4h	  
No	  mentioned	   No	  infarct	  reduction,	  but	  improved	  
functional	  outcomes	  at	  day	  3	  &	  10	  	  
	  
IMAGES	  trial,	  2004*	   Human	  stroke	   MgSO4	   IV	  
	  
0.2	  +	  0.034	  mmol/kg/h	  for	  
24h	  
Within	  12h	   Normal	  patient	  care	   No	  based	  on	  neurological	  outcome,	  
except	  in	  lacunar	  stroke	  patients	  
	  
#
Authors	  mentioned	  (unpublished	  data)	  that	  same	  dose	  administered	  IV	  was	  ineffective.	  	  *IMAGES	  trial	  has	  been	  included	  for	  references	  purposes	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TABLE	  2.	  Summary	  of	  animal	  studies	  using	  magnesium	  following	  global	  cerebral	  ischemia	  
Reference	   Animal	  model	   Mg	  salt	   Route	   Magnesium	  dose	   Time	  of	  treatment	   Post-­‐ischemic	  temperature	  
monitoring	  
Neuroprotection/outcome	  
Blair	  et	  al.,	  1989	   10min:	  2VO	  rat	   MgCl2	   IV	   5.0	  mmol/kg	   Immediately	  before	  ischemia	  
	  
No	  	   No;	  Mg	  exacerbated	  CA1	  injury	  due	  to	  
elevated	  plasma	  glucose	  levels	  
	  
Tsuda	  et	  al.,	  1991	   20min:	  4VO	  rat	   MgCl2	   IC:	  CA1	  
region	  
1	  µl	  of	  50	  mM	  	   10min	  before,	  0,	  2,	  12,	  24	  or	  
48h	  after	  ischemia	  
	  
No	  	   Yes;	  at	  10min	  before	  &	  0,	  2,	  12,	  24h	  
after	  ischemia;	  based	  on	  CA1	  injury	  
Okawa,	  1992	  	   18min:	  aorta	  occlusion	  
dog	  
MgSO4	   IV	   0.66	  mmol/kg	  +	  	  
0.33	  mmol/kg/h	  for	  3h	  +	  
0.083	  mmol/kg/h	  for	  45h	  
	  
Immediately	  after	  ischemia	   No	  	   Yes;	  based	  on	  neurological	  outcome	  
Sirin	  et	  al.,	  1998	   15min:	  4VO	  rat	   MgSO4	   SC	   5	  mmol/kg	  	   48h	  before	  ischemia	   No	  	   Yes;	  reduced	  CA1	  injury	  &	  improved	  
neurological	  outcomes	  
Milani	  et	  al.,	  1999	   15min:	  4VO	  rat	   MgCl2	   SC	   2.5	  mmol/kg	  x	  4	  
5.0	  mmol/kg	  x	  4	  
7.5	  mmol/kg	  x	  4	  
	  
5.0	  mmol/kg	  x1	  	  
	  
1,	  2,	  24	  &	  48h	  after	  ischemia	  
for	  2.5,	  5	  &	  7.5	  mmol/kg	  dose	  
	  
	  
2h	  after	  ischemia	  for	  5	  
mmol/kg	  dose	  
	  
First	  few	  hours	  after	  ischemia	  rats	  
housed	  at	  30°C	  
No;	  based	  on	  CA1	  &	  subiculum	  injury	  





IV	   0.36	  mmol/kg	  +	  0.06,	  0.12,	  
0.24	  or	  0.48	  mmol/kg/h	  for	  
48h	  
	  
0.36	  mmol/kg	  +	  0.12	  
mmol/kg/h	  for	  48h	  










Yes;	  reduced	  CA1	  injury	  when	  0.12	  
mmol/kg/h	  infusion	  dose	  used	  
	  
Yes;	  before	  ischemia.	  No;	  at	  8h	  after	  
ischemia;	  based	  on	  CA1	  injury	  
	  
Zhou	  et	  al.,	  2003	   10min:	  2VO	  gerbil	  
	  
MgSO4	   IP	   16.6	  mmol/kg	  	   30min	  before	  ischemia	  
	  
No	   Yes;	  based	  on	  TUNEL	  staining	  
Zhu	  et	  al.,	  2004b	   8min:	  2VO	  rat	   MgSO4.	  
7H2O	  
	  
IV	   0.36	  mmol/kg	  +	  	  
0.06	  or	  0.12	  or	  0.24	  
mmol/kg/h	  for	  48h	  
Before	  ischemia	   Maintained	  normothermic	  or	  self-­‐
regulated	  
No	  when	  animals	  maintained	  
normothermic;	  based	  on	  CA1	  injury	  	  
Yes	  when	  combined	  with	  
hypothermia	  
	  
Zhu	  et	  al.,	  2005	   8min:	  2VO	  rat	   MgSO4.	  
7H2O	  
	  
IV	   0.36	  mmol/kg	  +	  	  
0.12	  mmol/kg/h	  for	  48h	  
Immediately	  before	  or	  2h	  after	  
ischemia	  	  
Maintained	  normothermic	  or	  
hypothermic	  
	  
No;	  based	  on	  CA1	  injury	  in	  
normothermic	  rats	  
Yes	  when	  combined	  with	  hypothermia	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Magnesium	  in	  Transient	  Focal	  Cerebral	  Ischemia	  
In	  the	  10	  studies	  using	  transient	  focal	  ischemia,	  6	  
reported	   positive	   outcomes	   with	   magnesium	  
treatment.	   As	   in	   the	   permanent	   focal	   ischemia	  
studies,	   some	   of	   the	   trials,	   while	   similar	   in	   key	  
respects,	   reported	   contrasting	   results.	   For	  
example,	  Marinov	  et	  al.,	  (1996)	  reported	  positive	  
findings	   when	   either	   of	   2	   doses	   of	   magnesium	  
sulphate	   (0.75	   or	   0.25	   mmol/kg)	   were	  
administered	  intra-­‐arterially	  before	  2	  or	  1.5	  hours	  
of	  MCAO	   in	   rats.	   In	   contrast,	   Zhu	   et	   al.,	   (2004a)	  
reported	   negative	   findings	   in	   trials	   consisting	   of	  
different	   doses	   of	   magnesium	   sulphate	   (0.18,	  
0.36,	   0.72	  or	   0.74	  mmol/kg)	   administered	  either	  
intra-­‐arterially	   or	   intravenously	   before	   45	  
minutes	   or	   2	   hours	   of	   MCAO	   in	   rats.	   In	   a	  
subsequent	   experiment	   from	   the	   Zhu	   laboratory	  
(Campbell	   et	   al.,	   2008b),	   rats	   administered	   0.36	  
mmol/kg	   magnesium	   intravenously	   before	  
MCAO,	   and	   allowed	   to	   self-­‐regulate	   their	   body	  
temperatures	  post-­‐ischemia,	  experienced	  up	  to	  4	  
hours	   of	  mild	   hypothermia	   and	   had	   significantly	  
reduced	  striatal	  infarct	  volumes.	  	  
	  
Similarly,	   Lee	   et	   al.,	   (2005)	   observed	   a	   modest,	  
magnesium-­‐induced	   hypothermic	   effect	   in	   that	  
magnesium	   treatment	   attenuated	   the	   post-­‐
ischemic	  hyperthermia	  normally	  observed	  in	  their	  
focal	   model.	   When	   administered	   immediately	  
after	   reperfusion,	   magnesium	   reduced	   infarct	  
volumes	   and	   improved	   behavioral	   outcomes	   in	  
rats.	   They	   ruled	   out	   magnesium’s	   hypothermic	  
effect	  as	  being	  responsible	  for	  the	  neuroprotection	  
by	   inducing	   the	   same	   level	   of	   hypothermia	   in	   a	  
separate	   group	   of	   animals,	   showing	   that	   these	  
animals	   did	   not	   have	   either	   reduced	   infarct	  
volumes	  or	  improved	  behavioral	  outcomes.	  	  
	  
The	   Schmid-­‐Elsaesser	   laboratory	   has	   been	  
exploring	   the	   efficacy	   of	   magnesium	   following	  
cerebral	  ischemia,	  alone	  and	  in	  combination	  with	  
other	   treatments	   (e.g.,	   tirilazad,	   hypothermia),	  
dating	   back	   to	   1999	   (Schmid-­‐Elsaesser	   et	   al.,	  
1999;	   Zausinger	   et	   al.,	   2003ab;	   Westermaier	   et	  
al.,	   2003;	   2005).	   To	   summarize	   their	   several	  
studies,	   they	  have	   shown	   that	  when	  magnesium	  
is	   administered	   before,	   during	   or	   after	  MCAO	   it	  
results	  in	  infarct	  volume	  reductions	  ranging	  from	  
25	  -­‐	  42%,	  with	  reductions	  of	  >31%	  being	  statistically	  
significant.	   After	   surgery,	   they	   routinely	  
monitored	  animals’	  body	  temperatures	  for	  1	  hour	  
after	   reperfusion	   and	   kept	   them	   in	   a	   warm	  
environment	   for	   the	   first	   eight	   hours	   (though	  
without	   further	   monitoring)	   to	   minimize	   the	  
possibility	   of	   hypothermia	   (Robert	   Schmid-­‐
Elsaesser,	  personal	  communication).	  
	  
Other	  Focal	  Cerebral	  Ischemia	  Models	  
Yang	   et	   al.,	   (2000)	   assessed	   the	   neuroprotective	  
efficacy	   of	   intravenously	   administered	  
magnesium	   at	   different	   time	   points	   following	  
ischemia	  (2,	  6	  or	  8	  hours)	  using	  an	  embolic	  stroke	  
model	   in	   rats.	   They	   found	   that	   magnesium	  
treatment	   administered	   2	   or	   6	   hours,	   but	   not	   8	  
hours,	  after	  ischemia	  significantly	  reduced	  infarct	  
volumes.	   In	   addition,	   magnesium	   treatment	  
appeared	   to	   improve	   animal	   survival	   and	  
neurological	   outcome.	   While	   animals’	   body	  
temperatures	   were	   monitored	   during	   surgical	  
recovery,	   it	   was	   not	   reported	   what	   measures	  
were	   taken	   to	   control	   their	   temperatures	   or	   to	  
ensure	   they	   did	   not	   become	   hypothermic	   until	  
the	  72-­‐hour	  trial	  end-­‐point.	  
	  
To	   assess	   the	   effects	   of	   magnesium	   on	   white	  
matter	   injury	   associated	   with	   lacunar	   stroke,	  
Lecrux	  et	  al.,	  (2008)	  injected	  the	  vasoconstrictive	  
peptide	  endothelin-­‐1	   into	   the	   internal	  capsule	   in	  
rats	   (the	   study	   was	   prompted	   by	   post-­‐hoc	  
analysis	   of	   the	   IMAGES	   stroke	   trial	   data,	   which	  
revealed	   that	   magnesium	   provided	   a	   small,	   but	  
significant	   benefit	   in	   lacunar	   stroke	   patients	  
(IMAGES,	   2004)).	   In	   this	   study,	   relatively	   high	  
subcutaneous	  doses	  of	  magnesium	  sulphate	  were	  
given,	   which	   increased	  magnesium	   serum	   levels	  
nearly	  four	  fold	  and	  reduced	  blood	  pressure.	  The	  
treatment	  did	  not	   influence	   infarct	   volumes,	  but	  
motor	   functional	   impairments	   were	   reduced	   in	  
magnesium	   treated	   animals	   when	   assessed	   at	   3	  
and	  10	  days.	  	  
	  
Efficacy	   of	   magnesium	   treatment	   in	   models	   of	  
global	  (forebrain)	  cerebral	  ischemia	  
	  
The	   results	   from	   9	   studies	   using	   magnesium	   in	  
models	  of	  global	  cerebral	  ischemia	  are	  summarized	  
in	  Table	  2.	  As	  in	  the	  focal	  ischemia	  studies,	  there	  
is	   considerable	   variability	   in	   study	   design	   and	  
protocols.	   At	   the	   histological	   level,	   4	   of	   the	  
studies	   found	  a	  neuroprotective	  effect,	  2	  studies	  
did	   not,	   while	   2	   studies	   reported	   a	   positive	  
outcome	   only	   when	   magnesium	   treatment	   was	  
combined	   with	   post-­‐ischemic	   hypothermia.	   One	  
study,	   using	   an	   aortic	   occlusion	   model	   in	   dogs,	  
reported	   improved	   neurological	   outcomes	   with	  
magnesium	   treatment.	   Again,	   this	   is	   moderate	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support	   for	   the	   contention	   that	   magnesium	   is	  
neuroprotective	  in	  these	  models.	  	  
	  
In	   the	   first	   study,	   by	   Blair	   et	   al.,	   (1989),	  
intravenous	  magnesium	  chloride	  appeared	  in	  fact	  
to	  exacerbate	  CA1	  neuronal	   injury.	   In	   this	   study,	  
the	   magnesium	   dose	   was	   relatively	   high	   (5	  
mmol/kg),	   and	   was	   considered	   responsible	   for	  
elevating	  serum	  glucose	  levels	  from	  150	  mg/dl	  to	  
220	   mg/dl,	   and	   thus	   contributing	   to	   increased	  
CA1	   neuronal	   loss.	   When	   hyperglycemia	   was	  
controlled	  by	  the	  simultaneous	  administration	  of	  
magnesium	   and	   insulin,	   CA1	   injury	   was	   no	  
different	  to	  saline	  treated	  controls.	  As	  a	  measure	  
to	  ensure	  the	  delivery	  of	  magnesium	  to	  the	  target	  
tissue,	   Tsuda	   et	   al.,	   (1991)	   administered	  
magnesium	   chloride	   (1µl;	   50	   mM	   solution)	  
directly	  to	  the	  CA1	  sector	  of	  the	  hippocampus	  at	  
10	  minutes	  before	   ischemia	  or	  at	  0,	  2,	  12,	  24	  or	  
48	  hours	  after	  ischemia.	  A	  neuroprotective	  effect	  
was	   observed	   in	   CA1	   neurons	   at	   all	   time	   points	  
except	   48	   hours	   post-­‐ischemia.	   A	   lower	   dose	   of	  
magnesium	  chloride	   (1	  µl;	   10	  mM)	  administered	  
at	   the	   24	   hour	   time	   point	   also	   showed	   a	  
neuroprotective	  trend,	  but	  was	  not	  significant	  at	  
the	   P	   <	   0.01	   level.	   Animal	   body	   temperatures	  
were	   not	   monitored	   during	   recovery,	   so	   a	  
potential	   confounding	   factor	   is	   that	   the	   animals	  
might	   have	   become	   hypothermic	   during	   this	  
period.	   The	   potential	   for	   hypothermia	   will	   also	  
have	   been	   compounded	   since	   the	   animals	   were	  
re-­‐anaesthetized	   in	   those	   groups	   receiving	  
magnesium	  post-­‐ischemia.	  	  
	  
While	   the	   implications	   of	   post-­‐ischemic	  
hypothermia	   will	   be	   discussed	   in	   more	   detail	  
later,	   it	   should	   be	   emphasized	   that	   3	   studies	  
(Milani	   et	   al.,	   1999;	   Zhu	   et	   al.,	   2004b;	   2005)	   in	  
which	   measures	   were	   taken	   to	   avoid	   post-­‐
ischemic	   hypothermia,	   including	   2	   from	   our	  
laboratory,	   found	   no	   significant	   neuroprotection	  
(CA1	   neuronal	   survival)	   despite	   starting	  
magnesium	   treatment	   before	   or	   early	   after	  
cerebral	   ischemia	   and	   using	   multiple	   and	  
continuous	  dosing	  regimens.	  Furthermore,	   in	  the	  
2	  studies	   from	  our	   laboratory	   (Zhu	  et	  al.,	  2004b;	  
2005),	   when	   either	   spontaneous	   or	   controlled	  
mild	   hypothermia	   occurred	   during	   treatment,	   a	  
neuroprotective	   effect	   was	   observed.	   In	   the	  
remaining	  studies	  (Okawa	  et	  al.,	  1992;	  Sirin	  et	  al.,	  
1998;	   Miles	   et	   al.,	   2001;	   Zhou	   et	   al.,	   2003)	   no	  
measures	   were	   reported	   to	   have	   been	   taken	   to	  
avoid	  post-­‐ischemic	  hypothermia,	  and	  all	  of	  these	  
reported	   positive	   histological	   or	   behavioral	  
outcomes.	  	  
	  
Reasons	  for	  inconsistent	  results	  with	  
magnesium	  following	  cerebral	  ischemia	  
	  
On	   the	   evidence	   from	   these	   studies,	   to	   the	  
question	   of	   whether	   magnesium	   is	   neuro-­‐
protective	   following	   cerebral	   ischemia,	   the	  
answer	  must	   be:	   sometimes.	   A	   second	   question	  
arises,	   then,	   as	   to	   what	   factor	   or	   factors	  
determine	   when	   magnesium	   will	   be	  
neuroprotective,	  and	  when	  it	  will	  not.	  Taking	  into	  
account	   the	  differences	   in	   study	  design	   (species;	  
ischemia	   model;	   post-­‐surgical	   temperature	  
control;	   dosage,	   route	   and	   time	   of	   magnesium	  
administration)	  we	  propose	   several	   explanations	  
that	   may	   reasonably	   account	   for	   the	  
inconsistencies	  in	  the	  reported	  data.	  
	  
Confounding	  effects	  of	  post-­‐ischemic	  
hypothermia	  	  
As	  previously	  reported	  (Meloni	  et	  al.,	  2006)	  there	  
is	   reason	   to	   believe	   that	   the	   discrepant	   results	  
found	   in	   these	   studies	   most	   likely	   can	   be	  
attributed	   to	   the	   confounding	   effects	   of	   post-­‐
ischemic	  hypothermia.	   In	  the	  magnesium	  studies	  
described	   in	   Tables	   1	   and	   2,	   the	   animals	   were	  
invariably	   maintained	   normothermic	   during	  
ischemia,	   but	   in	  most	   cases	   there	   is	   no	  mention	  
of	  body	  temperature	  monitoring	  or	  maintenance	  
during	   recovery	   from	   surgery	   and	   in	   the	   post-­‐
ischemic	  period.	  This	   is	   crucial	  because	   it	   is	  now	  
accepted	   and	   documented	   that	   post-­‐surgical	  
hypothermia	   commonly	   occurs	   in	   these	   models	  
of	  cerebral	   ischemia,	  and	  it	  has	  been	  shown	  that	  
post-­‐ischemic	   hypothermia	   has	   confounded	   the	  
results	  of	  previous	  studies	  (Buchan	  and	  Pulsinelli,	  
1990;	   Corbett	   et	   al.,	   1990;	   Welsh	   et	   al.,	   1990;	  
Dietrich	  et	  al.,	  1995;	  Behringer	  et	  al.,	  2002).	  This	  
is	  especially	   relevant	   in	  magnesium	  studies	  since	  
there	   is	   also	   evidence	   that	  magnesium	   itself	   has	  
hypothermia	   inducing	  properties	   (Zweifler	   et	   al.,	  
2004;	  Wadhwa	   et	   al.,	   2005).	   Therefore,	   in	   those	  
studies	   that	   did	   not	   actively	   maintain	   animals	  
normothermic	   after	   ischemia,	   the	   occurrence	   of	  
spontaneous	   hypothermia	   cannot	   be	   ruled	   out,	  
and	  in	  fact	  is	  highly	  likely.	  	  
	  
Further	   than	   that,	   direct	   evidence	   of	   the	  
synergistic	   effects	   of	   mild	   hypothermia	   with	  
magnesium	   has	   been	   generated	   from	   several	  
studies	   in	   our	   laboratory.	   In	   an	   early	   global	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ischemia	   study	   (Miles	   et	   al.,	   2001)	   we	   did	   not	  
monitor	  or	  control	  for	  animal	  body	  temperatures	  
after	   ischemia;	   in	   this	   study	   we	   observed	   a	  
neuroprotective	   effect.	   In	   subsequent	   studies	  
(Zhu	   et	   al.,	   2004b;	   2005),	   however,	   using	   the	  
same	  model	  and	  magnesium	  treatment,	  but	  using	  
controlled	   normothermic	   conditions	   after	  
ischemia,	   we	   did	   not	   see	   a	   neuroprotective	  
effect.	   Moreover,	   we	   observed	   that	   if	   body	  
temperature	   was	   only	   monitored	   without	   being	  
controlled,	   the	   animals	   did	   become	   mildly	  
hypothermic	   during	   surgical	   recovery,	   and	  
magnesium	   treatment	   in	   these	   animals	   did	  
significantly	   reduce	   CA1	   neuronal	   death.	   Note	  
that	  control	  animals	  also	  became	  hypothermic	  to	  
a	   similar	   degree,	   yet	   they	   did	   not	   show	  
neuroprotection.	  	  
	  
In	   subsequent	   experiments,	   when	  we	   compared	  
magnesium	  efficacy	  in	  normothermic	  animals	  and	  
in	   animals	   rendered	   mildly	   hypothermic	   (35°C)	  
for	  6	  hours	  immediately	  after	  global	  ischemia,	  we	  
observed	   that	   treatment	   with	   magnesium	   and	  
mild	   hypothermia	   together	   increased	   CA1	  
neuronal	   survival.	   Importantly,	   no	   neuro-­‐
protection	  was	  observed	  either	   in	  normothermic	  
animals	   receiving	   magnesium	   or	   in	   animals	  
rendered	  hypothermic	  for	  6	  hours	  post-­‐ischemia.	  
We	  have	  also	  obtained	  similar	  findings	  with	  focal	  
ischemia	   experiments.	   For	   example,	   we	   have	  
demonstrated	   that	   following	   focal	   ischemia,	  
magnesium	   treatment	   in	   normothermic	   animals	  
does	   not	   result	   in	   reduced	   infarct	   volumes.	   In	  
contrast,	   if	   magnesium	   treatment	   is	   combined	  
with	  a	  period	  of	  mild	  hypothermia	   (spontaneous	  
or	  controlled)	  reduced	  brain	  infarcts	  are	  observed	  
(Campbell	   et	   al.,	   2008ab).	   In	   our	   controlled	  
hypothermia	   experiments	   using	   a	   permanent	  
focal	  model	   (Campbell	   et	   al.,	   2008b)	  we	   did	   not	  
observe	   a	   protective	   effect	   with	   mild	  
hypothermia	  alone.	  
	  
Taken	  together,	   these	  experiments	   illustrate	  two	  
important	   points.	   The	   first	   is	   that	   ischemic	  
control	   animals,	   though	   they	   might	   experience	  
some	   level	  of	  hypothermia,	   are	  unlikely	   to	   show	  
any	   evidence	   of	   neuroprotection.	   The	   second	   is	  
that	   the	   combination	   of	   magnesium	   and	   mild	  
hypothermia	   does	   not	   appear	   to	   act	   in	   an	  
additive	  way,	  but	  rather	  synergistically	  to	  unmask	  
a	  neuroprotective	  effect.	  These	  findings	  highlight	  
the	   necessity	   to	   maintain	   post-­‐ischemic	   animal	  
body	   temperatures	   in	   drug	   evaluation	   studies	  
and,	  since	  in	  the	  majority	  of	  magnesium/cerebral	  
ischemia	   studies	   this	   was	   not	   reported	   to	   have	  
been	   done,	   there	   is	   reason	   to	   question	   the	  
validity	  of	  the	  results.	  
	  
Dosage,	  route	  and	  time	  of	  magnesium	  
administration	  	  
It	   is	   a	  matter	   of	   speculation	   as	   to	   the	   degree	   to	  
which	   magnesium	   dosage	   and	   route	   of	  
administration	   is	   another	   contributing	   factor	   for	  
the	   discrepant	   findings,	   in	   large	   part	   due	   to	   the	  
fact	  that	  the	  optimal	  dose	  of	  magnesium	  remains	  
unknown.	  	  
	  
As	   a	   rule	   of	   thumb,	   early	   experimental	   and	  
clinical	   studies	   have	   aimed	   to	   achieve	   serum	  
concentrations	  of	  about	  double	  the	  baseline	  (i.e.,	  
to	  increase	  serum	  magnesium	  from	  ≈	  0.8	  to	  ≈	  1.5	  
mmol/l),	  which	   seems	   reasonable	  as	  magnesium	  
at	  this	  level	  appears	  to	  be	  safe	  and	  well	  tolerated	  
(Muir	  and	  Lees,	  1995;	  1998).	  However,	  data	  from	  
our	   laboratory	   indicate	   that	   magnesium	   doses	  
that	   double	   baseline	   serum	   levels	   may	   be	   too	  
high.	   For	   example,	   magnesium	   doses	   that	  
resulted	  in	  serum	  magnesium	  levels	  >1.4	  mmol/L	  
(e.g.,	   using	   an	   IV	   loading	   dose	   of	   0.36	  mmol/kg,	  
followed	   by	   an	   infusion	   of	   0.24	   or	   0.48	  
mmol/kg/h)	   provided	   no	   or	   minimal	   CA1	  
protection.	  On	  the	  other	  hand,	  a	  lower	  dose	  (0.36	  
mmol/kg	   IV,	   then	   0.12	   mmol/kg/h),	   which	  
resulted	   in	   serum	   magnesium	   from	   1	   -­‐	   1.2	  
mmol/l,	   provided	  marked	   CA1	   survival	   following	  
global	   ischemia	   (note	   that	   in	   these	   experiments	  
the	   animals’	   body	   temperatures	   were	   not	  
monitored	  during	  the	  post-­‐ischemia	  period;	  Miles	  
et	  al.,	  2001).	  In	  addition,	  we	  have	  shown	  that	  the	  
higher	  loading	  dose	  of	  0.72	  mmol/kg,	  when	  given	  
before	   focal	   ischemia	   (in	   animals	   that	   were	  
maintained	   normothermic	   in	   the	   6	   hour	   post-­‐
ischemic	   period),	   produced	   a	   trend	   towards	  
increased	  infarct	  volume.	  
	  
The	   time	   of	   administration	   will	   also	   have	   a	  
marked	   influence	   on	   the	   potential	   neuro-­‐
protective	  effect	  of	  any	  intervention.	  Most	  of	  the	  
studies	   here	   administered	  magnesium	   before	   or	  
immediately	  after	  induction	  of	  cerebral	  ischemia;	  
hence,	  increased	  magnesium	  levels	  were	  present	  
in	   serum,	   and	   possibly	   the	   brain,	   at	   the	   time	   of	  
ischemia.	   Post-­‐ischemic	   treatments	   with	  
magnesium,	   following	   both	   focal	   and	   global	  
cerebral	   ischemia,	   have,	   however,	   produced	  
positive	   outcomes,	   with	   treatment	   as	   late	   as	   6	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hours	  after	  focal	  ischemia	  (Yang	  et	  al.,	  2000)	  and	  
24	  hours	  after	  global	   ischemia	  showing	  a	  benefit	  
(Tsuda	   et	   al.,	   1991).	   Even	   allowing	   that	  
hypothermia	   has	   likely	   confounded	   some	  
outcomes,	   it	   is	  encouraging	  to	  note	  that	  delayed	  
treatment	  with	  magnesium	  can	  be	  effective.	  	  
	  
While	   different	   routes	   of	   administration	  
(intravenous,	   intra-­‐arterial,	   intraperitoneal,	  
subcutaneous,	   intracranial)	   have	   been	   used	   to	  
deliver	  magnesium,	   it	   is	   difficult	   to	   comment	  on	  
how	   this	   may	   have	   influenced	   outcomes	   in	   the	  
absence	  of	  measures	  such	  as	   the	  serum	  and	  CSF	  
concentrations	   achieved.	   Again	   of	   particular	  
interest	   is	   the	   positive	   study	   using	   intracranial	  
delivery	   (Tsuda	   et	   al.,	   1991),	   which	   reported	  
efficacy	   even	   at	   24	   hours	   post-­‐ischemia.	   By	  
bypassing	   the	   blood	   brain	   barrier,	   intracranial	  
delivery	   would	   guarantee	   increased	   brain	  
magnesium	  and	  thus	  maximize	  its	  effects.	  	  
	  
	  
CSF	  magnesium	  levels	  and	  magnesium	  salt	  
Only	  1	  cerebral	  ischemia	  study	  has	  examined	  the	  
extent	   to	   which	   exogenously	   administered	  
magnesium	   penetrates	   into	   either	   brain	   or	   CSF.	  
This	   study,	   by	   Okawa	   et	   al.,	   (1992),	   used	   an	   IV	  
loading	   dose	   (0.664	   mmol/kg)	   followed	   by	   an	  
infusion	   of	   magnesium	   sulphate	   (0.332	  
mmol/kg/h	  for	  3	  h,	  then	  0.083	  mmol/kg/h	  for	  45	  
h)	   in	  dogs	   subjected	   to	  global	   cerebral	   ischemia.	  
They	   showed	   a	   significant	   increase	   in	   CSF	  
magnesium	   lasting	   from	   20	   minutes	   to	   7	   days	  
after	  treatment.	  Interestingly,	  dogs	  not	  subjected	  
to	   global	   ischemia,	   but	   treated	   with	   the	   same	  
magnesium	   regimen,	   did	   not	   show	   significantly	  
elevated	   CSF	   magnesium.	   In	   a	   study	   using	   rats	  
not	  subjected	  to	  cerebral	  ischemia,	  Sjöström	  and	  
Wester	   (1990)	   showed	   elevated	   brain	   and	   CSF	  
magnesium	  shortly	  after	   IV	  administration	  of	  2.0	  
mmol/kg	  magnesium	  chloride.	  The	  Okawa	   et	  al.,	  
(1992)	   study	   suggests	   that	   exogenously	  
administered	   magnesium	   may	   have	   increased	  
access	   to	   the	   brain	   following	   cerebral	   ischemia,	  
making	   it	   likely	   that	   in	   cerebral	   ischemia	  
experiments	  magnesium	  has	  been	  present	   in	  the	  
target	  tissue,	  and	  thus	  able	  to	  exert	  both	  vascular	  
and	  neural	  effects.	  
	  
Magnesium	   sulphate	   and	   magnesium	   chloride	  
have	   both	   been	   used	   in	   models	   of	   cerebral	  
ischemia,	  with	  both	  positive	  and	  negative	  results,	  
yet	   no	   studies	   have	   directly	   compared	   their	  
efficacy.	   The	   only	   study	   that	   has	   assessed	   both	  
magnesium	   salts	   was	   an	   early	   global	   ischemia	  
study	   from	   our	   laboratory	   (Miles	   et	   al.,	   2001).	  
Our	  data	  appeared	   to	   favour	  greater	  efficacy	   for	  
magnesium	  sulphate,	  but	  unfortunately	  the	  trials	  
with	   the	   two	   magnesium	   salts	   were	   not	  
performed	  concurrently,	   and	  once	  again	   there	   is	  
the	   likelihood	   of	   post-­‐ischemic	   hypothermia	  
confounding	   the	   results.	   Interestingly,	   in	   our	  
experiments	   animals	   treated	   with	   magnesium	  
chloride	   did	   not	   become	   hyperglycaemic	  
(unpublished	  observation),	  which	  is	  in	  contrast	  to	  
two	  earlier	  studies	  (Blair	  et	  al.,	  1989;	  Izumi	  et	  al.,	  
1991).	   A	   possible	   contributing	   factor	   to	   the	  
hyperglycaemia	   reported	   by	   Blair	   et	   al.,	   (1989)	  
and	   Izumi	   et	   al.,	   (1991)	   is	   that	   they	   found	  
magnesium	   treatment	   was	   associated	   with	  
hypothermia,	  which	   can	   reduce	   insulin	   secretion	  
(Polderman,	   2009)	   predisposing	   the	   animals	   to	  
hyper-­‐glycaemia.	  
	  
In	  summary,	  the	  discrepancies	  in	  the	  outcomes	  of	  
these	   studies	   are	   explicable	   in	   light	   of	   several	  
unanswered	   questions	   that	   still	   surround	  
magnesium	   treatment	   for	   cerebral	   ischemia.	   On	  
the	   available	   evidence,	   it	   seems	   fair	   to	   say	   that	  
magnesium	   does	   indeed	   have	   neuroprotective	  
properties	   when	   a	   suitable	   dose	   is	   given	   to	  
achieve	   moderately	   increased	   (above	   normal)	  
levels	   in	   the	   target	   tissue	   in	   conjunction	   with	   a	  
mild	  degree	  of	  hypothermia.	  	  
	  
Future	  use	  of	  magnesium	  following	  stroke	  and	  
cerebral	  ischemia	  
	  
As	  it	  stands,	   in	   light	  of	  the	  failure	  of	  the	  IMAGES	  
stroke	   trial	   to	   find	   a	   significant	   treatment	   effect	  
with	  magnesium	   (IMAGES,	   2004),	   the	   future	  use	  
of	   magnesium	   for	   the	   treatment	   of	   stroke,	   and	  
possibly	   other	   forms	   of	   cerebral	   ischemia,	   will	  
depend	  heavily	  on	  the	  outcome	  of	  the	  FAST-­‐MAG	  
Phase	   3	   trial	   (Saver	   et	   al.,	   2004,	   Stroke	   Trials	  
Directory,	  2010).	  This	  trial	   is	  currently	  underway,	  
and	   is	   assessing	   whether	   field	   administration	   of	  
magnesium	   within	   2	   hours	   of	   stroke	   onset	  
improves	  clinical	  outcomes.	  In	  essence,	  the	  FAST-­‐
MAG	  trial	  will	  address	  whether	  the	  long	  delay	  to	  
magnesium	   treatment	   in	   the	   IMAGES	   trial	  
(enrolment	   up	   to	   12	   hours	   after	   the	   onset	   of	  
stroke)	   was	   the	   principal	   reason	   for	   its	  
ineffectiveness.	   However,	   based	   on	   our	   own	  
assessment	   of	   magnesium	   under	   normothermic	  
conditions,	  we	  predict	  that	   if	  FAST-­‐MAG	  patients	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are	  maintained	   normothermic	   this	   trial	   will	   also	  
show	   little	   or	   no	   benefit.	   As	   discussed,	   the	  
evidence	  suggests	  that	  in	  order	  for	  magnesium	  to	  
produce	  a	  positive	  outcome	  after	  stroke/cerebral	  
ischemia	   it	   needs	   to	   be	   combined	   with	   mild	  
hypothermia	   (Meloni	   et	   al.,	   2009).	   Fortunately,	  
hypothermia	   induction	   may	   only	   require	   a	  
reduction	   in	   body	   temperature	   of	   1	   -­‐	   2°C	  
involving	   basic	   cooling	  measures,	   which	  may	   be	  
achievable	   in	  conscious	  patients.	   It	   is	  anticipated	  
that	   future	   cerebral	   ischemia	   experimental	  
studies	   will	   play	   a	   vital	   role	   in	   assessing	  
magnesium	   in	   combination	   with	   hypothermia,	  
and	   potentially	   with	   other	   agents	   as	   well,	   with	  





There	   is	  evidence	  from	  several	  models	  and	  using	  
a	  number	  of	  treatment	  regimens	  that	  magnesium	  
has	   neuroprotective	   properties	   that	   can	   reduce	  
brain	   damage	   and	   neurological	   deficits	   after	  
cerebral	   ischemia.	   Given	   that	   hypomagnesaemia	  
is	   known	   to	   occur	   after	   stroke,	   magnesium	  
supplementation	   has	   a	   place	   in	   the	   normal	  
supportive	   care	   of	   such	   patients.	   Beyond	   that,	  
the	  question	  remains	  as	  to	  whether,	  and	  by	  how	  
much,	   supplementation	   should	   aim	   to	   increase,	  
rather	  than	  just	  restore,	  serum	  magnesium	  levels.	  
The	   FAST-­‐MAG	   trial	   may	   provide	   part	   of	   the	  
answer,	   though	   probably	   without	   being	  
definitive.	  	  
	  
The	   rationale	   for	   trialing	   magnesium	   as	   a	  
neuroprotective	  agent	   following	  stroke	  has	  been	  
based	   on	   its	   role	   in	   maintaining	   normal	   brain	  
functions,	   on	   its	   known	   cellular	   actions	   that	   are	  
anticipated	   to	   counteract	   damaging	   ischemic	  
processes	   and	   subsequently	   on	   positive	  
experimental	   data	   from	   animal	   models	   of	  
cerebral	  ischemia.	  However,	  close	  scrutiny	  of	  the	  
animal	   data	   shows	   that	   about	   46%	   of	   studies	  
have	   not	   shown	   a	   neuroprotective	   effect,	   and	  
that	  the	  majority,	  if	  not	  all,	  of	  the	  positive	  studies	  
were	   potentially	   confounded	   by	   post-­‐ischemic	  
hypothermia.	   In	   addition,	   experimental	   design	  
has	  not	  always	  been	  well-­‐founded	  with	  respect	  to	  
magnesium	  dosage,	  and	  to	  the	  time	  and	  route	  of	  
magnesium	   administration.	   Moreover,	   recent	  
animal	   studies	   under	   controlled	   post-­‐ischemic	  
conditions	   indicate	   that	   magnesium	   is	   only	  
neuroprotective	   when	   combined	   with	  
hypothermia.	   Finally,	   additional	   information	  
regarding	   the	   efficacy	   of	  magnesium	  as	   a	   stroke	  
treatment	  will	  be	  available	  on	  completion	  of	   the	  
FAST-­‐MAG	   trial,	   but	   in	   the	   meantime	   the	  
neuroprotective	  potential	  of	  magnesium	  remains	  
a	   valid	   subject	   for	   investigation	   in	   cerebral	  
ischemia	   models,	   with	   emphasis	   on	   its	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Subarachnoid	  haemorrhage	  (SAH)	  caused	  by	  a	  ruptured	  aneurysm	  accounts	   for	  only	  5%	  of	  strokes,	  but	  
occurs	   at	   a	   fairly	   young	   age	   and	   carries	   a	  worse	   prognosis.	  Delayed	   cerebral	   ischemia	   is	   an	   important	  
cause	   of	   death	   and	   dependence	   after	   aneurysmal	   SAH.	   The	   current	   mainstay	   of	   preventing	   delayed	  
cerebral	  ischemia	  is	  nimodipine	  and	  maintenance	  of	  normovolemia,	  but	  even	  with	  this	  strategy	  delayed	  
cerebral	   ischemia	  occurs	   in	  a	   considerable	  proportion	  of	  patients.	  Magnesium	   is	  an	   inexpensive,	  easily	  
available	  neuroprotective	  agent	  that	  reduces	  cerebral	  vasospasm	  and	  infarct	  volume	  after	  experimental	  
SAH.	   In	   a	   meta-­‐analysis	   of	   all	   randomized	   clinical	   trials,	   magnesium	   shows	   a	   tendency	   to	   reduce	   the	  
occurrence	  of	  delayed	  cerebral	  ischemia	  and	  poor	  outcome	  after	  SAH,	  but	  the	  question	  if	  magnesium	  is	  
advantageous	  in	  SAH	  patients	  is	  still	  in	  abeyance.	  Currently	  a	  large	  phase	  III	  trial	  aiming	  for	  1200	  patients	  
is	   being	   conducted	   that	   will	   hopefully	   provide	   definite	   evidence	   whether	   magnesium	   treatment	   is	  




Subarachnoid	   haemorrhage	   (SAH)	   caused	   by	   a	  
ruptured	   aneurysm	   accounts	   for	   only	   5%	   of	  
strokes,	   but	   occurs	   at	   a	   fairly	   young	   age	   and	  
carries	   a	   worse	   prognosis	   than	   other	   types	   of	  
stroke	  (van	  Gijn	  et	  al.,	  2007).	  The	  cardinal	  feature	  
is	   a	   history	   of	   unusually	   severe	   headache	   that	  
started	  suddenly,	  but	  patients	  frequent	  deteriorate	  
into	   unconsciousness	   shortly	   after	   onset.	   On	  
admission	   two-­‐thirds	   of	   all	   patients	   have	  
depressed	   consciousness,	   of	   whom	   half	   are	   in	  
coma	   (Brilstra	   et	   al.,	   2000).	   The	   school	   of	  
Hippocrates	  already	  described	  the	  clinical	  picture	  
of	   a	   SAH:	   "When	   persons	   in	   good	   health	   are	  
suddenly	   seized	   with	   pains	   in	   the	   head,	   and	  
straightway	   are	   laid	   down	   speechless,	   and	  
breathe	   with	   stertor,	   they	   die	   in	   seven	   days,	  
unless	  fever	  comes	  on"	  (Hippocrates	  et	  al.,	  1527;	  
Clarke,	  1963).	  Attila	  the	  Hun	  is	  suspected	  to	  have	  
had	   a	   SAH	   as	   he	   died	   suddenly	   after	   severe	  
headache	   developed	   during	   sexual	   intercourse	  
(Babinski,	  1893).	  
	  
The	   incidence	   of	   SAH	   in	  most	   populations	   is	   6-­‐7	  
per	   100000	   person-­‐years	   (Linn	   et	   al.,	   1996).	  
About	   one	   in	   eight	   patients	   die	   before	   reaching	  
the	  hospital.	  The	  in-­‐hospital	  case	  fatality	  is	  about	  
one-­‐third	  (Nieuwkamp	  et	  al.,	  2009).	  Of	  patients	  
who	   survive	   the	   SAH	   approximately	   one-­‐third	  
remain	   dependent.	   Because	   of	   the	   young	   age	  
SAH	   occurs,	   and	   its	   poor	   prognosis,	   the	   loss	   of	  
productive	   life	  years	  from	  SAH	  is	  as	   large	  as	  that	  
from	  ischemic	  stroke,	  the	  most	  frequent	  subtype	  
of	  stroke.	  	  
	  
The	   presence	   of	   an	   aneurysm	   was	   first	  
demonstrated	   by	   an	   angiograph	   of	   the	   carotid	  
artery	   by	   Moniz	   in	   1933	   (Moniz,	   1933),	   6	   years	  
after	   he	   had	   introduced	   this	   technique	   (Moniz,	  
1927).	   Aneurysms	   arise	   at	   sites	   of	   arterial	  
branching,	  usually	  at	  the	  base	  of	  the	  brain,	  either	  
on	   the	   circle	   of	   Willis	   itself	   or	   at	   a	   nearby	  
branching	  point.	  Most	  intracranial	  aneurysms	  will	  
never	   rupture.	   Risk	   factors	   for	   subarachnoid	  
haemorrhage	   are	   hypertension,	   smoking,	   and	  
excessive	  alcohol	  intake,	  all	  of	  which	  more-­‐or-­‐less	  
double	  the	  risk	  (Feigin	  et	  al.,	  2005).	  
	  
Diagnosis	   is	   made	   by	   CT	   brain	   scanning.	  
Recurrent	  bleeding	  is	  the	  most	  imminent	  danger;	  
a	  first	  aim	  is	  therefore	  occlusion	  of	  the	  aneurysm.	  
Endovascular	   obliteration	   by	   means	   of	   platinum	  
spirals	   (coiling)	   is	   the	   preferred	   mode	   of	  
treatment,	   but	   some	   patients	   require	   a	   direct	  
neurosurgical	   approach	   (clipping)	   (Molyneux	   et	  
al.,	  2002).	  
	  
Delayed	  cerebral	  ischemia	  
	  
For	  those	  patients	  who	  survive	  the	  first	  24	  hours	  
after	   the	   haemorrhage,	   delayed	   cerebral	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ischemia	  (DCI)	  is	  consistently	  the	  leading	  cause	  of	  
death	   and	   disability,	   adversely	   affecting	   more	  
than	  one	  in	  five	  of	  all	  patients	  who	  have	  suffered	  
SAH	   and	   survived	   (Dorsch,	   1995;	   Roos	   et	   al.,	  
2000).	  
	  
Unlike	   thrombo-­‐embolic	   stroke,	   cerebral	  
ischemia	  after	  SAH	  has	  a	  gradual	  onset	  and	  often	  
involves	   more	   than	   the	   territory	   of	   a	   single	  
cerebral	  artery	  or	  one	  of	  its	  branches.	  The	  clinical	  
manifestations	   evolve	   gradually,	   over	   several	  
hours,	  and	  consist	  of	  hemispheric	  focal	  deficits,	  a	  
reduction	  in	  the	  level	  of	  consciousness,	  or	  both.	  It	  
is	   mainly	   a	   diagnosis	   of	   exclusion,	   when	   clinical	  
deterioration	   occurs	   and	   hydrocephalus,	  
recurrent	   bleeding,	   hypoxia,	   and	   metabolic	  
abnormalities	   have	   been	   ruled	   out.	   The	   peak	  
frequency	  of	  cerebral	   ischemia	   is	   from	  5-­‐14	  days	  
after	   SAH.	   The	   time	   course	   for	   delayed	   cerebral	  
ischemia	   parallels	   that	   of	   angiographic	  
vasospasm,	   but	   arterial	   narrowing	   –	   a	   complex	  
process	   in	   itself	   –	   is	   neither	   a	   necessary	   nor	   a	  
sufficient	   condition.	   Although	   about	   70%	   of	  
patients	  may	  develop	  arterial	  narrowing,	  only	  20-­‐
30%	   will	   manifest	   neurological	   deficits	   (Weir	   et	  
al.,	  1999;	  Rabinstein	  et	  al.,	  2004).	  
	  
Nimodipine	   is	   a	  dihydropyridine	   calcium	  channel	  
blocker	   that	   selectively	   blocks	   the	   voltage-­‐
dependent	  L-­‐type	  calcium	  channel.	  Nimodipine	  is	  
accepted	   as	   beneficial	   in	   preventing	   DCI	   and	  
subsequent	   poor	   outcome	   when	   given	   orally	   6	  
times	  (60	  mg)	  for	  21	  days	  after	  the	  haemorrhage	  
(Dorhout	  Mees	  et	  al.,	  2007b).	  The	   initial	  thought	  
was	  that	  nimodipine	  could	  prevent	  or	  ameliorate	  
cerebral	   vasospasm,	   but	   nimodipine	   does	   not	  
influence	   large	   vessel	   diameter	   and	   its	   pivotal	  
method	  of	  action	  must	  be	  explained	  otherwise.	  
	  
Cerebral	   vasospasm,	   although	   often	   used	   as	   a	  
synonym,	   apparently	   is	   a	   too	   simplistic	  
explanation	   for	   delayed	   cerebral	   ischemia.	  
Research,	   however,	   has	   focused	   on	   the	  
mechanisms	   involved	   in	   the	   development	   of	  
cerebral	  vasospasm	  as	  a	  means	  by	  which	  cerebral	  
ischemia	   can	   be	   prevented.	   The	   precise	   under-­‐
lying	   pathogenic	   mechanisms	   remain	   obscure,	  
but	   it	   seems	   that	   endothelial	   mechanisms	  
provide	   the	  most	  prominent	   contribution	   to	   this	  
process,	   and	   there	   is	   growing	   evidence	   that	   the	  
constituents	   of	   a	   subarachnoid	   blood	   clot,	  
especially	   oxyhaemoglobin,	   a	   product	   of	  
haemoglobin	   breakdown,	   seem	   to	   be	   the	  
principle	   initiating	   factor	   (Pluta	   et	   al.,	   1998;	  
Dumont	  et	  al.,	  2003;	  Kolias	  et	  al.,	  2009).	  
	  
The	   current	  mainstay	   of	   preventing	   and	   treating	  
DCI	  include	  neuroprotection	  with	  nimodipine	  and	  
maintenance	   of	   normovolemia,	   but	   even	   with	  
this	   strategy	   DCI	   still	   occurs	   in	   up	   to	   30%	   of	  
patients	  and	  improvement	  in	  clinical	  outcome	  has	  
been	   modest	   (Hop	   et	   al.,	   1997;	   Brilstra	   et	   al.,	  
2000;	   Roos	   et	   al.,	   2000;	   Dorhout	   Mees	   et	   al.,	  
2008).	   Reducing	   the	   consequences	   of	   ischemia	  
through	  neuroprotection	  may	   therefore	   improve	  
outcome	   after	   SAH.	   DCI	   after	   SAH	   is	   a	   unique	  
pathophysiological	   process	   because	   the	   timing	  
and	   development	   of	   potential	   cerebral	   ischemia	  
can	  be	  predicted.	  The	   interval	  of	  4	  or	  more	  days	  
between	  the	  bleeding	  and	   the	  onset	  of	   ischemia	  
provides	   an	   opportunity	   for	   preventive	  
treatment.	  
	  
Magnesium	  and	  cerebral	  ischemia:	  
opportunities	  and	  concerns	  
	  
Magnesium	  is	  a	  popular	  drug	  for	  acute	  treatment	  
of	   ischemia	  because	  of	   its	  ease	  of	  use,	   low	  cost,	  
and	   favourable	   side-­‐effect	   profile.	   In	   several	  
experimental	   models	   of	   cerebral	   ischemia,	   a	  
significant	   neuroprotective	   effect	   of	   magnesium	  
has	   been	   demonstrated	   with	   reported	   infarct	  
reduction	  of	  25-­‐61%	  (Izumi	  et	  al.,	  1991;	  Marinov	  
et	   al.,	   1996;	   Muir,	   1998).	   Putative	   modes	   of	  
action	   include	   inhibition	   of	   the	   presynaptic	  
release	   of	   the	   excitatory	   amino	   acid	   glutamate,	  
and	   blockade	   of	   the	   postsynaptic	   NMDA	  
glutamate	   receptor	   and	   voltage	   dependent	  
calcium	   channels	   (van	   den	   Bergh	   et	   al.,	   2004b).	  
Magnesium	  reduces	  the	  production	  of	  endothelin	  
and	   completely	   attenuates	   the	   vasoconstrictive	  
effect	   of	   endothelin,	   possibly	   by	   inhibiting	  
calcium	   channel-­‐mediated,	   smooth-­‐muscle	  
contraction	   (Kemp	   et	   al.,	   1999;	   Berthon	   et	   al.,	  
2003).	   Furthermore,	   magnesium	   increases	  
cardiac	  contractility,	  which	  may	  improve	  cerebral	  
perfusion	  in	  dysautoregulated	  brain	  tissue.	  	  
	  
However,	   acute	   ischemic	   stroke	   has	   not	   the	  
quality	   of	   cerebral	   vasospasm-­‐associated	   DCI	   in	  
SAH	   that	   occurs	   mostly	   more	   than	   4	   days	   after	  
the	  initial	  bleeding,	  allowing	  the	  administration	  of	  
a	   treatment	   before	   ischemia	   develops.	   Delayed	  
treatment	   might	   explain	   why	   magnesium	   was	  
ineffective	   in	   ischemic	   stroke	   in	   the	   IMAGES	  
study	  (Muir	  et	  al.,	  2004).	  Again	  a	  precedent	  exists	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for	   nimodipine,	   which	   was	   ineffective	   when	  
tested	   in	   ischemic	   stroke.	   A	   study	   of	   acute	  
administration	   of	   magnesium	   in	   stroke	   (FAST-­‐
MAG)	  is	  underway	  (Saver	  et	  al.,	  2004).	  
	  
Another	   concern	   about	   the	   suitability	   of	  
magnesium	   to	  protect	   the	   ischemic	   brain	   is	   that	  
regulation	   of	   cerebrospinal	   fluid	   magnesium	   is	  
largely	   maintained	   following	   acute	   brain	   injury	  
and	   limits	   the	  brain	  bioavailability	  of	  magnesium	  
sulphate.	   Current	   dose	   regimens	   may	   only	  
marginally	  increase	  concentrations	  of	  magnesium	  
in	   CSF	   in	   brain-­‐injured	   humans	   (McKee	   et	   al.,	  
2005),	  with	  this	  modest	  increase	  occurring	  in	  the	  
range	   of	   10-­‐19%.	   However,	   experimental	  
evidence	  suggests	  that	  this	  modest	  elevation	  may	  
be	  sufficient	  for	  neuroprotection.	  In	  a	  study	  using	  
31P-­‐MR	   spectroscopy	   (MRS)	   to	   investigate	  
intracellular	  brain	  free	  magnesium	  in	  37	  patients	  
with	   good-­‐grade	   aneurysmal	   SAH,	   patients	  were	  
randomized	   for	   magnesium	   therapy	   and	  
compared	   (Wong	   et	   al.,	   2009).	   Magnesium	  
treatment	   after	   aneurysmal	   SAH	   produced	   a	  
small	  (+13%;	  mean	  difference	  0.018	  ±	  0.007	  mM),	  
but	   significant	   elevation	   of	   intracellular	   free	  
magnesium.	   In	   a	   randomized	   controlled	   trial	  
where	   magnesium	   therapy	   was	   compared	   with	  
nimodipine,	   CSF	   magnesium	   concentration	   was	  
non-­‐statistically	   higher	   in	   the	   magnesium	   group	  
(1.19	   ±	   0.20	   vs	   1.14	   ±	   0.21;	   p=	   0.26)	   (Schmid-­‐
Elsaesser	  et	  al.,	  2006).	  
	  
The	   negative	   effect	   of	   magnesium	   on	   blood	  
pressure	   may	   also	   have	   an	   impact	   on	   results.	  
Currently,	  vasopressors	  are	  often	  used	  to	  prevent	  
hypotension	   in	   SAH	   patients,	   and	   DCI	   is	   often	  
treated	  with	   induced	   hypertension	  with	   the	   aim	  
to	   increase	   cerebral	   perfusion.	   However,	   the	  
lowering	  effect	  of	  magnesium	  on	  blood	  pressure	  
is	  limited	  and	  far	  less	  than	  that	  of	  nimodipine.	  
	  
Finally,	   there	   is	   a	   dose	   related	   association	  
between	  magnesium	  sulphate	  administration	  and	  
hypocalcaemia,	   but	   symptomatic	   hypocalcaemia	  
is	   rare	  and	   it	  does	  not	  result	   in	  an	   increased	  risk	  
of	   poor	   outcome	   (van	   den	   Bergh	   et	   al.,	   2008b).	  
There	   is	  no	  basis	   for	   routine	  supplementation	  of	  
calcium	   in	   patients	   with	   hypocalcaemia	   when	  
treated	   with	   magnesium.	   Of	   course,	  
supplementation	   might	   be	   considered	   in	  
individual	   patients	   to	   prevent	   isolated	   clinical	  
symptoms	   of	   hypocalcaemia	   such	   as	   muscle	  
weakness	  or	  cardiac	  arrhythmias.	  	  
Hypomagnesemia	  in	  subarachnoid	  haemorrhage	  
	  
In	  observational	  clinical	  studies,	  the	  vast	  majority	  
of	   SAH	   patients	   develop	   hypomagnesaemia	   at	  
some	   time	   within	   three	   weeks	   after	   the	  
haemorrhage	  (Warren	  et	  al.,	  1993;	  van	  den	  Bergh	  
et	   al.,	   2003).	   Low	   magnesium	   serum	   levels	   are	  
frequently	   present	   at	   admission	   and	   are	   thus	  
most	   likely	   caused	   by	   intracellular	   shift	   of	  
magnesium	   ions.	   Intracellular	   Mg2+	   levels	   are	  
indeed	   increased	   in	   SAH.	   However,	   90%	   of	   the	  
intracellular	  Mg2+	  is	  complexed	  with	  ATP,	  and	  the	  
increase	   of	   intracellular	   Mg2+	   during	   ischemia	  
may	  also	  be	  the	  result	  of	  the	  release	  of	  Mg2+	  from	  
this	   complex.	   ATP	   binds	   with	   Mg2+	   with	   an	  
associate	   constant	   of	   4,	   while	   binding	   affinity	  
with	  ADP	   is	   about	  2	   times	   smaller.	   The	   cytosolic	  
and	   mitochondrial	   Mg2+	   concentration	   will	  
increase	  in	  cells	  with	  a	  poor	  energy	  state	  and	  less	  
ATP	  (Jung	  et	  al.,	  1990;	  Saris	  et	  al.,	  2000;	  Wong	  et	  
al.,	   2009).	   The	   increase	   of	   intracellular	   Mg2+	   is	  
even	   less	   than	   might	   be	   expected	   from	   ATP	  
utilization,	   probably	   because	   of	   a	   disappearance	  
of	   Mg2+	   by	   binding	   to	   other	   cell	   components.	  
Hypomagnesaemia	  that	  developed	  later	  on	  in	  the	  
course	  might	  also	  be	  caused	  by	  renal	  loss	  as	  very	  
often	  is	  the	  case	  in	  critically	  ill	  patients.	  	  
	  
The	   diminished	   availability	   and	   subsequent	  
decreased	  extracellular	  Mg2+	  after	  SAH	   results	   in	  
significantly	   increased	   intracellular	   free	   Ca2+	   in	  
cerebral	   vascular	   muscle	   cells.	   This	   may	   cause	  
cerebral	  microvascular	  constriction,	  followed	  by	  a	  
proinflammatory	   response,	   inducing	   vascular	  
smooth	   muscle,	   endothelial	   and	   neuronal	   cell	  
damage	   (Barbour	   et	   al.,	   2002).	   Furthermore,	  
hypomagnesaemia	   results	   in	   a	   reduced	  
endothelial	   NO	   release	   by	   which	   means	  
hypomagnesaemia	   can	   induce	   vasoconstriction	  
(Pearson	   et	   al.,	   1998;	   Shechter,	   2000).	   All	   the	  
above	   gives	   rise	   to	   the	   concept	   of	   a	   causal	  
relationship	  between	  the	  decreased	  availability	  of	  
magnesium	  and	   the	  development	  of	   vasospasm-­‐	  
associated	   DCI.	   When	   testing	   this	   hypothesis	   in	  
107	   prospectively	   studied	   consecutive	   patients,	  
we	   found	   that	   hypomagnesaemia	   during	   day	   4	  
and	  10	  after	   the	  haemorrhage	   increased	  the	  risk	  
for	   DCI	   three	   fold	   (van	   den	   Bergh	   et	   al.,	   2003).	  
Apart	   from	   DCI,	   in	   a	   study	   in	   62	   patients,	   more	  
than	  one-­‐third	  had	  hypomagnesaemia	  at	  admission	  
which	   was	   independently	   related	   to	   cardiac	  
dysrhythmias,	  especially	  a	   long	  PR	   interval	  and	  a	  
shorter	  QTc	  interval	  (van	  den	  Bergh	  et	  al.,	  2004a).	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This	   link	   with	   cardiac	   complications	   might	   be	  
another	   reason	   why	   hypomagnesaemia	   may	   be	  
related	   to	   poor	   outcome	   (van	   der	   Bilt	   et	   al.,	  
2009).	  
	  




Magnesium	   has	   a	   vasorelaxing	   effect	   in	  
oxyhaemoglobin-­‐induced	   vasospasm	   and	   it	  
ameliorates	   cerebral	   vasospasm	   in	   experimental	  
SAH	   (Miura,	   1988;	   Ram	  et	   al.,	   1991;	   Pyne	  et	   al.,	  
2001),	  although	  no	  effect	  of	  magnesium	  sulphate	  
on	   the	   angiographic	   diameter	   of	   large	   cerebral	  
vessels	  in	  a	  monkey	  model	  of	  SAH	  could	  be	  noted	  
(Macdonald	   et	   al.,	   2004).	   Neither	   does	  
magnesium	   infusion	   decrease	   middle	   cerebral	  
artery	   blood	   flow	   velocities	   in	   patients	   with	   DCI	  
(van	  den	  Bergh,	  unpublished	  data).	  
	  
Magnesium	   induces	   a	   dose-­‐dependent	  
vasodilatation,	   reduces	   cerebrovascular	   tone,	  
increases	   CBF	   and	   protects	   the	   metabolism	  
(Seelig	   et	   al.,	   1983;	   Altura	   and	   Altura,	   1984;	  
Torregrosa	   et	   al.,	   1994)	   However,	   in	   a	   human	  
study	  in	  6	  patients,	  magnesium	  sulphate	  infusion	  
did	   not	   increase	   cerebral	   blood	   volume	   and	  
cerebral	   blood	   flow	   compared	   with	   pre-­‐
treatment	   levels,	   or	   compared	   with	   6	   control	  
patients	  (Wong	  et	  al.,	  2010a).	  
	  
We	  have	  demonstrated	  in	  an	  experimental	  model	  
that	   the	   duration	   of	   ischemic	   depolarizations	  
after	   SAH	   is	   substantially	   reduced	   after	   pre-­‐
treatment	   with	   magnesium	   sulphate	   (van	   den	  
Bergh	   et	   al.,	   2002).	   Magnesium	   also	   postpones	  
anoxic	   depolarization	   (van	   der	   Hel	   et	   al.,	   1998).	  
This	   maintenance	   of	   the	   membrane	   potential	  
may,	   at	   least	   partly,	   explain	   the	  neuroprotective	  
properties	  of	  magnesium	  in	  SAH.	  We	  have	  shown	  
in	   a	   rat	   model	   of	   SAH	   that	   pre-­‐treatment	   with	  
magnesium	   sulphate	   reduces	   acute	   cerebral	  
lesion	   volume	   with	   more	   than	   60%	   (van	   den	  
Bergh	  et	  al.,	  2002).	  
	  
Large	  randomized	  controlled	  trials	  
In	  2005,	   the	  “Magnesium	  and	  Acetylsalicylic	  acid	  
in	   Subarachnoid	   Haemorrhage”	   (MASH-­‐I)	   trial	  
was	   published,	   in	   which	   283	   patients	   between	  
November	   2000	   and	   January	   2004	   were	  
randomized	   to	   placebo	   or	   a	   continuous	   infusion	  
of	  64	  mmol/l/day	  of	  magnesium	  sulphate	  starting	  
within	  4	  days	  of	  SAH	  and	  continuing	  14	  days	  after	  
occlusion	  of	   the	  aneurysm	  (van	  den	  Bergh	  et	  al.,	  
2005).	   The	   results	   showed	   a	   trend	   towards	   less	  
cerebral	   ischemia	   in	   patients	   allocated	   to	  
magnesium	  and	   improved	  overall	   outcome,	  with	  
a	   35%	   reduction	   in	   DCI	   (RR	   0.65;	   95%	   CI	   0.40–
1.05)	  and	  a	  23%	  reduction	  in	  poor	  outcomes	  (RR	  
0.77;	   0.54–1.09).	   The	   mean	   magnesium	   level	  
during	   treatment	   was	   1.47	   ±	   0.32	   mmol/L,	   and	  
side	  effects	  were	  mild	  and	  sparse	  (van	  Norden	  et	  
al.,	  2005).	  A	  post-­‐hoc	  analysis	  suggested	  that	  the	  
treatment	   effect	   of	   magnesium	   is	   larger	   after	  
endovascular	   occlusion	   than	   after	   neurosurgical	  
clipping,	   which	   underlines	   the	   conclusion	   that	  
further	   trials	   are	   not	   at	   risk	   of	   being	  
underpowered	   if	   the	  proportion	  of	  endovascular	  
treated	  patients	   increases	   (van	  den	  Bergh	  et	   al.,	  
2009).	  
	  
In	   2010,	   the	   results	   of	   the	   Intravenous	  
Magnesium	   Sulphate	   in	   Aneurysmal	  
Subarachnoid	   Haemorrhage	   (IMASH)	   trial	   were	  
published	   (Wong	   et	   al.,	   2010b).	   IMASH	   was	   a	  
phase	   III	   randomized,	   clinical,	   international	  
multicentre	   trial	   that	   evaluated	   the	   effect	   of	  
magnesium	   sulphate	   on	   the	   clinical	   outcome	   of	  
327	  patients	  with	  aneurysmal	  SAH,	  of	  which	  90%	  
were	   recruited	   in	  Hong	   Kong	   and	   China	   and	   the	  
remaining	   10%	   in	   Australia	   from	   2002	   to	   2008.	  
After	   randomization,	   20	   mmol	   of	   magnesium	  
sulphate	  was	  given	  over	  30	  minutes,	  followed	  by	  
infusion	  of	  80	  mmol/day,	  or	  equivalent	  volume	  of	  
saline,	  within	   48	  h	   after	   onset	   of	   symptoms	  and	  
continued	   for	   up	   to	   14	   days	   from	   the	   day	   of	  
haemorrhage.	   Mean	   time	   from	   ictus	   to	   start	   of	  
study	  drug	  infusion	  was	  32	  ±	  15	  (SD)	  hours.	  More	  
than	   90%	   of	   the	   patients	   completed	   at	   least	   10	  
days	   of	   study	   drug	   infusion.	   The	   randomization	  
was	  single-­‐blinded.	  The	  study	  aimed	  for	  a	  plasma	  
magnesium	  concentration	  in	  the	  treatment	  group	  
of	   twice	   the	   serum	  baseline	   level,	  but	  below	  2.5	  
mmol/L.	   Average	   serum	   magnesium	  
concentrations	  in	  the	  treatment	  group	  were	  1.67	  
±	   0.27	   mmol/L	   compared	   with	   0.91	   ±	   0.16	  
mmol/L	  in	  controls.	  	  
	  
The	   proportion	   of	   patients	   with	   a	   6-­‐month	  
favourable	   outcome,	   defined	   as	   an	   extended	  
Glasgow	  Outcome	  Scale	  of	  5	  to	  8,	  were	  similar	  for	  
both	   treatment	   groups	   (OR	   1.0;	   95%	  CI	   0.7-­‐1.6).	  
Also	   in	   the	   secondary	   outcome	   analyses,	   which	  
included	   incidence	  of	   clinical	   vasospasm,	  Barthel	  
Index,	  modified	   Rankin	   score,	  modified	   National	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velocities	   as	   measured	   by	   transcranial	   Doppler,	  
there	   were	   no	   significant	   differences	   between	  
the	  2	  groups.	  	  
	  
Although	   the	   study	   was	   underpowered,	   the	  
results	  do	  not	  support	  a	  significant	  clinical	  benefit	  
of	   magnesium	   therapy	   in	   SAH.	   Possible	  
explanations	   for	   the	   differences	   in	   results	  
between	   MASH-­‐1	   and	   IMASH	   are	   the	   assumed	  
predominant	   Asian	   origin	   of	   recruited	   patients	  
and	   the	   time	  window	  of	  administration;	   too	   late	  
or	   too	   short.	   In	   the	   MASH-­‐1	   study	   the	   median	  
start	   of	   treatment	   was	   28	   hours,	   and	   it	   was	  
continued	   for	   at	   least	   2	   weeks.	   On	   the	   other	  
hand,	   the	   achieved	   serum	   magnesium	  
concentration	  might	  have	  been	  too	  high,	  as	  in	  the	  
treatment	   group	   higher	   magnesium	   concen-­‐
trations	   were	   associated	   with	   a	   worse	   outcome	  
(Wong	   et	   al.,	   2010c).	   Furthermore,	   the	   average	  
serum	  magnesium	   concentration	   of	   0.91	   ±	   0.16	  
mmol/L	   in	   the	   control	   group	  was	  quite	  high	  and	  
could	  have	  diluted	  the	  results.	  
	  
Is	  there	  an	  optimal	  serum	  magnesium	  
concentration	  for	  neuroprotection?	  
In	   animal	  models	   of	   stroke,	   evidence	  was	   found	  
for	   a	   dose–response	   effect,	   with	   optimal	   serum	  
magnesium	  concentrations	  of	  approximately	  1.40	  
to	  1.50	  mmol/l	  (Marinov	  et	  al.,	  1996;	  Yang	  et	  al.,	  
2000;	  Miles	  et	  al.,	  2001).	  
	  
The	   mean	   serum	   magnesium	   level	   of	   1.47	  
mmol/L	  achieved	   in	  the	  MASH-­‐1	  study	  was	  close	  
to	  the	  proposed	  optimal	  serum	  magnesium	  level	  
for	  achieving	  maximal	  neuroprotection.	   In	  a	  sub-­‐
study	   performed	   in	   patients	   with	   a	   serum	  
magnesium	   concentration	   ≥	   1.10	   mmol/L,	   we	  
found	   no	   linear	   relationship	   between	   serum	  
magnesium	   levels	   and	   risk	   reduction	   for	   DCI	  
(Dorhout	   Mees	   et	   al.,	   2007a).	   Magnesium	  
sulphate	  therapy	  results	  in	  a	  stable	  risk	  reduction	  
of	   DCI	   over	   a	   broad	   range	   of	   achieved	   serum	  
magnesium	  concentrations,	  and	  strict	  titration	  of	  
the	   dosage	   therefore	   does	   not	   seem	   necessary,	  
although	   concentrations	   below	   1.28	   mmol/l	  
could	  decrease	  the	  effect	  on	  DCI.	   In	  contrast,	  no	  
such	   relationship	   was	   observed	   for	   poor	  
outcome.	   Risks	   tended	   to	   be	   higher	   in	   patients	  
with	   magnesium	   concentrations	   above	   the	   75th	  
percentile	   (1.62	   mmol/L)	   with	   an	   OR	   for	   poor	  
outcome	   of	   4.9	   (95%	   CI	   1.2	   to	   19.7)	   in	   patients	  
with	   a	   serum	   concentration	   above	   1.62	  mmol/L	  
compared	   to	   the	   lowest	   quartile	   (1.10-­‐1.28	  
mmol/L).	  
	  
The	  aim	  of	  the	  IMASH	  study	  to	  achieve	  a	  plasma	  
magnesium	   concentration	   of	   twice	   the	   serum	  
baseline	   level	   resulted	   in	   an	   average	   serum	  
magnesium	  concentration	  in	  the	  treatment	  group	  
of	   1.67	   ±	   0.27	  mmol/L,	  which	  might	   have	   had	   a	  
negative	  effect	  on	  clinical	  outcome.	  Of	  course,	  an	  
optimal	   neuroprotective	   concentration	   of	   serum	  
magnesium	  can	  only	  be	  validated	  if	  current	  large	  
trials	  show	  that	  magnesium	  therapy	  is	  effective.	  	  
	  
Systematic	  review	  and	  meta-­‐analysis	  
We	   assessed	   in	   a	   systematic	   review	   whether	  
magnesium	   decreases	   the	   occurrence	   of	  
secondary	   ischemia	   and	   poor	   outcome	   after	  
aneurysmal	   SAH.	   We	   sought	   to	   identify	   all	  
unconfounded	   clinical	   controlled	   trials	   with	  
magnesium	   in	   patients	   with	   aneurysmal	   SAH.	  
Trials	   were	   identified	   in	   the	   Stroke	   Group	   Trials	  
Register	   of	   the	   Cochrane	   Library,	   PUBMED	   and	  
MEDLINE.	  Outcome	  measures	  were	  DCI	  and	  poor	  
outcome.	   An	   estimate	   of	   the	   treatment	   effect	  
across	   trials	   was	   calculated	   with	   the	   Mantel-­‐
Haenszel	   method	   according	   to	   the	   intention-­‐to-­‐
treat	  principle.	  
	  
Between	   2002	   and	   2010,	   four	   non-­‐randomized	  
and	   eight	   randomized	   controlled	   trials	   on	  
magnesium	   were	   published,	   all	   but	   one	  
comparing	   magnesium	   therapy	   with	   placebo	   in	  
addition	   to	   nimodipine.	   The	   exception	   was	   a	  
small	   randomized	  controlled	   trial	   in	  104	  patients	  
that	   found	   similar	   outcomes	   in	   patients	   treated	  
with	   nimodipine	   versus	   patients	   treated	   with	  
magnesium	  (Schmid-­‐Elsaesser	  et	  al.,	  2006).	  When	  
the	   four	   non-­‐randomized	   studies	   are	   combined,	  
118	   patients	   with	   magnesium	   therapy	   were	  
compared	  with	   a	   historical	   control	   group	   of	   138	  
patients	  (Chia	  et	  al.,	  2002;	  Prevedello	  et	  al.,	  2006;	  
Stippler	  et	  al.,	  2006;	  Friedlich	  et	  al.,	  2009).	  When	  
the	   results	   are	   pooled,	   it	   all	   boils	   down	   to	   the	  
conclusion	  that	  a	  trend	  towards	  less	  symptomatic	  
vasospasm	  was	  found	  in	  favour	  of	  the	  treatment	  
group	   and,	   if	   provided,	   a	   positive	   effect	   with	   a	  
less	  extent	  on	  outcome.	  
	  
Seven	   trials	   totalling	   954	   patients	   were	   eligible	  
for	   the	   meta-­‐analyses	   [Table	   1]	   (Veyna	   et	   al.,	  
2002;	   van	   den	   Bergh	   et	   al.,	   2005;	   Wong	   et	   al.,	  
2006;	   Muroi	   et	   al.,	   2008;	   Westermaier	   et	   al.,	  
2010;	  Akdemir	  et	  al.,	  2010;	  Wong	  et	  al.,	  2010b).	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All	   used	   magnesium	   sulphate	   in	   addition	   to	  
nimodipine.	   The	   overall	   relative	   risk	   for	  DCI	  was	  
0.86	   (95%	   CI	   0.67-­‐1.11)	   (Figure	   1),	   and	   for	   poor	  
outcome	  0.89	  (95%	  CI	  0.78-­‐1.02)	  (Figure	  2).	  	  
	  
Headache	  
In	  patients	  with	  SAH,	  headache	  typically	  is	  severe,	  
usually	   lasts	   for	   1-­‐2	   weeks	   and	   often	   requires	  
treatment	  with	  opioids.	  Opioids,	  however,	  have	  a	  
wide	   range	   of	   potential	   side	   effects,	   which	  may	  
have	   a	   negative	   effect	   on	   patient	   comfort	   and	  
functional	  outcome.	  Blocking	  the	  NMDA	  receptor	  
is	   thought	   to	   be	   involved	   in	   pain	  modulation	   by	  
preventing	   the	   induction	   of	   central	   pain	  
sensitization.	   Several	   studies	   have	   reported	   that	  
magnesium	   reduces	   perioperative	   pain	   or	  
analgesic	   requirements.	   Headache	   relief	   would	  
be	   an	   important	   additional	   effect	   of	  magnesium	  
because	   this	   would	   reduce	   the	   need	   of	   opioids	  
with	   their	   potentially	   harmful	   side	   effects.	   In	   a	  
sub-­‐study	   of	   the	   MASH-­‐1	   trial	   we	   found	   that	  
magnesium	   treatment	   was	   associated	   with	   less	  
severe	  headache	  and	  less	  frequent	  use	  of	  opioids	  
(Dorhout	   Mees	   et	   al.,	   2010).	   These	   data	   imply	  
that	   intravenous	   magnesium	   therapy,	   besides	   a	  
supposed	   beneficial	   effect	   on	   outcome,	   also	  
provides	  pain	  relief	  for	  SAH	  patients.	  
	  
On-­‐going	  phase	  3	  clinical	  controlled	  trials	  
There	   is	   currently	   one	   on-­‐going	   phase	   3	   clinical	  
controlled	   trial	   evaluating	   the	   effect	   of	  
magnesium	   in	   SAH.	   The	   Magnesium	   in	  
Aneurysmal	   Subarachnoid	   Haemorrhage	   (MASH-­‐
II)	   study	   is	   a	   phase	   III	   randomized,	   clinical,	  
international	   multicentre	   trial	   that	   studies	   the	  
effect	   of	   magnesium	   sulphate	   after	   aneurysmal	  
SAH	  [ISRCTN68742385]	  (van	  der	  Bilt	  et	  al.,	  2009).	  
Study	   medication	   (64	   mmol/day	   magnesium	  
sulphate	   or	   placebo)	   is	   given	   via	   continuous	  
infusion	  within	  4	  days	  and	  until	  20	  days	  after	  the	  
haemorrhage.	  Outcome	  is	  determined	  with	  the	  
modified	   Rankin	   scale	   three	   months	   after	   the	  
haemorrhage.	   Analysis	   will	   be	   according	   to	   the	  
intention-­‐to-­‐treat	  principle.	  So	  far,	  in	  August	  2010,	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Figure	  1.	  Studies	  with	  magnesium	  in	  addition	  to	  nimodipine	  –	  effect	  on	  delayed	  cerebral	  ischemia.	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over	   1000	   patients	   have	   been	   included	   in	   6	  
Dutch,	  1	  UK,	  and	  1	  Chilean	  hospital.	  Based	  on	  the	  
results	   of	   the	   MASH-­‐1	   study	   sample	   size,	  
calculations	   indicate	   that	   1200	   patients	   are	  
needed	   to	   give	   a	   statistically	   significant	   result	  
(with	   α	   =	   5%	   and	   a	   power	   of	   80%).	   We	   aim	   to	  
include	  these	  patients	  before	  the	  end	  of	  2011.	  A	  
first	   interim	   analysis	   was	   performed	   after	   300	  
patients	  and	  the	  second	  and	  last	   interim	  analysis	  
was	   performed	   after	   recruitment	   and	   follow-­‐up	  
of	   750	   patients.	   At	   both	   interim	   analyses,	   the	  
Data	   Monitoring	   Committee	   gave	   unanimous	  




In	  conclusion,	  magnesium	  is	  a	  promising	  agent	  to	  
prevent	   the	   occurrence	   of	   delayed	   cerebral	  
ischemia	   and	   to	   improve	   outcome	   in	   patients	  
with	   SAH.	   Hence,	   at	   present,	   the	   evidence	   is	  
insufficient	   and	   larger	   randomized	   controlled	  
trials	   are	   needed	   to	   determine	   the	   safety	   and	  
efficacy	  of	  magnesium	  sulphate	  infusion	  before	  it	  
can	   be	   recommended	   for	   patients	   with	  
aneurysmal	  SAH.	  Currently,	  a	   large	  phase	   III	   trial	  
is	   being	   conducted	   that	   will	   hopefully	   provide	  
definite	  evidence	  whether	  magnesium	  treatment	  
is	  beneficial	  in	  SAH	  patients.	  
	  
In	   the	  meantime,	   it	   is	  probably	  wise	   to	  maintain	  
serum	  magnesium	  in	  the	  high-­‐normal	  range,	  e.g.	  
0.8-­‐1.0	   mmol/l,	   after	   SAH	   to	   prevent	   the	  
hypomagnesaemia	   associated	   neurological	   and	  
cardiac	   complications.	   Magnesium	   therapy	   can	  
be	  considered	  as	  a	  safe	  alternative	  for	  morphine	  
in	  the	  treatment	  of	  headache.	  In	  case	  magnesium	  
therapy	   is	   considered	   as	   a	   remedy	   to	   improve	  
outcome,	   target	   serum	   magnesium	   levels	   are	  
probably	   around	   1.4	   mmol/l	   and	   better	   not	  
exceed	  1.6	  mmol/l.	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Stroke	  is	  the	  second	  leading	  cause	  of	  death	  and	  a	  leading	  cause	  of	  disability	  worldwide.	  Unfortunately,	  
current	   therapies	   for	   acute	   ischemic	   stroke	   are	   of	   extremely	   limited	   effectiveness.	   The	   ideal	   neuro-­‐
protective	   agent	   for	   stroke	   would	   be	   inexpensive,	   readily	   available,	   easy	   to	   administer	   and	   have	   no	  
significant	  adverse	  side	  effects.	  	  Intravenous	  magnesium	  sulphate	  offers	  promise	  as	  just	  such	  an	  agent.	  In	  
clinical	   trials	   to	   date,	   administration	   of	   magnesium	   sulphate	   has	   shown	   favourable	   trends	   toward	  
neuroprotection	   in	   resuscitated	   cardiac	   arrest	   patients,	   in	   cardiac	   bypass	   surgery	   and	   carotid	  
endarterectomy.	   In	   acute	   stroke,	   eight	   pilot	   clinical	   trials	   of	   magnesium	   sulphate	   have	   shown	   good	  
safety,	  and	  the	  subset	  of	  pilot	  trials	  with	  randomized	  controls	  have	  shown	  favourable	  effects	  on	  clinical	  
outcome	   point	   estimates.	   The	   first	   phase	   3	   trial	   of	   magnesium	   sulphate	   for	   focal	   stroke	   was	   the	  
Intravenous	  Magnesium	  Efficacy	  in	  Stroke	  (IMAGES)	  Trial.	  Hampered	  by	  late	  administration	  of	  the	  study	  
agent,	   IMAGES	   overall	   produced	   a	   neutral	   result,	   but	   exploratory	   analyses	   identified	   early	   (under	   3	  
hour),	   	   lacunar	   stroke,	   haemorrhagic	   stroke,	   and	   severely	   hypertensive	   patients	   as	   having	   a	   potential	  
differential	   beneficial	   response	   to	   magnesium	   that	   deserved	   further	   investigation.	   The	   Field	  
Administration	  of	  Stroke	  Therapy	  –	  Magnesium	  (FAST-­‐MAG)	  trial	  has	  been	  specifically	  designed	  to	   test	  




Stroke	  is	  the	  second	  leading	  cause	  of	  death	  and	  a	  
leading	   cause	   of	   disability	   worldwide	   (Lopez	   et	  
al.,	   2006).	   More	   than	   5.3	   million	   individuals	   die	  
from	  a	  stroke	  each	  year,	  and	  many	  more	  survive	  
with	   permanent	   incapacities.	   One	   in	   six	  
individuals	  worldwide	  will	  suffer	  a	  stroke	  in	  their	  
lifetime	   (Kaste	  et	   al.,	   2010).	   In	  Western	   nations,	  
ischemic	   cerebral	   infarctions	   account	   for	   about	  
80%	  of	  strokes,	  intracerebral	  haemorrhages	  15%,	  
and	  subarachnoid	  haemorrhages	  4%.	  	  
	  
Unfortunately,	   current	   therapies	   for	   acute	  
ischemic	   stroke	   are	   of	   extremely	   limited	  
effectiveness.	   To	   date,	   the	   only	   United	   States	  
Food	   and	   Drug	   Administration	   (FDA)-­‐approved	  
pharmacologic	   treatment	   for	   acute	   ischemic	  
stroke	   remains	   intravenous	   tissue	   plasminogen	  
activator	   (tPA),	  a	  thrombolytic	  agent	  which	  must	  
be	   administered	   within	   3	   hours	   of	   symptom	  
onset,	  and	  only	  after	  neuroimaging	  has	  ruled	  out	  
intracerebral	   haemorrhage	   (Adams	  et	   al.,	   2007).	  
tPA	  carries	  significant	  bleeding	  risks,	  is	  costly,	  and	  
is	   not	   being	   used	   in	  most	   acute	   stroke	   patients.	  
Current	   estimates	   are	   that	   only	   3-­‐8%	   of	   acute	  
ischemic	   stroke	   patients	   in	   the	   US	   receive	   tPA	  
(California	   Acute	   Stroke	   Pilot	   Registry	   (CASPR)	  
Investigators,	   2005;	   	   Reeves	   et	   al.,	   2005).	   The	  
only	  other	  pharmacologic	  agent	  of	  proven	  utility	  
in	  acute	   ischemic	  stroke	   is	  aspirin,	  which	  confers	  
only	   minimal	   benefit,	   helping	   only	   one	   of	   every	  
77	   patients	   treated	   (Sandercock	   et	   al.,	   2008).	  
Mechanical	   embolectomy	   devices	   have	   been	  
developed	   and	   approved	   for	   the	   technical	  
indication	   of	   removing	   acute	   thrombi	   from	   the	  
cerebral	   vasculature,	   but	   have	   not	   yet	   been	  
demonstrated	   in	   a	   randomized	   clinical	   trial	   to	  
improve	   patient	   outcome	   and	   are	   employed	   in	  
only	   a	   tiny	   fraction	   of	   stroke	   patients	   nationally	  
(Smith	  et	  al.,	  2008;	  The	  Penumbra	  Pivotal	  Stroke	  
Trial	   Investigators,	   2009).	   New,	   effective,	   widely	  
applicable	   treatments	   for	   acute	   ischemic	   stroke	  
are	  desperately	  needed.	  
	  
Magnesium	  sulphate:	  a	  highly	  promising	  
neuroprotective	  therapy	  for	  stroke	  
	  
When	   focal	   occlusions	   disrupt	   blood	   flow	   to	   the	  
brain,	   a	   cascade	   of	   molecular	   events	   producing	  
cell	   injury	   ensues	   (Schaller	   and	   Graf,	   2004;	  
Obrenovitch,	   1995).	   Cell	   death	   proceeds	   rapidly	  
in	   the	   infarct	   core,	   where	   blood	   flow	   is	   most	  
drastically	   curtailed,	   but	   more	   slowly	   in	   the	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ischemic	  penumbra,	  where	  blood	  flow	  is	  variably	  
reduced	   and	   molecular	   elaboration	   of	   neuronal	  
injury	   may	   proceed	   over	   3-­‐12	   hours	   or	   more.	  
Central	  molecular	  events	  in	  the	  ischemic	  cascade	  
include	   accumulation	   of	   intracellular	   calcium,	  
release	   of	   excitatory	   amino	   acid	   neuro-­‐
transmitters,	   generation	   of	   oxygen	   free	   radicals,	  
nitric	   oxide	   formation,	   and	   the	   release	   of	  
cytokines	   by	   infiltrating	   polymorphonuclear	  
leukocytes.	   These	   and	   additional	   events	   afford	  
numerous	   targets	   for	  pharmacologic	  blockade.	  A	  
multitude	   of	   neuroprotective	   drugs	   interfering	  
with	   various	   pathways	   of	   ischemic	   injury	  
substantially	  reduce	  infarct	  volume	  in	  focal	  stroke	  
animal	   models	   when	   administered	   10-­‐120	  
minutes	  after	  ischemia	  onset,	  including	  excitatory	  
amino	   acid	   antagonists,	   oxygen	   free	   radical	  
scavengers,	  and	  voltage	  sensitive	  calcium	  channel	  
blockers	  (Green	  and	  Shuaib,	  2006).	  
	  
The	  ideal	  neuroprotective	  agent	  for	  stroke	  would	  
be	   inexpensive,	   readily	   available,	   easy	   to	  
administer	   and	   have	   no	   significant	   adverse	   side	  
effects.	   An	   agent	   demonstrated	   to	   be	   safe	   and	  
potentially	   beneficial	   in	   both	   ischemic	   and	  
haemorrhagic	   stroke	   would	   have	   the	   added	  
benefit	  of	  potentially	  earlier	  administration	  prior	  
to	   obtaining	   a	   head	   CT	   or	   brain	   MRI	   scan.	  
Intravenous	  magnesium	   sulphate	   offers	   promise	  
as	  just	  such	  an	  agent.	  
	  
Laboratory	   studies	   have	   identified	   multiple	  
neuronal	  and	  vascular	  effects	  of	  magnesium	  that	  
likely	   contribute	   to	   the	   potent	   neuroprotective	  
effects	   observed	   in	   stroke	   models	   (Muir,	   2000).	  	  
In	   a	  wide	   variety	   of	   in	   vitro	   systems	   and	   animal	  
models,	  magnesium	  has	  been	   shown	   to	  produce	  
cerebral	   arteriolar	   vasodilation	   and	   increased	  
cerebral	  blood	  flow,	  inhibit	  presynaptic	  release	  of	  
excitatory	   neurotransmitters,	   noncompetitively	  
block	   the	   N-­‐methyl-­‐D-­‐aspartate	   (NMDA)	  
receptor,	   presynaptically	   potentiate	   adenosine,	  
block	   voltage-­‐gated	   calcium	   channels,	   suppress	  
cortical	   spreading	   depression	   and	   anoxic	  
depolarizations,	   relax	   vascular	   smooth	   muscle	  
resulting	   in	   vasodilation	   of	   large	   and	   small	  
vascular	  beds	  and	   increased	  cerebral	  blood	  flow,	  
antagonize	   endothelin-­‐1	   and	   other	   vaso-­‐
constrictors,	   and	   replete	   an	   underlying	   and/or	  
ischemia-­‐induced	  Mg	  deficient	  state.	  Magnesium	  
ions	   cross	   the	   intact	   blood-­‐brain	   barrier	  
efficaciously	   so	   that	   intravenous	   magnesium	  
sulphate	   significantly	   raises	   cerebrospinal	   fluid	  
and	   brain	   extracellular	   fluid	   magnesium	   to	  
supraphysiologic	   levels	   (Thurnau	   et	   al.,	   1987;	  
Wester	   et	   al.,	   1984).	   The	   brain	   penetration	   of	  
magnesium	   may	   increase	   even	   further	   in	  
ischemic	  regions	  where	  the	  blood-­‐brain	  barrier	  is	  
disrupted	   (Sjostrom	   and	   Wester,	   1994).	  
Magnesium	   sulphate	   is	   neuroprotective	   in	  
preclinical	   models	   of	   cerebral	   and	   spinal	   cord	  
ischemia,	   excitotoxic	   injury,	   and	   head	   trauma.	  
Magnesium	  (Mg)	   is	  economical,	  widely	  available,	  
simple	   to	   administer	   and	   has	   a	   long	   established	  
safety	   and	   tolerability	   profile	   in	   myocardial	  
infarction	   and	   eclampsia,	   as	   well	   as	   in	   initial	  
human	  focal	  stroke	  studies.	  Unlike	  most	  synthetic	  
neuroprotective	   compounds,	   parenteral	  
magnesium	  has	  no	  major	  adverse	  effects	  in	  doses	  
that	   achieve	   serum	   levels	   in	   the	   range	   of	  
preclinical	  neuroprotective	  concentrations.	  
	  
Magnesium	   is	   neuroprotective	   in	   rodent	  models	  
of	   reversible	   and	   permanent	   focal	   cerebral	  
ischemia.	   In	   contrast	   to	   commercially-­‐supported	  
neuroprotective	  compounds,	  magnesium	  has	  not	  
been	   the	   subject	   of	   a	   systematic	   preclinical	  
development	   program.	   However,	   academic	  
investigations	   have	   demonstrated	   benefits	   in	  
diverse	  models	  and	   laboratories,	   satisfying	  a	  key	  
criterion	   of	   stroke	   drug	   development	   guidelines	  
often	  not	  met	  by	  commercially-­‐supported	  agents	  
(Stroke	   Therapy	   Academic	   Industry	   Roundtable	  
(STAIR),	   1999).	   At	   least	   nine	   preclinical	   studies	  
(eight	   reported)	   have	   examined	   the	   effect	   of	  
systemic	   magnesium	   sulphate	   upon	   final	   infarct	  
size	  in	  animal	  focal	  ischemic	  stroke	  models	  (Muir,	  
2000;	   2001).	   Eight	   of	   the	   nine	   demonstrated	  
substantial	   decreases	   in	   infarct	   size	   in	   treated	  
animals,	  with	   reductions	   ranging	   from	  26-­‐61%	   in	  
unconfounded	   studies.	   A	   recent	   study	  
demonstrated	   synergistic	   effects	   of	   magnesium	  
when	   combined	   with	   antioxidant	   and	  
hypothermic	   therapies	   in	   a	   rat	   MCAO	   stroke	  
model,	  suggesting	  that	  magnesium	  is	  a	  promising	  
first	   agent	   upon	   which	   to	   build	   a	   combination	  
neuroprotection	  regimen	  (Scholler	  et	  al.,	  2004).	  
	  
Clinical	  trials	  of	  magnesium	  sulphate	  in	  diverse	  
settings	  of	  acute	  cerebral	  ischemia	  
	  
Uniquely	   among	   neuroprotective	   agents	   being	  
developed	   for	   focal	   stroke,	  magnesium	   sulphate	  
has	   shown	   signals	   of	   potential	   efficacy	   in	  
numerous	  controlled	  clinical	  trials	  in	  closely	  allied	  
settings	   of	   acute	   human	   cerebral	   ischemia,	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including	   1)	   delayed	   cerebral	   infarction	   after	  
subarachnoid	  haemorrhage,	  2)	  newborn	  hypoxic-­‐
ischemic	   injury,	   3)	   global	   cerebral	   ischemia	  after	  
cardiac	  arrest,	  and	  4)	  ischemic	  brain	  injury	  during	  
cardiac	   and	   cerebrovascular	   surgical	   procedures.	  	  
For	  detailed	  review	  of	  the	  first	  setting,	  the	  reader	  
is	  referred	  to	  Chapter	  14	  in	  this	  volume.	  We	  here	  
briefly	  survey	  the	  clinical	  trial	  experience	  with	  the	  
latter	  two	  conditions.	  	  
	  
Global	  cerebral	  ischemia	  after	  cardiac	  arrest	  
Paramedic,	   field-­‐administration	   of	   magnesium	  
sulphate	   showed	   favourable	   trends	   toward	  
neuroprotection	   in	   resuscitated	   cardiac	   arrest	  
patients	   in	   the	   Brain-­‐Cardiopulmonary	  
Resuscitation	   (B-­‐CPR)	   trial	   (Longstreth	   et	   al.,	  
2002).	   	   The	   B-­‐CPR	   trial	   tested	   magnesium	  
sulphate	   and	   diazepam	   in	   a	   2	   x	   2	   factorial,	  
placebo-­‐controlled	   design.	   Paramedic	   personnel	  
injected	   study	   medications	   to	   out-­‐of-­‐hospital	  
cardiac	   arrest	   patients	   immediately	   following	  
return	  of	  spontaneous	  circulation.	  Three	  hundred	  
patients	   were	   randomized	   to	   intravenous	  
magnesium	   sulphate	   (2	   g)	   or	   matching	   placebo,	  
and	   then	   to	   diazepam	   (10	   mg)	   or	   matching	  
placebo.	   The	   pre-­‐specified	   primary	   outcome	  
measure	   was	   awakening,	   defined	   as	   having	  
comprehensible	   speech	   or	   following	   commands.	  
The	   study	   was	   powered	   to	   detect	   only	   a	  
substantial	  treatment	  effect	  –	  absolute	  difference	  
in	   the	  primary	  endpoint	  of	  20%.	  The	  magnesium	  
sulphate	   group	   showed	   a	   trend	   toward	   efficacy,	  
with	   46.7%	   awakening	   among	   those	   who	  
received	   only	   magnesium	   versus	   37.3%	   among	  
those	  who	  received	  only	  placebo	   (risk	  difference	  
9.3%,	  CI	  -­‐6.4	  to	  25.1%).	  In	  contrast,	  the	  diazepam	  
group	   showed	   no	   evidence	   of	   treatment	   effect.	  
No	   adverse	   effects	   of	   prehospital	   administration	  
of	  magnesium	  sulphate	  therapy	  were	  noted	  
	  
Brain	  ischemic	  during	  surgical	  procedures	  
The	   operative	   setting	   uniquely	   allows	   the	  
administration	   of	   neuroprotective	   agents	   to	  
occur	   prior	   to	   the	   onset	   of	   ischemia,	   when	  
benefit	   will	   be	   greatest.	   Individual	   randomized	  
controlled	   trials	   have	   suggested	   benefits	   of	  
magnesium	   sulphate	   for	   neuroprotection	   in	  
cardiac	   bypass	   surgery	   and	   carotid	  
endarterectomy.	  	  
	  
In	  on-­‐pump,	  coronary	  artery	  bypass	  graft	  surgery,	  
neuropsychological	   dysfunction	   occurs	   in	   up	   to	  
50-­‐80%	   of	   patients	   at	   the	   time	   of	   discharge,	  
related	   in	  part	   to	   intra-­‐operative	  brain	   ischemia.	  
The	   Cleveland	   Clinic	   trial	   randomized	   350	  
patients	   undergoing	   elective	   cardiac	   bypass	  
surgery	  to	  magnesium	  sulphate	  or	  placebo	  during	  
the	   operation	   and	   for	   the	   first	   24	   hours	  
postoperatively.	   Patients	   received	   a	   2	   g	   loading	  
dose	   and	   subsequent	   titration	   of	   a	   continuous	  
infusion	   to	  maintain	   serum	  magnesium	   levels	   at	  
twice	   normal.	   Magnesium	   exerted	   a	   benefit	   on	  
early	   cognitive	   function.	   On	   the	   study’s	   primary	  
endpoint	   of	   neurologic	   decline	   or	   neurologic	  
death	   at	   96	   hours	   post-­‐operatively,	   magnesium	  
patients	   outperformed	   placebo	   (p=0.01)	   (Bhudia	  
et	  al.,	  2006).	  By	  3	  months	  post-­‐operatively,	  there	  
were	   no	   performance	   differences	   between	  
groups,	  possibly	   reflecting	  a	   test	  ceiling	  effect	  as	  
placebo	  patients	  improved.	  
	  
In	  carotid	  endarterectomy,	  cerebral	  ischemia	  due	  
to	   intraoperative	   hypoperfusion	   and	  microembolic	  
events	   produces	   clinical	   deficits	   evident	   on	  
detailed	   neurocognitive	   testing.	   Standardized	  
neuropsychometric	  evaluation	  has	  demonstrated	  
cognitive	   decline	   in	   up	   to	   25%	   of	   patients	  
undergoing	   carotid	   surgery.	   The	   Columbia	  
University	   trial	   randomly	   assigned	   108	   patients	  
undergoing	  carotid	  surgery	  to	  placebo	  infusion	  or	  
one	   of	   three	   magnesium	   sulphate	   dose	   tiers	  
(Mack	  et	  al.,	  2009).	  The	  highest	  magnesium	  dose	  
tier	  was	  a	  4	  g	  loading	  dose	  followed	  by	  16	  g	  over	  
the	   next	   24	   hours.	  On	   a	   neuropsychological	   test	  
battery	   the	   day	   after	   surgery,	   patients	   treated	  
with	   intravenous	   magnesium	   infusion	  
demonstrated	   less	   postoperative	   neurocognitive	  
impairment	  than	  those	  treated	  with	  placebo	  (OR	  
0.27,	  95%	  CI	  0.10–0.74,	  p	  =	  0.01).	  	  
	  
Pilot	  clinical	  trials	  of	  magnesium	  sulfate	  in	  focal	  
stroke	  
	  
There	   have	   been	   eight	   pilot	   clinical	   trials	   of	  
magnesium	   sulphate	   in	   acute	   stroke,	   exploring	  
dose	   optimization,	   feasibility,	   safety,	   and	   signals	  
of	  efficacy.	  Among	  these,	  6	  were	  randomized	  and	  
2	  uncontrolled.	  	  All	  showed	  good	  safety	  with	  each	  
randomized	   controlled	   trial	   (RCT)	   showing	  
favourable	   effects	   on	   clinical	   outcome	   point	  
estimates	   (Wester	   et	   al.,	   1984;	   Muir	   and	   Lees,	  
1995;	  Muir	   and	   Lees,	   1998;	   Galeas	   et	   al.,	   1998;	  
Bradford	  et	  al.,	  1998;	  Lampl	  et	  al.,	  2001;	  Saver	  et	  
al.,	   2002;	   Muir	   et	   al.,	   2004).	   A	   meta-­‐analysis	   of	  
the	   four	   phase	   2	   RCTs	   with	   combinable	   data	  
(total	  of	  162	  patients)	  found	  a	  favourable	  clinical	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outcome	  trend,	  with	  late	  disability	  or	  death	  seen	  
in	   44.3%	   of	   magnesium	   sulphate	   patients	  
compared	   with	   52.7%	   of	   placebo	   patients	   (OR	  
0.67,	  95%	  CI,	  0.35-­‐1.26)	  (Muir,	  2001).	  
	  
The	  pilot	   trial	   that	  optimized	  a	  dose	   regimen	   for	  
subsequent	   phase	   3,	   pivotal	   trials	   was	   the	   dose	  
ranging	  study	  reported	  by	  Muir	  and	  Lees	   (1998).	  
They	  sought	  a	  regimen	  that	  efficiently	  and	  safely	  
achieved	   a	   doubling	   of	   the	   serum	   magnesium	  
concentration.	  This	  target	  was	  selected	  as	  serum	  
concentrations	   of	   3.48	   mEq/L	   and	   above	   had	  
been	   neuroprotective	   in	   preclinical	   models	   of	  
focal	   cerebral	   ischemia,	   and	   doubling	   of	   serum	  
concentrations	   was	   known	   to	   be	   efficacious	   in	  
the	   prophylaxis	   and	   treatment	   of	   seizures	   in	  
preeclamptic	   and	   eclamptic	   women	   (the	   normal	  
range	   for	   serum	  magnesium	   is	  1.4	  –	  1.7	  mEq/L).	  
They	  randomized	  25	  patients	  to	  placebo	  or	  one	  of	  
three	   magnesium	   sulphate	   dose	   schedules:	  
loading	   infusions	   of	   8,	   12,	   or	   16	   mmol,	   all	  
followed	   by	   a	  maintenance	   infusion	   of	   65	  mmol	  
over	   24	   hours.	   All	   dose	   tiers	   were	   found	   safe,	  
with	   no	   major	   effects	   on	   heart	   rate,	   blood	  
pressure,	   blood	   glucose,	   or	   other	   physiologic	  
variables.	  Serum	  magnesium	  concentrations	  rose	  
to	   target	   levels	   most	   rapidly	   in	   the	   highest	  
loading	  infusion	  group	  and	  were	  maintained	  in	  all	  
groups	  for	  at	   least	  24	  hours.	  The	  highest	   loading	  
dose	  infusion	  regimen	  was	  therefore	  identified	  as	  
safe	   and	   most	   efficient,	   and	   taken	   forward	   to	  
later	  phase	  clinical	  trials.	  	  	  
	  
A	   distinctive	   pilot	   trial	   was	   undertaken	   to	  
demonstrate	   the	   feasibility	   and	   safety	   of	   having	  
paramedics	   initiate	   magnesium	   sulphate	   in	   the	  
field,	   prior	   to	   hospital	   arrival.	   Magnesium	  
sulphate’s	   properties	   make	   it	   a	   particularly	  
attractive	   agent	   to	   study	   in	   the	   prehospital	  
setting	   (Table	   1).	   In	   the	   Field	   Administration	   of	  
Stroke	   Therapy	   –	   Magnesium	   (FAST-­‐MAG)	   Pilot	  
Trial,	   the	   primary	   prespecified	   feasibility	   trial	  
endpoint	   was	   reduction	   in	   time	   interval	   from	  
paramedic	  arrival	  on	  scene	  to	  start	  of	  study	  agent	  
infusion,	  compared	  with	  a	  historical	  control	  group	  
of	   ambulance-­‐arriving	   patients	   enrolled	   in	  
standard	   post-­‐hospital	   arrival	   fashion	   in	   acute	  
neuroprotective	  trials	  (Saver	  et	  al.,	  2004).	  Twenty	  
patients	   were	   enrolled,	   all	   receiving	   active	  
therapy	   of	   a	   4	   g	   loading	   dose	   initiated	   by	  
paramedics	   in	   the	   field,	   followed	   by	   a	   16	   g	  
maintenance	  infusion	  administered	  upon	  hospital	  
arrival.	   Substantially	   more	   rapid	   initiation	   of	  
neuroprotective	   therapy	   was	   found	   with	   field	  
administration	   versus	   historic	   controls,	   with	   the	  
mean	  interval	  from	  paramedic	  arrival	  on	  scene	  to	  
initiation	  of	  study	  drug	  being	  23	  minutes	  in	  field-­‐
initiation	   patients	   vs	   141	   minutes	   in	   hospital-­‐
initiated	   patients	   (p<0.0001).	   Experimental	  
neuroprotective	   therapy	   was	   started	   2	   hours	  
earlier	   as	   a	   result	   of	   the	   strategy	   of	   prehospital	  
initiation	  of	  therapy.	  
	  
The	   pharmacologic	   efficacy	   of	   field	  
administration	   in	   the	   FAST-­‐MAG	   Pilot	   Trial	   was	  
assessed	   by	   measuring	   the	   serum	   magnesium	  
level	   10	   minutes	   after	   completion	   of	   the	   bolus	  
loading	   dose.	   In	   the	   19	   patients	   completing	   the	  
loading	  dose,	  post	  bolus	  serum	  magnesium	  levels	  
were	   mean	   3.6	   mEq/L	   (range	   2.4-­‐5),	  
	  
	  
Table	  1.	  Properties	  of	  Magnesium	  Sulphate	  Advantageous	  for	  Prehospital	  Study	  	  
Magnesium	  Sulphate	  	  Properties	   Import	  for	  Prehospital	  Trial	  
Stable	  at	  room	  temperature	   • Can	  be	  stored	  in	  rescue	  vehicles	  
No	  major	  antithrombotic	  effects	   • Can	  be	  used	  in	  ischemic	  and	  haemorrhagic	  stroke	  
• May	  be	  started	  in	  ambulance	  prior	  to	  CT	  or	  MR	  scan	  
Loading	  intravenous	  dose	  quickly	  
achieves	  target	  blood	  levels	  	  
• Paramedics	  can	  efficiently	  initiate	  through	  standard	  
field	  intravenous	  line	  
Well-­‐established	  safety	  record	  in	  
clinical	  practice	  
• Extensive	  monitoring	  not	  required	  
Neuroprotective	  in	  multiple	  stroke	  
models	  	  
• Promising	  agent	  for	  efficacy	  study	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demonstrating	   successful	   achievement	   of	   target	  
supraphysiologic,	   neuroprotective	   levels	   of	  
magnesium	   sulphate	   in	   all	   patients	   completing	  
the	   loading	   dose.	   These	   results	   of	   paramedic	  
loading	  dose	  administration	  were	  comparable	   to	  
those	   of	   standard	   in	   hospital	   loading	   dose	  
administration	   in	   the	   dose-­‐optimization	   clinical	  
trial	  of	  Muir	  and	  Lees	  (1998).	  	  
	  
Safety	   and	   exploratory	   efficacy	   endpoints	   in	   the	  
FAST-­‐MAG	  Pilot	   trial	  were	   encouraging.	  No	  drug	  
related	   serious	   major	   adverse	   event	   was	  
observed.	  	  Although	  conclusions	  derived	  from	  an	  
open-­‐label,	   small	   pilot	   trial	   must	   be	   extremely	  
guarded,	   clinical	   efficacy	   suggested	   potential	  
beneficial	   treatment	   effects.	   Dramatic	   early	  
recovery,	   defined	   as	   complete	   recovery	   or	  
improvement	   by	   10	   or	   more	   points	   on	   the	  
National	   Institute	   of	  Health	   Stroke	   Scale	   (NIHSS)	  
by	   24	   hours,	   occurred	   in	   27%	  of	   cerebral	   infarct	  
patients.	   This	   response	   compares	   quite	  
favourably	  with	   rates	   of	   dramatic	   early	   recovery	  
noted	   in	   the	   NINDS-­‐tPA	   Trial	   1	   placebo	   group	  
(12%)	   and	   approximates	   the	   treatment	   effect	   of	  
tPA	   in	   yielding	   dramatic	   early	   recovery	   in	   the	  
NINDS-­‐tPA	  Trial	  1	  (27%)	  (Haley	  et	  al.,	  1997).	  
	  
IMAGES	  phase	  3	  trial	  
	  
The	  first	  phase	  3	  trial	  of	  magnesium	  sulphate	  for	  
focal	   stroke	   was	   the	   Intravenous	   Magnesium	  
Efficacy	   in	   Stroke	   (IMAGES)	   trial	   (Muir	   et	   al.,	  
2004).	   Funded	   by	   the	   British	   Medical	   Research	  
Council,	   IMAGES	   was	   an	   international	   trial	   that	  
enrolled	   2589	   patients	  within	   12	   hours	   of	   onset	  
to	  receive	  4	  g	  magnesium	  sulphate	  bolus	  followed	  
by	   16.25	   g	   magnesium	   sulphate	   maintenance	  
infusion	  over	  24	  hours	  or	  matched	  placebo.	  	  
	  
The	   performance	   of	   IMAGES	   demonstrated	   a	  
worldwide	  consensus	  that	  magnesium	  sulphate	  in	  
focal	   human	   stroke	   shows	   robust	   promise	   and	  
merits	  phase	  3	  trial	   testing.	  However,	   the	  design	  
of	   IMAGES	   had	   a	   critical	   drawback	   common	  
among	  trials	  of	  its	  era:	  a	  late	  enrollment	  window.	  
IMAGES	   permitted	   enrollment	   of	   patients	   up	   to	  
12	   hours	   after	   symptom	   onset,	   well	   after	  
ischemic	  injury	  has	  already	  reached	  completion	  in	  
many	   patients.	   Additionally,	   IMAGES	   required	  
that	   a	   patient’s	   deficit	   be	   persistent	   for	   at	   least	  
one	   hour	   before	   enrollment	   could	   occur,	  
precluding	   agent	   initiation	   within	   the	   first	   60	  
minutes	  of	  onset	  in	  the	  trial.	  	  
The	  IMAGES	  trial	  overall	  had	  a	  neutral	  result,	  but	  
trial	   data	   suggest	   that	   the	   nonpositive	   outcome	  
may	   have	   been	   due	   to	   late	   administration	   of	  
study	   agent.	   The	   primary	   efficacy	   endpoint	   in	  
IMAGES	   was	   death	   and	   disability	   at	   3	   months,	  
identified	   by	   the	   joint	   binary	   outcome	   of	  
outcome	  of	   a	  Barthel	   score	  <	  95	  and	  a	  modified	  
Rankin	   score	   >	   1.	   On	   this	   endpoint,	   the	   point	  
estimate	   favouring	   magnesium	   did	   not	   reach	  
statistical	   significance	   (OR	   0.95,	   95%	   CI	   0.80-­‐
1.13).	   	  However,	   the	   vast	  majority	  of	  patients	   in	  
IMAGES	   were	   enrolled	   late	   after	   stroke	   onset.	  
Median	   time	   to	   treatment	   was	   7	   hours.	   The	  
single	   hour	   with	   a	   plurality	   of	   enrolled	   patients	  
was	  hour	  12.	  Only	  71	  patients	  (3.1%	  of	  the	  entire	  
IMAGES	   cohort)	  were	  enrolled	  within	  3	  hours	  of	  
onset,	   only	   16	   patients	   (0.6%)	   were	   enrolled	  
within	   2	   hours,	   and	   no	   patients	   were	   enrolled	  
within	  1	  hour.	  	  
	  
IMAGES	   generally	   confirmed	   the	   safety	   of	  
magnesium	   sulphate	   administration	   in	   acute	  
stroke.	   No	   statistically	   significant	   differences	  
were	  noted	  in	  time	  to	  first	  serious	  adverse	  event	  
or	   to	  mortality.	  Nominal	   differences	   in	  mortality	  
did	   not	   reach	   statistical	   significance	   (OR	   1.22,	  
95%	   CI	   0.98-­‐1.53)	   and	   no	   individual	   causes	   of	  
death	   were	   in	   excess	   in	   the	   magnesium	   group.	  
Mild	   cardiovascular	   effects	   of	   magnesium	   were	  
observed,	   as	   expected.	   Magnesium	   slightly	  
reduced	  the	  blood	  pressure	  during	   the	  period	  of	  
infusion,	   on	   average	   by	   4	   points	   systolic	   and	   3	  
points	  diastolic.	  This	  reduction	  disappeared	  by	  24	  
hous	  after	  the	  end	  of	  the	  infusion.	  Heart	  rate	  was	  
minimally	   reduced	  at	  12	  hours	   into	   the	   infusion,	  
but	   not	   at	   other	   time	   points.	   No	   increase	   in	  
clinically	   reported	   hypotension,	   cardiac	   failure,	  
cardiac	   conduction	   block,	   or	   flushing	   was	  
reported	  n	  the	  magnesium	  group.	  	  
	  
Exploratory	   analyses	   in	   IMAGES	   identified	   four	  
patient	   subgroups	   with	   potential	   differential	  
beneficial	   response	   to	   magnesium	   that	   deserve	  
further	   investigation:	   1)	   lacunar	   stroke,	   2)	  
haemorrhagic	   stroke,	   3)	   severely	   hypertensive	  
patients,	   and	   4)	   early,	   under	   3	   hour,	   treated	  
patients.	   Among	   765	   patients	   with	   lacunar	  
syndromes,	   unfavourable	   outcomes	   were	   less	  
common	  in	  the	  treatment	  group,	  OR	  0.70	  (0.53-­‐	  
0.92)	   (Aslanyan	  et	   al.,	   2007).	   This	   observation	   is	  
intriguing	   in	   light	   of	   in	   vitro	   models	   indicating	  
that	   magnesium	   has	   biological	   protective	  
activities	   in	  white	  matter	   ischemia	   (Lecrux	  et	  al.,	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2008).	   Among	   1193	   patients	   with	   initial	   blood	  
pressures	   higher	   than	   the	   trial	   median,	  
unfavourable	   outcomes	   also	   were	   less	   common	  
in	   treated	  patients	   (OR	  0.78,	   0.61-­‐0.99)	   (Muir	  et	  
al.,	   2004).	   The	   optimal	   treatment	   of	   elevated	  
blood	  pressure	  in	  acute	  stroke	  remains	  uncertain;	  
it	   is	   possible	   that	   the	   slight	   antihypertensive	  
action	   of	   magnesium	   sulphate	   was	   beneficial	   in	  
these	   patients,	   in	   addition	   to	   neuroprotective	  
actions.	  While	   ischemic	  stroke	  patients	  were	   the	  
primary	   target	   of	   IMAGES,	   7%	   of	   enrolled	  
patients	  had	  primary	  supratentorial	   intracerebral	  
haemorrhages.	   Among	   these	   168	   patients,	   the	  
OR	   for	   an	   unfavorable	   outcome	   was	   nominally	  
lower	   among	   magnesium-­‐treated	   patients:	   0.84	  
(0.41-­‐1.74)	   (Muir	   et	   al.,	   2004).	   Primary	  
haemorrhage	  patients	   are	   another	   group	  among	  
whom	   mild	   antihypertensive	   effects,	   as	   well	   as	  
neuroprotective	  effects,	  could	  be	  beneficial.	  	  
	  
Few	  patients	  were	  enrolled	  in	  IMAGES	  in	  the	  first	  
three	   hours	   after	   stroke	   onset,	   the	   time	   period	  
when	  acute	  stroke	  treatments	  are	  most	  effective;	  
however,	   among	   these	   patients,	   results	   were	  
quite	  encouraging.	  There	  are	  not	  enough	  under	  1	  
or	   under	   2	   hour	   patients	   to	   permit	   analysis	   of	  
these	   subgroups,	   but	   79	   patients	   (3.3%	   of	   the	  
study	   cohort)	   were	   enrolled	   within	   3	   hours.	   On	  
the	   IMAGES	   primary	   endpoint,	   the	   global	   odds	  
ratio	   comparing	   magnesium	   vs	   placebo	   for	   a	  
favorable	   death	   or	   disability	   outcome	   was	   0.66	  
(95%CI	  0.25-­‐1.70)(Muir	  et	  al.,	  2004).	  Considering	  
the	   modified	   Rankin	   component	   of	   the	   IMAGES	  
primary	  endpoint,	   a	  non-­‐disabled	  outcome	   (mRS	  
0-­‐1)	   was	   achieved	   in	   45.9%	   of	   magnesium	  
patients	   vs	   33.3%	   of	   placebo	   patients,	   a	   12.6%	  
absolute	  difference.	  Mortality	  observations	  in	  the	  
IMAGES	   under	   3	   hour	   cohort	   were	   also	  
favourable,	   with	   death	   observed	   in	   26%	   of	  
placebo	  vs	  19%	  of	  magnesium	  patients	  (OR	  0.65,	  
95%	   CI	   0.23	   -­‐	   1.92).	  With	   the	   small	   numbers	   of	  
patients,	   these	   results	   do	   not	   reach	   statistical	  
significance,	  but	  do	  represent	  a	  suggestive	  signal	  
of	   potential	   efficacy	   of	   magnesium	   within	   very	  
early	  time	  windows.	  	  
	  
The	  key	  variable	  of	  time	  and	  the	  prehospital	  
strategy	  for	  magnesium	  sulphate	  
	  
In	   the	   past	   several	   decades,	   more	   than	   100	  
neuroprotective	   agents	   have	   been	   tested	   in	  
randomized	   controlled	   clinical	   trials	   in	   acute	  
ischemic	  stroke	  (Kidwell	  et	  al.,	  2001;	  Hong	  et	  al.,	  
2011).	   Several	   agents	   have	   shown	   promising	  
findings	  in	  safety	  and	  preliminary	  efficacy	  phase	  2	  
trials.	   However,	   no	   agent	   has	   been	   shown	  
unequivocally	  to	  be	  beneficial	   in	  definitive	  phase	  
3	  trials	  and	  none	  has	  been	  approved	  by	  the	  FDA	  
as	   indicated	   for	   ischemic	   stroke.	   	   These	   results	  
have	   led	  many	   investigators	   to	  ask	   the	  question,	  
“Why	   do	   neuroprotective	   drugs	  work	   in	   animals	  
but	   not	   humans?”	   (DeGraba	   and	   Pettigrew,	  
2000).	   Leading	   basic	   and	   clinial	   neuroscientists	  
have	   identified	   4	   key	   design	   defects	   of	   past	  
human	   clinical	   trials	   of	   neuroprotective	   clinical	  
trials:	   1)	   failure	   to	   administer	   study	   agents	   at	  
neuroprotective	   doses	   in	   humans	   because	   of	  
limiting	   side	   effects;	   2)	   failure	   to	   select	   patients	  
for	   trials	   who	   will	   respond	   to	   the	   known	  
mechanisms	  of	  action	  of	  study	  drug;	  3)	  failure	  to	  
employ	   sample	   sizes	   large	   enough	   to	   detect	  
modest	  benefits	  of	  study	  agent;	  and	  4)	  failure	  to	  
treat	   patients	   early	   enough	   after	   stroke	   onset	  
(DeGraba	   and	   Pettigrew,	   2000;	   Stroke	   Therapy	  
Academic	   Industry	   Roundtable	   II	   (StairII)	   2001;	  
Gorelick,	   2000;	   De	   Keyser	   et	   al.,	   1999;	   	   Fisher,	  
2003;	   Ovbiagele	   et	   al.,	   2003;	   Wahlgren	   and	  
Ahmed,	  2004;	  Muir	  and	  Teal,	  2005).	  
	  
The	  NIH	  Field	  Administration	  of	  Stroke	  Therapy	  –	  
Magnesium	   (FAST-­‐MAG)	   trial	   was	   designed	   to	  
remedy	   each	   of	   these	   past	   difficulties.	   The	   trial	  
employs	  magnesium	  sulphate	  at	  doses	  known	  to	  
be	  both	  well	   tolerated	  and	   to	   yield	   serum	   levels	  
neuroprotective	   in	  animal	  models.	  The	  trial	   tests	  
an	  agent	  likely	  to	  be	  beneficial	  for	  both	  gray	  and	  
white	   matter	   ischemic	   injury,	   based	   on	  
vasodilating	   effects	   in	   both	   superficial	   and	   deep	  
circulations	   and	   cytoprotective	   effects	   in	   both	  
gray	   and	   white	   matter.	   The	   trial	   is	   adequately	  
powered	   to	   detect	   even	   a	   modest	   treatment	  
effect,	  and	  will	  be	  larger	  than	  95%	  of	  all	  previous	  
phase	  3	  neuroprotective	  trials.	  Most	  importantly,	  
the	   FAST-­‐MAG	   trial	   is	   designed	   to	   address	   the	  
crucial	  factor	  of	  delayed	  time	  to	  treatment	  which	  
has	   hindered	   all	   past	   human	   clinical	   trials	   of	  
neuroprotective	  drugs.	  	  
	  
Rodent	   and	   nonhuman	   primate	   experimental	  
studies	   suggest	   the	   duration	   of	   the	   therapeutic	  
window	   within	   which	   neuroprotective	  
intervention	   can	   ameliorate	   bioenergetic	   failure	  
in	  the	   ischemic	  penumbra	   is	  very	  brief,	  generally	  
less	   than	   2-­‐3	   hours.	   Most	   animal	   studies	   of	  
neuroprotective	  agents	   initiate	   therapy	  within	  1-­‐
60	  minutes	  after	   ischemia	  onset.	  For	  magnesium	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sulphate	   specifically,	   a	   strong	   time	   constraint	  
upon	   potential	   benefit	   was	   found	   in	   a	   rodent	  
middle	   cerebral	   artery	  occlsuion	  model.	   Treating	  
with	   magnesium	   sulphate	   at	   2	   hours	   after	  
occlusion	   reduced	   infarct	   size	   by	   61%,	   while	  
treatment	  at	  6	  hours	  reduced	  infarct	  size	  by	  48%	  
and	  treatment	  at	  8	  hours	  reduced	   infarct	  size	  by	  
19%	  (Yang	  et	  al.,	  2000).	  
	  
However,	   although	   it	   is	   in	   the	   first	   2	   hours	   of	  
onset	  that	  neuroprotective	  agents	  in	  general	  and	  
magnesium	   sulphate	   in	   particular	   are	   most	  
beneficial	   in	  focal	  animal	  stroke	  models,	  no	  prior	  
human	   clinical	   neuroprotective	   agent	   trial	   has	  
enrolled	  any	  substantial	  cohort	  of	  patients	  in	  this	  
time	   window	   (Kidwell	   et	   al.,	   2001;	   Ferguson	   et	  
al.,	   2004).	   Early	   neuroprotective	   trials	   permitted	  
initiation	   of	   therapy	   at	   lengthy	   intervals	   after	  
symptom	   onset,	   up	   to	   48	   hours,	   well	   after	   the	  
critical	   period	   for	   stabilizing	   the	   penumbral	  
region	   had	   closed.	   More	   recent	   trials	   have	  
utilized	   shorter	   entry	   windows,	   but	   continue	   to	  
treat	   few	   patients	   within	   the	   first	   1	   or	   2	   hours.	  
Validating	  methods	  to	  safely	  initiate	  experimental	  
neuroprotective	  therapies	  more	  quickly	   is	  critical	  
if	   the	   dramatic	   benefits	   of	   neuroprotective	  
agents	   evident	   in	   the	   laboratory	   are	   to	   be	  
achieved	   in	   human	   stroke	   victims.	   This	  
perspective	   is	   supported	   by	   the	   pooled	   analysis	  
of	  the	  first	  6	  major	  intravenous	  tPA	  trials	  (Brott	  et	  
al.,	   2002).	  Due	   to	   the	  powerful	  effect	  of	   time	   to	  
treatment	  upon	  benefit	   of	   tPA,	   the	   sample	   sizes	  
required	   to	   demonstrate	   treatment	   benefit	  
escalate	   rapidly	   with	   increasing	   time	   window.	   A	  
trial	   enrolling	  patients	   in	   the	  0-­‐90	  minute	   epoch	  
would	   require	   a	   sample	   size	   of	   only	   90	   to	  
demonstrate	  benefit,	  a	  91-­‐180	  minute	  trial	  would	  
require	   a	   sample	   size	   of	   528,	   a	   181-­‐270	  minute	  
trial,	   816,	   and	   a	   271-­‐360	   minute	   trial	   a	   sample	  
size	  of	  4007.	  	  
	  
Enrolling	   patients	   in	   the	   field	   in	   acute	  
neuroprotective	   trials	   is	   a	   highly	   promising	  
approach	   to	   the	   challenge	   of	   testing	  
neuroprotective	   agents	   in	   hyperacute	   time	  
epochs.	   The	   FAST-­‐MAG	   trial	   is	   the	   first	   phase	   3	  
focal	   stroke	   trial	   in	   the	   field,	   but	   recent	   trials	   in	  
both	   cardiac	   and	   other	   brain	   disorders	  
demonstrate	  the	  feasibility	  and	  advantages	  of	  the	  
prehospital	  treatment	  approach.	  In	  the	  analogous	  
setting	  of	  acute	  myocardial	  ischemia,	  randomized	  
clinical	   trials	   have	   shown	   that	   paramedic	  
prehospital	   diagnosis	   and	   initiation	   of	  
defibrillation	   and	   thrombolytic	   therapy	   reduces	  
time	   to	   treatment	   start	   and	   improves	   clinical	  
outcome	  (Bozik	  et	  al.,	  2001).	  In	  status	  epilepticus,	  
the	   Prehospital	   Treatment	   of	   Status	   Epilepticus	  
(PHTSE)	  trial	  showed	  that	  paramedic	   initiation	  of	  
anticonvulsants	   in	   the	   field	   is	   safe,	   reliable,	   and	  
yields	   better	   clinical	   outcomes	   than	   standard	   in-­‐
hospital	  therapy	  (Alldredge	  et	  al.,	  2001).	  In	  global	  
brain	   ischemia	   due	   to	   cardiac	   arrest,	   the	  
Melbourne	   hypothermia	   trial	   demonstrated	   a	  
benefit	   of	   paramedic-­‐initiated,	   whole	   body	  
cooling	   in	   resuscitated	   out	   of	   hospital	   cardiac	  
arrest	  patients	  (Bernard	  et	  al.,	  2002)	  	  
	  
Prehospital	   trials	   of	   treatments	   for	   focal	   stroke	  
face	  several	  design	  challenges,	  including	  accurate	  
identification	   of	   stroke	   patients,	   rating	   of	  
pretreatment	   stroke	   severity,	   elicitation	   of	  
informed	   consent	   in	   the	   field	   prior	   to	   hospital	  
arrival,	   and	   randomization	   to	   appropriate	  
treatment	   arm.	   The	   Field	   Administration	   of	  
Stroke	   Therapy	   –	   Magnesium	   (FAST-­‐MAG)	  
investigators	  developed	  several	  novel	  methods	  to	  
address	  these	  obstacles,	  first	  in	  a	  pilot,	  20	  patient	  
feasibility	  trial	  (Saver	  et	  al.,	  2004)	  and	  then	  in	  an	  
ongoing,	  pivotal,	  1700	  patient	  phase	  3	  trial.	  	  	  
	  
• Stroke	   identification	   –	   LAPSS:	   Paramedics	  
identify	  stroke	  patients	  using	  the	  Los	  Angeles	  
Prehospital	   Stroke	  Screen	   (LAPSS),	   an	  8	   item	  
diagnostic	   inventory	   that	   takes	   1-­‐2	   minutes	  
to	   perform,	   is	   well	   validated,	   and	   is	   a	  
standard	   part	   of	   ambulance	   personnel	  
training	  worldwide.	  	  
• Stroke	   severity	   rating	   –	   LAMS:	   The	   Los	  
Angeles	   Motor	   Scale	   (LAMS)	   is	   a	   0-­‐5	   point	  
rating	  of	  motor	  deficit	  severity	  that	  is	  derived	  
directly	   from	   the	   face,	   arm,	   and	   grip	  
weakness	   exam	   section	   of	   the	   LAPSS.	  When	  
performing	   the	   LAPSS,	   paramedics	   also	  
automatically	   perform	   the	   LAMS.	   Though	  
simple	   and	   rapid,	   the	   LAMS	   is	   a	   useful	  
assessment	   of	   stroke	   deficit	   severity,	  
correlating	   well	   with	   concurrently	   measured	  
13	   item	  NIH	  Stroke	  Scale	  (NIHSS)	  scores,	  and	  
predicting	   final	   three	   month	   disability,	  
activity	   of	   daily	   living,	   and	   neurologic	   deficit	  
outcomes	   nearly	   as	   well	   as	   the	   full	   NIHSS	  
(Llanes	  et	  al.,	  2004).	  	  
• Informed	   consent	   elicitation	   –	   cellular	  
telemedicine:	   Most	   recent	   prehospital	  
treatment	   trials	   have	   been	   conducted	   for	  
conditions	   that	   render	   patients	   incompetent	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to	   provide	   consent,	   such	   as	   cardiac	   arrest,	  
under	   regulations	   permitting	   waiver	   of	  
explicit	  consent	   in	  emergency	  circumstances.	  
In	   acute	   stroke,	   however,	   many	   patients	  
retain	   decision-­‐making	   capacity	   and	   require	  
fully	   informed	   consent.	   Having	   paramedics	  
elicit	   consent	   has	   the	   drawbacks	   of	   having	  
nonstroke	  experts	   answering	   subject	  queries	  
and	   of	   diverting	   paramedic	   attention	   from	  
prehospital	   duties.	   In	   the	   cellular	   tele-­‐
medicine	   enrolment	   system	   developed	   for	  
FAST-­‐MAG,	   rescue	   vehicles	   carry	   written	  
informed	   consent	   forms	   and	   cellular	   phones	  
that	   permit	   instant	   connection	   to	   on-­‐call	  
enrolling	   physician–investigators	   (Sanossian	  
et	   al.,	   2009).	   The	   physician–investigator	  
discusses	   the	  trial	  by	  phone	  with	   the	  patient	  
or	   their	   legally	   authorized	   representative	  
while	   paramedics	   perform	   prehospital	   care	  
duties	  unimpeded.	  	  
• Pre-­‐encounter	  randomization:	  Keep	  It	  Simple	  
and	   Straightforward	   (KISS)	   is	   an	   important	  
principle	   in	   prehospital	   research.	   In	   the	  
potentially	   chaotic	   prehospital	   setting,	  
complex	   randomization	   schemes	   and	  
multiple	  drug	  source	  bins	  have	  a	  high	   risk	  of	  
leading	   to	   administration	   of	   unintended	  
treatment	  regimens.	  To	  promote	  reliable	  and	  
rapid	   administration	   of	   study	   agent,	   the	  
randomized	  phase	  3	  FAST-­‐MAG	  trial	  employs	  
a	  pre-­‐encounter	   randomization	   system.	  Each	  
ambulance	   is	   stocked	  with	   only	   one	   blinded	  
study	  kit	  at	  a	  time.	  When	  the	  study	  kit	  is	  used	  
in	   a	   patient,	   the	   ambulance	   is	   restocked	  
within	   24	   hours	   with	   the	   next	   kit	   in	   that	  
ambulance’s	   permuted	   block	   treatment	  
schedule.	  When	  given	  approval	  to	  start	  study	  
procedures	   by	   the	   enrolling	   physician-­‐
investigator,	   paramedics	   can	   quickly	   and	  
unambiguously	   proceed	   with	   administering	  
the	   sole,	   “pre-­‐randomized”	   kit	   available	   in	  
the	  vehicle.	  	  
Using	   these	   techniques,	   the	   FAST-­‐MAG	   Phase	   3	  
Trial	   during	   its	   initial	   years	   of	   performance	   has	  
already	  enrolled	  more	  patients	  in	  the	  hyperacute,	  
under	   2	   hour	   period	   than	   all	   prior	   acute	   stroke	  
treatment	   trials	   combined.	   	   By	   late	   January	   of	  
2011,	   1190	   patients	   had	   been	   enrolled,	   with	   a	  
median	   time	   interval	   from	   last	   known	   well	   to	  
start	  of	  study	  infusion	  of	  46	  minutes	  (Saver	  et	  al.,	  
2011).	   Fully,	   869	   patients	   (73%)	   were	   enrolled	  
within	  the	  first	  hour	  after	  onset,	  and	  another	  286	  
(24%)	   in	   the	   second	   hour.	   In	   this	   initial	   cohort,	  
patient	   demographics	   are	   typical	   for	   the	   stroke	  
population,	  with	  average	  age	  69	  and	  58%	  of	   the	  
population	   male.	   Stroke	   mimicking	   conditions	  
have	  been	  enrolled	  at	  a	   low	  rate,	  3%,	  below	  the	  
5%	   allotted	   in	   trial	   sample	   size	   projections.	   The	  
enrolling	   event	   was	   acute	   cerebral	   ischemia	   in	  
73%	  of	  patients	  and	  intracerebral	  haemorrhage	  in	  
24%.	   These	   preliminary	   observation	   findings	  
indicate	  that	  the	  FAST-­‐MAG	  trial	  is	  accomplishing	  
several	   innovations	   in	   stroke	   clinical	   trials,	  
including	   being:	   1)	   the	   first	   prehospital	  
randomized	   stroke	   trial;	   2)	   the	   first	   treatment	  
trial	   to	   enrol	   a	   substantial	   cohort	   of	   patients	   in	  
first	  60	  minutes	  after	  onset	   (the	   “golden	  hour”);	  
and	   3)	   the	   first	   trial	   testing	   neuroprotective	  
therapy	   delivery	   in	   advance	   of	   recanalization	  
therapy,	  potentially	  permitting	  more	  brain	  tissue	  
to	   still	   be	   salvageable	   when	   reperfusion	   is	  
achieved.	  
	  
Commercial	   sponsors	   have	   been	   reluctant	   to	  
conduct	   paramedic	   administered	   trials	   of	  
neuroprotective	   agents	   because	   of	   perceived	  
regulatory	   hurdles	   and	   because	   of	   the	   lack	   of	  
established	   phase	   3	   trial	   methodology	   in	   the	  
prehospital	   setting.	   Successful	   completion	  of	   the	  
FAST-­‐MAG	   trial	   may	   blaze	   a	   trail	   for	   future	  
neuroprotective	   field	   trials,	   both	   governmental	  
and	   commercial,	   and	   could	   lead	   to	   a	   resurgence	  
of	  research	  activity	  in	  neuroprotection	  for	  stroke.	  	  
	  
Acute	   stroke	   investigators	   have	   suggested	   the	  
desirability	   of	   paramedic	   treatment	   of	   acute	  
stroke	   in	   the	   field	   (Alberts,	   1997;	   The	   European	  
Ad	   Hoc	   Consensus	   Group,	   1998;	   Rajajee	   and	  
Saver,	  2005).	  A	  vision	  of	  future	  stroke	  care	  widely	  
shared	   in	   the	   stroke	   research	   community	   is:	   1)	  
paramedic	   administration	   of	   a	   group	   of	  
complementary	   neuroprotective	   agents	   in	   the	  
field	   to	   protect	   the	   brain	   during	   transfer	   and	  
extend	   the	   time	   window	   for	   recanalization	  
therapy;	   2)	   definitive	   thrombolysis	   or	   other	  
revascularization	   procedure	   on	   hospital	   arrival;	  
and	   3)	   in-­‐hospital	   administration	   of	   a	   second	  
group	   of	   neuroprotective	   agents	   specifically	  
active	   against	   reperfusion	   injury	   (Table	   2).	   The	  
FAST-­‐MAG	  Trial	  constitutes	  the	  first	  major	  test	  of	  
the	  prehospital	  element	  of	   this	  stroke	  treatment	  
strategy.	   The	   need	   for	   a	   prehospital	   neuro-­‐
protective	   agent	   has	   become	   even	  more	   urgent	  
with	  the	  dissemination	  of	  designated	  Stroke	  Center	  
systems	  throughout	  the	  United	  States	  (Schwamm	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Table	  2.	  	  Vision	  for	  Future	  Comprehensive	  Acute	  Ischemic	  Stroke	  Care	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et	   al.,	   2005).	   At	   the	   end	   of	   2010,	   18	   states	   and	  
additional	   counties,	   encompassing	   52%	   of	   the	  
American	   populace,	   had	   adopted	   regulations	  
requiring	   routing	   of	   ambulances	   directly	   to	  
designated	   Stroke	   Centers	   (Song	   and	   Saver,	  
2011).	   Identification	   of	   a	   proven	   prehospital	  
treatment	  agent	  would	  help	  mitigate	   the	   impact	  
of	   the	   resulting	   slight	   increase	   in	   average	  
prehospital	  transport	  time	  for	  stroke	  patients.	  	  
Paramedics	   reach,	   within	   2	   hours	   of	   onset,	   20-­‐
50%	   of	   the	   600,000	   ischemic	   stroke	   patients	   in	  
the	   United	   States	   each	   year.	   Positive	   results	   in	  
the	   FAST-­‐MAG	   clinical	   trial	   would	   mean	   that	  
120,000	  –	   300,000	  Americans	   suffering	   an	   acute	  
stroke	   each	   year	   could	   potentially	   benefit	   from	  
treatment	  with	  magnesium	   sulfate	   therapy.	   This	  
would	   represent	   a	   tremendous	   advance	   in	  
reducing	  the	  nationwide,	  and	  worldwide,	  burden	  
of	  stroke.	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The	   relationship	   between	  Mg	   and	   cancer	   is	   still	   a	   puzzle	   to	   disentangle.	   The	   knowledge	   derived	   from	  
preclinical	   studies	   reveals	   a	   complex	   scenario	   in	  which	   low	  magnesium	  has	  both	  anti-­‐	   and	  pro-­‐tumour	  
effects,	  such	  as	  inhibition	  of	  tumour	  growth	  at	  its	  primary	  site	  and	  facilitation	  of	  tumour	  implantation	  at	  
its	  metastatic	  sites.	  In	  different	  cell	  types,	  neoplastic	  transformation	  dramatically	  disrupts	  the	  controlled	  
and	  coordinated	  fluctuations	  of	  intracellular	  magnesium,	  an	  event	  that	  offers	  selective	  advantages	  to	  the	  
cells.	   It	   is	   difficult	   to	   translate	   the	   lesson	   learnt	   from	   experimental	   models	   to	   humans.	   Based	   on	  
epidemiological	  studies,	  Mg	  deficiency	  seems	  to	  be	  linked	  to	  increased	  risk	  of	  some	  types	  of	  cancers.	  The	  
demonstration	   of	   an	   impairment	   of	  magnesium	  homeostasis	   in	   oncologic	   patients	   further	   complicates	  
the	  field.	  We	  need	  more	  translational	  and	  clinical	  data	  to	  draw	  firm	  conclusions	  about	  the	  contribution	  




Although	  cancer	  mortality	  has	  declined	  in	  the	  last	  
two	   decades,	   particularly	   in	   western	   countries	  
(Jemal	  et	  al.,	  2010),	  cancer	  exacts	  a	  very	  high	  toll	  
as	   a	   leading	   cause	   of	   death	   all	   over	   the	   world.	  
Great	   strides	   have	   been	   made	   to	   disclose	   the	  
molecular	  bases	  of	  neoplasia,	  but	  how	  to	  prevent	  
or	  cure	  cancer	  still	  remains	  a	  largely	  unanswered	  
question.	  	  
	  
There	   is	   general	   agreement	   about	   the	   environ-­‐
mental	   origin	   of	   cancer.	   It	   has	   been	   estimated	  
that	  more	  than	  two-­‐thirds	  of	  human	  cancers	  can	  
be	   prevented	   by	   changes	   in	   lifestyle.	   Statistical	  
and	   epidemiological	   data	   point	   to	   diet	   as	  
responsible	   for	   about	   35%	   of	   human	   cancer	  
mortality	   (Doll	   and	   Peto,	   1981).	   While	   many	  
dietary	   constituents	   transform	   normal	   cells	   into	  
malignant	   ones	   in	   vitro	   and	   stimulate	   the	  
development,	   growth	   and	   spread	   of	   tumours	   in	  
vivo,	   evidence	   from	   population	   and	   laboratory	  
studies	   indicate	   that	   many	   microconstituents	  
inhibit,	  retard	  or	  reverse	  tumorigenesis	  (Manson,	  
2003).	   There	   is	   general	   agreement	   about	   the	  
inverse	  correlation	  between	  regular	  consumption	  
of	   fruit,	   cereals	   and	   vegetables	   and	   the	   risk	   of	  
cancer.	   Edible	   plant	   matter	   contains	   many	  
beneficial	   microconstituents,	   vitamins	   and	  
minerals.	  In	  particular,	  magnesium	  (Mg),	  which	  is	  
predominantly	   obtained	   by	   eating	   unprocessed	  
grains	  and	  green	   leafy	  vegetables,	   is	  an	  essential	  
micronutrient	   implicated	   in	   a	   large	   array	   of	  
regulatory,	   metabolic	   and	   structural	   activities	  
(Wolf	  and	  Trapani,	  2008).	  Evidence	  suggests	  that	  
the	   occidental	   diet	   is	   relatively	   deficient	   in	   Mg	  
because	   of	   a	   preference	   for	   calorie-­‐rich,	   micro-­‐
nutrient-­‐poor	  foods,	  low	  Mg	  content	  in	  water	  and	  
soil,	  and	  processing	  of	  many	  food	  items	  (Ford	  and	  
Mokdad,	  2003).	   Inadequate	  dietary	   intake	  of	  Mg	  
is	   not	   the	   only	   cause	   of	   Mg	   deficiency.	   Mg	  
homeostasis	   is	  very	  tightly	  tuned	   in	  the	   intestine	  
and	  the	  renal	  tubules	  through	  a	  complex	  network	  
of	   transporters,	   some	   of	   which	   have	   recently	  
been	   defined	   at	   the	   molecular	   level	   (Quamme,	  
2010).	  Consequently,	  Mg	  deficiency	  accompanies	  
chronic	   gastrointestinal	   and	   renal	   diseases,	  
therapies	   with	   some	   classes	   of	   diuretics	   or	  
anticancer	   drugs,	   and	   also	   complicates	   diabetes	  
mellitus.	   In	   addition,	   it	   is	   common	   in	   alcoholics	  
and	  in	  the	  elderly	  (Ford	  and	  Mokdad,	  2003).	  	  
	  
Considerable	   debate	   remains	   about	   the	   role	   of	  
Mg	   in	  human	   tumours,	   partly	   due	   to	   the	   lack	  of	  
reliable	   and	   selective	   analytical	   procedures	   to	  
measure	  Mg.	   However,	   there	   has	   been	   a	   recent	  
resurgence	   of	   interest	   in	   the	   relationship	  
between	  Mg	   and	   tumours	   both	   in	   experimental	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and	   in	   clinical	   oncology,	   leading	   to	   the	   question	  
whether	   Mg	   is	   Dr	   Jekyll	   or	   Mr	   Hyde	   in	   tumour	  
biology	  and	  clinics.	  	  
	  
Low	  magnesium	  and	  cancer:	  insights	  from	  
human	  studies	  
	  
Although	  not	  conclusive,	  a	  clinical	  study	  indicated	  
a	   potential	   benefit	   of	   Mg	   deficiency	   in	   patients	  
with	   malignant	   tumours	   (Parsons	   et	   al.,	   1974).	  
These	   results	   have	   been	   sustained	   by	   the	   fact	  
that	  Mg	  is	  required	  in	  all	  the	  steps	  involved	  in	  cell	  
growth,	   from	   receptor-­‐mediated	   intracellular	  
signalling	   and	   transphosphorylation	   reactions	   to	  
gene	   transcription,	   protein	   synthesis,	   DNA	  
duplication	   and	   cell	   division	   (Wolf	   and	   Trapani,	  
2008).	   Another	   study	   showed	   that	   the	   serum	  
level	   of	   Mg	   is	   frequently	   decreased	   in	   patients	  
with	   solid	   tumours,	   independent	   of	   therapies,	  
and	  that	  this	  decrease	  correlated	  to	  the	  stage	  of	  
malignancy	   (Sartori	   et	   al.,	   1992).	   This	   finding	  
seems	  to	  be	  due	  to	  the	  avidity	  of	  the	  tumours	  for	  
Mg,	   which	   behave	   as	   Mg	   traps.	   Also,	   therapies	  
influence	   Mg	   homeostasis.	   It	   has	   been	   shown	  
that	   serum	  Mg	  decreases	   at	   the	   end	  of	   the	   first	  
week	  of	  radiotherapy	  (Cohen	  and	  Kitzes,	  1985)	  as	  
well	   as	   after	   treatment	   with	   different	   chemo-­‐
therapeutics	   that	   induce	   Mg	   waste.	   Indeed,	  
cisplatin	   is	   nephrotoxic	   (Yao	   et	   al.,	   2007),	   and	  
cetuximab,	   a	   monoclonal	   antibody	   against	   the	  
Epidermal	  Growth	  Factor	  (EGF)	  receptor,	  reversibly	  
and	   specifically	   inhibits	   Mg	   reabsorption	   in	   the	  
renal	   distal	   convoluted	   tubule	   (Muallem	   and	  
Moe,	   2007).	   An	   obvious	   question	   is	   whether	  
radiation-­‐	   or	   drug-­‐induced	   hypomagnesemia	  
amplifies	   the	   effect	   of	   DNA	   damaging	   cancer	  
treatments	   by	   acting	   as	   a	   chemo-­‐	   and	   radio-­‐
sensitizer.	   Recently,	   decreased	   serum	   Mg	   has	  
been	   suggested	   to	   contribute	   to	   the	   therapeutic	  
effects	   of	   cetuximab	   in	   patients	   with	   colon	  
carcinoma	   (Vincenzi	   et	   al.,	   2008).	   However,	   it	   is	  
still	   controversial	   whether	   to	   supplement	  
severely	  hypomagnesemic	  oncologic	  patients	  with	  
Mg	  or	  not	  (Wolf	  et	  al.,	  2009).	  	  
	  
Several	   epidemiological	   studies	   have	   provided	  
evidence	   that	   a	   correlation	   exists	   between	  
dietary	   Mg	   and	   various	   types	   of	   cancer.	   A	   high	  
content	  of	  Mg	  in	  drinking	  water	  seems	  to	  protect	  
from	   liver	   and	   oesophageal	   cancer	   (Tukiendorf	  
and	  Rybak,	   2004;	   Yang	  et	   al.,	   2002).	   In	   addition,	  
Mg	   content	   in	   drinking	   water	   was	   inversely	  
correlated	   with	   death	   by	   breast,	   prostate,	   and	  
ovarian	   cancers,	   whereas	   no	   correlation	   existed	  
for	   other	   tumours	   (Yang	   et	   al.,	   2000a;	   2000b;	  
2002;	   Chiu	   et	   al.,	   2004).	   In	   particular,	   a	   high	  
serum	  calcium	  Ca:Mg	  ratio	  has	  been	  suggested	  as	  
a	   novel	   risk	   factor	   which	   increases	   the	  
development	   of	   postmenopausal	   breast	   cancer	  
(Sahmoun	  and	  Singh,	  2010),	   the	  most	  commonly	  
diagnosed	   cancer	   among	   women	   in	   North	  
America	  and	  Europe,	  with	  a	  mortality	   that	   ranks	  
second	   only	   to	   lung	   cancer	   (Jemal	   et	   al.,	   2010).	  
Indeed,	  in	  western	  populations,	  and	  even	  more	  in	  
postmenopausal	   women	   who	   are	   taking	   Ca	  
supplements	   to	   prevent	   osteoporosis,	   a	   high	  
Ca:Mg	  intake	  is	  rather	  common	  and	  determines	  a	  
negative	   Mg	   balance,	   since	   the	   two	   minerals	  
compete	   for	   the	   same	   transporters	   in	   almost	   all	  
tissues.	   Ca	   and	  Mg	  have	  equally	   important	   roles	  
in	   regulating	   cell	   growth	   (McKeehan	   and	   Ham,	  
1978)	   and	   Mg	   is	   considered	   the	   natural	   Ca	  
antagonist.	  It	  is	  therefore	  feasible	  that	  alterations	  
in	   Ca:Mg	   ratio	   might	   lead	   to	   dysregulated	   cell	  
functions.	   The	   ratio	   of	   Ca:Mg	   is	   also	   to	   be	  
considered	  in	  relation	  to	  colon	  cancer,	  one	  of	  the	  
three	   big	   killers,	   together	   with	   breast	   and	   lung	  
cancer,	  in	  western	  society.	  Ca	  has	  been	  indicated	  
as	   a	   chemopreventive	   agent	   for	   colon	   cancer	  
(Lamprecht	  and	  Lipkin,	  2003).	  	  	  
	  
It	   should	   also	   be	   pointed	   that	  Mg	  might	   have	   a	  
role	   in	   colon	   cancer	   prevention.	   Indeed,	   large	  
epidemiological	   studies	   in	   Sweden,	   in	   the	  
Netherlands,	   in	   the	   USA	   and	   in	   Taiwan	   have	  
demonstrated	  an	  association	  between	  low	  intake	  
of	  Mg	  and	  the	  risk	  of	  colon	  cancer	  (Larsson	  et	  al.,	  
2005;	  Folsom	  et	  al.,	  2006;	  van	  den	  Brandt	  et	  al.,	  
2007;	   Chiu	   et	   al.,	   2010)	   and	   a	   large	   population-­‐
based	   prospective	   study	   in	   Japan	   showed	   a	  
significant	   inverse	   correlation	   between	   dietary	  
intake	  of	  Mg	  and	  colon	  cancer	  in	  men,	  but	  not	  in	  
women	   (Ma	   et	   al.,	   2010).	   Intriguingly,	   the	  
association	  between	   low	   intake	  of	  Mg	  and	  colon	  
cancer	   seems	   to	   be	   due,	   at	   least	   in	   part,	   to	   the	  
increased	   formation	   of	   N-­‐nitroso	   compounds,	  
most	  of	  which	  are	  potent	  carcinogens	  (Chiu	  et	  al.,	  
2010).	   That	   Mg	   has	   a	   role	   in	   colon	   neoplasia	   is	  
supported	   by	   the	   association	   of	   adenomatous	  
and	   hyperplastic	   polyps	   with	   a	   genetic	  
polymorphism	   of	   Transient	   Receptor	   Potential	  
Melastatin	   (TRPM)-­‐7	   (Dai	   et	   al.,	   2007),	   a	  
ubiquitous	   ion	  channel	  with	  a	   central	   role	   in	  Mg	  
uptake	   and	   homeostasis	   (Schmitz	   et	   al.,	   2003).	  
Indeed,	   the	   subjects	   carrying	   the	   Thr1482-­‐Ile	  
variant	   allele	   are	   at	   high	   risk	   of	   Mg	   deficiency	  
Magnesium	  in	  the	  Central	  Nervous	  System	   	   Chapter	  16	  
 219	  
and,	   in	   turn,	   of	   colorectal	   neoplasia	   (Dai	   et	   al.,	  
2007).	   While	   total	   Mg	   consumption	   has	   been	  
linked	   to	   a	   significant	   lower	   risk	   of	   colorectal	  
adenoma	   and	   hyperplastic	   polyps	   (Dai	   et	   al.,	  
2007),	  unequivocal	  evidence	  that	  Mg	  reduces	  the	  
risk	   of	   cancer	   will	   only	   be	   obtained	   by	  
demonstrating	  that	  Mg	  supplementation	  prevents	  
colorectal	  cancer.	  	  
	  
The	   role	   of	   Mg	   in	   lung	   cancer	   is	   rather	  
controversial.	   The	   first,	   case-­‐control	   study	  
correlated	   low	  dietary	  Mg	  with	  poor	  DNA	   repair	  
capacity	   and	   increased	   lung	   cancer	   risk	   both	   in	  
men	  and	  women	  (Mahabir	  et	  al.,	  2008).	  	  This	  link	  
was	  more	  evident	  in	  the	  elderly,	  current	  smokers,	  
drinkers	   and	   in	   those	   with	   a	   late-­‐stage	   disease.	  
Apart	   from	   its	   role	   in	   maintaining	   genomic	  
stability,	  the	  authors	  proposed	  several	  additional	  
mechanisms	   by	  which	  Mg	  might	   have	   protected	  
against	   lung	   cancer,	   i.e.	   by	   regulating	   cell	  
multiplication	   and	   protecting	   against	   oxidative	  
stress,	   invariably	   associated	   with	   Mg	   deficiency	  
(Guerrero-­‐Romero	   and	   Rodriguez-­‐Moràn,	   2006).	  
Unexpectedly,	   these	   results	  were	   not	   supported	  
by	   a	   recent	   prospective	   analysis	   which	   showed	  
that	   dietary	   Mg	   intake	   slightly	   increased	   lung	  
cancer	   risk	   (Mahabir	   et	   al.,	   2010).	   These	  
contrasting	   data	   could	   result	   from	   recall	   bias.	   In	  
addition,	   residual	   confounders	   may	   account	   for	  
weak	   associations	   because	   smoking	   is	   a	   very	  
strong	  risk	  factor	  for	   lung	  cancer,	  and	  diet	  might	  
not	   be	   perfectly	   measured.	   More	   studies	   of	  
dietary	  Mg	   and	   lung	   cancer	   risk	   are	   required	   to	  
carefully	  consider	  measurement	  error	   issues	  and	  
confounders	  such	  as	  smoking.	  
	  
	  A	   last	   topic	   to	   consider	   is	   the	   implication	   of	  
inflammation	   in	   the	   initiation	   and	   development	  
of	   cancer	   in	   Mg	   deficient	   individuals.	   The	  
inflammation-­‐cancer	   connection	   is	   a	   well-­‐
established	   paradigm	   (Colotta	   et	   al.,	   2009)	   and	  
low	  Mg	  status	  has	  been	  clearly	   linked	  to	   increased	  
inflammatory	   stress	   in	   humans	   (Nielsen,	   2010).	  
While	   in	   some	   context,	   such	   as	   lymphomas,	  
inflammation	   exerts	   an	   anti-­‐neoplastic	   role,	  
cancer-­‐related	   inflammation	   is	   involved	   in	   the	  
early	   and	   late	   steps	   of	   the	   most	   common	   solid	  
tumours.	  Indeed,	  inflammatory	  mediators	  induce	  
genetic	   instability	   and	   contribute	   to	   the	  
proliferation	   of	   tumour	   cells,	   promote	   invasion,	  
metastasis	   and	   angiogenesis	   as	   well	   as	   an	  
impaired	   response	   to	   therapies	   (Colotta	   et	   al.,	  
2009).	  
In	  summary,	  Mg	  deficiency	  seems	  to	  be	  linked	  to	  
an	   increased	   risk	   of	   some	   types	   of	   cancers	   in	  
humans,	   but	   population	   studies	   are	   rather	  
complicated	   to	   interpret.	   Too	  many	   issues	   need	  
to	   be	   considered	   –	   genotype,	   risk	   factors,	  
interactions	   among	   different	   nutrients	   and,	   in	  
particular,	   the	   Mg:Ca	   ratio,	   the	   degree	   of	   the	  
inflammatory	  response,	  etc	  –	  to	  unravel	   the	  role	  
of	   low	  Mg	   in	   the	   complex,	   multistep	   process	   of	  
human	  cancerogenesis.	  	  
	  
Low	  magnesium	  and	  cancer:	  highlights	  from	  
animal	  models.	  
	  
Two	   main	   questions	   have	   been	   addressed	   in	  
animal	   models:	   1)	   whether	   a	   relationship	   exists	  
between	   Mg	   and	   the	   sensitivity	   to	   various	  
carcinogens;	   and	   2)	   whether	   primary	   tumour	  
growth	   and	   metastasis	   are	   affected	   by	   Mg	  
deficiency.	   Several	   studies	   indicate	   that	   Mg	  
exerts	   a	   protective	   effect	   in	   the	   early	   phases	   of	  
chemical	   cancerogenesis.	  Mg	  prevents	   lead-­‐	   and	  
nickel-­‐induced	   lung	   tumours	   in	   mice	   (Poirier	   et	  
al.,	   1984),	   inhibits	   nickel-­‐induced	   carcinogenesis	  
in	   the	   rat	   kidney	   (Kasprzak	   et	   al.,	   1994)	   and	  
protects	   against	   3-­‐methyl-­‐cholantrene	   induced	  
fibrosarcomas	   in	   rats	   (Patiroğlu	   et	   al.,	   1997).	  
Analogous	   with	   data	   in	   humans,	   Mg	   acts	   as	   a	  
protective	  agent	  in	  colorectal	  cancer	  by	  inhibiting	  
c-­‐myc	   expression	   and	   ornithine	   decarboxylase	  
activity	  in	  the	  mucosal	  epithelium	  of	  the	  intestine	  
(Mori	   et	   al.,	   1997).	  Whether	  Mg	   acts	   directly	   or	  
by	   controlling	   inflammation	   is	   an	   issue	   that	   has	  
not	   received	   adequate	   consideration	   until	   now.	  
However,	   it	   should	   be	   pointed	   out	   that	   the	  
inflammatory	  response	  in	  Mg	  deficient	  rodents	  is	  
very	   accentuated	   (Mazur	   et	   al.,	   2007)	   and,	   as	  
mentioned	   above,	   inflammation	   markedly	  
contributes	  to	  cancer.	  
	  
Back	   to	   the	   second	   question,	   i.e.	   whether	   Mg	  
deficiency	   impacts	   on	   tumour	   growth	   in	   vivo,	   a	  
study	   showed	   that	   dietary	   Mg	   deprivation	  
inhibited	   tumour	   growth	   in	   rats	   by	   limiting	  
glutathione	   (GSH)	   synthesis	   (Mills	   et	   al.,	   1986),	  
for	   which	   Mg	   is	   an	   obligatory	   cofactor.	   More	  
recently,	   in	   mice	   subcutaneously	   injected	   with	  
Lewis	   lung	   carcinoma,	   mammary	   adeno-­‐
carcinoma	  and	  colon	  carcinoma	  cells,	  a	  low	  Mg-­‐
containing	   diet	   was	   shown	   to	   inhibit	   primary	  
tumour	   growth,	   an	   effect	   that	   was	   promptly	  
reversed	   by	   re-­‐introducing	   Mg	   in	   the	   diet	  
(Nasulewicz	   et	   al.,	   2004).	   Surprisingly,	   Mg	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deficient	   mice	   developed	   far	   more	   lung	  
metastases	   than	   controls.	   Some	   cellular	   and	  
molecular	   aspects	   were	   investigated	   to	   explain	  
how	  a	   low	  Mg	  diet	   inhibited	  the	  development	  of	  
primary	   tumours	   while	   enhancing	  
metastatization.	  Regarding	  primary	  tumours,	   it	   is	  
noteworthy	   that	  Mg	  deficiency	  directly	   inhibited	  
tumour	   cell	   growth	   by	   downregulating	   cyclin	   B	  
and	   D3,	   crucial	   for	   the	   progression	   through	   the	  
cell	   cycle,	   and	   by	   upregulating	   p21,	   p27	   and	  
Jumonji,	   all	   involved	   in	   braking	   cell	   proliferation	  
(Nasulewicz	   et	   al.,	   2004;	  Maier	   et	   al.,	   2007).	  Mg	  
deficiency	   also	   affects	   tumour	   development	  
indirectly,	   because	   it	   promotes	   DNA	   oxidative	  
damage	   (Maier	   et	   al.,	   2007)	   and	   impairs	  
angiogenesis,	   one	   of	   the	   hallmarks	   of	   cancer	  
(Hanahan	   and	   Weinberg,	   2000).	   Indeed,	   Mg-­‐
deficient	   mice	   develop	   tumours	   that	   are	  
significantly	   less	   vascularized	   than	   controls	  
(Maier	  et	  al.,	  2007).	  The	  angiostatic	  effect	  of	  low	  
Mg	  can	  be	  ascribed	  to	  two	  different	  mechanisms.	  
First,	   low	   Mg	   inhibits	   endothelial	   growth	   and	  
migration,	   pivotal	   steps	   in	   the	   formation	  of	   new	  
vessels	   (Bernardini	   et	   al.,	   2005).	   Second,	   it	   has	  
recently	   been	   shown	   that	   Mg	   deficiency	  
suppresses	   hypoxia-­‐inducing	   factor	   (HIF)-­‐1α	  
activity	   in	   paraganglion	   cells	   (Torii	   et	   al.,	   2009).	  
HIF1α	  is	  fundamental	  to	  initiate	  the	  cell	  response	  
to	   hypoxia	   and,	   therefore,	   the	   release	   of	  
angiogenic	   factors.	   If	   this	   finding	   will	   also	   be	  
confirmed	  in	  in	  vivo	  models,	  it	  might	  be	  involved	  
in	   impairing	  angiogenesis	  upon	  Mg	  deficiency.	   In	  
vitro,	  the	  suppression	  of	  HIF-­‐1α	  activity	  is	  due	  to	  
the	   upregulation	   of	   IPAS,	   which	   acts	   as	   a	  
dominant	  negative	  inhibitor	  by	  preventing	  HIF-­‐1α	  
DNA	   binding.	   Intriguingly,	   IPAS	   upregulation	   is	  
caused	   by	   the	   activation	   of	   NFκB,	   the	  
transcription	  factor	  orchestrating	  the	  inflammatory	  
response	   and	   also	   implicated	   in	   tumorigenesis	  
(Karin	   et	   al.,	   2006).	   Inflammation,	   which	   is	   very	  
intense	  in	  Mg	  deficient	  mice	  (Mazur	  et	  al.,	  2007),	  
might	   impact	   both	   on	   the	   growth	   of	   primary	  
tumours	   and	   on	   metastases.	   Indeed,	  
inflammatory	  mediators	  induce	  genetic	  instability	  
(Colotta	   et	   al.,	   2009)	   and	   might	   synergize	   with	  
low	   Mg	   in	   causing	   mutations	   thus	   allowing	   the	  
generation	   of	   highly	   aggressive	   cells.	   Tumour	  
Necrosis	   Factor	   (TNF)α,	   the	   target	   of	   NFκB	   and	  
prototypical	   pro-­‐inflammatory	   cytokine,	   is	  
increased	   in	   the	   serum	   of	   Mg	   deficient	   rodents	  
(Mazur	   et	   al.,	   2007).	   In	   spite	   of	   its	   name,	   TNFα	  
has	   several	   marked	   pro-­‐tumoural	   functions,	  
because	   it	   facilitates	   the	   epithelial	   to	  
mesenchymal	   transition,	   it	   enhances	   tumour	  
invasion	   and	   recruits	   leukocytes	   within	   the	  
tumour,	   thus	   amplifying	   the	   inflammatory	  
process	  (Drutskaya	  et	  al.,	  2010).	  Moreover,	  TNFα	  
contributes	  to	  immune	  suppression	  (Drutskaya	  et	  
al.,	  2010).	  Together	  with	  TNFα,	  interleukins	  (IL)	  1	  
and	   6,	   both	   induced	   under	   Mg	   deprivation,	  
augment	   the	   capacity	   of	   cancer	   cells	   to	  
metastatize	  (Royuela	  et	  al.,	  2008).	  TNFα	  and	  IL1s	  
also	   upregulate	   endothelial	   adhesion	   molecules	  
in	   lung	   capillaries,	   thus	   facilitating	   the	   tethering	  
of	   metastatic	   cells	   to	   the	   vessel	   wall	   and	   their	  
subsequent	   transmigration	   and	   colonization	   in	  
the	   adjacent	   tissues.	   In	   addition,	   Mg	   is	   an	  
absolute	   requirement	   for	   the	   function	   of	   the	  
metastasis-­‐suppressor	   gene	   product	   NM23-­‐H1	  
(Ma	   et	   al.,	   2008).	   NM23-­‐H1	   knockout	   mice	  
showed	   accelerated	   metastasis	   (Boissan	   et	   al.,	  
2005).	   It	   is	   therefore	   possible	   that	   low	   Mg	  
availability	   impairs	   NM23-­‐H1	   anti-­‐metastatic	  
activity	  in	  mice.	  	  
	  
Briefly,	   in	   rodents,	   Mg	   deficiency	   seems	   to	  
participate	   both	   in	   early	   (initiation)	   and	   in	   late	  
(progression)	   phases	   of	   tumorigenesis.	   The	  
following	   scenario	   is	   feasible.	   Low	  Mg	   promotes	  
oxidative	  stress	  and	  inflammation	  which	  generate	  
genetic	   instability	   and,	   therefore,	   increases	   the	  
risk	   of	   mutations.	   Since	   Mg	   is	   an	   essential	  
cofactor	  in	  almost	  all	  enzymatic	  systems	  involved	  
in	   DNA	   synthesis	   and	   repair,	   under	   low	   Mg	  
availability	   mutations	   may	   become	   permanent	  
thus	  generating	  the	  so-­‐called	  “initiated”	  cell.	  The	  
persistence	  of	   oxidative	   stress	   and	   inflammation	  
together	   might	   generate	   further	   mutations,	  
which	  render	  the	  cell	  immortal	  and	  self	  sufficient	  
in	   terms	   of	   proliferation.	   Some	   cells	   might	   also	  
acquire	   an	   invasive,	   metastatic	   phenotype	   and	  
colonize	  distant	  organs	  (Figure	  1).	  	  
	  
Magnesium	  and	  cancer:	  lessons	  from	  cultured	  
cells	  
	  
Even	   though	   studies	   on	   cultured	   cells	   can	   only	  
focus	   on	   some	   isolated	   aspects	   of	   the	   complex	  
events	   implicated	   in	   the	   development	   of	  
tumours,	   they	   have	   produced	   an	   extraordinary	  
body	   of	   knowledge.	   The	   field	   of	  Mg	   research	   in	  
cancer	  makes	  no	  exception.	  	  




Figure	  1.	  A	  low	  Mg	  content	  in	  the	  diet	  might	  influence	  both	  early	  and	  late	  steps	  of	  tumorigenesis	  in	  mice.	  
Upper	  panel:	  By	  inducing	  oxidative	  stress	  and	  inflammation	  and	  by	  inhibiting	  DNA	  repair	  enzyme,	  low	  Mg	  
enhances	   the	   risk	   of	   DNA	   damage	   and,	   therefore,	   might	   synergize	   with	   carcinogens	   giving	   rise	   to	   an	  
initiated	   cell,	   which	   is	   potentially	   capable	   of	   originating	   a	   tumour.	   Lower	   panel:	   Once	   the	   tumour	   has	  
developed,	  low	  Mg	  facilitates	  metastasis	  by	  further	  damaging	  DNA	  and	  by	  inducing	  inflammatory	  events,	  in	  





The	  impact	  of	  extracellular	  Mg	  on	  tumour	  cells	  
Based	  on	   the	   results	   obtained	   in	   humans	   and	   in	  
animal	   models,	   the	   effects	   of	   low	   extracellular	  
Mg	  on	  tumour	  cells	  has	  been	  investigated.	  While	  
normal	   diploid	   cells	   are	   very	   sensitive	   to	   low	  
extracellular	  Mg	  and	  are	  rapidly	  growth	  retarded,	  
neoplastic	   cells	   are	   rather	   refractory	   to	   Mg	  
deprivation	   (Wolf	   et	   al.,	   2009).	   Indeed,	   tumour	  
cells	   require	   longer	   times	   and	   much	   lower	  
concentrations	   of	   extracellular	   Mg	   than	   normal	  
cells	   to	   slow	  their	  proliferation	   rate	   (Wolf,	  2004;	  
Maier	  et	  al.,	  2007).	  Another	  peculiarity	  of	  tumour	  
cells	   is	   their	   avidity	   for	   Mg,	   which	   accumulates	  
within	   the	   cells	   even	   when	   extracellular	   Mg	  
concentrations	  are	  low.	  The	  molecular	  mechanisms	  
involved	  have	  not	  been	  completely	  disclosed,	  but	  
it	   is	   known	   that	   Na-­‐dependent	   Mg	   extrusion	   is	  
impaired	   in	   tumour	   cells	   and	   contributes	   to	  
elevate	   intracellular	   Mg	   (Wolf	   et	   al.,	   2007).	   In	  
addition,	   TRPM7	   is	   overexpressed	   in	   breast	  
tumours	  and	  in	  neoplastic	  cultured	  cells	  (Guilbert	  
et	   al.,	   2009),	   and	   this	   feature	  may	  well	   account	  
for	  the	  avidity	  of	  cancer	  cells	  for	  extracellular	  Mg.	  
Also	   nuclear	   Mg	   content	   is	   higher	   in	   neoplastic	  
than	   in	   normal	   cells	   (Lukacs	   et	   al.,	   1996).	  
Considering	   that	   Mg	   acts	   a	   second	   messenger	  
and	   activates	   a	   vast	   array	   of	   enzymes,	   it	   is	  
noteworthy	   that	   not	   only	   does	   intracellular	   Mg	  
increase,	   but	   it	   is	   also	   differently	   distributed	   in	  
transformed	  vs	  normal	  cells.	  	  
	  
The	  role	  of	  intracellular	  Mg	  in	  tumour	  cells	  
A	   very	   simple	   question	   is	   then	   raised:	   does	  
intracellular	   Mg	   impact	   on	   different	   aspects	   of	  
the	  neoplastic	  phenotype?	  Before	  addressing	  this	  
issue,	   it	   is	   useful	   to	   rapidly	   review	   the	   latest	  
hypotheses	  proposed	  to	  explain	  the	  contribution	  
of	   Mg	   to	   normal	   cell	   proliferation.	   Since	   Mg	  
participates	   in	  all	   the	  major	  metabolic	  processes	  
as	  well	  as	  to	  redox	  reactions,	  it	  is	  no	  surprise	  that	  





Figure	  2.	   	   Intracellular	  Mg	  controls	  cell	  proliferation.	   In	  normal	  cells,	   the	  binding	  of	  a	  growth	  factor	  to	   its	  
receptor	  determines	  membrane	  perturbations	  which	  decrease	  Mg	  binding	  affinity	   for	  negatively	   charged	  
membrane	   sites,	   thus	   increasing	   intracellular	   Mg	   levels.	   Increased	   intracellular	   Mg	   promotes	   polysome	  
formation,	   protein	   synthesis,	   DNA	   synthesis	   and	   ultimately	   cell	   division	   (according	   to	   Rubin,	   2007).	   In	  
neoplastic	   cells,	   the	  membranes	   are	   altered	   and	  differently	   organized.	   These	  modifications	   decrease	   the	  





it	  has	  a	  direct	  role	   in	  controlling	  cell	  survival	  and	  
growth.	   Cell	   survival	   is	   strictly	   related	   to	   attach-­‐
ment	   to	   the	   extracellular	   matrix.	   Adhesion	   and	  
consequent	   spreading	   are	   mediated	   by	   diverse	  
molecules,	   most	   notably	   by	   integrins	   which	  
require	   divalent	   cations	   such	   as	   Ca	   and	   Mg	   to	  
function	   (Rouslathi	   and	   Pierschbacher,	   1987).	  
Once	  the	  cells	  adhere	  and	  spread,	  they	  are	  alive,	  
metabolically	   active	   and	   ready	   to	   respond	   to	  
growth	  factors.	  According	  to	  a	  recently	  proposed	  
model	   (Rubin,	  2007),	   intracellular	  Mg	   levels	   vary	  
in	   quiescent	   vs	   growth	   factor-­‐activated,	   prolifer-­‐
ating	   cells.	   In	   quiescent	   cells,	   cytosolic	   Mg	  
stabilizes	   the	   plasma	  membrane	   and	   subcellular	  
organelles	  by	  complexing	  with	  negatively	  charged	  
phospholipids	   (Suh	   and	   Halle,	   2007),	   while	  
nuclear	  Mg	  stabilizes	  the	  double	  helix	  and	  retains	  
the	   chromatin	   structure	   (Figure	   2).	   Binding	   of	  
growth	   factors	   to	   their	   cognate	   receptors	  
perturbs	   the	   membranes	   and,	   consequently,	  
decreases	  Mg	  binding	  affinity	  for	  the	  membrane,	  
thus	  resulting	  in	  increased	  focal	  concentrations	  of	  
intracellular	   Mg	   (Rubin,	   2007).	   Also	   Mg	   influx	  
from	   the	   extracellular	   milieu	   contributes	   to	  
increase	   total	   intracellular	   Mg	   in	   response	   to	  
growth	   factors.	   In	   particular,	   EGF	   regulates	   Mg	  
transepithelial	   transport	   by	   increasing	   TRPM6	  
activity	   and	   surface	   expression	   (Thebault	   et	   al.,	  
2009).	  Intracellular	  Mg	  then	  behaves	  as	  a	  second	  
messenger	   and	   regulates	   a	   wide	   variety	   of	  
reactions	  ultimately	  leading	  to	  cell	  division.	  	  
	  
Neoplastic	   transformation	   dramatically	   disrupts	  
these	   controlled	   and	   coordinated	   fluctuations	   of	  
intracellular	   Mg	   (Figure	   2).	   Membrane	   perturb-­‐
ations	   that	   are	   typically	   associated	   with	   the	  
neoplastic	   phenotype	   determine	   the	   release	   of	  
intracellularly	   bound	  Mg.	   Accordingly,	   a	   seminal	  
study	   showed	   a	   significant	   increase	   of	   intra-­‐
cellular	  Mg	  in	  human	  brain	  tumours	  by	  31P-­‐NMR	  
(Taylor	  et	  al.,	  1991).	  	  
	  
Having	   high	   intracellular	   Mg	   might	   represent	   a	  
selective	  advantage	  for	  the	  transformed	  cells.	  Mg	  
forms	   complexes	  with	   ATP,	   ADP	   and	   GTP,	   being	  
necessary	   for	   the	   activity	   of	   enzymes	   implicated	  
in	   the	   transfer	   of	   phosphate	   groups	   such	   as	  
glucokinase,	   phosphofructokinase,	   phospho-­‐
glycerate-­‐kinase	   and	   pyruvate	   kinase	   (Gunther,	  
2008),	   enzymes	   of	   glycolysis,	   which	   is	   known	   to	  
be	  the	  preferential	  pathway	  utilized	  by	  neoplastic	  
cells	   to	   produce	   energy	   despite	   the	   presence	   of	  
oxygen.	  This	  issue	  has	  recently	  been	  reappraised.	  
The	   expression	   of	   TRPM7	   and,	   therefore,	   the	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capability	   of	   the	   cells	   to	   take	   up	   Mg	   has	   been	  
associated	  with	  the	  transition	  from	  a	  quiescent	  to	  
a	   proliferative	   metabolic	   state	   in	   which	   it	   is	  
aerobic	   glycolysis	   that	   generates	   the	   energy	  
necessary	  for	  cell	  growth	  (Sahni	  et	  al.,	  2010).	  
	  
Mg	   also	   complexes	   with	   DNA	   polymerase,	  
ribonucleases,	   adenylcyclase,	   phosphodiesterases,	  
guanylate-­‐cyclase,	   ATPases	   and	   GTPases,	   being	  
therefore	  implicated	  in	  the	  metabolism	  of	  nucleic	  
acids	   and	   proteins	   and	   in	   signal	   transduction.	   In	  
addition,	  Mg	  activates	   telomerase	   (Lue,	   1999),	   a	  
ribonucleoprotein	   that	   is	   responsible	   for	  
maintaining	   the	   terminal	   repeats	   of	   telomeres	  
and	  conferring	   limitless	  replicative	  potential.	   It	   is	  
because	  of	  the	  reactivation	  of	  telomerase	  activity	  
that	  transformed	  cells	  become	   immortal	   (Hanahan	  
and	  Weinberg,	  2000).	  	  
	  
Intriguingly,	   the	   nuclear	   Ser/Thr	   phosphatase	  
PPM1D	   (also	   known	   as	   WIP1),	   which	   is	   over-­‐
expressed	   in	   human	   primary	   breast,	   gastric,	  
pancreatic,	  ovarian	  and	  neuroblastoma	   tumours,	  
requires	  Mg	  for	   its	  activity.	  PPM1D	  is	   involved	  in	  
the	   regulation	   of	   several	   essential	   signalling	  
pathways	   that	   are	   implicated	   in	   cancer	  
pathogenesis	   (Le	   Guezennec	   and	   Bulavin,	   2010).	  
The	   oncogenic	   properties	   of	   PPM1D	   were	  
originally	   thought	   to	   stem	   from	   its	   ability	   to	  
dephosphorylate	   and,	   consequently,	   inactivate	  
the	   p53	   tumour	   suppressor	   gene.	   However,	  
recent	   studies	   have	   shown	   that	   PPM1D	   also	  
targets	   other	   key	   stress	   response	   kinases	   that	  
function	   in	  DNA	  damage	   response	  and	   repair.	   In	  
addition,	   PPM1D	   complements	   several	  
oncogenes,	  such	  as	  Ras,	  Myc,	  and	  HER-­‐2/neu,	  for	  
cellular	  trans-­‐formation	  both	  in	  vitro	  and	  in	  vivo.	  
Therefore,	  a	  rise	  in	  intracellular	  Mg	  might	  result	  in	  
a	   permanent	   activation	   of	   PPM1D	   and	   potently	  
contribute	   to	   several	   steps	   of	   tumour	  
development.	  	  
	  
A	  last	  issue	  needs	  consideration.	  Tumours	  should	  
be	   regarded	   as	   complex	   tissues	   in	  which	  normal	  
cell	   types	   within	   the	   stroma	   serve	   as	   active	  
collaborators	   in	  cancer	  progression.	  Many	  of	   the	  
growth	   signals	   driving	   the	   proliferation	   and	  
invasion	   of	   carcinoma	   cells	   originate	   from	   the	  
stromal	   cell	   components	   of	   the	   tumour	   mass.	  
Indeed,	   low	   Mg	   modulates	   the	   functions	   of	  
normal	   cells	   present	   in	   the	   tumour	   micro-­‐
environment.	   In	   particular,	   endothelial	   cells	  
cultured	   in	   low	   Mg	   release	   higher	   amounts	   of	  
metalloproteases	  and	  growth	  factors	  (Ferrè	  et	  al.,	  
2010).	   Similar	   results	   were	   obtained	   in	   cultured	  
human	   fibroblasts	   (Maier	   et	   al.,	   unpublished	  
results).	   In	   addition,	   low	   Mg	   promotes	  
endothelial	   and	   fibroblast	   senescence	   (Killilea	  
and	  Maier,	  2008)	  and	  senescent	  cells	  can	  modify	  
the	   tissue	   environment	   in	   a	  way	   that	   synergizes	  
with	   oncogenic	   mutations	   to	   promote	   the	  
progression	   of	   cancers	   (Campisi,	   2003).	   On	   the	  
other	  hand,	  low	  Mg	  impairs	  the	  acquisition	  of	  an	  
angiogenic	   phenotype	   in	   vitro.	   Yet,	   the	   question	  
about	   the	   role	   of	   Mg	   deficiency	   in	   cancer	  
remains:	  good	  or	  bad?	  	  
	  
A	  synthetic	  view	  
	  
How	  do	  we	  reconcile	  this	  wealth	  of	  information?	  
Although	   some	   results	   are	   controversial,	   it	   is	  
possible	   to	   conclude	   that	   most	   of	   the	   data	  
available	  point	  to	  low	  Mg	  as	  a	  contributing	  factor	  
to	   tumorigenesis.	   Mg	   deficiency	   increases	  
oxidative	   stress,	  which	  causes	  DNA	  damage,	  and	  
impairs	  DNA	  repair	  mechanisms.	  It	  therefore	  may	  
lead	   to	  mutations	   that	   produce	   oncogenes	   with	  
dominant	   gain	   of	   function,	   and	   tumour	  
suppressor	   genes	  with	   recessive	   loss	   of	   function	  
(Hanahan	   and	   Weinberg,	   2000).	   Upon	  
transformation,	   the	   cells	   lose	   the	   capability	   to	  
regulate	  Mg	  homeostasis.	  Mg	  also	  accumulates	  in	  
the	   cell	   when	   Mg	   availability	   is	   low,	   its	  
distribution	   is	   altered	   and	   is	   not	   subject	   to	  
coordinated	   fluctuations	   in	   response	   to	   various	  
stimuli.	   Low	  extracellular	  Mg	  also	  affects	  normal	  
stromal	  cells	  that	  can	  release	  growth	  factors	  and	  
proteases,	   thus	   potentiating	   tumour	   growth	   and	  
development.	   In	   addition,	   in	   vivo	   low	   Mg	  
activates	   an	   inflammatory	   response,	   which	   has	  




The	  connection	  between	  Mg	  and	  cancer	  is	  rather	  
strong,	   but	   several	   questions	   remain.	   First,	   it	  
might	   be	   asked	   whether	   Mg	   deficiency	   is	  
sufficient	  for	  the	  development	  of	  cancer.	  Indeed,	  
low	   Mg	   increases	   the	   levels	   of	   reactive	   oxygen	  
species,	   which	   mutate	   DNA	   and,	   therefore,	  
generate	  genetic	  instability.	  Another	  candidate	  as	  
a	   potential	   carcinogen	   in	   Mg	   deficiency	   is	  
inflammation.	   However,	   it	   is	   more	   likely	   that	   a	  
low	  Mg	   state	   only	   contributes	   to	   tumorigenesis	  
by	  synergizing	  with	  many	  different	  factors.	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A	   second	   aspect	   that	   is	   often	   underevaluated	   is	  
the	   effect	   on	   the	   tumour	   of	   an	   aberrant	   Ca:Mg	  
ratio	   that	   is	   inevitably	   created	   in	  Mg	   deficiency.	  
Even	   though	   Ca	   and	   Mg	   have	   become	   the	   gold	  
standard	  when	  discussing	  nutritional	   supplements,	  
the	  balance	  between	  the	  two	  cations	  needs	  to	  be	  
carefully	  evaluated	  both	  in	  vitro	  and	  in	  vivo.	  
	  
A	   third	  question	  arises	  about	  whether	  outcomes	  
in	   the	   cancer	   mouse	   model	   can	   predict	   a	   real	  
human	  disease	  mechanism.	  Mg	  deficiency	  retards	  
primary	  tumour	  growth	  but	  enhances	  metastases	  
in	   mice.	   It	   would	   be	   relevant	   to	   consider	   the	  
balance	  between	  cancer-­‐promoting	  and	   inhibiting	  
responses	  by	  low	  Mg	  in	  humans	  also.	  	  
	  
The	  last	  big	  question	  is	  whether	  knowledge	  about	  
the	   connection	  between	   low	  Mg	  and	  cancer	   can	  
be	   translated	   into	   useful	   approaches	   to	   prevent	  
and	   treat	   cancer.	   Most	   of	   the	   data	   available	  
suggest	   that	   Mg	   could	   be	   a	   chemo-­‐preventive	  
agent.	   Therefore,	   correcting	   Mg	   intake	   might	  
represent	   an	   effective	   and	   low	   cost	   preventive	  
measure	   to	   reduce	   cancer	   risk.	   The	   picture	   is	  
different	   in	   oncologic	   patients,	   because	  
hypomagnesemia	   might	   be	   beneficial	   since	   it	  
sensitizes	  	  	  	  	  neoplastic	  	  	  	  	  cells	  	  	  	  	  to	  	  	  	  radiation	  	  	  or	  	  
chemotherapeutics.	   Therefore	   the	   “hamletic”	  
doubt	   remains:	   to	   treat	   or	   not	   to	   treat	   hypo-­‐
magnesemic	  oncologic	  patients?	  	  
Conclusion	  
Future	  research	  should	   focus	  on	  elucidating	  how	  
Mg	   is	   involved	   in	   preventing	   cancer	   by	  
modulating	   crucial	   events	   in	   signal	   transduction	  
pathways	   and	   the	   cell	   cycle.	   Hints	   might	   derive	  
from	   nutrigenomics,	   i.e.	   the	   use	   of	   high-­‐
throughput	   genomic	   methods	   in	   nutritional	  
studies,	  which	  can	  provide	  information	  about	  the	  
cross-­‐talk	  between	  Mg	  and	  genes.	  The	  next	   step	  
should	   lead	   to	   translation	   of	   this	   basic	   research	  
into	   nutritional	   preventive	   protocols	   for	   human	  
tumours,	   an	   approach	   that	   will	   involve	   many	  
scientific	   disciplines.	   The	   challenge	   is	   great,	   but	  
the	  reward	  might	  be	  enormous.	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  an	  update	  in	  clinical	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Magnesium	   (Mg)	   is	   essential	   for	   cell	   functions	   such	   as	   transport	   of	   calcium	   and	   potassium	   ions,	   and	  
modulates	   signal	   transduction,	   energy	  metabolism,	   and	   cell	   proliferation.	   Several	   studies	   elucidated	   a	  
reduced	  concentration	  of	  Mg	  in	  patients	  with	  Parkinson’s	  disease	  (PD),	  and	  experimentally,	  severe	  loss	  of	  
dopaminergic	  neurons	  exclusively	   in	   the	   substantia	  nigra	   in	  1-­‐year-­‐old	   rats	   that	  had	  been	  subjected	   to	  
continuously	   low	  Mg	   intake	  (one-­‐fifth	  of	   the	  normal	   level)	  over	  generations.	  A	  study	  conducted	  by	  the	  
authors	   revealed	   a	   significant	   and	   striking	   effect	   of	  Mg	   to	  prevent	  neurite	   and	  neuron	  pathology,	   and	  
also	   to	  ameliorate	  neurite	  pathology	   in	  a	   rat	  Parkinson	  disease	   (PD)	  model	   involving	  culture	  of	  ventral	  
mesencephalic-­‐striatal	   cells	   with	   1-­‐methyl-­‐4-­‐phenylpyridinium	   (MPP+).	  Mg	   is	   expected	   to	   prevent	   and	  





Parkinson’s	   disease	   (PD)	   is	   a	   neurodegenerative	  
disease	   occurring	   in	   middle-­‐aged	   and	   aged	  
humans	   characterized	   by	   clinical	   symptoms	  
including	  tremor	  and	  rigidity	  (Parkinson,	  1817).	  It	  
has	   been	   reported	   that	   almost	   90%	   of	   the	  
patients	   are	   sporadic	   and	   10%	   are	   familial.	  
Sporadic	   PD	   shows	   neuropathological	   features	  
involving	   the	   appearance	   of	   Lewy	   bodies	   (Lewy,	  
1912;	  Tretiakoff,	  1919)	  and	  loss	  of	  neurons	  in	  the	  
substantia	  nigra	   (Figures	  1	  and	  2)	  and	  substantia	  
innominata.	  After	  establishment	  of	  the	  disease	  as	  
an	   entity,	   it	   was	   revealed	   that	   dopaminergic	  
neurons	  in	  the	  ventral	  tegmental	  area,	  noradren-­‐
ergic	   neurons	   in	   the	   locus	   coeruleus	   and	  motor	  
vagal	  nucleus,	  serotonergic	  neurons	  in	  the	  dorsal	  
raphe	   nucleus,	   and	   neurons	   in	   the	   sympathetic	  
ganglia	   and	   visceral	   autonomic	   nervous	   system	  
are	  involved	  in	  the	  disease	  with	  neuronal	  loss	  and	  
presence	   of	   Lewy	   bodies	   (Jellinger,	   1999).	   In	   the	  
present	  manuscript,	  the	  authors	  review	  the	  role	  of	  
magnesium	   (Mg)	   in	   the	   pathogenesis	   and	   patho-­‐
mechanisms	  in	  clinical	  and	  basic	  aspects	  of	  PD.	  
	  
Mg	  in	  Parkinson’s	  disease	  and	  related	  diseases	  
	  
Uitti	   et	   al.,	   (1989)	   analysed	   four	   brain	   regions	  
(frontal	  cortex,	  caudate	  nucleus,	  substantia	  nigra	  
and	   cerebellum)	   for	   concentrations	  of	  24	  metals	  
(Ag,	  Al,	  As,	  B,	  Be,	  Ca,	  Cd,	  Co,	  Cr,	  Cu,	  Fe,	  K,	  Pb,	  Mg,	  
Mn,	   Mo,	   Na,	   Ni,	   P,	   Se,	   Ti,	   V,	   W,	   Zn)	   by	   atomic	  
absorption	   and	   atomic	   emission	   spectroscopy	   in	  
brains	   of	   9	   patients	   with	   PD,	   15	   patients	   with	  
other	   chronic	   neurological	   diseases	   and	   12	  
subjects	  of	  controls.	  The	  results	  were	  that	  brains	  
of	  PD	  and	  parkinsonism	  secondary	  to	  neurofibrillary	  
tangle	   disease	   showed	   lower	   concentrations	   of	  
Mg	   in	   the	   caudate	   nucleus	   and	   copper	   in	   the	  
substantia	  nigra	   than	   control	   brains.	  Barbiloni	  et	  
al.,	   (1999)	   performed	   in	   vivo	   phosphorus	  
magnetic	  resonance	  spectroscopy	  on	  the	  occipital	  
lobes	   of	   13	   patients	   with	   PD,	   15	   patients	   with	  
multiple	   system	   atrophy	   and	   16	   age-­‐matched	  
healthy	   subjects.	   They	   reported	   that	   patients	  
with	   PD	   showed	   significantly	   increased	   contents	  
of	   inorganic	   phosphate	   (Pi),	   decreased	   cytosolic	  
free	  [Mg2+],	  and	  unchanged	  phosphocreatine	  and	  
pH.	  Bocca	  et	  al.,	  (2006)	  examined	  concentrations	  
of	   Ca,	   Cu,	   Fe,	   Mg,	   Si	   and	   Zn	   by	   inductively	  
coupled	   plasma	   atomic	   emission	   spectrometry	  
(ICP-­‐AES)	   in	   blood,	   urine	   and	   cerebrospinal	   fluid	  
(CSF)	   of	   91	   PD	   patients	   and	   18	   controls.	   They	  
concluded	   that	   Mg	   concentration	   in	   CSF	   of	   PD	  
patients	  decreased	  with	  the	  duration	  and	  severity	  
of	  the	  disease.	  	  	  
	  	  
It	   has	   been	   proposed	   that	   Mg	   deficiency	   is	  
involved	   in	   the	   pathogenesis	   of	   parkinsonism-­‐
dementia	  complex	  (PDC)	  and	  amyotrophic	  lateral	  	  





Figure	  1.	  Midbrain	  and	  upper	  pons.	  The	  substantia	  
nigra	   and	   locus	   coeruleus	   in	   the	   patient	   with	  
Parkinson’s	   disease	   show	   marked	   depigmentation	  
as	  compared	  with	  those	  of	  controls.	  
	  
sclerosis	  (ALS)	  in	  the	  Chamorro	  population	  on	  
Guam,	  which	  is	  a	  member	  of	  the	  Mariana	  Islands	  
in	  the	  western	  Pacific	  Ocean,	  as	  well	  as	  in	  the	  Kii	  
peninsula	  of	  Japan	  and	  in	  West	  New	  Guinea	  (Yase	  
1978,	   Garruto	   et	   al.,	   1984).	   PDC	   is	   a	   disease	  
entity	   that	   was	   established	   by	   Hirano	   et	   al.,	  
(1961a;	   1961b)	   that	   affects	   the	   neurons	   in	   the	  
substantia	   nigra,	   brainstem,	   and	   temporal	   and	  
frontal	  cortex.	  The	  disease	  is	  characterized	  by	  the	  
presence	   of	   neurofibrillary	   tangles	   in	   the	  
remaining	  neurons,	  and	  disease-­‐specific	  granular	  
hazy	   inclusions	   in	   the	   astrocytes	   (Oyanagi	  et	   al.,	  
1997;	   Oyanagi,	   2005),	   tau-­‐positive	   fine	   granules	  
in	   the	   cerebral	   white	   matter	   (Yamazaki	   et	   al.,	  
2005),	   and	   widespread	   TDP-­‐43-­‐immunopositive	  
inclusions	   (Hasegawa	   et	   al.,	   2007).	   Patients	  
exhibit	   parkinsonism	   and	   dementia,	   and	   usually	  
die	  within	  about	  5	  years	  from	  infectious	  diseases	  
(Hirano	   et	   al.,	   1961a;	   1961b;	   Chen	   and	   Chase,	  
1985).	  ALS	  is	  a	  motor	  neuron	  disease	  affecting	  the	  
Betz	   cells	   in	   the	   cerebral	   cortex,	   and	   facial	   and	  
hypoglossal	   nuclei	   in	   the	  brainstem	  and	  anterior	  
horn	  cells	  in	  the	  spinal	  cord,	  and	  usually	  patients	  
die	  of	   respiratory	   failure	  within	  5	  years	  after	   the	  
onset.	  	  
	  
Possible	  pathomechanisms	  in	  Parkinson’s	  
disease	  
	  
Mitochondrial	  damage	  and	  oxidative	  stress	  
Increased	  	  expression	  of	  4-­‐hydroxy-­‐2-­‐nonenal	  
(HNE)	  (Yoritaka	  et	  al.,	  1996),	  decreased	  activity	  of	  
mitochondrial	  complex	  I	  and	  a	  decreased	  amount	  
	  
	  
Figure	   2.	   The	   substantia	   nigra	   of	   a	   patient	   with	  
Parkinson’s	  disease	  shows	  severe	  loss	  of	  neurons	  
as	   compared	   with	   a	   control	   subject.	   Some	  
remaining	  neurons	  represent	  Lewy	  bodies.  
	  
of	  alpha-­‐ketoglutarate	  dehydrogenase	  complex	  
(KGDHC)	  in	  the	  pigmented	  neurons	  of	  the	  substantia	  
nigra	   (Hattori	   et	   al.,	   1991;	   Mizuno	   et	   al.,	   1994)	  
have	   been	   reported	   in	   affected	   patients.	   In	   the	  
substantia	   nigra,	   decreased	   activity	   of	   catalase	  
and	   peroxidase	   (Ambani	   et	   al.,	   1975)	   and	  
increased	   amounts	   of	   protein	   carbonyls,	   8-­‐
hydroxy-­‐2'-­‐deoxyguanosine	   (8-­‐OHdG)/8-­‐hydroxy-­‐
guanine	   (8-­‐OHG),	   4-­‐hydroxynonenal-­‐lysine	   and	  
malondialdehyde-­‐lysine	   (MDAL)	   (Alam	   et	   al.,	  
1997a,b;	   Zhang	   et	   al.,	   1999;	   Dalfo	   et	   al.,	   2005)	  
have	  been	  reported.	  
	  
1-­‐Methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine	  
(MPTP)	   was	   the	   first	   human	   parkinsonian	   agent	  
to	  be	  characterized.	  It	  is	  converted	  to	  1-­‐methyl-­‐4-­‐
phenylpyridinium	   (MPP+)	  by	  monoamine	  oxidase	  
B	   in	   astrocytes.	   MPP+	   damages	   mitochondrial	  
complex	  I	  of	  dopaminergic	  neurons	  after	  transfer	  
by	   the	   dopamine	   transporter,	   and	   increased	  
calcium	   permeability	   of	   the	   mitochondrial	  
membrane	   induces	   free	   radicals	   (Smeyne	   et	   al.,	  
2005).	   MPP+	   has	   been	   used	   to	   induce	   selective	  
degeneration	   of	   dopaminergic	   neurons	   in	   an	  
experimental	   model	   of	   PD	   (Nakamura	   et	   al.,	  
2000).	  In	  addition,	  rotenone,	  6-­‐hydroxydopamine	  
(6-­‐OHDA),	   paraquat	   and	   annonacin	   have	   been	  
used	   as	   noxious	   agents	   to	   create	   in	   vivo	  models	  
of	   PD	   (Fornai	   et	   al.,	   2003;	   Champy	   et	   al.,	   2004;	  
Bove	   et	   al.,	   2005)	   (Figure	   3).	   Dopamine	   and	  
dopamine	  quinones	  themselves	  are	  considered	  to	  
be	  causes	  of	  oxidative	  stress.	  PINK1	  (PTEN-­‐induced	  
putative	  kinase	  1)	  maintains	  mitochondrial	  function	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Figure	   3.	   Possible	   relationship	   between	   mito-­‐
chondria,	  rough	  ER	  and	  Lewy	  body	  formation.	  
	  
	  
and	   the	   gene	   is	   causative	   in	   some	   familial	   PD	  
(Valente	  et	  al.,	  2004).	  	  
	  
Unfolded	   protein	   retention	   and	   endoplasmic	  
reticulum	  stress	  
Alpha-­‐synuclein	  was	  found	  as	  a	  main	  component	  
of	  the	  Lewy	  bodies	  and	  the	  gene	  was	  found	  to	  be	  
a	   causative	   gene	   of	   a	   rare	   autosomal	   dominant	  
PD	   (Polymeropoulos	   et	   al.,	   1997).	   It	   has	   been	  
reported	  that	  multiplication	  of	  the	  gene	  was	  to	  
be	   the	   cause	   of	   the	   disease	   (Singleton	   et	   al.,	  
2003).	   It	   has	   been	   suggested	   that	   aggregates	   of	  
alpha-­‐synuclein	   cause	   potentiation	   of	   oxidative	  
stress,	  	  possibly	  	  with	  	  interaction	  	  with	  	  iron.	  	  
	  
Synuclein	  was	  considered	  to	  be	  degraded	  in	  the	  
proteasome.	  Knockout	  of	   the	  26S	  proteasome	   in	  
the	  dopaminergic	  neurons	  induced	  “pale	  bodies”,	  
which	   is	   reported	   to	  be	  a	  prodrome	  of	   the	  Lewy	  
bodies	  (Bedford	  et	  al.,	  2008).	  	  	  
	  
Parkin	   and	   UCHL-­‐1	   are	   considered	   essential	   for	  
ubiquitination	   of	   the	   unfolded	   proteins,	   and	   the	  
gene	  mutations	  were	   found	   in	   some	   familial	  PD.	  
It	   is	   considered	   that	   oxidative	   stress	  may	   lead	   a	  
combination	   of	   Parkin	   and	   DJ-­‐1,	   and	   the	  
combination	  suffocates	  unfolded	  protein	  degrad-­‐
ation	   (Kitada	   et	   al.,	   1998;	   Bonifati	   et	   al.,	   2003).	  
Mg	  has	  also	  been	  reported	  to	  inhibit	  spontaneous	  
and	   iron-­‐induced	   aggregation	   of	   alpha-­‐synuclein	  
(Golts	  et	  al.,	  2002)	  (Figure	  4).	  	  
	  
Low	  Mg	  and	  Parkinson’s	  disease	  model	  	  
	  
In	   the	   course	   of	   investigations	   into	   the	   patho-­‐
genesis	  of	  the	  PDC,	  the	  present	  authors	  performed	  
an	   experiment	   in	   which	   rats	   were	   exposed	   to	  
restricted	   intake	   of	   Ca	   and/or	   Mg	   over	   two	  
generations.	   This	   resulted	   in	   severe	   loss	   of	  
dopaminergic	   neurons	   exclusively	   in	   the	  
substantia	  nigra	   in	  1-­‐year-­‐old	   rats	   that	  had	  been	  
subjected	   to	   continuously	   low	   Mg	   intake	   (one-­‐




Figure	  4.	  Scheme	  of	  possible	  pathomechanisms	  of	  dopaminergic	  neuron	  death	  in	  Parkinson’s	  disease.	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(Oyanagi	   et	   al.,	   2006).	   This	   finding	   suggested	   a	  
deep	   concern	   of	   low	   Mg	   intake	   over	   several	  
generations	  to	  the	  pathogenesis	  of	  degeneration	  
of	  the	  substantia	  nigra	  in	  humans.	  	  
	  
Therapeutic	  possibility	  by	  Mg	  for	  Parkinson’s	  
disease	  
	  
As	  a	  blocker	  of	  the	  glutamatergic	  NMDA	  
receptor	  	  
Mg	   controls	   cytochrome	   c	   release	   in	   mito-­‐
chondria	   (Eskes	   et	   al.,	   1998),	   and	   decreases	   the	  
activity	  of	  N-­‐methyl-­‐D-­‐aspartate	   (NMDA)	  receptors	  
in	   excitotoxicity	   (Mayer	   et	   al.,	   1984).	   Mg	  
treatment	   has	   also	   been	   shown	   to	   decrease	  
cerebral	   infarct	   volume	   in	   rats	   in	   vivo	   (Lyden	   et	  
al.,	   2000).	   The	   mechanism	   responsible	   for	   the	  
neuroprotective	  effect	  of	  Mg	  has	  been	  considered	  
to	   be	   reduced	   presynaptic	   release	   of	   the	  
neurotrans-­‐mitter	   glutamate	   (Lin	   et	   al.,	   2002),	  
and	   blockade	   of	   the	   glutamatergic	   NMDA	  
receptor	   (Nowak	   et	   al.,	   1984)(Figure	   5).	   A	  
relationship	   between	   decreased	   Mg	  
concentration	   in	   serum	   and	   migraine	   has	   been	  
reported	   in	   humans,	   and	   it	   has	   been	   suggested	  
that	  migraine	  might	  be	  caused	  by	  hypersensitivity	  
of	   the	   NMDA	   receptor	   to	   glutamic	   acid	   and	  
certain	   other	   neuro-­‐excitatory	   amino	   acids	   due	  
to	   Mg	   depletion	   (Cojocaru	   et	   al.,	   2006).	   A	  
decrease	  of	  cytosolic	  free	  Mg	  in	  the	  occipital	  lobe	  
of	   PD	   patients	   has	   also	   been	   demonstrated	   by	  
phosphorus	   magnetic	   response	   spectroscopy	  





Figure	  5.	  Metallic	  elements	  and	  neuron	  conduction.	  
	  
	  
Figure	   6.	   	   Severe	   atrophy	   and	   selective	   loss	   of	  
dopaminergic	   neurons	   in	   the	   substantia	   nigra	   in	  




As	  an	  inhibiter	  of	  oxidative	  stress	  
The	  present	  authors	  conducted	  a	  study	  to	  clarify	  
the	  effects	  of	  Mg	  administration	  in	  a	  rat	  PD	  model	  
involving	   culture	   of	   ventral	   mesencephalic-­‐
striatal	   cells	   with	   1-­‐methyl-­‐4-­‐phenylpyridinium	  
(MPP+),	   based	   on	   recent	   evidence	   for	   significant	  
loss	   of	   dopaminergic	   neurons	   exclusively	   in	   the	  
substantia	  nigra	  of	  1-­‐year-­‐old	  rats	  after	  exposure	  
to	   low	   Mg	   intake	   over	   generations	   (Oyanagi	   et	  
al.,	  2006)	  (Figure	  6).	  The	  results	  indicated	  that	  Mg	  
might	   protect	   dopaminergic	   neurons	   in	   the	  
substantia	   nigra	   from	   degeneration.	   The	  
concentration	   of	   Mg	   in	   the	   culture	   medium	  
varied	  from	  0.8	  mM,	  corresponding	  to	  the	  control	  
condition,	   to	  4.0	  mM.	  Effects	  were	  estimated	  by	  
counting	   the	   number	   of	   surviving	   dopaminergic	  
neurons	  immunopositive	  for	  tyrosine	  hydroxylase	  
and	   measuring	   the	   length	   of	   dopaminergic	  
neurites.	  An	   increase	   in	   the	  concentration	  of	  Mg	  
to	   1.2	   mM	   significantly	   inhibited	   the	   toxicity	   of	  
MPP+,	  and	  a	  concentration	  of	  4.0	  mM	  completely	  
prevented	   any	   decrease	   in	   the	   number	   of	  
dopaminergic	   neurons.	   The	   length	   of	   dopam-­‐
inergic	  neurites	  was	  significantly	  preserved	   in	   the	  
presence	  of	  Mg	  at	  1.2	  and	  4.0	  mM.	  An	  increase	  in	  
the	  concentration	  of	  Mg	  to	  1.2	  and	  4.0	  mM	  led	  to	  
a	  significant	  amelioration	  in	  the	  length	  of	  dopam-­‐
inergic	  neurites	  after	  MPP+	  toxicity	  (Figure	  7).	  




Figure	  7.	   Prevention	  of	  MPP+	   toxicity	  by	  Mg	   in	  a	  
Parkinson	   model	   (Hashimoto	   et	   al.,	   2008).	   a:	  
normal	  condition	  of	  cultured	  nigral	  dopaminergic	  
neurons.	  b:	   severe	   loss	  of	  dopaminergic	  neurons	  
and	  the	  neuritis	  after	  MPP+	  administration.	  c:	  An	  
increase	   in	   the	   concentration	   of	   Mg	   to	   1.2	   mM	  
significantly	  inhibited	  the	  toxicity	  of	  MPP+.	  
	  
This	  was	  the	  first	  report	  to	  document	  a	  significant	  
and	  striking	  effect	  of	  Mg	  for	  prevention	  of	  neurite	  
and	   neuron	   pathology,	   and	   also	   amelioration	   of	  
neurite	  pathology	   in	  a	  PD	  model.	   In	  addition,	  an	  
increase	  in	  the	  Mg	  concentration	  to	  1.2,	  2.0,	  and	  
4.0	  mM	  did	  not	  induce	  any	  degenerative	  features	  
in	   the	   cultured	   dopaminergic	   cells,	   suggesting	  
that	  a	  Mg	  concentration	  of	  up	   to	  4.0	  mM	   in	   the	  
extracellular	   space	  might	  not	   induce	  any	  neuron	  
degeneration	   in	   humans.	   Mg	   oxide	   per	   os	   has	  
often	   been	   used	   as	   a	   laxative	   for	   patients	   with	  
PD,	  but	  is	  reportedly	  not	  absorbed	  in	  the	  bowels,	  
thus	  not	  affecting	  the	  serum	  concentration	  of	  Mg	  
(Sakimura	   et	   al.,	   1998).	   Recent	   studies	   by	   the	  
authors	   using	   mice	   also	   established	   that	   no	  
significant	   alteration	  was	   found	   in	   the	  CSF	  of	  B6	  
mice	   injected	   intraperitoneally	   with	   Mg,	   even	  
though	   the	   serum	   Mg	   concentration	   was	  
significantly	   increased	   (Sun	  et	  al.,	   2009).	  Further	  
research	  is	  necessary	  to	  find	  Mg	  compounds	  that	  
can	   easily	   be	   absorbed	   in	   the	   bowels	   and	   pass	  
through	   the	   blood-­‐brain	   barrier,	   like	   Mg-­‐L-­‐
threonate	   (Slutsky	   et	   al.,	   2010)	   and	   besides,	   via	  
transporters	  that	  can	  carry	  Mg	  through	  the	  bowel	  
mucosa,	   blood-­‐brain	   barrier	   and	   plasma	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Alzheimer’s	   disease	   (AD)	   is	   the	   most	   common	   form	   of	   dementia.	   It	   is	   characterized	   by	   a	   progressive	  
cognitive	   impairment	   clinically,	   and	   excessive	   deposits	   of	   aggregated	   amyloid-­‐β 	   (Aβ)	   peptides	  
pathologically.	   Environmental	   factors,	   including	   nutrition	   and	   metal	   elements,	   are	   implicated	   in	   the	  
pathophysiology	   of	   AD.	   Magnesium	   (Mg)	   affects	   many	   biochemical	   mechanisms	   vital	   for	   neuronal	  
properties	  and	  synaptic	  plasticity,	   including	  the	  response	  of	  N-­‐methyl	  D-­‐aspartate	  (NMDA)	  receptors	  to	  
excitatory	   amino	   acids,	   stability	   and	   viscosity	   of	   the	   cell	   membrane,	   and	   antagonism	   of	   calcium.	   Mg	  
levels	  were	   found	  to	  be	  decreased	   in	  various	   tissues	  of	  AD	  patients	  and	  negatively	  correlated	  with	  clinical	  
deterioration.	  Moreover,	  Mg	  was	  demonstrated	  to	  modulate	  the	  trafficking	  and	  processing	  of	  amyloid-­‐β 	  
precursor	  protein,	  which	  plays	  a	  central	  role	  in	  the	  pathogenesis	  of	  AD.	  Here,	  we	  review	  in	  vitro	  and	  in	  




Alzheimer’s	   disease	   (AD)	   is	   the	   most	   prevalent	  
neurodegenerative	   disease	   in	   elderly	   people,	  
affecting	  approximate	  6-­‐8%	  of	  all	  individuals	  over	  
the	   age	   of	   65	   years.	   AD	   is	   characterized	   by	  
progressive	   cognitive	   impairment	   and	   distinct	  
neuropathological	   lesions	   in	   the	   brain,	   including	  
intracellular	   neurofibrillary	   tangles,	   and	  
extracellular,	   parenchymal	   and	   cerebrovascular	  
senile	   plaques	   (Braak	   and	   Braak,	   1991).	   Senile	  
plaques	   are	  mainly	   constituted	   of	   a	   39–42	   amino	  
acid	  peptide,	  amyloid-­‐β	  protein	  (Aβ)	  (Glenner	  and	  
Wong,	   1984;	   Masters	   et	   al.,	   1985),	   which	   is	  
generally	   accepted	   as	   being	   neurotoxic	   and	  
playing	   a	   central	   role	   in	   the	   pathogenesis	   of	  
neuronal	   dysfunction	   and	   synaptic	   failure	   in	  
Alzheimer's	   disease	   (Selkoe,	   1991;	   Hardy	   and	  
Selkoe,	   2002).	   Aβ	   is	   derived	   from	   full-­‐length	  
amyloid-­‐β	   precursor	   protein	   (APP)	   (Kang	   et	   al.,	  
1987;	  Qi-­‐Takahara	  et	  al.,	  2005),	  which	   is	  a	   type	   I	  
trans-­‐membrane	   protein	   composed	   of	   a	   large	  
extracellular	   domain,	   a	   short	   transmembrane	  
domain,	   and	   a	   cytoplasmic	   tail,	   by	   sequential	  
proteolytic	   cleavages	   by	   β-­‐secretase	   and	   γ-­‐
secretase.	  The	  β-­‐cleavage	  of	  APP,	  catalysed	  by	  the	  
well	   characterized	   transmembrane	   aspartyl	  
protease	   β-­‐site	   APP-­‐cleaving	   enzyme	   (BACE)	  
(Hussain	  et	  al.,	  1999;	  Sinha	  et	  al.,	  1999;	  Yan	  et	  al.,	  
1999;	  Haniu	  et	  al.,	  2000),	  cleaves	  APP	  at	  the	  NH2-­‐
terminus	   of	   the	   Aβ	   sequence	   (Seubert	   et	   al.,	  
1993)	   to	   generates	   a	   soluble	   version	   of	   APP	  
(sAPP)	  and	  a	  99-­‐residue	  COOH-­‐terminal	  fragment	  
(CTFβ	  or	  C99)	  which	  remains	  membrane	  bound.	  
	  
C99	   is	   further	   cleaved	   to	   release	   Aβ	   of	   varying	  
lengths,	   predominantly	   Aβ40	   and	   Aβ42	   (Selkoe,	  
2001;	   Hussain	   et	   al.,	   1999;	   Price	   et	   al.,	   1998;	  
Sinha	  et	  al.,	  1999;	  Christensen	  et	  al.,	  2004),	  by	  an	  
atypical	   aspartyl	   protease,	   γ-­‐secretase	   complex	  
which	   contains	   at	   least	   four	   different	   proteins,	  
namely	   Aph-­‐1,	   nicastrin,	   presenilin,	   and	   Pen-­‐2	  
(De	   Strooper,	   2003;	   Edbauer	   et	   al.,	   2003).	  
Proteolysis	  by	  γ-­‐secretase	  is	  heterogeneous;	  most	  
of	   the	   full-­‐length	   Aβ	   species	   produced	   is	   a	   40-­‐
residue	   peptide	   (Aβ40),	   whereas	   a	   small	  
proportion	  is	  a	  42-­‐residue	  COOH-­‐terminal	  variant	  
(Aβ42)	   (Esler	   and	   Wolfe,	   2001).	   However,	   prior	  
processing	   of	   APP	   by	   α-­‐secretase	   precludes	   the	  
formation	  of	  the	  neurotoxic	  Aβ.	  It	  cuts	  APP	  within	  
the	  Aβ	  region	  (between	  residues	  Lys16	  and	  Leu17	  
of	   Aβ),	   generating	   a	   sAPPα	   and	   a	   membrane-­‐
anchored	   83-­‐residue	   C-­‐terminal	   fragment	   (CTFα	  
or	   C83),	  which	   is	   also	   a	   substrate	   of	   γ-­‐secretase	  
(Esch	   et	   al.,	   1990;	   Sisodia,	   1992).	  α-­‐Secretase	   is	  
thought	   to	   be	   a	  metalloprotease,	   such	   as	   TNF-­‐α	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converting	   enzyme	   (TACE)	   or	   a	   disintegrin	   and	  
metalloprotease	   10	   (ADAM10)	   (Lammich	   et	   al.,	  
1999).	   Secreted	   APP	   exerts	   proliferative	   actions	  
in	   a	   variety	   of	   cell	   types	   as	   well	   as	   neurotropic	  
and	  neuroprotective	  effects	  (Mucke	  et	  al.,	  1996).	  
	  
Synaptic	   failure	   in	  AD	   is	   caused	  by	  accumulation	  
and	   oligomerization	   of	   Aβ42	   in	   limbic	   and	  
association	   cortices	   (Selkoe,	   2002).	  Mutations	   in	  
the	   APP	   gene	   or	   presenilin	   (PS)	   1	   or	   2	   genes,	  
which	   cause	  an	  autosomal	  dominant	  early	  onset	  
familial	   AD	   (<5%	   of	   AD	   patients),	   increases	   the	  
relative	   production	   of	   Aβ42	   (Wiltfang	   et	   al.,	  
2001).	   In	   the	  majority	   of	   patients	  with	   so-­‐called	  
sporadic	   late-­‐onset	   AD,	   an	   age-­‐dependent	  
accumulation	  of	  Aβ,	  caused	  by	  disturbed	  dynamic	  
balance	   between	   anabolic	   and	   catabolic	  
activities,	   has	   been	   implicated	   (Selkoe,	   1999;	  
2001b).	   Also,	   environmental	   factors,	   such	   as	  
metallic	   elements	   may	   play	   a	   protective	   or	  
disruptive	   role	   in	   the	   pathogenesis	   of	   AD	   (for	  
review,	  see	  Adlard	  and	  Bush,	  2006;	  Shcherbatykh	  
and	   Carpenter,	   2007).	   Different	   metals	   may	   be	  
involved	   in	   multiple	   aspects	   of	   the	   disease	  
process,	   such	   as	   the	   regulation	   of	   APP	   gene	  
expression	  and	  mRNA	  translation,	  the	  proteolytic	  
processing	   of	   APP,	   the	   aggregation	   and	  
degradation	   of	   Aβ,	   and	   the	   formation	   of	   neuro-­‐
fibrillary	   tangles.	   Heavy	   metals	   (e.g.	   lead,	  
mercury	   and	   cadmium)	   are	   neurotoxic	   and	  
associated	  with	  intellectual	  impairment	  (Bleecker	  
et	  al.,	  2005).	  Recent	  studies	  have	  implicated	  lead	  
exposure	  in	  the	  subsequent	  elevation	  of	  APP	  and	  
Aβ	   in	   animals	   (Basha	  et	   al.,	   2005b)	   as	  well	   as	   in	  
the	  aggregation	  of	  synthetic	  Aβ1–40	  in	  vitro	  (Basha	  
et	  al.,	  2005a).	   In	   the	  case	  of	  aluminium,	  another	  
“toxic”	  metal,	   its	   relevance	   to	   AD	   is	   ascribed	   to	  
the	  involvement	  in	  the	  formation	  of	  paired	  helical	  
filaments	   (PHF),	   the	   aggregation	   and	   toxicity	   of	  
Aβ,	   and	   the	   generation	   of	   oxidative	   species	   (for	  
review,	  see	  Gupta	  et	  al.,	  2005).	  Transition	  metals	  
(e.g.	  copper,	  zinc,	  and	  iron,	  which	  are	  essential	  in	  
cell	  biology)	  can	  induce	  Aβ	  aggregation	  (Huang	  et	  
al.,	   2004;	   Mantyh	   et	   al.,	   1993)	   and	   are	   found	  
concentrated	   in	  and	  around	  the	  amyloid	  plaques	  
in	   the	   AD	   brain	   (Lovell	   et	   al.,	   1998).	   Disturbed	  
homeostasis	   of	   these	   biometals	   in	   the	   AD	   brain	  
(decreased	   copper	   levels,	   and	   increased	   concen-­‐
trations	   of	   iron,	   zinc,	   and	  manganese)	   has	   been	  
reported	   (Cornett	   et	   al.,	   1998;	   Deibel	   et	   al.,	  
1996).	  An	  imbalance	  of	  zinc	  and	  copper	  has	  been	  
shown	   to	   significantly	   alter	   APP	   processing	   and	  
Aβ	   generation	   in	   relevant	   animal	  models	   (Bayer	  
et	  al.,	  2003;	  Borchardt	  et	  al.,	  1999;	  Phinney	  et	  al.,	  
2003;	  Sparks	  and	  Schreurs,	  2003;	  Lee	  et	  al.,	  2002;	  
Friedlich	  et	  al.,	  2004).	  
	  
Neurological	  function	  of	  magnesium	  
	  
The	   magnesium	   ion,	   Mg2+,	   is	   the	   second	   most	  
abundant	   intracellular	  cation,	   serving	   to	   stabilize	  
nucleic	  acid	  and	  protein	  structure	  (Subirana	  et	  al.,	  
2003;	   Brion	   and	  Westhof,	   1997),	   and	   regulating	  
over	   300	   enzymes	   as	   a	   cofactor	   (Romani	   et	   al.,	  
1992;	   1993;	   Zhao	   et	   al.,	   2002),	   including	   ATP-­‐
related	   enzymatic	   reactions	   (Hirata	   et	   al.,	   2002;	  
Ko	   et	   al.,	   1999).	   Physiological	   concentrations	   of	  
Mg	   are	   essential	   for	   synaptic	   conduction,	   and	  
required	   for	   normal	   functioning	   of	   the	   nervous	  
system.	   It	   has	   various	   effects	   at	   different	  
concentrations	   on	   intellectual	   and	   neuronal	  
functions	   via	   many	   bio-­‐chemical	   mechanisms,	  
including	  NMDA-­‐receptor	  responses	  to	  excitatory	  
amino	   acids	   and	   calcium	   influx	   (Nowak	   et	   al.,	  
1984;	   Mayer	   et	   al.,	   1984;	   Vandenberg	   et	   al.,	  
1987;	  Matsuda	  et	  al.,	  1987),	  inhibition	  of	  calcium	  
channels	   (Iseri	   and	   French,	   1984)	   and	   glutamate	  
release	   (Lin	   et	   al.,	   2002),	   effects	   on	   cell	  
membrane	   fluidity	   and	   stability	   (Ebel	   and	  
Gunther,	   1980),	   and	   toxic	   effects	   of	   calcium	  
(Alvarez-­‐Leefmans	   et	   al.,	   1987).	   These	  
mechanisms	   have	   important	   roles	   in	   chronic	  
neuronal	   degeneration	   and	   subsequent	  
development	  of	  dementia.	  	  
	  
The	  role	  of	  Mg	  in	  degenerative	  diseases	  has	  been	  
the	   focus	  of	   increased	   attention	   in	   recent	   years.	  
Continuous	   low	   Mg	   intake	   for	   two	   generations	  
induces	  exclusive	  loss	  of	  dopaminergic	  neurons	  in	  
rats	   (Oyanagi,	   2005),	   and	   may	   support	   the	   Mg	  
hypothesis	   in	   the	   pathogenesis	   of	   parkinsonism-­‐
dementia	   complex	   (PDC)	   of	   Guam.	   Mg	   supple-­‐
mentation	   prevents	   the	   loss	   of	   dopaminergic	  
neurons	   and	   ameliorates	   neurite	   pathology	   in	   a	  
PD	  model,	  indicating	  a	  role	  of	  Mg	  in	  protection	  of	  
dopaminergic	   neurons	   in	   the	   substantia	   nigra	  
from	   degeneration	   (Oyanagi	   et	   al.,	   2006;	  
Hashimoto	   et	   al.,	   2008).	   Also,	   Mg	   at	  
concentrations	  >	  0.75	  mM	  inhibits	  the	  aggregation	  
of	  α-­‐synuclein,	   induced	   either	   spontaneously	   or	  
by	   incubation	   with	   iron	   (Golts	   et	   al.,	   2002).	  
Microinjection	   of	   magnesium	   into	   cells	   caused	  
microtubule	   disassembly	   (Prescott	   et	   al.,	   1988).	  
Mg2+	   and	   Ca2+	   effectively	   induced	   formation	   of	  
approximately	   340	   kD	   aggregates	   of	   paired	  
helical	   filament	   tau	   (PHF-­‐tau)	   obtained	   from	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corticobasal	   degeneration	   (CBD)	   and	  AD	  but	   not	  
normal	  tau	  proteins	  isolated	  from	  fetal	  and	  adult	  	  
brains,	   as	   determined	   by	   sodium	   dodecyl	  
sulphate	   (SDS)-­‐polyacrylamide	   gel	   electrophoresis	  
and	   immunoblotting	   (Yang	   et	   al.,	   1999).	   This	  
finding	   suggests	   regional	   elevation	   of	   these	   ions	  
may	  trigger	  pathological	  deposition	  of	  PHF-­‐tau	  in	  
certain	  neurodegenerative	  disorders.	  	  
	  
Magnesium	  in	  AD	  
	  
Recent	  evidence	  suggests	  that	  Mg	  was	  implicated	  
in	   the	   pathogenesis	   of	   AD.	   Mg	   levels	   were	  
decreased	   in	   the	   serum	   and	   brain	   tissues	   of	   AD	  
patients	   in	   clinical,	   experimental	   and	   autopsy	  
studies	   (Durlach,	   1990;	   Glick,	   1990a;	   Lemke,	  
1995;	   Andrási	   et	   al.,	   2000;	   2005;	   Vural	   et	   al.,	  
2010).	  Moreover,	  serum	  Mg	  levels	  in	  AD	  patients	  
negatively	  correlated	  with	  the	  Global	  Deterioration	  
Scale	   (GDS)	   and	   the	   Clinical	   Dementia	   Rating	  
(CDR)	   (Cilliler	   et	   al.,	   2007).	   A	   causal	   relationship	  
between	   low	   Mg	   in	   hippocampal	   neurons	   and	  
impairment	  of	  learning	  was	  also	  demonstrated	  in	  
aged	   rats	   (Landfield	   et	   al.,	   1984).	   Magnesium	  
deficiency	   can	   lead	   to	   specific	   impairments	   in	  
emotional	   memory	   (Bardgett	   et	   al.,	   2005;	  
Bardgett	  et	  al.,	   2007),	  while	  magnesium	   therapy	  
facilitates	   cognitive	   function	   recovery	   following	  
brain	   injury;	   however,	   there	   are	   task	   and	   dose-­‐
dependent	   aspects	   to	   this	   recovery	   (Enomoto	  et	  
al.,	  2005;	  Hoane,	  2005;	  Hoane,	  2007).	   Increasing	  
brain	   magnesium	   leads	   to	   the	   enhancement	   of	  
both	   short-­‐term	   synaptic	   facilitation	   and	   long-­‐
term	   potentiation	   and	   improves	   learning	   and	  
memory	   functions	   in	   rats	   (Slutsky	   et	   al.,	   2010).	  
Interestingly,	   treatment	   of	   dementia	   patients	  
with	   nutritional	  Mg	   support	   efficiently	   improved	  
memory	   and	   other	   symptoms	   (Glick	   et	   al.,	  
1990b).	   However,	   therapeutic	   administration	   of	  
Mg	   is	   still	   controversial	   regarding	   the	   treatment	  
of	  AD,	  and	  high	  doses	  of	  Mg	  may	  have	  potential	  
detrimental	   side	  effects	   (Clark	  and	  Brown,	  1992;	  
Fung	   et	   al.,	   1995;	   Hallak,	   1998;	   Ladner	   and	   Lee,	  
1999).	  	  
	  
Neuronal	   degeneration	   occurs	   in	   PS1	   mutant	  
mice	  without	  extracellular	  Aβ	  deposits,	  suggesting	  
it	   is	   caused	   by	   the	   accumulation	   of	   intracellular	  
Aβ42	  (Chui	  et	  al.,	  1999).	  Deposits	  of	   intracellular	  
Aβ42	   are	   correlated	  with	   apoptotic	   cell	   death	   in	  
AD	  brains	   	   (Chui	  et	   al.,	   2001).	   The	  Aβ	   is	   derived	  
from	  APP	  through	  sequential	  cleavages	  by	  β-­‐and	  	  
γ-­‐secretases,	   whose	   enzymatic	   activities	   are	  
tightly	   controlled	   by	   subcellular	   localization.	  
Thus,	   delineation	   of	   how	   the	   intracellular	  
trafficking	   of	   these	   secretases	   and	   APP	   are	  
regulated	   is	   important	   for	   understanding	   AD	  
pathogenesis.	   Although	   APP	   trafficking	   is	  
regulated	  by	  multiple	  factors	  including	  PS1	  (Cai	  et	  
al.,	  2003),	  a	  major	  component	  of	  the	  γ-­‐secretase	  
complex,	   and	  phospholipase	  D1,	   a	   phospholipid-­‐
modifying	   enzyme,	   APP	   can	   reciprocally	   regulate	  
PS1	   trafficking.	   APP	   deficiency	   results	   in	   faster	  
transport	  of	  PS1	  from	  the	  trans-­‐Golgi	  network	  to	  
the	  cell	  surface	  and	  increased	  steady	  state	  levels	  
of	  PS1	  at	  the	  cell	  surface,	  which	  can	  be	  reversed	  
by	   restoring	   APP	   levels	   (Liu	   et	   al.,	   2009).	  
However,	   it	   is	   not	   known	   whether	   altered	  
magnesium	   level	  may	   also	   affect	   APP	   trafficking	  
or/and	   processing.	   Recently,	   it	   has	   been	  
demonstrated	   that	   magnesium	   modulated	   APP	  
processing	   in	   a	   time-­‐	   and	   dose-­‐dependent	  
manner:	   extracellular	   magnesium	   ([Mg2+]o)	   at	  
high	   doses	   increased	   CTFα	   level	   and	   sAPPα	  
release.	   In	   contrast,	   [Mg2+]o	   at	   low	   doses	  
enhanced	   CTFβ	   accumulation	   and	   Aβ	   secretion	  
(Yu	  et	  al.,	  2010).	  The	  mechanism	  of	  how	  varying	  
magnesium	  concentrations	   led	  to	  shifts	  between	  
α-­‐	   and	   β-­‐secretase	   cleavage	   of	   APP	   might	   be	  
partially	  explained	  by	  the	  evidence	  that	  [Mg2+]o	  at	  
high	  doses	  promoted	  retention	  of	  APP	  on	  plasma	  
membrane,	   whereas	   [Mg2+]o	   at	   low	   doses	  
reduced	  cell	  surface	  APP	  level	  (Yu	  et	  al.,	  2010).	  All	  
APP	   family	  members	   are	   predominantly	   cleaved	  
in	   the	   late	   secretory	   pathway,	   including	   the	  
plasma	  membrane	   and	   endosomes	   (Yamazaki	  et	  
al.,	   1996).	   Further,	   different	   secretase	   activities	  
show	   distinct	   subcellular	   localization,	   namely	  α-­‐
secretase	   at	   the	   plasma	  membrane	   (Lammich	  et	  
al.,	   1999;	   Skovronsky	   et	   al.,	   2000)	   and	   β/γ-­‐
secretases	   within	   endocytic	   compartments	  
(Vassar	  et	  al.,	  1999;	  Huse	  et	  al.,	  2000	  ;	  Cupers	  et	  
al.,	  2001	  ;	  Kaether	  et	  al.,	  2002;	  Ray	  et	  al.,	  1999).	  
Because	   targeting	   of	   APP	   to	   distinct	   subcellular	  
compartments	   determines	   processing	   into	  
amyloidogenic	   or	   non-­‐amyloidogenic	   products,	  
much	  attention	  has	  been	  focused	  on	  factors	  that	  
regulate	   APP	   trafficking.	   Interestingly,	   several	  
adaptor	   proteins	   are	   known	   to	   influence	   APP	  
transport	   and	   processing.	   For	   example,	   F-­‐
spondin,	   a	   secreted	   factor	   that	   binds	   to	   the	  
extracellular	   domain	   of	   APP	   (Ho	   and	   Sudhof,	  
2004),	   has	   been	   shown	   to	   increase	   levels	   of	   cell	  
surface	   APP,	   promote	   α-­‐cleavage	   of	   APP,	   and	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decrease	   β-­‐cleavage	   of	   APP	   (Hoe	   et	   al.,	   2005).	  
Similarly,	   the	   extracellular	   matrix	   protein	   Reelin	  
caused	   increased	   surface	   APP	   and	   a	   preference	  
for	  α-­‐cleavage	  over	  β-­‐cleavage	  (Hoe	  et	  al.,	  2006b).	  
These	   findings	   suggest	   that	   trafficking	   and	  
proteolysis	  of	  APP	  are	  regulated	  together.	  Thus	  a	  
function	  of	   [Mg2+]o	   in	  APP	   transport	   from/to	   the	  
cell	  surface	  might	  be	  a	  possible	  explanation	  for	  its	  
modulation	  of	  APP	  processing.	  In	  the	  light	  of	  Mg2+	  
as	   an	   antagonist	   of	   the	   NMDA	   receptor,	   our	  
finding	   is	   corroborated	   by	   the	   previous	   report	  
that	  chronic	  NMDA	  receptor	  activation	  decreased	  
α-­‐secretase-­‐mediated	   APP	   processing	   and	  
increased	   Aβ	   production	   in	   cultured	   cortical	  
neurons	   (Lesne	   et	   al.,	   2005).	   Furthermore,	  
several	   lines	   of	   evidence	   suggest	   that	   APP	  
metabolism	   and	   Aβ	   levels	   are	   closely	   correlated	  
with	  neural	  activity	  in	  animals	  (Fazeli	  et	  al.,	  1994;	  
Turner	  et	  al.,	  2004;	  Cirrito	  et	  al.,	  2005;	  2008)	  and	  
humans	   (Buckner	   et	   al.,	   2005).	   It	   has	   been	  
demonstrated	   that	   decreasing	   neuronal	   activity	  
by	   high	   [Mg2+]o	   (10	   mM	   MgCl2)	   resulted	   in	  
significant	   reduction	  of	  Aβ	   secretion,	  which	  may	  
involve	  a	  change	  in	  APP	  processing	  	  (Kamenetz	  et	  
al.,	   2003).	   However,	   the	   precise	   functional	  
mechanism	   of	   how	   magnesium	   regulates	   APP	  
transport	  and	  whether	  magnesium	  interacts	  with	  
α-­‐	  and	  β-­‐secretase,	  or	  regulates	  enzyme	  activity,	  
or	   their	   subcellular	   localization,	   remains	  
undetermined	   but	   will	   be	   part	   of	   our	   future	  
analysis.	  
	  
The	   dose	   dependent	   response	   of	   sAPPα	   to	  
increasing	   [Mg2+]o	   implies	   high	   concentrations	   of	  
Mg	   may	   exert	   protective	   effects	   against	   AD.	  	  
Various	   studies	   have	   strongly	   established	   that	  
secreted	   sAPPα	   possesses	   potent	   neurotrophic	  
and	  neuroprotective	  activities	  against	  excitotoxic	  
and	   oxidative	   insults	   (Mattson	   et	   al.,	   1993;	  
Schubert	   et	   al.,	   1993),	   p53-­‐mediated	   apoptosis	  
(Xu	  et	   al.,	   1999),	   and	   the	  proapoptotic	   action	  of	  
mutant	  PS1	  by	  activating	  the	  transcription	  factor	  
NF-­‐κB	   (Guo	   et	   al.,	   1998).	   Moreover,	   sAPPα	  
stimulates	  neurite	  outgrowth	  (Small	  et	  al.,	  1994),	  
regulates	  synaptogenesis	  (Morimoto	  et	  al.,	  1998),	  
exerts	   trophic	   effects	   on	   cerebral	   neurons	   in	  
culture	   (Araki	   et	   al.,	   1991),	   stabilizes	   neuronal	  
calcium	   homeostasis	   and	   protects	   hippocampal	  
and	   cortical	   neurons	   against	   the	   toxic	   effects	   of	  
glutamate	   and	   Aβ	   peptides	   (Furukawa	   et	   al.,	  
1996).	   It	   also	   has	   been	   shown	   that	   intra-­‐
cerebroventricular	   administration	   of	   secreted	  
forms	   of	   sAPPα	   to	   amnestic	   mice	   has	   potent	  
memory-­‐enhancing	   effects	   and	   blocks	   learning	  
deficits	   induced	   by	   scopolamine	   (Meziane	  et	   al.,	  
1998).	  
	  
Secreted	  Aβ	   increased	  upon	   low	  [Mg2+]o	   (0.0	  and	  
0.4	   mM)	   compared	   with	   physiological	   concen-­‐
tration	  of	  Mg	  (i.e.	  0.8	  mM),	  whereas	  high	  [Mg2+]o	  
(1.2,	   1.6,	   4.0	   mM)	   could	   not	   significantly	   lower	  
total	   extracellular	   Aβ	   level	   (Yu	  et	   al.,	   2010).	   The	  
data	  are	  consistent	  with	  several	   reports	  showing	  
a	   dissociation	   between	   sAPPα	   release	   and	   Aβ	  
generation	   both	   in	   vitro	   or	   in	   vivo	   (Loefler	   and	  
Huber,	  1993;	  Querfurth	  et	  al.,	  1994;	  Dyrks	  et	  al.,	  
1994;	   LeBlanc	  et	  al.,	   1998;	  Rossner	  et	  al.,	   2000),	  
suggesting	   that	   there	  might	   be	   a	  more	   complex	  
regulatory	   mechanism	   of	   these	   two	   processing	  
events	   of	   APP.	   For	   instance,	   constitutive	  
activation	   of	   PKC	   in	   guinea	   pig	   brain	   increased	  
sAPPα	   secretion	   without	   any	   effect	   on	   secreted	  
Aβ	   (Rossner	  et	  al.,	   2000),	   suggesting	   that	   the	  α-­‐	  
and	   β-­‐secretase	   pathways	   may	   be	   differentially	  
controlled.	   Because	   Yu	   et	   al.,	   (2010)	   examined	  
the	  effects	  of	  Mg	  only	  on	  the	  pathologically	  high	  
production	   of	   Aβ,	   the	   modulation	   of	   the	  
physiological	   Aβ	   production	   by	   Mg	   needs	   to	   be	  
established	   in	   future	   studies.	   The	   steady-­‐state	  
level	   of	  Aβ	  peptide	   is	   determined	  by	   the	   rate	  of	  
production	  from	  APP	  via	  β-­‐	  and	  γ-­‐secretases	  and	  
degradation	  by	  the	  activity	  of	  several	  degradative	  
enzymes,	   including	  neprilysin	  (Hama	  et	  al.,	  2001;	  
Iwata	  et	  al.,	  2001;	  Shirotani	  et	  al.,	  2001;	  Leissring	  
et	  al.,	   2003;	  Marr	  et	  al.,	   2004;	   review	   see	  Wang	  
et	   al.,	   2006),	   insulin	   degrading	   enzyme	   (IDE)	  
(Kurochkin	   et	   al.,	   1994;	   Farris	   et	   al.,	   2003),	  
endothelin-­‐converting	   enzyme	   (Eckman	   et	   al.,	  
2003)	   and	  MMPs	   (Roher	  et	   al.,	   1994;	  Backstrom	  
et	   al.,	   1996;	   Leissring	   et	   al.,	   2003).	   Yu	   et	   al.,	  
(unpublished	   data)	   also	   found	   that	   Mg	  
deprivation	   resulted	   in	   a	   50%	   decrease	   of	  
neprilysin	   activity	   without	   alteration	   in	   the	  
protein	   level	   of	   neprilysin	   and	   IDE.	   Thus,	   the	  
exacerbated	   accumulation	   of	   Aβ	   induced	   by	  
[Mg2+]o	   at	   0.0	   mM	   resulted	   from	   both	   the	  




Magnesium	   participates	   in	   the	   biochemical	  
mechanisms	  of	  neuronal	  properties	  and	  synaptic	  
functions,	   which	   are	   involved	   in	   the	   patho-­‐
physiology	   of	   neurodegenerative	   diseases.	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Magnesium	  was	   demonstrated	   to	  modulate	  APP	  
trafficking	  and	  processing,	  and	  its	  level	  was	  found	  
decreased	   in	   AD	   patients.	   Both	   clinical	   and	  
experimental	  data	   implicated	  a	  role	  of	  Mg	  in	  the	  
pathogenesis	  of	  AD.	  Given	  the	  prevalence	  of	  
magnesium	  inadequacy	  in	  the	  general	  population	  
(Ford	   and	   Mokdad,	   2003),	   magnesium	  
supplementation	   could	   constitute	   a	   potential	  
novel	  pharmacological	  target	  for	  the	  treatment	  of	  
AD	  via	  its	  action	  on	  APP	  processing.	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Magnesium	   status	   is	   highly	   associated	   with	   stress	   levels,	   with	   both	   stress	   and	   hypomagnesemia	  
potentiating	  each	  other’s	  negative	  effects.	   Indeed,	  hypomagnesemia	  has	  been	  associated	  with	  stressful	  
conditions	  such	  as	  photosensitive	  headache,	   fibromyalgia,	  chronic	   fatigue	  syndrome,	  audiogenic	  stress,	  
cold	   stress,	   and	  physical	   stress,	   amongst	  others.	  The	   role	  of	  magnesium	   in	   these	   conditions	   is	  unclear,	  
although	  a	  number	  of	  potential	  mechanisms	  for	  magnesium’s	  action	  have	  been	   identified	   including	  via	  
the	  glutamatergic,	  serotonergic,	  and	  adrenergic	  neurotransmitter	  systems,	  as	  well	  as	  via	  several	  neuro-­‐
hormones.	  The	  current	  review	  examines	  the	  link	  between	  magnesium	  deficiency	  and	  stress,	  focusing	  on	  
the	  association	  between	  magnesium	  and	  various	   stress	  pathologies,	  magnesium’s	  potential	   interaction	  





At	   the	   beginning	   of	   the	   twentieth	   century,	  
Walter	   Cannon	   pioneered	   research	   concerning	  
the	   importance	   of	   the	   sympathetic	   nervous	  
system	  in	  adaptation	  of	   the	  body	  (Quick,	  1994).	  
While	  Claude	  Bernard	  was	  the	  first	  who	  defined	  
the	   term	   of	   “milieu	   interieur”	   as	   being	   "the	  
constancy	   of	   the	   internal	   environment"	   (see	  
Cameron,	   2007),	   it	   was	   Walter	   Cannon	   who	  
coined	   the	   terms	   "homeostasis”	   and	   “fight-­‐or-­‐
flight	   response"	   (Quick,	   1994).	   Subsequently,	  
Hans	   Selye	   in	   1936	   adapted	   a	   concept	   from	  
physics	   describing	   the	   resistance	   of	   a	   body	   to	  
applied	  pressure	   in	  order	   to	  define	   the	  concept	  
of	   stress	   (Neylan,	   1998).	   General	   adaptation	  
syndrome,	   as	   he	   called	   it,	   is	   the	   non-­‐specific	  
response	  of	  the	  body	  to	  any	  demand	  for	  change.	  
It	   consists	   of	   three	   stages	   of	   adaptation:	   an	  
initial	  brief	  alarm	  reaction,	  a	  prolonged	  period	  of	  
resistance,	   and	   finally,	   the	   stage	   of	   exhaustion	  
and	  death.	   Although	   there	   is	   no	   generally	  
accepted	  definition,	   stress	   can	  be	  understood	   to	  
be	   a	   complex	   adaptive	   biochemical,	  
physiological,	  psychological	  and	  gene	  expression	  
change	   of	   the	   organism	   (stress	   response)	  
triggered	   by	   a	   stimulus	   (stressor)	   that	   was	  
interpreted	   by	   the	   brain	   as	   being	   dangerous	  
(McEwen,	  2008b;	  Kantorovich	  et	  al.,	  2008).	  
	  	  
The	   neuroendocrine	   response	   to	   stress	   initiates	  
hyperventilation,	   elevated	   blood	   pressure,	  
increased	   heart	   rate,	   a	   sudomotor	   response	  
(sweating),	   increased	   blood	   flow	   to	   skeletal	  
muscles,	   and	  perturbations	   of	   gut	   function	   (the	  
'fight	   or	   flight'	   defence	   reaction)	   in	   order	   to	  
enable	   body	   survival.	   More,	   the	   amygdala	  
activates	   neurons	   in	   the	   hippocampus	   and	  
neocortex,	   where	   threatening	   stimuli	   are	  
associated	   with	   fear,	   in	   order	   to	   adapt	   future	  
behaviour	  to	  avoid	  danger	  (Rupniak,	  2005).	  	  
	  
To	  further	  refine	  the	  stress	  concept,	  Sterling	  and	  
Eyer	   (1981)	   proposed	   the	   term	   allostasis	   to	  
describe	  the	  process	  of	  achieving	  stability	  through	  
change.	   As	   compared	   to	   homeostatic	   values	  
(blood	  oxygen,	  blood	  pH,	  and	  body	  temperature),	  
which	   have	   to	   be	   kept	   within	   a	   narrow	   range,	  
the	   allostatic	   mediators	   (hormones	   of	   the	  
hypothalamic-­‐pituitary-­‐adrenal	   axis,	   catechol-­‐
amines,	   and	   cytokines)	   may	   vary	   during	   daily	  
and	   seasonal	   routines	   (McEwen,	   2008b;	   Ablin	  
and	  Buskila,	  2010;	  Billard,	  2006).	  	  
	  
Nowadays,	  the	  profound	  implications	  of	  stress	  in	  
human	   pathology	   are	   unanimously	   recognized	  
and	  represent	  a	  dynamic	  field	  of	  research.	  There	  
is	   a	   continued	   interest	   in	   identifying	   new	  
possibilities	   to	   alleviate	   stress	   and	   improve	  
quality	  of	  life	  in	  a	  fast-­‐changing,	  modern	  world.	  
	  
The	  idea	  that	  magnesium	  (Mg)	  supplementation	  
modifies	   the	  effect	   of	   chronic	   stress	  dates	  back	  
to	   1981	   (Classen,	   1981).	   This	   hypothesis	   is	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certainly	   feasible	   given	   the	   cation’s	   ubiquitous	  
distribution	   and	   role	   throughout	   the	   body.	  
Indeed,	  Mg	   is	   the	   fourth	  most	   abundant	   cation	  
in	   the	   body	   and	   the	   second	   most	   abundant	  
intracellular	   cation.	   It	   is	   involved	   in	   a	   wide	  
variety	   of	   cellular	   processes	   including	   aerobic	  
and	   anaerobic	   metabolism,	   all	   bioenergetic	  
reactions,	   regulation	   of	   metabolic	   pathways,	  
signal	   transduction,	   ion	   channels	   activity,	   cell	  
proliferation,	   differentiation,	   apoptosis,	   angio-­‐
genesis,	   and	  membrane	   stabilization	   (Nishizawa	  
et	   al.,	   2007;	   Szewczyk	   et	   al.,	   2008;	   Turner	   and	  
Vink	   2007;	  Wolf	   et	   al.,	   2007).	  At	   a	   biochemical	  
level,	   more	   than	   325	   enzymes	   are	   Mg	  
dependent,	  many	   of	   which	   are	   nervous	   system	  
enzymes,	   thus	   reflecting	   the	   important	   role	  
potentially	   played	   by	   Mg	   in	   CNS	   physiological	  
and	  pathological	  function	  (Eby	  and	  Eby,	  2006).	  	  
	  
Magnesium	  interaction	  with	  stress	  pathways	  
	  
Acute	   stress	   has	   been	   shown	   to	   be	   associated	  
with	   increased	   plasma	  Mg	   levels	   and	   increased	  
urinary	  Mg	  excretion	  (Murck,	  2002;	  Whyte	  et	  al.,	  
1987).	   The	   shift	   of	  Mg	   from	   the	   intracellular	   to	  
the	  extracellular	  space	  initially	  plays	  a	  protective	  
role	   in	   order	   to	   diminish	   the	   adverse	   effects	   of	  
stress,	   but	   extended	   periods	   of	   stress	   result	   in	  
progressive	   Mg	   deficit	   and	   deleterious	   conseq-­‐
uences	   for	   health	   (Seelig,	   1994).	   Moreover,	  
stress	   and	   hypomagnesemia	   potentiate	   each	  
other’s	  negative	  effects	  in	  a	  veritable	  pathogenic	  
vicious	   circle.	   Low	   Mg/Ca	   ratios	   augment	   the	  
release	   of	   catecholamines	   in	   response	   to	   stress	  
(Caddell	   et	   al.,	   1986;	   Seelig,	   1994).	   Fatty	   acids	  
resulting	   from	  adrenergic-­‐induced	   lipolysis	   form	  
undissociated	   Mg	   soaps	   which	   further	  
exacerbates	   Mg	   depletion	   (Seelig,	   1994).	   Mg	  
deficiency	   also	   favours	   the	   release	   of	   vaso-­‐
constrictive	   and	   platelet	   aggregating	   factors	  
(derived	   from	   fatty	   acid	   metabolism	   and	  
endothelium),	   increases	   the	  thromboxane	  B2	  to	  
prostaglandin	   I2	   (TxB2/PgI2)	   ratio	   and	   enhances	  
intravascular	   blood	   coagulation	   (Ceremuzynski	  
et	  al.,	  1978;	  Franz	  2004;	  	  Dong	  et	  al.,	  2008;	  Soma	  
et	   al.,	   1988;	   Sontia	   and	   Touyz,	   2007).	   Most	  
interestingly,	  Mg	   deficiency	   itself	   doesn’t	   induce	  
specific	   pathology	   but	   reduces	   the	   tolerance	   to	  
secondary	  stress	  (Tejero-­‐Taldo	  et	  al.,	  2006).	  	  
	  
The	   active	   transport	   systems	   between	   plasma	  
and	   cerebrospinal	   fluid	   enable	   elevated	   and	  
relatively	  constant	  Mg	  concentrations	  in	  the	  CSF	  
(typically	   1.1	   mmol/l	   in	   CSF	   compared	   to	   0.8	  
mmol/l	   in	   plasma)	   (Oppelt	   et	   al.,	   1963;	   Murck	  
2002).	   There	   are	   reports	   that	   parenteral	  
administration	   of	   magnesium	   sulphate	  
augments	   cerebrospinal	   fluid	  Mg	   concentration	  
by	   20–25%	   in	   approximately	   4	   hours	   (Ko	  et	   al.,	  
2001;	   Muir,	   2002),	   although	   recent	   reports	  
suggest	  that	  Mg	  may	  not	  readily	  cross	  the	  intact	  
blood	   brain	   barrier	   (McKee	   et	   al.,	   2005;	   see	  
Chapter	  3).	  
	  
With	   respect	   to	   mechanisms	   of	   action,	   Mg	  
affects	  a	  number	  of	  neurotransmitter	  systems.	  It	  
inhibits	   the	   release	   of	   excitatory	   neuro-­‐
transmitters	   and	   also	   acts	   as	   a	   voltage-­‐gated	  
antagonist	   at	   the	   glutamate,	   N-­‐methyl-­‐D-­‐
aspartate	  (NMDA)	  receptor.	  Mg	  also	  antagonizes	  
calcium	   entry	   via	   voltage-­‐gated	   channels	   of	   all	  
types.	   In	   addition	   to	   exhibiting	   agonist	  
properties	  at	  γ-­‐aminobutyric	  acid	  A	  receptors,	   it	  
is	   an	   angiotensin	   II	   receptor	   antagonist.	   Mg	  
inhibits	   calcium/protein	   kinase	   C	   related	  
neurotransmission,	   increases	   reuptake	   of	  
glutamate	   via	   stimulation	  of	   the	  Na+/K+	  ATPase,	  
and	   is	   involved	   in	  mitochondrial	  ATP-­‐dependent	  
potassium	   channel	   activity	   (Bednarczyk	   et	   al.,	  
2005;	   Eby	   and	   Eby,	   2006;	   Muir	   2002;	   Murck	   ,	  
2002).	   Furthermore,	   Mg	   inhibits	   the	   phos-­‐
phorylation	  activity	  of	  glycogen	  synthase	  kinase-­‐
3	   (GSK-­‐3),	   increases	   brain-­‐derived	   neurotrophic	  
factor	   (BDNF)	   expression	   and	   enhances	   the	  
cAMP	   response	   element-­‐binding	   (CREB)/BDNF	  
pathway	   via	   the	   serotonergic	   system,	   all	  
mechanisms	   related	   to	   the	   antidepressant-­‐like	  
activity	  of	  this	  ion	  (Szewczyk	  et	  al.,	  2008).	  	  
	  
There	   is	   also	   an	   increasing	   body	   of	   evidence	  
indicating	   that	   psychological	   stress	   promotes	  
oxidative	   stress,	   mainly	   by	   auto-­‐oxidation	   of	  
catecholamines.	  Several	  studies	  have	  shown	  that	  
psychological	   stress	   exacerbates	   lipid	  
peroxidation,	  increases	  production	  of	  markers	  of	  
oxidative	   damage	   of	   DNA	   (8-­‐oxo-­‐7,8-­‐
dihydroguanine),	   and	   decreases	   plasma	   anti-­‐
oxidant	   activity	   (Seelig,	   1994;	   Sivonova	   et	   al.,	  
2004).	  Many	  of	  these	  processes	  are	  antagonized	  
by	   Mg	   (Cernak	   et	   al.,	   2000;	   Muir,	   2002;	  
Nishizawa	  et	  al.,	  2007).	  
	  
A	   stressor	   (either	   physical	   or	   psychological)	  
initially	   activates	   the	   hypothalamic-­‐pituitary-­‐
adrenal	   (HPA)	   axis	   and	   the	   autonomic	   nervous	  
system.	   Activating	   these	   systems	   leads	   to	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release	   of	   catecholamines	   from	   sympathetic	  
nerves	   and	   the	   adrenal	   medulla,	   and	   of	  
corticotropin-­‐releasing	   factor	   (CRF)	   and	  
vasopressin	   (AVP)	   from	   parvocellular	   neurons.	  
Seconds	   later,	   adrenocorticotropic	   hormone	  
(ACTH)	   is	   secreted	   from	   the	   anterior	   pituitary	  
gland	   and	   stimulates	   release	   of	   glucocorticoids	  
from	   the	   adrenal	   cortex	   (Rupniak,	   2005;	  
Carrasco	   and	   Van	   de	   Kar,	   2003).	   CRF	   is	   a	  
neurotransmitter	  involved	  in	  the	  coordination	  of	  
the	   endocrine,	   autonomic,	   behavioural	   and	  
immune	   responses	   to	   stress,	   and	   whose	  
administration	   elicits	   stress-­‐like	   effects	   (De	  
Souza	   et	   al.,	   1991;	   Carrasco	   and	   Van	   de	   Kar,	  
2003;	   Cratty	   and	   Birkle,	   1999).	   Magnesium	  
interacts	   either	   directly	   or	   indirectly	   with	   the	  
activity	  of	  a	  number	  of	   these	  neurotransmitters	  
and	   neurohormones.	   For	   example,	   Cratty	   and	  
Birkle	   (1999)	   showed	   that	   glutamate-­‐stimulated	  
CRF	   release	   is	   antagonized	   by	   the	   addition	   of	  
MgCl2	   to	   the	   incubation	  medium.	  Mg	   stabilizes	  
CRF	  receptor	  binding	  and	  is	  directly	  correlated	  to	  
the	   number	   of	   CRF	   binding	   sites	   (Perrin	   et	   al.,	  
1986).	   On	   the	   other	   hand,	   Mg	   stimulates	   the	  
Na+/K+ATPase,	   which	   decreases	   CRF-­‐receptor	  
sensitivity	  (De	  Souza,	  1995).	  
	  
Mg	   also	   decreases	   the	   release	   of	   ACTH	   and	  
modulates	   adrenocortical	   sensitivity	   to	   this	  
hormone.	   As	   intracerebroventricular	   admin-­‐
istration	   of	   angiotensin	   II	   (ATII)	   increases	   the	  
secretion	   of	   ACTH	   and	   AVP	   via	   CRF,	   it	   is	  
presumed	   that	   Mg	   induces	   a	   suppression	   of	  
HPA-­‐axis	   activity,	   at	   least	   partially,	   through	  
antagonism	   of	   ATII	   effects	   (Murck,	   2002).	  
Intracerebroventricular	  administration	  of	  artificial	  
CSF	   with	   low	   Mg	   concentration	   induces	   an	  
increase	   in	   cortisol	   secretion	   in	   cats	   (Garcy	   and	  
Marotta,	   1978).	   In	   stressful	   circumstances,	  
MgSO4	   administration	   reduces	   the	   release	   of	  
AVP	  (Jee	  et	  al.,	  2009),	  a	  neuropeptide	  that	  plays	  
an	  important	  role	  in	  the	  generation	  of	  emotions,	  
social	   behaviour	   (aggression),	   and	   learning	   and	  
memory	   (Neumann	   et	   al.,	   2010;	   Ebner	   et	   al.,	  
2000).	  	  
	  
Low	  blood	  Mg	   levels	  have	  been	  associated	  with	  
raised	  brain	  noradrenaline	   (NA)	  content	   in	  mice	  
selectively	  bred	  for	  hypomagnesemia	  (Amyard	  et	  
al.,	  1995).	  Such	  low	  Mg	  levels	  in	  blood	  have	  also	  
been	   associated	   with	   increased	   catecholamine	  
release	   in	   response	   to	   noise	   stress	   in	   rats,	   and	  
with	   significantly	   increased	   urinary	   excretion	  
(+200%)	   of	   NA	   (Caddell	   et	   al.,	   1986;	   Henrotte,	  
1997).	  Also,	  it	  has	  been	  proven	  that	  Mg	  exerts	  a	  
direct	   suppressive	   effect	   on	   locus	   coeruleus	  
activity	   and	   that	   poor	   Mg	   status	   increases	  
sensitivity	  to	  stress	  (Henrotte	  et	  al.,	  1997).	  	  
	  
Another	   pathway	   influenced	   by	   Mg	   is	   the	  
serotoninergic	  system.	  Mg	  acts	  like	  a	  cofactor	  for	  
tryptophan	  hydroxylase,	   intervenes	   in	  serotonin	  
receptor	   binding	   in	   vitro	   and	   exhibits	   a	   direct	  
enhancing	   effect	   on	   5-­‐HT1A	   serotonin	   receptor	  
transmission	   (Szewczyk	   et	   al.,	   2008;	   Mizoguchi	  
et	   al.,	   2008;	   Abaamrane	   et	   al.,	   2009).	  
Microdialysis	   studies	   showed	   that	   stressors	   can	  
change	   the	   extracellular	   levels	   of	   serotonin	   in	  
different	   brain	   areas	   including	   the	   hypo-­‐
thalamus,	   amygdala,	   frontal	   cortex	   and	   raphe	  
nuclei	   (Fujino	   et	   al.,	   2002;	   Funada	   and	   Hara,	  
2001).	   Serotonin	   is	   involved	   in	   neuroendocrine	  
regulation	  of	  stress	  through	  actions	  on	  prolactin,	  
oxytocin,	  AVP,	  CRF	  and	  ACTH	  activity	  (Jorgensen,	  
2007).	   HPA	   axis	   dysregulation	   and	   sensitization	  
of	  5-­‐HT2	  receptor-­‐mediated	  signalling	  induced	  by	  
CRF	   implicates	  chronic	  stress	   in	  the	  aetiology	  of	  
depression	   and	   anxiety	   (Szewczyk	   et	   al.,	   2008;	  
Magalhaes	  et	  al.,	  2010).	  	  
	  
It	   is	   also	   tempting	   to	   speculate	   that	   the	  
protective	  effect	  of	   the	  oestrogens	   in	  stress	  are	  
partially	  mediated	   by	  Mg	   (Carrasco	   and	  Van	   de	  
Kar,	   2003).	   For	   example,	   It	   is	   known	   that	  
oestrogens	  mediate	  the	  shift	  of	  Mg	  from	  plasma	  
to	   cells	   and	   increases	   intracellular	   levels	   of	  Mg	  
(Galland,	  1991;	  Seelig,	  1993;	  Seelig	  et	  al.,	  2004).	  
Likewise,	   serum	   levels	   of	   Mg2+	   and	   total	  
magnesium	   were	   inversely	   correlated	   with	  
oestrogen	   concentration	   level	   (Muneyyirci-­‐
Delale	  et	   al.,	   1999).	   In	   postmenopausal	  women	  
oestrogen	  replacement	   therapy	  suppresses	  HPA	  
axis	   responses	   to	   an	   emotional	   stressor	   (Dayas	  
et	  al.,	  2000).	  
	  
Besides	   cortisol,	   prolactin,	   is	   regarded	   as	   a	  
measurable	   marker	   of	   a	   coping	   strategy	   to	  
"psychological	   stress"	   (Sobrinho,	   2003).	  
Confirming	   that	   Mg	   levels	   can	   modulate	  
prolactin	   secretion	   during	   stress,	   pretreatment	  
with	   Mg-­‐aspartate	   significantly	   decreased,	   in	   a	  
dose-­‐dependent	   manner,	   the	   prolactin	   plasma	  
concentration	   of	   turkey	   pullets	   exposed	   to	  
immobilization	   stress	   compared	   to	   non-­‐treated	  
birds	  (Ali	  et	  al.,	  1987).	  In	  addition,	  Mg	  acts	  like	  a	  
positive	   allosteric	   modulator	   for	   oxytocin	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binding	   to	   the	   receptor,	   and	   in	   this	   way	  
facilitates	   the	  neuropeptide’s	  action	   to	  alleviate	  
stress	   (Gimpl	   et	   al.,	   2008;	   Labuschagne	   et	   al.,	  
2010;	  Uvnas-­‐Moberg	  and	  Petersson,	  2005).	  
	  
Magnesium	  deficiency,	  stress	  and	  
miscellaneous	  pathologies	  
	  
Clinical	   manifestations	   of	   hypomagnesemia	  
include	  neuromuscular	   irritability	   and	  weakness	  
(tremors,	   fasciculations,	   tetany	   and	   positive	  
Chvostek’s	  and	  Trousseau’s	  signs,	  although	  some	  
of	   these	   features	   may	   be	   due	   to	   concomitant	  
hypocalcemia),	  headaches,	  focal	  seizures,	  hyper-­‐
emotionality,	   generalized	   anxiety,	   panic	   attack	  
disorders,	   insomnia,	   fatigue,	   and	   asthenia	  
(Touyz,	  2004;	  Wacker	  and	  Parisi,	   1968;	  Eby	  and	  
Eby,	  2006;	  Rayssiguieret	  al.,	  1990;	  Durlach	  et	  al.,	  
1997).	   For	   symptomatic	   patients,	   plasma	  
magnesium,	   erythrocyte	   magnesium,	   plasma	  
calcium	   and	   daily	   magnesiuria,	   calciuria	   and	  
magnesium	   retention	   test	   should	   be	   evaluated	  
(Durlach	   et	   al.,	   1997;	   Cundy,	   2008).	   The	  
alleviation	   of	   clinical	   manifestations	   by	   oral	  
supplementation	   with	   5	   mg	   of	   magnesium	  
/kg/day	   confirms	   the	   diagnosis	   (Durlach	   et	   al.,	  
1997).	  
	  
Experimental	   data	   indicate	   that	   Mg-­‐deficient	  
rats	   exhibit	   slightly	   increased	   plasma	   cortico-­‐
sterone	   levels,	   increased	   irritability	   and	  
aggressive	   behaviour,	   and	   higher	   mortality	  
compared	   to	   controls	   (Caddell,	   2001;	   Henrotte	  
et	   al.,	   1997).	   Recent	   data	   also	   indicate	   that	  
genetic	   polymorphism	   of	   Na+/Mg2+	   exchanger	  
activity	  influences	  Mg2+	  efflux	  from	  erythrocytes	  
(Feillet-­‐Coudray	   et	   al.,	   2004).	   Extensive	   work	  
regarding	   the	   genetic	   predisposition	   for	   Mg	  
deficiency	   has	   been	   carried	   out	   by	   Henrotte	   et	  
al.,	   (1990)	   who	   showed	   that	   both	   major	   histo-­‐
compatibility	   complex	   (MHC)	   associated	   genes	  
(HLA	   and	   H-­‐2)	   and	   non-­‐MHC	   genes	   are	  
important	   contributing	   factors	   for	  Mg	   status.	   In	  
humans,	  Henrotte	  and	  Levy-­‐Leboyer	  (1985)	  also	  
found	  an	  interesting	  link	  between	  HLA-­‐B35,	  type	  
A	   personality	   and	   low	   Mg2+	   status.	   HLA-­‐B35	  
individuals	   are	   more	   frequently	   found	   among	  
stress-­‐sensitive	   type	   A	   behaviour	   subjects	   and	  
exhibit	   lower	  red	  blood	  cell	  Mg	  levels	  than	  non-­‐
carriers.	   Moreover,	   these	   individuals	   show	  
impaired	   cytotoxicity	   and	   higher	   titres	   to	  
antibodies	   after	   anti-­‐influenza	   vaccination,	   data	  
that	   establish	   a	   connection	   between	   genetic	  
background,	   Mg	   deficiency,	   stress	   and	  
autoimmunity.	   It	   is	   generally	   accepted	   that,	   in	  
response	   to	   a	   psychological	   stressor,	   type	   A	  
persons	   exhibit	   increased	   release	   of	  
catecholamines	  and	  cortisol,	  which	  consequently	  
lowers	   Mg	   levels	   and	   increases	   cardiovascular	  
risk	  as	  compared	  to	  type	  B	  behaviour	   (Henrotte	  
et	  al.,	  1985;	  Matthews,	  1982).	  
	  
Experimental	   Mg	   deficiency	   has	   also	   been	  
associated	  with	  disrupted	  sleep	  patterns.	  In	  rats,	  
Mg	   deficiency	   is	   associated	   with	   an	   increased	  
amplitude	   in	   daily	   variation	   of	   sleep	   and	   slow-­‐
wave	  sleep	  delta	  power,	  and	  has	  been	  noted	  to	  
shorten	   life	   span	  and	   lower	   reproductive	  ability	  
(Chollet	   et	   al.,	   2001;	   Motta	   et	   al.,	   1998).	   In	  
humans,	   chronic	   sleep	  deprivation	   is	   associated	  
with	   progressively	   decreasing	   levels	   of	   intra-­‐
cellular	   Mg,	   reduced	   duration	   of	   cardio-­‐
pulmonary	   exercise	   and	   increased	   hyper-­‐
sensitivity	   of	   the	   chronotropic	   response	   to	  
sympathetic	   nervous	   stimulation	   (Omiya	   et	   al.,	  
2009).	   Intriguingly,	   Mg	   depletion	   is	   associated	  
with	   decreased	   melatonin	   and	   its	   supple-­‐
mentation	   alleviates	   the	   symptoms	   (Billyard	   et	  
al.,	   2006;	   Depoortere	   et	   al.,	   1993;	   Held	   et	   al.,	  
2002).	  In	  elderly	  subjects,	  Mg	  administration	  (10	  
mmol	  and	  20	  mmol	  each	  for	  3	  days	  followed	  by	  
30	  mmol	  for	  14	  days)	  significantly	  increased	  slow	  
wave	   sleep,	   renin	   levels	   during	   the	   total	   night,	  
and	  aldosterone	   levels	   in	  the	  second	  half	  of	  the	  
night,	   but	   decreased	   cortisol	   levels	   in	   the	   first	  
part	  of	  the	  night	  (Held	  et	  al.,	  2002).	  	  
	  
Photosensitive	   headache	   is	   another	   condition	  
that	  is	  exacerbated	  by	  stress	  and	  Mg	  deficiency.	  
Even	   wearing	   of	   tinted	   spectacles	   indoors	   is	  
considered	   to	   be	   a	   valid	   indicator	   of	  
psychological	  distress.	  Patients	  most	  susceptible	  
to	   develop	   this	   condition	   include	   photophobic	  
individuals	   that	   experience	   ophthalmological	  
discomfort	  during	  visual	  stress	  tests.	  Sarchielli	  et	  
al.,	   (1992)	   showed	   that	   sufferers	   of	   migraine	  
with	   and	   without	   aura,	   and	   tension-­‐type	  
headaches,	   exhibit	   significantly	   lower	   levels	   of	  
serum	   and	   salivary	   Mg	   concentrations.	  
Hypomagnesaemia	   raises	   the	   sensitivity	   of	  
cerebral	   arteries	   to	   CO2	   which	   in	   turn	   favours	  
cerebral	   vasospasm	   and	   headache	   (Thomas	   et	  
al.,	   1994).	   Despite	   being	   controversial,	   some	  
authors	   recommend	   intravenous	   administration	  
of	   1	   gram	   of	   MgSO4	   for	   the	   treatment	   of	  
migraine	  headache	  (Durlach	  et	  al.,	  2005).	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Fibromyalgia	   is	   considered	   a	   stress–related	  
disorder,	   with	   both	   the	   onset	   and	   the	  
exacerbation	   of	   the	   syndrome	   associated	   with	  
intensely	   stressful	   periods.	   Patients	   with	  
fibromyalgia	   frequently	   exhibit	   chronic,	  
widespread	   pain	   caused	   by	   the	   increase	   in	   the	  
processing	   and	   handling	   of	   pain	   by	   the	   CNS	  
(Ablin	  and	  Buskila,	  2010).	  It	  has	  been	  shown	  that	  
there	   is	   an	   inverse	   correlation	   between	   Mg	  
levels	   and	   clinical	   parameters	   in	   patients	   with	  
fibromyalgia	  (Sendur	  et	  al.,	  2008).	  The	  beneficial	  
role	  of	  Mg	  in	  this	  pathology	  is	  presumably	  based	  
on	  its	  antagonistic	  effect	  upon	  NMDA	  receptors,	  
receptors	   that	   are	   significantly	   involved	   in	   the	  
process	   of	   central	   sensitization	   (Galland,	   1991).	  
Various	   studies	   have	   also	   shown	   that	   patients	  
with	  a	  chronic	  fatigue	  condition	  closely	  linked	  to	  
fibromyalgia	   exhibit	   low	   Mg	   levels	   that	   are	  
correlated	   with	   total	   antioxidant	   capacity	   of	  
blood	  and	  GSH	  concentrations,	  but	  not	  with	  lipid	  
peroxidation	   in	   vitro	   (Galland,	   1991;	   Manuel	   y	  
Keenoy	   et	   al.,	   2000).	   In	   these	   patients,	   weekly	  
intramuscular	   injections	   of	   1	   gram	   of	   MgSO4	  
resulted	   in	   a	   significant	   improvement	   in	   energy	  
levels,	   pain,	   and	   emotional	   reactions	   as	  
measured	   by	   the	   Nottingham	   health	   profile	  
score	  (Cox	  et	  al.,	  1991;	  Murck,	  2002).	  Durlach	  et	  
al.,	  (2002)	  suggest	  that	  fibromyalgia	  and	  chronic	  
fatigue	  syndrome	  are	  clinical	  forms	  of	  magnesium	  
depletion	   associated	   with	   dysfunction	   of	   the	  
biological	  clock.	  
	  
An	   interesting	   correlation	   has	   been	   reported	  
between	   Mg	   deficiency	   and	   attention-­‐deficit/	  
hyperactivity	   disorder	   (ADHD).	   Elevated	  
subjective	   stress	   levels	   and	   stress	   intolerance	   is	  
often	   mentioned	   as	   part	   of	   the	   clinical	  
presentation	  of	  ADHD,	  and	  often	  these	  patients	  
present	   high	   post-­‐stress	   cortisol	   concentrations	  
(Hirvikoski	   et	   al.,	   2009).	   	   In	   a	   study	   examining	  
116	  children,	  95%	  of	  children	  with	  this	  pathology	  
exhibited	  Mg	  deficiency	  (Kozielec	  and	  Starobrat-­‐
Hermelin,	   1997).	   Although	   evidence	   regarding	  
the	   improvement	   of	   ADHD	   symptoms	   by	   Mg	  
supplementation	  is	  mixed,	  some	  studies	  indicate	  
that	  a	  Mg-­‐B6	  regimen	  over	  at	   least	  two	  months	  
significantly	   alleviated	   hyperactivity	   and	  
hyperemotivity/aggressiveness	   and	   improved	  
attention	   at	   school	   (Mousain-­‐Bosc	   et	   al.,	   2006;	  
Rucklidge	   et	   al.,	   2009).	   Interestingly,	   ADHD	  
symptoms	   reappear	   in	   a	   few	   weeks	   after	   the	  
cessation	   of	   the	   treatment,	   together	   with	   a	  
decrease	   in	   erythrocyte	   Mg	   values	   (Mousain-­‐
Bosc	   et	   al.,	   2006).	   A	   Mg-­‐B6	   regimen	   has	   also	  
been	   shown	   to	  be	  effective	   in	   the	   treatment	  of	  
Tourette’s	   syndrome.	   Tourette’s	   syndrome	   is	  
associated	  with	  increased	  vulnerability	  to	  stress,	  
and	   Mg	   deficit	   is	   considered	   to	   be	   a	   central	  
precipitating	   event	   (Carrasco	   and	   Van	   de	   Kar,	  
2003;	   Grimaldi,	   2002).	   Hypomagnesemia	   is	  
linked	   with	   exacerbated	   neural	   excitability,	  
increased	   anxiety,	   orofacial	   tardive	   dyskinesia,	  
and	   migraine,	   symptoms	   that	   are	   alleviated	   by	  
the	   administration	   of	   a	   combination	   of	   0.5	  
mEq/kg	   Mg	   and	   2mg/kg	   vitamin	   B6	   (Garcia-­‐
Lopez	  et	  al.,	  2009;	  Stendig-­‐Lindberg	  et	  al.,	  1998).	  
	  
An	   inverse	   correlation	   between	   audiogenic	  
stress	   and	   erythrocyte	   Mg	   levels	   has	   been	  
observed	  (Galland,	  1991),	  and	  low	  Mg	  status	  has	  
been	   linked	   to	   self-­‐reported	   noise	   sensitivity,	  
noise-­‐induced	   emotional	   lability	   and	   noise-­‐
induced	   feelings	   of	   tenseness	   (Galland,	   1991).	  
Notably,	  exposure	  to	  long-­‐term	  road	  traffic	  noise	  
in	   both	   children	   and	   adults	   leads	   to	   elevated	  
night	   time	   secretion	   of	   noradrenaline	   and	  
cortisol	   when	   compared	   to	   controls	   (Ising	   and	  
Braun,	   2000).	   Mg	   administration	   is	   effective	   in	  
diminishing	  ototoxicity	  (Abaamrane	  et	  al.,	  2009;	  
Ehrenberger	   and	   Felix,	   1995)	   as	   well	   as	   in	  
alleviating	   transportation	   stress	   (Tang	   et	   al.,	  
2008;	   Peeters	   et	   al.,	   2005).	   Cold	   stress	   also	  
induces	  a	  decrease	  in	  Mg	  levels	  in	  CSF	  and	  raises	  
the	   incidence	  of	   clinical	  manifestations	   (Matsui,	  
2007).	   Interestingly,	   a	   correlation	   has	   been	  
described	   between	   Mg	   levels	   (in	   serum	   and	  
peritoneal	   fluid)	   and	   stress	   perception	   (Jung	   et	  
al.,	   2010;	   Garalejic	   et	   al.,	   2010)	   in	   relatively	  
healthy,	   adult	   women	   unable	   to	   conceive	   but	  
without	  identified	  organic	  causes	  of	  sterility.	  
	  	  
It	   is	   now	   well	   known	   that	   Mg	   deficiency	  
facilitates	   epileptiform	   discharges	   in	   hippo-­‐
campal	   slices	   (Gutierrez	   et	   al.,	   1999)	   and	   in	  
audiogenic	   seizures	   (Bac	   et	   al.,	   1998).	  
Hippocampal	  neurons	  are	  more	  sensitive	  to	   low	  
Mg	   than	   neurons	   from	   other	   brain	   regions	   and	  
their	  responses	  to	  Mg	  deficiency	  differ	  depending	  
on	   the	   developmental	   period	   (Furukawa	   et	   al.,	  
2009).	   Human	   studies	   show	   that	   stress	  
augments	   seizure	   frequency	   and	   severity	   in	  
epileptic	  patients	  (Sawyer	  and	  Escayg,	  2010).	  
	  
Data	   from	  a	   second	   examination	   of	   the	  
Copenhagen	  City	  Heart	   Study	   showed	   that	   self-­‐
reported	  high	   stress	   intensity	   and	  weekly	  stress	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were	   associated	   with	   almost	  a	   doubled	   risk	   of	  
fatal	  stroke	  (Truelsen	  et	  al.,	  2003).	  In	  ischemic	  or	  
hypoxic	  tissue,	  Mg	  antagonizes	  calcium’s	  effects	  
and	   decreases	   reactive	   oxygen	   species	  
production	  through	  phopholipases,	  lipoxygenase	  
and	   cyclooxygenase	   pathways.	   Likewise,	   in	  
conditions	   associated	   with	   cerebral	   ischemia,	  
Mg	   deficiency	   promotes	   vasoconstriction	   of	  
cerebral	  and	  coronary	  arteries,	  as	  well	  as	  anoxic	  
depolarizations	  and	  cortical	  spreading	  depression.	  
Accordingly,	   Mg	   supplementation	   potentially	  
plays	   a	   neuroprotective	   role	   (Turner	   et	   al.,	  
2004).	   Mechanical	   stress	   such	   as	   membrane	  
stretch	   or	   osmotic	   cell	   swelling	   can	   activate	  
TRPM7-­‐like	   channels	   (Numata	   et	   al.,	   2007),	  
which	   are	   involved	   in	   Mg	   transport.	   These	  
channels	   are	   members	   of	   the	   ubiquitously	  
expressed	   melastatin-­‐related	   subfamily	   of	  
transient	  receptor	  potential	   (TRP)	  channels,	  and	  
represent	  essential	  mediators	  of	  anoxic	  neuronal	  
death	   (Aarts	   and	   Tymianski,	   2005;	   Penner	   and	  
Fleig,	   2007).	   Low	   intracellular	   levels	   of	   Mg,	   a	  
process	  that	  exacerbates	  the	  effects	  of	  stress	  on	  
the	  organism,	  also	  activate	  TRPM7	  channels.	  
	  
Conscious,	   critically	   ill	   patients	   experience	  
unprecedented	   levels	   of	   stress,	   both	   physical	  
and	   psychological.	   However,	   even	   unconscious,	  
comatose	  or	   sedated	  patients	  can	  exhibit	   stress	  
initiated	   by	   peripheral	   stimuli	   that	   directly	  
activate	   limbic	   structures	   prior	   to	   cortical	  
involvement.	   These	   patients	   exhibit	   multiple	  
organ	  dysfunction	  and	  veritable	  endocrine	  chaos	  
(Papathanassoglou	   et	   al.,	   2010).	   In	   these	  
patients,	   hypomagnesemia	   is	   often	   associated	  
with	  hypokalemia	  and	  is	  considered	  to	  aggravate	  
the	   prognosis.	   Under	   these	   conditions,	  
prolongation	   of	  QT	   interval	   constitutes	   a	   useful	  
biomarker	   of	   electrolyte	   imbalance	   and	   the	  
requirement	   for	   replacement	   therapy	   (Whitted	  
et	   al.,	   2010).	   It	   is	   noteworthy	   that	   hypo-­‐
magnesemia	  has	  been	   linked	  with	  a	  decrease	   in	  
insulin	   sensitivity	   which	   can	   also	   affect	   the	  
neurological	   outcome	   of	   critically	   ill	   patients	  
(Polderman	  et	  al.,	  2003).	   In	  critically	   ill	  patients,	  
a	  daily	  Mg	  supplementation	  index	  higher	  than	  1	  
gram/day	   is	   associated	   with	   a	   lower	   mortality	  
rate.	   Mg	   supplementation	   is	   also	   recommended	  
for	  patients	  exposed	  to	  therapeutic	  hypothermia	  
who	   often	   exhibit	   hypomagnesemia	   due	   to	  
polyuresis	   (Dabbagh	   et	   al.,	   2006;	   Polderman	   et	  
al.,	  2003).	  
In	   a	   model	   of	   intraperitoneal	   sepsis,	  
MgSO4	  administration	  (750	  µmol/kg)	  attenuated	  
increased	   blood–brain	   barrier	   permeability	   and	  
caused	   a	   reduction	   in	   brain	   edema	   formation	  
(Esen	   et	   al.,	   2005).	   Similar	   results	   have	   been	  
observed	   in	  experimental	   traumatic	  brain	   injury	  
(Turner	   and	   Vink,	   2007)	   where	   intravenous	  
administration	   of	   MgSO4	   (250	   µmol/kg)	   also	  
significantly	   decreased	   the	   incidence	   of	   post-­‐
traumatic	   depression/anxiety	   as	   compared	   to	  
non-­‐treated	  animals	  (Fromm	  et	  al.,	  2004).	  	  
	  
Stress	   also	   influences	   the	   susceptibility	   to	  
neurodegenerative	   disorders	   such	   as	   multiple	  
sclerosis	   and	   Alzheimer’s	   disease	   (Brown	   et	   al.,	  
2006a;	   2006b;	   Esch	   et	   al.,	   2002a).	   Pro-­‐
inflammatory	   effects	   associated	   with	   stress	   are	  
exacerbated	  and	  exert	  deleterious	  actions	  upon	  
the	   neurons,	   including	   increased	   IL6	   levels	   that	  
initiate	   microglial	   activation.	   Increased	   iNos	  
levels	   are	   also	   expressed	   during	   critical	   periods	  
and	   the	   elevated	   stress	   hormones	   themselves	  
impair	   hippocampal	   neurogenesis	   and	   memory	  
(Esch	   et	   al.,	   2002a;	   2002b).	   Moreover,	   Mg	  
deficiency	  increases	  neuronal	  calcium	  influx	  and	  
consequently	   augments	   NO	   production	   that	   is	  
associated	   with	   cytotoxic	   effects	   (Eby	   and	   Eby,	  
2006).	   Recent	   data	   also	   indicate	   a	   possible	   link	  
between	   acute	   and	   sudden	   psychological	   stress	  
and	  the	  appearance	  of	  malignant	  primitive	  brain	  
tumours	   (Cabaniols	   et	   al.,	   2010).	   Furthermore,	  
long-­‐term	   survivors	   of	   brain	   cancer	   continue	   to	  
experience	   elevated	   levels	   of	   stress	   as	   the	   fear	  
of	   recurrence	   increases	   with	   time	   (Keir	   et	   al.,	  
2007).	   Epidemiological	   data	   have	   described	   an	  
inverse	   relationship	   between	   Mg	   content	   in	  
drinking	   water	   and	   incidence	   of	   some	   types	   of	  
cancers	   (Maier	  et	  al.,	   2007).	   A	  protective	  effect	  
of	  fresh	  vegetable	  and	  fruit	  intake	  has	  also	  been	  
noted.	  Although	  the	  role	  of	  Mg	  in	  carcinogenesis	  
is	  yet	  to	  be	  established,	   it’s	   involvement	   in	  DNA	  
stabilization	   has	   been	   described	  
(Anastassopoulou	   and	   Theophanides,	   2002;	  
Anghileri,	  2009;	  Wolf	  et	  al.,	  2009).	  	  
	  
Individuals	   with	   cardiovascular	   pathology	   are	  
most	   susceptible	   to	   the	   concerted	   effects	   of	  
stress	   and	   Mg	   deficiency.	   The	   inotropic	   and	  
chronotropic	   response	   induced	   by	   catechol-­‐
amine	   release	   produces	   an	   oxygen	   debt	   in	   the	  
myocardium.	  In	  a	  hypoxic	  tissue,	  Mg	  shifts	  from	  
the	  intracellular	  to	  the	  extracellular	  space,	  and	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calcium	   enters	   into	   cells,	   leading	   to	   increased	  
risk	   of	   arrhythmias	   and	   cardiac	   deterioration	  
(Seelig,	   1989).	   Interestingly,	   MgSO4	   is	  
successfully	   used	   in	   the	   treatment	   of	  
pheochromocytoma,	  a	  condition	  associated	  with	  
excessive	   release	   of	   catecholamine.	   In	   this	  
situation,	  Mg	  exhibits	  simultaneous	  beta-­‐agonist	  
effects	  and	  alpha-­‐adrenergic	  antagonist	  actions,	  
improves	   diastolic	   dysfunction	   and	   reduces	  
episodes	   of	   arrhythmia	   (James,	   2009).	  
Encouraging	   results	   have	   also	   been	   obtained	  
using	   Mg	   therapy	   in	   two	   newly	   described	  
cardiomyopathic	  syndromes:	  Irukandji	  syndrome	  
and	   stress	   cardiomyopathy.	   Irukandji	   syndrome	  
is	   caused	   by	   envenomisation	   from	   a	   jelly-­‐
fish	  (Carukia	   barnesi),	   which	   induces	   excessive	  
release	   of	   endogenous	   catecholamines.	  
Administration	  of	  MgSO4	  alleviates	  pain	  and	  the	  
cardiovascular	   response	   in	   Irukandji	   syndrome	  
but	   there	   is	   still	   a	   need	   for	   evidence-­‐based	  
guidelines	   in	   the	  management	   of	   this	   condition	  
(Tiong,	  2009;	  Nickson	  et	  al.,	  2009;	  Barnett	  et	  al.,	  
2005;	   Corkeron	   et	   al.,	   2004).	   Stress	   cardio-­‐
myopathy	   (also	   referred	   as	   Takotsubo	  
cardiomyopathy	   or	   transient	   left	   ventricular	  
apical	  ballooning	  syndrome)	   is	  an	  acute	  reversible	  
apical	   ventricular	   dysfunction	   provoked	   by	  
elevated	   levels	   of	   catecholamines.	   These	   stress	  
hormones	   enable	   the	   shift	   of	   β2-­‐adrenoceptor	  
transducing	   signal	   from	  Gs	  protein	   to	  Gi	  protein	  
causing	   negative	   inotropic	   effects	   (Lyon	   et	   al.,	  
2008).	  While	   there	   is	   no	   specific	   treatment	   for	  
this	  condition,	  some	  authors	  reported	  beneficial	  
results	   with	   Mg	   administration	   (Akashi	   et	   al.,	  
2008).	  
	  
Considerable	   evidence	   now	   supports	   the	   fact	  
that	   Mg	   presents	   beneficial	   effects	   in	   different	  
types	   of	   surgical	   stress,	   including	   induction	   and	  
maintenance	  of	  pneumoperitoneum,	  endotracheal	  
intubation,	   cardiopulmonary	   bypass,	   occlusion-­‐
reperfusion	   surgery	   and	   middle	   ear	   surgery	  
(James	   2009;	   Jee	  et	   al.,	   2009;	   Puri	  et	   al.,	   1998;	  
Ashton	   et	   al.,	   1991;	   Delhumeau	   et	   al.,	   1995;	  
Manrique	   et	   al.,	   2010;	   Dorman	   et	   al.,	   2000;	  
Kurian	   and	   Paddikkala	   2010;	   Ryu	   et	   al.,	   2009).	  
Considering	   the	   fact	   that	   pain	   induces	   the	  
release	   of	   stress	   mediators,	   the	   blockade	   of	  
neuronal	   NMDA	   receptors	   by	   Mg	   provides	  
additional	   positive	   effects.	   Even	   if	   Mg	   is	   not	   a	  
potent	   analgesic	   per	   se,	   several	   authors	   have	  
shown	   that	  Mg	   potentates	   the	   analgesic	   effect	  
of	  traditionally	  used	  pain	  relievers,	  reduces	  their	  
requirements	   and	   decreases	   the	   incidence	   of	  
postoperative	   shivering	   (Dabbagh	   et	   al.,	   2009;	  
Lysakowski	   et	   al.,	   2007).	   Following	   carotid	  
endarterectomy	   or	   cardiac	   surgery,	  Mg	   therapy	  
improves	   cognitive	   outcome	   and	   prevents	  
postoperative	  arrhythmias,	  especially	  in	  patients	  
with	   contraindications	   for	   beta-­‐blockers	   (Mack	  
et	  al.,	  2009;	  Dabrowski	  et	  al.,	  2008;	  Davis	  et	  al.,).	  
	  
In	  athletes	  who	  are	  subjected	  to	  severe	  physical	  
stress,	  Mg	   favourably	   stabilizes	   the	   membrane	  
integrity	   by	   binding	   with	   phosphate	   groups	   of	  
phospholipids	   located	   in	   cell	   and	   organelle	  
membranes	  (Golf	  et	  al.,	  1998).	  In	  these	  subjects,	  
17	   mmol	   magnesium	   supplementation	   per	   day	  
lowered	   serum	   cortisol	   levels	   and	   augmented	  
venous	   O2	   partial	   pressure	   leading	   to	   better	  
performance.	   Recent	   studies	   indicated	   that	  
magnesium	   intake	   should	   be	   at	   least	   260	  
mg/day	   for	   male	   and	   220	   mg/day	   for	   female	  
athletes	   (Nielsen	   and	   Lukaski,	   2006).	   According	  
to	  Couzy	  and	  colleagues	   (1990),	  Mg	  overdosage	  
in	   professional	   sportsmen	   may	   lead	   to	   hypo-­‐
zincemia.	   The	   overtraining	   syndrome	   described	  
in	  athletes	  is	  also	  a	  stress-­‐related	  condition	  that	  
designates	   the	   exhaustion	   stage	   of	   Selye's	  
general	   adaptation	   syndrome.	   This	   syndrome	   is	  
characterized	   by	   impairment	   of	   psychological	  
processing,	   systemic	   inflammatory	   response,	  
and	   HPA	   dysfunction	   (Angeli	   et	   al.,	   2004).	  
Magnesium	  deficiency	  has	  been	  reported	  in	  this	  
condition.	  
	  
Stress	  and	  the	  brain	  
	  
The	   brain	   is	   very	   susceptible	   to	   stress,	   largely	  
because	  corticosterone	  binds	  at	  this	  level	  to	  high	  
affinity	  mineralocorticoid	   receptors	   (Abaamrane	  
et	   al.,	   2009)	   and	   to	   glucocorticoid	   receptors	  
(GR),	   albeit	  with	  10-­‐fold	   lower	  affinity.	   The	  CA1	  
and	  dentate	  gyrus	  neurons	  of	   the	  hippocampus	  
express	   high	   amounts	   of	   both	   receptor	   types,	  
whereas	   CA3	   pyramidal	   neurons	   primarily	  
express	   mineralocorticoid	   receptors	   (Karst	   and	  
Joels,	   2003).	   A	   stress-­‐induced	   rise	   in	  
corticosteroid	   levels	   modulates	   short-­‐term	  
memory,	   generally	   by	   promoting	   storage	   of	  
information	   that	   is	   emotionally	   related	   to	   the	  
stressful	   event,	   but	   by	   suppressing	   information	  
that	  is	  not	  associated	  with	  it	  (Lupien	  and	  Maheu,	  
2007).	   Glucocorticoids	   contribute	   to	   the	  
consolidation	  of	   contextual	   fear	   conditioning,	   but	  
can	  also	  lead	  to	  memory	  impairments	  (Kolber	  et	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al.,	  2008;	  Leon-­‐Carrion	  et	  al.,	  2009).	  The	  inability	  
to	   remember	   important	   data	   worsens	   the	  
individual’s	   stress	   and	   makes	   the	   subject	   even	  
more	  vulnerable.	  Animal	   studies	  also	   show	   that	  
stress-­‐induced	   increases	   in	  NA	   levels	  modulates	  
declarative	  memory	  according	  to	  an	   inverted-­‐U-­‐
shaped	   function	   by	   enhancing	   the	   memory	   for	  
information	   unrelated	   to	   the	   source	   of	   stress	  
(Lupien	  and	  Maheu,	  2007).	  A	  strong	  link	  between	  
noradrenergic	   activation,	   glucocorticoid	   effects	  
and	   basolateral	   amygdala	   function	   has	   been	  
described	   (McGaugh	   and	   Roozendaal,	   2002;	  	  
Baldi	  and	  Bucherelli,	  2005).	  	  
	  
While	  acute	  stress	  affects	  memory	  in	  a	  reversible	  
way,	   chronic	   stress	   results	   in	   deleterious	  
changes	   in	   the	   hippocampus,	   especially	   an	  
atrophy	  of	  dendrites	  of	  pyramidal	  neurons	  in	  the	  
CA3	   region	   of	   the	   hippocampus,	   and	   in	   other	  
brain	  regions	  (prefrontal	  cortex,	  amygdala,	  brain	  
stem	   and	   pons).	   By	   antagonising	   NMDA	  
receptors,	   Mg	   prevents	   acute	   glucocorticoid	  
effects	   on	   neurogenesis	   (McEwen,	   2008a;	  
Slutsky	   et	   al.,	   2010).	   Mg	   removal	   from	   the	  
extracellular	  medium	  produces	  hyperexcitability	  
and	   cellular	   death	   in	   cultured	   hippocampal	  
neurons	   through	  a	  mechanism	  based	  on	  NMDA	  
receptor	  activation	  and	  Raf-­‐MEK-­‐MSK1	  signalling	  
pathway	   (Hughes	   et	   al.,	   2003).	   Moreover,	  
through	   the	   effects	   upon	   P-­‐glycoprotein,	   Mg	  
modulates	   the	   access	   of	   corticosteroids	   to	   the	  
brain	  (Murck,	  2002).	  Consistent	  with	  these	  data,	  
Mg	  deficiency	  represents	  an	   important	  factor	   in	  
the	  pathogenesis	  of	  aging	  defined	  by	  decreased	  
adaptability	  to	  stress,	  alteration	  of	  hippocampus	  
functioning,	  failure	  to	  turn	  off	  the	  hypothalamo-­‐
pituitary-­‐adrenal	   axis	   and	   hyperadreno-­‐
glucocorticism	   (Durlach	   et	   al.,	   1993;	   Steptoe,	  
2007).	  	  
	  
Stress	   exposure	   results	   in	   a	   long-­‐lasting	  
sensitization	  of	  the	  HPA	  axis	  to	  subsequent	  novel	  
stressors.	   Exposure	   to	   a	   single	   stressor	   induces	  
CRF-­‐dependent	  depression	  of	  postsynaptic	  NMDA	  
receptors	  that	  allows	  glutamate	  synapses	   in	  the	  
paraventricular	   nucleus	   of	   the	   hypothalamus	   to	  
undergo	   a	   short-­‐term	   potentiation	   (STP)	  
(Kuzmiski	  et	  al.,	   2010).	   There	   is	   a	  growing	  body	  
of	   evidence	   that	  Mg	   plays	   an	   important	   role	   in	  
synaptic	   plasticity	   and	   is	   involved	   in	   long-­‐term	  
potentiation	   (LTP)	   and	   long-­‐term	   depression	  
(LTD)	   of	   synaptic	   transmission	   (Billard,	   2006).	  
LTP	  is	  induced	  by	  cortical	  stimulation	  in	  Mg-­‐free	  
solutions	   and	   it	   is	   associated	   with	   massive	  
calcium	   influx	   through	   NMDA-­‐type	   receptors	  
(Nakano	   et	   al.,	   2010).	   Diamond	   et	   al.,	   (2007)	  
suggested	   that	   complex	   interactions	   between	  
LTP	   and	   LTD	   processes	   in	   the	   hippocampus	  
contribute	   to	   the	   storage	   of	   emotional	  
memories	  and	  stress-­‐induced	  amnesia.	  Whether	  
Mg	  can	  modulate	  effects	  of	  stress	  on	  LTP	  in	  the	  
hippocampus,	   amygdala	   and	   prefrontal	   cortex	  
remains	   to	   be	   established.	   Magnesium-­‐L-­‐
threonate	   administration	   in	   rats	   increases	   the	  
density	   of	   synaptophysin-­‐/synaptobrevin-­‐positive	  
puncta	   in	   DG	   and	   CA1	   subregions	   of	   the	  
hippocampus,	  which	  contributes	   to	   improvement	  
of	  cognitive	  functions	  (learning	  abilities,	  working	  
memory,	   short-­‐	   and	   long-­‐term	  memory	   in	   rats)	  
(Slutsky	  et	  al.,	  2010).	  Mg	  also	  acts	  synergistically	  
with	   the	   NMDA	   antagonist	   memantine	   on	  
hippocampal	   LTP,	   and	   there	   are	   data	   that	  
indicate	   that	   Mg	   leads	   to	   an	   improvement	   of	  
cognitive	   function	   in	   dementia	   (Danysz	   et	   al.,	  
2000;	  Frankiewicz	  et	  al.,	  1996).	  	  
	  
Mg	   is	   also	   involved	   in	   long-­‐term	   memory	  
formation	   through	   NA	   activated	   pathways.	  
Saturation	   by	   free	   Mg	   increases	   the	   affinity	   of	  
adenylate	   cyclase	   for	   adrenaline	   and	   excessive	  
stress	   affects	   the	   stability	   of	   this	   enzyme	   and	  
produces	  loss	  of	  activity.	  Moreover,	  by	  activating	  
adenylate	   cyclase	   in	   fat	   tissues,	   stress	   increases	  
the	   production	   of	   chelating	   metabolites	   like	  
ATP4−	  or	   citrate−,	  which	   reduce	   the	   level	  of	   free	  
Mg2+	  (Bennun,	  2010).	  	  
	  
Magnesium	  during	  the	  developmental	  period	  
	  
A	   number	   of	   studies	   have	   now	   suggested	   that	  
magnesium	   and	   stress	   may	   play	   an	   important	  
regulatory	   role	   in	   the	   early	   developmental	  
period.	   For	   example,	   in	   rhesus	   monkeys,	  
stressful	   pregnancy	   reduced	   the	   hippocampal	  
volume	   and	   impaired	   neurogenesis	   in	   the	  
dentate	  gyrus	  of	   the	  offspring	   (Bac	  et	  al.,	  1995;	  
Coe	   et	   al.,	   2003).	   An	   acoustic	   startle	   protocol	  
applied	  during	  the	  24-­‐weeks	  gestation	  time	  was	  
associated	  with	   increased	   levels	   of	   cortisol	   and	  
reduced	  exploratory	  behaviour	  in	  the	  3-­‐year-­‐old	  
descendants.	   Another	   study	   examining	   the	  
newborn’s	   response	   to	   moderate	   surgical	  
trauma	   showed	   that	   neonates	   are	   more	  
susceptible	   to	   stress	   than	   infants	   (Okur	   et	   al.,	  
1995).	   Although	   there	   were	   not	   significant	  
differences	   between	   infants	   and	   neonates	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regarding	   the	   elevations	   of	   cortisol	   and	   growth	  
hormones	   after	   surgical	   stress,	   Mg	  
concentrations	   declined	   more	   in	   newborns	  
compared	  to	  the	  other	  group.	  	  
	  
Both	  experimental	  and	  clinical	  data	  also	  suggest	  
that	   fetal	   Mg	   depletion	   (as	   a	   consequence	   of	  
maternal	   deficiency)	   and	   stress	   during	   critical	  
developmental	   periods	   are	   involved	   in	   the	  
pathogeny	   of	   sudden	   infant	   death	   syndrome	  
(Caddell,	  2001;	  Durlach	  et	  al.,	   2004).	  Durlach	  et	  
al.,	   (2002)	   also	   emphasize	   the	   importance	   of	  
chrono-­‐pathological	   stress	   due	   to	   primary	  
hypofunction	   of	   the	   biological	   clock	   and	   the	  
pineal	   dysfunction.	   Among	   the	   exogenous	  
stressors	   that	   may	   lead	   to	   this	   syndrome,	   it	   is	  
worth	   mentioning	   parental	   smoking,	   maternal	  
alcoholism,	   environmental	   pollutants,	   bottle	  
feeding,	   sleeping	   position,	   bedding,	   wrapping	  
and	  ambient	  temperature	  (Durlach	  et	  al.,	  2004).	  	  
	  
In	   fetal	   guinea	   pig	   brain,	   maternal	   MgSO4	  
administration	   during	   hypoxic	   stress	   exhibits	  
neuroprotective	   effects	   by	   ameliorating	   nuclear	  
membrane	   peroxidation	   and	   nuclear	   DNA	  
fragmentation	  (Maulik	  et	  al.,	  2001).	  Additionally,	  
maternal	   MgSO4	   treatment	   before	   anticipated	  
early	  preterm	  birth	  has	  proven	  to	  reduce	  the	  risk	  
of	   cerebral	   palsy	   in	   surviving	   infants	   (Marlow,	  
2009).	  Given	   the	  “anti-­‐stress”	  properties	  of	  Mg,	  
this	   discovery	   once	   more	   emphasizes	   the	  
importance	  of	  maternal	  Mg	  status	  on	  the	  neural,	  
hormonal	   and	   behavioural	   outcome	   of	   the	  
progenitors.	  
	  
Finally,	   children	   hospitalized	   for	   respiratory	  
pathology	   and	   who	   received	   sporadic	   parental	  
visits	   exhibited	   lower	   serum	   Mg	   level	   and	  
increased	   excretion	   of	   this	   cation	   compared	   to	  
children	  who	  received	  constant	  parental	  support	  
(Bednarek	  et	  al.,	  2004).	  There	  are	  also	  data	  that	  
suggest	  Mg	  deficiency	   in	  children	  brought	  up	   in	  
stressful	   orphanage	   conditions	   may	   lead	   to	   a	  
lower	   intelligence	   quotient	   (Manrique	   et	   al.,	  
2010;	  Papadopol	  et	  al.,	  2001).	  	  
	  
Magnesium	  and	  self-­‐damaging	  behaviour	  
	  
In	   order	   to	   cope	   better	   with	   stress,	   individuals	  
exhibit	   variable	   behavioural	   responses	   ranging	  
from	   improving	   lifestyle	   to	   self-­‐damage	   (e.g.	  
smoking,	  drinking,	  overeating)	  or	  risk-­‐taking.	  It	  is	  	  
well	   known	   that	   susceptibility	   to	   stress	   among	  
the	  population	  is	  diverse	  and	  there	  is	  a	  minority	  
who	   exhibit	   an	   extreme	   response	   to	   stress	   in	  
respect	   to	   intensity,	   features	   and	   extension	   of	  
time.	   The	   myriad	   of	   individual	   differences	  
regarding	  stress	  responses	  are	  mainly	  a	  result	  of	  
genetic	   background,	   developmental	   processes	  
(both	   prenatal	   and	   postnatal),	   and	   lifetime	  
experiences	  (McEwen,	  2007).	  
	  
Individuals	   exhibiting	   self-­‐damaging	   behaviour	  
are	  more	   likely	   to	   present	   hypomagnesemia	   as	  
alcohol	   itself	   depletes	   the	   organism	   of	   Mg	  
(Romani,	   2008).	  Depletion	  of	  Mg	   induced	   in	   rat	  
astrocytes	   by	   alcohol	   produces	   disturbances	   in	  
cytoplasmic	   and	   mitochondrial	   bioenergetic	  
pathways	  leading	  to	  Ca2+	  overload,	  ischemia	  and	  
stroke	  (Altura	  and	  Altura,	  1994).	  Eating	  disorders	  
are	   also	   commonly	   linked	   to	   hypomagnesemia	  
that	   may	   or	   may	   not	   be	   associated	   with	  
hypokalemia,	   hypocalcemia	   and	   hypophosphat-­‐
emia	  (Laird	  Birmingham	  2010;	  Touyz,	  2004).	  This	  
is	   particularly	   concerning	   where	   the	   normal	  
western	   diet	   is	   already	   low	   in	   magnesium.	   For	  
example,	  in	  most	  countries,	  the	  magnesium	  RDA	  
for	   women	   varies	   from	   240	   to	   400mg/day	   and	  
for	   adult	   men	   varies	   from	   310	   to	   420mg/day.	  
However,	   Mg	   intake	   in	   70%	   of	   the	   western	  
population	  is	  less	  than	  400	  mg	  Mg2+	  per	  day,	  and	  
for	   approximately	   20%	   of	   the	   population	   this	  
cation	   intake	   is	   less	   than	   one-­‐half	   of	   the	  
recommended	   dose	   (Eby	   and	   Eby,	   2006).	  
Persons	   with	   inadequate	   nutrition	   that	   often	  
accompanies	   chronic	   stressful	   lifestyle	  need	  Mg	  
supplementation	   as	   increased	   intake	   of	  
carbohydrates,	   fats,	   exaggerated	   consumption	  
of	  coffee	  and	  sodas	  reduce	  the	  Mg	  levels	   in	  the	  
organism	  (Seelig,	  1994;	  Nishimuta,	  2007).	  
	  
Mg	  administration	  can	  provide	  beneficial	  effects	  
by	   decreasing	   the	   susceptibility	   of	   stress-­‐	  
induced	   drug	   relapse.	   Mg	   decreases	   activity	   of	  
central	   glutamatergic	   synapses,	   especially	   those	  
involved	   in	   the	   reward	   system	   that	   is	   activated	  
by	   stress	   (Gilman,	   2007;	   Nechifor,	   2008),	   and	  
displays	  a	  modulatory	  effect	   for	  opioid	  receptor	  
binding	   (Turner	   and	   Vink,	   2007).	   Furthermore,	  
Mg	   administration	   indirectly	   influences	   hippo-­‐
campal	   neurogenesis	   through	   its	   effect	   upon	  
corticosteroid	   hormones,	   and	   in	   this	   way	   may	  
decrease	   the	   drug-­‐seeking	   behaviour	   in	   drug-­‐
addicted	  persons	  (Noonan	  et	  al.,	  2010).	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Magnesium	  and	  substance	  P	  	  
	  
Several	   authors	   have	   recently	   suggested	   that	  
many	   of	   the	   consequences	   of	  Mg	   deficiency	   in	  
stress	   may	   be	   explained	   by	   the	   release	   of	  
substance	  P.	  Substance	  P	  is	  a	  neuropeptide	  that	  
preferably	  activates	  tachykinin	  NK1	  receptors.	   It	  
is	   considered	   to	   be	   involved	   both	   in	   early	   (4-­‐7	  
days)	  and	   late	   (3	  weeks)	  phases	  of	   the	  systemic	  
response	   to	   Mg	   deficiency.	   In	   the	   early	   days	  
after	   the	   onset	   of	   a	   Mg-­‐restricted	   diet,	   low	  
concentrations	  of	  this	  cation	  diminishes	  the	  Mg-­‐
gated	   blockade	   of	   NMDA	   receptor	   channels,	  
which	   leads	   to	   the	   release	   of	   substance	   P	   and	  
calcitonin	  gene-­‐related	  peptide	  from	  the	  sensory	  
C	  fibres.	  The	  increased	  circulating	  levels	  of	  these	  
neuropeptides	  initiate	  an	  important	  “neurogenic	  
inflammation”	   characterized	   by	   raised	   levels	   of	  
inflammatory	   cells,	   inflammatory	   cytokines	   and	  
augmented	   production	   of	   reactive	   oxygen	   and	  
nitrogen	   species	   (Kramer	   et	   al.,	   2009;	   Tejero-­‐
Taldo	   et	   al.,	   2006).	   Brain	   microinjection	   of	  
substance	   P	   activates	   stress-­‐processing	  
pathways	   and	   induces	   defensive	   respiratory,	  
cardiovascular,	   gastrointestinal	   and	  
psychological	   changes,	   as	   well	   as	   stimulating	  
corticosterone	   secretion	   by	   the	   adrenal	   glands	  
(Rupniak,	   2005).	   	   Furthermore,	   in	   a	   model	   of	  
chronic	  psychosocial	  stress	  in	  shrews,	  the	  NK1	  
receptor	   antagonist	   SLV-­‐323	   alleviated	   dentate	  
cytogenesis	   and	   diminished	   the	   decrease	   of	  
hippocampal	  volume	   induced	  by	   stress	   (Czeh	  et	  
al.,	   2005).	   Thus,	   substance	   P	   is	   now	   widely	  
considered	   to	   be	   involved	   in	   the	   clinical	  




Mg	   still	   represents	   an	   emerging	   research	   field	  
despite	  being	  entered	  into	  medicine	  in	  the	  XVIIth	  
century	  as	  a	  constituent	  of	  Epsom	  salts	  (Durlach	  
2007).	   Although	   much	   has	   been	   discovered,	  
many	  aspects	  of	  magnesium	  still	  remain	  unclear	  
and	   await	   discovery.	   Undoubtedly,	   the	   future	  
will	   uncover	   new	  Mg	   compounds	   of	   medicinal	  
value,	  will	  further	  characterize	  Mg	  as	  a	  common	  
factor	   in	   more	   stress-­‐related	   pathologies,	   and	  
will	   result	   in	   the	   discovery	   of	   more	   Mg	  
transporters,	   while	   better	   methods	   for	   the	  
determination	  of	  intracellular	  levels	  of	  the	  cation	  
will	  pave	  the	  way	  for	  an	  improvement	  in	  simple	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Neuroses	  are	  a	   frequently	  encountered	  group	  of	  psychiatric	  diseases	  with	  a	   symptomatology	   including	  
neuronal	   hyperexcitability,	   anxiety,	   panic,	   phobic	   reactions,	   quite	   frequent	   tiredness,	   attention	  deficit,	  
anorexia	  or	  bulimia,	  and	  sleep	  disorders,	  amongst	  others.	  The	  main	  pathogenic	  mechanisms	  involved	  in	  
neurosis	  are	  increased	  activity	  of	  the	  glutamatergic	  cerebral	  systems	  (the	  increased	  synthesis,	  presynaptic	  
release	   and	   action	   upon	   NMDA	   receptors),	   an	   intense	   catecholamine	   release,	   and	   the	   decrease	   of	  
GABAergic	   cerebral	   systems	   activity.	   In	   most	   neurotic	   patients	   there	   is	   a	   reduction	   of	   plasma	   and	  
intracellular	  magnesium	  concentration.	  Magnesium	  administration	  decreases	  anxiety,	  panic	  and	  phobia	  
and	  ameliorates	  the	  attention	  deficit	  and	  sleep	  disorders.	  We	  consider	  that	  magnesium	  acts	  mainly	  by:	  a)	  
the	  reduction	  of	  presynaptic	  glutamate	  release;	  b)	  the	  reduction	  of	  NMDA	  receptor	  activity	  by	  competing	  
with	  calcium	  at	  NMDA	  receptor	  coupled	  calcium	  channels;	  c)	  the	  positive	  allosteric	  modulator	  effect	  at	  
the	   level	   of	   some	   metabotropic	   presynaptic	   glutamate	   receptors,	   thereby	   decreasing	   presynaptic	  
glutamate	   release	   and	   stimulating	   GABA	   release;	   and	   d)	   the	   decrease	   of	   catecholamine	   release	   by	   a	  
direct	   presynaptic	   effect	   under	   the	   action	   of	   some	   factors	   including	   calcium.	   The	   stimulation	   of	  
catecholamine	  release	  under	  stressful	  conditions	  leads	  to	  increased	  magnesium	  waste	  that	  is	  an	  essential	  
event	   in	   the	  appearance	  of	   the	   functional	   cerebral	   changes	  characteristic	  of	  neurosis	   symptomatology.	  
Unlike	  neuroses,	  neuroticism	  is	  not	  pathologic,	  but	  rather	  a	  normal	  state	  characterized	  by	  the	  dominance	  
of	   some	   neuropsychological	   symptoms.	   There	   are	   data	   that	   show	   that	   the	   level	   of	   magnesium	  





Magnesium	   is	   a	  nutrient	   essential	   for	   the	  health	  
of	   the	  whole	   organism,	   including	   the	   brain.	   It	   is	  
the	   fourth	   most	   abundant	   mineral	   in	   the	   body.	  
Due	   to	   its	   relationships	   with	   more	   than	   300	  
biochemical	   reactions,	   it	   is	   possible	   that	  
magnesium	  is	  involved	  in	  more	  aspects	  of	  human	  
body	   make-­‐up	   and	   metabolism	   than	   any	   other	  
mineral.	  Because	  the	  usual	  diet	  has	  drifted	  away	  
from	   green	   leafy	   vegetables	   and	   unprocessed	  
grains	   in	   favour	   of	   more	   refined	   and	   often	  
nutrient-­‐poor	  food	  options,	  magnesium	  inadequacy	  
has	  become	  quite	  common	   in	  many	  areas	  of	   the	  
world.	  One	   study	   shows	   that	  68	  %	  of	  Americans	  
are	  magnesium	  deficient	  (www.usda.gov).	  
	  
The	   role	   of	   magnesium	   is	   complex	   and	   its	  
deficiency	  is	  implicated	  in	  a	  number	  of	  nonspecific	  
neuropsychological	   changes	   such	   as	   agitation,	  
fear,	   anxiety,	   depression,	   dizziness,	   poor	  
attention,	   insomnia,	   and	   restlessness.	   Some	   of	  
these	   symptoms	   characterize	   the	   mental	   illness	  




Neuroses	  -­‐	  characteristics	  and	  classification	  
Neurosis	   is	   a	   functional	   disorder	   of	   the	   central	  
nervous	   system	   (CNS)	   generally	   characterized	  by	  
excessive	  anxiety	  without	  evidence	  of	  neurologic	  
disease,	  sometimes	  accompanied	  by	  defensive	  or	  
immature	   behaviours.	   It	   is	   a	   general	   term	  
describing	  a	  group	  of	  widespread	  mental	  illnesses	  
also	  known	  as	  neurotic	  disorders,	  and	  thus,	  those	  
suffering	  from	  them	  are	  said	  to	  be	  neurotics.	  It	  is	  
also	  an	  emotional	  disorder	   that	   affects	   a	  part	  of	  
the	  personality.	  Neuroses	   include	  a	   large	   variety	  
of	   psychiatric	   disorders	   exhibiting	   a	   range	   of	  
symptoms	   such	   as	   phobias,	   anxiety,	   tics	   and	  
others.	  These	  disorders	  are	  quite	  a	  heterogeneous	  
entity	   that	   is	   difficult	   to	   delimit.	   The	   myriad	   of	  
factors	   that	   have	   been	   implicated	   makes	   the	  
outline	   of	   a	   single	   psychopathological	   theory	   of	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neurosis	   difficult,	   and	   this	   has	   convinced	   some	  
modern	   authors	   to	   remove	   the	   term.	   Although	  
the	   American	  Diagnostic	   and	   Statistic	  Manual	   of	  
Mental	   Disorders	   (DSM)	   has	   eliminated	   the	  
category	   of	   neurosis,	  many	   authors	   still	   refer	   to	  
them.	  Sometimes	  it	   is	  named	  anxiety	  neurosis	  or	  
anxiety	  and	  phobic	  disorders.	  Anxiety,	  one	  of	  the	  
most	  common	  symptoms	  of	  neurosis,	  is	  a	  physical	  
symptom	   that	   frequently	   includes	   palpitations,	  
nausea,	   chest	   pain,	   sweating,	   and	   trembling,	  
amongst	  others.	  	  	  
	  
Some	   authors	   consider	   that	   the	   main	  
characteristics	   of	   neuroses	   are	   the	   existence	   of	  
psychic,	   somatic	   and	   behavioural	   troubles	  
without	   anatomical	   and	   psychological	   changes,	  
with	  the	  patient	  being	  aware	  of	  the	  pathology	  of	  
their	   symptoms	   but	   unable	   to	   control	   them	  
(although	  social	  adaptation	   is	   satisfactory	  except	  
in	  serious	  forms	  of	  the	  disorder).	  There	  is	  also	  an	  
obvious	   but	   variable	   response	   to	   therapy	  
(medicines,	   psychotherapy,	   relaxing	   techniques,	  
hypnosis).	   Historically,	   the	   definition	   and	  
classification	   of	   neuroses	   were	   frequently	  
restructured	   according	   to	   different	   explicative	  
theories.	   Therefore,	   the	   neuroses-­‐related	  
terminology	   is	  very	  variable.	  Essentially,	  neurotic	  
symptoms	   are	   considered	   as	   a	   symbolic	  
expression	  of	  an	   internal	  drama	   that	   the	   subject	  
is	   unable	   to	   control	   because	   its	   essential	  
elements	   drop	   out	   of	   their	   consciousness.	   Some	  
authors	  include	  the	  social	  phobias,	  agoraphobias,	  
hypochondria,	   panic	   disorder	   and	   even	   hysteria	  
in	   neuroses.	   Generally,	   neurosis	   means	   poor	  
ability	  to	  adapt	  to	  ones	  environment,	  an	  inability	  
to	   change	  one’s	   life	   pattern,	   and	   the	   inability	   to	  
develop	   a	   richer,	  more	   complex,	  more	   satisfying	  
personality	   (Boeree,	   2002).	   Some	   professionals	  
use	   the	   term	   to	  describe	  anxious	   symptoms	  and	  
associated	  behaviour,	  or	  to	  describe	  the	  range	  of	  
mental	   illnesses	   outside	   of	   the	   psychiatric	  
disorders.	   Others	   use	   the	   term	   neurosis	   to	  
describe	   the	   internal	   process	   itself	   that	   triggers	  
the	  anxiety	  characteristics.	  
	  
The	   International	   Classification	   of	   Diseases	   (ICD)	  
10	   (World	   Health	   Organisation,	   1992)	   grouped	  
the	   neurotic	   disorders	   together	   with	   stress	   and	  
somatophorm	   disturbances	   because	   of	   their	  
historical	  association	  with	  the	  term	  neurosis,	  and	  
because	   of	   their	   association	   with	   psychological	  
causes.	   The	   concept	   of	   neurosis	   was	   not	   the	  
major	   organizing	   principle.	   The	   combination	   of	  
symptoms	   is	   common	   (most	   frequent	   being	   the	  
associated	   depression-­‐anxiety),	   especially	   in	   the	  
less	   serious	   variants	   of	   these	   disturbances	   that	  
are	   met	   in	   the	   first	   instance.	   ICD-­‐10	   introduces	  
this	   type	   of	   disorder	   in	   the	   chapter	   “Neurotic,	  
stress-­‐related	  and	  somatoform	  disorders”:	  
	  
a)	   phobic	   anxiety	   disorders:	   agoraphobia	   with	  
panic	   attacks,	   agoraphobia	   without	   panic	  
attacks,	   social	   phobia,	   specific	   phobia,	   other	  
phobic	   anxiety	   disorders	   (specified	   and	  
unspecified)	  
b)	   other	   anxiety	   disorders:	   panic	   disorder,	  
generalized	   anxiety	   disorder,	   mixed	   anxiety	  
and	   depressive	   disorder,	   other	   anxiety	  
disorders	  (specified	  and	  unspecified)	  
c)	  	   obsessive-­‐compulsive	  disorders	  
d)	   reactions	   to	   severe	   stress,	   and	   adjustment	  
disorders	  
e)	   dissociative	  disorders	  
f)	   somatoform	  disorders	  
g)	   other	  neurotic	  disorders.	  
	  
Excessive	   anxiety	   and	   fear	   are	   common	  
symptoms	   of	   neurotic	   disorders.	   According	   to	  
Boeree	   (2002),	   the	   signs	   and	   symptoms	   of	  
neurosis	   refer	   to	   a	   variety	   of	   psychological	  
problems	   involving	   persistent	   experience	   of	  
negative	   affects	   including	   anxiety,	   sadness	   and	  
depression,	   anger,	   irritability,	   mental	   confusion,	  
low	   sense	   of	   self-­‐worth,	   behavioural	   symptoms	  
such	   as	   phobic	   avoidance,	   vigilance,	   impulsive	  
and	  compulsive	  acts,	  lethargy,	  cognitive	  problems	  
such	   as	   unpleasant	   and	   disturbing	   thoughts,	  
repetition	   of	   thoughts	   and	   obsessions,	   habitual	  
fantasizing,	   negativity	   and	   cynicism.	   Neurosis	   or	  
neurotic	   disorder	   can	   vegetatively	   affect	   the	  
person’s	   ability	   to	   function,	   thus	   affecting	   the	  
activities	  of	  daily	   living.	  Some	  factors	  (education,	  
culture)	  may	   serve	   to	   override	   any	   predisposing	  
physiological	   conditions,	   or	   to	   exacerbate	   them.	  
An	   essential	   point	   concerns	   the	   triggering	  
stressors	   in	   a	   person’s	   life,	   which	   lead	   to	   the	  
various	   emotional,	   behavioural,	   and	   cognitive	  
symptoms	  of	  neurosis.	  	  
	  
Relationship	  between	  magnesium	  and	  neuroses	  
There	   are	   studies	   that	   show	   the	   involvement	   of	  
magnesium	   in	   the	  pathogeny	  of	  most	   symptoms	  
that	   can	   appear	   in	   neuroses.	   The	   magnesium	  
level	   in	   the	   brain	   is	   more	   stable	   and	   decreases	  
more	   slowly	   than	   in	   other	   tissues,	   but	   small	  
decreases	  have	  important	  influences	  on	  neuronal	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functioning.	  Taking	   into	  account	  the	  existence	  of	  
some	   symptoms,	   both	   in	   magnesium	   deficiency	  
and	   in	   neurosis	   (latent	   tetany,	   hyperventilation	  
syndrome,	   anxiety,	   hyper	   emotionality,	   fatigue	  
and	   sometimes	   migraine,	   dizziness,	   nervous	   fits	  
such	  as	  panic	  attack,	  particularly,	  the	  sensation	  of	  
a	  “lump	  in	  the	  throat”),	  one	  can	  speculate	  that	  a	  
relationship	   between	  magnesium	   deficiency	   and	  
neurosis	  exists.	  	  
	  
The	   most	   frequent	   and	   characteristic	   form	   of	  
magnesium	   deficit	   disorders	   in	   the	   central	  
nervous	   system	   is	   nervous	   hyperexcitability	  
(Durlach,	   1998;	   Durlach	   et	   al.,	   1997),	   and	   hence	  
nervous	  forms	  of	  magnesium	  deficiency	  represent	  
the	  most	  commonly	  seen	  form	  in	  clinical	  practice	  
whatever	  the	  age.	  Nervous	  hyperexcitability	  is,	  at	  
the	  same	  time,	  one	  of	  the	  most	  frequent	  features	  
of	   neuroses.	   Oral	   administration	   of	   magnesium	  
leads	   to	   the	   correction	   of	   the	   symptomatology	  
and	   the	   normalization	   of	   the	   electropolygraphic	  
modifications,	  ECG	  and	  other	  static	  and	  dynamic	  
parameters.	  	  
	  
Panic	  is	  an	  essential	  symptom	  of	  neuroses.	  A	  few	  
studies	   have	   determined	   the	   plasma	  
concentration	   of	   magnesium	   and	   other	   bivalent	  
cations	   of	   panic	   disorder	   patients.	   Nahar	   et	   al.,	  
(2010)	   did	   not	   find	   significant	   differences	   in	   the	  
magnesium	   plasma	   concentration	   in	   panic	  
disorder	   patients	   versus	   the	   control	   group,	   but	  
the	   intracellular	   concentrations	   were	   not	  
determined.	   ATPase	   activity	   was	   studied	   in	   the	  
erythrocytes	  of	  the	  patients	  with	  phobic	  neurosis.	  
Sechenov	   (1975)	   found	   an	   increased	   activity	   of	  
the	  Mg2+ATPase	  in	  these	  patients	  but	  a	  decreased	  
activity	   of	   the	   Na+/K+ATPase	   as	   compared	   with	  
the	   control	   group.	   The	   significance	   of	   these	  
changes	  is	  not	  clear.	  
	  
In	  anxiety	  neurosis,	  there	  was	  not	  only	  a	  decrease	  
in	   magnesium	   concentration,	   but	   also	   modified	  
quantitative	   proportions	   between	   magnesium	  
and	   other	   blood	   plasma	   or	   cytoplasmic	  
components.	   It	   was	   shown	   that	   the	   blood	   fatty	  
acids/magnesium	   ratio	   was	   increased	   and	   the	  
magnesium	   level	   was	   decreased	   in	   anxiety	  
neurotic	  patients	  (Iakushev	  et	  al.,	  1989).	  
	  
Regarding	   the	   mechanism	   by	   which	   magnesium	  
reduces	   panic	   and	   anxiety,	  we	   consider	   that	   the	  
main	   elements	   are	   decreased	   glutamate	   action	  
and	   increased	   action	   of	   the	   GABAergic	   systems.	  
Magnesium	   reduces	   anxiety	   by	   a	   number	   of	  
mechanisms	   (Figure	   1).	   These	   include	   reducing	  
actions	   at	   the	   level	   of	   the	   calcium	   channel
	  
	  
Figure	  1.	  Magnesium	  mechanisms	  of	  action	  in	  anxiety	  and	  panic.	  -­‐,	  inhibition;	  +,	  stimulation	  (increase).	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coupled	   with	   NMDA	   receptors,	   reducing	   the	  
presynaptic	   cerebral	   release	   of	   epinephrine	   and	  
nor-­‐epinephrine,	   increasing	   GABA	   concentration	  
in	  some	  brain	  areas,	  and	  acting	  as	  a	  modulator	  of	  
glutamate	  release	  at	  the	  presynaptic	  level.	  
	  
Glutamate	   is	   the	   most	   important	   excitatory	  
neurotransmitter	   in	  mammalian	   brain.	   It	   acts	   at	  
three	  major	   receptor	   types	   including	   the	   NMDA	  
ionotropic	   receptor	   coupled	   to	   a	   Ca2+	   channel,	  
the	   AMPA	   (alpha-­‐amino-­‐3	   hydroxy-­‐5	   methyl-­‐4-­‐
isoxazole	   propionic	   acid)	   receptor,	   and	   the	  
metabotropic	   glutamate	   receptor	   (mGluR)	   group	  
(at	   least	   8	   subtypes).	   Glutamate	   metabotropic	  
receptors	   are	   divided	   into	   three	   groups,	   group	   I	  
including	  mGluR1	  and	  mGluR5	  subtypes,	  group	  II	  
including	   mGluR2	   and	   mGluR3	   subtypes,	   and	  
group	  III	  including	  mGluR4,	  mGluR6,	  mGluR7	  and	  
mGluR8	  subtypes.	  	  
	  
The	   most	   important	   postsynaptic	   receptor	  
population	  for	  glutamate	  is	  the	  NMDA	  receptors.	  
Dorsomedial	   hippocampal	   neurons	   express	   both	  
NMDA	  and	  AMPA	  receptors	  for	  glutamate	  (Bailey	  
et	   al.,	   2003;	   Goren	   et	   al.,	   2003).	   Magnesium	  
doesn’t	   have	   a	   noticeable	   influence	   upon	  AMPA	  
receptors	   and	   the	   existing	   data	   implicate	   the	  
NMDA	   hypothalamic	   receptors	   in	   producing	  
anxiety	   and	   panic	   disorders.	   Magnesium	   does	  
reduce	   the	   effect	   of	  NMDA	   receptor	   stimulation	  
and	   this	   is	   the	  main	  mechanism	   of	   its	   anxiolytic	  
effect	   (Coan	   and	   Collingridge,	   1985).	   Chronic	  
stress	   involved	   in	   the	   pathogeny	   of	   some	  
neuroses	   increases	   the	   hypothalamic	   NMDA	  
receptor	  expression	  (Lee	  et	  al.,	  2003).	  
	  
The	   mGluRs	   are	   a	   family	   of	   G-­‐protein	   coupled	  
receptors	   that	   have	   a	   widespread	   expression	   in	  
the	  CNS	  (Niswender	  and	  Conn,	  2010).	  They	  have	  
a	  modulator	   role	   in	   synaptic	   transmission	  and	   in	  
normal	  excitability	  in	  the	  brain,	  playing	  a	  key	  role	  
in	   the	   modulation	   of	   glutamatergic	   activity,	  
glutamate	   secretion	   and	   presynaptic	   release,	  
GABAergic	   system	   activity	   and	   in	   regulation	   of	  
neuroendocrine	   activity.	   The	   normal	   and	  
pathological	   implications	   of	   the	   activation	   of	  
these	   receptors	   are	   very	   different.	   Glutamate	  
action	   on	   these	   brain	   receptors	   is	   important	   in	  	  
normal	  and	   in	  pathologic	  situations	  such	  as	   fear,	  
anxiety,	   addiction,	   panic,	   withdrawal	   syndrome,	  
and	   posttraumatic	   stress	   disorders.	   Notably,	  
divalent	  cations	  modulate	   the	  activity	  of	  mGluRs	  
(Francesconi	   and	   Duvoisin,	   2004).	   A	   mounting	  
and	  important	  role	  in	  not	  only	  in	  anxiety,	  but	  also	  
in	   other	   CNS	   disorders,	   is	   attributed	   to	  
malfunction	   of	   the	   mGluRs.	   Regarding	   the	  
symptoms	   in	   neurosis	   (anxiety,	   fear,	   cognitive	  
impairment,	   working	  memory),	   the	  mGluR2	   and	  
the	   mGluR7	   are	   the	   most	   important	   types	   of	  
mGluRs	   and	   they	   are	   highly	   expressed	   in	  
hippocampus	   (Desai,	   1992).	   The	   mGluR7,	   in	  
particular,	   has	   a	   wide	   distribution	   in	   the	   brain,	  
and	  is	  preferentially	  localized	  to	  presynaptic	  axon	  
terminals	   in	   the	   amygdala	   and	   hippocampus	  
(Masugi	   et	   al.,	   1999).	   This	   receptor	   has	   a	   low	  
affinity	   for	   glutamate,	   and	   Niswender	   and	   Conn	  
(2010)	   consider	   that	   it	  only	  activates	   in	   the	   case	  
of	   overstimulation	   by	   glutamate,	   and	   reduces	  
glutamatergic	   activity.	   Selective	   stimulation	   of	  
mGluR7	  induced	  anxiolytic-­‐like	  effects	  in	  mice	  by	  	  
enhancement	   of	   GABAergic	   neurotransmission,	  
and	   by	   reduction	   of	   glutamate	   synthesis	   and	  
action	   (Stachowicz	   et	   al.,	   2008).	   The	   lack	   of	  
mGluR7	   caused	   a	   deficit	   in	   fear	   response	   and	  
conditioned	   taste	  aversion	   (Masugi	  et	  al.,	   1999).	  
Magnesium	   is	   important	   for	   mGluR7	   receptor	  
activity	   and	   may	   explain	   the	   enhancement	   of	  
anxiety	   in	   hypomagnesemia	   (Niswender	   and	  
Conn,	  2010).	  	  
	  
The	  agonists	  of	  some	  mGluRs	  are	  promising	  drugs	  
in	   the	   future	   treatment	   of	   some	   psychiatric	  
disorders.	   The	   agonists	   and	   positive	   allosteric	  
modulators	  of	  group	  I	  mGluRs	  might	  treat	  anxiety	  
disorders	  (Krystal	  et	  al.,	  2010).	  The	  mGluR	  group	  
II	   agonists	   block	   fear	   learning	   when	   they	   are	  
administrated	  into	  the	  amygdala	  prior	  to	  training	  
(Walker	   and	   Davis,	   2002).	   Mares	   et	   al.,	   (2010)	  
showed	   in	   immature	   rats	   that	   some	  mGluRs	   are	  
involved	   in	   production	   of	   anxiolysis.	  Magnesium	  
is	   also	   a	   positive	   allosteric	   modulator	   for	   some	  
mGluRs.	  
	  
The	   ratio	   between	   glutamate-­‐induced	   excitatory	  
activity	   and	   GABAergic	   inhibition	   in	   some	   brain	  
areas	   (such	   as	   the	   amygdala,	   dorsomedial	  
hypothalamus	  and	  cortex)	  plays	  an	  essential	  role	  
in	   behaviour	   and	   imbalances	   are	   involved	   in	   the	  
pathogenic	  mechanism	  of	  anxiety,	  panic	  disorder	  
and	   phobia.	   Experimental	   chronic	   inhibition	   of	  
GABA	   synthesis	   and	   enhancement	   of	  
glutamatergic	   activity	   in	   the	   dorsomedial	  
hypothalamus	   induced	   panic-­‐like	   responses	   in	  
rats	   (Johnson	   and	   Shekhar,	   2006).	   Glutamate	  
NMDA	  receptors	  are	  the	  most	  important	  receptor	  
group	   involved	   in	   experimental	   lactate-­‐induced	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panic-­‐like	   responses	   in	   rats,	   but	   other	   receptors	  
for	  glutamate	  are	  also	  involved.	  	  	  
	  
Carbamazepine,	  an	  antiepileptic	  drug,	  is	  also	  used	  
for	  the	  treatment	  of	  many	  nonepileptic	  disorders,	  
including	   anxiety.	   The	   anxiolytic	   effects	   of	  
carbamazepine	   seem	   to	  be	  mediated,	   at	   least	   in	  
part,	   by	   interactions	  with	   the	   GABAergic	   system	  
because	   muscimol	   (a	   GABAA	   receptor	   agonist)	  
enhanced	   the	   carbamazepine	   anxiolytic	   effect.	  
The	   anxiogenic	   effect	   of	   NMDA	   administration	  
was	  also	  reversed	  by	  carbamazepine	  (Rezvanfard	  
et	  al.,	  2009).	  In	  our	  studies	  (Nechifor	  et	  al.,	  2005;	  
2007),	  carbamazepine	  administration	  in	  therapeutic	  
doses	   in	   human	   subjects	   increased	   the	  
intracellular	   magnesium	   level.	   We	   believe	   that	  
the	   anxiolytic	   effect	   of	   carbamazepine	   is	   due,	   at	  
least	   in	   part,	   to	   the	   increased	   intracellular	  
magnesium	  concentration.	  
	  
GABA	   antagonizes	   glutamate	   hyperexcitation	   in	  
some	   brain	   regions	   such	   as	   the	   dorsomedial	  
hypothalamus	   and	   protects	   against	   anxiety	   and	  
panic	  disorders	  (Millan,	  2003).	  Favouring	  the	  idea	  
that	   the	   GABAergic	   system	   plays	   an	   important	  
role	   in	   preventing	   and	   reducing	   panic	   and	  
anxiety,	   a	   low	   GABA	   concentration	   in	   brain	   has	  
been	   associated	   with	   anxiety	   behaviours	   in	   rats	  
and	   mice.	   In	   rats,	   chronic	   administration	   of	   1-­‐
allylglicine	   (a	   GABA	   synthesis	   inhibitor)	   in	   the	  
dorsomedial	   hypothalamus	   induced	   panic	  
disorder	   and	   enhanced	   panic-­‐like	   behaviour	  
produced	  by	  sodium	  lactate	  infusion	  (Schekhar	  et	  
al.,	  1996;	  2003).	  A	  reduction	  of	  GABAergic	  system	  
activity	   has	   also	   been	   shown	   in	   non-­‐medicated	  
panic	   disorder	   patients.	   The	   subjects	   without	  
major	   depression	   had	   a	   22%	   reduction	   of	   the	  
total	   occipital	   cortex	   GABA	   concentration	  
compared	   with	   the	   normal	   control	   group	  
(Goddard	  et	  al.,	  2001).	  Crestani	  et	  al.,	  (1999)	  and	  
Goddard	  et	  al.,	  (2001)	  also	  showed	  that	  impaired	  
brain	  GABA	  and	  benzodiazepine	  receptor	  activity	  
is	   involved	   in	   phobic	   behaviours	   in	   mice.	  
Glutamatergic	   system	   hyperactivity	   is	   also	  
involved	   in	   other	   symptoms	   of	   neurosis,	   for	  
example	   the	   dysregulation	   of	   the	   fear	   memory,	  
the	  extinction	  of	  the	  fear	  memory	  and	  post-­‐stress	  
neuroses.	   An	   NMDA	   receptor	   agonist,	   D-­‐
cycloserine	   (5	  mg/kg),	   blocked	   fear	   extinction	   in	  
rats	  (Yang	  et	  al.,	  2007).	  
	  
The	  catecholamines	  are	  also	  involved	  in	  fear	  and	  
panic	  disorders.	  The	  injection	  of	  an	  α1-­‐blocker	  in	  
the	   dorsomedial	   hypothalamus	   blocks	   panic-­‐like	  
responses	   of	   animals	   (Johnson	   and	   Shekhar,	  
2006).	  The	  systemic	  administration	  of	  yohimbine	  
induced	   panic-­‐like	   responses,	   by	   blocking	  
presynaptic	   α2-­‐receptors	   and	   increasing	   epi-­‐
nephrine	   and	   norepinephrine	   release	   (Lowry	   et	  
al.,	   2003).	   Yohimbine	   administration	   in	   healthy	  
subjects	   increases	   the	   plasma	   level	   of	  
norepinephrine,	   increases	   adrenergic	   activity,	  
and	  results	   in	   increased	  anxiety	  and	  nervousness	  
in	   the	   patients.	   Charney	   et	   al.,	   (1984)	   found	   a	  
significant	   positive	   correlation	   between	   the	  
plasma	  level	  of	  the	  norepinephrine	  metabolite,	  3-­‐
methoxy-­‐4-­‐hydroxyphenylglicol	   (MHPG),	   and	  
patient	   anxiety	   and	   panic	   attacks.	   Notably,	  
magnesium	   reduces	   epinephrine	   and	   nor-­‐
epinephrine	   synthesis	   and	   release,	   decreases	  
anxiety	  and	  could	  prevent	  the	  panic	  attacks.	  
	  
Magnesium	   deficiency,	   even	   when	   mild,	  
increases	   susceptibility	   to	   various	   types	   of	  
neurologic	  and	  psychological	   stressors	   in	  healthy	  
human	   subjects	   and	   diverse	   groups	   of	   patients.	  
Repletion	   of	   deficiency	   reverses	   this	   increased	  
stress	   sensitivity,	   and	   pharmacologic	   loading	   of	  
magnesium	   salts	   induces	   resistance	   to	  
neuropsychological	   stressors.	   Mild	   magnesium	  
deficiency	   appears	   to	   be	   common	   among	  
patients	   with	   disorders	   considered	   functional	   or	  
neurotic	  and	  appears	  to	  contribute	  to	  a	  symptom	  
complex	   that	   includes	   asthenia,	   sleep	   disorders,	  
irritability,	   hyperarousal,	   spasm	   of	   striated	   and	  
smooth	   muscle,	   and	   hyperventilation	   (Galland,	  
1991-­‐1992).	   Stress,	   being	   a	   frequent	   cause	   of	  
neurosis,	   influences	  magnesium	  concentration	   in	  
the	  organism.	  Adrenergic	  stress	  induces	  a	  shift	  of	  
magnesium	   from	   the	   intracellular	   to	   the	  
extracellular	   space	   and	   increases	   urinary	  
magnesium	   loss.	   In	   contrast,	   magnesium	  
deficiency	   increases	   the	   vulnerability	   of	   human	  
body	  to	  stress	  and	  the	  damage	  induced	  by	  stress	  
(Galland,	   1991).	   Magnesium	   deficiency	   also	  
increases	   neuronal	   excitability,	   not	   only	   by	  
increasing	   the	   excitatory	   effect	   of	   glutamate	  
mediated	   by	   NMDA	   receptors,	   but	   possibly	   by	  
increasing	   the	   calcium	   current	   in	   pre-­‐	   and	   post-­‐
synaptic	   membranes	   and	   by	   alteration	   of	   the	  
Na+/K+	  ATPases	  (Morris,	  1992).	  
	  
Glutamate	   induces	   a	   powerful	   stimulation	   of	  
norepinephrine	   release	   in	   the	   amygdala	   and	   in	  
hippocampal	   slices	   (Fink	   et	   al.,	   1992).	  Mg2+	   ions	  
and	   MK-­‐801	   (dizocilpine,	   an	   NMDA	   receptor	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antagonist)	   reduced	   the	  NMDA-­‐evoked	   overflow	  
of	   norepinephrine.	   Norepinephrine	   release	  
related	   to	   the	   stimulation	  of	  AMPA	  receptors	  by	  
glutamate	   does	   not	   seem	   to	   be	   influenced	   by	  
Mg2+.	  Since	  the	  activation	  of	  mGluR4	  and	  mGluR7	  
induces	   a	   decrease	   in	   glutamate	   release	   from	  
presynaptic	  areas	  (Schrader	  and	  Tasker,	  1997),	   it	  
is	   possible	   that	   presynaptic	  mGluRs	   can	   thereby	  
influence	  norepinephrine	  release.	  
	  	  
Another	   important	   problem	   is	   the	   frequency	   of	  
sleep	   disturbances	   in	   patients	   with	   neurosis.	  
There	   are	   data	   that	   support	   the	   possible	  
involvement	  of	  magnesium	  in	  sleep	  regulation.	  In	  
rats,	   magnesium	   deficiency	   is	   associated	   with	   a	  
decrease	   in	   sleep	   time.	   Magnesium	   content	   in	  
four	   brain	   areas	   was	   also	   highly	   and	   positively	  
correlated	   with	   the	   length	   of	   sleep	   periods	  
(Chollet	   et	   al.,	   2000).	   Erythrocyte	   magnesium	  
concentrations	   are	   low	   in	   adult	   human	   subjects	  
with	   chronic	   sleep	   deprivation	   (1.1	   ±	   0.4	  mg/dl)	  
versus	  a	  control	  group	  (1.8	  ±	  0.4	  mg/dl)	   (Tanabe	  
et	   al.,	   1997).	   The	   reduction	   of	   sleep	   time	   is	  
frequently	   associated	   with	   chronic	   fatigue.	  
Chronic	   sleep	   deprivation	   is	   associated	   with	   an	  
increase	   of	   plasma	   catecholamine	   release	   and	  
with	  a	  decrease	  of	  intracellular	  magnesium	  level.	  
These	  changes	  occur	  relatively	  quickly.	  In	  healthy	  
male	   students	   (20-­‐24	   years	   aged),	   4	   weeks	   of	  
partial	   sleep	   deprivation	   was	   sufficient	   for	   the	  
appearance	   of	   these	   changes	   in	   the	   intracellular	  
concentration	   of	  magnesium,	   and	   in	   the	   plasma	  
epinephrine	   and	   norepinephrine	   concentrations.	  
The	  students	  with	  chronic	  sleep	  deprivation	  over	  
the	  4-­‐week	  period	  (sleep	  was	  <	  80%	  compared	  to	  
ordinary	   days)	   had	   significantly	   decreased	  
intracellular	   magnesium	   levels	   (Takase	   et	   al.,	  
2004a;	  2004b).	  	  
	  
Experimental	   magnesium	   restricted	   diets	   in	   rats	  
also	   increases	   the	   cerebral	   dopamine	   and	  
norepinephrine	   concentration.	   This	   rise	   is	  
associated	  with	  a	  decrease	  of	   sleep	   time	  and	  an	  
increase	   in	   electroencephalographic	  wakefulness	  
(Poenaru	   et	   al.,	   1984).	   Magnesium	   deficiency	   is	  
accompanied	  by	  a	  decrease	  of	  sleep	  duration	  and	  
by	  an	  increase	  of	  brain	  dopamine	  level	  (Chollet	  et	  
al.,	   2000).	   These	   data	   strongly	   support	   the	  
reduction	   of	   cerebral	   catecholamine	   release	   by	  
magnesium.	   The	   effect	   of	   MgSO4	   (0.5	   mg	  
MgSO4/h	  between	  20.30	  hours	  till	  7.00	  hours)	  on	  
sleep	   electroencephalogram	   (EEG,	   recorded	  
between	   23.00	   and	   7.00	   hours)	   in	   healthy	   adult	  
men	  showed	  an	   increase	  of	   the	   third	  sleep	  cycle	  
with	   unchanged	   delta	   power	   throughout	   the	  
night	  (Murch	  and	  Steiger,	  1998).	  The	  activation	  of	  
GABA	   receptors	   is	   very	   important	   for	   the	  
initiation	   and	   maintenance	   of	   nor-­‐rapid-­‐eye	  
movement	   (NREM)	   sleep.	  Magnesium	  stimulates	  
the	   activity	   of	   cerebral	   GABAergic	   systems	   by	  
behaving	   as	   a	   modulator	   of	   GABA	   receptors,	  
increasing	  their	  activity.	  	  
	  
Magnesium	  has	   a	   favourable	   effect	  with	   respect	  
to	   sleep	   onset	   and	   maintenance	   and	   also	  
tiredness,	   which	   appears	   as	   a	   consequence	   of	  
sleep	  deprivation.	  In	  their	  studies	  of	  chronic	  sleep	  
deprivation,	   Tanabe	   et	   al.,	   (1998)	   reported	   a	  
reduction	   of	   intracellular	   magnesium	   level.	   This	  
reduction	   was	   associated	   with	   a	   decreased	  
exercise	   tolerance.	   Specifically,	   when	   subjects	  
were	   submitted	   to	   a	   bicycle	   ergometer	  
cardiopulmonary	   exercise	   test,	   the	   sleep-­‐
deprived	   subjects	   had	   a	   decreased	   exercise	  
tolerance.	   The	   administration	   of	   100	   mg	  
magnesium	  orally	  per	  day	  for	  1	  month	   improved	  
the	   exercise	   tolerance.	   There	   was	   no	   difference	  
between	   the	   sleep-­‐deprived	   patients	   and	   the	  
normal	  sleep	  patients	  regarding	  the	  peak	  oxygen	  
uptake	  and	  anaerobic	  threshold.	  The	  mechanism	  
through	   which	   chronic	   sleep	   deprivation	   can	  
reduce	   intracellular	   magnesium	   concentration	   is	  
unknown,	   but	   we	   consider	   that	   the	   excess	  
catecholamines	   that	   appear	   in	   sleep	   deprivation	  
could	  accelerate	  magnesium	  disposal.	  Hornyak	  et	  
al.,	   (1998)	   showed	   that	  magnesium	   therapy	   can	  
be	   useful	   in	   periodic	   leg	   movements	   related	   to	  
insomnia.	   Magnesium	   was	   administered	   orally,	  
12.4	  mmol	  in	  the	  evening	  during	  4-­‐6	  weeks.	  After	  
magnesium	   administration,	   periodic	   limb	  
movements	   during	   sleep	   decreased	   significantly	  
and	  the	  total	  sleep	  duration	  increased.	  
	  
Attention	   deficit	   and	   hyperactivity	   disorders	  
(ADHD)	   are	   only	   found	   in	   school	   children	   and	   in	  
many	   patients	   with	   neurosis.	   In	   these	   patients,	  
the	   plasma	   and	   erythrocyte	   magnesium	   level	   is	  
low.	   In	   an	   animal	   experimental	   model	   of	  
attention	   deficit,	   the	   hippocampal	   glutamate-­‐
stimulated	   release	   of	   norepinephrine	   was	  
significantly	   higher.	   The	   stimulatory	   effect	   of	  
glutamate	   on	   norepinephrine	   release	   was	  
reduced	   by	   1µM	   CNQX	   (an	   AMPA	   receptor	  
antagonist)	  suggesting	  that	  in	  this	  case	  the	  AMPA	  
receptor	   stimulation	   by	   glutamate	   plays	   an	  
important	   role.	   The	   NMDA	   receptor	   antagonist	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MK-­‐801	   (10µM)	   did	   not	   reduce	   the	   glutamate-­‐
stimulated	   release	   of	   norepinephrine	   (Howells	  
and	  Russell,	   2008).	  An	   involvement	  of	  dopamine	  
in	   attention	   deficit	   disorder	   from	   the	   neurotic	  
patient	   is	   also	  possible,	  because	   in	  patients	  with	  
ADHD	   there	   is	   dysfunction	   of	   the	   dopaminergic	  
system.	   In	   an	  experimental	   rat	  model	   for	  ADHD,	  
glutamate-­‐stimulated	   dopamine	   release	   in	   the	  
substantia	   nigra	   is	   higher.	   Warton	   et	   al.,	   (2009)	  
consider	   that	   abnormal	   dopaminergic	   system	  
function	  in	  ADHD	  could	  be	  the	  result	  of	  a	  change	  
in	   dopamine	   central	   neurons	   (dopamine	  
synthesis,	   dopamine	   transporters	   or	   dopamine	  
receptors),	   or	   an	   indirect	   effect	   of	   imbalanced	  
glutamate	   regulation	   of	   dopaminergic	   neurons.	  
We	  think	  that	  a	  similar	  process	  also	  occurs	  in	  the	  
case	  of	  attention	  deficit	   in	   the	  neurotic	  patients.	  
Magnesium	  can	  directly	  reduce	  dopamine	  release	  
at	   the	  presynaptic	   level	   and	   can	  also	   reduce	   the	  
stimulatory	   effect	   of	   glutamate	   on	   dopamine	  
release.	   Treatment	   with	   Mag-­‐B6	   was	   useful	   in	  
attention	   deficit	   syndrome	   and	   in	   hyperactivity	  
treatment	  (Nogovitsina	  and	  Levitina,	  2006;	  2007).	  
Mag-­‐B6	  improved	  behaviour,	  decreased	  the	  level	  
of	   anxiety	   and	   aggression,	   increased	   attention	  
and	   corrected	   the	   magnesium	   homeostasis	   in	  
children	  with	  ADHD.	  
	  
Both	   bulimia	   and	   anorexia	   are	   also	   symptoms	  
found	   in	   patients	  with	  neurosis.	   In	   patients	  with	  
anorexia	   nervosa	   (DSM-­‐IV	   criteria),	   a	   decreased	  
magnesium	   level	   was	   found	   compared	   to	   the	  
control	  group.	  About	  60%	  of	  the	  patients	  had	  low	  
serum	  magnesium	  (Birmingham	  et	  al.,	  2004).	  
	  
In	   neurotic	   and	   stressed	   patients,	   sexual	  
dysfunction	   (reduced	   libido	   and	   sexual	   potency)	  
is	   frequently	   present.	   This	   dysfunction	   is	   largely	  
caused	   by	   increased	   prolactin	   (PRL)	   synthesis.	   It	  
was	   experimentally	   shown	   that	   immobilization	  
and	  other	   forms	  of	   stress	   (also	   implicated	   in	   the	  
pathogeny	  of	   some	  cases	  of	  neuroses)	   increased	  
PRL	   secretion.	   Pretreatment	   of	   the	   animals	  with	  
magnesium	  aspartate	  in	  doses	  of	  100	  mg,	  200	  mg	  
and	   400	   mg	   significantly	   decreased	   the	   stress-­‐
induced	   PRL	   secretion	   in	   a	   dose-­‐dependent	  
manner	   	   (Ali	  et	   al.,	   1987).	  D-­‐aspartate	   increased	  
PRL	  secretion	  by	  stimulation	  of	  NMDA	  receptors.	  
In	   the	   fish	   S.	   Mossambicus,	   magnesium	   also	  
lowered	  PRL	  secretion	  (Bonga	  et	  al.,	  1983).	  
	  
There	   are	   a	   number	   of	   mechanisms	   by	   which	  
magnesium	   may	   reduce	   PRL	   levels	   in	   neurosis,	  
thereby	  lowering	  or	  preventing	  the	  effects	  of	  this	  
anterior	  pituitary	  hormone.	  It	  can	  directly	  reduce	  
secretion	  of	  PRL	  at	   the	   level	  of	  secretory	  cells,	   it	  
can	   inhibit	   stimulation	   by	   prolactin	   releasing	  
hormone	   at	   the	   pituitary	   level	   to	   decrease	   PRL	  
secretion	   (Kasahara	   et	   al.,	   1993),	   it	   can	   reduce	  
the	   stimulatory	   effect	   of	   glutamate	   on	   pituitary	  
PRL	   release,	   and	   finally,	   magnesium	   can	   reduce	  
the	   stimulatory	   effect	   of	   calcium	   ions	   on	   PRL	  
secretion.	   In	   cultures	   of	   adult	   female	   rats,	  
pituitary	  cell	  glutamate	  significantly	  increased	  the	  
rate	  of	  PRL	   release.	  This	   release	  was	  augmented	  
4-­‐fold	   after	   elimination	   of	   magnesium	   from	   the	  
perfusate	   (Login,	   1990).	   Both	   NMDA	   (100	   µM)	  
and	  kainate	  (100	  µM)	  increased	  PRL	  secretion	  by	  
NMDA	   receptor	   stimulation,	   whereas	   AMPA	  
receptor	   agonists	   did	   not	   modify	   PRL	   secretion	  
and	   release.	   The	   antagonism	   between	  
magnesium	  and	  the	  calcium	  channels	  coupled	  to	  
the	   NMDA	   receptors	   is	   the	   essential	   factor	   in	  
reduction	  of	  PRL	  secretion	  by	  this	  bivalent	  cation.	  
	  
Magnesium	  treatment	  of	  neuroses	  
There	  are	  a	   limited	  number	  of	  studies	  that	  show	  
a	  beneficial	  effect	  of	  magnesium	   in	  treatment	  of	  
the	  different	  symptoms	  of	  the	  diseases	  known	  as	  
neurotic	   disorders.	   Using	   mice,	   Poleszak	   et	   al.,	  
(2004)	  demonstrated	  that	  doses	  of	  20	  and	  30	  mg	  
magnesium/kg	   (doses	   which	   did	   not	   affect	  
locomotor	   activity)	   produced	   anxiolytic-­‐like	  
effects	  measured	  using	  the	  plus-­‐maze	  test.	  These	  
doses	   were	   acutely	   or	   chronically	   administered	  
and	   resulted	   in	  at	   least	  a	  58%	   increase	   in	   serum	  
magnesium	   concentration.	   Magnesium	   induced	  
the	   anxiolytic-­‐like	   effects	   without	   tolerance	   to	  
these	   activities,	   suggesting	   a	   potential	   anxiolytic	  
activity	  in	  these	  disorders	  in	  human.	  
	  
Singewald	   et	   al.,	   (2004)	   showed	   in	   an	   animal	  
experiment	   (mice)	   that	   magnesium	   depletion	  
leads	   to	   enhanced	   depression-­‐	   and	   anxiety-­‐
related	  behaviour,	  which	  was	  further	  validated	  by	  
the	   reversibility	   of	   the	   behavioural	   changes	   by	  
known	  antidepressant	  and	  anxiolytic	   substances.	  
Using	   a	   rat	   model,	   Fromm	   et	   al.,	   (2004)	  
demonstrated	   a	   reduced	   incidence	   of	   anxiety	  
after	   traumatic	   brain	   injury	   using	   magnesium	  
sulphate	   as	   an	   interventional	   treatment.	   The	  
study	  of	  Bockova	  et	  al.,	  (1992)	  demonstrated	  that	  
the	   combination	   of	   an	   anxiolytic	   with	   a	  
magnesium	  salt	  (lactate)	  resulted	  in	  a	  more	  rapid	  
reduction	  of	  the	  symptoms	  of	  anxious	  depressive	  
neurosis.	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Taborska	   (1995)	   showed	   the	   curative	   effect	   of	  
magnesium	   salts	   in	   patients	   suffering	   panic	  
disorders	   and	   latent	   tetany.	   The	   symptoms	   of	  
panic	  disorder	  are,	  with	   few	  exceptions,	  virtually	  
identical	  with	   those	  of	   latent	   tetany.	   The	  author	  
examined	   20	   patients	   treated	   in	   a	   psychiatric	  
outpatient	  unit	   for	  panic	  disorder,	  examining	   for	  
latent	   tetany	   plus	   serum	   and	   red	   blood	   cell	  
magnesium.	  He	  found	  a	  concomitant	  incidence	  of	  
latent	   tetany	   with	   a	   decreased	   level	   of	  
intracellular	   magnesium.	   Remission	   of	   problems	  
common	  to	  both	  nosological	  entities	  occurred	   in	  
90%	   of	   cases,	   in	   response	   to	   therapy	   with	  
magnesium	  salts.	  
	  
A	   double-­‐blind,	   randomized,	   placebo-­‐controlled	  
study	  evaluated	  the	  efficacy	  and	  safety	  of	  a	  fixed	  
combination	   containing	   two	   plant	   extracts	   and	  
magnesium	   in	   the	   treatment	   of	   264	   patients	  
presenting	   generalized	   anxiety	   of	   mild-­‐to-­‐
moderate	  intensity.	  It	  was	  demonstrated	  that	  the	  
preparation	   was	   safe	   and	   more	   effective	   than	  
placebo	  (Hanus	  et	  al.,	  2004).	  
	  
The	   studies	   of	   Durlach	   et	   al.,	   (1997)	   concluded	  
that	   the	   primary	   or	   secondary,	   acute	   or	   chronic	  
nervous	   forms	  of	  magnesium	  deficiency	   induced	  
by	   insufficient	   magnesium	   intake	   remain	  
reversible	   over	   a	   long	   period	   by	   simply	  
normalizing	   the	   magnesium	   intake.	   Untreated	  
chronic	   forms	   may	   however	   bring	   irreversible	  
organic	  disorders.	  	  
	  
Physiological	   oral	   magnesium	   supplementation	  
(5mg/kg/day)	  is	  simple	  and	  can	  be	  carried	  out	  via	  
the	  diet	  or	  with	  magnesium	  salts.	  This	  treatment	  
is	   able	   to	   cure	   all	   the	   functional	   symptoms	   of	  
magnesium	   deficiency,	   including	   signs	   of	  
neuromuscular	   hyperexcitability	   and	   psychiatric	  
symptoms,	   which	   frequently	   mimic	   a	   neurotic	  
pattern.	   It	   is	   necessary	   to	   highlight	   the	   curative	  
and	   preventive	   importance	   of	   oral	   physiological	  
maternal	   magnesium	   supplementation,	   not	   only	  
during	   pregnancy,	   but	   also	   in	   the	   child	  
throughout	   life	   from	   infancy	   to	   older	   age,	   to	  
possibly	   prevent	   the	   so-­‐called	   constitutional	  
factor	  of	  neurolability.	  
	  
We	   should	   emphasize	   that	   the	   nervous	  
consequences	   of	   magnesium	   deficiency	   remain	  
functional	   with	   an	   atomical	   integrity	   for	   a	   long	  
time.	   They	   are,	   however,	   completely	   reversible	  
since	  they	  can	  be	  restored	  to	  normal	  with	  simple	  
oral	   physiological	   magnesium	   supplementation	  




Neuroticism	   is	  a	   fundamental	  personality	   trait	   in	  
the	  study	  of	  psychology.	  Unlike	  neurosis,	  it	  is	  not	  
pathological	   in	   itself	   but	   is	   a	   tendency	   that	   can	  
become	   pathological	   in	   certain	   conditions.	   It	   is	  
also	   a	   risk	   factor	   for	   “internalizing”	   mental	  
disorders	   such	   as	   phobia,	   depression,	   panic	  
disorders	   and	   other	   anxiety	   disorders,	  
traditionally	   called	   neuroses	   (Hettema	   et	   al.,	  
2006).	   Neuroticism	   is	   an	   enduring	   tendency	   to	  
experience	   negative	   emotional	   states	   like	  
hyperemotivity,	   hyperexcitability,	   anxiety,	   anger,	  
impulsivity	   and	   other	   psychosomatic	  
manifestations.	   It	   is	   sometimes	   called	   emotional	  
instability.	   Individuals	   who	   score	   high	   on	  
neuroticism	   are	  more	   likely	   than	   the	   average	   to	  
experience	   such	   feelings	   as	   anxiety,	   anger,	   guilt	  
and	   depressed	   mood	   (Matthews	   and	   Deary,	  
1998).	  They	  are	  emotionally	  reactive	  and	  respond	  
to	   events	   that	   would	   not	   affect	   most	   people.	  
Moreover,	   their	   reactions	   tend	   to	   be	   more	  
intense	   than	   normal.	   They	   are	   more	   likely	   to	  
interpret	   ordinary	   situations	   as	   threatening,	   and	  
minor	   frustrations	   as	   hopelessly	   difficult.	   Their	  
negative	   emotional	   reactions	   tend	   to	   persist	   for	  
unusually	  long	  periods	  of	  time,	  which	  means	  they	  
are	   often	   in	   a	   bad	   mood.	   These	   problems	   in	  
emotional	   regulation	   can	   diminish	   a	   neurotic’s	  
ability	   to	   think	  clearly,	  make	  decisions,	  and	  cope	  
effectively	  with	  stress.	  	  
	  
Neuroticism	   appears	   to	   be	   related	   to	   physiol-­‐
ogical	   differences	   in	   the	   brain.	   Hans	   Eysenck	  
theorized	  that	  neuroticism	  is	  a	  function	  of	  activity	  
in	   the	   limbic	   system,	   and	   his	   research	   suggests	  
that	   people	   who	   score	   highly	   on	   measures	   of	  
neuroticism	   have	   a	   more	   reactive	   sympathetic	  
nervous	   system,	   and	   are	   more	   sensitive	   to	  
environmental	   stimulation	   (Eysenck	   and	  Eysenck,	  
1985).	   Behavioural	   genetics	   researchers	   have	  
found	   that	   a	   significant	  portion	  of	   the	   variability	  
on	  measures	  of	  neuroticism	  can	  be	  attributed	  to	  
genetic	   factors	   (Viken	   et	   al.,	   1994).	   As	   Boeree	  
(2002)	  shows,	  neuroticism	  may	  be	  a	  predisposing	  
physiological	  condition	  for	  neurosis.	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Table	  1.	  Mean	  magnesium	  values	  (mmol/L)	  in	  children	  from	  an	  orphanage	  (Group	  I)	  and	  a	  state	  school	  
(Group	  II).	  Adapted	  from	  Papadopol	  et	  al.,	  2001.	  
	  
	  	  	  	  	  	  




Table	  2.	  Comparison	  of	  outcomes	  of	  personality	  traits.	  Adapted	  from	  Papadopol	  et	  al.,	  2001.	  
	  
	  
p:	  significance	  level.	  
	  
	  
Relationship	  between	  magnesium	  and	  
neuroticism	  
As	  has	  already	  been	  shown,	  magnesium	  deficiency	  
manifests	   at	   the	   central	   nervous	   system	   level	   as	  
hyperemotivity,	   hyperexcitability,	   anxiety,	   and	  
impulsivity,	   amongst	   others,	   and	   these	   are	   also	  
observed	   in	  neuroticism.	  A	   relationship	  between	  
magnesium	   deficiency	   and	   neuroticism	   is	  
therefore	  suggested.	  Some	  studies	  (Tuchendria	  et	  
al.,	  1998)	  suggest	  that	  magnesium	  deficiency	  can	  
be	   a	   causal	   factor	   of	   neurotic	   tendencies	   in	  
elderly	  persons.	  In	  a	  group	  of	  80	  aged	  persons,	  all	  
cases	   with	   erythrocyte	   magnesium	   deficit	  
presented	  two	  or	  more	  neurotic	  tendencies,	  most	  
frequent	  being	  the	  depressive	  ones.	  	  
	  
There	   are	   also	   a	   few	   studies	   on	   magnesium	  
deficiency	   in	   children	   and	   its	   relationship	   with	  
personality	  traits.	  Specifically,	   this	  relationship	   in	  
children	   and	   teenagers	   was	   examined	   in	   two	  
groups	   of	   pupils	   from	   different	   socioeconomic	  
backgrounds,	  namely	  an	  orphanage	  (group	  I)	  and	  
a	  regular	  state	  school	  (group	  II)	  (Papadopol	  at	  al,	  
2001).	  Magnesium	  level	  and	  personality	   features	  
were	   compared,	   including	   psychoticism,	   neuro-­‐
ticism	   and	   extraversion.	   With	   regard	   to	   the	  
magnesium	  level	  (Table	  1),	  one	  can	  see	  a	  discord	  
between	   serum	   magnesium	   levels	   and	  
erythrocyte	   levels.	   It	   is	  known	  that	  serum	  values	  
of	   magnesium	   are	   less	   stable	   than	   erythrocyte	  
values,	   being	   quite	   easily	   influenced	   by	   factors	  
such	   as	   stress	   or	   physical	   activity	   that	   increases	  
magnesium	   requirements.	   Serum	   magnesium	  
may	   be	   normal	   in	   spite	   of	   a	   significant	  
magnesium	   deficiency.	   The	   children	   from	   the	  
orphanage	  had	   a	  more	  uniform	   lifestyle,	  with	   	   a	  
more	   regular	   program	   of	   eating,	   sleeping	   and	  
physical	  activities.	  Nutrition	  is	  also	  very	  important	  
for	  the	  tissue	  magnesium	  levels.	  The	  nutrition	  of	  
the	  children	  from	  the	  orphanage	  is	  characterized	  
by	   a	   satisfactory,	   uniform	   level	   for	   all	   the	  
children,	  while	   the	  nutrition	  of	   the	  children	  who	  
	   Group	  I	   Group	  II	   t-­‐test	   p	  
Serum	  magnesium	  
Erythrocyte	  magnesium	  
0.83	  +/-­‐	  0.09*	  
1.82	  +/-­‐	  0.18	  
0.78	  +/-­‐	  0.06	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Table	  3.	  Relationship	  between	  magnesium	  deficit	  and	  neuroticism	  in	  children	  from	  an	  orphanage	  (Group	  I)	  
and	  a	  state	  school	  (Group	  II).	  Adapted	  from	  Papadopol	  et	  al.,	  2001.	  
	  












r:	  Pearson	  correlation	  index;	  n:	  number	  of	  subjects;	  p:	  significance	  level.	  
	  
live	   with	   their	   families	   is	   very	   variable	   but	  
generally	   better	   because	   of	   socioeconomic	  
differences.	  
	  
The	   distribution	   of	   the	   subjects	   with	   respect	   to	  
personality	   features	   in	   the	   two	   groups	   differed	  
significantly	   in	   terms	   of	   psychoticism	   and	  
neuroticism	   (Table	   2).	   The	   more	   numerous	  
pathological	  tendencies	  of	  group	  I	  were	  probably	  
a	   consequence	   of	   the	   unfavourable	   emotional	  
climate	   from	   the	   institutionalized	   milieu.	   An	  
investigation	   of	   the	   relationship	   between	  
magnesium	   levels	   and	   personality	   features	  
pointed	   out	   only	   one	   significant	   difference	  
between	   the	   two	   groups,	   namely	   neuroticism	  
(Table	   3).	   The	  positive	   correlation	   in	  magnesium	  
deficit-­‐neuroticism	   suggests	   that	   magnesium	  
deficit	   may	   be	   a	   causal	   factor	   in	   this	   negative	  
aspect	  of	  personality.	  
	  
In	   a	   study	   by	   Nizankovska-­‐Blaz	   et	   al.,	   (1993)	   on	  
249	   girls	   and	   boys	   aged	   5-­‐15	   years,	   serum	  
magnesium	   level	   was	   decreased	   in	   24	   children	  
and	   neurotic	   reactions	   or	   concentration	  
disturbances	  were	  observed	  in	  21	  of	  them.	  	  
	  
In	   conclusion,	   all	   the	   available	   clinical	   and	  
experimental	   data	   prove	   the	   involvement	   and	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For	  many	  years,	  magnesium	  has	  been	  described	  as	  a	  crucial	  factor	  for	  cellular	  activity.	  In	  this	  chapter,	  a	  
brief	   overview	  of	   pharmacology	   and	   genetics	   of	  magnesium	   transport	  will	   be	   followed	  by	   a	   review	  of	  
clinical	   and	   biological	   studies	   of	   Mg-­‐vitamin	   B6	   supplementation	   in	   attention	   deficit/hyperactivity	  
disorder	   (ADHD)	   and	   autism	   (autistic	   spectrum	   disorders	   family,	   ASD)	   in	   children.	   Although	   no	   study	  
carried	   out	   on	   a	   rational	   basis	   has	   been	   published	   to	   date,	   some	   experimental	   and/or	   clinical	   works	  
support	   a	  positive	  effect	  of	   such	   therapy	   in	   these	  pathologies.	  All	   the	   individual	  observations	   report	   a	  
decrease	  in	  hyperactivity	  and	  a	  stabilization	  of	  scholarly	  behaviour	  with	  treatment.	  These	  data	  strongly	  




Magnesium	   is	   the	   second	   most	   abundant	   intra-­‐
cellular	   cation	   in	   the	   body.	   Its	   main	   action	   is	   to	  
regulate	  enzyme	  activity,	  to	  control	  the	  activity	  of	  
various	   calcium	   and	   potassium	   channels,	   and	   to	  
promote	   membrane	   stabilization.	   It	   is	   also	  
responsible	   for	   the	   maintenance	   of	   the	   trans-­‐
membrane	   gradients	   of	   sodium	   and	   potassium.	  
Magnesium	   depletion	   is	   known	   to	   be	   associated	  
with	   many	   clinical	   diseases	   including	   hypo-­‐
calcemia,	   hypokalemia,	   cardiac	   arrhythmias,	  
neuromuscular	   excitability,	   hypertension,	   athero-­‐
sclerosis,	   and	   osteoporosis.	   Some	   evidence	  
indicates	   that	  magnesium	   could	   also	   be	   involved	  
in	   neurological	   diseases	   such	   as	   attention	  
deficit/hyperactivity	   disorder	   and	   autism.	  
However,	   no	   direct	   study	   has	   been	   published	   to	  
confirm	  this	  assumption.	  
	  
Attention	   deficit/hyperactivity	   disorder	   (ADHD)	  
and	   autism	   (autistic	   spectrum	   disorders,	   ASD;	  
pervasive	   developmental	   disorders,	   PDD)	   are	  
different	   neurological	   disorders	  which	   have	   been	  
described	   for	   many	   years,	   and	   in	   which	   the	  
involvement	   of	   a	   deficient	   magnesium	   pathway	  
could	   be	   suspected	   given	   the	   presence	   of	   active	  
transport	   for	   such	   cations	   through	   transient	  
receptor	   potential	  melastatin	   (TRPM)	   channels	   in	  
the	  brain.	  	  
	  
ADHD	   is	   the	   most	   common	   neurobehavioral	  
disorder	   presenting	   for	   treatment	   in	   youth.	  
Children	  with	  ADHD	  are	  “a	  group	  at	  risk”	  as	  far	  as	  
their	   further	   emotional	   and	   social	   development	  
and	   educational	   possibilities	   are	   concerned	  
(Spencer	   et	   al.,	   2002).	   An	   effective	   intervention	  
for	   many	   hyperactive	   children,	   besides	   methyl-­‐
phenidate	   and	   other	   psycho-­‐stimulant	   drugs,	   is	  
the	  use	  of	  vitamin	  B6	  (pyridoxine)	  and	  magnesium	  
(Mg).	   For	   over	   30	   years,	   parents	   have	   given	   high	  
doses	  of	  pyridoxine	  and	  Mg	   to	   their	   children	  and	  
have	  observed	  decreased	  physical	  aggression	  and	  
improved	   social	   responsiveness.	   However,	   up	  
until	   today,	   very	   few	   studies	   have	   reported	   a	  
possible	   association	   between	   magnesium	  
supplementation,	   ADHD	   symptoms,	   and	   the	   Mg	  
status	   of	   the	   children.	   The	   first	   such	   study	  
(Liebscher	   and	   Liebscher,	   2003)	   suggested	   that	  
patients	   with	   ADHD	   should	   be	   considered	   as	  
potentially	   Mg-­‐deficient	   as	   opposed	   to	   an	  
incorrect	   interpretation	   of	   the	   serum	   Mg	   test	  
(tetanic	   patients	   have	   lower	   Mg	   values	   than	  
normals).	   Other	   studies	   from	   Kozielec	   et	   al.,	   for	  
the	   first	   time	   reported	   an	   intra-­‐erythrocyte	  
magnesium	  deficiency	   in	  ADHD	  children	   (Kozielec	  
and	  Starobrat-­‐Hermelin,	  1997).	  We	  also	  published	  
similar	   data	   (Mousain-­‐Bosc	   et	   al.,	   2004,	   2006).	  
However,	   it	   is	   not	   a	   true	   “Mg	   deficiency”	   with	  
clinically	   associated	   respiratory	   repletion,	   as	   is	  
observed	   in	   familial	   hypomagnesaemia	   with	  
secondary	   hypocalcemia	   (Shalev	   et	   al.,	   1998;	  
Mousain-­‐Bosc	  et	  al.,	  2004).	  More	  precisely,	  it	  may	  
be	   called	   “intracellular	   Mg	   deficiency”	   affecting	  
mainly	  neural	  transmission,	  which	  is	  very	  sensitive	  
to	  such	  ionic	  variations.	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Another	   group	   of	   neuronal	   diseases	   in	   which	  
magnesium	   has	   been	   implicated	   is	   ASD/PDD/	  
autism.	  Studies	  from	  18	  different	  research	  groups	  
have	  shown	  that	  vitamin	  B6	  and	  Mg	  are	  beneficial	  
to	   about	   half	   of	   autistic	   individuals,	   with	   no	  
significant	  adverse	  effects.	  Eleven	  of	  these	  studies	  
involved	  a	  double-­‐blind,	  placebo	  controlled	  design	  
and	   have	   documented	   decreases	   in	   behavioural	  
problems,	   improvements	   in	   appropriate	  
behaviour,	   and	   normalisation	   of	   brain	   wave	  
activity	   and	   urine	   biochemistry.	   There	   is	   also	  
evidence	   that	   B6	   and	   Mg	   may	   reduce	   seizure	  
activity.	   Parent	   reports	   confirm	   improvement	   in	  
attention,	   learning,	   speech/language,	   and	   visual	  
contact.	   More	   recently,	   in	   a	   pilot	   study	   of	   a	  
moderate	  dose,	  multivitamin/mineral	  supplement	  
for	   children	   with	   autistic	   spectrum	   disorder,	  
Adams	   and	   Holloway	   (2004)	   found	   significant	  
improvements	   in	   sleep	   and	   gastrointestinal	  
problems	  compared	  to	  the	  placebo	  group.	  Despite	  
all	   these	   data,	   the	   intervention	   using	   Mg-­‐B6	  
remains	   controversial	   and	   contradictory	   studies	  
have	   been	   published	   (Vink,	   2001;	   Helpern,	   1993;	  
Mousain-­‐Bosc	  et	  al.,	  2006;	  Shalev	  et	  al.,	  1998).	  	  
	  
New	   data	   reporting	   a	   possible	   association	  
between	   Mg-­‐B6	   supplementation,	   neurobehav-­‐
ioural	   symptoms,	   and	  Mg	   status	  of	   children	  have	  
subsequently	  been	  published,	  opening	  a	  new	  way	  
for	   research	   in	   this	   domain.	   This	   chapter	   will	  
present	   a	   review	   of	   essential	   works	   published	   in	  
this	  domain.	  
	  




The	   protein	   involved	   in	   Mg	   permeable	   channels	  
belongs	   to	   the	   family	   of	   TRPM	  proteins	   (Schmidt	  
and	   Taylor	   1988;	   Chubanov	   et	   al.,	   2004).	   The	  
transient	   receptor	   potential	   (TRP)	   superfamily	  
consists	  of	  a	  large	  number	  of	  cation	  channels	  that	  
are	   mostly	   permeable	   to	   both	   monovalent	   and	  
divalent	  cations.	  The	  28	  mammalian	  TRP	  channels	  
can	   be	   subdivided	   into	   six	   main	   subfamilies:	   the	  
TRPC	   (canonical),	   TRPV	   (vanilloid),	   TRPM	  
(melastatin),	  TRPP	  (polycystin),	  TRPML	  (mucolipin)	  
and	   the	   TRPA	   (ankyrin)	   groups.	   TRP	   channels	   are	  
expressed	  in	  almost	  every	  tissue	  and	  cell	  type	  and	  
play	  an	  important	  role	  in	  the	  regulation	  of	  various	  
cell	   functions.	   Currently,	   significant	   scientific	  
effort	   is	   being	   devoted	   to	   understanding	   the	  
physiology	  of	  TRP	  channels	  and	   their	   relationship	  
to	   human	   diseases.	   At	   this	   point,	   only	   a	   few	  
channelopathies	  in	  which	  defects	  in	  TRP	  genes	  are	  
the	  direct	  cause	  of	  cellular	  dysfunction	  have	  been	  
identified.	   In	   addition,	   mapping	   of	   TRP	   genes	   to	  
susceptible	  chromosome	  regions	  (e.g.	  translocations,	  
breakpoint	   intervals,	   increased	   frequency	   of	  
polymorphisms)	   has	   been	   considered	   as	   being	  
suggestive	  of	  the	  involvement	  of	  these	  channels	  in	  
hereditary	  diseases.	  Moreover,	  a	  strong	  indication	  
of	  involvement	  of	  TRP	  channels	  in	  several	  diseases	  
comes	  from	  the	  correlations	  between	  the	  levels	  of	  
channel	   expression	   and	   the	   disease	   symptoms.	  
Finally,	   TRP	   channels	   are	   involved	   in	   some	  
systemic	   diseases	   due	   to	   their	   role	   as	   targets	   for	  
irritants,	   inflammation	   products,	   and	   xenobiotic	  
toxins.	   The	   analysis	   of	   transgenic	   models	   allows	  
further	   extrapolations	   of	   TRP	   channel	   deficiency	  
to	  human	  physiology	  and	  disease.	  
	  
Two	   receptors,	   TRPM6	   and	   TRPM7,	   have	   been	  
identified	  as	  Mg	  permeable	  ion	  channels	  and	  their	  
specificity	   is	  due	  to	  their	   link	  with	  protein	  kinase.	  
This	   is	   the	   reason	   why	   they	   are	   defined	   as	  
chanzymes.	  Theses	  chanzymes	  are	  involved	  in	  Mg	  
reabsorption	  in	  kidney	  and	  intestine.	  The	  intake	  of	  
Mg	   is	   driven	   by	   a	   transmembrane	   potential	   that	  
facilitates	   the	   entry	   of	   the	   cation	   through	   the	  
TRPM6	   channel	   at	   the	   apical	   part	   of	   epithelial	  
cells.	  The	  hypothesis	  is	  in	  favor	  of	  a	  Na-­‐dependent	  
flux	   through	   ATP-­‐dependent	   mechanisms	   (De	  
Franceschi	  et	  al.,	  2000;	  Nilius	  et	  al.,	  2007).	  
	  
In	  the	  kidney,	  different	  transport	  pathways	  for	  Mg	  
exist	   along	   the	   nephron.	   The	  majority	   of	   filtered	  
Mg	   is	   reabsorbed	   in	   the	   thick	   ascending	   limb	   of	  
the	   loop	   of	   Henle	   via	   the	   paracellular	   route.	  
Observations	   using	   genetic	   studies	   in	   affected	  
individuals	   disclosed	   the	   first	   molecular	  
components	   of	   epithelial	  Mg	   transport:	   the	   tight	  
junction	   protein	   paracellin-­‐1	   (claudin-­‐16)	   which	  
was	  discovered	  as	  a	  key	  player	   in	  paracellular	  Mg	  
and	   calcium	   reabsorption	   in	   the	   thick	   ascending	  
limb	   of	   the	   loop	   of	   Henle	   and	   the	   distal	  
convoluted	   tubule	   (De	   Franceschi	   et	   al.,	   2000;	  
Nilius	  et	  al.,	  2007).	  Mutations	  of	   this	  protein	   lead	  
to	  familial	  hypomagnesemia	  with	  hypercalciuria	  and	  
nephrocalcinosis,	   a	   combined	   urinary	   Mg	   and	  
calcium	  wasting	  which	   almost	   invariably	   leads	   to	  
progression	  to	  end	  stage	  renal	  disease.	  
	  
The	   discovery	   of	   TRPM	   receptors	   involved	   in	  Mg	  
homeostasis	   (Borella	   et	   al.,	   1993;	  Montell,	   2003)	  
serves	   to	   identify	   the	   genes	   involved	   in	   primary	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inherited	  hypomagnesaemia	  by	   genetic	   engineer-­‐
ing	  and	  molecular	  cloning.	  Several	  genes	  encoding	  
proteins	   are	   directly	   involved	   in	   renal	   Mg	  
handling.	   The	   family	   of	   paracellin-­‐1	   (PCLN-­‐1)	  
proteins	   is	   directly	   involved	   in	   Mg	   and	   calcium	  
reabsorption	   in	   the	   distal	   convoluted	   tubule	  
(DCT).	   Diseases	   such	   as	   hypomagnesaemia	   with	  
secondary	   hypocalcaemia	   (HSH)	   are	   observed.	  
Reabsorption	   of	   Mg	   in	   the	   DCT	   is	   active	   and	  
transcellular.	  The	  renal	  Mg	  leak	  in	  HSH	  patients	  is	  
due	   to	   the	   role	   of	   TRPM6	   in	   active	   transcellular	  
Mg	   reabsorption	   in	   the	   DCT.	   The	   strong	  
interaction	   between	   TRPM6	   and	   TRPM7	   involves	  
the	   apical	  Mg	   channel	   responsible	   for	   its	   uptake	  
from	   urine	   into	   DCT	   cells.	   In	   HSH	   patients,	   renal	  
Mg	   wasting	   not	   only	   contributes	   to	   the	  
development	  of	  hypomagnesemia	  in	  the	  postnatal	  
period,	   but	   also	   prevents	   an	   adequate	  
conservation	   of	   absorbed	  Mg	   under	   supplement-­‐
ation.	   The	   secondary	   hypocalcemia	   is	   due	   to	   an	  
inhibition	   of	   parathyroid	   hormone	   caused	   by	  
profound	   hypomagnesemia.	   Affected	   children	  
typically	   manifest	   during	   the	   first	   months	   of	   life	  
with	  generalised	  convulsions	  or	  signs	  of	  increased	  
neuromuscular	   excitability	   like	   muscle	   spasms	   or	  
tetany.	   Reduced	   clinical	   symptoms	   and	   the	  
normalization	   of	   calcium	   homeostasis	   are	  
guaranteed	  by	  immediate	  intravenous	  magnesium	  
administration	   of	   followed	   by	   a	   long-­‐term	  
substitution	  with	  high	  oral	  doses	  of	  magnesium.	  
	   	  
HSH	   can	   also	   be	   characterized	   as	   an	   autosomal	  
recessive	   disease	   due	   to	   the	   gene	   mapped	   on	  
chromosome	   9q22.	   Mutational	   studies	   on	   the	  
TRPM	   6	   receptor	   have	   shown	   the	   same	   type	   of	  
HSH.	  So,	  TRPM	  6	   is	   identified	  as	  a	  Mg	  permeable	  
ion	   channel	   that	   causes	   a	   combined	   defect	   of	  
intestinal	  and	  renal	  magnesium	  transport.	  
	  
The	  TRPM6	  protein	  is	  52%	  homologous	  to	  TRPM7	  
and	  was	  studied	  together	  with	  TRPM7	  in	  order	  to	  
study	   their	   regulation.	   They	   were	   functionally	  
characterized	  as	  a	  constitutively	  active	  ion	  channel	  
permeable	  to	  a	  variety	  of	  cations	  like	  calcium	  and	  
Mg.	   So,	   TRPM6	   and	   TRPM7	   are	   closely	   related	  
members	  of	   the	  TRPM	   ion	   channel	   family	  named	  
after	   its	   founding	   member,	   melastatin.	   The	  
pathophysiologic	  consequences	  of	  a	  TRPM6	  defect	  
for	  Mg	  transport	  in	  intestine	  and	  distal	  convoluted	  
tubule	   are	   important.	   In	   the	   intestine,	   an	   active	  
transcellular	   transport	   and	   a	   passive	   paracellular	  
pathway	  were	  identified.	  Both	  TRPM6	  and	  TRPM7	  
proteins	   share	   the	   unique	   feature	   of	   an	   atypical	  
kinase	  domain	  at	  their	  C-­‐terminus,	  for	  which	  they	  
have	  been	  termed	  chanzymes	  (Basso	  et	  al.,	  2000;	  
Schlingmann	   and	   Gudermann,	   2005).	   The	   apical	  
entry	   into	   the	   epithelial	   cell	   is	   a	   basolateral	  
extrusion	   mechanism	   that	   links	   Mg	   export	   to	  
sodium	   influx.	   These	   transport	   processes	   yield	  
curvilinear	  kinetics	  for	  intestinal	  Mg	  absorption.	  In	  
addition,	   it	   has	   been	  described	   that	   an	   increased	  
intake	   of	   oral	   magnesium	   enhances	   passive	  
paracellular	   absorption.	   It	   can	   therefore	   be	  
supposed	   that	   HSH	   patients	   with	   defective	  
transcellular	  Mg	   transport	   are	   able	   to	   achieve	   at	  
least	   subnormal	   serum	   magnesium	   levels	   and	  
relief	  of	  symptoms.	  	  
	  
Electrophysiological	   and	   biochemical	   analyses	  
identified	   TRPM7	   as	   an	   important	   player	   in	  
cellular	   Mg	   homeostasis.	   The	   critical	   role	   of	  
TRPM6	   in	   epithelial	   Mg	   transport	   emerged	   from	  
the	   discovery	   of	   loss-­‐of-­‐function	   mutations	   in	  
patients	   with	   a	   severe	   form	   of	   hereditary	   HSH.	  
TRPM6	   plays	   an	   important	   role	   as	   an	   influx	  
pathway	   for	   Mg	   (Schmidt	   and	   Taylor,	  
1988;	  Chubanov	  et	  al.,	  2004).	  	  
	  
In	   summary,	  TRP	  channels	  have	  a	  multifunctional	  
role	   and	   are	   involved	   in	   many	   fundamental	   cell	  
functions	   in	   physiopathology	   and	   diseases.	   The	  
TRP	   superfamily	   is	   implicated	   in	   channelopathies	  
involving	   an	   activation	   of	   a	   membrane	   cation	  
channel.	   The	   TRPM	   subfamilies	   are	   distinct	  
families,	  whereas	  both	  TRPM6	  and	  TRPM7	  (serine	  
/threonine	   kinase)	   exhibit	   high/variable	  
permeability	  to	  calcium	  and	  Mg	  and	  are	  regulated	  
through	  intracellular	  levels	  of	  Mg	  and	  Mg-­‐ATP.	  The	  
defects	   in	   these	   ion	   channels	   supposedly	   cause	  
various	   diseases	   described	   as	   channel-­‐opathies.	  
The	   genetic	   defect	   in	   TRP	   channels	   has	   been	  
identified	   as	   the	   direct	   cause	   of	   hereditary	  
disease.	   Mutations	   on	   the	   TRPM6	   gene	   are	  
likened	   to	   human	   proteinuric	   kidney	   disease.	  
TRPM7,	   the	   closest	   relative	   of	   TRPM6,	   is	   also	  
implicated	   in	   some	   neurodegenerative	   diseases	  
such	   as	   amyotrophic	   lateral	   sclerosis	   and	  
Parkinson’s	  disease.	  
	  
Involvement	  of	  magnesium	  in	  membrane	  
stability	  and	  gene	  expression	  
Membrane	   stability	   is	   influenced	   by	   many	  
parameters	   including	   ionic	   conductance,	   ionic	  
fluxes	   and	  Mg	   (Ebel	   and	   Gunther,	   2005;	  Wolf	   et	  
al.,	   2009).	   Because	   of	   the	   activity	   of	   the	  
superfamily	   of	   TRP	   channels,	   the	   effect	   of	  Mg	   is	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observed	   on	   many	   membranes.	   It	   has	   been	  
reported	   that	   the	   concentration	   of	   extracellular	  
Mg	   can	   affect	   blood	   flow,	   blood	   pressure	   and	  
vascular	   reactivity	   in	   intact	   mammals	   (Schmidt	  
and	  Taylor,	  1988,	  Van	  der	  Wiijst	  et	  al.,	  2009).	  The	  
red	   cell	   membrane	   properties	   have	   also	   been	  
explored;	   Mg	   regulates	   stability	   and	   extends	   the	  
gross	   elasticity	   of	   the	   red	   cell	   membrane.	  
Magnesium-­‐depleted	  cells	  also	  undergo	  structural	  
changes	   on	   heating	   below	   the	   temperature	   at	  
which	  vesiculation	  sets	  in.	  
	  
There	  is	  a	  drastic	  change	  in	  ionic	  flux	  through	  the	  
outer	   and	   inner	   cell	   membranes	   both	   in	   the	  
impaired	   membranes	   of	   cancer,	   and	   in	   Mg	  
deficiency.	  Researchers	   from	  the	  School	  of	  Public	  
Health	   at	   the	   University	   of	   Minnesota	   have	   just	  
concluded	   that	   diets	   rich	   in	   Mg	   reduced	   the	  
occurrence	   of	   colon	   cancer	   (Chakraborti	   et	   al.,	  
2002;	  Aaron,	  2006).	   In	  another	  study	   (Macdonald	  
et	  al.,	  2004;	  Susanna	  et	  al.,	  2005)	  women	  with	  the	  
highest	   magnesium	   intake	   demonstrated	   a	   40%	  
lower	   risk	   of	   developing	   cancer	   than	   those	   with	  
the	  lowest	  intake	  of	  the	  mineral.	  
	  
Magnesium	  linked	  to	  the	  phospholipids,	  and	  more	  
particularly	   to	   phosphatidylserine,	   reduces	  
membrane	   fluidity	   and	   increases	   the	   stability	   of	  
pre-­‐synaptic	   vesicle	   membranes.	   Lecithins	  
(phosphatidylcholines)	   and	   phosphatidylserines	  
are	   brain	   nutrients	   that	   modulate	   acetylcholine	  
metabolism,	  and	  act	  to	  stimulate	  memory.	  A	  2003	  
study	   (Demougeot	   et	   al.,	   2004)	   describes	   the	  
lecithins	   as	   promoting	   the	   synthesis	   and	   the	  
working	  of	  neurotransmitters	  involved	  in	  memory	  
processes.	   The	   mechanism	   of	   beneficial	   action	  
was	  linked	  to	  activation	  of	  phospholipase	  systems	  
in	  the	  hippocampus	  by	  choline.	  
	  
In	  obstetric	  and	  embryonic	  research,	  different	  Mg	  
salts	   have	   been	   studied,	   such	   as	   MgCl2,	   Mg-­‐
acetate	   and	   Mg-­‐citrate.	   They	   are	   known	   to	  
increase	  and	  decrease	   the	  membrane	  stability	  on	  
the	   two	   faces	   of	   the	   amnion.	  MgSO4,	  Mg-­‐lactate	  
and	   Mg-­‐nitrate	   increased	   the	   stability	   on	   the	  
maternal	   side,	   but	  decreased	   it	   on	   the	   fetal	   side.	  
Thus,	   addition	   of	   Mg	   salts	   modifies	   human	  
amniotic	  membrane	  stability.	  
	  
In	   response	   to	   a	   Mg	   deficiency,	   five	   gene	  
alterations	   could	   be	   identified	   using	   DNA	   arrays:	  
osteopontin,	   the	   cholecystokinin	   A	   receptor,	  
connexin	   45,	   a	   growth	   hormone	   receptor	   and	  
BAG1.	   Other	   fundamental	   studies	   in	   bacteria	  
characterized	   an	   'M-­‐box',	   a	   genetic	   switch	   that	   is	  
sensitive	   to	   cellular	   Mg	   levels	   through	   the	  
conformation	   of	   its	   newly	   synthesized	   RNA.	   This	  
Mg	   sensing	   ribo-­‐switch	   controls	   transcription	  
termination	   in	   front	   of	   a	   Mg	   transporter	   gene.	  
Magnesium	   therefore	   acts	   directly	   as	   a	   genetic	  
regulator	  in	  genetic	  expression	  of	  RNA	  in	  order	  to	  
control	  metal	  ion	  homeostasis	  (De	  Rose,	  2007).	  As	  
Mg	  has	   been	   shown	   to	   activate	   gene	   expression,	  
the	   mitochondrial	   genome	   must	   be	   affected.	  
Treatment	  of	  mild	  mitochondrial	  dysfunction	  may	  
include	   administration	   of	  mitochondrial	   cofactors	  
like	  magnesium	  (Martin	  et	  al.,	  2007).	  
	  
Action	  of	  magnesium	  on	  synaptic	  facilitation	  	  
In	   2006,	   a	   review	   article	   (Billard,	   2006)	   indicated	  
that	   Mg	   is	   involved	   in	   age-­‐related	   deficits	   in	  
transmitter	   release,	   neuronal	   excitability,	   and	  
some	   forms	   of	   synaptic	   plasticity	   such	   as	   long-­‐
term	  depression	  of	  synaptic	  transmission.	  Further	  
studies	   presented	   by	   Slutsky	   et	   al.,	   (2010)	   show	  
that	  Mg	   is	   essential	   for	  maintaining	   normal	   body	  
and	  brain	  functions.	  
	  
Learning	   and	   memory	   are	   fundamental	   brain	  
functions	   affected	   by	   dietary	   and	   environmental	  
factors.	   Increasing	   brain	   Mg	   using	   a	   newly	  
developed	  Mg	   compound	   (Mg-­‐L-­‐threonate)	   leads	  
to	   the	   enhancement	   of	   learning	   ability,	   working	  
memory,	  and	  short	  and	  long-­‐term	  memory	  in	  rats.	  
Functionally,	   Mg	   increased	   the	   number	   of	  
functional	   pre-­‐synaptic	   release	   sites,	   while	   it	  
reduced	   their	   release	   probability.	   These	   findings	  
suggest	   that	   an	   increase	   in	   brain	   Mg	   enhances	  
both	   short-­‐term	   synaptic	   facilitation	   and	   long-­‐
term	   potentiation	   and	   improves	   learning	   and	  
memory	   functions.	  Magnesium	   impacts	   upon	   the	  
release	  of	  neurotransmitters,	  and	  other	  mediators	  
or	  modulators	  (Slutsky	  et	  al.,	  2010).	  
	  
Magnesium	  in	  blood	  
The	   study	   of	   the	   regulation	   of	   Mg	   has	   gained	  
particular	   interest	   in	   the	   last	   decades	   thanks	   to	  
the	   molecular	   characterization	   of	   specific	  
magnesium	   transporters	   and	   the	   exploitation	   of	  
molecular	   biology	   techniques	   to	   clarify	   their	  
cellular	   and	   physiological	   function(s).	  Magnesium	  
can	  be	  detected	  both	  in	  the	  plasma	  in	  the	  cationic	  
form	   (Mg2+)	   and	   in	   blood	   cells,	   namely	   in	  
erythrocytes.	   All	   these	   assays	   are	   today	   well	  
described	   and	   can	   be	   performed	   in	   many	  
laboratories.	   In	   contrast,	   experimental	   tools	   to	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trace	  cellular	  Mg2+	  and	  to	  define	  its	  homeostasis	  in	  
living	   cells	   have	   not	   witnessed	   corresponding	  
progress.	   It	   was	   not	   until	   recently	   that	   efforts	  
were	   made	   to	   design	   more	   appropriate	  
fluorescent	   indicators	   that	   could	   translate	   the	  
advances	  of	   live	   imaging	  techniques	   into	  the	  field	  
of	  Mg2+	  research	  (Trapani	  et	  al.,	  2010).	  
	  
Phosphorus	   magnetic	   resonance	   spectroscopy	  
also	  offers	  an	  opportunity	   to	  measure	   in	  vivo	   the	  
free	   cytosolic	   Mg2+	   of	   different	   tissues.	   In	  
particular,	   this	   technique	   has	   been	   employed	   in	  
human	  brain	  and	  in	  skeletal	  muscle	  providing	  new	  
hints	  on	  Mg2+	  homeostasis	  and	  on	  its	  involvement	  
in	   cellular	   bioenergetics.	   In	   skeletal	  muscle	   it	   has	  
been	   shown	   that	   the	   changes	   in	   free	   Mg2+	  
concentration	  occurring	  during	  contraction	  and	  in	  
post-­‐exercise	   recovery	   are	   mainly	   due	   to	   the	  
influence	   of	   cytosolic	   pH.	   The	   possibility	   of	  
assessing	  the	  free	  cytosolic	  Mg2+	  concentration	   in	  
the	   human	   brain	   offered	   the	   chance	   of	   studying	  
the	   involvement	   of	  Mg2+	   in	   different	   neurological	  
pathologies,	   and	   particularly	   in	   those	   where	  
defective	   mitochondrial	   energy	   production	  
represents	   the	   primary	   causative	   factor	   in	   the	  
pathogenesis.	   Moreover,	   it	   has	   also	   been	   shown	  
that	   the	  measurement	   of	   brain	  Mg2+	   can	   help	   in	  
the	   differential	   diagnosis	   of	   neurodegenerative	  
diseases	  sharing	  common	  clinical	  features,	  such	  as	  
Multiple	   System	  Atrophy	   and	   Parkinson's	   disease	  
(Ebel	  et	  al.,	  2004;	  Iotti	  and	  Malucelli,	  2008).	  
	  
Magnesium	   concentrations	   in	   plasma	   and	   cells	  
could	   be	   affected	   by	   diet,	   disease	   and	   genetic	  
factors.	   It	   is	   known	   that	   carcinogenesis	   induces	  
disturbances	   in	  Mg	   distribution,	   which	   cause	  Mg	  
mobilization	  through	  blood	  cells	  and	  Mg	  depletion	  
in	   non-­‐neoplastic	   tissues.	   Magnesium	   deficiency	  
seems	  to	  be	  carcinogenic,	  and	  in	  the	  case	  of	  solid	  
tumours,	  a	  high	   level	  of	  supplemental	  Mg	  inhibits	  
carcinogenesis.	   Both	   carcinogenesis	   and	   Mg	  
deficiency	   increase	   the	   plasma	   membrane	  
permeability	   and	   fluidity.	   Scientists	   have	   in	   fact	  
found	   out	   that	   there	   is	  much	   less	  Mg	   binding	   to	  
membrane	   phospholipids	   of	   cancer	   cells,	   than	   to	  
normal	  cell	  membranes	  (Wolf	  et	  al.,	  2008).	  
	  
A	   progressive	   elevation	   in	   external	   Mg	   levels	   in	  
blood	   will	   produce	   a	   progressive	   inhibition	   of	  
most	   contractile	   elements.	   The	   contractile	  
response	   observed	   upon	   withdrawal	   of	   external	  
Mg	   are	   dependent	   upon	   calcium	   concentrations	  
and	   the	  polarity	  of	   the	  membrane.	  This	   response	  
is	   not	   related	   to	   an	   inhibition	   of	   the	   Na+/K+	  
ATPase.	   It	   is	  known	  that	  Mg,	   in	  combination	  with	  
Na+	   and	   K+,	   play	   a	  major	   role	   in	   regulating	   blood	  
pressure	  and	  arteriolar	  tone	  (Altura	  et	  al.,	  1978).	  
	  
Magnesium	   concentration	   in	   plasma	   and	   cells	  
could	   also	   be	   affected	   by	   genetic	   disease.	   The	  
genetic	   factors	   involved	   in	   the	   regulation	   of	   Mg	  
homeostasis	  were	   studied	   in	   low	   (MgL)	   and	   high	  
(MgH)	   magnesium	   status	   strains	   of	   mice.	   In	   this	  
model,	   magnesium-­‐deficiency	   affects	   plasma,	  
erythrocyte	  and	  urine	  Mg	  concentrations	  in	  similar	  
proportions	  in	  the	  two	  strains	  (Schlingmann	  et	  al.,	  
2002;	   Montell,	   2005;	   Günter,	   2007;	   Ozgo	   et	   al.,	  
2007)	  
	  
Clinical	  symptoms	  of	  ADHD	  syndrome	  
	  
Clinical	  cases	  
ADHD	   has	   been	   described	   since	   the	   beginning	   of	  
the	  twentieth	  century	  and	  was	  called	  hyperkinesia	  
or	  “psycho-­‐motor	  instability”.	  It	  affects	  3	  to	  9	  %	  of	  
the	   population	   of	   children	   and	   adults	   (Feillet-­‐
Coudray,	   2005;	   Biederman,	   2006).	   The	   clinical	  
picture	   is	   that	   of	   a	   hyperirritable,	   impulsive,	  
aggressive	   child	   with	   an	   attention	   deficit.	   The	  
diagnosis	  is	  basically	  done	  at	  six	  years	  of	  age	  when	  
the	   child	   presents	   at	   primary	   school.	   These	  
symptoms	  impair	  emotional	  development	  and	  can	  
lead	   to	   serious	   social	   and	   family	   disorders.	   In	  
adults,	   statistics	   show	   a	   powerful	   link	   between	  
ADHD	  and	  serious	  problems	  in	  life.	  These	  findings	  
support	   the	   idea	   that	   when	   diagnosed	   in	   the	  
community,	   ADHD	   is	   a	   clinically	   significant	   and	  
highly	   disabling	   disorder	   in	   adults	   and	   must	   be	  
treated	   very	   early	   in	   children.	   However,	   parents’	  
and	   children’s	   histories	   should	   be	   studied.	   In	  
parents,	   behavioural	   disorders	   such	   as	  
hyperactivity,	   aggressiveness,	   emotional	   lability,	  
stress,	  or	  maternal	   spasmophilia	  may	  be	  present.	  
During	   pregnancy,	   several	   symptoms	   can	   be	  
observed	   including	  weariness,	   stress,	   anxiety	   and	  
breakdown,	  arterial	  hypertension,	  muscle	  cramps,	  
contractions,	   sleeping	   disorders,	   diet	   deficiency,	  
and	  twin	  pregnancy.	  
	  
The	   first	   signs	   of	   ADHD	   generally	   appear	   during	  
the	  first	  year	  of	  life	  and	  include	  sleeping	  disorders	  
(short	   sleeping	   and	   waking	   to	   a	   small	   intensity	  
noise),	  spasm	  of	  the	  sob,	  tremor	  of	  the	  hands	  and	  
the	   arms,	   intense	   emotionality,	   frequent	   tears,	  
hyper-­‐excitability,	  frequent	  fidgeting	  or	  squirming,	  
inability	  to	  keep	  one's	  seat,	  inclination	  to	  put	  their	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life	   in	   danger,	   climbing,	   and	   an	   inability	   to	   see	  
potential	   danger.	   The	   adaptation	   to	   nursery	  
school	   at	   three	   or	   four	   years	   of	   age	   becomes	  
rapidly	  difficult,	  with	  hyper-­‐excitability,	  impulsivity	  
and	  difficulty	  in	  being	  a	  good	  listener.	  
	  
At	   six	   years	   of	   age,	   all	   the	   clinical	   symptoms	   of	  
ADHD	  as	  described	  in	  the	  DMS-­‐IV	  manual	  (Findling	  
et	  al.,	  1997)	  are	  present,	  including:	  	  
	  
-­‐	   hyperactivity:	   fidgets	   with	   hands	   or	   feet,	   or	  
squirms	  in	  seat;	  gets	  up	  from	  seat	  when	  expected	  
to	  remain	  seated;	  runs	  about	  or	  climbs	  when	  it	   is	  
not	  appropriate;	   is	  "on	  the	  go"	  or	  often	  acts	  as	   if	  
"driven	   by	   a	  motor";	   talks	   excessively;	   blurts	   out	  
answers	  before	  questions	  have	  been	  finished;	  has	  
difficulty	   in	   awaiting	   their	   turn;	   interrupts	   or	  
intrudes	  on	  others;	  has	  an	   inclination	  to	  put	  their	  
life	  in	  danger.	  
-­‐	   impulsivity:	  becomes	  aggressive,	  doesn’t	  control	  
their	   movements;	   gets	   angry	   and	   has	   difficulty	  
stopping	  this	  aggression.	  
-­‐	  attention	  deficit:	  symptoms	  of	  inattention	  should	  
be	   present	   for	   at	   least	   six	   months	   and	   when	  
children	   are	   attending	   primary	   school;	   does	   not	  
give	   close	   attention	   to	   detail	   or	   makes	   careless	  
mistakes	   in	   schoolwork	   or	   other	   activities;	   has	  
trouble	   maintaining	   attention	   on	   tasks	   or	   play	  
activities;	  does	  not	  follow	  instructions	  and	  fails	  to	  
finish	   schoolwork,	   chores	   or	   duty	   in	   the	   work	  
place	   (not	   due	   to	   opposite	   behaviour	   or	   lack	   of	  
understanding	  instructions	  but	  due	  to	  slowness	  to	  
execute	   the	   tasks);	   has	   trouble	   organizing	  
activities;	   avoids	   dislikes	   or	   does	   not	   want	   to	   do	  
things	   that	   take	   a	   lot	   of	  mental	   effort	   for	   a	   long	  
period	  of	   time;	   loses	   things	  needed	   for	   tasks	  and	  
activities	   (toys,	   pencils,	   books	   or	   tools);	   is	   often	  
easily	   inattentive;	   is	   often	   forgetful	   in	   daily	  
activities	  and	  has	  memory	  difficulties.	  	  
	  
In	   addition,	   other	   clinical	   symptoms	   frequently	  
occur	   and	   must	   been	   considered	   as	   main	  
symptoms.	  These	  include:	  	  
-­‐	   sleeping	   disorders:	   mild	   sleeping	   problems;	  
cannot	  put	  to	  sleep;	  has	  nightmares,	  broken	  sleep;	  
is	  frightened	  by	  the	  night	  and	  awakes	  weary;	  very	  
frequent	  abdominal	  pains	  occurring	  with	  stress.	  
-­‐	   unexplained	  weariness:	  weariness	   begins	   in	   the	  
morning	   with	   slowness	   to	   stand	   up,	   to	   get	  
dressed,	   and	   abnormal	   weariness	   in	   sports	  
activities.	  
-­‐	  feeling	  of	  faintness	  with	  or	  without	  losing	  consc-­‐	  
iousness;	   twitches	   in	   the	   face	  or	   in	   the	  breathing	  
reflect	   hyper-­‐excitability;	   gnaws	   one's	   nails;	  
anxiety,	   stress,	  mood	  disorders,	   easily	  upset;	   loss	  
of	   trust	   and	   loss	   of	   respect	   of	   oneself;	   often	  
breaks	  down;	  is	  afraid	  of	  people	  and	  frightened	  to	  
die.	  The	  medical	  examination	  reveals	  a	  Chvostek's	  
signs	  in	  66%	  sign	  of	  hyper-­‐excitable	  children.	  	  
	  
In	  the	  clinical	  description	  of	  ADHD,	  biological	  data	  
are	   usually	   not	   evoked.	   However,	   for	   instance,	  
hyper-­‐excitability	   can	   be	   revealed	   by	   an	  
intracellular	   Mg	   deficiency	   since	   Mg	   has	   been	  
shown	   to	   be	   involved	   in	   the	   control	   of	   some	  
nervous	  system	  processes.	  
	  	  	  	  
Clinical	  Case	  Study	  1	  
In	   the	   first	   months	   of	   her	   life,	   patient	   OCE	  
presented	  signs	  of	  hyper-­‐excitability.	  She	  twiddled	  
her	   fingers,	   jumped	   to	   a	   lower	   level	   noise	   and	  
woke	  often.	  A	  prescribed	  calcium	  therapy	  was	  not	  
effective	   and	   the	   tremors	   persisted.	   Alternate	  
calcium	  and	  Mg	  therapy	  improved	  all	  the	  signs.	  
	  
At	   five	   years,	   before	   beginning	   primary	   school,	  
patient	   OCE	   again	   presented	   signs	   of	   hyper-­‐
excitability.	  She	  was	  fidgety	  and	  didn’t	  stay	  in	  her	  
seat.	   Sleeping	   disorders	   reappeared	   where	   she	  
awoke	   very	   often	   and	   slept	   very	   little.	   She	   was	  
impulsive	   and	   slapped	   children,	   although	   it	   was	  
not	  intentional.	  She	  didn’t	  control	  herself	  and	  was	  
subject	   to	   terrible	   fits	  of	   anger.	   The	  possibility	  of	  
Mg	   deficiency	   was	   raised	   since	   her	   mother	   has	  
suffered	   from	   "spasmophilia"	   for	   some	   years.	  
Both	   OCE	   and	   her	  mother	   showed	   a	   decrease	   in	  
erythrocyte	  Mg	  levels.	  
	  
After	   two	   months	   of	   Mg-­‐B6	   treatment,	   OCE	   felt	  
better.	   She	   became	   cool,	   good,	   less	   capricious,	  
didn’t	   play	   the	   fool,	   and	   her	   sleeping	   was	   calm.	  
Erythrocyte	   Mg	   increased	   and	   the	   therapy	   was	  
accordingly	   stopped.	   Some	   months	   later,	   all	   the	  
ADHD	  signs	  rapidly	  reappeared	  including	  attention	  
deficit,	   hyperactivity,	   sleeping	   disorders	   and	  
impulsiveness.	   Biological	   control	   confirms	   the	  
diagnosis	   of	   Mg	   metabolism	   disorder	   (Mg	  
imbalance),	   a	   “genetic	   disease".	   The	   Mg-­‐B6	  
treatment	   was	   recommenced	   with	   symptoms	  
resolving.	  However,	  each	  time	  OCE	  stopped	  taking	  
the	   treatment,	   ADHD	   symptoms	   returned!	   OCE	  
received	   Mg	   therapy	   over	   the	   eight-­‐year	   period	  
made	   up	   of	   6mg/kg/day	   Mg	   and	   0.6	   mg/kg/day	  
vitamin	  B6	  (Figure	  1).	  
	  





Figure	   1.	   Evolution	   of	   biological	   parameters	   for	  
magnesium	   in	   the	   case	   of	   patient	   OCE	   (born	  
February,	   1997)	   during	   the	   follow-­‐up	   (ADHD	  
syndrome).	   Ser-­‐Mg:	   total	   serum	   magnesium	  
concentrations	   in	   mmol/l;	   Erc-­‐Mg:	   magnesium	  
concentrations	  in	  erythrocytes	  (obtained	  after	  red	  
cell	  lysis)	  in	  mmol/l.	  	  
	  
	  
Clinical	  Case	  Study	  2	  
Patient	  NIC	  was	  seventeen	  years	  old	  when	  he	  first	  
came	  to	  the	  consulting	  office.	   In	  the	  first	  years	  of	  
his	   life,	   he	   demonstrated	   sleeping	   disorders,	  
restless	   sleep,	   frequent	   tears,	   had	   a	   delay	   with	  
communication,	   was	   an	   emotional	   child,	   uneasy,	  
over-­‐excitable,	   and	   a	   little	   aggressive.	   Upon	  
admission	   to	   secondary	   school,	   behavioural	  
disorders	   persisted.	   He	   was	   impulsive,	   didn’t	  
control	  himself,	  was	  aggressive	  and	  was	  dyslexic.	  
	  
A	   diagnosis	   of	   ADHD	   was	   made	   and	   psycho-­‐
stimulant	   treatment	   was	   prescribed	   over	   three	  
years.	   He	   never	   took	   the	   prescribed	   dosage	  
because	   his	   physician	   (his	   grandfather)	   and	   his	  
pharmacist	  had	  warned	  the	  parents	  of	  the	  risks	  of	  
this	   medication	   (methylphenidate).	   Rapidly,	   he	  
presented	  side	  effects	  to	  this	  treatment,	  including	  
sleeping	   disorders,	   muscular	   pains,	   weariness,	  
"feeling	   lethargic",	   behavioural	   disorders,	  
"became	   as	   a	   zombie",	   headaches,	   palpitations,	  
anxiety	  attacks,	  breakdowns,	  and	  "was	  frightened	  
to	   die".	   His	   parents	   were	   worried	   by	   these	   side	  
effects,	  and	  read	  our	  publications	  at	  the	  beginning	  
of	   2007.	   The	   levels	   of	   erythrocyte	   Mg,	   calcium,	  
and	   ionized	   calcium	   had	   dramatically	   decreased.	  
The	  parents	   decided	   to	   stop	   the	  psychostimulant	  
treatment.	   A	   Mg	   supplementation	   (300	   mg)	  
spectacularly	  improved	  patient	  NIC's	  behaviour.	  In	  
some	  weeks,	  NIC	  became	  cool	  and	  more	  relaxed.	  
An	   excellent	   participation	   in	   scholarly	   activities	  
and	   a	   better	   concentration	   in	   tasks	   resulted	   in	  
excellent	   scholastic	   results	   in	   four	   months.	   NIC	  
received	  the	  "congratulations	  of	  the	  schoolboard"	  
at	  the	  end	  of	  2007!	  NIC	  could	  control	  himself,	  was	  
not	  aggressive,	  had	  no	  behavioural	  disorders,	  and	  
had	   self-­‐confidence.	   In	   six	   months,	   all	   the	  
biological	   disturbances	   were	   normalized.	   At	   the	  
school	  of	   “masonry	   for	  historic	  monuments",	  NIC	  
has	  excellent	   assessments	  –	   "a	  good	   student	  and	  
hardworker"!	  NIC	  received	  a	  Mg	  supplementation	  
for	  more	  than	  three	  years	  and	  each	  time	  when	  he	  
tried	   to	   decrease	   the	   dose,	   clinical	   symptoms	  
reappeared.	  	  
	  
The	   disease,	   called	   hypomagnesemia	   with	  
secondary	   hypocalcemic,	   is	   heritable.	   NIC’s	   sister	  
was	   also	   emotional	   and	   hypersensitive	   while	   his	  
brother	  was	  hyper-­‐excitable,	   always	   "on	   the	   go	   "	  
and	  had	  both	  sleeping	  and	  behavioural	  disorders.	  
She	  had	  Mg	  deficiency	  and	  now	  feels	  better	  with	  
Mg	   therapy.	   His	   mother	   presented	   with	   cramps,	  
muscular	   pains,	   pins	   and	   needles	   in	   the	   hands,	  
stress	   and	  migraines.	   A	   biological	   profile	   showed	  
an	  erythrocyte	  Mg	  deficiency.	  After	  six	  months	  of	  
Mg	   therapy,	   the	   signs	  disappeared.	   The	  maternal	  
grandfather	   suffers	   from	   Alzheimer’s	   disease.	  
NIC’s	  father	  was	  emotionally	  stressed,	  uneasy	  and	  
for	   several	   years	   experienced	   sleeping	   disorders,	  
heart	   disease,	   attention	   deficit,	   and	   above	   all	  
memory	   disorders.	   He	   is	   only	   forty	   years	   of	   age!	  
He	  had	  an	  erythrocyte	  Mg	  deficiency	  and	  after	  six	  
months	   of	   the	   same	   treatment,	   their	   memory	  
improved	  (Figure	  2).	  
	  
In	   March	   2007,	   the	   methylphenidate	   treatment	  
was	  stopped	  and	  the	  magnesium	  therapy	  was	  set	  
up.	   A	   clear	   behavioral	   improvement	   was	  
observed.	   However,	   after	   the	   three	   years	   of	  
magnesium	  therapy,	  all	  biological	  data	  remain	  
stable.	   This	   result	   could	   suggest	   an	   alteration	   of	  
the	   Mg	   transport.	   It	   encouraged	   us	   to	   perform	  
additional	  experiments	  on	  Mg	  channels	  in	  order	  to	  
check	  their	  expression	  in	  various	  tissues.	  
	  
Experimental	  Study	  Number	  1	  
In	   order	   to	   study	   relationships	   between	  
hyperactivity	   symptoms	   and	   Erc-­‐Mg	   levels,	   we	  
designed	  an	  open	  study	  on	  40	  children	  with	  ADHD	  
syndrome.	   For	   ethical	   reasons,	   we	   chose	   not	   to	  
perform	   a	   double-­‐blind	   study	   against	   either	  
psychostimulants	   (methylphenidate)	   or	   placebo.	  
We	  felt	  that	  parents	  would	  not	  support	  such	  a	  design.	  
	  





Figure	   2.	   Evolution	   of	   biological	   parameters	   for	  
magnesium	  and	  calcium	  in	  the	  case	  of	  patient	  NIC	  
during	   the	   follow-­‐up	   (ADHD	   syndrome).	   Ser-­‐Mg:	  
total	  serum	  magnesium	  concentrations	  in	  mmol/l;	  
Erc-­‐Mg:	   magnesium	   concentrations	   in	   eryth-­‐
rocytes	   (obtained	   after	   red	   cell	   lysis)	   in	   mmol/l;	  
Total	   Ca:	   total	   serum	   calcium	   concentrations	   in	  
mmol/l;	   Ionized	  calcium	  concentrations	  in	  mmol/l	  
in	  serum.	  	  
	  
	  
In	  addition,	  psychostimulants	  were	   found	  to	  alter	  
Mg	  	  homeostasis	  (Tolbert	  et	  al.,	  1993).	  Our	  results	  
(Mousain-­‐Bosc	  et	  al.,	  2004)	  showed	  a	   statistically	  
significant	   improvement	   of	   the	   symptoms	   after	  
Mg-­‐B6	   supplementation,	   together	   with	   a	   rise	   in	  
Erc-­‐Mg	  values.	  
	  
In	   this	   study,	   a	   slight	   but	   significant	   intra-­‐
erythrocyte	   Mg	   depletion	   was	   evident	   in	   ADHD	  
patients	   together	  with	  a	  concomitant	  decrease	   in	  
intracellular	  calcium	  concentrations.	  As	  we	  know,	  
Mg	  is	  essential	  for	  normal	  central	  activity	  and	  Erc-­‐
Mg	   could	   be	   representative	   of	   intracellular	   Mg2+	  
concentrations.	   A	   decrease	   in	   Erc-­‐Mg	   without	  
changes	   in	   serum	   Mg	   concentrations	   could	   be	  
interpreted	   as	   an	   alteration	   in	   a	   Mg	   transporter	  
(Na+/Mg2+	   exchanger)	   in	   erythrocytes	   with	  
concomitant	   effects	   on	   neuronal	   Mg	  
concentrations.	   The	  difficulty	   in	   achieving	  normal	  
Erc-­‐Mg	   values	   under	   Mg-­‐B6	   treatment	   supports	  
this	  hypothesis.	  In	  addition,	  supplementation	  with	  
Mg	   pidolate	   was	   found	   to	   decrease	   Na+/Mg2+	  
exchanger	   activity	  with	   a	   concomitant	   rise	   in	  Mg	  
and	   K+	   contents	   of	   erythrocytes	   in	   sickle	   cell	  
disease	   (DMS-­‐IV).	   Erc-­‐Mg	   was	   described	   as	   a	  
controversial	   biological	   parameter	   for	   the	  
monitoring	  of	  Mg	  deficiency,	  in	  contrast	  to	  others	  
(Borella	   et	   al.,	   1993;	   Vink	   et	   al.,	   2009)	   who	  
consider	   Erc-­‐Mg	   as	   a	   suitable	   index.	   Moreover,	  
Basso	   et	   al.,	   (2000)	   and	   Helpern	   et	   al.,	   (1998)	  
present	  Erc-­‐Mg	  as	  not	  useful	  for	  the	  monitoring	  of	  
individual	  changes.	  We	  think	  that	  in	  this	  last	  study,	  
a	   3-­‐week	   treatment	   of	   Mg	   without	   B6	   was	   too	  
short	   to	   induce	   a	   durable	   increase	   in	   Erc-­‐Mg	  
(vitamin	  B6	  was	  described	  as	  enhancing	  Mg	  entry	  
into	   the	   cell).	   In	   any	   case,	   in	   our	   hands,	   Erc-­‐Mg	  
measurements	   were	   standardized	   and	   it	   appears	  
as	  a	  potent	  indicator	  of	  cellular	  Mg	  deficiency.	  
	  
Calcium	  and	  Mg	  cellular	  contents	  classically	  follow	  
the	  same	  pathway	  –	  when	  Mg	   increased,	  calcium	  
also	   increased.	   This	   may	   explain	   the	   significant	  
correlation	   between	   Erc-­‐Mg	   and	   intracellular	  
calcium	  values	  as	  well	  as	   the	   fact	   that	   in	  children	  
who	   have	   low	   intracellular	   calcium	   values,	   Mg	  
therapy	   increased	   intracellular	   calcium	   levels.	   It	  
can	   be	   hypothesized	   that	   a	   genetic	   factor,	  which	  
modulates	   Na+/Mg2+	   exchanger	   activity,	   may	   be	  
important	   in	   the	   regulation	   of	   Mg	   metabolism	  
(Heath	  and	  Vink,	  1998).	  
	  
We	   also	   found	   that	   increased	   hyperactivity	   and	  
decreased	   scholastic	   attention	   were	   associated	  
with	   decreased	   Erc-­‐Mg	   values.	   This	   observation	  
was	   supported	   by	   the	   fact	   that	   Mg-­‐B6	   supple-­‐
mentation	   induced	   a	   rise	   in	   Erc-­‐Mg	   values	   and	   a	  
concomitant	   improvement	   of	   the	   clinical	  
symptoms.	   What	   are	   the	   respective	   roles	   of	  
pyridoxine	   and	  Mg	   in	   these	   observations?	   It	   was	  
classically	   accepted	   that	  Mg	   is	   administered	  with	  
pyridoxine	  to	  decrease	  irritable	  side-­‐effects	  of	  the	  
B6	  therapy.	  We	  show	  here	  evidence	  of	  the	  role	  of	  
Mg	   itself	   in	   this	   therapy.	   Previous	   data	   support	  
this	   observation.	   In	   ADHD	   disorders,	   in	   which	  
disruptive	   behaviour	   with	   hyperactivity	   was	  
found,	   psychostimulants	   are	   used	   to	   improve	  
mental	   health,	   probably	   by	   increasing	   synaptic	  
noradrenaline	   activity.	   In	   children	   who	   received	  
methylphenidate,	   a	   significant	   increase	   (6%)	   in	  
plasma	  Mg	   concentrations	   was	   found	   depending	  
on	  the	  dosage	  of	  the	  drug,	  showing	  a	  relationship	  
between	   improvement	   of	   hyperactivity	   and	   Mg	  
metabolism	   (Schmidt	   et	   al.,	   1994	   (Tolbert	   et	   al.,	  
1993).	   More	   recently,	   in	   autistic	   children	   with	  
behavioural	   disorders	   and	   hyperactivity	  
(Zilbovicius	  et	  al.,	  2000;	  Schmidt	  and	  Taylor,	  1988;	  
Chakraborti	   et	   al.,	   2002),	   positive	   emission	  
tomography	   (PET)	   has	   shown	   a	   significant	  
decrease	   in	   cerebral	   blood	   flow	   localized	   at	   the	  
temporal	   lobe	   level	   in	   76%	   of	   the	   children	  
examined.	  Taken	  together	  with	  the	  fact	  that	  intra-­‐
erythrocyte	  free	  Mg2+	  is	  associated	  with	  increased	  
blood	   pressure	   (Zilbovicius	   et	   al.,	   2000)	   and	   that	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brain	   from	   rats	   fed	   with	   low	  Mg	   diets	   are	   more	  
susceptible	   to	   permanent	   brain	   focal	   ischemia	  
(Gervais	   et	   al.,	   2004),	   we	   can	   hypothesize	   that	  
intracellular	  Mg2+	  deficiency	  could	  be	  responsible,	  
at	   least	   in	  part,	  of	  some	  central	  activity	  disorders	  
observed	  in	  these	  children.	  
	  
The	   duration	   of	   the	   treatment	   necessary	   to	   get	  
significant	   improvement	   seems	   to	   be	   about	   8	  
weeks.	   Since	   the	   cause	   of	   this	   deficiency	   is	   yet	  
unknown,	   and	   since	   the	   symptoms	   reappeared	  
when	  the	  Mg-­‐B6	  diet	  was	  stopped,	  the	  treatment	  
must	   be	  maintained	   for	   a	   long	   time.	   In	   addition,	  
while	   it	  was	  difficult	   to	   find	   an	   evident	   biological	  
link	  between	  central	  disorders	  and	  Erc-­‐Mg	  values,	  
this	  biological	  parameter	  could	  be	  used	   to	  select,	  
among	   the	   large	   population	   of	   children	   with	  
hyperactive	   symptoms,	   a	   small	   population	   with	  
behavioural	   abnormalities	   that	   is	   relevant	   for	   a	  
Mg-­‐B6	   diet.	   It	   is	   evident	   that	   another	   accessible	  
Mg	   store,	   more	   significant	   for	   central	   disorders,	  
has	  to	  be	  found.	  
	  
In	   conclusion,	   this	   study	   provides	   additional	  
information	  about	  the	  therapeutic	  role	  of	  a	  Mg-­‐B6	  
regimen	  in	  children	  with	  ADHD.	  This	  effect	  seems	  
to	  be	  associated,	  at	  least	  in	  part,	  to	  a	  cellular	  Mg2+	  
deficiency,	   as	   evidenced	   by	   intra-­‐erythrocyte	  Mg	  
measurements.	   Installing	   a	   Mg-­‐B6	   supplem-­‐
entation	   for	   some	   weeks	   restored	   higher	   intra-­‐
erythrocyte	  Mg2+	  values	  and	  significantly	   reduced	  
the	   clinical	   symptoms	   of	   these	   diseases.	   As	  
chronic	  Mg	  deficiency	  was	  shown	  to	  be	  associated	  
to	   hyperactivity,	   irritability,	   sleep	   disturbances,	  
and	   low	   scholar	   attention,	   besides	   other	  
traditional	   therapeutic	   treatment,	   a	   Mg	  
supplementation	   could	   be	   required	   in	   children	  
with	  ADHD.	  
	  
Etiology	  and	  risk	  factors	  for	  ADHD	  	  
The	  etiology	  of	  ADHD	   is	  not	  yet	  known,	  although	  
the	  causes	  are	  considered	  multifactorial:	  	  
	  
-­‐	   genetics:	   twin	   studies	   indicate	   that	   heritability	  
ranges	   from	   60%	   to	   90%.	   Various	   genes	   are	  
currently	   being	   studied	   	   (Mg	   is	   involved	   in	   gene	  
expression	   and	   essential	   for	   membrane	   stability)	  
(Ozgo	  et	  al.,	  2007).	  
	  
-­‐	   brain	   abnormalities:	   it	   is	   believed	   that	   the	  
dopaminergic	   system	   is	   involved	   in	   ADHD.	  
Magnesium	  has	  an	  impact	  by	  reducing	  the	  release	  
of	   neurotransmitters	   and	   other	   mediators.	  
Magnesium	   also	   stabilizes	   the	   membranes	  
(Nemoto	  et	  al.,	  2006).	  
	  
-­‐	   environmental	   and	   perinatal	   factors:	   studies	   in	  
rats	   suggest	   that	   a	   magnesium-­‐deficient	   diet	  
influences	   not	   only	   mineral	   metabolism	   but	   also	  
protein	   metabolism.	   Growth	   retardation	   results	  
from	   the	   low	   food	   intake	   that	   is	   induced	   by	  
magnesium	   deficiency,	   which	   provokes	   an	  
alteration	   in	   energy	  metabolism.	   But	   the	   protein	  
nutritional	   status	   in	  Mg-­‐deficient	   rats	   is	   restored	  
by	   dietary	  Mg	   supplementation	   in	   seven	   days.	   In	  
women,	   maternal	   Mg	   intake	   has	   an	   immediate	  
effect	   on	   placental	   vascular	   flow.	   Magnesium	  
sulphate	   reduces	   the	   vasoconstriction	   effect	   of	  
angiotensin	   II	   in	   human	   placenta.	   Reduced	  
placental	   vascular	   flow	   is	   at	   least,	   in	   part,	  
responsible	   for	   placental	   insufficiency	   and	  
intrauterine	   growth	   retardation.	   Magnesium	  
deficiency	   increases	   the	   risks	   of	   miscarriage,	  
premature	  delivery,	  fetal	  growth	  retardation,	  twin	  
pregnancy,	  thyroid	  dysfunction	  and	  stress	  (due	  to	  
illness/depression	   leading	   to	   a	   loss	   of	  Mg	   by	   the	  
kidneys,	   and	   increased	  Mg	   requirements)(Takaya	  
et	  al.,	  2006).	  
	  
-­‐	  essential	  fatty	  acid	  imbalance:	  nutritional	  factors	  
such	  as	  essential	  fatty-­‐acid	  (EFA)	  deficiencies	  have	  
been	  associated	  with	  ADHD.	  The	  principal	  omega-­‐
3	   fatty	   acid	   in	   the	   brain,	   DHA,	   is	   highly	  
accumulated	   in	  nervous	   tissue	  membranes	  and	   is	  
important	   for	   neural	   function.	   Studies	   of	   diet	  
showed	  that	  children	  with	  ADHD	  consumed	  equal	  
amounts	   of	   omega-­‐3	   and	   omega-­‐6	   fatty	   acid,	  
compared	   to	   control	   children.	   However,	   ADHD	  
children	  had	  significantly	   lower	   levels	  of	  DHA	  and	  
total	   omega-­‐3	   fatty	   acids,	   higher	   omega-­‐6	   fatty	  
acids,	  and	   lower	  ratios	  of	  omega-­‐3/omega-­‐6	  fatty	  
acids,	  compared	  to	  control	  children.	  These	  results	  
suggest	   that	   adolescents	   with	   ADHD	   have	  
abnormal	  EFA	  profiles,	  which	  are	  not	  explained	  by	  	  
differences	   in	   intake.	   The	   role	   of	   Mg	   will	   be	  
evoked	  in	  the	  hypothesis	  of	  imbalance	  of	  essential	  
fatty	   acids.	   Vitamin	   B6	   is	   also	   an	   important	  
cofactor	   for	   numerous	   metabolic	   reactions	  
including	  metabolism	  of	  serotonin,	  GABA	  (gamma-­‐
amino-­‐butyric	   acid)	   and	   dopamine	   (Colter	   et	   al.,	  
2008,	  Gonon,	  2009).	  
	  
Treatment	  of	  ADHD	  
Conventional	   therapy	   is	   often	   multimodal	  
including	   behavioural	   therapies	   and	  medications.	  
Approved	  drugs	  for	  ADHD	  are	  psychostimulants	  





Figure	  3.	  Biological	  data	  obtained	  at	  the	  first	  visit	  
for	  65	  ADHD	  and	  22	  non-­‐ADHD	  children.	   Ser-­‐Mg:	  
total	  serum	  magnesium	  concentrations	  in	  mmol/l;	  	  
Erc-­‐Mg:	  magnesium	  concentrations	  in	  erythrocyte	  
(obtained	  after	  red	  cell	   lysis)	   in	  mmol/l.	  Only	  Erc-­‐
Mg	  appeared	  to	  be	  significantly	  lower	  than	  before	  




Figure	  4.	  Biological	  data	  obtained	  3	  months	  after	  
the	  first	  visit	  for	  the	  same	  children.	  Ser-­‐Mg:	  total	  
serum	  magnesium	  concentrations	  in	  mmol/l;	  Erc-­‐
Mg:	  magnesium	  concentrations	  in	  erythrocyte	  
(obtained	  after	  red	  cell	  lysis)	  (in	  mmol/l).	  Erc-­‐Mg	  
recovered	  normal	  values	  (statistically	  significant	  at	  
p<0.05).	  
	  
(amphetamine	   derivatives),	   including	   methyl-­‐
phenidate.	  Psychostimulant	  medications	  approved	  
by	   the	   U.S.	   Food	   and	   Drug	   Administration	   (FDA)	  
include	   methylphenidate	   (Ritalin®,	   Concerta®),	  
and,	  more	  recently,	  atomoxetine	  (Strattera®).	  
	  
In	   2008,	   a	   study	   by	   the	   National	   Centre	   of	  
Scientific	  Research	  (CNRS)	  in	  France	  (Gonon,	  2009)	  
concluded	   that	   "although	   psychostimulants	  
alleviate	   the	   core	   symptoms	   of	   attention	   deficit	  
hyperactivity	   disorder	   (ADHD),	   recent	   studies	  
confirm	   that	   their	   impact	   on	   the	   long-­‐term	  
outcomes	   of	   ADHD	   children	   is	   null.	  
Psychostimulants	   enhance	   extracellular	   dop-­‐
amine”.	  Numerous	  review	  articles	  assert	  that	  they	  
correct	   an	   underlying	   dopaminergic	   deficit	   of	  
genetic	   origin.	   This	   dopamine-­‐deficit	   theory	   of	  
ADHD	   is	   often	   based	   upon	   an	   overly	   simplistic	  
dopaminergic	   theory	   of	   reward.	   Psychostimulant	  
medication	  does	  not	  improve	  long-­‐term	  academic	  
outcomes	   of	   the	   ADHD	   children.	   Therefore,	   this	  
hypothesis	   should	   not	   be	   put	   forward	   to	   bias	  
ADHD	   management	   towards	   psychostimulants.	  
The	   American	   Journal	   of	   Psychiatry	   in	   June	   2009	  
published	  a	  study	  entitled	  "Sudden	  death	  and	  use	  
of	   stimulant	   medications	   in	   youths”	   funded,	   in	  
part,	   by	   the	   FDA	   and	   the	   National	   Institute	   for	  
Mental	  Health	  (Gould	  et	  al.,	  2009).	  Side	  effects	  are	  
described	   for	   psychostimulant	   medications	   over	  
some	  years.	  	  
	  
As	   we	   have	   seen	   previously,	   dietary	   factors	   and	  
Mg	   deficiency	   can	   play	   a	   significant	   role	   in	   the	  
etiology	   of	   ADHD	   syndrome.	   In	   our	   study,	   Mg	  
deficiency	   was	   found	   in	   89%	   of	   children	   with	  
ADHD,	   whereas	   only	   23%	   of	   non-­‐ADHD	   children	  
present	   with	   low	   erythrocyte	   Mg	   deficiency	  
(Table1).	  
	  
Clinical	   symptoms	  of	  autistic	   spectrum	  disorders	  
(ASD)	  
	  
The	   prevalence	   of	   autism	   increases	   continuously	  
and	   remains	   an	   extreme	   challenge	   to	   clinical	  
researchers.	   It	   is	   a	   neurobiological	   condition	  
having	   its	   origins	   in	   a	   disturbance	   of	   the	   cellular	  
structure	  of	  the	  brain	  during	  pregnancy.	  Generally	  
speaking,	  there	  is	  no	  "cure"	  for	  such	  children	  and	  
the	   holy	   grail	   of	   finding	   a	   neuropharmacological	  
reversal	   of	   symptoms	   is	   currently	   being	  
researched	  worldwide.	  
	  
For	   some	  years,	  one	  must	   insist	  on	   the	  screening	  
of	   the	   early	   signs	   of	   autism	   during	   the	   two	   first	  
years	   of	   the	   life	   as	   described	   in	   the	   DMS-­‐IV	  
manual:	  
• Relationship	   disorders;	   child	   is	   “too	   good”	  
with	  very	  few	  smiles.	  	  
• Visual	   contact	   disorders;	   missing	   or	   poor	  
visual	  attention;	  doesn't	  look	  at	  the	  parents;	  
look	  is	  shifty.	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Table	  1.	  	  
	  
Value	  in	  mmol/l	   Non	  ADHD	  (N=22)	   ADHD	  (N=85)	  
Threshold	  value	   %	  children	  <	  threshold	  
Ser-­‐Mg	   0.85	   0.00	   27.69	  
Erc-­‐Mg	   2.46	   22.73	   81.54	  
Ionized	  Ca	   1.18	   0.00	   19.05	  
	   	   	   	  
At	  least	  one	  criterion	  under	  threshold	   23.81	  (5/21)	   88.89	  (56/63)	  
	  
	  
• Difficulty	   in	   listening;	   seems	   not	   to	   hear;	  
delayed	   communication;	   doesn't	   repeat	  
words.	  
• Motor	   affectation;	   doesn't	   take	   the	   toys;	  
stereotyped	  movements	  of	   the	  hands;	   sits	  
and	   walks	   belatedly;	   hypo-­‐tonicity	   or	  
hyper-­‐tonicity.	  	  
• Sleeping	  disorders;	  broken	  sleep;	  crying.	  
• Feeding	   difficulties;	   slobbers;	   cannot	  
swallow;	  refuses	  food.	  
	  
The	  major	  feature	  of	  autism	  spectrum	  disorder	  is	  
that	   the	   symptoms	   only	   manifest	   themselves	  
after	  the	  age	  of	  eighteen	  months	  and	  before	  the	  
age	  of	   three.	   It	   is	  considered	   like	  a	   regression	  of	  
development	   (Burn,	   2009).	   We	   can	   explain	   that	  
ASD	   are	   disorders	   of	   brain	   function	   and	   not	   of	  
brain	  structure.	  
	  
After	   three	   years,	   the	   clinical	   picture	   of	   ASD	  
becomes	  typical:	  
	  
•	   Impairment	  of	  social	  interactions.	  
-­‐	   visual	   contact:	   doesn't	   look	   at	   the	  parents	  
and	  the	  siblings;	  gives	  a	  blank	   look;	   look	   is	  
shifty.	  
-­‐	   connection	   with	   equals:	   has	   no	   interest	  
with	   the	   parents,	   with	   the	   friends	   at	   the	  
primary	   school;	   seems	   to	   be	   "in	   their	  
bubble".	  
-­‐	   delight	   partitions:	   has	   no	   emotional	  
relationship	   with	   the	   family,	   cannot	  
express	   their	   pleasure	   for	   the	   event;	   does	  
not	   show	   social	   reciprocity	   in	   the	   form	   of	  
an	  answer	  to	  a	  human	  presence.	  
•	   Loss	  of	  communication.	  
-­‐	   delayed	   communication:	   speaks	   belatedly;	  
some	  sounds	  or	  some	  syllables	  are	  emitted	  
late;	   few	   spontaneous	   verbal	   exchanges;	  
lack	  of	  creativity	  in	  thought.	  
-­‐	   no	  communication:	  doesn't	  repeat	  words.	  
-­‐	   stereotypical	   language:	   repeats	   the	   same	  
word	  sometimes	  without	  significance.	  	  	  
-­‐	   social	  mimicking:	   cannot	   reproduce	   some-­‐
thing	  after	  a	  long	  time	  earnestly	  trying.	  	  
•	   Stereotyped	  restricted	  behavior.	  
-­‐	   stereotyped	   interest:	   has	   very	   poor	  
interest	   or	   repeats	   the	   same	   answer	   for	  
something.	  	  
-­‐	   customs.	  	  
-­‐	   handling	   things:	   difficulty	   to	   take	   the	  
things,	  to	  take	  toys,	  and	  can	  have	  abnormal	  
movements.	  	  
-­‐	   motor	   affectation:	   to	   walk,	   moves	   with	  
difficulty;	  to	  bring	  something	  to	  somebody,	  
cannot	  take	  initiative.	  
•	   Abnormal	  or	  delayed	  functioning.	  	  
-­‐	   language.	  	  
-­‐	   social	  interactions.	  	  
-­‐	   symbolic	   games:	   doesn't	   understand	   the	  
rules	   of	   the	   game;	   cannot	   dream	   up	   the	  
game.	  	  
-­‐	   behavioural	   disorders	   like	   sleeping	  
disorders,	   aggressiveness,	   impulsivity;	  
attention	  deficit;	  cannot	  listen.	  	  
	  
Magnesium	   metabolism	   could	   be	   involved	   in	  
autism,	   autism	   spectrum	   disorder	   or	   pervasive	  
developmental	   disorder	   (Rimland	   et	   al.,	   1978).	  
Magnesium	  prevents	  against	  encephalopathy	  and	  
developmental	  delay	  (Doyle	  et	  al.,	  2008).	  
	  
Clinical	  Case	  Study	  3	  
Patient	   ARN,	   three	   years	   old,	   presents	   all	   the	  
clinical	   signs	   of	   ASD,	   an	   autistic	   disorder	   that	  
began	   after	   two	   years	   of	   age.	   The	   adaptation	   at	  
the	   nursery	   school	   became	   difficult.	   His	   mother	  
describes	   behavioural	   disorders,	   with	   incessant	  
restlessness,	   doesn't	   listen,	   puts	   own	   life	   in	  
danger,	   let's	   go	   the	  mother's	  hand	   in	   the	   street,	  
crosses	   the	   street	   without	   looking	   around,	   has	  
important	  sleeping	  and	  communication	  disorders,	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doesn't	  speak,	  is	  always	  squealing,	  and	  his	  glance	  
is	   shifty.	   At	   school,	   the	   headmaster's	   evidence	  
was	  spectacular	  –	  "ARN	  become	  isolated,	  doesn't	  
draw,	  has	  no	   interest	  with	   the	  activities,	  doesn't	  
listen	   about	   the	   forbidden	   subjects.	   He	   doesn't	  
speak,	   expresses	   himself	   by	   shouting,	   and	   his	  
glance	  is	  shifty”.	  During	  the	  examination,	  patient	  
ARN	  was	  nervous,	  restless,	  tetanized,	  he	  clenched	  
his	   fists	   and	   shook	   his	   hands.	   In	   the	   face	   of	   all	  
these	   clinical	   symptoms,	   the	   possibility	   of	   a	   Mg	  
deficiency	   is	   raised.	   His	  mother	   has	   presented	   a	  
Mg	  deficiency	  for	  several	  years.	  
	  
With	  Mg-­‐B6	  therapy,	  (6	  mg/kg/day	  of	  Mg	  and	  0.6	  
mg/kg/day	  of	  vitamin	  B6),	  ARN	  improved	  quickly	  
month	   after	   month,	   probably	   because	   Mg	  
supplementation	   was	   set	   up	   very	   early	   in	   life	  
before	  the	  age	  of	  four	  years.	  ARN	  becomes	  cool,	  
obedient,	   wants	   to	   get	   dressed	   alone,	   put	   his	  
shoes	  on,	  takes	  interest	  in	  the	  family	  activities,	  is	  
looking	   to	   manipulate	   the	   computer,	   begins	  
drawing,	  doesn't	  cry,	  says	  some	  words	  and	  some	  
sentences.	   At	   school,	   he	   begins	   to	   participate	   in	  
the	  games,	  takes	  a	  book,	  shows	  the	  pictures	  and	  
repeats	   the	   words.	   The	   improvements	   are	  
spectacular.	   After	   six	   months	   of	   treatment,	   he	  
can	   pronounce	   complete	   sentences	   and	   draws.	  
After	   eighteen	   months	   of	   therapy,	   the	   parents	  
stopped	   therapy,	   however	   the	   behavioural	  
disorders	   reappeared	  with	   incessant	   restlessness	  
at	   home	   and	   school	   in	   two	   weeks.	   Another	  
attempt	   to	   stop	   the	   treatment	   was	   also	  
unsuccessful	   where	   he	   became	   tired	   and	  
depressed.	  The	  parents	  now	  do	  not	  want	  to	  stop	  
the	  treatment	  anymore.	  
	  
Today,	   patient	   ARN	   is	   twelve,	   doesn't	   present	   a	  
behavioural	   disorder	   and	   communication	   and	  
language	  is	  almost	  normal.	  He	  begins	  high	  school	  
and	   has	   taken	  Mg-­‐B6	   supplementation	   for	   eight	  
years	   (additional	   biological	   data:	   karyotype	   is	   46	  
XY;	  fragile	  X	  negative).	  	  
	  
Clinical	  Case	  Study	  4	  
Patient	   FLO	   was	   four	   years	   old	   when	   the	  
diagnosis	   of	   typical	   autism	  was	  made.	  When	   he	  
was	   seven	  years	  old,	   the	  parents	  were	   informed	  
about	  our	  work	  on	  Mg	  and	  autism.	  He	  presented	  
communication	  disorders,	  could	  not	  emit	  sounds,	  
didn't	   talk,	   had	   abnormal	   visual	   reactions,	   didn't	  
look	   someone	   in	   the	  eyes,	   had	   a	  blank	   look	   and	  
his	   look	   was	   shifty.	   The	   behavioural	   disorders	  
were	   important	   with	   many	   anxiety	   attacks,	   a	  
difficulty	   to	   calm,	   impulsiveness	   and	   constant	  
movement	  with	  fits	  of	  anger.	  He	  had	  no	  creativity	  
for	   games	   and	   didn't	   know	   how	   to	   play.	  
Erythrocyte	   Mg	   was	   low.	   The	   same	   observation	  
was	   made	   in	   his	   parents	   (Figures	   5-­‐7),	   despite	  
them	   having	   a	   balanced	   diet	   including	   fishes,	  
meats,	  fruits	  and	  vegetables.	  
	  
After	  two	  months	  of	  treatment	  with	  6	  mg/kg/day	  
magnesium	   and	   0.6	   mg/kg/day	   vitamin	   B6,	  
patient	  FLO	  was	  more	  cool,	  stayed	  at	  school	  with	  
pleasure,	  began	  to	  talk	  with	  little	  sentences,	  was	  
less	  in	  “his	  bubble”,	  and	  was	  looking	  for	  his	  father	  
when	  he	  came	  back	  from	  work.	  He	  was	  beginning	  
to	   play	   with	   friends.	   After	   three	   years	   of	  
treatment,	   FLO	   talks	   appropriately,	   understands	  
the	   language,	  goes	  to	  a	  normal	  school	  where	  his	  
reading	   skills	   have	   developed.	   During	   the	   first	  
discussion,	   the	   parents	   advise	   that	   they	   want	   a	  
third	  child.	  They	  both	  have	  evidence	  of	  important	  
Mg	  depletion.	  A	  preventive	  Mg	  supplementation	  
both	   before	   the	   desired	   pregnancy	   and	   during	  
the	   pregnancy	   seemed	   to	   be	   essential,	   and	  
indeed	   allowed	   good	   development	   of	   the	   baby	  
without	  baby	  blues	  in	  the	  mother.	  The	  little	  sister	  
is	   now	   two	   years	   old,	   bright,	   very	  much	   smiling	  
and	   is	   always	   in	   a	   good	   mood!	   (Additional	  
biological	   data:	   search	   for	  mutation	   in	   the	   gene	  
neuroligine	   NLGN3	   was	   negative;	   search	   for	  
mutation	   in	   the	   gene	   neuroligine	  NLGN	   4	   X	  was	  
also	  negative).	  
	  
Experimental	  Study	  Number	  2	  
In	  order	  to	  study	  the	  effect	  of	  Mg-­‐B6	  for	  treating	  
social,	  communication	  and	  behavioural	  responses	  
of	   children	   with	   pervasive	   developmental	  
disorders	  (PDD)	  or	  autism	  in	  connection	  with	  the	  
Mg/calcium	  status	  of	   the	  child,	  we	  designed	  an	  
open	   study	   on	   33	   children	   with	   PDD	   syndrome.	  
Our	   results	   showed	   a	   statistically	   significant	  
improvement	   of	   the	   symptoms	   after	   Mg-­‐B6	  
supplementation	   together	   with	   a	   rise	   in	   Erc-­‐Mg	  
values	  (Mousain-­‐Bosc	  et	  al.,	  2006).	  
	  
Intraerythrocyte	   Mg	   (Erc-­‐Mg),	   serum	   Mg	   (s-­‐Mg)	  
and	   blood	   ionized	   calcium	   (i-­‐Ca)	  were	  measured	  
at	  different	  times.	  Clinical	  symptoms	  of	  PDD	  were	  
scored	   (0	   to	  4).	   In	   contrast	   to	   s-­‐Mg	  or	   i-­‐Ca,	  PDD	  
children	   exhibited	   significantly	   lower	   Erc-­‐Mg	  
values	  than	  controls	  (1.26	  times;	  16/33).	  The	  Mg-­‐	  
B6	   regimen	   led	   to	   an	   increase	   in	   Erc-­‐Mg	   values	  
(1.18	   times,	   11/17)	   and	   this	   supplementation	  
improved	  PDD	  symptoms	  in	  the	  large	  majority	  of	  




Figures	   5.	   Evolution	   of	   biological	   parameters	   for	  
magnesium	   and	   calcium	   in	   the	   case	   of	   patient	  
FLO	   (born	  November	  1999)	  during	   the	   follow-­‐up	  
(ASD/PED	   syndrome).	   Ser-­‐Mg:	   total	   serum	  
magnesium	   concentrations	   in	   mmol/l;	   Erc-­‐Mg:	  
magnesium	   concentrations	   in	   erythrocytes	  
(obtained	  after	  red	  cell	  lysis)	  in	  mmol/l;	  Total	  Ca:	  
total	   serum	   calcium	   concentrations	   in	   mmol/l;	  






Figure	   6.	   Evolution	   of	   biological	   parameters	   for	  
magnesium	   and	   calcium	   in	   the	   case	   of	   patient	  
FLO’s	   father	   during	   the	   follow-­‐up.	   Ser-­‐Mg:	   total	  
serum	  magnesium	  concentrations	  in	  mmol/l;	  Erc-­‐
Mg:	   magnesium	   concentrations	   in	   erythrocytes	  
(obtained	  after	  red	  cell	  lysis)	  in	  mmol/l;	  Total	  Ca:	  
total	   serum	   calcium	   concentrations	   in	   mmol/l;	  




children	   with	   no	   adverse	   effects:	   social	  
interactions	   (23/33,	   p<0.0001),	   communication	  
(24/33,	   p<0.0001),	   stereotypical	   restricted	  
behaviour	   (18/33,	   p<0.0001),	   and	   abnormal/	  
delayed	   functioning	   (17/33,	   p<0.0001);	   15/33	  
children	  improved	  in	  the	  first	  three	  groups	  of	  
	  
	  
Figure	   7.	   Evolution	   of	   biological	   parameters	   for	  
magnesium	   and	   calcium	   in	   the	   case	   of	   patient	  
FLO’s	  mother	  during	  the	  follow-­‐up.	  Ser-­‐Mg:	  total	  
serum	  magnesium	  concentrations	  in	  mmol/l;	  Erc-­‐
Mg:	   magnesium	   concentrations	   in	   erythrocytes	  
(obtained	  after	  red	  cell	  lysis)	  in	  mmol/l;	  Total	  Ca:	  
total	   serum	   calcium	   concentrations	   in	   mmol/l;	  




symptoms.	   When	   the	   Mg-­‐B6	   treatment	   was	  
stopped,	   PDD	   symptoms	   reappeared	   in	   a	   few	  
weeks.	   A	   statistically	   significant	   relationship	  was	  
found	   in	   Erc-­‐Mg	   values	   from	   children	   before	  
treatment	  and	  their	  mothers.	  	  
	  
The	   neurobiological	   basis	   of	   a	   Mg/vit	   B6	  
supplementation	   supposes	   the	   existence	   of	   an	  
impaired	   neuronal	   Mg	   pathway	   which	   could	   be	  
reversed	   with	   Mg-­‐B6	   therapy.	   As	   we	   have	  
previously	   discussed,	   Mg	   acts	   as	   an	   ionic	  
membrane	   regulator	   and	   modulator	   of	   ion	  
transfer	  through	  membrane	  channels.	  In	  brain,	   it	  
has	   been	   shown	   that	   traumatic	   injury	   causes	   a	  
decline	   in	  Mg2+	  concentrations,	   focally	  as	  well	  as	  
in	   the	   blood	   circulation,	   and	   contributes	   to	   the	  
development	   of	   neurologic	   deficit	   (Vink	   et	   al.,	  
2009).	  Similarly,	  brain	  ischaemia	  caused	  a	  decline	  
in	  intracellular	  free	  Mg2+	  concentrations	  (Basso	  et	  
al.,	   2000)	   and	   Mg	   salt	   administration	   improves	  
motor	   outcome	   in	   this	   situation	   (Ebel	   and	  
Gunther,	  2005).	  One	  of	  its	  most	  important	  modes	  
of	  action	   is	   to	   inhibit	   the	  glutamate	  N-­‐methyl-­‐D-­‐
aspartate	   (NMDA)	   channel	   (Zilbovicius	   et	   al.,	  
2000).	   The	   activity	   of	   this	   channel	   generates	   an	  
influx	  of	  calcium	  and,	  in	  turn,	  leads	  to	  excitotoxic	  
cell	  death	  and	  apoptosis	   (Borella	  et	  al.,	  1993).	   In	  
the	  same	  way,	  abnormal	  dietary	  deficiency	  of	  Mg	  
as	   well	   as	   abnormalities	   in	  Mg	  metabolism	   play	  
important	   roles	   in	   different	   types	   of	   heart	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diseases,	   and	   Mg	   influences	   catecholamine	  
signalling	  in	  such	  diseases	  (Gervais	  et	  al.,	  2004).	  	  
	  
Recently,	   in	   primary	   autistic	   children,	   positive	  
emission	   tomography	   (PET)	   has	   been	   used	   to	  
demonstrate	   a	   significant	   decrease	   in	   cerebral	  
blood	   flow	   localized	   to	   the	   temporal	   lobes	   in	  
16/21	   of	   children	   (Zilbovicius	   et	   al.,	   2000;	  
Macdonald	  et	  al.,	  2004;	  Demougeot	  et	  al.,	  2004).	  
Taken	   together	   with	   the	   fact	   that	   Mg	   has	   been	  
shown	  to	  increase	  blood	  pressure	  (Macdonald	  et	  
al.,	   2004)	   and	   that	   brain	   from	   rats	   fed	  with	   low	  
Mg	   diets	   are	   more	   susceptible	   to	   permanent	  
brain	   focal	   ischaemia	   (Demougeot	   et	   al.,	   2004),	  
we	   can	   hypothesize	   that	   intracellular	   Mg2+	  
depletion	  could	  be	  responsible,	  at	  least	  in	  part,	  of	  
some	   central	   activity	   disorders	   observed	   in	  
PDD/autistic	  children.	  
	  
In	   our	   study,	   an	   intra-­‐erythrocyte	   Mg	   depletion	  
was	  evidenced	  in	  almost	  half	  of	  the	  PDD	  children.	  
To	  explain	   such	  a	  phenomenon,	   two	  hypotheses	  
can	   be	   proposed:	   (i)	   a	   metabolic	   inhibition	   of	  
membrane	   Na+/K+	   ATPase	   (observed	   in	   autism	  
(Kurup	  and	  Kurup,	  2003)	  with	  concomitant	  rise	  in	  
intracellular	  calcium	  and	  decrease	  in	  intracellular	  
Mg2+;	  (ii)	  a	  genetic	  defect	  in	  magnesium	  transport	  
through	   plasma	  membrane	   (Na+-­‐Mg2+	   exchanger	  
(Ebel	   et	   al.,	   2004;	   Ebel	   and	   Gunther,	   2005)	   or	  
TRPM	  chanzymes	  (Montell,	  2005).	  As	  Erc-­‐Mg	  can	  
be	   considered	   as	   representative	   of	   some	  
intracellular	   Mg2+	   concentrations,	   a	   decrease	   in	  
Erc-­‐Mg	   without	   changes	   in	   serum	   Mg	  
concentration	   could	   be	   interpreted	   as	   an	  
alteration	   of	  Mg2+	   transport	   through	   the	   plasma	  
membrane.	   The	   demonstration	   that	   TRPM7	   is	  
critical	   for	   Mg2	   homeostasis	   evoked	   the	  
possibility	   that	  mutation	   of	   TRPM	   channels	  may	  
cause	   disease	   in	   humans	   as	   a	   result	   of	   reduced	  
intracellular	  Mg2+	   levels.	   Indeed,	  mutations	  were	  
found	   in	   the	   case	   of	   hypomagnesemia	   with	  
secondary	   hypocalcemia	   (Schlingmann	   et	   al.,	  
2008)	  and,	  in	  this	  case,	  symptoms	  associated	  with	  
TRPM6	   mutations	   were	   improved	   by	  
supplementation	   with	   high	   Mg	   doses,	   in	  
agreement	   with	   increased	   Mg	   entry	   through	   a	  
passive	   mode	   of	   Mg	   influx.	   This	   genetic	  
hypothesis	  was	   also	   supported	   by	   our	   own	   data	  
showing	   a	   positive	   correlation	   between	   low	   Erc-­‐
Mg	   values	   in	   PDD	   children	   and	   their	   mothers.	  
Similarly,	  Feillet-­‐Coudray	  et	  al.,	  (2006)	  have	  found	  
that,	   in	   mice	   genetically	   selected	   for	   low	  
magnesium	   levels,	   Mg	   efflux	   from	   erythrocytes	  
was	   significantly	   increased.	   The	   genetic	  
regulation	  of	  erythrocyte	  Mg	  content	  depends	  on	  
the	  modification	  of	  Mg	  influx	  (Schlingmann	  et	  al.,	  
2002).	   To	   confirm	   such	   a	   hypothesis,	   a	   genetic	  
study	   of	   a	   PDD	   child’s	   family	   has	   clearly	   to	   be	  
developed.	  
	  
When	  PDD	  children	  were	  supplemented	  with	  Mg-­‐
B6	   treatment,	   Erc-­‐Mg	   values	   more	   or	   less	  
increased	   in	   only	   65%	   of	   children.	   The	   impair-­‐
ment	   to	   get	   normal	   Erc-­‐Mg	   values	   under	   Mg-­‐
vitB6	   treatment	   supports	   the	   hypothesis	   of	   a	  
defect	   in	  Mg	   transport	   in	   erythrocytes.	   In	   sickle	  
cell	   disease,	   Mg	   pidolate	   supplementation	   was	  
found	   to	   decrease	   Na+/Mg2+	   exchanger	   activity	  
with	  a	  partial	  rise	  in	  Mg	  and	  K+	  content	  of	  eryth-­‐
rocytes	  (De	  Franceschi	  et	  al.,	  2000).	  Doses	  of	  Mg-­‐
B6	  and	  the	  duration	  of	  treatment,	  which	  have	  not	  
been	   taken	   into	  account	   in	  our	  study,	  could	  also	  
explain	   such	   an	   observation.	   Concerning	   the	  
respective	   roles	   of	   pyridoxine	   and	   Mg	   in	   these	  
observations,	   it	  was	   classically	  accepted	   that	  Mg	  
is	  associated	  with	  pyridoxine	  to	  decrease	  irritable	  
side-­‐effects	  of	   the	  B6	   therapy	  and	   that	  B6	   is	   the	  
main	   factor	   involved	   in	   the	   improvement	   of	  
clinical	   symptoms	   in	   autistic	   patients.	   Following	  
Erc-­‐Mg	  values	  during	  Mg-­‐B6	  treatment,	  we	  bring	  
here	   evidence	   of	   the	   role	   of	   Mg	   itself	   in	   this	  
therapy.	  	  
	  
Mg-­‐B6	   treatment	   of	   PDD	   children	  was	   shown	   to	  
improve	   symptoms	   of	   the	   disease.	   Three	   of	   the	  
four	   main	   groups	   of	   clinical	   signs	   described	   in	  
DSM-­‐IV	   were	   significantly	   reduced	   and,	   for	   the	  
first	   time,	   we	   found	   that	   8/12	   of	   children	   who	  
improved	  under	  treatment	  showed	  higher	  Erc-­‐Mg	  
values.	   Persons	   only	   slightly	   deficient	   in	   Mg	  
become	  irritable,	  highly-­‐strung,	  sensitive	  to	  noise,	  
hyperexcitable,	   apprehensive	   and	   beligerent.	   If	  
the	   deficiency	   was	   more	   severe	   or	   prolonged,	  
they	   may	   develop	   twitching,	   tremors,	   irregular	  
pulse,	   insomnia,	  muscle	  weakness,	   jerkiness,	  and	  
leg	  and	  foot	  cramps.	  These	  symptoms	  can	  also	  be	  
found	   in	   some	   cases	   of	   PDD/autism.	   Although	  
this	  study	  was	  an	  open,	  non-­‐controlled	  study,	  we	  
found	   a	   relationship	   between	   clinical	   signs	   of	  
PDD/autism	   and	   a	   biological	   parameter,	   namely	  
Erc-­‐Mg.	   However,	   we	   were	   unable	   to	   establish	  
any	   correlation	   between	   improvement	   of	  
symptoms	   and	   increase	   in	   Erc-­‐Mg.	   Various	  
possibilities	  might	  explain	  this	  lack	  of	  correlation.	  
Firstly,	  Erc-­‐Mg	  is	  probably	  not	  the	  best	  biological	  
parameter	  to	  follow	  the	  relationship	  between	  Mg	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homeostasis	   and	   the	  neurological	   dysfunction	  of	  
PDD/autism.	   Contradictory	   reports	   have	   been	  
published	  on	  the	  use	  of	  Erc-­‐Mg	  as	   index	  of	  Mg2+	  
status	  (Borella	  et	  al.,	  1993,	  Basso	  et	  al.,	  2000)	  and	  
new	   biological	   tests	   that	   could	   help	   to	   study	  
genetic	  alterations	  of	  Mg	  transport	  (lymphocytes,	  
etc.)	   have	   to	   be	   tested.	   Secondly,	   other	  
neurofunctional	   disorders	   may	   be	   involved	   in	  
autism,	   such	   as	   a	   decrease	   in	   temporal	   blood	  
flow.	   Even	   if	   low	   Erc-­‐Mg	   levels	   have	   been	  
correlated	   with	   a	   decrease	   in	   blood	   pressure,	  
there	   is	  no	  evidence	   to	  associate	  blood	  pressure	  
and	  cerebral	  blood	  flow	  in	  all	  cases.	  
	  
In	   conclusion,	   this	   study	   presents	   new	  
information	   about	   the	   therapeutic	   role	   of	   a	  Mg-­‐
B6	   regimen	   in	  children	  with	  PDD	  syndrome.	  This	  
effect	  seems	  to	  be	  associated,	  at	  least	  in	  part,	  to	  
a	   cellular	   Mg	   depletion	   as	   evidenced	   by	  
intraeythrocyte	  Mg	  measurements.	  Children	  with	  
pervasive	   developmental	   disorders	   (including	  
autism)	   exhibit	   low	   Erc-­‐Mg	   levels.	   Parents	  
frequently	   showed	   similar	   low	   Erc-­‐Mg	   values	  
suggesting	   a	   genetic	   defect	   in	   Mg	   transport.	  
Installing	   a	   Mg-­‐B6	   supplementation	   for	   some	  
weeks	   restored	   intraerythrocyte	   Mg	   values	   and	  
significantly	   reduced	   the	   clinical	   symptoms	   of	  
these	  diseases.	  	  
	  
Etiology:	  role	  of	  magnesium	  during	  pregnancy	  
	  
Since	   developmental	   disorders	   appear	   early	  
during	   fetal	   development,	   Mg	   therapy	   could	   be	  
justified	   even	   during	   pregnancy.	   The	   efficacy	   of	  
Mg	   supplementation	   is	   more	   important	   if	  
treatment	  is	  in	  the	  early	  years	  of	  life.	  Magnesium	  
activates	   protein	   and	   amino	   acid	   synthesis	   and	  
Mg	   deficiency	   leads	   to	   fetal	   growth	   retardation	  
by	  reducing	  the	  nutritive	  utilization	  of	  protein	  as	  
a	   result	   of	   decreased	   protein	   absorption	   and	  
synthesis.	   Another	   study	   found	   a	   low	   cerebral	  
blood	  flow	   in	  the	  temporal	   lobe	  probably	  due	  to	  
low	  Mg	  levels	  in	  the	  cells	  (Zilbovicius	  et	  al.,	  2000).	  
	  
Effect	  of	  magnesium	  in	  fragile-­‐X	  syndrome	  
	  
Fragile-­‐X	   syndrome	   is	   an	   X-­‐linked	   disorder	  
characterized	   primarily	   by	   speech	   delay	   and	  
moderate	   mental	   retardation	   and	   neuro-­‐
behavioural	   disorders.	   The	   incidence	   of	   fragile	   X	  
syndrome	  is	  estimated	  at	  1/4000-­‐1/6000	  in	  males	  
and	   half	   that	   for	   females	   (Wiesner	  et	   al.,	   2004).	  
This	  disease	  is	  linked	  to	  the	  mutation	  of	  the	  FMR1	  
gene	   located	   on	   the	   X	   chromosome,	  
characterized	  by	  expansion	  (CGG	  amplification)	  at	  
the	  FRAXA	  site	  (Xq27.3)	  in	  the	  non-­‐coding	  region	  
of	   the	   first	  exon	   (Weisman-­‐Shomer	  et	  al.,	  2002).	  
These	  authors	  also	  showed	  that	  two	  factors	  were	  
indispensable	   for	   the	   stabilization	   of	   the	   CGG	  
tetraplex:	  magnesium	  and	  ATP.	  	  
We	  report	  a	  single	  case	  of	  a	  child	  referred	  to	  our	  
pediatrics	  unit	  for	  a	  behavioural	  disorder	  and	  for	  
whom	   Fragile	   X	   syndrome	   had	   previously	   been	  
genetically	   confirmed.	   Considering	   the	   genetic	  
origin	  of	  this	  disease,	  performing	  the	  clinical	  and	  
biological	   evaluation	   of	   the	   patient’s	   family	  
completed	   our	   work.	   Both	   the	   patient	   and	   his	  
affected	   family	   members	   were	   given	   a	   Mg	   and	  
vitamin	   B6	   supplementation	   and	   evaluated	   over	  
three	   years.	   The	   family	   were	   followed	   clinically	  
and	  biologically	  for	  the	  three	  years,	  including	  the	  
children	   with	   the	   mental	   retardation,	   pervasive	  
development	   disorder	   or	   attention	   deficit	  
hyperactivity	   disorder.	   All	   children	   carried	   a	  
mutation	   produced	   by	   expansion	   at	   the	   FRAXA	  
site	   at	   Xq	   27.3	   and	   showed	   Mg	   and	   calcium	  
disorders	   (normal	   serum	   Mg	   concentration,	   but	  
decreased	   erythrocyte	   Mg	   and	   plasma	   ionized	  
Ca2+).	   The	   mother	   presented	   a	   premutation	   by	  
expansion	   at	   the	   FRAXA	   site	   at	   Xq	   27.3	   with	  
symptoms	   of	  Mg	   depletion	   (emotivity,	   asthenia,	  
stress).	  Mg-­‐B6	  supplementation	  (6mg/kg/day	  Mg	  
and	   0.6	   mg/kg/day	   vitamin	   B6,	   orally)	   for	   three	  
years	   reduced	   clinical	   symptoms	   in	   the	   mother	  
and	   improved	   the	   behaviour	   of	   the	   children	  
(aggressiveness,	   lack	   of	   attention	   at	   school)	  
concomitant	  with	  an	  increase	  of	  intraerythrocyte	  
Mg.	  When	  the	  Mg-­‐B6	  treatment	  was	  stopped	  for	  
two	   months	   in	   one	   of	   the	   children,	   clinical	  
symptoms	  reappeared.	  	  
In	   2007,	   the	   hypothesis	   was	   put	   forward	   that	  
Fragile	   X	   syndrome	   (Fra-­‐X)	   is	   caused	   by	   the	  
transcriptional	   silencing	   of	   the	   FMR1	   gene	   that	  
encodes	   the	   Fra-­‐X	   mental	   retardation	   protein	  
(FMRP)	  (Dolen	  et	  al.,	  2007;	  Hayashi	  et	  al.,	  2007).	  
However,	   the	   pathogenesis	   of	   this	   disease	   is	  
unknown.	   According	   to	   one	   proposal,	   many	  
psychiatric	   and	   neurological	   symptoms	   of	   Fra-­‐X	  
result	   from	  the	  unchecked	  activation	  of	  mGluR5,	  
a	  metabotropic	   glutamate	   receptor.	   To	   test	   this	  
hypothesis,	  FMR1	  mutant	  mice	  presenting	  a	  50%	  
reduction	   in	  mGluR5	   expression	  were	   generated	  
and	  studied	   in	  terms	  of	  the	  range	  of	  phenotypes	  
with	   relevance	   to	   the	   human	   disorder.	   Results	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demonstrated	   that	   mGluR5	   contributes	  
significantly	  to	  the	  pathogenesis	  of	  the	  disease,	  a	  
finding	   that	   has	   significant	   therapeutic	  
implications	   for	   Fragile	   X	   and	   related	  
developmental	   disorders.	   In	   line	   with	   this	  
observation,	  Hou	  et	  al.,	  (2006)	  demonstrated	  that	  
mGluR-­‐LTD	   induces	   a	   transient,	   translation-­‐
dependent	   increase	   in	   FMRP	   that	   is	   rapidly	  
degraded	  by	  the	  ubiquitin-­‐proteasome	  pathway.	  	  
The	   successful	   management	   of	   this	   disease	   by	  
Mg-­‐	  B6	  supplementation	  observed	  in	  the	  present	  
study,	   with	   an	   early	   and	   late	   evaluation	   at	   3	  
years,	  supports	  the	  argument	  that	  a	  deficit	  in	  Mg	  
influences	   the	   appearance	   of	   Fra-­‐X	   and	   that	   by	  
replacing	  this	  Mg,	  the	  disease	  symptoms	  may	  be	  
managed.	  Berthelot’s	  group	   (Martin	  et	  al.,	  2007)	  
has	  previously	  demonstrated	  in	  rats	  that	  a	  deficit	  
in	  Mg	  acts	  by	  reducing	  the	  level	  of	  proteasomes,	  
protein	   complexes	   that	   act	   at	   the	   level	   of	   the	  
mGluR5	   receptor	   already	   implicated	   in	   this	  
disease.	   Conversely,	   Picado	   et	   al.,	   (1994)	   noted	  
an	   increase	   in	   the	   levels	   of	   Mg/NA	   in	   patients	  
with	   behavioural	   problems	   and	   for	   whom	  
hypertension	   was	   diagnosed.	   It	   has	   been	  
demonstrated	   that	   for	   behavioural	   disorders	   in	  
which	   hyperactivity	   and	   autism	   in	   particular	   are	  
involved,	   for	   which	   current	   treatment	   regimens	  
are	   difficult	   to	   standardize,	   management	   of	  
disease	   symptoms	   with	   Mg-­‐B6	   supplementation	  
is	   possible	   (Mousain-­‐Bosc	   et	   al.,	   2006).	  
Magnesium	   depletion	   represents	   one	   possible	  
explanation	   for	   the	   appearance	   of	   Fra-­‐X	  
syndrome.	   Studies	   show	   that	   Mg-­‐B6	  
supplementation	  given	  to	  subjects	  improved	  their	  
behavioural	  disorders.	  The	  presence	  of	  a	  genetic	  
mutation	  together	  with	  Mg	  deficiency	  in	  mothers	  
may	   constitute	   an	   indication	   for	   regular	  
evaluation	   of	   Mg	   status,	   and	   supplementation	  
with	  Mg-­‐B6	  during	  pregnancy.	  We	  present	  herein	  
some	  unpublished	  data	  obtained	  with	  3	  cases	  of	  
Fra-­‐X	  abnormality	  (poster	  presentation	  in	  Gordon	  




This	   review	   brings	   additional	   information	   about	  
the	   therapeutic	   role	   of	   a	   Mg-­‐B6	   regimen	   in	  
children	   with	   ADHD	   or	   ASD/autism	   syndrome.	  
This	   effect	   seems	   to	   be	   associated,	   at	   least	   in	  
part,	   to	   a	   cellular	  Mg	  depletion	   as	   evidenced	  by	  
intraeythrocyte	  Mg	  measurements.	  Children	  with	  
ADHD	   or	   PDD/ASD	   (pervasive	   developmental	  
disorders/autistic	   spectrum	   disorders),	   including	  
autism,	   exhibit	   low	   Erc-­‐Mg	   levels.	   Parents	  
frequently	   showed	   similar	   low	   Erc-­‐Mg	   values	  
suggesting	   a	   genetic	   defect	   in	   Mg	   transport.	  
Installing	   a	   Mg-­‐B6	   supplement-­‐ation	   for	   some	  
weeks	   restored	   higher	   intraerythrocyte	   Mg	  
values	   and	   significantly	   reduced	   the	   clinical	  
symptoms	  of	  these	  diseases.	  
	  
However,	  in	  a	  recent	  meta-­‐analysis	  of	  all	  studies,	  
Nye	  et	  al.,	   (2010)	  arrived	  at	  the	  same	  conclusion	  
as	  what	  they	  published	  in	  2005:	  “Due	  to	  the	  small	  
number	   of	   studies,	   and	   the	   methodological	  
quality	   of	   studies,	   no	   recommendation	   can	   be	  
advanced	   regarding	   the	   use	   of	   B6-­‐Mg	   as	   a	  
treatment	   for	   autism.	   There	   is	   simply	   not	  
sufficient	   evidence	   to	   demonstrate	   treatment	  
efficacy”.	   Together	   with	   the	   fact	   that	   both	   the	  
American	   Psychiatric	   Association	   and	   the	  
American	  Academy	  of	  Pediatrics	  have	  stated	  that	  
megavitamin	   treatment	   for	   learning	   disabilities	  
and	   autism	   is	   not	   justified,	   it	   helps	   explain	   the	  
dearth	  of	   clinical	   studies	   investigating	   the	  use	  of	  
magnesium	   and	   vitamin	   B6	   (Mg-­‐B6)	   in	   the	  
treatment	   of	   autism	   and	   autistic	   spectrum	  
disorders.	  
	  
Magnesium	   is	   known	   to	   be	   crucial	   for	   brain	  
activity	   and	   its	   involvement	   in	   the	  prevention	  of	  
neurobehavioural	   diseases	   seems	   to	   be	  
established.	  As	  a	   clinical	  double-­‐blind	   study	  with	  
Mg-­‐B6	   treatment	   over	   placebo	   cannot	   be	  
accepted	   for	   regulatory	   and	   ethical	   reasons,	   it	  
was	   suggested	   to	   put	   children	   under	   an	  
“alternative	   treatment”	   before	   the	   conventional	  
drug	  therapy.	  We	  hope	  that	  the	  combined	  use	  of	  
new	  tools	  to	  measure	  intracerebral	  Mg2+	  levels	  as	  
proposed	  by	  the	  group	  of	  Iotti	  et	  al.,	  (2008),	  and	  
a	   more	   specific	   clinical	   evaluation,	   will	   help	   to	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Schizophrenia	  and	  bipolar	  disorders	  are	  two	  of	  the	  most	  severe	  CNS	  conditions.	  Changes	  in	  plasma	  and	  
intracellular	  magnesium	   concentration,	   as	   well	   as	   in	   other	   bivalent	   cations,	   have	   been	   found	   in	   both	  
psychoses.	  Our	  data,	  as	  well	  as	   that	  of	  other	  authors,	  has	  shown	  that	  schizophrenic,	  paranoid	  patients	  
admitted	   in	   the	   acute	   state	   and	  without	   previous	   treatment,	   have	   significantly	   decreased	   intracellular	  
magnesium	   levels	   compared	   to	   healthy	   subjects.	   Therapy	  with	   haloperidol	   (a	   typical	   antipsychotic)	   or	  
with	   risperidone	   (an	   atypical	   antipsychotic)	   both	   significantly	   raised	   the	   intracellular	   magnesium	  
concentration	  without	  causing	  significant	  changes	   in	  plasma	  magnesium	  concentration.	  The	   increase	   in	  
intracellular	   magnesium	   concentration	   was	   positively	   correlated	   with	   the	   improvement	   in	   clinical	  
symptomatology.	  We	  consider	  that	  magnesium	  acts	   foremost	  by	  reducing	  glutamate	  release	  and	  by	   its	  
action	  upon	  NMDA	  receptors,	  and	  results	   in	  an	  augmentation	  in	  the	  activity	  of	  the	  GABAergic	  systems.	  
Unlike	   the	  hypothesis	   that	  only	   implicates	   zinc	  deficits	   in	   the	  pathogeny	  of	   schizophrenia,	  we	  consider	  
that	   both	   intracellular	  magnesium	   and	   extracellular	   zinc	   deficits	   are	   equally	   involved	   in	   schizophrenia	  
pathogeny.	   In	   patients	   with	   untreated	   bipolar	   disorder,	   our	   data	   showed	   a	   significant	   decrease	   in	  
intracellular	  magnesium	  concentration	  and	  plasma	  zinc	  concentration	  during	  the	  manic	  episode.	  Therapy	  
with	  mood	  modulators	   (carbamazepine	   and	   valproic	   acid)	   increased	   total	   intracellular	  magnesium	  and	  
plasma	  zinc	  concentrations	  without	  having	  a	  significant	  effect	  on	  total	  plasma	  magnesium	  concentration.	  
Other	   data	   showed	   that	   lithium	   also	   increases	   intracellular	   magnesium	   concentration.	   The	   fact	   that	  
mood	   modulators	   with	   different	   mechanisms	   of	   action	   have	   in	   common	   the	   increase	   of	   intracellular	  
magnesium	  concentration	  is	  an	  argument	  to	  consider	  this	  augmentation	  as	  an	  important	  element	  of	  their	  




Psychoses	  are	  amongst	  the	  most	  severe	  diseases	  
of	  the	  CNS.	  They	  are	  diseases	  in	  thought	  processes	  
and	  behaviour	   leading	   to	   a	   loss	   of	   contact	  with	  
reality.	   Various	   neurological	   and	   psychiatric	  
pathologies	   are	   associated	   with	   changes	   of	  
plasma	   and	   intracellular	   magnesium	   and	   other	  
bivalent	   cations.	   Such	   changes	   in	   magnesium	  
concentrations	  have	  been	  observed	  in	  brain	  injury,	  
stroke,	   headaches,	   epilepsy,	   major	   depression	  
and	  others	  (Altura	  and	  Altura,	  1999;	  Durlach	  and	  
Bac,	   1997).	   Schizophrenia	   and	  bipolar	  psychosis	  




Schizophrenia	   is	   a	   chronic	   and	   severe	   brain	  
disorder	   whose	   incidence	   is	   quite	   difficult	   to	  
evaluate.	  Nonetheless,	  there	  are	  data	  that	  show	  
that	   the	   prevalence	   of	   this	   disease	   could	   arrive	  
at	   0.5%	   of	   population	   (Kirkbride	   et	   al.,	   2008;	  
Takei	  et	  al.,	  1992).	   It	   is	  a	  psychiatric	   illness	   that	  
results	   in	   difficulty	   in	   telling	   the	   difference	  
between	   real	   things	   and	   ideas	   and	   non-­‐real	  
ideas,	   which	   causes	   disturbed	   thinking	   and	  
strong	   and	   inappropriate	   emotions.	   Four	   basic	  
types	  of	  schizophrenia	  have	  been	  described:	  
a) catatonic	  schizophrenia;	  
b) disorganized	  schizophrenia	  (hebephrenic	  
	   schizophrenia);	  
c) paranoid	  schizophrenia;	  
d) undifferentiated	  schizophrenia.	  
Identifying	   the	   changes	   in	   magnesium	   concen-­‐
tration	  in	  schizophrenic	  patients	  can	  be	  difficult,	  
and	   sometimes	   contradictory,	   as	   a	   result	   of	  
several	   factors	   including	   diversity	   of	   types	   of	  
disease,	   unknown	   time	  of	   onset	   of	   the	  disease,	  
and	  particularities	  of	   the	  disease	  evolution	  with	  
periods	   of	   reduced	   intensity	   in	   occurring	  
symptoms.	   In	   all	   circumstances,	   the	   association	  
of	   other	   diseases	   can	   also	   modify	   intra	   and	  
extracellular	   concentrations	   of	   magnesium	   and	  
other	  bivalent	  cations.	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Some	  authors	  have	  shown	  increased	  plasma	  Mg	  
concentrations	   in	   schizophrenic	   patients.	  
Specifically,	   Jabotinsky-­‐Rubin	   et	   al.,	   (1993)	  
consider	   that	   schizophrenic	   patients	   present	  
increased	   Mg	   plasma	   concentrations,	   but	   that	  
haloperidol	   administration	   reduces	   Mg	   levels.	  
These	   authors	   also	   show	   that	   decreased	   Mg	  
concentration	   is	   involved	   in	   the	   generation	   of	  
extrapyramidal	   side	   effects	   of	   haloperidol,	   and	  
consider	   that	   in	   schizophrenia,	   hyper-­‐
magnesemia	   might	   be	   correlated	   with	   some	  
failure	  of	  the	  catecholamine	  systems	  in	  the	  CNS.	  
Gattaz	  et	   al.,	   (1983)	   found	  a	  higher	  Mg	   level	   in	  
the	   CSF	   of	   the	   schizophrenic	   patients.	   It	   was	  
stated	   that	   schizophrenia	   appears	   to	   increase	  
magnesium	   concentration	   in	   CSF,	   which	   was	  
associated	   with	   decreased	   neuronal	   cGMP	  
concentration.	  
	  
In	   contrast,	   other	   authors	   didn’t	   find	   any	  
differences	   in	   magnesium	   concentration	  
between	   healthy	   subjects	   and	   schizophrenic	  
patients.	   In	   the	   studies	   of	   Kornhuber	   et	   al.,	  
(1994),	   post-­‐mortem	   determination	   of	   Mg	  
concentrations	   in	   brain	   didn’t	   show	   any	  
differences	   between	   the	   schizophrenic	   patient	  
group	   and	   a	   control	   group.	   Athanassesnas	  
(1983)	   indicated	  that	   there	  was	  no	  difference	   in	  
plasma	  Mg2+	  and	  Ca2+	  concentrations	  in	  drug	  free	  
schizophrenic	  patients.	  
	  
Finally,	   other	   research	   has	   shown	   low	   Mg2+	  
concentration	   in	   the	  CSF	  of	  acute	   schizophrenic	  
patients,	  but	  that	  the	  levels	  increase	  in	  remitted	  
schizophrenics	   (Levine	   et	   al.,	   1996).	   Other	  
authors	   indicated	   that	   patients	   with	   chronic	  
schizophrenia	   present	   magnesium	   deficiency	  
(Kirov	  et	  al.,	  1990;	  Kanofsky	  and	  Sandyk,	  1991).	  
Magnesium	   deficiency	   was	   also	   noted	   in	  
psychosis	   induced	   by	   cancer	   chemotherapy	  
(Matzen	  and	  Martin,	  1985).	  
	  
Our	   studies	   (Nechifor	  et	   al.,	   2004)	   showed	   that	  
intraerythrocyte	  total	  magnesium	  concentration	  
is	   significantly	   lower	   in	   patients	   with	   paranoid	  
schizophrenia	  before	  treatment,	  as	  compared	  to	  
normal	   subjects.	   The	   level	   of	   intraerythrocyte	  
magnesium	   was	   4.82	   ±	   0.32	   mg/dl	   in	   acute	  
paranoid	  schizophrenia	  patients	  as	  compared	  to	  
5.82	   ±	   0.11	   mg/dl	   in	   the	   normal	   control	   group	  
(p<0.05).	  In	  this	  study,	  there	  were	  no	  differences	  
between	   plasma	   magnesium	   concentrations	   of	  
schizophrenic	   patients	   and	   the	   healthy	   subjects	  
(18.2	  ±	  11	  mg/L	  in	  schizophrenic	  patients;	  18.7	  ±	  
2.17	  mg/L	  in	  the	  control	  group).	  
	  
Kirov	   and	   Tsachev	   (1990)	   observed	   a	   rise	   in	  
plasma	   magnesium	   level	   in	   schizophrenic	  
patients	   in	   clinic	   remission,	   but	   other	   studies	  
haven’t	   found	   any	   correlation	   between	   the	  
decrease	   in	   plasma	   magnesium	   concentration	  
and	   the	   symptoms	   of	   schizophrenic	   patients	  
(Kirov	  et	  al.,	  1994).	  
	  
The	   analysis	   of	   extracellular	   magnesium	   and	  
other	   bivalent	   cation	   concentrations	   in	   post-­‐
mortem	   schizophrenic	   patients	   in	   a	   variety	   of	  
cerebral	  areas	  (hippocampus,	  amygdala,	  caudate	  
nucleus,	   cortex)	   showed	   significant	   differences	  
between	   the	  drug-­‐free	   schizophrenic	  group	  and	  
treated	   schizophrenic	   patients.	   There	   weren’t	  
significant	   differences	   regarding	   magnesium	  
concentration,	   but	   drug-­‐free	   schizophrenic	  
patients	   presented	   an	   increased	   copper	   level	  
and	  a	  reduced	  zinc	  level.	  
	  
We	   tested	   the	   effects	   of	   two	   different	   anti-­‐
psychotic	  drugs	   (haloperidol	  and	   risperidone)	   in	  
therapeutic	   doses	   on	   plasma	   and	   erythrocyte	  
total	   magnesium	   concentrations	   in	   acute,	  
paranoid,	  adult	  schizophrenic	  patients.	  Our	  data	  
(Nechifor	  et	  al.,	  2004)	   showed	  that	  both	   typical	  
antipsychotic	  drugs	  (haloperidol	  and	  risperidone)	  
induced	   a	   rise	   in	   the	   intraerythrocyte	  
magnesium	   concentration	   and	   also	   improved	  
the	  clinical	  symptoms	   in	  paranoid	  schizophrenia	  
patients.	  The	  data	  indicated	  a	  rise	  in	  erythrocyte	  
magnesium	   concentration	   after	   haloperidol	  
treatment	   from	   4.82	   ±	   0.32mg/dl	   to	   5.46	   ±	  	  
0.19mg/dl	   (p<0.05)	   and	   after	   risperidone	  
treatment	   to	   5.28	   ±	   0.21	   mg/dl	   (p<0.05).	   The	  
antipsychotic	   drugs	   tested	   have	   very	   different	  
mechanisms	   of	   action.	   Haloperidol	   is	   a	   strong	  
blocker	  of	  D1,	  D2	  and	  α1	  receptors,	  and	  a	  weak	  
blocker	   of	   5-­‐HT2A	   receptors.	   Risperidone	   is	   a	  
strong	   blocker	   of	   D2	   receptors	   and	   5-­‐HT2A	  
receptors,	  but	  a	  very	  weak	  blocker	  of	  D1	  receptors.	  
	  
Renn	   et	   al.,	   (2010)	   also	   found	   an	   increased	  
magnesium	   level	   in	   schizophrenic	   patients	  
treated	   with	   antipsychotics,	   which	   is	   in	  
agreement	  with	  our	  data.	  These	  data	  favour	  the	  
idea	  that	  an	  increase	  in	  magnesium	  concentration	  
is	   not	   a	   peripheral	   phenomenon,	   but	   an	  
essential	   element	   for	   the	   mechanism	   of	   action	  
of	   the	   antipsychotic	   drugs	   utilized	   in	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schizophrenia	  treatment.	  However,	  there	   is	  also	  
contrary	   information	   whereby	   treatment	   with	  
classic	   neuroleptics	   decrease	   plasma	   concen-­‐
trations	   of	   magnesium,	   and	   chronic	   treatment	  
with	   neuroleptics	   may	   even	   produce	   hypo-­‐
magnesemia	   in	   some	   schizophrenics	   (Alexander	  
et	  al.,	  1979).	  
	  
Regarding	   the	   involvement	   of	   variations	   in	  
magnesium	   concentration	   in	   the	   etiopathogeny	  
of	   psychosis,	   we	   should	   take	   into	   account	   that	  
intracellular	   magnesium	   plays	   more	   roles	   than	  
extracellular	   magnesium,	   and	   intracellular	   total	  
magnesium	   and	   free	   Mg2+	   are	   compart-­‐
mentalized	   between	   cell	   organelles	   and	   the	  
cytosol	   (Gunther	   et	   al.,	   2006).	   In	   terms	   of	   the	  
glutamatergic	   hypothesis	   of	   schizophrenia	   that	  
involves	   the	   imbalance	   between	   glutamate	   and	  
dopamine	   with	   an	   excess	   of	   glutamate	   (Krebs,	  
1992),	   an	   increase	   in	  magnesium	   concentration	  
induced	   by	   typical	   and	   atypical	   neuroleptic	  
administration	  is	  mainly	  involved	  in	  reduction	  of	  
NMDA	   receptor	   activation	  by	   glutamate.	   In	   this	  
circumstance,	   Mg2+	   reduces	   the	   neuronal	   Ca2+	  
entrance	   through	   Ca2+	   channels	   coupled	   with	  
NMDA	  receptors.	  We	  suppose	   that	  Mg2+	  acts	   in	  
the	  same	  way	  in	  the	  experimental	  phencyclidine	  
model	  of	  psychosis.	  We	  believe	  that	  the	  increase	  
in	  cell	  Mg	  level	  is	  important	  for	  the	  antipsychotic	  
action	  of	  haloperidol	  and	  risperidone.	  The	  effect	  
of	  magnesium	  could	  be	  produced	  by	  decreasing	  
the	  neuronal	   response	  to	  glutamate	  stimulation	  
of	  NMDA	   receptors,	   decreasing	   the	   presynaptic	  
release	   of	   glutamate,	   decreasing	   formation	   of	  
peroxide	   radicals,	   and	   increasing	   GABAergic	  
activity	   and	   glycine	   synthesis;	   glycine	   inhibits	  
catecholamine	  release	  (Johnson	  et	  al.,	  1994).	  
	  
The	   increase	   in	   magnesium	   concentration	   can	  
reduce	   anxiety,	   hallucinations	   and	   agitation	  
whereas	   hypomagnesemia	   could	   exacerbate	  
anxiety	   and	   hallucinations.	   Ang	   et	   al.,	   (1993)	  
considered	   that	   hypomagnesemia	   is	   one	   of	   the	  
causes	   of	   antipsychotic	   treatment	   resistance.	  
The	   improvement	   of	   the	   clinical	   state	   and	   the	  
increase	  in	  intracellular	  magnesium	  concentration	  
leads	   to	   the	   idea	   that	   magnesium	   might	   be	  
involved	  in	  the	  development	  of	  the	  antipsychotic	  
drugs’	   therapeutic	   effect.	   The	   positive	   effect	   of	  
increased	   magnesium	   concentration	   could	   be	  
explained	   by	   the	   decreased	   activity	   of	   NMDA	  
receptors,	   using	   the	   same	   reasoning	   that	   the	  
excessive	   activity	   of	   some	   glutamatergic	   brain	  
systems	   are	   involved	   in	   some	   psychotic	  
symptoms.	  
	  
Some	   post-­‐mortem	   studies	   in	   human	   subjects	  
have	   also	   showed	   abnormalities	   of	   GABAergic	  
systems	   in	   schizophrenia	   patients.	   There	   is	  
evidence	   for	   a	   deficit	   in	   GABA-­‐containing	  
interneurons	  in	  the	  prefrontal	  cortex	  (Beasley	  et	  
al.,	   2002;	   Reynolds	   et	   al.,	   2001).	   There	   are	  
biochemical	  and	  morphological	  arguments	   for	  a	  
deficit	   in	   GABAergic	   systems	   in	   schizophrenia	  
and	  this	  deficit	  is	  limited	  to	  the	  parvum-­‐albumin	  
class	   of	   GABAergic	   interneurons	   (Blum	   and	  
Mann,	   2002).	   It	   is	   possible	   that	   by	   increasing	  
neuronal	   magnesium	   concentration	   with	  
antipsychotic	   drugs,	   GABAergic	   systems	   are	  
activated	  and	  the	  partial	  deficit	  of	  the	  GABAergic	  
cortical	   systems	   are	   corrected.	   Regarding	   the	  
mechanisms	   by	   which	  magnesium	   can	   increase	  
the	  activity	  of	  the	  GABAergic	  systems,	  there	  are	  
at	   least	  two	  possibilities:	  by	  enhancing	  vesicular	  	  
GABA-­‐transporter	  activity	  (Gerstein	  et	  al.,	  2005)	  
or	   by	   modulation	   of	   GABAA	   receptor	   activity	  
(Stanley	   et	   al.,	   1995).	   There	   is	   evidence	   that	  
magnesium	   potentiates	   the	   function	   of	   native	  
and	   recombinant	   GABAA	   receptors	   and	  
Moykkyven	  et	  al.,	  (2001)	  suggested	  a	  putative	  Mg	  
binding	  site	  on	  the	  GABAA	  receptor	  complex.	  
	  
One	  of	  the	  most	  promising	  therapeutic	  prospects	  
is	   the	   use	   of	   drugs	   acting	   at	   metabotropic	  
glutamate	   receptors.	   Krystal	   et	   al.,	   (2010)	  
described	   the	  potential	   of	  mGluR2	   and	  mGluR5	  
agonists	  and	  allosteric	  positive	  modulators	  in	  the	  
treatment	   of	   schizophrenia.	   Magnesium	   has	   a	  
positive	   modulator	   effect	   at	   the	   level	   of	   some	  
mGlu	  receptors.	  We	  believe	  that	  the	  increase	  in	  
intracellular	   magnesium	   concentration	   after	  
antipsychotic	  drug	  treatment	  allows	  magnesium	  
to	   exert	   this	   modulator	   role,	   especially	   at	  
mGluR5	   and	   mGluR2,	   and	   possibly	   at	   mGluR7	  
level.	   By	   these	   means,	   magnesium	   not	   only	  
reduces	   the	   glutamate	   action	   at	   the	   level	   of	  
NMDA	   receptors,	   but	   also	   can	   increase	   the	  
GABAergic	   activity	   and	   reduce	   presynaptic	  
glutamate	  release.	  
	  
Autism	   is	   one	   of	   the	   main	   symptoms	   of	  
schizophrenia	   but	   there	   are	   also	   patients	   with	  
autism	   (especially	   children)	   who	   are	   not	  
considered	   to	   be	   schizophrenic.	   In	   autistic	  
children	   that	   are	   not	   schizophrenic,	   Strambi	   et	  
al.,	  (2006)	  showed	  that	  there	  are	  no	  differences	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in	   intracellular	   Mg	   in	   autistic	   children	   versus	  
normal	   children.	   Unlike	   autistic	   children,	  
patients	   with	   schizophrenia	   have	   significantly	  
lower	   plasma	   and	   intracellular	   Mg	  
concentrations	   compared	   to	   normal	   subjects.	  
We	   consider	   this	   fact	   as	   an	   argument	   for	   a	  
different	   pathogeny	   of	   autism	   compared	   with	  
schizophrenia.	  Regarding	  the	  effect	  of	  treatment	  
with	   vitamin-­‐B6-­‐magnesium	   in	   children	   with	  
autism	  syndrome	  (non-­‐schizophrenic),	   there	  are	  
contradictory	   data.	   Nyl	   and	   Brice	   (2002)	  
maintain	  that	   in	  these	  children	  (a	  small	  number	  
of	   cases	   studied),	   a	   favourable	   effect	   of	   this	  
treatment	  might	  exist.	  However,	  Findling	  (1997)	  
showed	   no	   significant	   differences	   between	   the	  
treated	  and	  placebo	  group.	  
	  
Eating	   disorders	   and	   cognitive	   dysfunction	   has	  
also	   been	   identified	   in	   schizophrenia	   (Wobrock	  
et	  al.,	  2009).	  The	  serum	  levels	  of	  glutamate	  and	  
glutamine	  in	  schizophrenic	  people	  with	  anorexia	  
and	   cognitive	   impairment	   were	   significantly	  
higher	  than	  those	  in	  the	  control	  group.	  Based	  on	  
these	   findings,	   Nakazato	   et	   al.,	   (2010)	  
hypothesized	   that	   changes	   in	   the	   glutamate	  
concentration	  are	   involved	  in	  the	  mechanism	  of	  
cognitive	   impairment	   and	   anorexia	   of	  
schizophrenic	   patients.	   We	   are	   in	   agreement	  
with	   this	   point	   of	   view	   and	   we	   consider	   that	  
magnesium,	   by	   decreasing	   the	   action	   of	  
glutamate	   upon	   NMDA	   receptors,	   could	  
contribute	   to	   the	   improvement	   of	   these	  
symptoms	  in	  schizophrenic	  patients.	  
	  
Although	   the	   etiopathogeny	   of	   schizophrenia	   is	  
not	   sufficiently	   known,	   we	   consider	   that	   	   an	  
increase	   in	   magnesium	   concentration	   by	  
antipsychotic	   therapy	   is	   not	   just	   a	   secondary	  
phenomenon,	   but	   is	   part	   of	   the	   mechanism	   of	  
action	   of	   antipsychotics.	   We	   consider	   that	   the	  
data	   above	   indicates	   that	   the	   changes	   of	  
intracellular	   magnesium	   concentration	   are	  
important	   for	   neuroleptic	   drug	   action	   in	  
schizophrenic	   patients,	   and	   the	   fact	   that	  
antipsychotic	   drugs	   with	   different	   chemical	  
structures	  and	  mechanisms	  of	  action	  induce	  the	  
increase	   in	   intracellular	   magnesium	   levels,	  
further	   supports	   this	   idea.	  Contrary	   to	  Andrews	  
(1992),	   who	   supported	   only	   the	   zinc	   deficiency	  
theory	   of	   schizophrenia,	   we	   consider	   that	  
intracellular	   magnesium	   and	   plasma	   zinc	  
deficiency	   play	   an	   important	   role	   in	   the	  
pathogenic	   mechanism	   of	   schizophrenia.	   The	  
increase	  in	  intracellular	  magnesium	  concentration	  
is	   important,	  and	   is	  not	   just	  a	   side	  effect	  of	   the	  





Bipolar	   disorder	   (BD),	   also	   called	   manic-­‐
depressive	   psychosis,	   is	   an	   affective	   psychosis.	  
It	   is	   a	   recurrent	   and	   severe	  psychiatric	   disease	  
characterized	  by	  episodes	  of	  mania	  followed	  by	  
depression	   and	   by	   mood	   instability.	   Without	  
adequate	  treatment,	  BD	  is	  associated	  with	  high	  
rates	  of	  mortality.	  BD	  is	  considered	  a	  relatively	  
frequent	   psychiatric	   disease.	   Vacheron-­‐Trystan	  
et	  al.,	  (2004)	  consider	  that	  the	  prevalence	  of	  BD	  
over	   a	   lifetime	   is	   around	   1%	   in	   the	   general	  
population.	   There	   are	   several	   forms	   of	   BD.	  
According	   to	  DSM	   IV,	   the	   first	   type	   of	   BD	   (the	  
most	   frequent	   one)	   has	   a	   dominance	  of	  manic	  
symptoms,	   associated	   with	   periods	   of	  
depression.	   	   According	   to	   DSM	   IV,	   there	   are	  
two	   main	   subtypes	   of	   BD:	   type	   I	   BD	   with	   at	  
least	   one	  manic	   episode	   or	   several	   manic	   and	  
depressive	   episodes,	   and	   type	   II	   BD	   which	   is	  
related	   to	   patients	   enduring	   recurrent	  
depressive	  episodes.	  
	  
There	   is	   some	   data,	   some	   contradictory,	  
regarding	  magnesium	  and	  other	  bivalent	  cation	  
concentrations	   in	   patients	   with	   bipolar	  
disorder,	   although	   they	   haven't	   all	   been	  made	  
in	  the	  same	  type	  of	  BD	  or	  at	  the	  same	  stage	  of	  
this	   disease.	   Decreasing	   Mg	   level	   could	  
exacerbate	   anxiety,	   weakness	   and	   other	  
symptoms	   in	   BD	   patients	   (Kirov	   and	   Tsachev,	  
1990).	   	  Frazer	  et	  al.,	   (1983)	  found	  an	  increased	  
level	   of	   erythrocyte	   magnesium	   concentration	  
in	   patients	   with	   bipolar	   disorder	   before	  
hospitalization.	   Contrary	   to	   this,	   George	  et	   al.,	  
(1994)	   highlight	   significant	   changes	   of	  
magnesium	  concentration	  in	  CSF	  of	  BD	  patients	  
and	  cannot	  establish	  a	  correlation	  between	  the	  
disease	  outcome	  and	  this	  cation	  concentration.	  
Some	   authors	   have	   reported	   a	   decreased	  
plasma	   magnesium	   concentration	   in	   BD	  
patients	  compared	  to	  healthy	  control	  (Herzberg	  
and	   Herzberg,	   1977)	   while	   others	   found	   a	  
disturbed	   ratio	   between	   plasma	   calcium	   and	  
magnesium	   concentrations.	   An	   increased	  
calcium/magnesium	   ratio	   was	   correlated	   with	  
manic	   agitation	   (Carman	   et	   al.,	   1979).	   The	  
current	   medication	   is	   mood	   modulators,	   the	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most	   commonly	   used	   drug	   from	   this	   category	  
being	   lithium,	   and	   some	   anticonvulsive	  
substances	   that	   have	   proven	   to	   be	   effective	   in	  
BD,	   such	   as	   carbamazepine,	   sodium	   valproate,	  	  
and	   lamotrigine	   	   (Arban	   et	   al.,	   2005).	   More	  
rarely	   used	   in	   the	   treatment	   of	   BD	   are	  
gabapentine	  and	  topiramate.	  Also,	  some	  atypical	  
antipsychotics	  such	  as	  olanzapine,	  clozapine	  and	  
risperidone	  have	  been	  administered	  in	  BD.	  
	  
Lithium	   was	   and	   remains	   one	   of	   the	   most	  
utilized	   mood	   modulators	   in	   BD	   therapy,	  
especially	   in	   patients	   with	   the	   dominance	   of	  
manic	  symptoms,	  although	  its	  therapeutic	  utility	  
has	  a	  tendency	  to	  diminish	  (Gay	  and	  Olie,	  2005).	  
The	   data	   describing	   the	   influence	   of	   lithium	  
administration	   upon	   serum	   magnesium	  
concentrations	   are	   variable.	  Most	   studies	   show	  
that	   repeated	   lithium	   salt	   administration	  
increases	   magnesium	   concentration.	   Lithium	  
increases	   the	   intracellular	   magnesium	   concen-­‐
tration	  by	  competing	  with	  magnesium	  for	  some	  
intracellular	   binding	   sites	   (Leyden	   et	   al.,	   2000).	  
Some	  data	  demonstrate	  Li+/Mg2+	  competition	  at	  
therapeutic	   intracellular	   Li+	   concentration	   (after	  
treatment)	   in	   human	   neuroblastoma	   SH-­‐SY5Y	  
cells	  (Abukhdeir	  et	  al.,	  2003).	  After	  experimental	  
loading	   of	   neuroblastoma	   cells	  with	   1-­‐2	  mM	  of	  
extracellular	  Li+,	  the	  intracellular	  free	  magnesium	  
concentration	   was	   significantly	   higher.	   With	  
respect	   to	   Li+	   and	   Mg+	   competition	   at	   some	  
intracellular	   sites,	   the	   existing	   data	   have	  
identified	   the	   following	   molecules	   as	   sites	   of	  
competition:	   G-­‐protein	   transducin	   in	   the	  
guanosine	   5'-­‐diphosphate	   bound	   conformation	  
(Srinivasan	   et	   al.,	   2004);	   inositol	   mono-­‐
phosphatase;	   glycogen	   synthase	   kinase	   3	   (GSK-­‐
3);	   fructose	   1,6	   biphosphatase;	   biphosphate	  
nucleotidase	   (Gould	   et	   al.,	   2004);	   and	   finally,	  
ATP	   and	  ADP	  phosphate	   binding	   sites.	   It	   is	   also	  
possible	  that	  other	  intracellular	  binding	  sites	  for	  
Li+/Mg2+	   competition	   exist.	   Rybakowski	   and	  
Szaynerman	  (1976),	  hypothesized	  that	  magnesium	  
could	   increase	  the	   intracellular	   influx	  of	   lithium.	  
This	   could	   be	   another	   means	   of	   magnesium	  
involvement	  in	  the	  mechanism	  by	  which	  lithium	  
reduces	   the	   clinical	   symptoms	   from	   bipolar	  
disorders.	  
	  
Our	  data	  (Nechifor	  et	  al.,	  2006;	  2007)	  show	  that	  
adult	   patients	   with	   bipolar	   disorder	   type	   I	  
presenting	   acute	   manic	   attacks	   and	   with	   no	  
previous	   treatment	   exhibit	   lower	   intracellular	  
magnesium	   levels	   than	   the	   control	   group.	  
Plasma	   zinc	   concentration	  was	   also	   significantly	  
lower	   (0.72	   ±	   0.02	   mg/l	   versus	   89	   ±	   0.12	   mg/l	  
(p<0.05).	   There	   were	   no	   significant	   differences	  
between	   patients	   with	   bipolar	   disorder	   type	   I	  
and	   the	   control	   group	   with	   respect	   to	   plasma	  
total	  magnesium	  concentration.	  
	  
Carbamazepine	   treatment	   (600mg/day	   per	   os	  
for	  4	  weeks)	   and	   sodium	  valproate	   (900mg/day	  
for	   4	  weeks)	   significantly	   increased	   intracellular	  
magnesium	   levels	   from	  45.0	  ±	  1.87	  mg/l	  before	  
treatment	   to	   52.02	   ±	   0.9	   mg/l	   after	   sodium	  
valproate,	   and	   53.72	   ±	   2.18	   mg/l	   after	  
carbamazepine	   (p<0.05).	   Plasma	   magnesium	  
concentration	   wasn’t	   significantly	   modified	   but	  
there	   was	   a	   significant	   rise	   in	   plasma	   zinc	  
concentration	   (Nechifor	   et	   al.,	   2005;	   2006).	  
Walden	   et	   al.,	   (1993)	   showed	   that	   magnesium	  
deficiency	   decreased	   the	   beneficial	   effect	   of	  
carbamazepine	   in	   the	   treatment	   of	   epilepsies	  
but	   we	   think	   that	   hypomagnesemia	   also	  
decreases	   the	   effect	   carbamazepine	   in	   the	  
treatment	   of	   affective	   disorders.	   Magnesium	  
oxide	   increases	   the	   verapamil	   maintenance	  
therapy	  in	  mania	  (Giannini	  et	  al.,	  2000).	  This	  fact	  
favours	   the	   idea	   that	  an	   increase	   in	  magnesium	  
concentration	   is	   important,	  maybe	  essential	   for	  
the	  therapeutic	  effect	  of	  some	  drugs	  used	  in	  BD	  
treatment.	   Magnesium	   valproate	   reduces	   the	  
hyperactivity	   in	  an	  animal	  model	  of	  mania.	  This	  
effect	   of	   magnesium	   valproate	   could	   be	  
abolished	  by	  bicuculline,	  suggesting	  that	  actions	  
on	   postsynaptic	   GABA	   may	   also	   be	   involved	   in	  
the	   antimanic	   action	   of	   magnesium	   valproate	  
(Cao	  and	  Peng,	  1993).	  
	  
We	   consider	   that	   the	   increase	   in	   intracellular	  
magnesium	   concentration	   is	   an	   important	  
feature	   of	   carbamazepine,	   valproic	   acid	   and	  
other	   mood	  modulators	   used	   in	   BD	   treatment.	  
We	   also	   consider	   that	   transmembrane	   calcium	  
influx	   plays	   an	   important	   role	   in	   the	  
development	  of	  some	  psychiatric	  disorders.	  The	  
calcium	   channel	   antagonists	   (verapamil	   and	  
others)	   increase	   the	   carbamazepine	   effect.	  
Magnesium,	   acting	   like	   a	   natural	   calcium	  
antagonist	   on	   some	   ionic	   channels,	   is	   a	   factor	  
that	  contributes	  at	  the	  pharmacodynamic	  effect	  
of	   some	  mood	  modulators.	   In	   contrast,	   calcium	  
ions	   have	   an	   antagonistic	   effect	   on	  
carbamazepine	   action.	   Carbamazepine	   reduces	  
the	   neuronal	   excitability	   and	   glutamate	   release	  





Figure	  1.	  	  The	  mechanism	  of	  magnesium’s	  involvement	  in	  mood	  modulator	  action.	  +	  	  =	  stimulation;	  
	  -­‐	  	  	  =	  inhibition	  	  	  
	  
	  
and	  we	  consider	  that	  this	  effect	  is	  due,	  at	  least	  in	  
part,	   by	   increasing	   magnesium	   concentration.	  
The	   increase	   in	   intracellular	   magnesium	  
concentration	   at	   the	   neuronal	   level	   is	  
important	   for	   all	   the	   mood	   modulator	   drugs	  
utilized	   in	  BD	  therapy,	  and	  not	  only	   for	   lithium	  
(Nechifor	   et	   al.,	   2008).	   Some	   of	   the	   possible	  
mechanisms	  describing	  magnesium’s	  involvement	  
in	   mood	   modulator	   action	   are	   presented	   in	  
Figure	   1.	   Gobbi	   and	   Janiri	   (2006)	   showed	   that	  
magnesium	   valproate	   significantly	   modulated	  
the	   response	   induced	   by	   NMDA-­‐receptor	  
stimulation.	  Chuinard	  et	  al.,	  (1990)	  showed	  that	  
magnesium	   aspartate	   administration	   was	  
effective	  in	  stabilizing	  the	  mood	  of	  rapid-­‐cycling	  
BD,	  which	  favours	  the	  idea	  that	  the	  increase	  in	  
magnesium	   concentration	   is	   an	   important	  
factor	   of	   lithium	   and	   other	   mood	   modulators	  
mechanism	   of	   action.	   Heiden	   et	   al.,	   (1999)	  
administered	   magnesium	   sulphate	   iv	   as	  
supplementary	   treatment	   in	   severe	   acute	  
mania.	  
	  
In	   conclusion,	   we	   suggest	   that	   the	   increase	   in	  
plasma	   zinc	   level	   and	   the	   erythrocyte	  
magnesium	   level	   is	   not	   a	   peripheral	  
phenomenon	  but	   is	   involved	   in	  the	  mechanism	  
by	   which	   some	   mood	   modulators	   can	   reduce	  
clinical	  symptoms	  of	  bipolar	  disorders,	  not	  only	  
the	   manic	   episodes	   of	   BD	   but	   also	   the	  
depressive	   periods.	   The	   changes	   in	   intra	   and	  
extracellular	  plasma	  magnesium	  concentrations	  
and	   other	   bivalent	   cations	   are	   an	   important	  
part	  of	  the	  mechanism	  of	  action	  of	  some	  mood	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Abstract	  
The	  treatment	  of	  major	  depression	  (MD)	  is	  still	  a	  major	  unmet	  medical	  need	  in	  the	  majority	  of	  patients.	  
Sixty	  percent	  of	  cases	  of	  MD	  are	  treatment-­‐resistant	  depression	  (TRD),	  showing	  that	  classical	  treatments	  
for	   MD	   are	   poorly	   effective	   to	   non-­‐effective.	   Magnesium	   has	   been	   largely	   removed	   from	   processed	  
foods,	   especially	   refined	  grains,	   in	   the	  Western	  world,	  harming	   the	  brain	  and	   causing	  mood	  disorders.	  
Magnesium	   deficiency	   causes	   N-­‐methyl-­‐D-­‐aspartate	   (NMDA)	   coupled	   calcium	   channels	   to	   be	   biased	  
towards	  opening	  which	  causes	  neuronal	  injury	  and	  neurological	  dysfunction,	  which	  we	  believe	  results	  in	  
MD.	  Oral	  administration	  of	  Mg	  to	  animals	  produced	  antidepressant-­‐like	  effects	  that	  were	  comparable	  to	  
those	  of	  antidepressant	  drugs.	  Cerebral	  spinal	  fluid	  (CSF)	  Mg	  has	  been	  found	  to	  be	  low	  in	  suicidal	  TRD.	  
The	  first	  report	  of	  Mg	  treatment	  for	  agitated	  depression	  was	  published	  in	  1921	  showing	  success	   in	  220	  
out	   of	   250	   cases.	   One	   2008	   randomized	   clinical	   trial	   showed	   that	  Mg	  was	   as	   effective	   as	   the	   tricyclic	  
antidepressant	   imipramine	   in	   treating	  MD.	   Intravenous	   and	   oral	  Mg	   protocols	   have	   been	   reported	   to	  
rapidly	  terminate	  MD	  safely	  and	  without	  side	  effects.	  Brain	  Mg	  deficiency	  reduces	  serotonin	  levels,	  and	  
antidepressant	   drugs	   have	   been	   shown	   to	   have	   the	   action	   of	   raising	   brain	   Mg.	   Excessive	   calcium,	  
glutamate	  and	  aspartate	  intake	  can	  greatly	  worsen	  MD.	  We	  believe	  that,	  when	  taken	  together,	  there	  is	  
more	   than	   sufficient	  evidence	   to	   implicate	   inadequate	  dietary	  Mg	  as	   contributing	   to	   the	   cause	  of	  MD,	  
and	  we	  suggest	  that	  physicians	  prescribe	  Mg	  for	  its	  prevention	  and	  treatment.	  
	  
	  
Incidence	  of	  major	  depression	  
	  
Neuropsychiatric	  disorders	  account	  for	  36%	  of	  all	  
non-­‐communicable	  illnesses.	  They	  are	  the	  leading	  
cause	   of	   all	   disability	   (more	   than	   twice	   that	   of	  
cardiovascular	   diseases	   and	   malignant	  
neoplasms)	   in	   the	   United	   States	   and	   Canada.	  
Depressive	   disorders	   cause	   40%	   of	   all	  
neuropsychiatric	  disorders	  (World	  Health	  Report,	  
2004).	   Without	   magnesium	   (Mg)	   treatment,	  
major	  depression	  (MD)	  is	  expected	  to	  affect	  up	  to	  
25	   percent	   of	   the	   American	   population	   at	   some	  
point	   in	   their	   lives.	   Besides	   core	   symptoms	   of	  
depression,	   i.e.	   depressed	   mood	   and	   lack	   of	  
energy,	   other	   symptoms	   may	   vary,	   but	  
nevertheless	   have	   strong	   effects	   on	   patient	  
quality	   of	   life.	   These	   include	   increased	   or	  
decreased	   appetite	   and	   weight	   and	   sleep	  
disturbances,	   in	   particular	   difficulties	   falling	  
asleep,	   maintaining	   sleep	   and,	   in	   melancholic	  
depression,	   early	  morning	   awakening.	   Emotional	  
reactivity	   can	  be	   very	  different	  with	   increases	   in	  
sensitivity	   to	   social	   challenges,	   easy	   upset,	  
sadness	   on	   the	   one	   hand	   and	   an	   unresponsive	  
mood,	   which	   leaves	   patients	   with	   “feelings	   of	  
feelinglessness”	   on	   the	   other	   hand.	   Feelings	   of	  
guilt	   and	   sadness	   can	   be	   very	   pronounced,	  
leading	   to	   suicidal	   ideation	   and	   finally	   suicide	  
itself.	  	  
	  
Increasing	  incidence	  of	  depression	  
	  
Americans	  are	  developing	  MD	  at	  higher	  rates	  and	  
younger	   ages	   than	   ever	   before.	   People	   born	  
around	  1900	   rarely	   had	   childhood	  or	   early	   adult	  
depression,	   and	   only	   about	   one	   percent	   ever	  
developed	   depression.	   People	   born	   between	  
1935	   and	   1944	   had	   a	   one	   percent	   incidence	   of	  
depression	   by	   age	   15,	   a	   2	   percent	   rate	   of	  
depression	  by	  age	  25,	  and	  9	  percent	  incidence	  by	  
age	  45.	   People	  born	   in	   1955,	   had	   a	  one	  percent	  
incidence	   of	   depression	   by	   age	   15,	   a	   6	   percent	  
incidence	   by	   age	   25,	   and	   a	   lifetime	   incidence	   of	  
25	  percent	  (Meyer	  and	  Quenzar,	  2005).	  	  
	  
The	  onset	  of	  depression	  has	  greatly	   increased	   in	  
incidence,	  and	   it	   is	  affecting	  people	  much	  earlier	  
in	   their	   lives	   during	   the	   late	   20th	   century	   and	  
early	   21st	   century	   than	   before	   the	   20th	   century	  
(Meyer	   and	   Quenzar,	   2005).	   The	   reasons	   for	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these	  findings	  are	  not	  quite	  clear,	  but	  inadequate	  
dietary	   Mg	   is	   prevalent	   in	   America	   and	   is	   the	  
most	   likely	   cause.	   There	   is	   probably	   a	   real	  
increase	   in	  depression,	  coupled	  with	  a	  change	   in	  
diagnostic	   habits,	   which	   has	   to	   do	   with	   the	  
element	  of	  stigma.	  Lower	  stigma	  leads	  to	  a	  higher	  
rate	   of	   diagnosis.	   Modern	   antidepressant	   drugs	  
are	   better	   tolerated	   than	   first	   generation	  
antidepressive	  treatments	  that,	  in	  terms	  of	  a	  risk-­‐
benefit	   analysis,	   makes	   less	   severely	   affected	  
subjects	   candidates	   for	   psychopharmacological	  
intervention.	   Unfortunately,	   antidepressant	   and	  
anti-­‐anxiety	  medications	  commonly	  in	  use	  have	  a	  
tendency	  to	  promote	  suicide,	  especially	   in	  young	  
people	  (Stone,	  2009).	  	  
	  
Classical	  depression	  treatments	  
	  
Among	   those	   who	   seek	   professional	   help	   for	  
clinical	   depression,	   some	   patients	   find	   relief	   for	  
their	   condition	   using	   therapies	   based	   on	  
modification	   of	   monoaminergic	   systems.	   Newer	  
generation	   antidepressants	   are	   now	   used	   and	  
they	   include	   selective	   serotonin	   reuptake	  
inhibitors	   (SSRIs),	   combined	   serotonin/noradren-­‐
aline	  reuptake	   inhibitors,	  and	  drugs	  that	   interact	  
with	   monoaminergic	   receptors	   such	   as	  
mirtazapine.	  First	  generation	  antidepressants	  like	  
monoamine	   oxidase	   inhibitors	   (MAOIs)	   and	  
tricyclic	   antidepressants	   are	   now	   rarely	   used	  




A	   large	   proportion	   of	   the	   burden	   caused	   by	  
depression	   is	   attributable	   to	   treatment-­‐resistant	  
depression	   (TRD).	   Only	   half	   of	   patients	   who	   are	  
treated	  with	  a	   first	   line	  pharmacological	   therapy	  
of	   an	   SSRI	   respond	   and	   only	   30%	   experience	  
remission	   (Trivedi	  et	   al.,	   2006).	   If	   a	   second	   drug	  
also	   fails,	   a	   commonly	   used	   criterion	   for	   TRD	   is	  
fulfilled.	  Treatment-­‐resistant	  depression	   is	  highly	  
recurrent	  with	  as	  many	  as	  80%	  of	  those	  requiring	  
multiple	   treatments	   relapsing	   within	   a	   year	   of	  
achieving	   remission.	   For	   those	   with	   a	   more	  
protracted	   illness,	   the	   probability	   of	   recovery	  
within	   10	   years	   is	   about	   40%.	   Patients	  with	   TRD	  
are	  more	   likely	   to	   suffer	   from	  comorbid	  physical	  
and	  mental	  disorders,	   to	  experience	  marked	  and	  
protracted	   functional	   impairment,	   and	   to	   incur	  
higher	   medical	   and	   mental	   healthcare	   costs.	  
Thus,	   in	   order	   to	   reduce	   the	   substantial	   burden	  
caused	   by	   depression,	   TRD	   is	   a	   central	   focus	   of	  
medical	   research	   (Fekadu	   et	   al.,	   2009).	   Apart	  
from	   the	   complete	   non-­‐responders	   there	   are	  
many	   patients	   who	   fulfil	   criteria	   of	   “remission”	  
but	   still	   have	   symptoms	   severe	   enough	   to	  
interfere	   with	   their	   quality	   of	   life,	   i.e.	   residual	  
symptoms	   (Nierenberg	   et	   al.,	   2010).	   Besides	  
quality	  of	   life	   implications	  of	   residual	   symptoms,	  
their	   presence	   predicts	   relapse	   of	   depressive	  
disorders.	   This	   shows	   that	   even	   in	   the	   group	   of	  
remitted	   subjects	   an	   unmet	   medical	   need	  
remains.	  
	  
Markers	  and	  risk	  factors	  of	  major	  depression	  
	  
Major	   depression	   is	   a	   disorder	   that	   has	   both	  
psychological	   and	   physiological	   causes	   and	   risk	  
factors.	   Because	   psychological	   causes	   may	   trigger	  
pathophysiologic	  mechanisms,	  there	  is	  overlap.	  In	  
this	   article	   we	   are	   focusing	   primarily	   on	   the	  
physiology	  of	  MD	  with	  some	  reference	  of	  MD	  as	  a	  
stress-­‐related	  disorder.	  We	  also	  focus	  on	  systems	  
that	  may	  be	  related	  to	  Mg-­‐dependent	  regulation.	  	  
	  
Biological	  markers	  of	   depression	  or	  depression-­‐
vulnerability	  
	  
There	   are	   certain	   biomarkers	   which	   have	   been	  
described	   in	   patients	   with	   depression	   and	   in	  
“high	   risk”	   populations;	   meaning	   those	   who	  
never	  have	  had	  MD,	  but	  who	  have	  a	  close	  relative	  
that	  does	  (Lauer	  et	  al.,	  1995;	  Modell	  et	  al.,	  1998).	  
These	   biomarkers	   include	   an	   increased	   stress	  
hormone	  axis	  (HPA-­‐axis),	  a	  higher	  density	  of	  rapid	  
eye	  movements	  in	  sleep	  EEGs	  and	  less	  slow-­‐wave	  
sleep	   (SWS),	   particularly	   in	   the	   first	   sleep	   cycle	  
(Krieg	   et	   al.,	   2001).	   Lower	   SWS	   and	   higher	   HPA	  
axis	  activity	  were	  also	  identified	  as	  risk	  factors	  for	  
a	  relapse	  in	  patients,	  who	  were	  in	  remission	  after	  
a	  depressive	  episode	  (Hatzinger	  et	  al.,	  2004).	  Not	  
all	  studies	  confirm	  these	  points,	  in	  particular	  with	  
regard	   to	   HPA	   axis	   findings	   (Ising	   et	   al.,	   2005).	  
This	  suggests	  biological	  variability	  in	  subjects	  with	  
a	  risk	  for	  depression.	  	  
	  
A	   more	   recently	   identified	   potential	   marker	   for	  
depression	   is	   aldosterone,	   which	   is	   increased	   in	  
patients	  with	  depression	   (Emanuele	  et	  al.,	   2005;	  
Murck	  et	   al.,	   2003).	   This	  may	   be	   of	   importance,	  
as	   aldosterone	   is	   a	   primary	   regulator	   of	  Mg.	   As	  
both	   aldosterone	   and	   cortisol	   are	   regulated	   by	  
ACTH	   there	   could	   be	   a	   correlation	   between	   the	  
two	  phenomena	  (Murck,	  2002).	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Typical	   sleep	  disturbances	  occur	   in	  MD	   including	  
falling	   asleep,	   staying	   asleep	   and	   early	   morning	  
awakening,	   or	   hypersomnia	   and	   excessive	  
napping.	   Sleep	   EEG	   patterns	   have	   been	   identified	  
for	   MD.	   Rapid	   eye	   movement	   (REM)	   sleep	  
changes	  occur	  with	  a	   shorter	   latency	   to	   the	   first	  
occurrence	   of	   REM,	   a	   higher	   number	   of	   eye	  
movements	  during	  REM	  sleep,	   i.e.	   a	  higher	  REM	  
density,	  and	  in	  some	  subjects	  reduced	  duration	  of	  
slow	  wave	  sleep	  (Steiger	  and	  Kimura,	  2010;	  Thase	  
et	   al.,	   1997).	   Subjective	   reports	   of	   sleep	  
disturbances	   may	   also	   be	   predictive	   of	   a	  
depressive	  episode.	  A	  review	  of	  eight	  epidemiol-­‐
ogical	  studies	  concluded	  that	  insomnia,	  lasting	  for	  
a	   period	   of	   2	   weeks,	   was	   predictive	   for	  
development	  of	  depression	  in	  the	  subsequent	  1	  -­‐	  
3	   years	   (Riemann	   and	   Voderholzer,	   2003).	  
Insomnia	   at	   baseline	   and	   1	   year	   post-­‐baseline	  
compared	   with	   those	   with	   no	   sleep	   complaints	  
was	  strongly	  predictive	  of	  a	   future	  MD	  (adjusted	  
odds	  ratio,	  OR=39.8;	  P<0.01)	  (Ford	  and	  Kamerow,	  
1989).	  Another	  study	   (van	  den	  Berg	  et	  al.,	  2007)	  
found	   a	   similar	   association	   for	   hypersomnia.	  
Sleep	  disturbances	  and	  neuroendocrine	  data	  are	  
correlated,	   in	   particular	   hypercortisolism	   is	  
correlated	   with	   the	   number	   of	   awakenings	   and	  
reduced	  SWS	  (Hubain	  et	  al.,	  1998).	  
	  
Several	   cardiovascular	   factors,	   especially	   low	  
systolic	   blood	   pressure,	   are	   risk	   factors	   for	   MD	  
(Gilmore	   et	   al.,	   1995;	   Paterniti	   et	   al.,	   2000).	  
Subjects	   with	   MD	   show	   lower	   heart	   rate	  
variability	  (HRV)	  (Udupa	  et	  al.,	  2007).	  Insomnia	  is	  
related	   to	   a	   lower	   HRV	   (Spiegelhalder	   et	   al.,	  
2010).	   Heart	   rate	   variability	   appears	   to	   increase	  
with	  successful	   treatment.	  Reduced	  HRV	   is	  a	  risk	  
factor	   for	   depression	   in	   patients	   with	   coronary	  
heart	  disease	  (Pizzi	  et	  al.,	  2008).	  	  
	  
Inflammatory	   markers	   are	   an	   additional	   area	   of	  
potentially	   useful	   predictive	   markers	   for	  
depression.	  Plasma	  interleukin	  6	  (IL-­‐6),	  TNFα	  and	  
prostaglandin	  E2	   (PDE2)	  are	  of	   relevance	   (Murck	  
et	   al.,	   2004;	   Zorrilla	   et	   al.,	   2001).	   Elevated	  
inflammatory	   markers	   are	   related	   to	   non-­‐
response	   to	   the	   most	   frequently	   used	  
antidepressants	   today,	   i.e.	   SSRIs	   (Eller	   et	   al.,	  
2008;	   O'Brien	   et	   al.,	   2007).	   Anti-­‐inflammatory	  
agents	  appear	  to	  have	  anti-­‐depressant	  effects,	  as	  
in	   the	   case	   of	   TNFα-­‐antagonists	   (Uguz	   et	   al.,	  
2009),	   cyclooxygenase	   inhibition	   (Muller	   et	   al.,	  
2006)	   and	   omega-­‐3	   fatty	   acids	   (Murck	   et	   al.,	  
2004).	  
Changes	  in	  dietary	  magnesium	  
	  
Against	   the	   widespread	   belief	   that	   Western	  
countries	   have	   the	   best-­‐fed	   people	   on	   planet	  
Earth,	   there	   is	   evidence	   that	   serious	   deficits	   in	  
dietary	  Mg	  in	  the	  Western	  world	  are	  related	  to	  an	  
increased	   risk	   for	   MD	   and	   biological	   markers	   of	  
depression.	   For	   a	   long	   time	   it	  was	   not	   accepted	  
that	   food	   could	   have	   any	   influence	   on	   brain	  
structure	   or	   its	   function	   including	   cognitive,	  
mood	   and	   intellectual	   development.	   It	   is	   now	  
absolutely	   certain	   that	  Mg	  plays	   vital	   roles	   in	   all	  
major	  metabolisms	   in	  oxidation-­‐reduction	  and	   in	  
ionic	   regulation,	   among	   its	   other	   roles	   in	   the	  
brain	   (Bourre,	   2006)	   and	   in	   mood	   disorders	  
Dietary	   magnesium	   intake	   has	   steadily	   declined	  
over	   the	   preceding	   century,	   due	   to:	   a)	   the	  
practice	   of	   refining	   grain	   to	   make	   processed	  
foods;	   b)	   making	   dietary	   choices	   low	   in	  
magnesium-­‐rich	   foods	   such	  as	  whole	   grains,	   rice	  
and	  wheat	  bran,	  nuts,	  seeds,	  chocolate,	  peanuts,	  
peanut	   butter	   and	   green	   leafy	   vegetables;	   c)	  
strong	   chemical	   sequestration	   of	   metals	   during	  
food	   processing;	   and	   d)	   complete	   removal	   of	  
minerals	   from	   drinking	   water	   processed	   by	  
distillation,	   de-­‐salination	   and	   reverse	   osmosis	   so	  
prevalent	   in	   the	   Middle	   East,	   Australia	   and	  
elsewhere.	  Only	  16%	  of	  the	  original	  Mg	  and	  24%	  
of	  the	  original	  zinc	  found	  in	  whole	  wheat	  remain	  
in	   refined	   wheat	   (Anonymous,	   2002).	   These	  
circumstances	   reduced	   average	   bioavailable	   Mg	  
consumption	   from	   450	   mg	   in	   the	   19th	   century	  
and	  before,	  to	  250	  mg	  per	  day	  or	  less	  in	  the	  20th	  
and	   early	   21st	   centuries,	   resulting	   in	   significant	  
and	   unhealthy	   Mg	   deficiency	   in	   the	   majority	   of	  
the	   population	   (Seelig	   and	   Rosanoff,	   2003).	  
Approximately	   68%	   of	   U.S.	   adults	   consume	   less	  
than	   the	   U.S.	   recommended	   daily	   allowance	  
(RDA)	  of	  Mg	  (420	  mg	  /	  day	  for	  men,	  320	  mg	  /	  day	  
for	   women),	   with	   19%	   consuming	   less	   than	   half	  
of	   the	   RDA	   (Jacka	   et	   al.,	   2009).	   Deficiency	   of	  
dietary	   Mg	   has	   been	   related	   to	   depressive	  
disorders	   (Rasmussen	   et	   al.,	   1989;	   Hashizume	  
and	   Mori,	   1990).	   The	   pathological	   signs	   of	   Mg-­‐
deficiency	   and	   possible	   reasons	   for	   its	  
development	  have	  been	  reviewed	  earlier	  (Morris,	  
1992;	  Durlach,	  1984;	  Durlach	  et	  al.,	  1995;	  Durlach	  
et	   al.,	   1997;	   Durlach,	   2002).	   A	   recent	   study	  
confirmed	   the	   epidemiological	   relationship	  
between	   low	   dietary	   Mg	   intake	   and	   the	   risk	   of	  
developing	   depression	   (Jacka	   et	   al.,	   2009).	  
Conversely,	   extensive	   marketing	   and	   resultant	  
consumption	   of	   excitotoxic	   glutamates	   and	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aspartates	   have	   very	   greatly	   increased	   over	   the	  
same	   period,	   even	   though	   there	   is	   a	   strong	  
connection	   between	   dietary	   and	   endogenous	  
excitotoxin	   excess	   and	   neurological	   dysfunction	  
and	  mental	   illness	  (Blaylock,	  1999;	  Walton	  et	  al.,	  
1993).	  	  
	  
Regulation	  of	  brain	  magnesium	  
	  
The	  concentration	  of	  Mg	  within	  the	  brain	  results	  
from	  a	  highly	  regulated	  process.	  Its	  concentration	  in	  
cerebrospinal	   fluid	   (CSF)	   is	   higher	   than	   that	   in	  
plasma,	   pointing	   to	   the	   existence	   of	   active	  
transport	   systems	  between	   these	   compartments	  
(Morris,	  1992).	  Magnesium	  moves	  out	  of	  CSF	  into	  
blood	   by	   passive	   diffusion	   and	   bulk	   filtration	  
(Oppelt	   et	   al.,	   1963).	   These	   dynamics	   result	   in	  
relative	   stability	   of	   intracerebral	  Mg	   concentration	  
even	   in	   case	   of	  Mg	   depletion.	   Up	   to	   40	   days	   of	  
Mg	   depletion	   led	   only	   to	   a	   small	   global	   intra-­‐
cerebral	   decrease	   in	   Mg	   concentration	   in	   rats,	  
however	   important	   regional	   differences	   existed	  
(Poenaru	   et	   al.,	   1997).	   The	   brainstem	   seemed	  
particularly	   vulnerable	   to	   Mg	   depletion.	  
Increasing	   Mg	   administration	   had	   no	   strong	  
influence	   on	   CSF	  Mg	   concentrations.	   Only	   small	  
changes	   in	   CSF	   Mg	   after	   prolonged	   supple-­‐
mentation	  were	  reported	  in	  dogs	  (Kemeny	  et	  al.,	  
1961;	  Schain,	  1964).	  However,	  chronic	  dietary	  Mg	  
deficits	   led	   to	   proportional	   changes	   in	   CSF	   and	  
brain	  cellular	  Mg	  (Chutkow,	  1974).	  	  
	  
It	  is	  of	  importance	  to	  note	  that	  metabolism	  of	  Mg	  
depends	   on	   endocrine	   parameters.	   Administration	  
of	  aldosterone	  led	  to	  an	  enhancement	  of	  urinary	  
excretion	   of	  Mg	   in	   humans	   (Horton	   and	   Biglieri,	  
1962).	   Acute	   β-­‐adrenergic	   stimulation	   with	  
adrenaline	   or	   salbutamol	   reduced	   plasma	  Mg	   in	  
humans	   (Whyte	   et	   al.,	   1987),	   pointing	   to	   an	  
adrenergic	   mechanism	   of	   Mg	   regulation.	   The	  
parathyroid	   is	   influenced	   by	   Mg	   in	   its	   function,	  
and	   it	   regulates	   Mg	   levels	   and	   distribution	  
(Zofkova	   and	   Kancheva,	   1995).	   Inadequate	  
central	   nervous	   system	   (CNS)	   concentration	   of	  
Mg2+	  has	  a	  critical	  level	  below	  which	  neurological	  
dysfunction	   occurs	   (Yasui	   et	   al.,	   1997;	   Langley,	  
1991).	  
	  
Acute	   emotional	   stress,	   which	   involves	   an	  
activation	  of	  the	  SNS	  and	  the	  HPA	  axis,	   led	  to	  an	  
increase	  in	  Mg	  excretion	  in	  humans	  (Grases	  et	  al.,	  
2006)	   and	   experimental	   animals	   (Altura	   et	   al.,	  
1992),	   the	   latter	   resulting	   from	   reduced	   tissue	  
and	   serum	  Mg.	   Swim	   stress	   in	   animals	   led	   to	  an	  
activation	  of	  several	  stress	  hormone	  systems	  and	  
an	   increase	   in	   Mg	   in	   plasma,	   but	   a	   decrease	   in	  
brain	  Mg	  (Poleszak	  et	  al.,	  2005).	  This	  shows	  that	  
tissue	   Mg	   is	   more	   relevant	   than	   plasma	   Mg.	  
Stress	   induced	   decrease	   in	   brain	   Mg	   could	   be	  
counteracted	   with	   additional	   administration	   of	  
the	   tricyclic	   antidepressant	   imipramine.	   This	  
finding	   is	   complicated	   by	   observation	   that	   co-­‐
administration	  of	  both	   imipramine	  and	  Mg	  has	  a	  
beneficial	   behavioural	   effect,	   but	   does	   not	  
counteract	   the	   reduction	   of	   brain	   Mg-­‐
concentration	   resulting	   from	   swim	   stress.	  
Therefore,	  increased	  sympathetic	  nervous	  system	  
(SNS)	   activity	   could	   lead	   to	   increased	   Mg	  
excretion.	   This	   suggests	   that	   stressful	   activities	  
result	   in	   lowered	   Mg	   content	   of	   the	   CNS	   and	  
potentially	  and	  increased	  risk	  of	  depression.	  	  
	  
Similarly,	   thyroid	   function	   is	   related	   to	   Mg	  
regulation.	   In	   135	   non-­‐medicated	   patients	   with	  
mild	   to	   moderate	   major	   depressive	   disorder,	   a	  
significant	  correlation	  between	  mean	  serum	  Mg2+	  
levels	   and	  mean	   circulating	   T4	   thyroid	   level	   was	  
observed.	   There	   was	   no	   significant	   correlation	  
between	   any	   other	   thyroid	   indices	   and	   either	  
serum	  Mg2+	   or	   Ca2+.	  The	   thyroid	  axis	   is	  known	  to	  
regulate	  Mg	  metabolism	  possibly	  by	  regulation	  of	  
transport	   of	   Mg2+	   from	   extracellular	   to	   intra-­‐
cellular	   fluid	   compartments.	   For	   T4,	   and	   to	   a	  
lesser	   extent	   serum	  Mg2+,	   the	   most	   consistent	  
changes	   were	   observed	   with	   response	   to	   anti-­‐
depressant	  treatment	  (Joffe	  et	  al.,	  1996).	  
	  
Changes	  of	  serum	  magnesium	  in	  major	  
depression	  
	  
Our	   following	   review	   of	   serum	   Mg	   and	  
depression	   shows	   greatly	   conflicting	   results,	  
perhaps	   because	   99%	  of	  Mg	   is	   intracellular	  with	  
only	   1%	   being	   found	   in	   serum	   (Mann	   and	  
Truswell,	   2002),	   and	   perhaps	   because	   some	   of	  
the	   work	   used	   magnesium	   oxide,	   which	   is	   not	  
bioavailable	   (Firoz	  and	  Graber,	  2001;	  Lindberg	  et	  
al.,	  1990;	  Walker	  et	  al.,	  2003;	  Enya	  et	  al.,	  2004).	  
	  
In	   patients	   with	   low	   serum	   Mg,	   depressive	  
symptoms	   have	   been	   observed	   (Hashizume	   and	  
Mori,	   1990).	   Deficits	   of	   Mg	   may	   result	   from	  
inadequate	  intake,	  malabsorption,	  or	  renal	  loss	  of	  
Mg	   that	   occurs	   in	   certain	   disease	   states	   such	   as	  
alcoholism	   and	   diabetes,	   and	   with	   certain	   drug	  
therapies	   (antidiuretics,	   aminoglycosides,	   fluoro-­‐
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quinolones,	   cisplatin,	   digoxin,	   cyclosporin,	  
amphotericin	   B)	   (Morris,	   1992).	   Resulting	   Mg-­‐
deficiencies	   may	   lead	   to	   depressive	   symptoms	  
which	   are	   secondary	   to	   an	   underlying	   somatic	  
disease,	   like	   diabetes	   mellitus	   (Barragan-­‐
Rodriguez	  et	  al.,	  2007).	  In	  depressed	  patients,	  an	  
early	   study	   reported	   a	   decrease	   in	   total	   plasma	  
Mg,	   but	   not	   in	   ionized	   Mg,	   with	   an	   increase	   in	  
total	   Mg	   occurring	   after	   treatment	   with	  
electroconvulsive	  therapy	  or	  tryptophan	  (Frizel	  et	  
al.,	   1969).	   Higher	   serum	   (Bjorum,	   1972)	   and	  
plasma	  Mg	  levels	  have	  been	  reported	  in	  patients	  
with	   recurrent	   depression	   independent	   from	  
their	   actual	   state,	   i.e.	   as	   a	   trait	   marker	   (Cade,	  
1964;	  Widmer	  et	  al.,	  1992).	  Widmer	  stressed	  the	  
importance	   of	   gender	   and	   clinical	   subtypes	   of	  
depressive	   disorder.	   They	   also	   reported	   an	  
association	  between	   increases	   in	  plasma	  Mg	  and	  
severity	   of	   depression	   and	   of	   plasma	   cortisol	  
(Widmer	   et	   al.,	   1995).	   Another	   group	   reported	  
that	   depressive	   symptoms	   were	   positively	  
correlated	   with	   serum	   Mg	   in	   longstanding	  
depression	   and	   remission,	   but	   not	   in	   acute	  
depression	   (Linder	   et	   al.,	   1989).	   A	   further	   study	  
shows	  the	  same	  relation	  in	  patients	  with	  unipolar	  
depression	   (Hasey	  et	  al.,	  1993).	   In	  other	   studies,	  
this	  finding	  could	  not	  be	  confirmed	  (Naylor	  et	  al.,	  
1972;	   George	   et	   al.,	   1994).	   A	   further	   study	  
compared	   serum	  Mg	   and	   serum	   Ca/Mg	   ratio	   of	  
145	  drug	   free	  patients	  with	  MD.	  They	  compared	  
MD	  patients	   to	  a	  group	  of	  non-­‐mood	  disordered	  
patients	  without	   finding	   any	   difference	   between	  
groups	   (Young	  et	  al.,	   1996).	   In	   another	   study	  no	  
changes	   in	   absolute	   values	   of	   plasma	   Mg	  
concentration	  could	  be	  observed	  in	  patients	  with	  
a	   variety	   of	   psychiatric	   disorders.	   An	   association	  
between	   the	   amount	   of	  Mg	   plasma	   disturbance	  
(either	  higher	  or	  lower	  than	  normal)	  and	  severity	  
of	   clinical	   disturbance	   was	   shown	   (Kirov	   et	   al.,	  
1994).	   Research	   subjects,	   who	   did	   not	   meet	  
criteria	  of	   any	   specific	  psychiatric	  disorder,	  were	  
studied	   to	   explore	   their	   experiences	   with	  
depression,	  anxiety	  and	   stress	   in	   relation	   to	  Mg-­‐
levels.	   Subjects	   were	   not	   differentiated	   on	   the	  
basis	  of	  high	  vs	  low	  Ca/Mg	  ratios,	  but	  on	  the	  basis	  
of	  Mg	  tertiles.	  The	  group	  in	  the	  middle	  tertile	  had	  
the	   lowest	   levels	   of	   depression	   and	   stress	   in	  
comparison	   to	   upper	   and	   lower	   tertiles	   (Jung	   et	  
al.,	   2010).	   A	   more	   recent	   study	   found	   a	  
decreased	   serum	   Mg	   concentration	   in	   patients	  
with	   more	   severe	   depression	   (Hamilton	  
depression	   score	   >	   23),	   whereas	   no	   change	  was	  
observed	   for	   less	   severely	   affected	   subjects	  
(Nechifor,	   2009).	   The	   studies	   of	   Kirov	   et	   al.,	  
(1994)	  and	   Jung	  et	  al.,	   (2010)	   could	  point	   to	   the	  
fact	   that	   closer	   specification	   of	   depressive	  
disorders	   may	   be	   required.	   Gender	   differences	  
(with	   lower	   concentrations	   in	   women)	   exist	   in	  
plasma	   Mg	   concentrations	   in	   patients	   with	  
depression	   (Herzberg	   and	   Herzeberg,	   1977;	  
Herzberg	   and	   Bold,	   1972;	   George	   et	   al.,	   1994),	  
possibly	  contributing	  to	  the	  variability	  seen	  in	  the	  
mentioned	   studies.	   Furthermore,	   it	   appears	   that	  
medication	   should	   be	   controlled,	   as	   anti-­‐
depressant	   compounds	   have	   been	   reported	   to	  
influence	   Mg	   metabolism,	   as	   measured	   as	  
changes	   in	   erythrocyte	  Mg	   concentration	   in	   the	  
course	   of	   antidepressant	   treatment	   (Nechifor,	  
2009).	   It	   is	  unclear	   if	   this	   is	  a	  direct	  effect	  of	  the	  
compounds	   (sertraline	   and	   amitriptyline)	   or	   an	  
indirect	   effect	   of	   clinical	   improvement	   of	  
subjects.	  	  
	  
In	   patients	   with	   depression,	   an	   increase	   in	  
aldosterone	   concentration	   has	   been	   observed	  
(Murck	   et	   al.,	   2002a).	   Under	   physiologic	  
conditions	   an	   increase	   in	   aldosterone	  
concentration	   should	   lead	   to	   an	   increased	  
excretion	  of	  Mg	  .	  Reports	  of	  an	  increase	  in	  serum	  
Mg	   points	   to	   a	   disturbance	   in	   Mg	   regulation	   in	  
these	   patients,	   which	  may	   also	   involve	   a	   higher	  
grade	  of	  Mg	  mobilization	  from	  intracellular	  pools.	  
On	   the	   other	   hand	   a	   decreased	   sensitivity	   of	  
mineralocorticoid	   receptors	   (MR),	   which	   are	   the	  
primary	   responsible	   receptor	   for	   aldosterone	  
regulation	  in	  the	  kidney,	  has	  been	  reported.	  This	  
points	  to	  a	  potentially	  complex	  Mg	  dysregulation.	  
It	   would	   be	   of	   importance	   to	   determine	   the	  
relationship	   between	   Mg	   and	   aldosterone	  
concentration	  in	  order	  to	  clarify	  this	  issue.	  	  
	  
In	   contrast	   to	   peripheral	   changes	   in	   plasma	   or	  
serum,	   changes	   within	   the	   CNS	   point	   to	   a	   brain	  
Mg	  deficiency.	  In	  subjects	  with	  MD,	  a	  decrease	  in	  
CSF	  Mg	  concentration	  has	  been	  confirmed	  (Banki	  
et	   al.,	   1986;	   Banki	   et	   al.,	   1985).	   A	   more	   recent	  
study	  found	  an	  increase	  in	  the	  Ca/Mg	  ratio	  of	  CSF	  
in	  patients	  with	  depression	   (Levine	  et	  al.,	   1999).	  
Most	   recently,	   post-­‐mortem	   studies	   in	   patients	  
that	   had	   depression	   showed	   a	   reduced	   Mg	  
concentration	  in	  brain	  tissue	  (Nowak	  et	  al.,	  2010).	  
Human	   brain	   Mg	   measurements	   by	   phosphorus	  
nuclear	  magnetic	   resonance	  spectroscopy	   (NMR)	  
have	  demonstrated	  a	   reduced	  Mg	   concentration	  
in	   depressed	   patients	   who	   were	   refractory	   to	  
treatment	   with	   an	   SSRI	   (Iosifescu	   et	   al.,	   2005).	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This	   method	   provides	   the	   best	   means	   to	  
determine	  Mg	  concentrations	  in	  specific	  anatomical	  
areas	  in	  living	  brains.	  
	  
Functional	  impact	  of	  magnesium	  
	  
An	   examination	   of	   the	   role	   of	   Mg	   in	   neurons	  
provides	  some	  insight	  into	  the	  cause	  and	  possible	  
treatment	  of	  MD.	  Weston	   in	  1921	   reported	   that	  
Meltzer	   and	   Auer	   first	   showed	   in	   1905	   that	   the	  
primary	  effect	  of	  Mg	  treatment	  upon	  nerve	  cells	  
was	   that	   of	   paralysis	   without	   any	   preceding	  
excitation,	  and	  the	  effect	  seemed	  to	  be	  exclusively	  
of	  an	  inhibitory	  character	  (Weston,	  1921-­‐1922).	  
	  
Monoaminergic	  systems	  and	  magnesium	  
	  
The	   locus	   coeruleus	   (LC)	   is	   the	   principal	  
anatomical	   structure	   of	   the	   noradrenergic	  
system.	   Its	   activity	   is	   related	   to	   that	   of	   the	   SNS,	  
and	   it	   shows	   overactivity	   in	   melancholic	  
depression.	   Magnesium	   infusion	   led	   to	   an	  
increase	   in	   circulating	   noradrenaline	   (NA)	   in	  
humans	   in	   one	   study	   (Leppert	   et	   al.,	   1994),	  
whereas	   no	   changes	   in	   catecholamines	   were	  
reported	   in	   another	   (Zofkova	   et	   al.,	   1993).	  
Magnesium	   deficiency	   on	   the	   other	   hand	  
increased	   plasma	   catecholamines	   in	   response	   to	  
noise	   stress	   in	   rats	   (Caddell	   et	   al.,	   1986).	   Mice	  
selectively	  bred	  for	  low	  blood	  Mg	  levels	  showed	  a	  
significantly	   higher	   brain	   NA	   content	   without	   a	  
change	   in	   dopamine,	   HVA,	   and	   serotonin	  
compared	   to	   those	  with	  high	  Mg	   levels	   (Amyard	  
et	   al.,	   1995).	   This	   was	   interpreted	   as	   a	   higher	  
sensitivity	   to	   stress	   in	   mice	   with	   low	   blood	   Mg	  
content.	  A	  suppressive	  effect	  of	  Mg	  on	  LC	  activity	  
has	   been	   demonstrated	   (Shiekhattar	   and	   Aston-­‐
Jones,	   1992)	   and	   interpreted	   as	   an	   NMDA	  
antagonistic	   mechanism.	   Magnesium	   deficiency	  
reduced	   behavioural	   activity	   from	   dopaminergic	  
activation	   by	   amphetamine	   and	   apomorphine	  
(Kantak,	  1988).	  The	  antidepressant-­‐like	  effects	  of	  
Mg	   are	   dependent	   on	   its	   interaction	   with	  
serotonergic,	   noradrenergic	   and	   dopaminergic	  
receptors	  (Cardoso	  et	  al.,	  2009).	  
	  
Glutamatergic	  system	  and	  magnesium	  	  
	  
Magnesium	   depletion	   is	   specifically	   deleterious	  
to	   neurons	   by	   causing	   NMDA-­‐coupled	   calcium	  
channels	  to	  be	  biased	  towards	  opening	  (Sapolsky,	  
1992).	   At	   normal	   neuronal	   resting	   membrane	  
potentials,	   pores	   of	   the	   NMDA	   glutamate-­‐gated	  
ion	  channels	  are	  blocked	  by	  Mg2+	  ions	  (Bear	  et	  al.,	  
2001;	   Mark	   et	   al.,	   2001;	   Kandel	   et	   al.,	   1995;	  
McMenimen,	   2006).	   The	   ion	   channel	   of	   the	  
NMDA	   receptor	   complex	   is	   subject	   to	   voltage-­‐
dependent	   regulation	   by	  Mg2+	   ions	   (Mark	   et	   al.,	  
2001;	   Alberts	   et	   al.,	   2002;	   Decollogne	   et	   al.,	  
1997).	   Importantly,	   different	   types	   of	   NMDA	  
receptors	  exist,	  on	  the	  basis	  of	  their	  constitution	  
subunits.	   Besides	   NR1	   subunits,	   which	   are	  
constitutional	   for	   all	   subtypes,	   NR2	   elements	  
define	   their	   diversity.	   NR2	   exists	   in	   flavours	   of	  
NR2A,	   NR2B,	   NR2C	   and	   NR2D.	   Of	   particular	  
interest,	   NMDA	   receptors	   which	   contain	   NR2A	  
and	   NR2B	   receptors,	   are	   more	   sensitive	   to	  
voltage	  sensitive	  Mg	  block	  (Kuner	  and	  Schoepfer,	  
1996).	   This	   direct	   interaction	   of	   Mg	   with	   the	  
NMDA	   receptor	   intracellular	   mechanism	  
influences	   its	   activity.	   In	   hippocampal	  
synaptosomes,	   the	   Mg	   block	   of	   the	   NMDA	  
dependent	   ion	   channel	   is	   removed	  by	   activation	  
of	   protein	   kinase	   C	   (PKC)	   without	   changing	  
membrane	   potential	   (Pittaluga	   et	   al.,	   2000).	  
Intracellular	   administration	   of	   a	   PKC	   agonist	  
accordingly	  potentiated	  NMDA	  receptor	   function	  
in	   cultured	   hippocampal	   neurons	   (Xiong	   et	   al.,	  
1998).	  This	  could	  lead	  to	  a	  feed-­‐forward	  cycle;	  an	  
NMDA	  dependent	  Ca2+	  current	  may	  increase	  PKC	  
activity	  leading	  to	  further	  release	  of	  the	  Mg-­‐block	  
of	  the	  NMDA	  dependent	  ion-­‐current.	  Mg	  also	  has	  
a	   direct	   influence	   on	   PKC	   function.	   The	   catalytic	  
subunit	  of	  PKC	  requires	  Mg	  as	  a	  cofactor	  (Hannun	  
and	   Bell,	   1990),	   and	   deactivation	   of	   PKC	   by	  
adenosine	   triphosphate	   (ATP)	   depends	   on	   the	  
presence	   of	   Mg	   (Wolf	   et	   al.,	   1985).	   Besides	  
influencing	   NMDAergic	   neurotransmission,	   Mg	  
depletion	   affects	   hippocampal	   excitability	   via	  
non-­‐NMDAergic	   Ca	   currents,	   which	   can	   also	   be	  
suppressed	   by	   verapamil,	   a	   Ca-­‐channel	   blocker	  
(Pohl	   et	   al.,	   1992;	   Walden	   et	   al.,	   1992).	   These	  
findings,	   when	   put	   together,	   illustrate	   several	  
possible	  mechanisms	  for	  Mg	  to	   limit	  the	  kindling	  
state	  via	  modulation	  of	  different	  elements	  of	  the	  
Ca–PKC-­‐second	  messenger	  system.	  	  
	  
Normally	   operating	   NMDA	   receptors	   admit	   into	  
neurons	   only	   the	   amount	   of	   Ca2+	   that	   is	   vital	   to	  
their	  function,	  but	  abnormally	  functioning	  NMDA	  
receptors	  (due	  to	  inadequate	  Mg)	  increase	  influx	  
of	  cellular	  Ca2+	  beyond	  manageable	  levels	  leading	  
to	  the	  generation	  of	  toxic	  reactive	  oxygen	  species	  
and	  of	  toxic	  amounts	  of	  nitric	  oxide	  (NO)	  radicals	  
(Blaylock,	  1999;	  Mark,	  2001;	  Carafoli,	  2005).	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Stress	  hormone	  systems	  (HPA	  and	  RAAS)	  and	  
magnesium	  	  
	  
Acute	   intravenous	   Mg	   administration	   decreased	  
adrenocorticotrophic	   hormone	   (ACTH)	   secretion	  
in	  healthy	  subjects	  (Murck	  and	  Steiger,	  1998),	  but	  
did	   not	   lead	   to	   a	   change	   in	   cortisol	   secretion	  
(Zofkova	   et	   al.,	   1993;	  Murck	   and	   Steiger,	   1998).	  
Subchronic	   oral	   administration	   of	  Mg	   in	   healthy	  
elderly	   subjects	   led	   to	   a	   decrease	   in	   cortisol	  
concentration	  without	  a	  change	  in	  ACTH	  (Held	  et	  
al.,	   2002).	   Chronic	   oral	   administration	   of	   high-­‐
dose	   Mg	   leads	   to	   considerable	   reductions	   in	  
cortisol	   and	   lowered	   stress	   responsiveness.	  Both	  
effects	   are	   in	   line	   with	   a	   decrease	   in	   central	  
corticotropin-­‐releasing	   hormone	   release,	   but	  
differential	   effects	   occur	   at	   the	   level	   of	   the	  
adrenal	   cortex.	   The	   possibility	   of	   an	   NMDA	  
antagonistic	   effect	   of	  Mg	   has	   been	   discussed	   in	  
the	   context	   of	   hippocampal	   function.	   Both	  
systems	   also	   influence	   endocrine	   regulation	   and	  
hypo-­‐thalamic	  activity.	  	  
	  
Inflammatory	  system	  and	  magnesium	  	  
	  
Magnesium	   depletion	   has	   been	   studied	   for	   its	  
effects	   on	   inflammatory	   markers.	   Feeding	   rats	  
Mg-­‐depleted	  food	   led	  to	  a	  nearly	  3-­‐fold	   increase	  
in	  plasma	  	  IL-­‐6,	  a	  significant	  increase	  of	  fibrinogen	  
and	  other	  acute	  phase	  proteins	  and	  a	   significant	  
reduction	   in	   Zn	   (Malpuech-­‐Brugere	  et	   al.,	   2000).	  
Mg	   deficiency	   also	   amplifies	   endotoxin-­‐induced	  
lethality	   in	   rats,	   which	   was	   correlated	   with	  
increased	  TNFα	  production	  (Malpuech-­‐Brugere	  et	  
al.,	  1999).	   In	  rat	  models,	  Mg	  deficiency	   led	  to	  an	  
increase	  in	  thromboxane	  (TBX2)	  and	  prostaglandin	  
E2	  (PGE2)	  (Nigam	  et	  al.,	  1986;	  Soma	  et	  al.,	  1988).	  
For	   a	   review	   of	   the	   correlation	   between	   Mg	  
deficiency	  and	  inflammatory	  changes,	  see	  Nielsen	  
et	  al.,	   (2010).	  Of	  considerable	   importance	   is	   that	  
NMDA-­‐ergic	   mechanisms	   may	   activate	  
inflammatory	  mechanisms	  (Muller	  et	  al.,	  2009).	  	  
	  
Magnesium	  in	  animal	  and	  human	  research	  
	  
In	   the	   following	   sections	   we	   summarize	   data	  
concerning	   effects	   of	   Mg	   in	   animals	   and	  
preliminary	   findings	   in	   humans.	   One	   important	  
issue	  to	  keep	  in	  mind	  is	  the	  unresolved	  question:	  
Does	   Mg	   treat	   a	   Mg	   deficit	   or	   is	   Mg	   to	   be	  
regarded	   as	   a	   pharmacological	   agent,	   i.e.	  
independent	  of	  a	  pre-­‐existing	  deficit?	  We	  will	  not	  
be	   able	   to	   answer	   this	   question	   on	   the	   basis	   of	  
current	   data.	   Nevertheless,	   in	   the	   long	   run	   it	   is	  
important	   to	   identify	   specific	   characteristics	   of	  
subjects	   who	   may	   benefit	   from	   Mg	   treatment.	  
Most	   subjects	   having	   MD	   treatable	   with	  
magnesium	   also	   have,	   or	   have	   had,	   other	  
disorders	   that	   are	   also	   treatable	   with	   magnesium	  
(Eby,	  1999-­‐2010).	  
	  
The	   functional	   systems	   described	   above	   have	  
been	   recognized	   as	   potential	   pharmacological	  
targets	   for	   treatment	   of	   depression.	   All	   current	  
commercial	   antidepressants	   are	   based	   on	   the	  
hypothesis	   of	   a	  monoamine	  dysfunction.	  On	   the	  
other	   hand,	   NMDA	   receptor	   antagonists,	   and	   in	  
particular	   those	   for	   the	   NR2B	   subtype,	   have	  
demonstrated	   clinical	   efficacy	   (Berman	   et	   al.,	  
2000;	   Preskorn	   et	   al.,	   2008).	   The	   HPA	   axis	   has	  
long	   been	   recognized	   as	   a	   potential	   target	   for	  
antidepressants	   (Flores	   et	   al.,	   2006;	   Holsboer,	  
2000;	   Jahn	   et	   al.,	   2004).	   More	   recently,	   anti-­‐
inflammatory	   mechanisms	   like	   COX-­‐2	   inhibitors	  
(Muller	  et	  al.,	  2006)	  and	  TNFα-­‐antagonists	   (Uguz	  
et	   al.,	   2009)	   have	   been	   demonstrated.	   In	   the	  
following	   text	   we	   report	   behavioural	   effects	   by	  
Mg	   in	   animal	   models	   as	   well	   as	   human	   clinical	  
data.	  The	  specific	  mechanism	  of	  these	  effects	  by	  
Mg	  has	  yet	  to	  be	  elucidated.	  
	  
Animal	  Models	  and	  magnesium	  
	  
Animal	  models	  have	  provided	  insight	  into	  roles	  of	  
stress	  on	  Mg	  status,	  effects	  of	  Mg	  deficiency,	  and	  
effects	  of	  Mg	  treatment	  in	  depression.	  
	  
Mg	   is	   involved	   in	  behavioural	  control	   in	  rats.	  Mg	  
deficiency	   led	   to	   a	   reduction	   in	   offensive	  
behaviour	  and	  an	  increase	  in	  defensive	  behaviour	  
(Kantak,	   1988).	   Apomorphine-­‐	   and	   L-­‐
amphetamine	   mediated	   behaviour	   was	  
suppressed	  by	  Mg	  deficiency,	  suggesting	  that	  Mg	  
is	   an	   important	   factor	   for	   the	   stimulatory	   action	  
of	   catecholamines,	   possibly	   at	   the	   postsynaptic	  
site.	   In	  the	  forced	  swim	  test,	  a	  screening	  test	  for	  
possible	   antidepressive	   potency	   of	   substances,	  
Mg	   reduced	   immobility	   similar	   to	   the	   nor-­‐
adrenaline	   reuptake	   inhibitor	   imipramine	  
(Decollogne	   et	   al.,	   1997).	   Compared	   to	   control	  
mice	   fed	  a	  normal	  diet,	  mice	  receiving	  a	   low	  Mg	  
diet	  (10%	  of	  daily	  requirement)	  for	  several	  weeks	  
displayed	  increased	  immobility	  time	  in	  the	  forced	  
swim	   test,	   indicating	   enhanced	   depression-­‐like	  
behaviour.	   In	   addition,	   partial	   magnesium	  
depletion	   feeds	   increased	   anxiety-­‐related	  
Mg	  and	  major	  depression	   	   Chapter	  23	  
 
 320	  
behaviour	   in	   the	   light/dark	   and	   open	   field	   test,	  
while	   locomotor	  activity	  and	  motor	  coordination	  
was	  not	   influenced.	  Magnesium	  depletion	   led	   to	  
depression	   and	   anxiety-­‐related	   behaviour	   in	  
mice.	   These	   changes	   due	   to	  Mg	  deficiency	  were	  
prevented	  by	  coadministration	  of	  desipramine	  or	  
hypericum	   extract	   (Singewald	   et	   al.,	   2004).	   A	  
dependency	   of	   intracellular	  Mg	   and	   behavioural	  
regulation	  appears	  to	  exist.	  Mice	  selected	  for	  low	  
vs	  high	  erythrocyte	  Mg	  levels	  showed	  pronounced	  
neurobiological	  differences	  (Henrotte	  et	  al.,	  1997).	  
Low	  Mg	  mice	  showed	  a	  more	  restless	  behaviour,	  
a	   more	   aggressive	   behaviour	   under	   stressful	  
conditions	   and	   higher	   brain	   and	   urine	   NA	   levels	  
compared	  to	  mice	  with	  high	  erythrocyte	  Mg.	  It	  is	  
not	   clear	   if	   a	   correlation	   between	  
intraerythrocyte	   and	   intraneuronal	   Mg	  
concentration	  exists.	  	  
	  
Of	   importance	   is	   that	   Mg	   deficiency	   leads	   to	  
depression-­‐like	   changes	   and	   that	   Mg	  
administration	   has	   “therapeutic”	   effects	   on	  
depression-­‐like	   behaviour.	   Magnesium	   adminis-­‐
tration	   led	   to	   anxiolytic	   effects	   in	   the	   elevated	  
plus	  maze,	  and	  antidepressant	   like	  effects	   in	   the	  
forced	   swim	   test	   (Poleszak	   et	   al.,	   2004).	   In	  
stressed	   rats,	   Mg	   and	   imipramine	   acted	  
synergistically	  on	  immobility	  time	  as	  measured	  in	  
the	  forced	  swim	  test,	  i.e.	  non-­‐efficacious	  doses	  of	  
both	   compounds	   combined	   led	   to	   a	   positive	  
behavioural	  response	  (Poleszak	  et	  al.,	  2006).	  The	  
mechanism	   is	   complex	   and	   appears	   to	   involve	  
NMDAergic	   (Poleszak	   et	   al.,	   2008),	   GABAergic	  
(Poleszak,	   2008)	   and	   serotoninergic	   (Poleszak,	  
2007)	  modulation.	  
	  
Human	  studies	  and	  magnesium	  
	  
There	   are	   a	   number	   of	   open	   label	   studies	   on	  
therapeutic	   effects	   of	   Mg	   administration	   in	  
treating	   depression,	   depression-­‐like	   and	   anxiety	  
illnesses.	   As	   early	   as	   1921	   a	   report	   on	   the	  
therapeutic	   effect	   of	   Mg	   was	   published	   in	   the	  
first	   issue	   of	   the	   American	   Journal	   of	   Psychiatry	  
(and	   immediately	   forgotten).	   In	   220	   out	   of	   250	  
doses	  of	  magnesium	  sulphate	  (one	  or	  two	  cc	  of	  a	  
25	   or	   50	   percent	   solution)	   given	   hypodermically	  
to	   50	   patients	   having	   agitated	   depression,	   with	  
several	   having	   various	   other	   agitated	   states,	  
treatment	   caused	   patients	   to	   relax	   and	   sleep	  
from	  four	  to	  six	  hours	  resulting	   in	  a	  90%	  success	  
rate	  for	  Mg	  (Weston,	  1921-­‐22).	  The	  sedative	  side	  
effects	   from	   giving	   too	   much	   Mg	   were	   quickly	  
and	   easily	   reversed	  by	   giving	   similar	   amounts	   of	  
calcium	  chloride	  given	  hypodermically.	  
	  
Later	  studies	  showed	  a	  beneficial	  effect	  of	  Mg	  in	  
treatment	  of	  rapid	  cycling	  bipolar	  disorder	  in	  ten	  
patients	  (Chouinard	  et	  al.,	  1990)	  in	  an	  open	  label	  
study	   for	   periods	   up	   to	   32	   weeks.	   Magnesium	  
was	   found	   to	   produce	   clinical	   results	   at	   least	  
equivalent	  to	  those	  of	  lithium	  in	  50%	  of	  patients.	  
The	  possibility	   that	  Mg	  could	  replace	  or	   improve	  
efficacy	   of	   lithium	   without	   side	   effects	   as	   a	  
preventive	   treatment	  of	  manic-­‐depressive	   illness	  
was	  suggested.	  
	  
In	   tests	   of	   magnesium	   lactate	   and	   vitamin	   B6	  
(pyridoxine)	   in	   treatment	   of	   25	   patients	   with	  
anxiety-­‐depression	  and	  epilepsy,	  the	  combination	  
exerted	   positive	   non-­‐specific	   influences	   on	   the	  
patients’	   mental	   state,	   especially	   with	   regard	   to	  
affective	  disorders.	  Effects	  emerged	  on	  day	  14	  of	  
treatment	   and	   achieved	   a	   statistically	   significant	  
level	  by	  day	  28.	  Treatment	  was	  well	  tolerated	  and	  
did	  not	  cause	  any	  side	  effects	  (Kalim	  et	  al.,	  2004).	  	  
	  
Further	   support	   comes	   from	   improvement	   of	   a	  
subject	   with	   the	   rare	   hereditary	   disorder	   of	  
Gitelman's	   syndrome,	   which	   leads	   to	   a	   lack	   of	  
reabsorption	   of	   electrolytes	   including	   Mg.	  
Intravenous	   supplement	   of	  magnesium	   sulphate	  
(20	   mEq/day	   dissolved	   in	   100	   ml	   normal	   saline	  
given	   over	   2	   hours	   each	   day	   for	   3	   days)	  
immediately	   terminated	   both	   depression	   and	  
paraesthesia,	   suggesting	   that	   hypomagnesemia	  
played	   a	   role	   in	   clinical	   manifestations	   of	  
depression	   (Enya	   et	   al.,	   2004).	   Oral	   magnesium	  
oxide	   treatment	   was	   ineffective	   and	   promoted	  
diarrhoea.	  Magnesium	  oxide	  should	  not	  be	  given	  
in	   treatment	   of	   mental	   illnesses	   since	   it	   is	   not	  
bioavailable	   generally	   and	   it	   does	   not	   pass	   the	  
blood-­‐brain	  barrier.	  
	  
Mood	   stabilizing	   properties	   of	   Mg	   have	   been	  
demonstrated	   in	   case	   reports	   in	   patients	   with	  
mania	   (Pavlinac	   et	   al.,	   1979).	   In	   an	   open	   study	  
with	   intravenous	  magnesium	   sulphate	   used	   as	   a	  
supplementary	   therapy	   to	   lithium,	   benzo-­‐
diazepines,	   and	   neuroleptics	   in	   mania,	   marked	  
clinical	   improvement	   was	   observed	   in	   the	   10	  
patients	   included.	   This	   was	   accompanied	   with	   a	  
significant	   reduction	   in	   requirement	   for	  
neuroleptic	   and	   benzodiazepine	   (Heiden	   et	   al.,	  
1999).	  In	  a	  further	  open	  trial	  in	  mania,	  the	  effect	  
of	   a	   Mg–verapamil	   combination	   was	   compared	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with	   that	   of	   verapamil	   alone,	   and	   the	  
combination	   was	   superior	   for	   manic	   symptoms	  
(Giannini	  et	  al.,	  2000).	  	  
	  
Four	  case	  histories	  were	  presented	  showing	  rapid	  
recovery	   (less	   than	   7	   days)	   from	  MD	   using	   125-­‐
300	   mg	   of	   magnesium	   (as	   glycinate	   and	  
taurinate)	   with	   each	   meal	   and	   at	   bedtime	   (Eby	  
and	   Eby,	   2006).	   Related	   and	   accompanying	  
mental	   illnesses	   in	   these	   case	   histories,	   which	  
were	   also	   benefited,	   included	   traumatic	   brain	  
injury,	   headache,	   suicidal	   ideation,	   anxiety,	  
irritability,	   insomnia,	   cocaine,	   alcohol	   and	  
tobacco	  abuse,	  hypersensitivity	  to	  calcium,	  short-­‐
term	   memory	   loss	   and	   IQ	   loss.	   Post	   partum	  
depression	   (PPD)	   appeared	   prevented	   in	   several	  
case	  histories	  with	  Mg,	  wherein	  the	  patients	  had	  
previously	   had	   severe	   PPD	   without	   Mg.	   The	  
possibility	  that	  magnesium	  deficiency	  is	  the	  main	  
cause	   of	   most	   MD	   and	   related	   mental	   health	  
problems,	   including	   IQ	   loss	   and	   addiction,	   was	  
described	   as	   enormously	   important	   to	   public	  
health	   and	   was	   recommended	   for	   immediate	  
further	   study	   (Eby	   and	   Eby,	   2006).	   Magnesium	  
was	  usually	  claimed	  as	  effective	  for	  treatment	  of	  
depression	   in	   general	   use,	   by	   depressives	   who	  
had	   read	   “Depression	   Treatment:	   A	   Cure	   for	  
Depression	   using	   Magnesium?”	   on	   the	   Internet	  
(Eby,	  1999-­‐2010).	  
	  
To	   date	   only	   one	   randomized,	   double	   blind,	  
controlled	   trial	   exists	   concerning	   effects	   of	   Mg	  
administration	   on	   MD.	   Magnesium	   chloride	  
(MgCl2)	  was	  evaluated	   in	  the	  treatment	  of	  newly	  
diagnosed	   depression.	   Twenty-­‐three	   elderly	  
patients	   with	   type	   2	   diabetes	   and	   hypo-­‐
magnesemia	   were	   enrolled	   and	   randomly	  
allocated	  to	  receive	  orally	  either	  50	  mL	  of	  a	  MgCl2	  
5%	   solution	   (equivalent	   to	   450	  mg	   of	   elemental	  
Mg)	  or	  50	  mg	  imipramine	  daily	  during	  12	  weeks.	  
Widowhood	   or	   divorce	   in	   the	   previous	   six	  
months,	  alcoholism,	  degenerative	  illnesses	  of	  the	  
nervous	   central	   system,	   previous	   or	   current	  
treatment	   with	   antidepressants,	   chronic	  
diarrhoea,	   use	   of	   diuretics,	   and	   reduced	   renal	  
function	  were	  exclusion	  criteria.	  At	  the	  end	  of	  the	  
treatment	   period,	   depression	   scores	   were	  
identical	  between	  groups.	  Serum	  Mg	  levels	  were	  
significantly	   higher	   in	   subjects	   receiving	   MgCl2	  
than	  in	  subjects	  receiving	  imipramine	  (p	  =	  0.0005)	  
(Barragán-­‐Rodríguez	  et	  al.,	  2008).	  Several	  studies	  
in	   indications	  that	   involve	  depressed	  mood	  exist.	  
In	   a	   double-­‐blind,	   placebo-­‐controlled	   trial	   in	  
chronic	   fatigue	   syndrome,	   a	   disorder	   related	   to	  
atypical	   depression,	   weekly	   intramuscular	  
injections	   of	   2ml	   magnesium	   sulphate	   (50%)	   or	  
placebo	   for	   6	   weeks	   showed	   significant	  
superiority	  of	  Mg	  over	  placebo	  on	  energy	   levels,	  
pain,	   and	   emotional	   reactions	   as	   measured	   by	  
the	   Nottingham	   health	   profile	   score	   (Cox	   et	   al.,	  
1991).	  	  
	  
In	   another	   placebo	   controlled	   study	   of	  
premenstrual	   syndrome,	   which	   has	   depressive	  
elements,	   effects	   of	   oral	  Mg	   for	   the	   duration	   of	  
two	   menstrual	   cycles	   was	   observed	   (Facchinetti	  
et	   al.,	   1991).	   The	   medication	   consisted	   of	   3	   x	  
360mg	   Mg	   in	   the	   form	   of	   Mg–pyrrolidone	  
carboxylic	  acid.	   It	  was	  administered	   from	  day	  15	  
of	  the	  menstrual	  cycle	  to	  onset	  of	  menstrual	  flow.	  
Mg	  showed	  a	  significant	  superiority	  to	  placebo	  in	  
the	   total	   score	   of	   the	   Menstrual	   Distress	  
Questionnaire	   score	   and	   especially	   the	   cluster	  
“negative	   affect”.	   In	   the	   same	   indication,	  
combination	  of	  200mg	  Mg	  and	  50mg	  vitamin	  B6,	  
but	  not	  individual	  treatments	  alone,	  administered	  
daily	  for	  the	  duration	  of	  one	  menstrual	  cycle	  in	  a	  
Latin	   square	   design	   was	   superior	   compared	   to	  
placebo	   on	   premenstrual	   symptoms	   such	   as	  
nervous	   tension,	   mood	   swings,	   irritability	   and	  
anxiety	   (De	   Souza	   et	   al.,	   2000).	   Another	   study	  
using	   a	   crossover	   design	   found	   only	   an	  
improvement	   in	   symptoms	   related	   to	   fluid	  
retention	  in	  women	  taking	  200mg	  Mg	  or	  placebo	  
in	   the	   second	   menstrual	   cycle	   (Walker	   et	   al.,	  
1998).	  	  
	  
Adverse	  effect	  of	  calcium	  in	  depression	  	  
	  
Decreases	   in	   CSF	   calcium	   accompanied	   mood	  
elevation	   and	   motor	   activation	   in	   depressed	  
patients.	   Similarly,	   decreases	   in	   CSF	   calcium	  
occurred	   during	   acute	   psychotic	   agitation	   or	  
mania.	   Periodic	   recurrences	   of	   such	   agitated	  
states	   were	   accompanied	   at	   their	   onset	   by	  
transient	   increases	   in	   serum	   calcium	   and	  
phosphorus.	  Several	  observations	  suggested	  that	  
such	   serum	   ion	   shifts	   triggered	   the	   more	  
enduring	  and	  opposite	  shifts	   in	  CSF	  calcium	  and,	  
in	   turn,	  manic	   behaviour.	   Progressive	   restriction	  
of	   dietary	   calcium	   was	   earlier	   reported	   to	  
mitigate	  and	  finally	  abolish	  both	  rhythmic	  rises	  in	  
serum	  calcium	  and	  periodic	  agitated	  episodes.	  A	  
modest	   oral	   calcium	   lactate	   supplement	  
(approximately	   one	   additional	   U.S.	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agitation	   and	   worsened	   depression.	   In	   manic	  
patients,	   symptomatology	   grew	   significantly	   and	  
substantially	   worse	   during	   2	   to	   6	   weeks	   of	   oral	  
vitamin	  D	  administration.	  
	  
On	  the	  other	  hand,	   in	  12	  patients,	  subcutaneous	  
injections	   of	   synthetic	   salmon	   calcitonin	  
decreased	   serum	   calcium	   and	   phosphorus,	  
increased	   cerebrospinal	   fluid	   calcium,	   and	  
augmented	   depressive	   symptomatology.	   Salmon	  
calcitonin,	  which	  lowers	  blood	  calcium	  levels,	  also	  
decreased	   quantified	   motor	   activity,	   frequency	  
and	  severity	  of	  periodic	  agitated	  episodes,	  serum	  
creatine	   phosphokinase	   and	   prolactin,	   and	  
nocturnal	   sleep,	   while	   vitamin	   D	   or	   calcium	  
lactate	  raised	  them	  (Carman	  and	  Wyatt,	  1979).	  A	  
dietary	   supplement	   of	   500mg	   calcium	  
immediately	   and	   severely	   worsened	   MD,	   which	  
was	   extinguishable	   within	   one	   hour	   by	   orally	  
treating	   with	   400mg	   gel	   capsules	   of	   Mg	   as	  
magnesium	  glycinate	  (Eby	  and	  Eby,	  2006).	  	  
	  
In	  a	  study	  of	  electrolytes	  in	  CSF	  from	  depressives,	  
a	  positive	  correlation	  was	  found	  between	  calcium	  
concentration	   and	   symptom	   severity	   in	  
hospitalized	   depressed	   patients.	   CSF	   calcium	  
levels	   tended	   to	   decrease	   as	   patients	   improved.	  
In	  rapidly	  cycling	  patients,	  CSF	  calcium	  was	  higher	  
during	   depression	   than	   during	   mania	   (Jimersom	  
et	  al.,	  1979).	  	  
	  
Major	   depression	  was	   found	   to	  be	   accompanied	  
by	  hyperactivity	  of	   subcellular	   calcium	  signalling,	  
and	  any	  means	  of	  reducing	  pathological	  neuronal	  
calcium	   ion	   flow	   to	   reduce	   pathological	   nitric	  
oxide/NMDA	   neuronal	   output	   would	   have	  
antidepressant	   effects	   (Paul,	   2001).	  
Hypercalcemia	   from	   excessive	   vitamin	   D	   intake,	  
hyperparathyroidism	   or	   other	   causes	   has	   been	  
suggested	   to	   lead	   to	   clinical	   depression	   by	  
lowering	  brain	  Mg	  (Keddie,	  1987).	  	  
	  
Biomarkers	  of	  magnesium	  and	  magnesium-­‐
related	  functions	  	  
	  
Although	   there	   is	   considerable	   interest	   in	  
understanding	  roles	  of	  Mg	  in	  brain	  chemistry	  and	  
explanation	   of	   its	   role	   there,	   we	   found	   little	  
consensus	  as	  to	  the	  value	  of	  Mg	  measurements	  in	  
blood	   (serum,	  plasma	  or	   cellular)	  as	  a	  diagnostic	  
tool	   useful	   in	   treating	   depression.	   CSF	  
concentrations	   of	   Mg	   in	   depression	   were	   also	  
conflicted,	   although	   there	   appeared	   agreement	  
that	   CSF	   Mg2+	   values	   were	   low	   only	   in	   severe	  
depression	   associated	   with	   suicide	   attempts,	  
supporting	   the	   notion	   that	   Mg	   would	   be	   useful	  
specifically	   for	   TRD,	   which	   is	   often	   much	   more	  
severe	  than	  treatable	  depression.	  	  
	  
Since	  99%	  of	  Mg	  is	  intracellular,	  serum	  Mg	  testing	  
of	   the	   remaining	   1%	   in	   serum	   produces	  
misleading	   results	   (Mann	   and	   Truswell,	   2002).	  
Although	   serum	   values	   less	   than	   0.9	   mmol/Mg	  
demonstrate	   Mg	   deficiency	   in	   non-­‐depressives	  
(Liebscher	  and	  Liebscher,	  2004),	  it	  is	  often	  normal	  
or	   elevated	   in	   depression.	   Consequently,	   serum	  
tests	   are	   of	   negative	   utility	   due	   to	   their	  
misleading	   nature,	   and	   red	   blood	   cell	   tests	   are	  
also	   of	   questionable,	   perhaps	   negative,	   value.	  
Although	   various	   tests	   for	   Mg	   deficiency	   and	  
calcium	  excess	  appear	  desirable,	  the	  response	  to	  
Mg	   treatment	   with	   calcium	   reduction	   is	   always	  
the	  deciding	  criteria.	  
	  
Brain	   compartments	   of	   Mg	   are	   isolated	   from	  
blood	   and	   bone	   compartments	   requiring	  
different	   analytical	   means.	   Measuring	   brain	   Mg	  
can	   be	   safely	   accomplished	   in	   humans	   using	  
phosphorus	   NMR	   spectroscopy	   (Iosifescu	   et	   al.,	  
2008;	   Iotti	   and	  Maulcelli,	   2008).	   This	   test	   needs	  
to	   be	   validated	   by	   repeated	   trials	   as	   a	   reliable	  
means	  to	  determine	  low	  brain	  Mg	  in	  diagnosis	  of	  
low	  brain	  Mg	  as	  cause	  of	  MD.	  	  
	  
A	   health	   warning	   is	   therefore	   warranted	  
regarding	  potential	  misinterpretation	  of	  "normal"	  
serum	   Mg.	   In	   case	   of	   doubt,	   restoration	   of	   Mg	  
stores	   in	   deficient	   patients	   is	   simple,	   tolerable,	  
and	   inexpensive	   and	   can	   be	   clinically	   beneficial	  





Dietary	   fibres	   affect	   intestinal	   absorption	  of	  Mg.	  
Inulin,	   a	   prebiotic	   that	   supports	   bifidobacteria	  
and	   lactobacilli,	   has	   been	   confirmed	   to	   be	  
important	   in	   absorption	   of	   Mg	   in	   the	   large	  
intestines	   (Scholz-­‐Ahrens	   and	   Schrezenmeir,	  
2007;	   Rondón	   et	   al.,	   2008)	   nearly	   doubling	   Mg	  
absorption	   and	   reducing	   tendency	   to	   diarrhoea,	  
but	   increasing	  gas,	  while	   taking	  Mg.	   Large	  doses	  
of	   psyllium	   seed	   husks	   greatly	   reduced	  
absorption	  of	  Mg	   (Asvarujanon	  et	   al.,	   2004)	   and	  
gum	  arabic	  significantly	   increased	  both	   intestinal	  
and	  renal	  excretion	  of	  Mg	  (Nasir	  et	  al.,	  2008),	  and	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both	   should	   be	   avoided.	   Indole-­‐3-­‐carbinol	   (I3C)	  
(200	   mg/meal)	   was	   found	   in	   a	   case	   study	   to	  
greatly	   reduce	   the	   necessity	   for	   frequent	   Mg	  
treatment	   to	   prevent	   relapse	   (Eby	   and	   Eby,	  
2006).	  
	  
Useful	   Mg	   compounds	   are	   those	   that	   have	   a	  
sufficiently	   low	   first	   stability	   constant	   to	   be	  
bioavailable	   and	   include	   magnesium	   acetate,	  
chloride,	   citrate,	   gluconate,	   glycinate,	   lactate,	  
malate,	   oxalate,	   succinate,	   sulphate	   and	   tartrate	  
(Furia,	   1968).	   The	   bioavailability	   of	   magnesium	  
oxide	   is	   extremely	   limited,	   ranging	   from	   0	   -­‐	   4%	  
(Firoz	   and	   Graber,	   2001;	   Lindberg	   et	   al.,	   1990;	  
Walker	  et	  al.,	  2003;	  Enya	  et	  al.,	  2004).	  Studies	   in	  
which	   magnesium	   oxide	   is	   used	   produce	  
misleading	   results	   when	   compared	   with	   results	  
obtained	   using	   other	   compounds	   of	   Mg	   for	   the	  
same	  indication.	  	  
	  
Future	  clinical	  research	  
	  
We	   are	   concerned	   that	   there	   were	   only	   a	   few	  
clinical	   trials	  of	  Mg	  for	  human	  depression	  found.	  
We	   suggest	   that	   future	   trials	   be	   of	   larger	  
populations	   in	   formal,	   double	   blind,	   placebo-­‐
controlled	   clinical	   trials,	   or	   comparative	   trials	  
against	   a	   proven	   antidepressant	   such	   as	  
imipramine	   50	  mg	   daily.	   Only	  when	   evidence	   of	  
efficacy	   has	   become	   clearer	   are	   physicians	   likely	  
to	  adopt	  Mg	  for	  MD.	  	  
	  
From	  reports	  reviewed	  herein,	  we	  suggest	  that	  in	  
future	   clinical	   research	   in	   depression	   that	   the	  
initial	   treatment	   utilize	   iv	   drip	   magnesium	  
sulphate	  in	  the	  manner	  of	  Enya	  et	  al.,	  (2004),	  (20	  
mEq/day	  dissolved	  in	  100	  ml	  normal	  saline	  given	  
over	  2	  hours	  each	  day	   for	  3	  days),	   to	  provide	  an	  
expected	   rapid	   (<3	   days)	   initial	   induction	   of	  
remission.	  Treatment	  is	  to	  be	  followed	  by	  an	  oral	  
bioavailable	   Mg	   (125	   –	   300	   mg	   4	   t/d)	  
maintenance	  treatment	  in	  the	  manner	  of	  Eby	  and	  
Eby	   (2006)	   or	   Barragán-­‐Rodríguez	   (2008)	   using	  
bioavailable	   Mg	   compounds	   with	   emphasis	   on	  
magnesium	   glycinate	   and	   taurinate.	   Magnesium	  
oxide	   must	   not	   be	   used	   since	   it	   is	   non-­‐
bioavailable	   (Firoz	  and	  Graber,	  2001;	  Lindberg	  et	  
al.,	  1990;	  Walker	  et	  al.,	  2003;	  Enya	  et	  al.,	  2004).	  
During	   iv	   administration,	   cardiac	   monitoring	  
should	   be	   performed.	   Protocols	   for	   iv	  
administration	  of	  magnesium	  sulphate	  have	  been	  
widely	   used	   for	   treatment	   of	   eclampsia.	   The	  
antidote	   to	   magnesium	   overdose	   is	   calcium	  
gluconate	  or	  calcium	  chloride.	  Since	  99%	  of	  Mg	  is	  
intracellular,	   serum	  Mg	   testing	   of	   the	   remaining	  
1%	   found	   in	   serum	   will	   produce	   misleading	  
results	   (Mann	   and	   Truswell,	   2002)	   and	   it	   should	  
not	  be	  used	  in	  future	  research.	  	  
	  
Impediments	  to	  success	  and	  precautions	  	  
	  
We	   are	   concerned	   that	   there	   are	   some	  
impediments	  to	  proper	  absorption	  of	  Mg	  in	  large	  
therapeutic	   doses	   by	   the	   oral	   route	   with	  
intestinal	   issues,	   especially	   inflammatory	   bowel	  
disease	   (Galland,	   1988)	   and	   diarrhoea	   being	  
primary	  concerns.	  Large	  doses	  of	  oral	  Mg	  without	  
calcium	   may	   exponentially	   increase	   Candida	  
albicans	   intestinal	   growth	   (Holmes	   et	   al.,	   1991),	  
causing	   or	   worsening	   diarrhoea	   and	   impairing	  
absorption	   of	   Mg,	   while	   adding	   calcium	   may	  
greatly	   and	   immediately	   worsen	   depression.	  
Candida	   albicans	   overgrowth	   may	   be	   prevented	  
or	  treated	  naturally	  by	  greatly	  reducing	  intake	  of	  
sugars	  and	  treating	  with	  large	  amounts	  of	  Bacillus	  
Coagulans	   probiotic	   and	   biotin.	   We	   are	   very	  
concerned	   that	   magnesium	   oxide	   will	   be	   given	  
with	   failure	   to	   respond	  becoming	  highly	  evident,	  
thus	   damaging	   the	   reputation	   of	   Mg	   as	   an	  
effective	   treatment	   for	   depression.	   Do	   not	   give	  
magnesium	  oxide	   because	   it	   has	   been	   shown	   to	  
be	   not	   bioavailable.	   Additionally,	   magnesium	  
aspartate	   and	   magnesium	   glutamate	   have	  
neurotoxic	   ligands	   and	   they	  must	   be	   avoided	   to	  




Lack	   of	   definitive,	   large-­‐scale,	   double-­‐blind,	  
placebo-­‐controlled	   clinical	   trials	   is	   the	   limiting	  
factor	   for	  making	   strong	   treatment	   recommend-­‐
ations	  using	  Mg.	  Countering	  that	  point	  of	  view	  is	  
the	   good	   safety	   of	   Mg	   compared	   to	   side-­‐effect	  
prone	   antidepressant	   and	   anti-­‐anxiety	  
medications.	  
	  
From	  evidence	  reviewed	  here	  and	  from	  the	  2010	  
review	  by	  Eby	  and	  Eby,	  the	  relationship	  between	  
low	  Mg	  intake	  as	  a	  risk	  factor	  for	  MD	  appears	  to	  
have	   extremely	   important	   preventative	   and	  
treatment	   implications.	   A	   dietary	   supplement	   of	  
600	   to	   800	   mg/day	   Mg	   (other	   than	   magnesium	  
oxide)	  should	  be	  a	  universal	  prevention	  strategy.	  	  
	  
Mechanisms,	   which	   lead	   to	   CNS	   Mg	   depletion,	  
should	  be	  further	  studied	  in	  an	  effort	  to	  discover	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new	  targets	  and	  medication	  for	  MD.	  Evidence	  for	  
a	   Mg	   regulation	   effect	   of	   psychoptropic	   drugs	  
already	   exists,	   however	   the	   exact	   mechanism	   is	  
unclear.	   Reasonable	   candidates	   go	   beyond	  
monoaminergic	   mechanisms	   and	   may	   include	  
manipulation	   of	   the	   renin-­‐angiotensin-­‐
aldosterone	  system	  and,	  less	  studied,	  specific	  Mg	  
transport	   mechanisms.	   The	   best	   direct	  
measurement	  of	  brain	  Mg	  is	  by	  phosphorus	  NMR	  
spectroscopy,	   but	   this	  will	   probably	   be	   reserved	  
for	  research	  purposes.	  	  
	  
Although	   more	   research	   is	   clearly	   needed,	   we	  
suggest	   that	   it	   is	   past	   time	   to	   give	   Mg	   in	  
appropriate	   doses	   and	   to	   reduce	   intake	   of	  
calcium,	   glutamate	   and	   aspartate	   for	   the	  
prevention	  and	  treatment	  of	  MD,	  especially	  TRD,	  
and	   anxiety,	   since	   we	   can	   expect	   rapid	  
improvements	   in	   patient	   health	   and	   major	  
reductions	   in	   patient	   expenses	   without	   side	  
effects.	  We	  did	   not	   pay	   attention	   to	   those	   early	  
Mg	  and	  brain	  pioneers	  Meltzer	  and	  Auer	  in	  1905	  
and	   other	   magnesium	   researchers	   over	   the	   last	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Addiction	   to	   different	   substances	   is	   considered	   to	   be	   a	   psychiatric	   disorder.	   Magnesium	   reduces	   the	  
intensity	  of	  addiction	  to	  opiates	  and	  psychostimulants	  (cocaine,	  amphetamine,	  nicotine,	  and	  others).	   It	  
also	  decreases	  the	  auto-­‐administration	  of	  cocaine	  and	  the	  relapse	  into	  cocaine	  and	  amphetamine	  intake,	  
as	  well	  as	  reducing	  the	  experimental	  addiction	  to	  morphine,	  cocaine	  and	  other	  substances	  in	  animals.	  In	  
heroin	   addicts,	   alcohol	   consumers	   and	   other	   drug	   abusers,	   the	   plasma	   and	   intracellular	   magnesium	  
concentration	  is	  lower	  compared	  to	  healthy	  subjects.	  We	  consider	  that	  one	  of	  the	  mechanisms	  by	  which	  
magnesium	   reduces	   the	   consumption	   of	   some	   highly	   addictive	   substances	   is	   its	   moderate	   effect	   of	  
stimulating	   the	   reward	   system.	  However,	   other	  main	  mechanisms	   involved	   in	  magnesium’s	   action	   are	  
the	  reduction	  of	  dopamine	  and	  glutamate	  release	  at	  presynaptic	  terminals	  in	  the	  brain,	  the	  decrease	  of	  
NO	  synthase	  activity,	  the	  stimulation	  of	  GABAergic	  system	  activity,	  the	  reduction	  of	  postsynaptic	  NMDA	  
receptor	   activity,	   and	   the	   reduction	   of	   some	   neuromediators	   released	   by	   Ca2+	   and	   acting	   at	   calcium	  
channels.	   Apart	   from	   the	   action	   of	  magnesium	   ions	   during	   emerging	   addiction,	   administration	   of	   this	  
cation	   after	   the	   appearance	   of	   withdrawal	   syndrome	   reduces	   the	   intensity	   of	   the	   clinical	   symptoms.	  
There	   are	   data	   that	   show	   that	   stress	   increases	   the	   vulnerability	   of	   people	   to	   develop	   addiction	   to	  
different	   substances,	   and	   also	   reduces	  drug-­‐free	   time	  and	   increases	   the	   incidence	  of	   relapse	   in	   heroin	  
addicts.	  Stress	   increases	   catecholamine	   release	  and	  stimulates	  magnesium	  release	   from	  the	  body.	  This	  





Drug	   dependence	   is	   today	   considered	   a	   chronic	  
medical	   illness	  (Kosten,	  1998)	  producing	  significant	  
changes	   in	   the	   biochemistry	   and	   function	   of	   the	  
brain	   (McLellan	   et	   al.,	   2000).	   Koob	   and	   Le	  Moal	  
(2001)	   presented	   the	   neurobiology	   of	   addiction	  
from	   the	   perspective	   of	   allostasis,	   whereby	  
addiction	   is	   considered	   a	   cycle	   of	   progressively	  
increasing	   dysregulation	   of	   reward	   systems,	  
producing	   compulsive	  use	  of	  drugs	  with	   the	   loss	  
of	  control	  over	  drug-­‐taking.	  
	  
There	  is	  a	  large	  group	  of	  substances	  that	  result	  in	  
more	   or	   less	   intense	   addiction,	   which	   is	  
characterized	   by	   three	   major	   features:	  
compulsive	  use	   (intake),	  craving,	  and	  withdrawal	  
syndrome	   (when	  administration	   is	   stopped).	   The	  
number	   of	   substances	   for	   which	   a	   more	   or	   less	  
intense	   dependence	   was	   signalled	   is	   relatively	  
high	   and	   is	   growing	   continuously.	   These	   include	  
the	   opiates	   (morphine,	   heroin,	   etc.),	   the	  
psychodysleptics	  (LSD),	  alcohol,	  cannabinoids	  and	  
psychostimulants.	  
	  
The	  main	  brain	  structures	  involved	  in	  development	  
of	  drug	  dependence	  are	  the	  nucleus	  accumbens,	  
ventral	   tegmentum,	   the	   periductal	   grey	  
substance,	   the	   mesolimbic	   system,	   and	   the	  
nucleus	  coeruleus.	  Dysfunction	  in	  the	  mesolimbic	  
system,	   nucleus	   accumbens,	   prefrontal	   cortex,	  
and	   ventral	   tegmental	   area	   are	   considered	  
involved	   in	   the	   mechanism	   of	   drug	   abuse	  
disorders	  (Miguel-­‐	  Hidalgo,	  2009).	  	  
	  
The	  molecular	  mechanisms	   involved	   in	  addiction	  
are	   complicated	   but	   the	   main	   chemical	   neuro-­‐
mediators	   involved	   are	   dopamine,	   glutamate,	  
serotonin,	   endogenous	   opioid	   peptides,	   nitric	  
oxide	   (NO)	   and	   others.	   The	   glutamatergic,	  
dopaminergic	   and	   opioid	   mechanisms	   are	  
considered	   the	   most	   involved	   (Grass	   and	   Olive,	  
2007).	   These	   mechanisms	   not	   only	   involve	   the	  
neurons	   but	   also	   the	   neuroglia.	   There	   are	  many	  
factors	   that	   can	   influence	   the	   intensity	   of	  
addiction	   or	   withdrawal	   syndrome	   symptoms.	  
Amongst	  them	  are	  magnesium	  and	  other	  bivalent	  
cations	  (Ruiz	  Martinez	  et	  al.,	  1990).	  





Opiates	   are	   the	   cause	   of	   one	   of	   the	   most	  
powerful	   and	   frequent	   addictions,	   with	   heroin	  
intake,	  especially,	  resulting	  in	  unique	  medical	  and	  
social	   problems.	   There	   are	   data	   that	   show	   that	  
magnesium	   decreases	   the	   intensity	   of	   opioid	  
addiction,	  with	  administration	  of	  Mg	  acetate	  (0.5	  
mEq/kg/day)	   reducing	   the	   experimental	   physical	  
dependence	   (Nechifor	   et	   al.,	   2004b).	   The	  
intensity	   of	   symptoms	   in	   naloxone-­‐induced	  
withdrawal	   syndrome	   reduced,	   even	   when	  
magnesium	   administration	   was	   stopped	   during	  
the	   period	   of	   withdrawal	   syndrome.	  
Administration	  of	  Mg	  aspartate	  (732	  mg/day)	  for	  
12	   weeks	   in	   heroin-­‐addictive	   patients	   was	   also	  
beneficial	   (Daini	   et	   al.,	   2006;	   Karakiewicz	   et	   al.,	  
2007).	   Magnesium	   can	   potentially	   reduce	   the	  
intensity	   of	   addiction	   through	   a	   number	   of	  
mechanisms	  (Figure	  1),	  including:	  	  
- decreasing	   dopamine	   synthesis	   and	   pre-­‐
synaptic	  release	  in	  brain;	  
- decreasing	   the	   activity	   of	   glutamate	   NMDA	  
receptors;	  
- decreasing	  the	  activity	  of	  brain	  NOS	  and	  NO	  
synthesis;	  
- modulating	   the	   opioid	   coupling	   at	   brain	   µ	  
receptors;	  
- increasing	   glutamate	   metabolism	   (as	   the	  
main	   excitatory	   amino	   acid	   involved	   in	  
addiction)	   by	   enhancing	   glutamate	  
decarboxylase	  activity;	  
- increasing	   GABAergic	   activity	   in	   some	   brain	  
areas	   by	   increasing	   the	   vesicular	   GABA	  
transporter	  synthesis	  (Gerstein	  et	  al.,	  2005).	  	  
	  
Magnesium	   also	   potentiates	   the	   function	   of	  
GABAA	   receptors	   suggesting	   a	   putative	   Mg2+	  
binding	   site	   on	   the	   GABAA	   receptor	   protein	  
(Möykkynen	  et	  al.,	  2001).	  
	  
	  
Figure	  1.	   	  Mechanisms	  by	  which	  magnesium	  reduces	   the	   intensity	  of	  opiate	  addiction.	  –	  =	   inhibition;	  +	  =	  
stimulation;	  DA	  =	  dopamine;	  NOS	  =	  nitric	  oxide	  synthase.	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Dopamine	   is	   considered	   the	   most	   important	  
molecule	  in	  development	  of	  pharmacodependence.	  
Indeed,	   substances	   that	   result	   in	   pharmaco-­‐
dependence	   strongly	   increase	   the	   level	   of	  
dopamine	   in	   the	   midbrain.	   As	   an	   example,	  
morphine	  produces	  a	  dose-­‐dependent	  increase	  in	  
dopamine-­‐containing	   neurons	   in	   the	   substantia	  
nigra	  and	  ventral	  tegmentum	  in	  rat	  brain	  (Trulson	  
and	   Arasteh,	   1985).	   Magnesium	   can	   reduce	  
dopamine	   release	   in	   some	   brain	   structures	  
through	   direct	   presynaptic	   action	   at	   the	   level	   of	  
some	   dopaminergic	   synapses,	   by	   inhibiting	  
calcium	   induced	  brain	  dopamine	   release,	   and	  by	  
decreasing	   the	   stimulatory	   action	   of	   glutamate	  
upon	  dopamine	   release.	  Brain	  dopamine	   level	   in	  
mice	   is	   significantly	   increased	   following	   icv	  
administration	   of	   CaCl2.	   Magnesium,	   an	  
antagonist	   to	   calcium,	   inhibits	   the	   dopamine	  
release	  (Sutoo	  and	  Akiyama,	  2000).	  
	  
There	   are	  NMDA	   receptors	   at	   the	   level	   of	   some	  
dopaminergic	   nerve	   endings	   whose	   stimulation	  
also	  increases	  dopamine	  release.	  The	  reduction	  in	  
NMDA	   receptor	   stimulation	   by	   magnesium	   can	  
reduce	   dopamine	   release	   induced	   by	   the	  
addictive	   substance	   (Chéramy	   et	   al.,	   1994).	  
Extracellular	  Mg2+	  blocks	  NMDA	  ion	  channels	  in	  a	  
voltage	   dependent	   manner	   and	   increases	   the	  
receptor	  affinity	  for	  glycine	  (Paoletti	  et	  al.,	  1995).	  
Glycine	   inhibits	   the	   glutamate-­‐evoked	   release	   of	  
noradrenaline,	   and	   possibly	   other	   catecholamines	  
(Johnson	  et	  al.,	  1994).	  In	  this	  way,	  the	  facilitating	  
effect	   of	   magnesium	   on	   glycine	   linkage	   at	   its	  
binding	   sites	   could	   reduce	   the	   glutamate	  
stimulating	   effect	   of	   presynaptic	   catecholamine	  
release	  (dopamine	  release	  being	  an	  essential	  step	  
of	   addiction	   development).	   A	   selective	   inhibitor	  
of	   the	   glycine	   transporter	   (Gly	   T1)	   significantly	  
increased	   dopamine	   release	   (Bennett	   and	  
Gronier,	   2005).	   This	   fact	   indicates	   that	   glycine	  
reduces	  dopamine	  release,	  in	  this	  way	  decreasing	  
the	   intensity	   of	   addictive	   processes.	   Notably,	  
magnesium	   increases	   both	   glycine	   synthesis	   and	  
release.	  	  
	  
Vaupel	   et	   al.,	   (1995)	   showed	   that	   nitric	   oxide	  
synthase	   (NOS)	   inhibitors	   (L-­‐nitroarginine,	   L-­‐
nitroarginine	   methyl	   ester)	   reduce	   several	   signs	  
of	   opiate	   withdrawal	   (Kimes	   et	   al.,	   1993).	   This	  
fact	   supports	   the	   involvement	   of	   nitric	   oxide	   in	  
the	  pathogenic	  signs	  of	  withdrawal	  syndrome.	  	  
Mg2+	   also	   inhibits	   NOS	   and	   we	   consider	   that	   in	  
this	   way,	   it	   also	   reduces	   the	   intensity	   of	  
symptoms	  from	  withdrawal	  syndrome.	  
	  
Chronic	   morphine	   administration	   decreases	   the	  
NMDA	   receptor	   sensibility	   to	   Mg	   binding.	   The	  
glutamatergic	   systems	   provide	   important	  
regulation	  of	  dopamine	  function,	  while	  the	  GABA	  
system	   can	  modulate	   basal	   levels	   and	   stimulate	  
dopamine	   and	   glutamate	   release.	   The	   idea	   of	   a	  
major	   role	   of	   the	   glutamatergic	   system	   in	  
morphine	   addiction	   has	   also	   been	   proposed	  
(Sekiya	   et	   al.,	   2004)	   on	   the	   basis	   that	   icv	  
administration	   of	   DLBOA	   (a	   potent	   glutamate	  
transporter	   inhibitor)	   to	   morphine-­‐dependent	  
rats	   significantly	   facilitates	   the	   expression	   of	  
naloxone-­‐precipitated	   withdrawal.	   Mg	   action	   is	  
mainly	  due	  to	  its	  effects	  on	  neuronal	  activity,	  but	  
also	   impacts	   upon	   neuroglial	   activity.	   Glial	   cells	  
from	  the	  CNS	  play	  an	  important	  role	  in	  regulation	  
of	   glutamatergic	   transmission.	   Some	   substances	  
that	   give	   rise	   to	   addiction	   alter	   the	   functions	   of	  
astrocytes	  while	   others	   affect	   glial	   cell	   functions	  
(Miguel-­‐Hidalgo,	  2009).	  Astrocyte	   involvement	   in	  
the	   control	   of	   glutamate	   uptake	   and	   release	   is	  
important	  for	  the	  development	  of	  addiction.	  	  
	  
Substance	  P	  and	  its	  NK1	  receptors	  also	  play	  a	  role	  
in	  opiate	  addiction	  and	  in	  stress	  (Commons	  et	  al.,	  
2010).	   This	   neuropeptide	   modulates	   NMDA	  
receptor	   responses	   to	   glutamate	   stimulation	  
(Parker	   et	   al.,	   1998).	   Magnesium	   reduces	   the	  
synthesis	   and	   action	   of	   substance	   P	   and	   we	  
believe	   that	   in	   this	   way,	   it	   can	   decrease	   the	  
intensity	  of	  addiction.	  Stress	   induces	  magnesium	  
depletion	   and	   increases	   the	   vulnerability	   to	  
development	   of	   addiction	   or	   of	   relapse.	   We	  
consider	   that	   low	   magnesium	   levels	   play	   an	  




Psychostimulants	  are	  a	  group	  of	  substances	  with	  
various	   chemical	   structures	   and	   different	  
mechanisms	   of	   actions,	   partly	   common,	   partly	  
different,	   which	   results	   in	   a	   strong	   activation	  of	  
some	  CNS	  processes.	  All	  psychostimulants	  induce	  
a	   certain	   degree	  of	   addiction,	   but	   its	   intensity	   is	  
very	   different.	   The	   most	   utilized	   psycho-­‐
stimulants	   are	   cocaine	   and	   its	   derivatives,	  
amphetamines,	  caffeine	  and	  nicotine.	  
	  	  
	  




In	   cocaine	   abusers,	   magnesium	   reduced	   the	  
craving	  for	  this	  substance	  (Margolin	  et	  al.,	  1992).	  
Cocaine	   craving	   scores	  were	   78%	   lower	   in	   those	  
taking	   magnesium	   than	   in	   patients	   taking	  
placebo.	   Mg	   also	   reduced	   cocaine	   self-­‐
administration	   in	   patients	   and	   cocaine	  
consumption	   in	   rats	   (Kantak	   et	   al.,	   1998).	   In	  
cocaine	  addicts,	  the	  plasma	  level	  of	  Mg2+	  is	  higher	  
than	   in	   heroin	   addicts	   (Tonioni	   et	   al.,	   2009).	  
NMDA	  receptors	  are	  essential	   for	   cocaine	  action	  
in	   brain.	   NMDA	   antagonists	   and	   some	   NMDA-­‐
coupled	   ion	   channel	   blockers	   (like	   magnesium)	  
may	   modify	   the	   cocaine	   effects	   (Kantak	   et	   al.,	  
1998).	  
	  
Our	   data	   shows	   that	   magnesium	   never	  
determines	   dependence.	   Mg	   has	   a	   moderate	  
effect	   of	   stimulating	   the	   brain	   reward	   system.	  
MgC12	  results	   in	  an	  increase	  in	  time	  spent	   in	  the	  
conditioning	   compartment	   in	   the	   case	   of	  
conditioned	   place	   preference	   (CPP)(Nechifor	   et	  
al.,	   2010).	   We	   consider	   that,	   apart	   from	   other	  
mechanisms,	   the	   small	   stimulation	   on	   the	   brain	  
reward	   system	   is	   important	   in	   realizing	  
magnesium’s	   effect	   of	   reducing	   cocaine	  
consumption.	  
	  
There	   are	   also	   data	   showing	   that	   genes	   are	  
important	  for	  the	  behaviour	  of	  drug	  abusers	  who	  
have	   a	   strong	   genetic	   determination.	   The	   allelic	  
variations	   associated	   with	   the	   dopamine	  
transporter	   showed	   a	   relationship	   with	   the	  
paranoia	   of	   cocaine-­‐dependent	   people	  
(Gellertnet	  et	  al.,	  1999).	  We	  consider	  that	  genetic	  
deficiencies	   in	  magnesium	   transport	   at	   the	   level	  
of	   the	   neuronal	   membrane	   may	   be	   involved	   in	  
the	   speed	   of	   addiction	   development	   and	   in	   the	  
severity	  of	  withdrawal	  syndrome.	  
	  
Caffeine	  
Caffeine	   is	   one	   of	   the	   most	   consumed	  
psychoactive	   substances,	   although	   the	   existence	  
of	  caffeine	  dependence	  is	  controversial	  (Huges	  et	  
al.,	   1992;	   Daly	   and	   Fredholm,	   1998).	   There	   are	  
data	   suggesting	   that	   caffeine	   results	   in	   a	   clinical	  
dependence	   syndrome	   very	   similar	   to	   that	  
produced	   by	   other	   psychoactive	   substances,	   as	  
well	   as	   from	   the	   point	   of	   view	   of	   the	   caffeine-­‐
induced	  craving	  (Ogawa	  and	  Ueki,	  2007).	  Caffeine	  
has	   only	   weak	   reinforcing	   proprieties,	   but	  
withdrawal	  syndrome	  is	  a	  reality	  and	  is	  similar	  to	  
that	   produced	   by	   other	   drugs	   of	   abuse.	   Rats	  
chronically	  exposed	  to	  1	  g/L	  caffeine	  a	  day	  for	  20	  
days	   developed	   caffeine	   withdrawal	   syndrome	  
(Dingle	  et	  al.,	  2008).	  
	  
Caffeine	   blocks	   both	   A l 	   and	   A2	   adenosine	  
receptors.	   Chronic	   administration	   of	   xanthines	  
(caffeine,	   theophylline)	   causes	   a	   significant	  
increase	   in	   the	   number	   of	   adenosine,	   nicotine	  
and	  serotoninergic	   receptors	   in	   the	  brain.	   It	  also	  
increases	  the	  number	  of	  L-­‐type	  calcium	  channels	  
in	  the	  neuronal	  membrane.	  The	  blockade	  of	  both	  
A 1 	   and	   A2	   receptors	   is	   necessary	   for	   the	   full	  
spectrum	  of	  caffeine’s	  pharmacologic	  effects.	  
	  
The	  Ca2+	  ions	  from	  the	  endoplasmic	  reticulum	  are	  
very	   important	   for	   normal	   cell	   function.	   Any	  
change	  in	  intracellular	  calcium	  concentration	  can	  
have	   an	   impact	   on	   neuronal	   activity.	   Caffeine	  
enhances	  the	  intracellular	  Ca2+	  peak.	  This	  effect	  is	  
higher	  in	  young	  animals	  and	  is	  altered	  with	  aging	  
(Alshuaib	   et	   al.,	   2006).	   Caffeine-­‐releasable	  
calcium	   ions	   may	   stimulate	   glutamate	   synthesis	  
and	   release,	   which	   increases	   NMDA	   receptor	  
activity.	   Wang	   (2007)	   showed	   that	   caffeine-­‐
mediated	   glutamate	   release	   is	   produced	   by	  
activation	   of	   protein	   kinase	   C	   pathways	   and	  
involves	   an	   interaction	   between	   caffeine	   and	  
presynaptic	   adenosine	   A 1 	   receptors.	   The	  
importance	   of	   caffeine	   action	   on	   adenosine	  
receptors	   also	   comes	   out	   of	   the	   fact	   that	   these	  
receptors	   act	   as	   regulators	   of	   neurotransmitter	  
release	  in	  the	  brain	  (Sebastiao	  and	  Ribeiro,	  2009).	  
Adenosine	   stimulates	   all	   types	   of	   adenosine	  
receptors.	   The	   omnipresence	   of	   A1,	   A2	   and	   A3	  
receptors	   in	   CNS	   neurons	   and	   neuroglia	   reflect	  
the	   major	   role	   of	   adenosine	   in	   modulating	  
synaptic	  activity	   in	  many	  brain	   regions,	   including	  
those	  involved	  in	  dependence.	  
	  
Blockade	   of	   adenosine	   A1A	   and	   A2A	   receptors	   is	  
involved	   in	   the	   development	   of	   caffeine	  
addiction.	  Burgalassi	  et	  al.,	   (2009)	  showed	  that	  a	  
substantial	   number	   of	   heavy	   caffeine	   drinkers	  
satisfy	   the	   research	   criteria	   for	   dependence.	  
Adenosine	   A l 	   and	   A2	   receptors	   have	   a	   greater	  
involvement	   in	   addiction	   processes,	   as	   well	   as	  
development	   of	   withdrawal	   syndrome,	   rather	  
than	  in	  development	  of	  caffeine	  dependence.	  
	  
Adenosine	   and	   adenosine	   receptors	   are	   also	  
involved	   in	   morphine	   dependence	   and	   opioid	  
withdrawal.	  Adenosine	  is	  able	  to	  reduce	  the	  dose-­‐	  
dependent,	   naloxone-­‐precipitated	   withdrawal	   in	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guinea	   pigs	   exposed	   to	   morphine.	   Caffeine	  
significantly	   increases	   naloxone-­‐precipitated	  
withdrawal	   (Capasso,	   2000).	   Research	   on	   guinea	  
pig	   isolated	   ileum	   exposed	   to	  morphine	   showed	  
that	   the	   contraction	   induced	   by	   naloxone	   was	  
increased	   by	   caffeine	   (P1	   antagonist)	   in	   a	  
concentration	   dependent	   manner	   (Capasso	   and	  
Loizzo,	   2001).	   The	   caffeine	  effect	   is	   amplified	  by	  
low	  Mg2+	  concentration.	  
	  
A1	  receptor	  antagonists	  such	  as	  caffeine	  increase	  
the	   presynaptic	   release	   of	   dopamine	   and	  
glutamate.	   This	   is	   thought	   to	   be	   the	   main	  
mechanism	   for	   caffeine	   dependence.	   A1	  
receptors	   are	   located	   in	   presynaptic	   areas	   of	  
glutamatergic	   neurons	   and	   Mg	   can	   reduce	  
caffeine	  dependence	  by	  blocking	  NMDA	  coupled	  
Ca2+	  channel	  activity,	   reducing	   the	  capacity	  of	  A1	  
receptor	   antagonists	   (such	   as	   caffeine)	   to	  
stimulate	  glutamate	  and	  dopamine	  release,	  or	  by	  
reducing	   the	  glutamate	   stimulation	  of	  dopamine	  
presynaptic	  release.	  It	  is	  not	  very	  clear	  if	  caffeine	  




Amphetamine	   is	  a	  very	  potent	  sympathomimetic	  
agent	   in	   stimulating	   the	   CNS.	   The	   main	  
mechanism	   of	   action	   is	   by	   release	   of	   biogenic	  
amines	   from	   their	   storage	   sites	   in	   presynaptic	  
parts	   of	   central	   synapses.	   The	   dependence	   and	  
stereotypical	   behaviour	   associated	  with	  amphet-­‐
amine	   is	   induced	   by	   stimulation	   of	   dopamine	  
release.	  Disturbance	  of	  perception	  and	  psychotic	  
behaviour	  may	  be	  due	  to	  release	  of	  serotonin	  and	  
dopamine	   in	   the	   mesolimbic	   system	   (Hoffman,	  
2001).	   There	   is	   also	   a	   small	   stimulating	   effect	   of	  
amphetamine	   on	   some	   serotonin	   receptors.	  
Increased	   intraneuronal	   Mg2+	   concentration	   is	  
thought	   to	   reduce	   the	   intensity	   of	  
psychostimulant	   addiction.	   Evidence	   in	   favour	   is	  
the	   fact	   that	   Li+	   (which	   increases	   intracellular	  
magnesium	   concentration)	   has	   an	   antagonistic	  
effect	   with	   amphetamine	   at	   the	   level	   of	   the	  
nucleus	   accumbens.	   Li+	   also	   decreased	  
dopaminergic	   transmission	   stimulated	   by	  
amphetamine	   (Gray	   et	   al.,	   1997).	   After	  
administration	   of	   1	   mg/kg	   amphetamine,	  
dopamine	   levels	   increase	   by	   427%	   versus	   the	  
basal	   level.	   This	   dopamine	   release	   is	   calcium	  
potentiated.	   The	   replacement	   of	   calcium	   by	  
magnesium	   reduces	   the	   response	   to	  
amphetamine	   administration	   (Warburton	   et	   al.,	  
1996).	   It	  was	  also	  remarked	  that	  structural	  brain	  
abnormalities	   are	   associated	   with	   amphetamine	  
abuse.	   These	   differences	   included	   lower	   cortical	  
gray	   matter	   quantity	   and	   higher	   striatal	   volume	  
than	  in	  normal	  subjects	  (Berman	  et	  al.,	  2008).	  We	  




Existing	   data	   shows	   that	   nicotine	   addiction	  
develops	   in	   chronic	   smokers	   with	   over	   10-­‐20	  
cigarettes/day.	   Chronic	   smoking	   decreases	   the	  
level	  of	  serum	  magnesium	  (Niemela	  et	  al.,	  1997;	  
Nechifor	   et	   al.,	   2004a),	   while	   magnesium	  
administration	  decreases	   the	  number	  of	   smoked	  
cigarettes	   as	   well	   as	   nicotine	   addiction.	  
Specifically,	   2	   ampoules/day	   Magne-­‐B6	  
administration	   for	   four	   weeks	   significantly	  
decreased	   the	   number	   of	   cigarettes	   smoked	   by	  
heavy	   smokers	   (smokers	   with	   over	   20	  
cigarettes/day)	   (Nechifor	   et	   al.,	   2004a).	   The	  
Fagerstrom	  score	  was	  significantly	  reduced	  in	  the	  
smoker	   group	   that	   received	   magnesium,	   from	  
7.93	   ±	   0.17	   before	   magnesium	   to	   6.78	   ±	   0.18	  
after	   magnesium	   (p<0.05).	   Mg2+	   can	   potentially	  
reduce	  nicotine	  addiction	  by:	  
	  
-­‐	   acting	   as	   a	   partial	   antagonist	   of	   calcium	  
entry	   into	   neurons,	   thereby	   decreasing	  
glutamate	   release	   and	   glutamatergic	  
transmission,	   which	   is	   stimulated	   by	  
nicotine;	  	  
-­‐	   decreasing	   nicotine-­‐induced	   pre-­‐synaptic	  
release	   of	   dopamine	   and	   other	  
catecholamines;	  
-­‐	   increasing	   magnesium	   concentration	   in	   the	  
neuron	   producing	   a	   decrease	   in	   sodium	  
concentration.	   This	   decreases	   the	   stimulant	  
effect	  of	  nicotine	  on	  nicotine	  receptors.	  
-­‐	   decreasing	   the	   nicotine	   addictive	   effect	   by	  
diminishing	   the	   nicotine	   effect	   on	   GABA	  
synthesis.	   Nicotine	   diminishes	   GABA	  
synthesis	  and	  release	  in	  some	  brain	  areas	  by	  
stimulation	   of	   nicotine	   presynaptic	  
receptors;	  
-­‐	   enhancing	   some	   of	   the	   GABA	   effects	   and	  
diminishing	   some	   effects	   of	   the	   excitatory	  
amino	   acids	   in	   drug	   dependence.	   GABA	  
antagonizes	   some	  of	   the	   glutamate-­‐induced	  
stimulatory	  effects	  of	  NMDA	  receptors.	  	  
	  
Like	   nicotine,	   synaptically	   released	   acetylcholine	  
stimulates	   nicotinic	   receptors	   and	   in	   this	   way	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enhances	   glutamatergic	   activity	   (Guo	   et	   al.,	  
2005).	   The	   release	   of	   DA	   from	   the	   nucleus	  
accumbens	   and	   substantia	   nigra	   was	   stimulated	  
by	  glutamate,	  and	  nicotine	  enhanced	  this	  release	  
(Marien	  et	  al.,	  1983).	  Such	  DA	  secretion	   induced	  
by	  glutamate	  and	  nicotine	  is	  Ca2+	  dependent	  and	  
was	   inhibited	   by	   Mg2+.	   We	   think	   that	   this	   is	   an	  
essential	   mechanism	   for	   magnesium	   action	   to	  




Alcohol	   induced	   dependence	   is	   one	   of	   the	  most	  
widespread	   dependencies.	   Abuse	   and	   addiction	  
depend,	   at	   least	   partially,	   on	   the	   activation	   of	  
mesolimbic	  dopaminergic	  systems.	  The	  activation	  
of	   these	   systems	   is	  achieved	  directly	  by	  ethanol,	  
but	   also	   by	   acetaldehyde,	   which	   results	   from	  
ethanol	   metabolism.	   Acetaldehyde	   increases	  
dopaminergic	   neuronal	   activity	   in	   the	   nucleus	  
accumbens,	   ventral	   tegmental	   area	   and	   in	   other	  
parts	  of	  the	  CNS	  (Foddai	  et	  al.,	  2004;	  Diana	  et	  al.,	  
2008).	  Alcohol-­‐dehydrogenase	  drastically	   inhibits	  
the	   effects	   of	   ethanol	   on	   dopaminergic	   neurons	  
of	  the	  ventral	  tegmental	  area	  (VTA).	  We	  consider	  
that	   magnesium	   could	   reduce	   the	   stimulating	  
effect	   of	   ethanol	   on	   dopaminergic	   systems	   by	  
directly	   reducing	   the	   presynaptic	   release	   of	  
dopamine,	   but	   also	   by	   decreasing	   acetaldehyde	  
production.	  	  
	  
There	   is	   important	   evidence	   implicating	   the	  
endogenous	   opioids	   in	   the	   processes	   of	   reward	  
and	   reinforcement	   (Gianoulakis,	   2009).	  
Endogenous	   opioids,	   like	   morphine,	   induce	   an	  
increase	   of	   dopamine	   concentration	   in	   the	  
nucleus	  accumbens,	  which	  is	  considered	  the	  most	  
important	   structure	   for	   drug	   addiction.	   This	   is	  
considered	   a	   common	   effect	   for	   many	   drugs	  
involved	   in	   abuse.	   Ethanol	   increases	   beta-­‐
endorphin	   release.	   The	   stimulation	   of	   opioid	  
receptors	   (especially	  of	  µ	  receptors)	   seems	   to	  be	  
important	   for	   ethanol	   addiction,	   with	   low	  
morphine	   doses	   increasing	   ethanol	   consumption	  
(Hertz,	   1997).	   Magnesium	   reduces	   receptor	  
binding	   of	   morphine	   and	   other	   µ	   receptor	  
agonists	   (Mendez	   et	   al.,	   2001;	   Rodriguez	   et	   al.,	  
1992).	   This	   way,	   magnesium	   could	   reduce	   the	  
stimulation	   of	   dopamine	   synthesis	   produced	   by	  
large	   quantities	   of	   opioid	   peptides,	   which	  
themselves	  are	  induced	  by	  ethanol	  in	  the	  nucleus	  
accumbens	  and	  VTA.	  We	  therefore	  consider	  that	  
Mg	   could	   decrease	   ethanol	   addiction	   and	  
hypomagnesemia	   could	   increase	   alcohol	  
consumption.	  Mendez	  et	  al.,	   (2001)	  showed	  that	  
the	   reinforcing	   properties	   of	   ethanol	   may	   be	  
partially	   mediated	   by	   ethanol	   regulation	   of	   µ	  
receptors	   in	   dopaminergic	   neurons	   from	  
mesolimbic	  systems.	  A	  modulation	  of	  µ	  receptors	  
from	   the	   frontal	   and	   prefrontal	   cortex	   is	   also	  
possible.	  	  
	  
There	  are	  also	  findings	  that	  suggest	  that	  mGluR5	  
receptors	  modulate	  ethanol	  self-­‐administration	  in	  
rats	   (Schroeder	   et	   al.,	   2005).	   Dopamine	   is	   the	  
most	   important	  neurotransmitter	   involved	  in	  the	  
reward	   mechanism	   and	   it	   influences	   the	  
development	  of	  alcohol	  dependence	  and	  relapse.	  
Two	   polymorphisms	   of	   the	   D2	   dopamine	  
receptors	   seem	   to	   suffer	   2.5	   times	  more	   risk	   to	  
develop	   ethanol	   dependence	   (Prasad	   et	   al.,	  
2010).	   Embry	   and	   Lippman	   (1987)	   considered	  
that	   magnesium	   deficiency	   plays	   an	   important	  
role	   in	   the	  alcohol-­‐withdrawal	   system.	  There	  are	  
data	   that	   show	   that	   magnesium	   administration	  
decreases	   the	   intensity	   of	   symptoms	   from	   the	  
withdrawal	   syndrome.	   The	   alcohol	   induces	  
hypomagnesemia	   and	   increases	   urinary	  
magnesium	   loss.	   Low	   concentrations	   of	   ethanol	  
deplete	  free	  intracellular	  magnesium	  (Babu	  et	  al.,	  
1999).	  Consistent	  with	  Shane	  and	  Flink	  (1992),	  we	  
believe	   that	   magnesium	   deficiency	   is	   not	   only	  
involved	   in	   the	   intensity	   of	   alcohol	   withdrawal,	  
but	   also	   in	   the	   development	   of	   alcohol	  
dependence.	  
	  
The	   NMDA	   receptors	   from	   the	   nucleus	  
accumbens	   and	   the	   mesolimbic	   structures	   are	  
involved	   in	   drug	   reward	   and	   reinforcement.	  
Ethanol	   sensitivity	   of	   NMDA	   receptors	   from	   the	  
nucleus	   accumbens	   is	   important	   for	   ethanol-­‐
induced	   neuroadaptation	   of	   the	   reward	   system.	  
Chronic	   alcohol	   administration	   results	   in	   an	  
increased	   glutamate	   binding	   to	   the	   NMDA	  
receptors	   (Hu	   and	   Ticku,	   1995).	   This	   highlights	  
the	   importance	   of	   glutamate	   action	   in	  
development	  of	  alcohol	  addiction.	  The	  activation	  
of	   NMDA	   receptors	   in	   rats	   increases	   during	   the	  
alcohol	   withdrawal	   syndrome	   (Sanna	   et	   al.,	  
1993).	   Electrolyte	   abnormalities	   are	   common	   in	  
chronic	  alcoholics	  and	  during	  alcohol	  withdrawal	  
syndrome	   (Stasinkyniene,	   2002).	   Alcohol	  
consumption	   is	   one	   of	   the	   major	   causes	   for	  
hypomagnesemia,	   which	   is	   one	   of	   the	   most	  
important	  cation	  imbalances	  in	  alcoholic	  patients	  
and	  during	  withdrawal	  (Carl	  and	  Halzbach,	  1994).	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In	   alcoholic	   patients,	   urinary	   magnesium	   loss	  
increases	   2-­‐3	   fold	   (Romain,	   2008)	   and	   brain	  
intracellular	   Mg2+	   level	   are	   reduced	   (Li	   et	   al.,	  
2001;	   Pasternak,	   1999).	   Low	   ethanol	  
concentrations	   deplete	   type	   2	   astrocytes	   of	  
intracellular	   free	  magnesium	   (Babu	  et	  al.,	   1999).	  
The	   Mg2+	   dependent	   decay	   off-­‐rate	   of	   NMDA	  
miniature	   synaptic	   currents	   (mEPSes)	   was	   also	  
significantly	   reduced	   by	   ethanol	   (Zhang	   et	   al.,	  
2005),	   suggesting	   that	   ethanol	   not	   only	  
contributes	  to	  increase	  the	  release	  of	  magnesium	  
from	  the	  body,	  but	  also	  to	  increase	  magnesium’s	  
effect	  at	  the	  NMDA	  receptor	  level.	  
	  
Mg2+	   ions	  modulate	  neuronal	  excitability	  and	  are	  
involved	   in	   alcohol-­‐related	   behaviours.	   Uusi-­‐
Oukari	  et	  al.,	  (2001)	  found	  that	  the	  putative	  Mg2+	  
binding	   sites	   differ	   between	   alcohol	   insensitive	  
(AT)	  and	  alcohol	  sensitive	  (ANT)	  rats	   lines.	   In	  the	  
presence	   of	   GABA,	   the	   effect	   of	   low	   Mg	  
concentration	  was	   higher	   in	   cerebral	   cortex	   and	  
in	   the	   caudate-­‐putamen	   of	   AT	   rats	   than	   in	   the	  
ANT	   animals.	   Alcohol	   sensitive	   rats	   have	  
alterations	   of	   the	   alpha	   6	   subunit	   –	   containing	  
GABAA	   receptors.	   It	   is	   possible	   that	   these	  
receptors	  might	   be	   involved	   in	   the	   sensitivity	   of	  
different	   lines	   of	   rats	   to	   alcohol	   and	   also	   in	   the	  
different	   sensibility	   of	   animals	   to	   sedative	   drugs	  
(Uusi-­‐Oukari	   M	   et	   al.,	   2001).	   Magnesium	  
administration	   only	   during	   the	   withdrawal	  
syndrome	  of	  ethanol	  addicts	  reduced	  the	  clinical	  
symptoms.	  
	  
Hallucinogens	  (psychedelic	  substances)	  
	  
Hallucinogens	   are	   substances	   that	   induce	  
hallucinations,	   disorders	   of	   thinking	   and	  
delusions.	   The	   most	   potent	   hallucinogen	   is	   LSD	  
(lysergic	   acid	   diethylamide)	   that	   produces	   a	  
significant	  hallucinogen	  effect	  at	  a	  dose	  of	  as	  little	  
as	   25-­‐50	   ug.	   Other	   psychedelic	   drugs	   are	  
derivatives	   with	   indolaminic	   structure	   (psyloc-­‐
ibine,	   DMT	   and	   others)	   and	   substances	   with	  
phenethylaminic	   structure	   (mescaline,	   MDMA,	  
and	   DOM).	   The	   precise	   mechanism	   of	   action	   of	  
these	  substances	  is	  not	  yet	  known,	  but	  a	  positive	  
correlation	   between	   the	   relative	   affinity	   of	  
hallucinogens	   for	   serotonin	   5-­‐HT2	   receptors	   and	  
their	   potency	   to	   induce	   hallucination	   has	   been	  
observed	  (Titeler	  et	  al.,	  1988).	  
	  
The	  hallucinogens	  (LSD,	  phencyclidine,	  psilocybin,	  
mescaline,	  DMT	  and	  others)	  give	  a	  strong	  psychic	  
dependence,	   but	   the	   concept	   of	   addiction	   is	  
controversial.	   The	   presence	   of	   withdrawal	   from	  
hallucinogens	   has	   not	   been	   clearly	   established	  
because	   these	   drugs	   don’t	   seem	   to	   induce	  
physical	   dependence.	   The	   most	   utilized	  
hallucinogen	  is	  LSD.	  	  
	  
There	   are	   data	   that	   favour	   the	   idea	   that	   all	  
phencyclidine	   receptors	   in	   the	   brain	   are	  
associated	  with	  NMDA	   receptors.	  Notably,	   there	  
is	   an	   interaction	   of	   L-­‐glutamate	   and	  magnesium	  
with	   the	   phencyclidine	   recognition	   site	   in	   the	  
brain	   (Loo	   et	   al.,	   1987).	   The	   agonists	   of	   NMDA	  
receptors	   induce	   a	   high	   affinity	   state	   in	   the	  
phencyclidine	   receptors.	   This	   is	   another	  
possibility	   by	   which	   Mg2+	   can	   influence	  
phencyclidine	   action.	   Mg2+	   inhibits	   MK-­‐801	   (a	  
ligand	   for	   the	   NMDA	   ion	   channel	   phencyclidine	  
site)	  binding	  in	  the	  cortex	  (Chahal	  et	  al.,	  1998).	  It	  
is	   possible	   for	   magnesium	   to	   also	   decrease	  
phencyclidine	  action	  this	  way.	  However,	  Rothman	  
et	   al.,	   (1989)	   demonstrated	   the	   existence	   of	   a	  
high-­‐affinity,	   phencyclidine	   binding	   site	  
associated	   with	   the	   dopamine	   reuptake	   carrier.	  
The	   hallucinogen	   could	   therefore	   influence	  
synaptic	   dopamine	   concentration.	   It	   is	   still	  
unknown	   how	   Mg2+	   influences	   dopamine	  
reuptake.	  	  
	  
Regarding	   other	   hallucinogens	   such	   as	   psilocin	  
(from	   Psilocybe	   mushrooms)	   and	   phenylethyl-­‐
amine,	   subchronic	   experimental	   intoxication	   in	  
rats	  disturbs	  magnesium	  concentrations	   (Majdanik	  
et	  al.,	  2007).	  Low	  magnesium	  concentration	  also	  
resulted	   from	   chronic	   mescaline	   and	   LSD	  
administration.	   Hypomagnesemia	   is	   associated	  
with	  an	  increased	  intracellular	  entrance	  of	  Ca2+	  in	  
these	   conditions.	   In	   cerebral	   vasospasm,	   which	  
appears	  in	  chronic	  hallucinogen	  intoxication,	  both	  
magnesium	  and	  the	  calcium	  antagonist	  verapamil	  
block	   this	   effect	   (Altura	   and	   Altura,	   1983).	   The	  
NMDA	   receptor	   is	   coupled	   with	   an	   ion	   channel	  
and	   has	   regulatory	   sites	   for	   phencyclidine,	  
glycine,	  and	  also	   for	  magnesium	  and	  zinc.	   In	   this	  
way,	   it	   might	   be	   possible	   for	   an	   interaction	  
between	   magnesium	   and	   phencyclidine	   to	   exist	  
with	  respect	  to	  the	  activity	  of	  NMDA	  receptors.	  
	  
Lerma	   et	   al.,	   (1991)	   suggest	   that	   interactions	  
between	  Mg2+	   and	   phencyclidine	   at	   the	   level	   of	  
the	  NMDA	  channels	  are	  competitive.	   Indeed,	  0.5	  
mM	   Mg	   caused	   a	   four-­‐fold	   decrease	   in	  
phencyclidine	   potency.	   In	   vitro	   incubation	   of	  
Mg	  and	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phencyclidine	   stimulated	   brain	   slides	   with	   1.2	  
mM	  MgC12	  shows	  that	  Na	  efflux	  produced	  by	  the	  




Magnesium	   aspartate	   decreases	   benzodiazepine	  
addiction	  (lorazepam,	  alprazolam,	  or	  bromazepam)	  
(Hantouche	   et	   al.,	   1998).	   The	   decrease	   in	  
addiction	   intensity	  was	  manifested	   as	   prolonged	  
delay	   in	   benzodiazepine	   reintake,	   reduction	   of	  
withdrawal	   intensity,	   and	   reduction	   of	   anxiety	  
during	   benzodiazepine	   discontinuation.	   In	  
benzodiazepine	   withdrawal	   syndrome,	   strong	  
anxiety	   is	   present.	   This	   phenomenon	   is	  
associated	  with	  a	  potentiation	  of	  AMPA	  receptor	  
activity	   and	   AMPA	   receptor	   currents	   in	  
hippocampal	   pyramidal	   neurons.	   Calcium/	  
calmodulin–dependent	   protein	   kinase	   (PK)	   II	   has	  
a	   contribution	   by	   enhancing	   the	   glutamatergic	  
synaptic	   activity	   during	   benzodiazepine	  
withdrawal	   (Shen	  et	   al.,	   2010).	   In	   some	  patients	  
that	   received	   Mg	   L-­‐aspartate,	   cessation	   of	  
benzodiazepines	   was	   obtained	   without	   onset	   of	  
withdrawal	   syndrome.	   It	   is	   possible	   that	  
magnesium	   ions	   acting	   at	   the	   level	   of	   AMPA	  
receptors	   influence	   the	   calcium/calmodulin	  
dependent	  PK	   II	   to	  reduce	  the	  anxiety	  and	  other	  





Delta	   9-­‐tetrahydrocannabinol	   is	   the	   principal	  
psychoactive	  compound	  in	  marijuana,	  although	  it	  
is	  widely	  used	  in	  a	  number	  of	  forms.	  It	  induces	  an	  
important	   psychic	   dependence,	   but	   only	   a	  
modest	   physical	   dependence.	   Bac	   and	   Germain	  
Fattal	   (2006)	   showed	   that	  magnesium	  deficiency	  
increased	   the	   neurotoxicity	   of	   THC	   at	   low	   doses	  
in	   rats.	   Hyperagressiveness	   and	   THC	   induced	  
muricidal	  behaviour	  in	  rats	  was	  also	  increased	  by	  
magnesium	   deficiency.	   Otherwise,	   there	   is	   very	  
little	  data	   regarding	   the	   influence	  of	  magnesium	  





Regarding	   the	   involvement	   of	   magnesium	   in	  
addiction,	  we	  consider	  that	  is	  important	  not	  only	  
at	  the	  neuronal	  level,	  but	  also	  at	  neuroglial	  level.	  
According	   to	   data	   that	   shows	   that	   the	   glial	   cells	  
are	   involved	   i n 	   addictive	   behaviour,	   mainly	  
through	   the	   regulation	   of	   glutamate	   transport	  
and	   activity,	   we	   believe	   that	  magnesium	   acts	   at	  
the	   neuroglial	   level	   by	   reducing	   the	   action	   of	  
glutamate.	  There	  are	  NMDA	  receptors	  at	  the	  glial	  
level	   (in	   oligodendrocytes,	   microglia	   and	  
astrocytes)	   (Verkhratsky	   and	   Kirchhoff,	   2007),	  
and	   at	   both	   these	   receptors	   and	   the	   neuronal	  
NMDA	  receptor	   level,	   there	   is	  a	   calcium	  channel	  
that	  can	  be	  influenced	  by	  magnesium.	  
	  
We	   consider	   that	   the	   ability	   of	   magnesium	   to	  
reduce	   addiction	   to	   d i f ferent 	   substances	   and	  
reduce	   the	   intensity	   of	   addiction	   to	   different	  
substances	   is	   essentially	   related	   to	   the	  
association	  of	  two	  different	  factors	  –	  its	  ability	  to	  
produce	   a	   moderate	   stimulation	   of	   the	   brain	  
reward	   system	   (Nechifor	   et	   al.,	   2010),	   and	   its	  
capacity	   to	   reduce	   the	   activity	   of	   glutamatergic	  
substances,	   importantly	   involved	   in	   compulsive	  
use	  disorders.	  
	  
Compulsive	   drug-­‐taking	   behaviour	   is	   an	  
important	   characteristic	   element	   in	   addiction.	  
The	  existence	  of	  a	  strong	  reinforcement	  activity	  is	  
a	  determining	  factor	  for	  drug	  addiction	  (Koob	  and	  
Bloom,	   1988).	   Reducing	   the	   intensity	   of	  
dependence	   on	   different	   compounds	   involves	  
reducing	   their	   reinforcing	   proprieties.	   Response-­‐
reinforcement	   learning	   is	   dependent	   on	   NMDA	  
receptor	   activation	   (Kelley	   et	   al.,	   1997).	   We	  
consider	   that	   magnesium	   reduces	   reinforcing	  
proprieties	   of	   different	   compounds	   by	   action	   on	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